Board Decisions

The Board of the Global Fund meets no less than twice a year. At each meeting, the Board takes a number of decisions which are legally binding on the Global Fund, including the Board, the Secretariat and the Office of the Inspector General. These decisions also determine how the Global Fund engages with in-country partners.

Search for a decision point by: title, date, meeting or decision point number to read the text in full.

Loading...
Date
YYYY-MM-DD
Title Number Board Meeting
2007-11-13 B16 GF/B16/DP04 Approval of Round 7 Approval of Round 7
<ol><li> The Board approves for funding for an initial two years, subject to paragraphs 2 and 3 below, the Round 7 proposals recommended for funding by the Technical Review Panel (TRP) and listed in Annex 2 to the Report of the TRP and Secretariat on Round 7 Proposals (GF/B16/5) as:<ol type="i"><li>'Category 1';</li><li>'Category 2'; and</li><li>'Category 2B',</li></ol><br/>with the clear understanding that the grant amounts requested for the "Phase 1 Period" in such Annex are maximum upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts.</li><li> The applicants whose proposals are recommended for funding as 'Category 1' shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than eight weeks after receipt of notification in writing by the Secretariat to the applicant of the Board's decision.</li><li> The applicants whose proposals are recommended for funding as 'Category 2 and Category 2B' shall:<ol type="i"><li>provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after receipt of notification in writing by the Secretariat to the applicant of the Board's decision; and</li><li>conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as 'Category 3' as indicated in Annex 2 to GF/B16/5, although such applicants are encouraged to resubmit a proposal in a future funding round after major revision of the relevant proposal.</li><li>The Board declines to approve for funding those proposals categorized by the TRP as 'Category 4' as indicated in Annex 2 to GF/B16/5.</li></ol>
2017-12-15 B38 GF/B38/EDP06 Approval of Guideline for Annual Performance Assessment of Board Direct Reports Approval of Guideline for Annual Performance Assessment of Board Direct Reports
<p>The Board:</p> <ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Guideline for Annual Performance Assessment of Board Direct Reports as set forth in Annex 1 to GF/B38/ER04. This Guideline shall apply to the assessment of the performance of the Executive Director and the Inspector General during 2018 and onward.</li> <li>The Board directs the Ethics and Governance Committee (EGC) to review the guideline every three years, starting in 2020, to ensure its continued relevance.</li> <li>The Board delegates to the EGC the authority to approve revisions to the Guideline for Annual Performance Assessment to Board Direct Reports and to report such changes to the Board.</li> <li>The Board delegates to the EGC the authority to appoint a member of the EGC in replacement of the Board Chair or Vice Chair for the purposes of the performance assessment of the Executive Director or Inspector General in the event of a recusal of any of the said officials.</li> </ol>
2017-11-15 B38 GF/B38/DP09 Approval of Policy to Combat Fraud and Corruption Approval of Policy to Combat Fraud and Corruption
<ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Global Fund Policy to Combat Fraud and Corruption as set forth in Annex 4 to GF/B38/06 – Revision 2;</li> <li>The Board directs the Executive Director to develop an implementation plan, and to periodically report to the Board through the Ethics and Governance Committee on its implementation of the Policy to Combat Fraud and Corruption, as part of regular updates pursuant to the Ethics and Integrity Framework; </li> <li>Consistent with his/her authority to implement the Policy to Combat Fraud and Corruption, the Executive Director shall have delegated authority to approve exceptions to the Policy. This provision does not apply to access rights of the Office of the Inspector General for which the Inspector General shall have such delegated authority; and</li> <li>The Board further directs that appropriate and regular reporting be made by the Executive Director and Inspector General to the Ethics and Governance Committee or the Audit and Finance Committee on the exercise of the authority delegated under paragraph 3 of this Decision Point; and</li> <li>The authority delegated to the Executive Director and the Inspector General, as the case may be, under paragraph 3 of this Decision Point expires at the moment when the Board has adopted the framework the Board has requested the Secretariat to develop in GF/B37/DP07.</li> </ol>
2018-03-08 B38 GF/B38/EDP13 Approval of the Global Fund Honorarium Framework Approval of the Global Fund Honorarium Framework
<p>Approves the Global Fund Honorarium Framework, as set forth in Annex 1 to GF/B38/ER09.</p>
2017-11-30 B38 GF/B38/EDP01 Principles of the LFA Procurement Method Principles of the LFA Procurement Method
<p>The Board, taking into account the specific nature of Local Fund Agent (the “LFA”) services as described in GF/B38/ER01 decides to:</p> <ol> <li>Replace its prior decision on Re-tendering Local Fund Agent Contracts (GF/B15/DP50) with the Principles of the LFA Procurement Method: Differentiation; Ensuring value-for-money through monitoring LFA performance and cost; Encouraging the diversity of LFA service providers; and Unique contracting arrangements, as set forth in Part 6 of GF/B38/EDP01 (the “Principles of the LFA Procurement Method”);</li> <li>Delegate to the AFC the authority to approve modifications to the Principles of the LFA Procurement Method; and</li> <li>Delegate to the Secretariat the authority to approve the procedures for procurement of LFA services in accordance with the Principles of the LFA Procurement Method Budgetary implications: no additional resources required</li> </ol>
2017-11-14 B38 GF/B38/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the 38th Board Meeting (GF/B38/01) is approved.</p>
2018-02-23 B38 GF/B38/EDP12 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP12 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-01-23 B38 GF/B38/EDP10 Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of: <ol type="i"> <li>Beatrijs Stikkers-Muller as Chair of the Audit and Finance Committee;</li> <li>Anthony Garnett as Vice-Chair of the Audit and Finance Committee;</li> <li>Sandra Thurman as Chair of the Ethics and Governance Committee;</li> <li>Grace Rwakarema as Vice-Chair of the Ethics and Governance Committee;</li> <li>Kieran Daly as Chair of the Strategy Committee; and</li> <li>Abdalla Osman as Vice-Chair of the Strategy Committee.</li> </ol> </li> </ol> <ol start="2"> <li>The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 11 May 2018 and serve for two years or until the appointment of their successor.</li> </ol>
2017-11-14 B38 GF/B38/DP06 2018 Corporate Work Plan and Budget Narrative and the 2018 Operating Expenses Budget 2018 Corporate Work Plan and Budget Narrative and the 2018 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the following:</p> <ol> <li>2018 Corporate Work Plan and Budget Narrative, as set forth in GF/B38/04B; and </li> <li>2018 Operating Expenses Budget in the amount of up to USD 312.0 million, as set forth in GF/B38/04A- Revision 1 (the “2018 OPEX Budget”), which includes USD 15.92 million for the Office of the Inspector General’s 2018 operating expenses and up to USD 12.0 million as exceptional, one-off impact of the Global Health Campus infrastructure investment.</li> </ol> <p>However, the Board reaffirms the agreement that the total operating expenses over the 2017-2019 period will remain within USD 900.0 million and requires that the Secretariat undertake a comprehensive review of both the operating expense budget for 2019 and the operating expenses required to meet the Global Fund’s strategic objectives, in connection with the presentation of the 2019 operating expense budget.</p>
2017-11-14 B38 GF/B38/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Mr. Rico Gustav from the Communities constituency is designated as Rapporteur for the 38th Board Meeting.</p>
2018-01-12 B38 GF/B38/EDP08 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to <span>GF/B38/EDP08</span> (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-01-12 B38 GF/B38/EDP07 Report of the 38th Board Meeting Report of the 38th Board Meeting
<p>Report of the 38th Board Meeting</p>
2018-03-13 B38 GF/B38/EDP14 Appointment of new Member to the Global Fund Strategy Committee Appointment of new Member to the Global Fund Strategy Committee
<ol> <li>The Board approves the appointment of Madame Estelle Tiphonnet-Diawara, representing the French Constituency, as a voting member of the Strategy Committee (“SC”) for a term that will expire in May 2018, or until the appointment of her successor.</li> </ol>
2017-11-14 B38 GF/B38/DP03 Appointment of the Executive Director Appointment of the Executive Director
<p>The Board appoints Peter Sands to serve as the next Executive Director of the Global Fund for a four-year term.</p>
2017-11-15 B38 GF/B38/DP08 Targets for Key Performance Indicators 3, 6a, 6b, 6e and 12b Targets for Key Performance Indicators 3, 6a, 6b, 6e and 12b
<ol> <li>Based on the recommendation of the Audit and Finance Committee contained in GF/AFC05/DP01, the Board approves the 2018 performance target for Key<br />Performance Indicator 12b as presented in GF/B38/05A and notes the review of the 2018 target planned for Q1 2018.</li> <li>Based on the recommendation of the Strategy Committee contained in GF/SC05/DP04, the Board: <ol type="a"> <li>Approves the performance targets for Key Performance Indicators 3, 6a i, 6a ii, 6b and 6e as presented in GF/B38/05A; and</li> <li>Agrees to postpone its review and approval of the performance target for Key Performance Indicator 6a iii, until such time as a baseline is available.</li> </ol> </li> </ol>
2018-04-11 B38 GF/B38/EDP16 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B38/EDP16 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b,or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-06-24 B43 GF/B43/EDP02 Appointment of Independent Committee Members of the Standing Committees of the Board Appointment of Independent Committee Members of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of the following individuals to serve as non-voting independent members of the Audit and Finance Committee (the “AFC”) listed below, in the areas of expertise listed by their name: <ol type="i"> <li>Robert Samels, financial audit; and</li> <li>Diana Isiye, forensic investigation.</li> </ol> </li> <li>The Board approves the appointment of the following individual to serve as non-voting independent member of the Ethics and Governance Committee (the “EGC”) listed below, in the area of expertise listed by his name: <ol type="i"> <li>Mohammad Ali Mubarak Kisubi, ethics.</li> </ol> </li> <li>The Board notes each independent committee member appointed under this decision point is entitled to receive honoraria in accordance with the Global Fund’s Honorarium Framework.</li> <li>The Board notes each independent committee members appointed under this decision point shall begin their term on 24 June 2020 and serve for two years or until the appointment of their respective successors.</li> </ol> <p> </p>
2020-10-28 B43 GF/B43/EDP16 Approval of Additional Funding to Address the Health Crisis in Venezuela Approval of Additional Funding to Address the Health Crisis in Venezuela
<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding in 2021 presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B44/ER16 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B44/ER16 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B44/ER16 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 6,000,000, for the year 2021, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>
2020-10-05 B43 GF/B43/EDP13 Appointment of two Replacement Members on the Audit and Finance Committee, and one Replacement Member on the Ethics and Governance Committee Appointment of two Replacement Members on the Audit and Finance Committee, and one Replacement Member on the Ethics and Governance Committee
<ol> <li>The Board approves the appointment of Ms Shirley Carruthers, representing the Canada, Switzerland and Australia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> <li>The Board approves the appointment of Mr Chimi Dorji, representing the South East Asia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Ms Nathalie Olijslager, representing the Point Seven Constituency, as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> </ol>
2017-12-13 B38 GF/B38/EDP04 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 1,321,996,861 and EUR 52,050,991; this includes country allocation funding as well as US$ 32,737,727 of catalytic investments for matching funds.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-10-21 B43 GF/B43/EDP14 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-12-01 B38 GF/B38/EDP03 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of GF/B38/ER02 (“Table 2”);</li> </ol>
2017-11-14 B38 GF/B38/DP04 Recognition of Dr. Marijke Wijnroks Recognition of Dr. Marijke Wijnroks
<p>The Board wishes to sincerely thank Dr. Marijke Wijnroks for her leadership of the Global Fund as Interim Executive Director.</p> <p>Dr. Wijnroks has led the Secretariat’s work to begin implementing the Global Fund Strategy 2017-2022, while overseeing a tremendous volume of grant-making and also inspiring colleagues to continue innovative work that is focused on achieving impact. The Board extends its gratitude for Dr. Wijnroks’ ongoing work to prepare for the arrival of the incoming Executive Director, paving the way for the new leader to move forward with a strong and committed team.</p> <p>The Board commends Dr. Wijnroks for her longstanding dedication and contribution to the Global Fund. Prior to her leadership as Interim Executive Director, Dr. Wijnroks served as Board Member for the Point 7 constituency, and as Chief of Staff from 2013 to 2017.</p> <p>Throughout this time, her passion for the organization’s mission, her commitment to those most in need of advocacy and support, and her unwavering optimism have inspired many. The Board wishes Dr. Wijnroks continued success in all endeavors.</p>
2019-05-15 B41 GF/B41/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Allan Maleche from the Developing Country NGO constituency is designated as Rapporteur for the 41st Board Meeting.</p>
2019-05-16 B41 GF/B41/DP09 Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Aida Kurtović for her leadership as Chair of the Board. Over her time working with the Global Fund as Board Member for the Eastern Europe and Central Asia Constituency, Vice-Chair and Chair of the Board, Aida has shown a high degree of personal commitment, willingness to devote time and energy to the work of the Global Fund, and particular attention to engagement with constituencies. The Board recognizes her significant contribution to the priorities of the Global Fund over many years.</p> <p>The Board also expresses sincere gratitude to Amb. John Simon for his leadership as ViceChair of the Board. He has served the Global Fund with dedication, and has been an active driver of governance effectiveness, relationship building and collaboration that will have a lasting impact on the Global Fund.</p> <p>During their tenure, the outgoing Chair and Vice-Chair have presided over significant deliberations and decisions that will continue to shape the future of the Global Fund. Under their leadership, the Board appointed the Executive Director, guided resource mobilization efforts, adopted key decisions, including, the Revised Eligibility Policy and criteria regarding potential engagement with on-eligible countries in crisis, a strengthened Board Leadership Selection Process, the CCM evolution initiative, the Allocation Methodology and Catalytic Investments for the 2020-2022 Allocation Period, and integrated additional public donors into the Global Fund Governance Structure.</p> <p>The Board wishes Aida and John every success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively</p>
2019-11-13 B41 GF/B41/EDP18 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p><span>The Board:</span></p> <ol> <li><span>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER13 (“Table 2”);</span></li> <li><span>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>
2019-09-13 B41 GF/B41/EDP09 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for the country disease components, and its constituent grant, as listed in the Table 1 of GF/B41/ER06 (“Table 1”);</li> <li>Acknowledges the country disease components’ constituent grant will be implemented by the proposed Principal Recipient listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-10-11 B41 GF/B41/EDP12 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for the country disease component, and its constituent grant, as listed in the Table 1 of GF/B41/ER09 (“Table 1”);</li> <li>Acknowledges the country disease component’s constituent grant will be implemented by the proposed Principal Recipient listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> </ol> <p>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for the country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>
2019-05-16 B41 GF/B41/DP05 Approval of the Amended and Restated Policy on Restricted Financial Contributions Approval of the Amended and Restated Policy on Restricted Financial Contributions
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the Amended and Restated Policy on Restricted Financial Contributions, as set forth in Annex 1 to GF/B41/06 – Revision 1, which shall supersede the Amended and Restated Policy on Restricted Financial Contributions approved by the Global Fund Board in May 2017 under decision point GF/B37/DP08.</p>
2019-07-01 B41 GF/B41/EDP01 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B41/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-08-13 B41 GF/B41/EDP06 Eligibility of Venezuela’s Malaria Component for the 2020-2022 Allocation Period Eligibility of Venezuela’s Malaria Component for the 2020-2022 Allocation Period
<p>Based on the recommendation of the Strategy Committee described in GF/B41/ER04, the Board:</p> <ol> <li>Notes that the Eligibility Policy (GF/B39/02) provides that certain non-eligible countries may be recommended to be eligible for malaria in the event of a significant resurgence in malaria cases;</li> <li>Acknowledging the Secretariat and technical partners’ recommendation described in GF/B41/ER04, decides that Venezuela’s malaria component will be eligible for funding for the 2020-2022 allocation period due to significant resurgence; and</li> <li>Notes that any resultant grant(s) will be subject to and governed by existing policy and processes.</li> </ol>
2017-11-15 B38 GF/B38/DP07 Resource Mobilization Action Plan 2018-2019 Resource Mobilization Action Plan 2018-2019
<ol> <li>The Board acknowledges the update on resource mobilization (GF/B38/19), and in that context, the Global Fund’s Sixth Replenishment as a key strategic priority.</li> <li>The Board requests its new Executive Director to develop a framework for a Resource Mobilization Action Plan (2018-2019), in consultation with partners and the Audit and Finance Committee, for the 39th Board meeting, followed by a detailed and fully costed plan to the relevant Committees in June 2018.</li> </ol>
2019-08-16 B41 GF/B41/EDP08 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER05 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-12-13 B38 GF/B38/EDP05 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>1.2 Set forth below is the Secretariat’s recommendation to approve grant extensions.</p> <p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/ER05 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>
2018-04-26 B38 GF/B38/EDP18 Key Performance Indicator 12b: Availability of affordable health technologies: Affordability Key Performance Indicator 12b: Availability of affordable health technologies: Affordability
<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves the 2018 performance target for Key Performance Indicator 12b as presented in GF/B38/ER13A.</p>
2018-03-23 B38 GF/B38/EDP15 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-02-16 B38 GF/B38/EDP11 Location of the 39th Board Meeting Location of the 39th Board Meeting
<ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of the Former Yugoslav Republic of Macedonia to host the Global Fund’s 39th Board Meeting on 9-10 May 2018; and</li> <li>Acknowledges the recommendation set forth in GF/B38/ER07.                              </li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board agrees to convene the 39th Board Meeting in Skopje, Former Yugoslav Republic of Macedonia.</li> </ol>
2017-11-14 B38 GF/B38/DP05 Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws
<p>Based on the recommendation of the Ethics and Governance Committee, the Board:</p> <ol> <li>Amends Article 7.1 of the Global Fund Bylaws by deleting the text which states “One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Global Fund to the extent required by Swiss law; and”, and replacing it with the following text: “One representative of the public donors which are not part of a voting donor constituency but have each pledged a contribution of at least $10 million in the current replenishment cycle; and”;</li> <li>Requests that the Secretariat invite the public donors included in the group which are not part of a voting donor constituency but have each pledged a contribution of at least $10 million in the current replenishment cycle to join this new non-voting Board constituency and develop a process for selecting its Board representation in accordance with the Bylaws and the Operating Procedures of the Board and Committees of the Global Fund; and</li> <li>Requests the Donor Voting Group report at the 39th meeting of the Global Fund Board on its revised process for public donor seat allocation, which will ensure that new public donors, who commit to the principles in the Framework Document of the Global Fund and contribute/pledge more than a defined threshold amount for two consecutive replenishment periods, will be integrated into a voting public donor constituency.</li> </ol>
2017-12-01 B38 GF/B38/EDP02 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<ul> <li>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,317,504,873 and EUR 434,148,572; this includes country allocation funding as well as US$46,519,790 and EUR 1,782,000 of catalytic investments for matching funds.</li> </ul> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-04-11 B38 GF/B38/EDP17 Decision on the Secretariat’s Recommendation on Additional Funding Decision on the Secretariat’s Recommendation on Additional Funding
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B38/EDP17 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the revised budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding. </li> </ol>
2018-01-12 B38 GF/B38/EDP09 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>Set forth below is the Secretariat’s recommendation to approve grant extensions.             </p> <p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/EDP09 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>
2019-11-11 B41 GF/B41/EDP15 Revisions to the Committee Leadership Selection Process, the Due Diligence Process and the EGC Size and Composition Revisions to the Committee Leadership Selection Process, the Due Diligence Process and the EGC Size and Composition
<ol> <li>The Board approves (i) the proposed amendments to the Operating Procedures of the Board and Committees of the Global Fund (“BCOP”) set out in Annex 1 of GF/B41/ER11; and (ii) the proposed amendments to the Charter of the Ethics and Governance Committee (“EGC Charter”) set out in Annex 2 of GF/B41/ER11.</li> <li>The Board endorses the due diligence process overview set out in Annex 4 of GF/B41/ER11.</li> <li>The proposed amendments to the BCOP shall enter into force upon the adoption of this decision point. The proposed amendments to the EGC Charter shall enter into force upon the expiry of the term of the current EGC in May 2020.</li> </ol>
2020-11-06 B43 GF/B43/EDP18 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER18 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-10-22 B43 GF/B43/EDP15 Decision on Inspector General, contractual negotiations Decision on Inspector General, contractual negotiations
<p class="p1">The Board</p> <p class="p1">Mandates the Chair of the Board and the Vice-Chair of the Board, acting jointly</p> <ol class="ol1"> <li class="li2">to negotiate the terms of an employment agreement with each of the final candidates identified by the Inspector General Nomination Committee for the position of Inspector General</li> <li class="li2">to execute on behalf of the Global Fund the employment agreement with the Inspector General ultimately appointed by the Board, and</li> <li class="li2">to set the annual salary of the Inspector General within the salary scale applicable for the position of Inspector General, as set out in the Amended and Restated Global Fund Human Resources Policy Framework.</li> </ol>
2020-10-30 B43 GF/B43/EDP17 Decision on extending the timeline for including COVID-19 products in the wambo.org pilot Decision on extending the timeline for including COVID-19 products in the wambo.org pilot
<p>The Board:</p> <ol> <li>Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following a recommendation by the Strategy Committee; and</li> <li>Based on the recommendation of the Strategy Committee (GF/SC14/DP05), the Board approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org to 31 May 2021 and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.</li> </ol>
2004-11-19 B09 GF/B09/DP21 Operational Implications of Offering Grants in Euros and Dollars (Report of the Monitoring, Evaluation, Finance and Audit Committee – GF-B9-8) Operational Implications of Offering Grants in Euros and Dollars (Report of the Monitoring, Evaluation, Finance and Audit Committee – GF-B9-8)
<p><b>Decision Point:</b> </p><p>1.1 The choice of currency will apply only to new proposals submitted after 1 January 2005. Specifically:</p><p>1.2 Grants approved in Rounds 1 through 4 which have not been signed by 1 January 2005 will continue to be denominated in USD (i.e. the currency choice applies from Round 5 onwards)</p><p>1.3 Phase 2 renewals are not regarded as new proposals and hence will continue to be denominated in the currency chosen for Phase 1.</p><p>1.4 The currency choice must be made at the time of submission of the Proposal. Specifically, the applicant cannot change its chosen currency at any time after submission of the Proposal (including during implementation). </p>
2004-11-19 B09 GF/B09/DP20 Budget 2005-7 Budget 2005-7
<p><b>Decision Point 1</b> </p><p>The Board approves the 2005 Secretariat Budget and associated Secretariat staffing as attached in Annex 6 to the report of the October 12 - 13 MEFA meeting and as informed by that report. </p><p><b>Decision Point 2</b> </p><p>The Board takes note that the additional budgetary costs associated with any new rounds of proposals are excluded from the base 2005 budget and are highlighted separately.</p><p><b>Decision Point 3</b> </p><p>The Board approves that the agreed costs associated with Rounds 5 and 6 will be treated by the Board as an integral part of the decision to launch the relevant Round.</p>
2004-11-19 B09 GF/B09/DP07 Memorandum of Understanding Memorandum of Understanding
<p>The Board approves the Memorandum of Understanding with Roll Back Malaria attached as Annex 3 to the Report of the Governance and Partnership Committee (GF/B9/7), and requests the Secretariat to provide periodic reports on cooperation between the Fund and RBM under the agreements.</p> <p>There are no material budgetary implications of this decision.</p>
2004-11-19 B09 GF/B09/DP13 Phase 2 Funding Phase 2 Funding
<p>Decision Point 1:</p> <p>The Board revokes, until the Thirteenth Board meeting, Decision 3* of Agenda Item 5 of the Seventh Board Meeting (reference GF/B8/2), and decides that Phase 2 decisions shall be made by the Board in accordance with the processes and subject to the policies set out in Annex 3 to Board Document GF/B9/8. </p> <p>The Board approves, until the Thirteenth Board meeting, the amendments to the Bylaws and Board Operating Procedures set out in Annex 4 to Board Document GF/B9/8.</p> <p>Budgetary implications for this decision point:</p> <p>The additional cost of this decision point is estimated at US$140,000, reflecting assumptions around the need for a) some level of periodic Fund Portfolio Manager effort to work with CCMs and grant recipients to answer questions and provide clarifications to the Board in response to situations where the Board does not endorse Secretariat recommendations for Phase 2 funding; and b) costs incurred to handle the communications protocol described above, including the development of the web pages to hold the Phase 2 materials, the compilation and posting of all materials in a timely manner, and the correspondence with Board constituencies as required by the process.</p> <p>Decision Point 2:</p> <p>The Board approves, at the final Board Meeting of each year, a maximum amount for Phase 2 commitments during the next calendar year; and</p> <p>The Board asks the Secretariat to report back to the Board at every Board Meeting on the Phase 2 decisions taken since the previous Board Meeting, including the cumulative amount approved to date in the current calendar year.</p> <p>There are no material budgetary implications for this decision point. </p>
2004-11-19 B09 GF/B09/DP19 Executive Director Performance Measurement Plan Executive Director Performance Measurement Plan
<p>Decision 1:</p> <p>The Board adopts the proposed methodology for measuring the Executive Director's performance:</p> <ul> <li>Assessment of Executive Director against two dimensions (Key Performance Indicators and competencies);</li> <li>Adoption of best practice "balanced scorecard" approach to define Executive Director Key Performance Indicators;</li> <li>Use of a system that can be used consistently at all levels of the Secretariat to measure performance, and integrated into other key processes such as talent development, strategic planning and budgeting.</li> </ul> <p>Decision 2:</p> <p>The Board approves the proposed 14 Key Performance Indicators for the Executive Director and associated 2005 targets (see page 10 of Annex 1 to GF/B9/15).</p> <p>Decision 3:</p> <p>The Board approves the competency model and associated behaviors that will be used to assess how the Executive Director has achieved targets (see page 12 of Annex 1 to GF/B9/15).</p> <p>Decision 4:</p> <p>The Board agrees to the timing and process for annual evaluation of Executive Director performance:</p> <ul> <li>KPIs and targets proposed by Executive Director and approved by Board before start of year;</li> <li>Assessment of competencies led by external evaluator (professional assessment firm);</li> <li>Final report on Executive Director performance prepared by a small Performance Assessment Committee (consisting of Board members) in January-February of each year.</li> </ul> <p>Decision 5:</p> <p>The Board agrees to the adoption of 5 key Board objectives, metrics and targets for which it has responsibility (related to results and impact, mobilizing resources, supporting country-level implementation, deciding on long-term strategy and providing best practice governance ), and agrees to an annual self-evaluation against these targets (see page 19 of Annex 1 to GF/B9/15, for details).</p>
2004-11-19 B09 GF/B09/DP10 Round 5: Call for Proposals Round 5: Call for Proposals
The Board agrees to launch a Call for Proposals for Round 5 with the intention of reviewing and approving recommended proposals at the Eleventh Board Meeting in July 2005.
2004-11-19 B09 GF/B09/DP08 Ethics Committee Ethics Committee
<p>The Board amends the Committee Rules and Procedures, para. 1.2.3, to read as follows:</p><p>The Ethics Committee may conduct business only when three or more members and the Chair are present.</p><p>There are no material budgetary implications of this decision.</p>
2004-11-19 B09 GF/B09/DP16 Continuity of Services Continuity of Services
<p><b>Decision Point 1</b> </p><p>The Board adopts the following system for addressing continuity of services in the context of the Phase 2 renewal decision:</p><ol type="a"><li>A recipient (typically a CCM) whose Request for Continued Funding is not approved may submit an Extra-ordinary Request for Continued Funding for Treatment.</li><li>The Extra-ordinary Request will be limited to expenses directly related to the continuation of treatment (including medicines [which, in the case of discontinuation of antiretroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on life-long treatment under the existing proposal at the time of the Extra-ordinary Request.</li><li>The Extra-ordinary Request will be limited to the amount required to provide services directly related to the continuation of treatment for one year from the date of submission of the Extra-ordinary Request, less the amount granted under the Phase 1 proposal not disbursed at the time of the Extra-ordinary Request.</li><li>In addition to a budget, the Extra-ordinary Request shall contain a description of the steps that are being taken to find sustainable sources of financing for the people on treatment, and to ensure that treatment is being delivered effectively.</li><li>The Secretariat will review these plans for sustainable financing and the budget, and provide a recommendation to the Board on their appropriateness. The Extra-ordinary Request will not be subject to a performance-based review unless the Secretariat has pre-existing information to suggest that the approach to care and/or quality of care was inadequate. The frequency and modality for the provision of the Secretariat's recommendations, and the mechanism by which funds are committed to the Extra-ordinary Requests will be in line with the decision that the Board adopts for the broader Phase 2 decision-making process.</li><li>Throughout the process, the Secretariat will actively engage with technical partners to identify mechanisms to ensure continuity of services.</li></ol><p>There are no material budgetary implications for this decision point.</p><p><b>Decision Point 2</b> </p><p>The Board asks the Secretariat to explore with key partners (including WHO, UNAIDS, the World Bank, bilateral agencies, recipients, non-governmental organizations, and people living with the three diseases) a process that will result in long-term solutions to the issues of continuity of treatment, care and support, and prevention services for HIV/AIDS, tuberculosis, and malaria. The Secretariat should report back to the PMPC on the process before the Tenth Board Meeting. The Secretariat should report back to the Board through the PMPC on potential solutions in time for the Eleventh Board Meeting.</p><p>Budgetary implications: The additional cost of implementing this recommendation is estimated at $90,000.</p>
2004-11-19 B09 GF/B09/DP17 Reprogramming in the light of scientific evidence Reprogramming in the light of scientific evidence
<p>Decision Point 1</p> <p>The Board decides to use the following language in its decisions for the approval of Category 1 and 2 proposals in order to recognize that the Secretariat may ask the Technical Review Panel to re-review proposals in the course of implementation:</p> <p>"This approval is subject to re-review by the Technical Review Panel if, after consultation with the recipient but in the sole discretion of the Global Fund, changes in scientific evidence (as identified in collaboration with WHO and other technical partners) materially affect the proposal."</p> <p>The Board further decides that following such re-review, should the TRP recommend that, in light of the new scientific evidence, the approach taken in the proposal should be changed, the Board should reconsider the approval of the proposal. The recipient will have the opportunity to submit a revised version of the relevant parts of the proposal prior to the Board's decision.</p> <p>There are no material budgetary implications for this decision point. </p> <p>Decision Point 2</p> <p>The Board expands the circumstances in which the Phase 2 decision-making process can be accelerated by modifying the existing decision on the Phase 2 process, as set forth in GF/B8/2, page 7, to read as follows:</p> <p>"The decision may be taken earlier in cases of (i) accelerated implementation; (ii) severe exchange rate fluctuations; or (iii) additional financing needs resulting from changes in scientific evidence."</p> <p>There are no material budgetary implications for this decision point.</p>
2004-11-19 B09 GF/B09/DP11 Comprehensive Funding Policy Comprehensive Funding Policy
<p><b>Decision Point 1:</b> </p><p>The Board requests the Secretariat to commission a background study of the options and choices available to the Global Fund in its fiscal management structure and processes. </p><p>There are no material budgetary implications for this decision point as it is anticipated that this study can be done on a pro-bono basis.</p><p><b>Decision Point 2:</b> </p><p>The Board requests the MEFA Committee to pursue a review of the Comprehensive Funding Policy and report back at the Tenth Board meeting in April 2005. </p><p>There are no material budgetary implications for this decision point.</p>
2004-11-19 B09 GF/B09/DP14 Report of the Ad-Hoc Working Group on Technical Support Report of the Ad-Hoc Working Group on Technical Support
<p>Decision Point 1</p> <p>The Board mandates the Secretariat to develop an early warning system to identify technical support needs and engage, in a timely and coordinated manner, partners in technical collaboration.</p> <p>Decision Point 2</p> <p>The Board requests the Secretariat to work closely with partners (multi- and bilateral partners, international and national NGOs, horizontal collaboration initiatives, private sector, academia) to facilitate the provision of technical support throughout the life cycle of the grant (proposal development, grant negotiation, implementation, monitoring and evaluation).</p> <p>Decision Point 3</p> <p>The Board mandates the appropriate committee(s) to provide guidance on the allocation of a specified proportion of grant money to be used for technical support to CCMs.</p> <p>Decision Point 4</p> <p>The Board recognizes the increased need for funding to respond to the rising demand placed on partners for technical support. The Board further mandates the appropriate committee(s) to provide guidance on the development of:</p> <p>a. specific funding mechanisms for technical partners to effectively respond to the growing technical support needs.</p> <p>b. appropriate funding strategies to facilitate the meaningful participation of affected communities and civil society organizations in CCMs and all phases of grant implementation.</p>
2004-11-19 B09 GF/B09/DP05 Partnership Forum Report Partnership Forum Report
<p>Decision Point 1:</p> <p>The Board takes note of the lessons learned presented in the report and instructs future Steering Committees and the Secretariat to take these into account for future events.</p> <p>There are no material budgetary implications for this recommendation.</p> <p>Decision Point 2</p> <p>The Board will consider the reconstitution of the Partnership Forum Steering Committee (PFSC) at its Eleventh meeting in July 2005. </p> <p>There are no material budgetary implications for this recommendation.</p>
2004-11-19 B09 GF/B09/DP12 Committee Review Report Committee Review Report
<p>The Board adopts the following recommendations on Committee structure, role and process:</p> <ul> <li>Streamline the number of core Board Committees from 6 to 4 to reflect the changing needs of the Fund<br /><br /> <ul> <li>Strategy &amp; Policy Committee</li> <li>Portfolio Management Committee</li> <li>Finance &amp; Audit Committee</li> <li>Ethics Committee</li> </ul> </li> </ul> <ul> <li>Maintain the Ethics Committee as a small standing committee. The Committee is to meet as ethical issues arise and are referred by the Board. The Committee will maintain its current size and continue to be comprised of Board members or their alternates only</li> </ul> <ul> <li>Require financial literacy to serve as the Chair or Member of the Finance &amp; Audit Committee</li> </ul> <ul> <li>Require Committee Chair selection to explicitly consider the Chair's Committee leadership and management skills, specifically an ability to enforce adherence to the Committee's role and an ability to drive meetings efficiently</li> </ul> <ul> <li>Confirm that only one delegate is permitted per Committee and that that delegate is expected to be available for all Committee meetings. In the event that membership must permanently change from one delegate to another, permit an overlap period of one committee meeting</li> </ul> <ul> <li>Confirm the role of Committees to frame issues and bring options and recommendations on major strategies and policies, with supporting rationale, to the full Board for decision - to provide operational oversight but otherwise leave implementation activities to the Secretariat</li> </ul> <ul> <li>Request Committee Chairs and Secretariat liaisons hold quarterly telephone calls. Parties should confirm that each is adhering to respective roles and discuss points of issue. This confirmation should be sent to the Board Chair and Vice Chair. Lack of agreement on roles should be reported to the Board Chair and Vice Chair for assistance in resolution if required.</li> </ul> <ul> <li>Eliminate duplicate assignment of issues to Committees and resolve issues of consistency and duplication at the end of each Board meeting among decisions taken by the Board</li> </ul> <ul> <li>Create a standard initiation manual for new Committee members and staff that communicates the roles and functions of the Committees and staff and expectations of Committee members to be approved by the Strategy and Policy Committee</li> </ul> <ul> <li>Committees should monitor their own performance and conduct an annual "health check" - formal role and scope should be assessed every 2-3 years</li> </ul>
2006-11-03 B14 GF/B14/DP03 Approval of Agenda Approval of Agenda
The agenda for the Fourteenth Board Meeting (GF/B14/1, Revision 2) is approved, as amended at the Fourteenth Board Meeting.
2006-11-03 B14 GF/B14/DP26 Process for the Development of a Policy on Product and Services Contributions Process for the Development of a Policy on Product and Services Contributions
The Board endorses the "Draft Paper on a Process to Develop a Policy on Donations of Products and Services" (GF/B14/9, Annex 7) and requests the Chair of the Finance and Audit Committee (FAC), in consultation with the Policy and Strategy Committee (PSC), to constitute the Joint Steering Group on Product and Service Donations as per the parameters outlined in Annex 7 of GF/B14/9. The Board requests the FAC to report back on progress at the Fifteenth Board meeting.
2006-11-03 B14 GF/B14/DP33 Policy on Secretariat Procurement of Goods and Services Policy on Secretariat Procurement of Goods and Services
The Board approves the amendments to the document entitled "Global Fund Policy on Secretariat Procurement of Goods and Services" (approved at the Fifth Board Meeting and presented as Annex 4 to GF/B5/8) as presented in Annex 6 to the Report of the Finance and Audit Committee (GF/B14/9).
2006-11-03 B14 GF/B14/DP23 Requesting Development of Roadmap for Collaboration with UNITAID Requesting Development of Roadmap for Collaboration with UNITAID
The Board requests the Policy and Strategy Committee to work with the Secretariat and the Finance and Audit Committee to develop a roadmap for future collaboration with UNITAID and present it for approval by the Board at the Fifteenth Board Meeting. 
2006-12-08 B14 GF/B14/EDP03 Action Plan for the Selection of the Executive Director of the Global Fund Action Plan for the Selection of the Executive Director of the Global Fund
The Board approves the Action Plan for the Selection of the Executive Director of the Global Fund, as presented by the Nomination Committee on 1 December 2006.
2004-11-19 B09 GF/B09/DP02 Approval of the Agenda Approval of the Agenda
<ul> <li>The agenda for the Ninth Board Meeting is approved.</li> </ul>
2004-11-19 B09 GF/B09/DP15 Technical Review Panel (TRP) Technical Review Panel (TRP)
<p>Decision Point 1</p> <p>The Board approves the list of persons contained in Annex 3 of the Report of the Portfolio Management and Procurement Committee (GF/B9/9) who have been recommended by the Portfolio Management and Procurement Committee and the Executive Director to fill the vacancies on the Technical Review Panel.</p> <p>There are no material budgetary implications for this decision point. </p> <p>Decision Point 2</p> <p>The Board approves the list of persons contained in Annex 4 that have been recommended by the PMPC and the Executive Director to comprise the TRP Support Group.</p> <p>There are no material budgetary implications for this decision point. </p> <p>Decision Point 3</p> <p>Board decides that the language used in its decisions for the approval of Category 2 proposals shall be modified to read as follows:</p> <p>"Recommended proposals provided adjustments and clarifications are met within a limited timeframe (the initial reply to TRP adjustments and clarifications should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further adjustments and clarifications should be completed within 4 months from the receipt of the initial reply from the applicant). The TRP Chair and/or Vice-Chair shall give final approval based on consultations with the primary and secondary reviewers."</p> <p>There are no material budgetary implications for this decision point. </p>
2004-11-19 B09 GF/B09/DP09 Round 5: Guidelines for Proposals and Call Round 5: Guidelines for Proposals and Call
The Board approves the Guidelines for the Fifth Call for Proposals.
2005-03-18 B09 GF/B09/EDP01 Extension of Deadline for the Signing of a Grant Aagreement for the Andean Regional Project (Malaria) Extension of Deadline for the Signing of a Grant Aagreement for the Andean Regional Project (Malaria)
The Board extends the deadline for the signing of a grant agreement for the Andean Regional Project - Malaria control in cross border areas of the Andean countries for three months to 19 June 2005.
2020-08-25 B43 GF/B43/EDP11 Extension of terms of the Board Chair and Vice-Chair Extension of terms of the Board Chair and Vice-Chair
<p>In response to the exceptional circumstances related to the current Covid-19 pandemic, the Board:</p> <ol> <li>Extends its recognition to Dr Donald Kaberuka, Chair of the Board, and Lady Roslyn Morauta, Vice-Chair of the Board, for their service since May 2019;</li> <li>Thanks the Ethics and Governance Committee for their recommendation and notes the analysis and review process preceding this decision; and</li> <li>Extends the terms of Dr Donald Kaberuka, as Chair of the Board, and Lady Roslyn Morauta, as Vice-Chair of the Board, to the adjournment of the first Board Meeting in 2022.</li> </ol>
2020-09-30 B43 GF/B43/EDP12 Extension of C19RM Timeline and Operational Flexibility for COVID-19 Extension of C19RM Timeline and Operational Flexibility for COVID-19
<p>The Board agrees that COVID-19 continues to pose a grave threat to the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and strengthen systems for health, and that continued support for country responses to COVID-19 is critical to safeguard Global Fund programs and country health systems. The Board acknowledges its previous decisions establishing the Global Fund COVID-19 Response Mechanism (C19RM) to provide additional support for country responses to COVID-19 (GF/B42/EDP11), and approving certain time-bound operational flexibilities to ensure the continued delivery of the Global Fund mission during the pandemic (GF/B42/EDP10). Noting that COVID-19 continues to jeopardize country health systems and impede progress in the Global Fund’s mission, and that additional funds may become available for C19RM, the Board:</p> <ol> <li>Approves that the Secretariat may approve requests for C19RM funds through 15 April 2021;</li> <li>Affirms that all other previously approved principles under GF/B42/EDP11 will continue to apply to C19RM;</li> <li>Requests the Secretariat to return to the Board, through its Committees as relevant, for additional consideration and approval should further extensions of C19RM be required as the pandemic continues to evolve, or if total additional funding for C19RM exceeds USD 500 million; and</li> <li>Approves that the operational flexibility under paragraph 3 of GF/B42/EDP10, delegating authority to the Secretariat to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing for Expert Review Panel-approved products, vector control products, and condoms, where such testing may delay the delivery of products to countries, will apply through 15 April 2021.</li> </ol>
2020-08-06 B43 GF/B43/EDP09 Secretariat Appointment Secretariat Appointment
<p>The Board hereby notes the Executive Director’s appointment of the following senior management official of the Global Fund:</p> <ol type="i"> <li>Adda Faye, as Chief Financial Officer.</li> </ol>
2020-08-03 B43 GF/B43/EDP10 Appointment of the Inspector General Nomination Committee Membership Appointment of the Inspector General Nomination Committee Membership
<p>The Board appoints the following individuals to serve as members of the Inspector General Nomination Committee (Nomination Committee) in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B43/DP03 and set out in Annex 1 to GF/B43/12 – Revision 1:</p> <ul> <li>Grace Rwakarema, Chair</li> <li>Thomas Alexander, Vice-Chair</li> <li>Allan Maleche, Member;</li> <li>Thomas Morrow, Member;</li> <li>David Webb, Member;</li> <li>Diana Isiye; Independent Member and,</li> <li>Norbert Hauser, Independent Member.</li> </ul>
2020-06-30 B43 GF/B43/EDP06 Indicator Revisions and Target Setting for Key Performance Indicators 6a: Resilient and Sustainable Systems for Health: - Procurement; 6f: Alignment with National Strategic Plans; 9C: Key populations and human rights domestic investments and 12b: Availability of affordable health technologies: Affordability Indicator Revisions and Target Setting for Key Performance Indicators 6a: Resilient and Sustainable Systems for Health: - Procurement; 6f: Alignment with National Strategic Plans; 9C: Key populations and human rights domestic investments and 12b: Availability of affordable health technologies: Affordability
<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves: <ol type="a"> <li>the revisions for Key Performance Indicator 6a as presented in GF/B43/ER06;</li> <li>the performance target for Key Performance Indicator 6f as presented in GF/B43/ER06; and</li> <li>the revisions for Key Performance Indicator 9c as presented in GF/B43/ER06.</li> </ol> </li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the revision to the 2020 performance target for Key Performance Indicator 12b as presented in GF/B43/ER06.</li> </ol>
2020-05-14 B43 GF/B43/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 43rd Board Meeting (GF/B43/01) is approved.</p>
2020-06-22 B43 GF/B43/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B43/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-06-25 B43 GF/B43/EDP04 Amended and Restated Policy on Conflict of Interest Amended and Restated Policy on Conflict of Interest
<ol> <li class="x_MsoNormal">Based on the recommendation of the Ethics and Governance Committee (GF/EGC12/EDP02), the Board approves the amended and restated Policy on Conflict of Interest, as set forth in Annex 1 to GF/B43/ER04;</li> <li class="x_MsoNormal"><span></span>Accordingly, the Board acknowledges that this decision point and the amended and restated Policy on Conflict of Interest shall supersede the decision point GF/B27/DP05, the previous Policy on Ethics and Conflicts of Interest for Global Fund Institutions as set forth in Annex 1 to GF/B27/07 and the previous Declaration of Interest Form set forth in Annex 2 to GF/B27/07.</li> </ol>
2020-07-07 B43 GF/B43/EDP07 Extending the wambo.org pilot to include COVID-19 products Extending the wambo.org pilot to include COVID-19 products
<ol> <ol> <li>The Board recognizes that the COVID-19 pandemic remains a global public health emergency and that failure to control the pandemic threatens to derail the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and to strengthen systems for health. The Board further recognizes the importance of ensuring rapid availability of quality COVID-19 products as part of the global response to COVID-19, and the significant benefits that beneficiaries in Global Fund-eligible and transitioned countries could potentially gain from improved access to pooled procurement volumes of these products.</li> <li>The Board notes the Secretariat is engaging with partners, notably WHO, UNICEF, UNITAID, GDF, FIND, Africa CDC and the newly-created Africa Medical Supply Platform, and taking an active role in the ACT-A partnership and the Diagnostics Consortium, to ensure collaboration, coherence and flexibility in providing procurement options and solutions for countries to address the challenges of managing supply constraints and access to quality health products in the context of COVID-19. In this rapidly evolving context, the Board wishes to leverage wambo.org, and the pilot for non-Global Fund-financed transactions as defined in GF/B42/DP05 (the Pilot) to facilitate broader access to COVID-19 product.</li> <li>The Board notes that the Secretariat is using the wambo.org platform to facilitate the procurement of certain COVID-19 products purchased by Global Fund Principal Recipients. The Board further notes that the framework of eligibility and quality assurance defined in GF/B42/EDP11 for COVID-19 products is being proposed to apply to products available to all eligible buyers on wambo.org.</li> <li>In order to allow broader access to these products, as presented in GF/B43/ER07, the Board decides to formally extend the scope of the Pilot to include for eligible buyers as defined in GF/B42/DP05, the purchase of all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients.</li> <li>Such non-Global Fund-financed transactions for COVID-19 products will:<br />- be individually subject to agreement by the Global Fund and, if applicable, to agreement by the product catalogue owners or manufacturers; <br />- not count towards the cap of USD 50 million of transactions for the Pilot otherwise applicable to non-COVID-19 products;<br />- be issued as Purchase Orders by wambo.org within the period ending in 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee.</li> <li>As with the Pilot, use of the wambo.org platform for non-Global Fund-financed transactions will remain optional for eligible buyers of COVID-19 products.</li> <li>Recognizing the extraordinary conditions due to the COVID-19 pandemic under which non-Global Fund-financed transactions for COVID-19 products will be processed, and the importance of maintaining the integrity of the Pilot as currently established, the Board further decides:<br />a. reporting of transactions for COVID-19 products will be included in the biannual reporting on the Pilot to the Strategy Committee, following the same principles as other transactions, in particular with respect to the determination of metrics for reporting, which will be agreed by the Strategy Committee in October 2020. However, COVID-19 product transactions will be disaggregated from reporting on other Pilot transactions, so as to enable integration with overall reporting on the COVID-19 response, and to avoid distorting reporting on the original Pilot.<br />b. these COVID-19 transactions, disaggregated from other Pilot transactions, will be included in the final independent evaluation of the Pilot, to be delivered no later than end of 2022.<br />c. with the Strategy Committee, to resume broader discussions of wambo.org’s future strategy for the Pilot and its role and market influence within the development of the Phase 2 of the Market Shaping Strategy and the next Global Fund Strategy in 2020-2021.</li> </ol> </ol>
2020-07-28 B43 GF/B43/EDP08 Approval of the Report of the 43rd Board Meeting Approval of the Report of the 43rd Board Meeting
<p class="x_MsoNormal"><span>The Board approves the Report of the 43<sup>rd</sup> Board Meeting, as set forth in GF/B43/13.</span></p>
2020-05-15 B43 GF/B43/DP03 Approval of the Terms of Reference of the Inspector General Nomination Committee and revisions to the Terms of Reference of the Inspector General Approval of the Terms of Reference of the Inspector General Nomination Committee and revisions to the Terms of Reference of the Inspector General
<p>The Board:</p> <ol> <li>Notes its responsibilities with regard to the recruitment process of the Inspector General as set out in Article 36 of the Operating Procedures of the Board and Committees of the Global Fund to Fight AIDS, Tuberculosis and Malaria;</li> <li>Based on the recommendation of the Chair and Vice-Chair of the Board (the “Board Leadership”), in consultation with the Ethics and Governance Committee, and its review of the contents of GF/B43/12 – Revision 1 approves: <ol type="a"> <li>The terms of reference of the 2020 Inspector General Nomination Committee, as set out in Annex 1 to GF/B43/12 – Revision 1; and,</li> <li>The revised terms of reference of the Inspector General, as presented in Annex 2 to GF/B43/12 – Revision 1, which shall enter into force upon the commencement of the term of the next Inspector General.</li> </ol> </li> <li>Requests the Board Leadership to submit a Chair, Vice-Chair and the membership of the nomination committee to the Board for approval.</li> </ol>
2020-06-25 B43 GF/B43/EDP05 Amended and Restated Code of Conduct for Governance Officials Amended and Restated Code of Conduct for Governance Officials
<ol start="1" type="1"> <li class="x_MsoListParagraphCxSpLast"><span>Based on the recommendation of the Ethics and Governance Committee (GF/EGC12/EDP01), the Board approves the revisions to the Code of Conduct for Governance Officials, as set forth in Annex 1 and 2 to GF/B43/ER05, developed in furtherance of the Ethics and Integrity Framework adopted by the Board at its 32nd Meeting (GF/B32/DP09);</span></li> <li class="x_MsoListParagraphCxSpLast">Accordingly, the Board acknowledges that this decision point and the revisions to the Code of Conduct for Governance Officials shall supersede the approval of the previous Code of Ethical Conduct for Governance Officials, as set forth in Annex A to GF/B33/15 – Revision 2, pursuant to paragraph 2 of the decision point GF/B33/DP10.</li> </ol>
2020-05-14 B43 GF/B43/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Ambassador Stéphanie Seydoux from the France constituency is designated as Rapporteur for the 43rd Board Meeting.</p>
2004-11-19 B09 GF/B09/DP03 Approval of Report of the Eighth Board Meeting Approval of Report of the Eighth Board Meeting
<ul> <li>The report of the Eighth Board Meeting is approved.</li> </ul>
2004-11-19 B09 GF/B09/DP18 Quality Assurance of Single- and Limited-Source Pharmaceutical Products Quality Assurance of Single- and Limited-Source Pharmaceutical Products
<p>The Board replaces the phrase "Option (c) is applicable only until December 31, 2004" in the Board decision on quality assurance (compliance with quality standards) from the Third Board Meeting (GF/B4/2, p. 23) with "Option (c) is applicable only until December 31, 2005</p><p>The Board invites the World Health Organization to work with the Secretariat to assess the impact of the expiry of the transition period established in Option (c) and to develop options on the quality assurance of single- and limited-source products, and to report back to the PMPC in time for the development of recommendations for the Tenth Board Meeting.</p>
2004-11-19 B09 GF/B09/DP04 Replenishment Leadership Replenishment Leadership
The Board approves the nomination of Mr Kofi Annan, Secretary-General of the United Nations, as Chair and Mr Sven Sandström as Vice Chair of the Voluntary Replenishment Mechanism of the Global Fund. The Board expresses its appreciation to both Mr Annan and Mr Sandström for their commitment and their willingness to undertake this important task.
2004-11-19 B09 GF/B09/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<ul type="disc"><li>Ms. Lucia Fiori from the Italian Constituency is designated as Rapporteur for the Ninth Board Meeting.</li></ul>
2004-11-19 B09 GF/B09/DP06 Country Coordinating Mechanisms (CCMs) (Report of the Governance and Partnership Committee) Country Coordinating Mechanisms (CCMs) (Report of the Governance and Partnership Committee)
<p>Decision Point 1</p> <p>The Board adopts the following requirements for CCMs:</p> <ol type="a"> <li>All CCMs are required to show evidence of membership of people living with and/or affected by the diseases;</li> <li>CCM members representing the non-government sectors must be selected by their own sector(s) based on a documented, transparent process, developed within each sector;</li> <li>CCMs are required to put in place and maintain a transparent, documented process to: <ol type="i"> <li>Solicit and review submissions for possible integration into the proposal;</li> <li>Nominate the Principal Recipient and oversee program implementation;</li> <li>Ensure the input of a broad range of stakeholders, including CCM members and non-members, in the proposal development and oversight process</li> </ol> </li> </ol> <p>There are no material budgetary implications of this decision.</p> <p>Decision Point 2</p> <p>The Board agrees to make the following word substitution in the CCM Guidelines:</p> <p>When the PRs and Chair or Vice Chairs of the CCM are the same entity, the CCM must should have a written plan in place to mitigate against this inherent conflict of interest.</p> <p>There are no material budgetary implications of this decision.</p>
2004-11-19 B09 GF/B09/DP22 Board Calendar Board Calendar
<p>Decision Point 1:</p> <p>The Board approves the Board Calendar for 2005 as attached.</p> <p>Decision Point 2:</p> <p>The Board accepts with gratitude the offer from Sweden to host the 1<sup>st</sup> Replenishment Conference in Stockholm.</p> <p>Decision Point 3:</p> <p>The Board accepts with gratitude the offer from the United Kingdom to host the 2<sup>nd</sup> Replenishment Conference.</p> <p>Decision Point 4:</p> <p>The Board accepts the invitation of Morocco to host the Twelfth Board meeting, and Latin America and the Caribbean to host a Board Meeting in 2008.</p>
2019-05-16 B41 GF/B41/DP07 2018 Statutory Financial Statements 2018 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2018 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B41/04.</p>
2006-12-01 B14 GF/B14/EDP02 Approval of Bridge Funding Recommendations for Madagascar Malaria Grant Approval of Bridge Funding Recommendations for Madagascar Malaria Grant
The Board approves additional funding of not more than US$2,412,466 for the Madagascar Round 4 malaria grant to Population Services Inc. (Grant Number MDG-405-G07-M).
2019-05-15 B41 GF/B41/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 41st Board Meeting (GF/B40/01) is approved.</p>
2019-10-09 B41 GF/B41/EDP11 Appointment of a Replacement Member on the Audit and Finance Committee Appointment of a Replacement Member on the Audit and Finance Committee
<p>The Board approves the appointment of Dr. Mohsen Asadi-Lari, representing the Eastern Mediterranean Region Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2020.</p>
2013-10-01 B29 GF/B29/EDP11 Revising the distribution of funding by disease in the new funding model allocation methodology Revising the distribution of funding by disease in the new funding model allocation methodology
<p>The Board decides:</p> <ol> <li>Prior to the initial allocation of available resources to Country Bands for the 2014 – 2016 allocation period, the Secretariat will apportion such resources among the three diseases based on the following distribution: 50% for HIV/AIDS, 32% for malaria, and 18% for tuberculosis.</li> <li>In accordance with Board Decision GF/B27/DP7, applicants will have flexibility in deciding how to allocate financing between the three diseases for their individual country programs.</li> <li>The Board reaffirms its prior decision to recognize the importance of core TB-HIV collaboration services to achieve successful outcomes in TB and HIV grants (GF/B18/DP12). Taking note of the insufficient progress in implementing this prior decision on TB-HIV collaboration services, the Board requests the Secretariat to ensure integrated TB-HIV services are addressed in the country-dialogue and concept-note development process for countries with high TB-HIV co-infection rates, as set forth in the WHO policy on collaborative TB/HIV activities: “Guidelines for National Programs and Other Stakeholder” (2012).</li> <li>The Strategy, Investment and Impact Committee will review this decision and propose appropriate modifications to the Board for approval prior to the 2017 – 2019 allocation period.</li> </ol>
2013-08-23 B29 GF/B29/EDP07 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (as indicated in the “Recommended Incremental Funding under the New Funding Model” column), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 8,941,930 for the following grants: PHL-607-G08-H ; SLB-810-G01-T ;ZAM-708-G19-M ; ZAM-711-G26-T</p>
2013-06-18 B29 GF/B29/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the Twenty-Ninth Board Meeting (GF/B29/1) is approved.</p>
2013-10-04 B29 GF/B29/EDP12 Appointment of Independent Member of the Audit and Ethics Committee Appointment of Independent Member of the Audit and Ethics Committee
<ol> <li>The Board approves the appointment of Mr. Mohamed Abdellatif as an independent member of the Audit and Ethics Committee (the “AEC”) to fill one current vacancy.</li> <li>Mr. Mohamed Abdellatif shall serve on the AEC until the end of his predecessor’s term.</li> </ol>
2013-09-06 B29 GF/B29/EDP08 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants) Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 842,017,272 for the following grants: CIV-809-G09-M ; GEO-H-GPIC ; GEO-T-GPIC ; GYA-304-G01-H ; LBR-M-PII ; LBR-M-MOH ; MKD-011-G04-T ; MEA-011-G01-H ; MEI-011-G01-H ; NGA-H-NACA ; NGA-H-ARFH ; NGA-H-SFHNG ; SAF-H-RTC ; SAF-910-G09-H ; SAF-304-G04-H ; SAF-H-NDOH ; SAF-H-NACOSA ; South Africa Grant TBD ; TNZ-M-MOFEA ; TNZ-809-G11-M ; TNZ-102-G01-M ; ZAM-811-G28-H ; ZAM-011-G29-H</p>
2013-06-18 B29 GF/B29/DP03 Approval of Report of the Twenty-Eighth Board Meeting Approval of Report of the Twenty-Eighth Board Meeting
<p>The report of the Twenty-Eighth Board Meeting (GF/B29/2) is approved.</p>
2013-11-01 B29 GF/B29/EDP13 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants) Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 401,799,230 for the following grants: AGO-911-G05-T ; CIV-910-G12-H ; CIV-910-G13-H ; ZAR-M-MOH ; ZAR-M-SANRU ; ZAR-M-PSI ; GHN-809-G11-H ; GUA-311-G05-H ; GUA-311-G06-H ; MLW-H-NAC ; MSA-910-G01-H ; NMB-T-MoHSS ; THA-M-DDC</p>
2013-08-16 B29 GF/B29/EDP04 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 56,526,508 for the following grants: BAN-T-NTP ; BAN-T-BRAC ; IDA-708-G14-H ; IDA-708-G15-H ; IND-M-MOH ; JAM-708-G02-H ; RUS-506-G05-H ; SUD-708-G10-M ; ZIM-809-G12-T</p>
2013-08-23 B29 GF/B29/EDP06 Decision on the Secretariat’s Funding Recommendations for Grant Renewals Decision on the Secretariat’s Funding Recommendations for Grant Renewals
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1 in the amount indicated for such grant, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for such grant shall be pursued by the Secretariat consistent with the principles of the recommendation set forth in the related Memo submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that the funding for the renewal of such grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of such grant shall be the sum of the amount set out in Table 1 below for such grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 6,026,955 for the following grant: MYS-H-MAC</p>
2013-08-02 B29 GF/B29/EDP02 Revision to the Declaration of Interest Form for Assessing Conflicts of Interest Revision to the Declaration of Interest Form for Assessing Conflicts of Interest
<p>The Board approves the revised Declaration of Interest Form attached as Annex 1 of GF/B29/ER1.</p>
2013-06-19 B29 GF/B29/DP06 Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Simon Bland for his leadership as Chair of the Board. He has served the Global Fund with a high degree of personal commitment and passion. During his tenure, Simon has successfully guided the Board through significant challenges and important decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Mphu Ramatlapeng for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mphu has been instrumental in driving governance reform, coordinating important deliberations, and facilitating decisions of the Board that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board through the Consolidated Transformation Plan, the development of a new funding model, and the appointments of the Executive Director and the Inspector General have pointed the Global Fund towards continued success and efficiency in achieving its mission.</p> <p>The Board wishes Simon and Mphu all the success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively.</p>
2013-06-18 B29 GF/B29/DP01 Appointment of Rapporteur Appointment of Rapporteur
Dr. Aziza Bennani from the Eastern Mediterranean Region constituency is designated as Rapporteur for the Twenty-Ninth Board Meeting.
2013-08-16 B29 GF/B29/EDP03 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants) Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Program Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 602,905,795 for the following grants: BLR-S10-G04-T ; CAM-H-NCHADS ; CAF-810-G08-M ; ECU-910-G06-H ; ECU-910-G07-H ; GIN-T-MSHP ; GYA-M-MOH ; HND-H-CHF ; HND-T-UECFSS ; IND-T-MOH ; IND-809-G10-T ; LAO-T-GFMOH ; MAL-809-G07-H ; MON-T-MOH ; MOZ-911-G09-H ; MOZ-911-G10-H ; NGA-809-G11-M ; NGA-809-G14-M ; STP-M-UNDP ; SNG-T-PLAN ; SNG-T-PNT ; SRL-911-G15-S</p>
2013-11-01 B29 GF/B29/EDP14 Decision on the Secretariat’s Funding Recommendations for Interim Applicant Decision on the Secretariat’s Funding Recommendations for Interim Applicant
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 285,226 for the following grant: SWZ-809-G06-M</p>
2013-09-06 B29 GF/B29/EDP09 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 27,934,678 for the following grants: CMR-011-G11-H ; NGR-708-G08-H ; RUS-304-G01-H ; YEM-708-G06-M</p>
2013-06-18 B29 GF/B29/DP04 Appointment of Inspector General Appointment of Inspector General
<p>The Board:</p> <ol> <li>Selects Martin O'Malley to serve as the next Inspector General of the Global Fund for a six-year term beginning on or around September 2013</li> <li>Requests the Board Chair and Vice-Chair to facilitate the appointment of Martin O'Malley to the position of Inspector General.</li> </ol>
2003-01-31 B04 GF/B04/DP05 Election of the Chair and Vice Chair Election of the Chair and Vice Chair
<p>1. The nomination of Secretary Tommy G. Thompson of the United States of America for Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis &amp; Malaria.</p><p>2. The nomination of Doctor Suwit Wibulpolprasert of Thailand for Vice Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria.</p>
2003-01-31 B04 GF/B04/DP18 Report of the Portfolio Management and Procurement Committee: Portfolio Management: Revising Eligibility Criteria Report of the Portfolio Management and Procurement Committee: Portfolio Management: Revising Eligibility Criteria
<p>The PMPC, after considering the report from the Secretariat recommends the following to the Board regarding the revision of eligibility criteria:</p> <ul> <li>Poverty and disease-related need (which encompasses both current disease burden and risk of growth) are the criteria that will be used to determine eligibility to apply for financing from the Global Fund.</li> </ul> <ul> <li>For the Third Round of applications to the Global Fund:</li> </ul> <p>a. Countries classified as "Low Income" by the World Bank are fully eligible to apply for support from the Global Fund;</p> <p>b. Countries classified as "Lower-Middle Income" by the World Bank are eligible to apply for support from the Global Fund but must meet additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources;</p> <p>c. Countries classified as "Upper-Middle Income" by the World Bank are eligible to apply for support if they face a very high current disease burden (a list of such countries will be provided to the Board and included in the Guidelines for Proposals) and they meet the additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources;</p> <p>d. Countries classified as "High Income" by the World Bank are not eligible to apply for support from the Global Fund;</p> <ul> <li>For the fourth and subsequent Rounds of applications to the Global Fund, WHO and UNAIDS will be asked to provide matrices categorizing countries based on disease-related need and poverty. These matrices will be used as the basis for categorization of eligible countries for each disease and will be presented to the Fifth Board meeting for use beginning with the Fourth Round of applications to the Global Fund.</li> </ul>
2013-08-02 B29 GF/B29/EDP01 Appointment of the External Auditor Appointment of the External Auditor
Based on the recommendation of the Audit and Ethics Committee, the Board approves the appointment of Ernst &amp; Young as the Global Fund’s external auditor for the 2013 fiscal year.
2003-01-31 B04 GF/B04/DP22 Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): 2003 Work Plan and Budget Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): 2003 Work Plan and Budget
<ul> <li>Recommend approval of the 2003 Secretariat Work Plan and Budget as present in Board Document GF/B4/11.</li> </ul> <ul> <li>(Deferred to GF/B4/11 report decisions) Direct the MEFA Committee to review the performance of the Secretariat on the 2003 Work Plan and Budget and report their findings at the June and October meetings of the Board in 2003.</li> </ul> <ul> <li>Direct the MEFA Committee to review the trustee agreement and performance and direct the Secretariat to negotiate new terms and fees for the trustee basedon emerging Global Fund needs.</li> </ul>
2013-06-19 B29 GF/B29/DP05 Approval of the 2012 Annual Report Approval of the 2012 Annual Report
The Board approves the 2012 Annual Report of the Global Fund, as set forth in GF/B29/11.
2013-10-01 B29 GF/B29/EDP10 Division between Indicative and Incentive Funding Division between Indicative and Incentive Funding
<p>The Board</p><ol><li>The Board affirms its goal of raising US$ 15 billion so that it can effectively support countries in their fight against HIV/AIDS, tuberculosis and malaria in the 2014 – 2016 period. The available resources will be awarded to indicative and incentive funding to invest strategically in areas where there is high potential to achieve impact and value for money while rewarding ambitious, high-quality expressions of full demand, based on robust National Strategic Plans or investment cases. The 2014 – 2016 allocation period is the first where principles adopted under the new funding model (GF/B28/DP4) will be applied. The Board notes that the current replenishment cycle will result in unique actions in order to adjust investments in notionally over- and under-allocated countries. Accordingly, the Board acknowledges implementation methodology developed for the 2014 – 2016 allocation period will be reviewed and modified, as appropriate, for future allocation periods. <br/><br/></li><li>The Board decides: <br/><br/><ol><li type="a">For each allocation period, a fixed percentage of the amount of resources approved by the Board for initial allocation (the “Initial Allocation”), after deduction of the amount allocated to the Country Band corresponding to higher income (GNI per capita) and lower disease burden (“Band 4”), will be used for allocating Incentive Funding to Country Bands 1, 2 and 3. For the 2014 – 2016 allocation period, the Incentive Funding fixed percentage will be set, based on the following Initial Allocation scenarios: 10% for up to US$ 11 billion, 15% for over US$ 11 billion and up to US$ 13.5 billion, or 20% for over US$ 13.5 billion. The balance of the Initial Allocation will be used for Indicative Funding. <br/><br/></li><li type="a">No Incentive Funding will be allocated to the countries within Band 4 since Band 4 is subject to a separate allocation methodology approved by the Strategy, Investment and Impact Committee (the “SIIC”), which recognizes the particular needs of countries / disease components in Band 4. <br/><br/></li><li type="a">A graduated reduction will be applied to the funding levels of disease components that have received funding at levels above their notional shares under the allocation methodology. For 2014 – 2016, this graduated reduction will seek to reflect a target minimum reduction of 20% across the portfolio of impacted disease components relative to the most recent available three-year disbursement levels. The Secretariat shall have discretion to apply appropriate reductions for such disease components to reach the target reduction across the portfolio. <br/><br/></li><li type="a">Disease components that will, after the reduction referred to above, receive funding at levels that exceed their notional shares under the allocation methodology by more than 50% over the 2014 – 2016 allocation period will not be eligible for Incentive Funding during the 2014 – 2016 allocation period. <br/><br/></li><li type="a">Additional resources that become available after the initial allocation of available resources, including accelerations in the graduated reductions described in paragraph 3 of this decision and additional contributions from donors, will be apportioned to fund Unfunded Quality Demand in accordance with the methodology approved by the SIIC for which countries in all four Country Bands will be eligible. <br/><br/></li><li type="a">The SIIC will review this decision and propose appropriate modifications to the Board for approval prior to the 2017 – 2019 allocation period.</li></ol></li></ol>
2016-08-03 B35 GF/B35/EDP11 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER10 ("Table 1);<br/><br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/><br/>4. Approves the additional incremental funding and implementation period recommended for the Uganda HIV disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and
2016-04-27 B35 GF/B35/DP08 Sustainability, Transition and Co-financing Policy Sustainability, Transition and Co-financing Policy
<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Sustainability, Transition and Co- Financing Policy, as set forth in Annex 1 to GF/B35/04 - Revision 1 (the "STC Policy").</p> <p>2.Accordingly, the Board:</p> <p>a.Acknowledges this decision point and the new co-financing policy set forth in the STC Policy supersede Board decision point GF/B30/DP05 and the previous Counterpart Financing Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Counterpart Financing Policy"); and</p> <p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Counterpart Financing Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period.</p>
2003-10-17 B06 GF/B06/DP3 Approval of Report of the Fifth Board Meeting Approval of Report of the Fifth Board Meeting
<p>The report of the Fifth Board Meeting was approved with the following changes:</p> <ul> <li>Page 5 - The Board asks the Governance and Partnership Committee …</li> </ul> <p>For the Board 6 meeting, that the constituencies of the Chair and Vice Chair be permitted to designate two Alternate Members, based on the condition that the delegate from those constituencies sitting as Chair or Vice Chair recuse themselves from all votes.</p>
2003-10-17 B06 GF/B06/DP4 Comprehensive Funding Policy Comprehensive Funding Policy
<p>The Board approved the following decisions:</p> <p>Decision Point 1</p> <p>Resource-mobilization should use a periodic replenishment model on a voluntary basis for all public donors, complemented by additional ad hoc contributions for all donors, including new public donors, the private sector, and individuals.</p> <p>Decision Point 2</p> <p>TRP-recommended proposals should be approved up to the total of resources available.</p> <p>Decision Point 3</p> <p>Proposals are approved for the entire term of the proposal (up to five years) with a financial commitment for the initial two years with the possibility of renewal for up to an additional three years, with the following conditions: </p> <p>a. The Board may approve proposals and commit funds for two years up to the cumulative uncommitted amount pledged through the calendar year of the Board decision;</p> <p>b. A sufficient amount of assets to meet the full cost of two years of implementation of approved grants must be deposited with the Trustee or readily available on demand prior to the Secretariat signing a grant agreement;</p> <p>c.    Based on successful implementation of a grant, funding beyond its first 2 years receives priority over the funding of new proposals;</p> <p>d. No funds for appeals should be reserved. Successful appeals should be funded immediately if resources are available or as soon as new resources become available. </p> <p>Decision Point 4</p> <p>Both cash and demand public promissory notes should be considered as assets. </p> <p>Decision Point 5</p> <p>The Board will announce a minimum of one Call for Proposals per calendar year.</p> <p>The Board can adjust this based on need and on resources available. </p> <p>A forecast of the resources available for the Round will be announced at the time that the Call for Proposals is issued. </p> <p>Decision Point 6</p> <p>At the final Board meeting of each year, beginning with the 2004 budget, the Global Fund will forecast resources and estimate demand for the next year. </p> <p>This estimate will show clearly the funds available for commitment. </p> <p>This estimate should be attached to the annual budget.</p> <p>This estimate should be updated at each Board meeting. </p> <p>Decision Point 7</p> <p>Technical merit will be the criteria used to determine proposal approval.</p> <p>The Technical Review Panel should refine its recommendations in category 2 in a way that will facilitate the Board's prioritization of proposals for approval. </p> <p>If it is necessary to further prioritize within these sub-categories, the following additional criteria will be used by the Board: poverty, disease burden, repeated failures for the same component and other criteria which the Board deems appropriate. </p> <p>Decision Point 8</p> <p>The Board will not partially approve components. </p> <p>Decision Point 9</p> <p>The Secretariat will work with the Trustee, the MEFA Committee, and other partners such as WHO and UNAIDS to develop financial models that provide regular estimates of resources available for commitment and of demand for Global Fund financing, to be presented to the Board at its seventh meeting. </p> <p>Decision Point 10</p> <p>The Secretariat will work with the Trustee and the MEFA Committee to determine the specific criteria on promissory notes to be considered as assets, to be presented to the Board at its seventh meeting.</p> <p>Decision Point 11</p> <p>The Secretariat will work with the MEFA Committee and with PMPC to determine the process for the extension of two-year grants, to be presented to the Board at its seventh meeting. </p> <p>Decision Point 12</p> <p>The Secretariat will work with PMPC to operationalize the principles for prioritization among TRP-recommended proposals, to be presented to the Board at its seventh meeting. </p> <p>Decision Point 13</p> <p>The Secretariat will work with the MEFA Committee to identify a set of indicators for assessing the performance of the Global Fund's financial policies, to be presented to the Board at its seventh meeting. </p>
2003-10-17 B06 GF/B06/DP9 Resource Mobilization and Communication Committee Resource Mobilization and Communication Committee
<ol> <li>The Board approved that the RMCC and the PMPC form a joint working group to develop proposals on the issue of in-kind donations.</li> <li>The RMCC will urgently develop a resource mobilization strategy, in full consultation with other partners, consistent with the comprehensive funding policy to raise funds sufficient to meet future needs. This strategy will include the sustainable mechanism for the agreed voluntary replenishment process.</li> <li>The Secretariat working closely with the RMCC will develop a workplan to implement this strategy.</li> <li>The RMCC and Secretariat will call upon outside experts to advise and assist them in the design and implementation of this strategy and workplan.</li> <li>The RMCC will report by one month before each Board Meeting on the Global Fund's progress in implementing this strategy.</li> </ol>
2003-10-17 B06 GF/B06/DP8 By-Laws and Board Operating Procedures Committee Rules and Procedures Partnership Forum By-Laws and Board Operating Procedures Committee Rules and Procedures Partnership Forum
<p>The Board approves the recommendations of the Governance and Partnership Committee as follows: </p> <ol> <li>To adopt the Revised Bylaws and Revised Board Operating Procedures as proposed by the Governance and Partnership Committee.</li> <li>To approve the Committee Rules and Procedures as proposed by the Governance and Partnership Committee.</li> <li>Mandate the Board Chair to convene the Ethics Committee and approve the Ethics Committee and its terms of reference.</li> </ol> <p>Partnership Forum</p> <ol> <li>To adopt the approach to the Partnership Forum process and event as proposed by the Governance and Partnership Committee;</li> <li>To agree specifically to hold the 2004 Partnership Forum event contiguous with the IAC AIDS 2004 Conference inBangkok;</li> <li>To agree to hold the Second Board meeting of 2004 in Geneva and not in connection with the Partnership Forum event;</li> <li>To mandate the Board Chair to convene the Steering Committee immediately to begin planning the Partnership Forum process and event; and</li> <li>To approve the Steering Committee and its Terms of Reference as proposed.</li> </ol>
2003-10-17 B06 GF/B06/DP12 Draft Budget for 2004 Draft Budget for 2004
<ol><li>The Board directs the MEFA Committee in its December 2003 meeting to finalize its review and recommendations of the 2004 budget, including comments made by the Board and to bring its final recommendation to the Board at its next meeting in 2004.</li><li>The Board authorizes the Secretariat to continue to operate with the ceiling of the 2003 budget until the 2004 budget can be adopted by the Board. During this interim period, in the event the Secretariat must incur specific expenses not included in the 2003 budget (e.g. Partnership forum venue costs), it shall do so with the understanding that the expense will be covered within the finally adopted 2004 budget. The Secretariat will present a report of its first quarter expenses to the Board in March.</li><li>The Board directs the MEFA Committee to finalize the review of the budget for 2005 and report to the Board for their decision in 2004.</li></ol>
2004-01-29 B06 GF/B06/EDP01 Review and Approval of Board Decision on category 2B proposals Review and Approval of Board Decision on category 2B proposals
<p>During the 6<sup>th </sup>Board meeting, the Board took the following decision:</p> <p>"The Board approves proposals in TRP category 2B, subject to the completion of TRP clarifications. This decision would become effective upon Board confirmation by email in January 2004. Meanwhile the Secretariat can proceed with resolving TRP clarifications for these proposals." </p> <p>The Board reviewed and confirmed its approval of the decision on category 2B proposals for a total amount of US$138,463,324.</p> <p>The Board noted that as of january 2004, US$604 million is forecastto be available for the Fourth Call for Proposals.</p> <p>The Board noted that this amount will be reducedby the aggregate amount of successful appeals of Third round decisions.</p> <p>The Board noted that the total amount of funds requested in proposals submitted to the AppealsPanel following round 3 and deemed eligible for review is US$101.5million.</p>
2013-08-23 B29 GF/B29/EDP05 Appointment to Replace Out-Going SIIC Member Appointment to Replace Out-Going SIIC Member
<p>The Board:</p> <ol> <li>Approves the appointment of the following individual to the Strategy, Investment and Impact Committee (‘SIIC’), to replace one out-going member:<br />a. Ambassador Philippe Meunier, representing France.</li> <li>Notes that Ambassador Philippe Meunier shall serve on the SIIC until the end of his predecessor’s term.</li> </ol>
2003-10-17 B06 GF/B06/DP5 Report of the TRP, including Round 3 Funding Decisions Report of the TRP, including Round 3 Funding Decisions
<ol> <li>The Board approves for funding the Round 3 categories 1 and 2A today, (15 October) subject to the completion of TRP clarifications.</li> <li>The Board approves proposals in TRP category 2B, subject to the completion of TRP clarifications. This decision would become effective upon Board confirmation by email in January 2004. Meanwhile the Secretariat can proceed with resolving TRP clarifications for these proposals.</li> <li>The completion of TRP clarifications in Category 1 should be completed within 4 weeks of the applicant's receipt of the initial decision of the Board, and given final approval by the TRP Chair and/or Vice Chair.</li> <li>The initial reply to TRP clarifications for proposals in Category 2 should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant. The TRP Chair and/or Vice Chair shall give final approval based on consultations with the primary and secondary reviewers.</li> <li>Proposals in Category 3 are not recommended in their current form but are encouraged to resubmit.</li> <li>Proposals in Category 4 are not recommended for funding.</li> <li>The Board requests the PMPC and GPC to examine the issue of non-CCM proposals that have been approved by the Board and that may be against the criteria for non-CCM proposals, and report to the Seventh Board Meeting.</li> <li>The Board requests the PMPC and GPC to review the applicability of the eligibility criteria to future non-CCM applications.</li> <li>The Board requests the GPC todevelop with reference to the Framework Document guidelinesrecommendations for alternative funding mechanisms where particular constraints exist about funding the proposed Principal Recipients and sub recipients. These recommendations should reflect the humanitarian spirit of the Global Fund and the desire to direct funds quickly and accountably to affected populations. These modalities, subject to approval by the Board, should also apply to all approved proposals in Round 3.</li> <li>The Board requests the GPC to examine the possible conflicts of interest between the Chairs of CCMs and the Principal Recipients, particularly in the process of selecting Principal Recipients.</li> <li>The Board requests the GPC to examine the eligibility of CCM applications when the composition of CCMs lacks representation of communities affected by the three diseases and civil society.</li> </ol>
2003-10-17 B06 GF/B06/DP10 Portfolio Management and Procurement Committee (including related TRP Recommendations) Portfolio Management and Procurement Committee (including related TRP Recommendations)
<p>The Board adopts the following decisions:</p> <p>Decision 1</p> <ol type="a"> <li>Following TRP renewal, approximately one-quarter of the TRP members will be rotated each Round.</li> <li>Members appointed from 2003 onwards will be appointed to serve a term of up to four Rounds.</li> <li>After each Round, the Chair and Vice Chair of the TRP will recommend with specific explanation to the selection panel the members whom should be asked to remain on the TRP (up to a maximum of four Rounds' service for each TRP member).</li> <li>The selection panel will select replacement TRP members from among the TRP Support Pool.</li> </ol> <p>Decision 2</p> <p>For the Fourth and subsequent rounds of applications to the Global Fund:</p> <ol type="a"> <li>Countries classified as "Low Income" by the World Bank are fully eligible to apply for support from the Global Fund.</li> <li>Countries classified as "Lower-Middle Income" by the World Bank are eligible to apply for support from the Global Fund but must meet additional requirements, including co-financing, focusing on poor or vulnerable populations and moving over time towards greater reliance on domestic resources.</li> <li>Countries classified as "High Income" by the World Bank are not eligible to apply for support from the Global Fund.</li> <li>Regional proposals that include a majority of eligible countries may submit applications to the Global Fund.</li> </ol> <p>Decision 3:</p> <p>The Board approves Option One for Round Four.</p> <ol type="a"> <li>Option 1:Countries classified as "Upper-Middle Income" by the World Bank are eligible to apply forsupportfrom the Global Fund only if they face very high current disease burden. This is defined (based on technical input from WHO and UNAIDS) for each disease as follows:<br /> <ol type="i"> <li>HIV/AIDS: if the country's ratio of adult HIV seroprevalence (as reported by UNAIDS, multiplied by 1000) to GNI per capita (Atlas method, as reported by the World Bank) exceeds 5;</li> <li>Tuberculosis: if the country is included on the WHO list of 22 high-burden countries, or on the WHO list of the 36 countries that account for 95% of all new TB cases attributable to HIV/AIDS;</li> <li>Malaria: if the country experiences more than 1 death due to malaria per 1000 people (as reported by WHO).</li> </ol> </li> <li>Eligible countries must meet additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources.</li> <li>The Board requests that the PMPC review the issue of future applications focusing exclusively on vulnerable populations that do not receive significant funding from domestic or external sources from Upper-Middle Income countries ineligible under Option 1.</li> <li>The PMPC will present recommendations to the Board for consideration at the Seventh Board Meeting.</li> </ol> <p>PROCUREMENT AND SUPPLY MANAGEMENT</p> <p>Decision 4:</p> <p>National Drug Regulatory Authorities (NDRA) laboratories or laboratories recognized by the NDRA should be used for quality monitoring by the PR. To ensure the respective laboratories have adequate capacity for full pharmacopoeial testing, they must meet one of the following criteria:</p> <ol type="a"> <li>Acceptance for collaboration with WHO pre-qualification project;</li> <li>Accredited in accordance with ISO17025 and/or EN45002;</li> <li>Accepted by a stringent authority. For the purposes of this policy a stringent drug regulatory authority is defined as a regulatory authority in one of the 28 countries which is either a Pharmaceutical Inspection Cooperation Scheme and/or International Conference on Harmonization.</li> </ol> <p>Decision 5:</p> <ol type="a"> <li>The principles for procurement and quality assurance of pharmaceuticals that were adopted during the Third Board meeting of the Global Fund apply to diagnostics and other non-pharmaceuticals: namely that a Principal Recipient (PR) is responsible for procurement, and is required to conduct competitive purchasing in order to obtain the lowest possible price for products of assured quality:</li> <li>For non-durable products, the same principles as for pharmaceuticals should be followed, namely that a PR is required to select from lists of pre-qualified products, where they exist, or products accepted by stringent regulatory agencies or products accepted by national standards.</li> <li>For durable products the lowest possible price should take into account the Total Cost of Ownership (TCO), including the cost of reagents and other consumables as well as costs for annual maintenance.</li> <li>Procurement methods for durable products may include either lease or purchase. The PR must provide a plan for service and maintenance of the products.</li> <li>The Secretariat will work with technical partners such as WHO, UNAIDS and bilateral agencies to ensure availability of information to recipients in regards to quality assurance and procurement systems related to high priority consumables and durables such as condoms, HIV rapid testing kits, CD4+ T cell monitoring, bed nets, microscopes, etc.</li> </ol> <p>Decision 6</p> <ol type="a"> <li>The Board recognizes the potential role of in-kind donations in significantly expanding the impact of the GF and in making a significant contribution to resource mobilization efforts through providing leverage for cash resources. In-kind donations also constitute a significant means by which the private sector may be involved with the Global Fund and contribute to achieving its goals, thus reflecting the public - private partnership principles upon which the Global Fund is based.</li> <li>The Board recognizes the considerable challenges to be confronted in operationalizing in-kind donations. There are different issues involved in managing in-kind donations in the form of services, non-health products, or health products, particularly pharmaceuticals, at both the global and country level.</li> <li>The Board requests that the PMPC, on the basis of input from the PSM-AP, and working jointly with other Committees, particularly with the Resource Mobilization Committee, to consider further the different operational and other issues surrounding in-kind donations of services, non-health, and health products. These general issues include, inter alia: <ul> <li>Guarding against conflicts of interest;</li> <li>Potential legal liabilities;</li> <li>Long term sustainability;</li> <li>Valuation of contribution.</li> </ul> </li> <li>The Board requests that, on the basis of work done by the private sector and others, the PSMAP will propose strategic options, capturing issues relating to the diversity of products and services, the managerial capacity of the Global Fund Secretariat and Principal Recipients, and the advantages/costs of channeling donations through the Global Fund vis-à-vis other existing mechanisms.</li> </ol> <p>Decision 7: Board refers to the Governance and Partnership Committee the issue of potential conflict of interests when products are manufactured in a state-owned laboratory and the Principal Recipient is a public entity and when products are manufactured or purchased in a state-owned structure and the state is responsible for quality.</p>
2004-02-19 B06 GF/B06/EDP02 Composition of the Global Fund Board (2004-2006) Composition of the Global Fund Board (2004-2006)
<p>The Board:</p> <ol> <li>Notes that the two-year term of the current Board Members began on 28 January 2002 (the appointment of Board Members is recorded in the minutes of the First Board Meeting), the current term of office of Board Members appointed to the first Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will expire this week. Therefore, Board membership must be confirmed by 28 January 2004.<br /><br /></li> <li><span></span>The final nominations for Board membership were received on 27 January 2004, by the Secretariat and are therefore proposed to the Board for approval in accordance with Article 7.4 of the Bylaws namely:<br /><br /><u>7.4 Functions</u><br /><br />Appoint Board Members selected in accordance with Article 7.2.<br /><br /></li> <li>Notes that Article 7.2 states:<br /><br /><u>7.2 Appointment of Foundation Board Members</u><br /><br />Each group mentioned in Article 7.1 of these Bylaws will determine a process for selecting its Foundation Board representation. Board Members will serve as representatives of their constituencies. Foundation Board members will serve on the Foundation Board for two years or such other term that the Foundation Board may determine.<br /><br />Board members shall be deemed to act in their capacity as representatives of their respective governments, organizations, constituencies and other entities.<br /><br /></li> <li>Approves the new Global Fund Board as listed in the attached document.</li> </ol>
2003-10-17 B06 GF/B06/DP11 Governance and Partnership Committee Governance and Partnership Committee
<ol> <li>The Board requested the GPC to address all outstanding issues of the Conflict of Interest Policy for submission to the Board.</li> <li>The Board endorsed the Memorandum of Understanding between the Fund and the Inter-American Development Bank and delegated the Stop TB and Roll Back Malaria Memoranda of Understanding to the GPC, after which they will both be presented for ratification by the Board at its subsequent meeting in 2004.</li> <li>The Board mandated the GPC to work further on the legal status of the Global Fund.</li> <li>The Board delegated authority to execute agreements on its behalf to the Chair, Vice Chair and Executive Director. As necessary and appropriate to maintain continuity of Secretariat operations, in the event the Executive Director is unavailable to exercise such authority the Chief Operating Officer or the Chief Fund Portfolio Director may do so.</li> <li>The Board requested the GPC to address the conditions under which the communities delegation can become a voting member without affecting the existing voting mechanism, and report back to the Seventh Board Meeting.</li> </ol>
2003-10-17 B06 GF/B06/DP6 Round 4: Funding Forecast, Timing and Renewal of Guidelines Round 4: Funding Forecast, Timing and Renewal of Guidelines
<ol><li>The Board requests the PMPC, with the support of the Secretariat, WHO, and UNAIDS to revise the Guidelines for Proposals for the Fourth Round and subsequent Rounds as needed, including taking account of the principles of harmonization.</li><li>The Secretariat should track in their financial projections the pledges as defined by the donor.</li><li>The Fourth Call for Proposal will be launched onJanuary 10, 2004.</li><li>The Board will approve Round 4 proposals at its June Board Meeting.</li><li>The Board reasserts the principles of the governing policy of the Global Fund, asks each stakeholder of the Global Fund to deploy every possible effort to increase the resources available for 2004, and subsequent years and requests that donors specify before the end of 2003 their contributions for 2004.</li><li>The PMPC will revise the guidelines for proposals by January 1 with input from all Board Members.</li></ol>
2004-02-19 B06 GF/B06/EDP03 Term of Office of Board Members Term of Office of Board Members
<p>The Board:</p> <ol> <li>Having read the following message from the Board Chair dated 30 January 2004: <br /><br />"I have been asked by several Board Members to resolve certain issues related to the renewal of Board memberships. There appear to be ambiguities in our By-Laws and Board Operating Procedures related to the terms of Board Members. Specifically, the length of the terms of Board Members is not clearly defined. In the absence of clear guidelines, the Global Fund Secretariat determined that Board membership commenced on January 28. While reasonable, this interpretation has created a significant gap in leadership positions, in particular in the position of Vice Chair. Dr. Lieve Fransen, Chair of the Governance and Partnership Committee, as well as other Committee members, which met this week in Geneva, have suggested that a better interpretation is that new Board Members terms commence at the first Board meeting of the calendar year. I am inclined to agree with this interpretation. I would to ask the Committee to develop language to amend the Board Operating Procedures to resolve this ambiguity for Board review at the March meeting. <br /><br />To resolve the immediate issue, I would like the Board to agree by resolution that new Board members will take their seat on the morning of March 18, the first day of our first Board meeting of the year. Such a solution would allow our current leadership to continue its work in the weeks leading up to the March Board meeting. The terms of office of our new Board Members would therefore extend to the first Board meeting of calendar year 2006, so that incoming Board Members would not lose any net time of service. <br /><br />(...)<br /><br />Sincerely, <br />Tommy G. Thompson <br />Chair, Global Fund Board of Directors" <br /><br /></li> <li>The Board approves that: <br /><br /> <ol> <li>New Board members will take their seat at the start of the first Board Meeting of 2004. <br /><br /></li> <li>The terms of office of new Board Members will extend to the first Board meeting of calendar year 2006.</li> </ol> </li> </ol>
2003-10-17 B06 GF/B06/DP1 Appointment of Rapporteur Appointment of Rapporteur
<p>Lennarth Hjelmåker was designated as Rapporteur for the Sixth Board Meeting.</p><ul type="disc"></ul>
2003-10-17 B06 GF/B06/DP2 Approval of Agenda Approval of Agenda
<p>The agenda for the Sixth Board Meeting was approved.</p>
2003-10-17 B06 GF/B06/DP13 Calendar 2004-2005 Calendar 2004-2005
<p>The Board adopted the attached Calendar for Board Meetings for 2004 and 2005, with the understanding that the dates will be confirmed at the beginning of each year.</p>
2003-10-17 B06 GF/B06/DP7 Monitoring and Evaluation Strategy Monitoring and Evaluation Strategy
<ol> <li>The Board endorses the Global Fund's Monitoring and Evaluation strategy as described by the MEFA Committee [the Monitoring and Evaluation Strategy document GF/B6/1 and annex 1 GF/B6/11.1 which describes the management arrangements for the Fund's M&amp;E].</li> <li>The Board approves the correction of the Round 1 grant amounts previously recorded as approved by the Board, in these cases, to reflect the Board's overall decision to approve the first two years of each proposal, thus endorsing the amounts agreed to in the grant agreements.</li> </ol>
2003-01-31 B04 GF/B04/DP23 Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Travel Policy Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Travel Policy
<ul><li>Current numbers of Board delegates from recipient countries,NGO's and Communities Living With the Diseases offered funding by the Secretariat for travel should be maintained.</li></ul><ul><li>Class of air travel guided by the current Secretariat travel policy and consistent with the WHO policy on class of air travel should be continued with emphasis placed on using the most economical available fares within those policies.</li></ul>
2003-01-31 B04 GF/B04/DP27 Report of the Secretariat and the Technical Review Panel on Round 2 Proposals Report of the Secretariat and the Technical Review Panel on Round 2 Proposals
<p>1. The Board is asked to approve for funding proposals recommended by the Technical Review Panel and according to the categories listed below, with the clear understanding that budgets requested are upper ceilings rather than final budgets and the Secretariat will report to the Board the results of the negotiations with the Principal Recipient on the final budget for acknowledgement.</p> <ul> <li>Category 1: Recommended proposals with no or minor modifications, which should easily be answered within 6 weeks and given the final approval by the TRP Chair and Co-Chair.</li> <li>Category 2: Recommended proposals provided clarifications are met within a limited timeframe (6 weeks for the applicant to respond, at most 6 months to obtain the final TRP approval should further clarifications be requested). The primary reviewer, secondary reviewer as well as TRP Chair and /or Co-Chair need to give final approval.</li> <li>Category 3: Not recommended in its present form but strongly encourage to re-submit.</li> <li>Category 4: Not recommended for funding.</li> </ul> <p>2. The Board is asked to acknowledge the lessons learnt of the Secretariat and the TRP during this process and allow adequate measures to be taken to improve Round 3. </p>
2003-01-31 B04 GF/B04/DP12 Report of the Governance and Partnerships Committee: Board Operating Procedures and Policies Report of the Governance and Partnerships Committee: Board Operating Procedures and Policies
<ul><li>Adopts the revisions to the Board Operating Procedures as proposed, except for paragraphs 22 and 23.</li></ul><ul><li>The Board has recognized the need for a revision of the By Laws and asks the Governance and Partnership Committee and Secretariat to review the By Laws and report back to the Board at their June 2003 meeting.</li></ul>
2003-01-31 B04 GF/B04/DP11 Report of the Governance and Partnerships Committee: CCMs Report of the Governance and Partnerships Committee: CCMs
<ul><li>Requests the Chairs of the Governance and Partnership Committee and the Portfolio and Procurement Committee consult together with the Executive Director to identify inputs on this issue for the Revised Proposal Guidelines for Round 3;</li></ul><ul><li>Requests the Committee to revisit the issue of CCMs, based on inputs from Board Members, and prepare recommendations for the next Board meeting;</li></ul>
2003-01-31 B04 GF/B04/DP07 Approval of Report of Third Board Meeting Approval of Report of Third Board Meeting
<p> Ratification of Board Committee leadership and composition: Approved to defer the ratification of Board Committee Chairs and Vice Chairs and committee composition until Friday, 31 January 2003, after the election of Board Chair and Vice Chair and after the committee reports have been heard.</p> <p>Report of the Third Board Meeting (GF/B4/2): The Board approves the Report of the Third Board Meeting with the deletion of the reference to any Article number in section 9.2.1, so that the last sentence reads, "(Legal advice will be sought on whether the implementation of this decision requires a change of the By-Laws)".</p>
2003-03-10 B04 GF/B04/EDP02 Approval of Kenyan NGO Round 1 Proposals for HIV/AIDS as approved by the CCM Approval of Kenyan NGO Round 1 Proposals for HIV/AIDS as approved by the CCM
The Board approves the outstanding Category 2 of Kenyan NGO Round 1 Proposals for HIV/AIDS as endorsed by the CCM.
2003-01-31 B04 GF/B04/DP08 Report of the Governance and Partnerships Committee: Partnership Forum Report of the Governance and Partnerships Committee: Partnership Forum
<ul><li>Mandates the Committee to work with the Secretariat to develop a comprehensive proposal for the Partnership Forum for the June Board Meeting.</li></ul><ul><li>Decides, exceptionally, to hold the Forum during the first half of 2004.</li></ul><ul><li>Recommends to the Committee to link the Forum with another meeting, preferably a Board Meeting, to minimize costs.</li></ul><ul><li>Requests the Secretariat to research similar events and establish lessons learned (e.g. from GAVI).</li></ul><ul><li>Requests the Secretariat to provide a list of events for 2004 for consideration at the June Board Meeting.</li></ul>
2003-01-31 B04 GF/B04/DP19 Report of the Portfolio Management and Procurement Committee: Portfolio Management: Identifying Neediest and Poorest Countries Report of the Portfolio Management and Procurement Committee: Portfolio Management: Identifying Neediest and Poorest Countries
<ul> <li>While the methodology for identifying the neediest and poorest countries is being developed, the Secretariat will supply information on needy and poor countries that have not received funding in Rounds 1 and 2 to the 4<sup>th</sup>Board meeting. The information presented to the 4<sup>th</sup>Board meeting on needy and poor countries will also be provided to partners to encourage them to support these countries in the process of applying to the Global Fund.</li> </ul> <ul> <li>(Deferred)For the Fifth Board meeting, the PMPC will provide recommendations on mechanisms for ensuring that the neediest and poorest are not systematically excluded from funding.</li> </ul>
2019-11-13 B41 GF/B41/EDP16 Indicator Revision and Performance Target for Key Performance Indicator 10: Resource Mobilization; Key Performance Indicator 12a: Availability of affordable health technologies: Availability; Key Performance Indicator 12b: Availability of affordable health technologies: Affordability Indicator Revision and Performance Target for Key Performance Indicator 10: Resource Mobilization; Key Performance Indicator 12a: Availability of affordable health technologies: Availability; Key Performance Indicator 12b: Availability of affordable health technologies: Affordability
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves:</p> <ol> <li>the wording revision for Key Performance Indicator 10 as presented in GF/B41/ER12</li> <li>the indicator revision and performance target for Key Performance Indicator 12a as presented in GF/B41/ER12</li> <li>the 2020 performance target for Key Performance Indicator 12b as presented in GF/B41/ER12</li> </ol>
2019-11-13 B41 GF/B41/EDP17 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p><span>The Board:</span></p> <ol> <li><span>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B41/ER13 (“Table 1”);</span></li> <li><span>Acknowledges each country’s disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</span></li> <li><span>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>
2019-05-15 B41 GF/B41/DP04 Catalytic Investments for the 2020-2022 Allocation Period Catalytic Investments for the 2020-2022 Allocation Period
<p>Based on the recommendation of the Strategy Committee (the “SC”), as presented in GF/B41/03 - Revision 1, the Board:</p> <ol> <li>Acknowledges that the total amount of sources of funds for allocation for the 2020-2022 allocation period will be decided by the Board in November 2019, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 6th Replenishment;</li> <li>Approves that the total amount of funding for catalytic investments in the 2020-2022 allocation period, as described in the Allocation Methodology approved under GF/B41/DP03, will be determined by the total amount of sources of funds for allocation for the 2020-2022 allocation period;</li> <li>Approves catalytic investments for the 2020 – 2022 allocation period as set forth in the scenarios described below: <ol type="i"> <li>USD 900 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are greater than or equal to USD 13.1 billion, USD 900 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 1 of Annex 1 of GF/B41/03 - Revision 1 (“Annex 1”);</li> <li>USD 800 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 13.1 billion and greater than or equal to USD 12.1 billion, USD 800 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 2 of Annex 1;</li> <li>USD 600 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 12.1 billion and greater than or equal to USD 11.1 billion, USD 600 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 3 of Annex 1;</li> <li>USD 400 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 11.1 billion and greater than or equal to USD 10.6 billion, USD 400 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 4 of Annex 1; and</li> <li>USD 200 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 10.6 billion and greater than or equal to USD 10.1 billion, USD 200 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 5 of Annex 1.</li> </ol> </li> <li>Requests the Secretariat to return to the SC with a new recommendation on catalytic investments if sources of funds for allocation for the 2020 – 2022 allocation period are below USD 10.1 billion, for SC recommendation to the Board;</li> <li>Agrees that in the event that sources of funds for allocation for the 2020-2022 allocation period are above the midpoint of the funding range specified for a scenario above, the Secretariat may recommend the Board to approve an additional total amount up to USD 100 million for catalytic investments, to be invested in the priority areas for the scenario immediately preceding the applicable scenario in the list above;</li> <li>Requests the Secretariat to (i) implement a rigorous approval process for all catalytic investments, including strategic initiatives, by a review body with clear and transparent management of conflicts of interest to maintain the integrity of decision making, whether financial or programmatic; (ii) execute a credible, robust technical review process on the activities, mechanisms, and the requested amounts; and (iii) report regularly to the SC on all catalytic investments; and</li> <li>Notes the Secretariat will (i) have flexibility to operationalize catalytic investments; (ii) update the SC and Board on such operationalization; (iii) have flexibility to reallocate associated costs among the approved priorities under any applicable scenario, within 10% of the approved amount of associated costs for a specific priority; and (iv) present any reallocations of associated costs exceeding 10% for a specific priority for the SC’s approval.</li> </ol>
2003-01-31 B04 GF/B04/DP17 Report of the Portfolio Management and Procurement Committee: Portfolio Management: TRP Renewal Report of the Portfolio Management and Procurement Committee: Portfolio Management: TRP Renewal
<p>The PMPC in order to ensure the sustainability and continuity of the TRP and to have a good proportional balance among the different experts recommends that:</p><ul><li>TRP membership should be expanded from 22 to 25 members, by adding 3 cross cutting experts.</li><li>The new membership should consist of 11 cross-cutters, 7 HIV/AIDS experts, 4 Malaria experts and 3 TB experts. While there is to be a maximum of 25 members of the TRP and 11 members must be cross-cutters, the chair and vice chair of the TRP may, at their discretion, adjust the number of experts from the different fields of disease expertise, with reference to the proposals submitted and the needs of the TRP.</li><li>The current Chair and Vice-Chair retain their positions as Chair and Vice-Chair and the 5 members who joined for Round 2 retain their positions on the panel on a voluntary basis</li><li>The remaining 18 seats be filled through an open, transparent, criteria-based selection process</li><li>7 of the seats be reserved for original members who may reapply (assuming 7 or more of them do so). If more than 7 reapply, those performing best against the criteria will be selected</li><li>Members of the Secretariat are ineligible to serve as TRP experts</li><li>Board/Alternate/Focal Points and CCM members must stand down from these roles if selected</li><li>Members would serve in their personal capacities</li></ul><ul><li>A qualified member from the PLWA (Persons Living with AIDS) community should be actively recruited among applicants.</li><li>Following TRP renewal, approximately one-third of the TRP members will be rotated each year. Members appointed from 2003 onwards will be appointed to serve a term of three years.</li><li>By April 2003, the PMPC and the Executive Director will recommend to the Board the candidates for the TRP for approval. The PMPC may decide to call on external and/or multi-lateral agencies (WJHO, UNAIDS, World Bank) for assistance as required. Further working methods will be developed on the 28<sup>th</sup>of January 2003.</li><li>By the 3<sup>rd</sup>round of TRP 64% of the TRP members will be new in comparison to the TRP appointed in March 2002</li><li>TRP members must not attend Board or Committee meetings as members of their constituency</li></ul><p>Staff from multilateral organizations will be allowed to serve on the TRP.</p>
2019-08-16 B41 GF/B41/EDP07 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B41/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and<br />Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-09-27 B41 GF/B41/EDP10 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B41/ER07 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-07-01 B41 GF/B41/EDP02 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER01 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-08-08 B41 GF/B41/EDP05 Approval of the Report of the 41st Board Meeting in Geneva Approval of the Report of the 41st Board Meeting in Geneva
<p class="x_MsoNormal"><span>The Board approves the Report of the 41st Board Meeting, as set forth in GF/B41/18.</span></p>
2019-05-15 B41 GF/B41/DP03 Allocation Methodology 2020 - 2022 Allocation Methodology 2020 - 2022
<ol> <li>The Board notes: <ol type="a"> <li>Its decision in April 2016 (GF/B35/DP10) that (i) established the allocation methodology for the 2017 - 2019 allocation period; (ii) acknowledged the technical parameters for the 2017 - 2019 allocation period; and (iii) affirmed the restatement of core parts of the principles and framework for the allocation-based funding model (the “Core Funding Model Principles”); and</li> <li>The decision by the Strategy Committee (the “SC”) in March 2019 (GF/SC09/DP02), under authority delegated by the Board, to establish technical parameters for the 2020 – 2022 allocation period (the “Technical Parameters”).</li> </ol> </li> <li>Accordingly, based on the recommendations of the SC, as presented in GF/B41/02, the Board: <ol type="a"> <li>Approves the allocation methodology presented in Annex 1 to GF/B41/02 (the “Allocation Methodology”);</li> <li>Acknowledges the Technical Parameters for the 2020 – 2022 allocation period, as presented in Annex 2 to GF/B41/02;</li> <li>Approves that no more than USD 800 million of sources of funds available for country allocations be used to ensure scale-up, impact and paced reductions, as<br />described in paragraph 4.c of the Allocation Methodology; and</li> <li>Reaffirms the Core Funding Model Principles, as presented in Annex 3 to GF/B35/05 – Revision 1.</li> </ol> </li> <li>Accordingly, the Board:<br /> <ol type="a"> <li>Requests the SC to review and approve, at its July 2019 meeting, the method by which the Secretariat will apply and report on the qualitative adjustment process; and</li> <li>Acknowledges that the Allocation Methodology and Technical Parameters shall apply for the 2020 – 2022 allocation period and supersede the 2017 – 2019 allocation methodology and technical parameters presented in GF/B35/05 – Revision 1.</li> </ol> </li> </ol>
2019-07-03 B41 GF/B41/EDP03 Revised Governance Performance Assessment Framework Revised Governance Performance Assessment Framework
<ol> <li>The Board approves the revised Governance Performance Assessment Framework as set forth in Annex 1 to GF/B41/ER01 (“Framework”), which shall enter into force upon Board approval of this decision point.</li> <li>The revised Framework shall supersede all prior versions of the Governance Performance Assessment Framework.</li> <li>The Board mandates the Ethics and Governance Committee (“EGC”) to regularly review the Framework and delegates decision-making powers to the EGC for any future changes to the Framework and any supporting materials related to it.</li> </ol>
2019-07-24 B41 GF/B41/EDP04 Decision on the Secretariat’s Recommendation on integration of Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on integration of Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p><span>The Board:</span><span></span></p> <ol> <li><span>Approves the revised budget recommended for each grant listed in Table 1 of GF/B41/ER03 (“Table 1”);</span><span></span></li> <li><span>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</span><span></span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>
2019-05-16 B41 GF/B41/DP06 2018 Annual Financial Report 2018 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2018 Annual Financial Report, which includes the 2018 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in Annex 1 to GF/B41/04.</p>
2019-11-07 B41 GF/B41/EDP14 Approval of Additional Funding to Address the Health Crisis in Venezuela Approval of Additional Funding to Address the Health Crisis in Venezuela
<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B41/ER10 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B41/ER10 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B41/ER10 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional USD 6,000,000, for the year 2020, to support the procurement of critical HIV, TB and malaria health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>
2019-10-11 B41 GF/B41/EDP13 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER09 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2003-01-31 B04 GF/B04/DP04 Election Procedure Election Procedure
<p>1. The Board of the Global Fund accepts the procedure for the conduct of the current Election for Chair and Vice Chair of the Board as presented in the Proposed Election Procedure to the Board on 31 January 2003.</p><p>2. The Board of the Global Fund mandates the Governance and Partnership Committee to constitute a sub-group to develop election procedures for future elections and a success policy and to revise the Board Operating Procedures accordingly.</p>
2003-01-31 B04 GF/B04/DP15 Resource Mobilisation: Resource Mobilisation Framework Resource Mobilisation: Resource Mobilisation Framework
<ol start="1" type="1"><li><b>(Deferred) </b> The Board is requested to instruct the Secretariat to pursue a resource mobilization strategy to achieve the fundraising targets for 2003 and 2004 identified in the Financial Prospectus (GF/B4/6a).</li></ol><ol start="2" type="1"><li><b>(Deferred) </b> The Board is requested to instruct the Resource Mobilization Committee to work with the Secretariat in the pursuit of these targets, particularly by identifying specific ways that Board Members can support the Fund's resource mobilization efforts.</li></ol><ol start="3" type="1"><li><b>(Deferred) </b> The Board is requested to encourage the Private Sector Board Delegation to prepare for the Resource Mobilization Committee a framework for options and processes by which the Fund can accept and/or channel in-kind donations in support of efforts to mobilize resources for its grantees.</li></ol>
2003-01-31 B04 GF/B04/DP01 Meeting Chair Meeting Chair
Mr. Seiji Morimoto, Vice Chair will chair this meeting as approved by the Board.
2003-01-31 B04 GF/B04/DP10 Report of the Governance and Partnerships Committee: Constituency Processes Report of the Governance and Partnerships Committee: Constituency Processes
<ul><li>Adopts the Guidelines on Constituency Processes as a useful compilation of best practice.</li></ul><ul><li>Adopts the Constituency Operations Statement as a transparent tool for understanding the processes of stakeholder groups and requests Board Members to complete the statement for their constituency, understanding that this statement will be made public.</li></ul><ul><li>Notes the importance of the role of focal points and supports the facilitation of the attendance of focal points for recipient country constituencies in attending Board and Committee Meetings.</li></ul>
2003-01-31 B04 GF/B04/DP20 Report of the Portfolio Management and Procurement Committee: Portfolio Management: Setting upper and lower limits on proposals Report of the Portfolio Management and Procurement Committee: Portfolio Management: Setting upper and lower limits on proposals
<ul> <li>(Deferred) The PMPC recommends that the Board endorse upper and lower limits for proposals submitted to the Global Fund.<br /><br /> <ul> <li>The PMPC recommends that the Board endorse the strongly preferred recommendation to use a lower limit of US$2 million per year per proposal.</li> <li>Alternatively, the minority option supports the use of a lower limit of US$2 million per year per proposal on all CCM applications, and a lower limit of $1 million per year per proposal on all non-CCM applications.</li> </ul> </li> </ul> <ul> <li>The Board encourages the Secretariat, working with the Portfolio Management and Procurement Committee, to include in the revised Guidelines for Proposals for the Third Round language regarding the preferred scale of grant applications. This should provide guidance to applicants to ensure that proposals are neither excessively large, in view of both national programmatic capacity and the limited resources of the Global Fund, nor excessively small, in view of both the Global Fund's goal to scale-up country responses and the administrative costs of processing applications.</li> </ul> <ul> <li>(Not Approved) The PMPC recommends that the Board endorse the strongly preferred recommendation to use a lower limit of US$2 million per year per proposal. Alternatively, the minority option supports the use of a lower limit of US$2 million per year per proposal on all CCM applications, and a lower limit of US 1 million per year per proposal on all non-CCM applications. The PMPC recommends that the Board endorse an upper limit on all proposals of US$50 million per year and of 50% of total public health sector expenditure per year (whichever figure is the lower).</li> </ul>
2003-01-31 B04 GF/B04/DP14 Resource Mobilisation: Financial Prospectus Resource Mobilisation: Financial Prospectus
<ol start="1" type="1"><li><b>(Deferred) </b> Agree that Board commitments should be fully covered by pledges, with agreement by donors that pledges for a given calendar year are callable on demand following commitments made in that or subsequent years.</li></ol><ol start="2" type="1"><li><b>(Deferred) </b> Agree that signed Grant Agreements should be fully covered by cash assets received in the Trustee Account, implying that payment of any unpaid pledges made for a current or previous calendar year must rapidly follow commitments.</li></ol><ol start="3" type="1"><li><b>(Not approved) </b> Endorse the financial targets and instruct the Executive Director and the proposed Board Resource Mobilization standing committee to pursue a corresponding resource mobilization strategy.</li></ol><ul><li><b>In 2003, a total of USD 2.5 billion is the minimum needed </b> to make commitments to high-quality proposals anticipated in Rounds Two and Three. This requires USD 1.6 billion of new pledges and payments in addition to payment of outstanding pledges for 2002 (equal to 90 million) and current pledges for 2003 (equal to 305 million).</li></ul><ul><li><b>In 2004, approximately USD 3.8 billion is needed </b> to make new commitments to high-quality proposals anticipated in Rounds Four and Five. New pledges of USD 3.5 billion are required in addition to payment of current pledges earmarked for 2004 (equal to 305 million).</li></ul>
2003-01-31 B04 GF/B04/DP24 Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Procurement Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Procurement
<ul><li><b>(Deferred) </b> The Secretariat Procurement Policy was deferred until the next Board Meeting. The Secretariat was requested to discuss the policy with WHO in an attempt to reconcile the difficulties identified by WHO. The policy should be reviewed by the Committee before it is resubmitted to the Board.</li></ul><ul><li>Request the Secretariat to urgently put in place contracting guidelines; contracting review and documentation processes; and comprehensive conflict of interest policies.</li></ul><ul><li>Decide that until the Board agrees to its own policies and procedures on procurement of goods and servicesfor the Secretariat, the Fund Secretariat should abide by the spirit and letter of the policies and procedures of WHO in these matters.</li></ul><ul><li>Decide that the rights of Board Members to ask questions on any contracting issue on which they desire information and clarification should be affirmed within the Board Operating Procedures. The process for addressing inquiries of Board Members on contracting matters should be elaborated within the Board Operating Procedures.</li></ul><ul><li>Direct the Secretariat to provide the MEFA Committee with an independent consultant remuneration scale at their next meeting.</li></ul>
2003-01-31 B04 GF/B04/DP16 Report of the Portfolio Management and Procurement Committee: Procurement Report of the Portfolio Management and Procurement Committee: Procurement
<p>The PMPC recommends that PSM Advisory Panel consider necessary policies for the Global Fund related to the procurement of diagnostics and other products related to the provision of medications. Refer to GF/B4/7) for further details.</p><p><b>(No options are approved by a 2/3 majority vote) </b> The PMPC requests that the Board adopt one of the three policies on domestic production as discussed GF/B4/7).</p><ul><li><b>Option 1:</b> Zero Price Premium</li><li><ul><li>Donors: Yes: 7 No: 2</li><li>Recipients: Yes: 2 No: 6 Abstain: 1 </li></ul></li><li><b>Option 2:</b> 15% Price Premium over the lowest price imported generics </li><li><ul><li>Donors: Yes: 1 No: 7 Abstain: 1  </li><li>Recipient: Yes: 0 No: 8 Abstain: 1</li></ul></li><li><b>Option 3:</b> 15% Price Premium over lowest imported product </li><li><ul><li>Donors: Yes: 2 No: 6 Abstain: 1</li><li>Recipients: Yes: 6 No: 2 Abstain: 1</li></ul></li></ul> <p>The PMPC recommends that the Board amend the policy adopted on exemption on duties, tariffs and taxes to allow but not to encourage that Fund resources be used to pay possible product duties, tariffs and taxes. The amended policy should read as follows: "The Fund strongly encourages the relevant national authorities in recipient countries to exempt from duties and taxes all products financed by Global Fund grants and procured by NGOs or any other Principal Recipient or sub-recipient."</p><p>The Board is invited to acknowledge PMPC's decisions 4.a - 4.l on pages 6-10.</p><ul><li>4a: The PMPC has agreed to the creation of a PSM Advisory Panel, according to the Terms of Reference in Part 1 Annex II, to provide technical advice to the PMPC as required</li><li>4b: The PMPC has agreed to consider the subject of product quality monitoring processes, on the basis of both WHO input and advice by the PSM Advisory Panel, and make appropriate recommendations to the Fifth Board Meeting.</li><li>4c: The PMPC has agreed to consider how the Global Fund should ensure the assessment of NDRA recognized laboratories for product quality monitoring, drawing on the advice of the PSM Advisory Panel, and make appropriate recommendations to the Fifth Board Meeting.</li><li>4d: The PMPC has agreed to consider potential PSM-related conflicts of interest based on advice of the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4e: The PMPC has agreed to consider issues related to global bidding mechanisms based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4f: The PMPC has agreed to approve the importance of capacity building for procurement and supply management as proposed by the PSM Task Force and request the Secretariat to ensure that information on the subject be made available to potential grantees and Principal Recipients.</li><li>4g: The PMPC has agreed on the Terms of Reference for a Pricing Reporting Mechanism design study, as attached in Part 1 Annex III, and has directed the Secretariat to commission this study and implement the resulting system for collecting and reporting prices paid for pharmaceutical products by Global Fund recipients by September 2003.</li><li>4h: The PMPC has agreed to refer the issueof the direct payment of suppliers to the Secretariat,with further analysis by the Advisory Panel as necessary.</li><li>4i: The PMPC has agreed to refer the issueof product prices used for budgeting proposals to the Secretariatfor operationalization, with further analysis by the Advisory Panel as necessary.</li><li>4j: The PMPC has agreed to consider issues related to in-kind contributions, if they are considered eligible by the Board of the Global Fund for resource mobilization, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4k: The PMPC has agreed to consider the previous recommendation made to the Third Board Meeting on the issue of international and national law, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4l: The PMPC has agreed to consider the previous recommendation made to the Third Board Meeting on the issue of supply chain management, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li></ul>
2003-01-31 B04 GF/B04/DP30 Decision Deferred to the Fifth Board Meeting: Report on the Legal Status Options for the Global Fund Decision Deferred to the Fifth Board Meeting: Report on the Legal Status Options for the Global Fund
<p>1. Request the Secretariat to pursue a legal status with the Swiss authorities that provides for the Global Fund with those privileges and immunities that are necessary for it to effectively fulfil its mandate. This status and its associated practical arrangements should ensure that the Global Fund's administration is efficient and no more costly than the current arrangements.</p><p>2. The Secretariat is asked to present to the Fifth Meeting of the Board, precise recommendations for change of status with all associated information.</p>
2003-01-31 B04 GF/B04/DP29 The Global Fund Work plan and Budget for 2003 The Global Fund Work plan and Budget for 2003
<p>1. Approve the Global Fund work plan and budget for 2003 with the proposed changes as presented in Part 2 of this report, with the understanding that some degree of flexibility is required in the specific allocation of resources during the year.</p> <p>2. Request the MEFA Committee to continuously work with the Secretariat to monitor budget implementation in relation to priority and end product accomplishment and report to the Board on budget performance semi-annually.</p> <p>3. Request the Secretariat, with MEFA Committee approval, to adjust this approved 2003 budget to reflect decisions made at the January 2003 Board meeting if those decisions impact the 2003 budget.</p>
2003-01-31 B04 GF/B04/DP13 Report of the Governance and Partnerships Committee: Partnerships Report of the Governance and Partnerships Committee: Partnerships
<ul><li><b>(Not Approved)</b> Acknowledge the approach to partnerships outlined in the paper and authorizes the Secretariat to pursue such partnerships as appropriate.</li></ul><ul><li>Asks the Governance Committee to examine and comment on partnership arrangements negotiated by the Secretariat in light of the framework and present them to the following Board for acknowledgement, or as appropriate, for approval.</li></ul><ul><li>Requests the Executive Director to provide ongoing updates of Global Fund partnership activity in his communications with the Board.</li></ul><ul><li>Board takes note with satisfaction of the MOU with UNAIDS.</li></ul>
2003-01-31 B04 GF/B04/DP28 Communications Strategy Communications Strategy
<ol start="1" type="1"> <li>Requests the Board to endorse the approaches to Communications outlined in the Communications Report GF/B4/10.</li> </ol> <ol start="2" type="1"> <li>Requests the Board to work with the Secretariat and to assist them in their need for additional spokespeople and partners in Communications.</li> </ol> <ol start="3" type="1"> <li>(Deferred) Requests the Board to endorse the logo and the Logo Policy and to instruct the Secretariat to continue the process of legal registrations of the logo.</li> </ol> <ol start="4" type="1"> <li>Recommends that the Resource Mobilization Committee Terms of Reference be revised to include communications, as recorded in the document below.</li> </ol>
2003-01-31 B04 GF/B04/DP32 Board Committees Board Committees
1.<b> </b> Chair and Vice Chair of the Board will discuss with the Executive Director on issues related to committee leadership and composition and revert to the Board as soon as possible.
2003-01-31 B04 GF/B04/DP06 Approval of the Agenda Approval of the Agenda
<p>One additional item is added to the Board’s agenda, proposed at 1800 today. The Board approves the revised Agenda.</p>
2003-02-25 B04 GF/B04/EDP01 Approval of Indonesia Round 1 Proposals for HIV/AIDS and Malaria Approval of Indonesia Round 1 Proposals for HIV/AIDS and Malaria
The Board approves the outstanding Category 2 of Indonesia Round 1 Proposals for HIV/AIDS and Malaria.
2003-01-31 B04 GF/B04/DP26 Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Monitoring and Evaluation Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Monitoring and Evaluation
<ul><li>Direct the Secretariat to draft a Monitoring and Evaluation Plan, which will be reviewed by the MEFA Committee and presented to the Board for approval by the June Board meeting.</li></ul><ul><li>Direct MEFA torecommend to the Board for approvala qualified external auditor to audit the Global Fund's financial statements in time to report the audit findings at the June 2003 Board meeting.</li></ul><ul><li>Direct MEFA to discuss the advantages and disadvantages of an independent Monitoring and Evaluation unit versus the use of external auditors to assure objective evaluation and recommend to the Board the preferred method for independent review.</li></ul>
2003-01-31 B04 GF/B04/DP03 Election Deferral Election Deferral
Regarding the election of Board Chair and Vice Chair, it is approved that this decision will be deferred until Friday, 31 January 2003. Nominations will be accepted by 1200 noon and announced at 1400 on Thursday, 30 January 2003.
2003-01-31 B04 GF/B04/DP25 Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Fiduciary Arrangements Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA): Fiduciary Arrangements
<ul><li>Acknowledge the evaluation of the Global Fund fiduciary arrangements undertaken by the Committee and direct the MEFA Committee to continue to improve the Fund's fiduciary arrangements that should include reviewing LFA performance and fees, developing a LFA conflicting of interest policy, together with the Governance and Partnership Committee, and report on the results of the Round 2 LFA selection. These actions should be reported to the Board in June 2003.</li></ul>
2003-01-31 B04 GF/B04/DP21 Report of the Portfolio Management and Procurement Committee: Portfolio Management: Appeals or Recourse Report of the Portfolio Management and Procurement Committee: Portfolio Management: Appeals or Recourse
<ul> <li>The PMPC unanimously agreed the appeal mechanism should be impartial, objective, independent, simple, speedy and well accepted by all stakeholders. However, strict criteria must be applied to minimize the number of appeal proposals.</li> </ul> <ul> <li>The PMPC decided that proposals rejected through the Secretariat screening, due to clear cut ineligibility criteria, are not eligible for appeal. Only those proposals in category three and four in both the current and the last Round (repeated failure cases) can appeal. The PMPC also agreed that CCMs only submit a new proposal on a different disease component than the one going through the appeal process (non-CCM proposals could only be submitted for a different disease component than the one going through the Appeal Process.)</li> </ul> <ul> <li>The PMPC member unanimously agreed on the following criteria:<br /><br /> <ul> <li>Appeals must have CCM endorsement, except in the event in which a non-CCM proposal was initially deemed eligible for TRP review by the Secretariat, in which non-CCM endorsement is required.</li> <li>Applicant shall provide the specific grounds upon which it claims the TRP was in error regarding information contained in the proposal. It is not permitted to provide additional information or justification additional to that contained in its proposal.</li> <li>The appeal panel should assess appeals using the same assessment criteria as used by the TRP.</li> <li>To prevent unfair treatment to other failed applicants who do not appeal, and to safeguard appeal panel independence from unnecessary pressure, a face-to-face discussion, negotiation between appeal panel and applicants is not allowed.</li> <li>The GF Board should endorse/reject the recommendation of the appeal panel via email.</li> <li>GF Board decision on the appeal is final.</li> <li>Appeal can be made only once.</li> </ul> </li> </ul> <ul> <li>The PMPC also endorsed a timeline for appeals, which allows CCMs to appeal within four weeks of notification, appeal process to be finalised within four weeks and Board endorsement within two weeks after the receipt of Panel recommendations.</li> </ul> <ul> <li>The PMPC endorsed a fourth option (see below): Appeal Panel to be composed by three high level experts to be proposed by WHO, UNAIDS and the World Bank and two TRP members, one disease expert and one cross-cutting expert, who were not either the primary or secondary reviewer of that specific proposal.<br /><br /> <ul> <li>Option 4: Appeal Panel <ul> <li>To be comprised by three high level experts to be proposed by WHO, UNAIDS and the World Bank. These would be joined by two TRP members, one disease expert and one cross cutting expert who were not either the primary or secondary reviewer of that specific proposal. The TRP members will change based on the proposal to be reviewed.</li> </ul> </li> </ul> </li> </ul> <ul> <li>(Deferred)  The PMPC asks the Board to acknowledge the need for increased contextual information to support the Technical Review process. Recognizing the need for more robust information and TRP deliberation, the PMPC will recommend to the Fifth Board meeting mechanisms to address this need.</li> </ul> <ul> <li>(Deferred)  The PMPC asks the Board to acknowledge the need for clarification of what the Global Fund means by "additionality". The PMPC will come up with suggested definitions for the Fifth Board meeting.</li> </ul> <ul> <li>Request the Board to allow the PMPC to revise the Guidelines for Proposals for the Third Round without further endorsement from the Board.</li> </ul>
2003-01-31 B04 GF/B04/DP09 Report of the Governance and Partnerships Committee: Conflicts of Interest Report of the Governance and Partnerships Committee: Conflicts of Interest
<ul><li>Adopts the revised Conflicts of Interest Policy (amendments on gifts and institutional definition) as presented.</li></ul><ul><li>Ask the Governance and Partnerships Committee to address the additional issues raised by the Board members, which the members shall put in writing.</li></ul><ul><li>Adopts the revised Disclosure of Interest Form and requests all covered individuals to submit the form by the deadline specified.</li></ul><ul><li>Requests the Board Chair to identify three of its members to form the Conflicts (or Ethics) Committee and mandates the Governance and Partnership Committee to establish procedures for the functioning.</li></ul><ul><li>Instructs the Executive Director to appoint an Ethics Officer from the Secretariat</li></ul>
2003-01-31 B04 GF/B04/DP02 Appointment of the Rapporteur Appointment of the Rapporteur
Dr. Julian Lob-Levyt is designated rapporteur of the 4<sup>th</sup> Board meeting.
2003-01-31 B04 GF/B04/DP31 Board Calendar 2003 Board Calendar 2003
<p>1. The Board endorses the following Committee Calendar:</p><ul><li>Chairs and Vice Chairs meet together on 3 April 2003</li><li>Committees meet on:<ul><li>Resource Mobilization and Communications - 1, 2 April 2003</li><li>Governance and Partnership - 2, 3 April 2003</li><li>Monitoring, Evaluation, Finance and Audit - 3, 4 April 2003</li><li>Portfolio Management and Procurement Committee - 3, 4 April 2003</li></ul></li></ul><p>2. Decide that the Calendar regarding Board meeting dates and Round 3 as proposed for 2003 is appropriate and instruct the Secretariat to plan accordingly.</p><p>3. <b>(Deferred)</b> Decide that the generic Calendar is a good model for future planning and instruct the Secretariat to use this generic Calendar as a basis for planning.</p>
2019-05-16 B41 GF/B41/DP08 Appointment of the External Auditor Appointment of the External Auditor
<p>Based on the recommendation of the Audit and Finance Committee, as set forth in GF/AFC09/DP03, the Board authorizes the reappointment of KPMG SA as the Global Fund’s independent external auditor for a second term of three years beginning with the 2019 financial year.</p>
2016-10-06 B35 GF/B35/EDP15 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1.a. and 1.b. of Section IV to GF/B35/ER12 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/>4. Approves the additional incremental funding and implementation period recommended for the Kenya malaria disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/>5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2006-11-03 B14 GF/B14/DP20 Targeted Funding Targeted Funding
The Board requests the Finance and Audit Committee, in consultation with the Policy and Strategy Committee, to develop a comprehensive policy on targeted financial contributions for consideration at the Fifteenth Board meeting.
2006-11-03 B14 GF/B14/DP21 UNITAID ACT Initiative UNITAID ACT Initiative
<p>The Board acknowledges UNITAID's offer to finance the purchase by UNICEF as procurement agent of artemisinin-based combination therapy (ACT) medicines (the "ACT Contributions"), for eligible programs financed by the Global Fund (the "GF Programs") for the scale-up of their existing ACT targets. The Board acknowledges, further, UNITAID's initial approval of US$9,050,000 (the "Initial ACT Funding") to finance ACT Contributions, and acknowledges UNITAID's intention to approve additional funding for ACT Contributions (the "Additional Funding") once the Fund Secretariat has determined the estimated maximum amount needed for the scale-up of potentially eligible Global Fund Programs through their Phase 2 (the "Maximum ACT Amount"). The Additional Funding shall be equal to the difference between the Maximum ACT Amount and the Initial ACT Funding.</p><p>The Board accepts, in principle, UNITAID's request that the Global Fund assume sole responsibility for (a) the determination of which GF Programs shall receive ACT Contributions; (b) the adjustment of the relevant grant agreements to reflect ACT scale-up; (c) the monitoring of GF Program results linked to ACT scale-up; (d) the authorization of shipments of ACT Contributions to GF Programs procured by UNICEF based on performance; and (e) the determination at the end of Phase 1 of funding (where applicable) of whether GF Programs that are receiving ACT Contributions shall continue to receive ACT Contributions during their Phase 2. However, the Global Fund discourages non-competitive use of procurement agents so this is not intended to set a precedent.</p><p>The Board requests the Secretariat to contact Country Coordinating Mechanisms and Principal Recipients which, based on past performance, appear to have demonstrated the capacity to scale up existing ACT targets, and invite them to apply for ACT contributions, by stating in their applications the value of such requested ACT contributions. Based on these applications, the Secretariat shall calculate the Maximum ACT Amount so that the UNITAID Board can approve the Additional Funding.</p><p>Once UNITAID has approved the Additional Funding, the Global Fund Board shall, if appropriate, delegate to the Secretariat the authority to do the following: </p><ol><li> enter into contracts with UNITAID and UNICEF to document how ACT Contributions by UNITAID will be financed and made available;</li><li> determine which GF programs shall receive ACT Contributions ("Approvals"), subject to the following: <ol type="a"><li> The Local Fund Agent shall make recommendations with respect to the capacity of Principal Recipients to implement the proposed scale-up, and the Secretariat shall consider such recommendations prior to any Approvals; </li><li> The Technical Review Panel ("TRP") shall make funding recommendations with respect to applications where the scale-up in ACT targets causes material variations in other objectives of the relevant GF Program; and</li><li> The total value of the ACT Contributions authorized by the Secretariat shall not exceed the Maximum ACT Amount; </li></ol></li><li>negotiate and execute amendments of grant agreements reflecting the approved scale-up and ACT Contributions; and</li><li>monitor the GF Program results linked to ACT scale-up and authorize the delivery of ACT Contributions procured by UNICEF to GF Programs based on performance. </li></ol><p>The Board requests the Secretariat to report back to it on implementation of this decision at the Fifteenth Board meeting.</p>
2014-08-01 B31 GF/B31/EDP18 Decision on the Secretariat’s funding recommendation for grant extensions Decision on the Secretariat’s funding recommendation for grant extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 1.</li> </ol> <p>Table 1: Secretariat’s Recommendations on Grant Extensions</p> <p>See attached table detailing total recommended funding amount of US$ 3,561,367 for US$ 3,561,367 (Ethiopia) and US$ 3,561,367 for US$ 3,561,367 (Syrian Arab Republic).</p>
2014-03-07 B31 GF/B31/DP12 Extension Policy Under The New Funding Model Extension Policy Under The New Funding Model
<ol> <li>The Board decides: <ol type="a"> <li>The Secretariat is authorized to extend a grant’s implementation period by a maximum of 12 months beyond the end date set forth in the relevant grant agreement: <ol type="i"> <li>When the extension does not require funding in addition to the amounts approved by the Board for such implementation period ; or</li> <li>When any portion of the extension requires funding in addition to the amounts approved by the Board for such implementation period, provided the period of additional funding does not exceed six months and the amount of additional funding does not exceed USD 10 million.</li> </ol> </li> <li>Any other circumstances warranting an extension will be recommended by the Secretariat to the Board for approval. </li> <li>The Secretariat will develop a framework for exercising the authority delegated under this decision, and report to the Board the extensions approved by the Secretariat under such authority through the monthly Grant Approvals Committee Report on funding recommendations.</li> <li>The Secretariat will review the implementation of this decision and present any recommended modifications to the Strategy, Investment and Impact Committee for approval.</li> </ol> </li> <li>The Board also decides that as of the date of this decision, the extension framework adoptedunder this decision supersedes all prior policies and decisions concerningextensions whether in whole or with respect to relevant parts, including thefollowing Board Decision Points:</li> <li>B24/EDP/5: Procedure forRolling Continuation Channel Mid-Term Performance Reviews and Extensions;</li> <li>GF/B20/DP31: ArchitectureReview – Transition Provisions;</li> <li>GF/B16/DP7, GF/B14/DP27 and GF/B13/DP2: Phase 2Decision-Making Policies and Procedures; and</li> <li>GF/B26/DP5: Delegation of Authority to Secretariat forGrant Operations. </li> </ol>
2014-03-28 B31 GF/B31/EDP01 Decision on the Secretariat’s Recommendations on Grant Extensions Decision on the Secretariat’s Recommendations on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevantimplementation periods and, where applicable, the additional funding requested forthe grants listed in Table 1.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ 35,730,528 for the following Ukraine grants: UKR-011-G08-H, UKR-011-G09-H and UKR-011-G10-H.</p>
2014-04-25 B31 GF/B31/EDP05 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants) Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ US$ 309,646,766 for the following grants: ETH-T-FMOH for Ethiopia, KEN-H-KRC and KEN-H-MOF for Kenya, MOR-011-G04-H and MOR-011-G05-T for Morocco, UGD-T-MoFPED for Uganda.</p> <p>NOTES:</p> <ol type="a"> <li>Discrepancies between the CCM Request figures and the Program Scorecard result from the clarifications process with the CCM after the Request for Renewal was submitted and/or from corrections and adjustments made by the Global Fund Secretariat at the time of grant renewal review. Based on Board Decision GF/B26/DP7 on the Modification of Rules Governing Grant Renewals dated 11 May 2012, a modified ceiling of 90% of the TRP adjusted Phase 2 amount is applied to the Grant Renewals. This also takes into account discrepancies between the CCM Request figures and the Secretariat’s recommendation.</li> </ol>
2014-10-13 B31 GF/B31/EDP24 Decision on the Secretariat’s Funding Recommendation for a Grant Renewal Decision on the Secretariat’s Funding Recommendation for a Grant Renewal
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 2 of Attachment 1 to GF/B31/ER26 (“Table 2”) in the amount indicated, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for the listed grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for the renewal of such existing grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the grant shall be the sum of the amount set out in Table 2 for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 2: Secretariat’s Funding Recommendation for a Grant Renewal (see attached: Macedonia, MKD-H-MOH)</p>
2014-06-06 B31 GF/B31/EDP13 Decision on the Secretariat’s Funding Recommendation for an Interim Applicant Decision on the Secretariat’s Funding Recommendation for an Interim Applicant
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 2, based on the understanding that the amount approved is upper ceilings rather than final funding amount for that period and that on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 2 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 2: Secretariat’s Funding Recommendation for an Interim Applicant.</p> <p>See attached table detailing total recommended funding amount of EUR 21,336,770 for NGR-708-G07-M (Niger).</p>
2014-11-03 B31 GF/B31/EDP27 Decision on the Secretariat’s Recommendation on a Grant Extension Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <p>Approves extension of the relevant implementation period for the grant listed in Table 2 of Attachment 1 to GF/B31/ER30.</p> <p>Table 2: Secretariat’s Recommendations on Grant Extension (see Annex for details)</p> <p>Tanzania (TNZ-607-G09-T)</p>
2014-09-05 B31 GF/B31/EDP22 Launch of the selection process for the next Inspector General Launch of the selection process for the next Inspector General
<p>The Board:</p> <ol> <li>Approves the establishment of a seven-member ad hoc nominations committee to assist the Board with its appointment of the next Inspector General (the “IG AHNC”) according to the Terms of Reference set out in Annex 1 of the Electronic Report to the Board that is numbered GF/B31/ER22.</li> <li>Appoints the following five individuals, based on nominations by the voting constituencies of the Board as well as the World Bank, to serve as members of the IG AHNC, each serving in his or her personal capacity: <ul> <li>Jan PAEHLER, who will also serve as Chair of the IG AHNC</li> <li>Pavel AKSENOV</li> <li>Galina MIKHLIN-OLIVER</li> <li>Navin RUGHOONUNUN</li> <li>Timothy ZIEMER</li> </ul> </li> <li>Delegates authority to the Board Chair, in consultation with the Board Vice Chair, and Chair and Vice Chair of the Audit and Ethics Committee, to appoint by 5 September 2014, the two remaining members of the IG AHNC that are not affiliated with a Board constituency, as stipulated in the Terms of Reference of the IG AHNC.</li> </ol>
2014-06-06 B31 GF/B31/EDP11 Appointment of Independent Member of the Audit and Ethics Committee Appointment of Independent Member of the Audit and Ethics Committee
<p>The Board approves the appointment of Ms. Jeya Wilson as an independent member of the Audit and Ethics Committee (the “AEC”) for a term that will expire on 9 March 2016, or until the appointment of her successor.</p>
2014-07-21 B31 GF/B31/EDP16 Appointment of the External Auditor Appointment of the External Auditor
<p>The Board authorizes the appointment of Ernst &amp; Young Ltd as the Global Fund’s external auditor for the 2014 fiscal year. </p>
2014-03-07 B31 GF/B31/DP10 Composition of and Allocation to Country Bands Composition of and Allocation to Country Bands
<ol> <li>Based on the recommendations of the Strategy, Investment and Impact Committee (the “SIIC”), the Board approves the composition of Country Bands for the 2014 – 2016 allocation period, as defined and set forth in Annex 1 to GF/B31/09 – Revision 1.</li> <li>In accordance with its decision to approve the transition framework recommended by the Finance and Operational Performance Committee and the SIIC (GF/B31/DP09), the Board acknowledges USD 15.8 billion is available for allocation to Country Bands for the 2014 – 2016 allocation period, consisting of the following: <ol type="a"> <li> USD 14.8 billion for indicative funding; and</li> <li> USD 950 million for incentive funding.</li> </ol> </li> <li>The Board approves the following allocation of indicative funding for the 2014 – 2016 allocation period: <ol type="a"> <li> Country Band 1: USD 11,250 million;</li> <li> Country Band 2: USD 915 million;</li> <li> Country Band 3: USD 1,530 million; and</li> <li> Country Band 4: USD 1,105 million.</li> </ol> </li> <li>The Board also decides incentive funding, in the amount of USD 950 million, will be apportioned across and within Country Bands 1, 2 and 3 in accordance with the methodology approved by the SIIC under authority delegated by the Board (GF/SIIC09/DP2). </li> </ol>
2014-06-06 B31 GF/B31/EDP14 Decision on the Secretariat’s Recommendations on Grant Extensions Decision on the Secretariat’s Recommendations on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 3.</li> </ol> <p>See attached table detailing total recommended funding amount of EUR 12,794,690 for BUR-H-SPCNLS (Burkina Faso) and US$ 1,277,361 for NEP-M-EDCD (Nepal).</p>
2014-04-25 B31 GF/B31/EDP03 Approval of the 2013 Statutory Financial Statements Approval of the 2013 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Statutory Financial Statements, which have been audited by Ernst &amp; Young Ltd, as set forth in GF/B31/ER02 Annex 2. </p>
2014-05-09 B31 GF/B31/EDP08 Approval of the Report of the Thirty-First Board Meeting Approval of the Report of the Thirty-First Board Meeting
<p>The Board approves the Report of the Thirty-First Board Meeting (GF/B31/19).</p>
2014-04-28 B31 GF/B31/EDP04 Appointment of Board Constituency representatives to the Finance and Operational Performance Committee Appointment of Board Constituency representatives to the Finance and Operational Performance Committee
<ol> <li>The Board acknowledges the nominations for membership of the Board’s Finance and Operational Performance Committee (the “FOPC”), as set forth in GF/B31/ER03 Revision 1”.</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the FOPC, representing the Board constituencies listed by their name, for a term that will expire on 1 May 2016 or until the appointment of their respective successors: <ul> <li>Hristijan Jankuloski, Developing Country NGO;</li> <li>Ren Minghui, Western Pacific Region;</li> <li>Nilaya Mitash, South East Asia;</li> <li>Rachel Ong, Communities;</li> <li>Safiatou Thiam, West and Central Africa;</li> <li>Kieran Daly, Private Foundations;</li> <li>Arun Thangaraj, Canada and Switzerland;</li> <li>Reinhard Tittel-Gronefeld, Germany;</li> <li>Nazzereno Todini, Private Sector; and</li> <li>Takeshi Osuga, Japan.</li> </ul> </li> <li>The Board appoints the following individuals to serve as non-voting members of the FOPC, representing the Board constituencies listed by their name, for a term that will expire on 1 May 2016, or until the appointment of their respective successors: <ul> <li>Alexandru Cebotari, World Bank; and</li> <li>Martins Pavelsons, Partners.</li> </ul> </li> </ol>
2014-11-07 B31 GF/B31/EDP28 Location of the Thirty-Second Board Meeting Location of the Thirty-Second Board Meeting
Based on the need to accommodate both the Board retreat and meeting, the Board agrees to convene the Thirty-Second Board Meeting in Montreux, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.
2014-03-07 B31 GF/B31/DP09 Transition from the Third to the Fourth Replenishment Period Transition from the Third to the Fourth Replenishment Period
<ol> <li>The Board notes its prior decision to approve the Amended and Restated Comprehensive Funding Policy (GF/B31/DP05) (the “CFP”) as a standard financial management framework, and acknowledges unique measures are required to facilitate the 2014 allocation of resources to Country Bands, the first under the allocation-based funding model, to manage the transition from the rounds-based system.</li> <li>Accordingly, based on the joint recommendation of the Finance and Operational Performance Committee (the “FOPC”) and the Strategy, Investment and Impact Committee (the “SIIC”), the Board adopts the following transition framework: <ol type="a"> <li>The total amount that will be allocated to Country Bands (the “Total Allocation”) using the allocation methodology will be comprised of the following amounts: <ol type="i"> <li>The Initial Allocation, in the amount of USD 10.22 billion, as approved under decision point GF/B31/DP08, which will determine the amount of incentive funding; and</li> <li>The amount of Sources of Funds, as defined in the CFP, originating from the Third Replenishment Period (2011 – 2013), or earlier, which have not been disbursed as at 31 December 2013 (the “Existing Funds”), in the amount of USD 5.55 billion, as recommended by the FOPC.</li> </ol> </li> <li>While each grant applicant’s portion of the Total Allocation must be requested by the applicant and approved by the Board prior to 31 December 2016, it may be utilized beyond such date in accordance with the terms of the relevant grant agreement;</li> <li>The Total Allocation will address the remaining pipeline of grant funding due to Board-approved proposals or other Board decisions originating from the Third Replenishment Period, or earlier, as at 31 December 2013, (the “Existing Grants Pipeline”) while taking a comprehensive approach such that performance and strategic impact are reflected in the investment of the entirety of funds;</li> <li>While each disease component’s portion of the Total Allocation will typically cover a period of four years starting from 1 January 2014, the Secretariat, working together with countries and/or regions, has the operational flexibility to structure longer or shorter grant implementation periods while applying the principles of the allocation model (GF/B28/DP4) to guide funding levels towards the amounts derived from the allocation formula;</li> <li>Accordingly, a 25-percent target minimum reduction compared to the most recent available four-year disbursement levels (the “Graduated Reduction”) will be applied across the portfolio of disease components that have funding levels above their notional shares under the allocation methodology; and</li> <li>If a disease component’s Existing Grants Pipeline exceeds the amount that would result from applying the Graduated Reduction described in paragraph 2.e. above, then instead of applying the Graduated Reduction, the disease component’s Existing Grants Pipeline will serve as a basis to determine its total allocation starting from 1 January 2014.</li> </ol> </li> <li>The Board notes the transition framework established under this decision represents measures tailored to address the unique circumstances and challenges of transitioning from the rounds-based system to the allocation-based funding model and shall not apply to subsequent allocations and Replenishment Periods.</li> </ol>
2014-03-07 B31 GF/B31/DP07 Regional Programs Regional Programs
<ol> <li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards investments that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7). </li> <li>Based on the recommendation of the Strategy, Investment and Impact Committee, as set forth in GF/B31/08B, the Board: <ol type="a"> <li>Decides that USD 200 million will be available for new Regional Programs over the 2014 – 2016 allocation period;</li> <li>Recognizes that Regional Programs will be presented to the Board for funding approval throughout the 2014 – 2016 allocation period; and</li> <li>Acknowledges funding applications that are submitted by a group of small island economies or other small countries that typically would not apply as individual countries due to inherent administrative inefficiencies (the “Multi-Country Applications”) will be funded from amounts allocated to the individual disease components participating in each Multi-Country Application. </li> </ol> </li> </ol>
2014-03-07 B31 GF/B31/DP04 2014 Operating Expenses Budget 2014 Operating Expenses Budget
<ol> <li>Based on the recommendation of the Finance and Operational PerformanceCommittee (the “FOPC”), the Board approves the 2014 operating expenses budgetin the amount of USD 298.8 million, as set forth in GF/B31/03 Part A (the “2014Operating Expenses Budget”), which includes USD 20.5 million for the Office ofthe Inspector General’s 2014 operating expenses.</li> <li>As previously decided by the Board (GF/B22/DP18), the Secretariat willmanage the 2014 Operating Expenses Budget’s exposure to foreign-exchange ratevolatility and include in its periodic reporting to the FOPC on budget mattersany measures taken to minimize such exposure.</li> </ol>
2014-07-21 B31 GF/B31/EDP17 Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Financial Statements
The Board notes the Audit and Ethics Committee’s (the “AEC”) responsibility to oversee financial accounting and reporting matters and requests that, following a limited review by the Global Fund’s external auditor, the AEC reviews and authorizes the publication of interim condensed consolidated financial statements which have been prepared by the Secretariat.
2014-03-07 B31 GF/B31/DP05 Amended and Restated Comprehensive Funding Policy Amended and Restated Comprehensive Funding Policy
<ol> <li>Based on the recommendation of the Finance andOperational Performance Committee, the Board approves the amended and restatedComprehensive Funding Policy, as set forth in GF/B31/04 – Annex 1 (the “Amendedand Restated CFP”). </li> <li>The Amended and Restated CFP supersedes all priorversions of the Comprehensive Funding Policy, and any related decisionspreviously adopted by the Board or its Committees that are inconsistent withthe Amended and Restated CFP. </li> </ol>
2014-03-07 B31 GF/B31/DP11 Revision to the OIG Disclosure Policy and the OIG Charter Revision to the OIG Disclosure Policy and the OIG Charter
<ol> <li>Based on the recommendation of the Audit and Ethics Committee, the Board approves the Policy for Disclosure of Reports Issued by the Inspector General, as revised and set forth in Annex 1 to GF/B31/12, which supersedes and replaces the disclosure policy adopted by the Board under GF/B20/DP23.</li> <li>Accordingly, the Board approves the following revision to Section 15 of the Charter of the Office of the Inspector General <a>[1]</a>(the “OIG Charter”) to align the OIG Charter with the revised Policy for Disclosure of Reports Issued by the Inspector General:</li> </ol> <blockquote> <p>“15. Reporting: Final reports of Office of the Inspector General regarding its <span style="text-decoration: line-through;">external</span> assurance and investigations work will be posted on the Global Fund’s public internet site in accordance with the Board-approved ‘Policy for Disclosure of Reports Issued by the Inspector General’<span style="text-decoration: line-through;">. Internal assurance findings will be promptly reported to the Executive Director and the AEC for internal action.</span>”</p> </blockquote>
2020-11-11 B44 GF/B44/DP03 Approval of 2021 Work Plan and Budget Narrative and the 2021 Operating Expenses Budget Approval of 2021 Work Plan and Budget Narrative and the 2021 Operating Expenses Budget
<ol> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the following: <ol type="a"> <li>2021 Work Plan and Budget Narrative, as set forth in GF/B44/02A; and</li> <li>The 2021 Operating Expenses Budget in the amount of US$315 million, as set forth in GF/B44/02B (the “2021 OPEX Budget”), which includes US$ 14.90 million for the Office of the Inspector General’s 2021 operating expenses.</li> </ol> </li> </ol>
2014-05-23 B31 GF/B31/EDP10 Approval of the Terms of Reference for the 2014 Ad-Hoc Working Group on Governance Approval of the Terms of Reference for the 2014 Ad-Hoc Working Group on Governance
<p>The Board approves the Terms of Reference for the 2014 Ad-Hoc Working Group on Governance, as set forth in Annex 1 to GF/B31/ER06.</p>
2014-11-03 B31 GF/B31/EDP26 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER30 ( “Table 1”); provided, however, that the disbursement of any and all funding for the grant “KAZ-T-NCTP” is subject to satisfactory resolution in line with the Global Fund policies by the Republic of Kazakhstan of all recoveries and other OIG matters now pending in draft or final forms;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>GF/B32/EDP26 - Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation (see Annex for details)</p> <p>Indonesia (IDN-M-PERDHAK and IDN-M-MOH), Kazakhstan (KAZ-T-HOPE and KAZ-T-NCTP), Timor Leste (TLS-M-MOH), Philippines (PHL-M-PSFI), Swaziland (SWZ-M-NERCHA), Zambia (ZMB-C-CHAZ, ZMB-C-MOH, ZMB-M-CHAZ and ZMB-M-MOH)</p>
2014-08-01 B31 GF/B31/EDP19 Decision on the Secretariat’s recommendation for discontinuation of funding for a renewal Decision on the Secretariat’s recommendation for discontinuation of funding for a renewal
<p>The Board:</p><ol><li>Declines approval of additional funding for the next implementation period for the Round 10 Jordan TB grant (JOR-011-G04-T).</li></ol><p>Table 1: Secretariat’s Recommendation for Discontinuation of Funding for a Renewal </p><p><i>See attached table.</i></p>
2014-04-25 B31 GF/B31/EDP06 Decision on the Secretariat’s Funding Recommendation for an Interim Applicant Decision on the Secretariat’s Funding Recommendation for an Interim Applicant
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grant’s total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches.</p> <p>See attached table detailing total recommended funding amount of EUR 731,918 for the following grant: MOL-H-PCIMU for Moldova.</p>
2014-09-25 B31 GF/B31/EDP21 Decision on the Secretariat’s Recommendations on Policy Exceptions for Processing Iraq TB Grant (IRQ-T-UNDP) Related Transition Funding Application Decision on the Secretariat’s Recommendations on Policy Exceptions for Processing Iraq TB Grant (IRQ-T-UNDP) Related Transition Funding Application
<ol> <li>The Board acknowledges the current political context and challenging implementation environment in Iraq due to ongoing conflicts. and</li> <li>Accordingly, the Board approves the following policy exceptions for processing IRQ-T-UNDP related transition funding application: <ol type="a"> <li>Maintaining the counterpart financing threshold at the level of 40%;</li> <li>Waiver of the “willingness to pay” requirement; and</li> <li>Waiver of the CCM eligibility requirements to access transition funding.</li> </ol> </li> </ol>
2014-10-13 B31 GF/B31/EDP23 Decision on the Secretariat’s recommendation on additional funding from the 2014 Allocation Decision on the Secretariat’s recommendation on additional funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER26 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation. (see attached: Moldova, HIV/AIDS, MDA-H-PAS, MDA-H-PCIMU).</p>
2014-05-26 B31 GF/B31/EDP09 Decision on the Secretariat’s Recommendation on a Grant Extension Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <ol> <li>Approvesextension of the relevant implementation period and, where applicable, theadditional funding requested for the grant listed in Table 1.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ 11,300,472 for the following grant: ZAR-911-G14-T for Democratic Republic of Congo (DRC).</p>
2014-03-07 B31 GF/B31/DP14 Appointment of Strategy, Investment and Impact Committee Members and Launch of New Call for Nominations of Members of the Finance and Operational Performance Committee Appointment of Strategy, Investment and Impact Committee Members and Launch of New Call for Nominations of Members of the Finance and Operational Performance Committee
<ol> <li>The Board acknowledges the nominations for membership of the Board’s Strategy, Investment and Impact Committee (the “SIIC”), as set forth in GF/B31/10”.</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Aida Kurtovic, Eastern Europe and Central Asia;</li> <li>Vinand Nantulya, Eastern and Southern Africa;</li> <li>Abdalla Osman, Eastern Mediterranean Region;</li> <li>Mirta Roses, Latin America and the Caribbean;</li> <li>Asia Russell, Developed Country NGO;</li> <li>Helga Fogstad, Point 7;</li> <li>Jason Lane, UK-Australia;</li> <li>Julia Martin, USA;</li> <li>Philippe Meunier, France; and</li> <li>Jan Paehler, European Commission.</li> </ol> </li> <li>Noting that the Chair of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the SIIC, the Board appoints the following individuals to serve as additional non-voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Lucica Ditiu, Partners; and</li> <li>Mbulawa Mugabe, UNAIDS.</li> </ol> </li> <li>The Board decides to launch a new call for nominations for the Finance and Operational Performance Committee (the “FOPC”) with a due date for nominations by 26 March 2014. The Chair and Vice-Chair of the Board will present its recommendation of candidates to the Board for approval by 15 April 2014.</li> <li>The Board notes that qualified candidates that have already been nominated, but not appointed, for a Committee role will remain in consideration for FOPC membership.</li> <li>The Board urges constituencies to nominate additional candidates that clearly demonstrate the competencies and skills that are required to perform the responsibilities of FOPC members. </li> </ol>
2014-04-25 B31 GF/B31/EDP07 Decision on the Secretariat’s Recommendation on a Grant Extension Decision on the Secretariat’s Recommendation on a Grant Extension
<p>TheBoard:</p> <p>Approvesextension of the relevant implementation period and, where applicable, theadditional funding requested for the grant listed in Table 3.</p> <p>See attached table detailing total recommended funding amount of US$ 12,973,121 for the following grant: SUD-011-G15-H for Sudan.</p>
2014-03-07 B31 GF/B31/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the Thirty-First Board Meeting (GF/B31/01) is approved.</p>
2014-06-06 B31 GF/B31/EDP12 Decision on the Secretariat’s Funding Recommendation for the Continuation of a Global Fund TB Program in the Central African Republic Decision on the Secretariat’s Funding Recommendation for the Continuation of a Global Fund TB Program in the Central African Republic
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation</p> <p>See attached table detailing total recommended funding amount of EUR 971,313 for CAF-911-G09-T (Central African Republic).</p>
2014-03-07 B31 GF/B31/DP03 Approval of Report of the Thirtieth Board Meeting Approval of Report of the Thirtieth Board Meeting
<p>The report of the Thirtieth Board Meeting (GF/B31/02) is approved.</p>
2014-06-23 B31 GF/B31/EDP15 Decision on the Secretariat’s funding recommendation for a grant renewal Decision on the Secretariat’s funding recommendation for a grant renewal
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation for a Grant Renewal</p> <p>See attached table detailing total recommended funding amount of EUR 981,882 for KOS-911-G05-T (Kosovo).</p>
2014-03-07 B31 GF/B31/DP06 Special Initiatives Special Initiatives
<ol> <li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards initiatives that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7) (the “Special Initiatives”). </li> <li>Based on the recommendation of the Strategy, Investment and Impact Committee (the “SIIC”), the Board decides that up to USD 100 million will be available over the 2014 – 2016 allocation period for the following Special Initiatives, as described in GF/B31/08A – Revision 1, in the amounts listed below: <ol type="a"> <li>USD 30 million for the Humanitarian Emergency Fund;</li> <li>USD 17 million for Country Data Systems; </li> <li>USD 29 million for Technical Assistance for Strong Concept Notes and PR Grant-making Capacity Building; </li> <li>USD 15 million for Technical Assistance on Community, Rights and Gender; and</li> <li>USD 9 million for Enhancing Value for Money and Financial Sustainability of Global Fund Supported Programs.</li> </ol> </li> <li>The funds available for Special Initiatives may be reallocated by the Secretariat among the Special Initiatives set forth under paragraph 2 above, upon the SIIC’s approval, in consultation with the Finance and Operational Performance Committee (the “FOPC”), of an updated budget and plan to implement such initiatives.</li> <li>The Secretariat shall recover investments towards Special Initiatives from funding provided through grant programs whenever possible.</li> <li>With respect to the use of funds available for the Special Initiatives, the Board requests the Secretariat to report to the FOPC on the financial implications and to the SIIC on the operational and strategic implications. </li> </ol>
2014-03-07 B31 GF/B31/DP13 Appointment of Audit and Ethics Committee Members Appointment of Audit and Ethics Committee Members
<ol> <li>The Board acknowledges the recommendations set forth in GF/B31/10 outlining the membership appointment recommendations for the Board’s Audit and Ethics Committee (the “AEC”).</li> <li>Accordingly, the Board approves the appointment of the following individuals to the AEC for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Graham Jocelyne as independent Chair of the AEC;</li> <li>Mohammed Abdellatif as independent member of the AEC;</li> <li>Gabor Amon as independent member of the AEC;</li> <li>Wendy Harrison as independent member of the AEC; and</li> <li>Christopher Kassami as a constituency-nominated member from the Eastern and Southern Africa Constituency.</li> </ol> </li> </ol>
2014-03-07 B31 GF/B31/DP08 2014 – 2016 Initial Allocation 2014 – 2016 Initial Allocation
<ol> <li>The Board acknowledges: <ol type="a"> <li>The Finance and Operational Performance Committee’s recommendation on the amount of announced replenishment results for the 2014 – 2016 Replenishment Period, net of certain adjustments and qualifying deductions, that will be allocated to Country Bands at the start of the Allocation Period (the “Initial Allocation”), as set forth in GF/B31/06, in accordance with the Comprehensive Funding Policy, as amended and restated under decision point GF/B31/DP05; and</li> <li>The Board’s approval of the Strategy, Investment and Impact Committee’s recommendation to apportion USD 100 million to finance Special Initiatives and USD 200 million to finance Regional Programs over the 2014 – 2016 period (GF/B31/DP06 and GF/B31/DP07 respectively).</li> </ol> </li> <li>Accordingly, the Board decides the Initial Allocation for the 2014 – 2016 Replenishment Period is USD 10.22 billion.</li> </ol>
2014-04-25 B31 GF/B31/EDP02 Approval of the 2013 Annual Financial Report Approval of the 2013 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Annual Financial Report, which includes the 2013 Consolidated Financial Statements that have been audited by Ernst &amp;amp; Young Ltd, as set forth in GF/B31/ER02 Annex 1.</p>
2014-10-13 B31 GF/B31/EDP25 Decision on the Secretariat’s Recommendation on a Grant Extension Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <p>Approves extension of the relevant implementation period for the grant listed in Table 3 of Attachment 1 to GF/B31/ER26.</p> <p>Table 3: Secretariat’s Recommendations on Grant Extension (see attached: Burundi, BRN-202-G05-M (BRN-M-SEPCNLS))</p>
2014-08-25 B31 GF/B31/EDP20 Decision on the Secretariat’s recommendations on grant extensions Decision on the Secretariat’s recommendations on grant extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 1.</li> </ol> <p>Table 1: Secretariat’s Recommendations on Grant Extensions</p> <p>See attached table detailing total recommended funding amount of US$ 69,353,613 for UGD-708-G07-H and US$ 1,200,000 for UGD-708-G13-H (Uganda).</p>
2014-03-07 B31 GF/B31/DP01 Appointment of Rapporteur Appointment of Rapporteur
Minister Benedict Xaba from the Eastern and Southern Africa constituency is designated as Rapporteur for the Thirty-First Board Meeting.
2004-06-30 B08 GF/B08/DP11 Fifth Call for Proposals Fifth Call for Proposals
<p><span>The Board requests the Secretariat to begin preparations for the Fifth Call for Proposals, to enable a decision at the Ninth Board Meeting on the Fifth Call for Proposals.</span></p><p><span>There are no material budgetary implications for this decision point.</span></p>
2006-04-28 B13 GF/B13/DP11 Executive Director Performance Review 2006 Executive Director Performance Review 2006
The Board approves the proposed 15 Key Performance Indicators for the Executive Director and associated 2006 targets as presented in Annex 1 of GF/B13/12.
2006-04-28 B13 GF/B13/DP07 Revision to the Continuity of Services Policy Revision to the Continuity of Services Policy
<p>The Board recognizes that the funding under the Continuity of Services Policy should apply to ongoing courses of treatment, whether the treatment is for a limited duration (such as tuberculosis) or is life-long (such as anti-retroviral therapy). To address this, the Board amends the decision at the Twelfth Board Meeting on Continuity of Services as set out in Annex 4 to the Report of the Policy and Strategy Committee (GF/B13/7).</p>
2006-04-28 B13 GF/B13/DP01 Approval of Agenda Approval of Agenda
The agenda for the Thirteenth Board Meeting (GF/B13/1) is approved, as amended at the Thirteenth Board Meeting.
2006-08-25 B13 GF/B13/EDP07 Approval of Bridge Funding Recommendation for Western Cape HIV/AIDS Round 3 South Africa Grant Approval of Bridge Funding Recommendation for Western Cape HIV/AIDS Round 3 South Africa Grant
The Board approves additional funding of up to USD5,729,444 for the Round 3 South Africa grant for the HIV/AIDS program entitled “Strengthening and Expanding the Western Cape HIV/AIDS prevention, treatment and care programmes” (Grant No SAF-304-G04-H) to ensure program continuation until January 31, 2007.
2006-04-28 B13 GF/B13/DP08 Annual Report Annual Report
The Board approves the Annual Report as presented in GF/B13/15 and as amended at the Thirteenth Board Meeting. 
2006-04-28 B13 GF/B13/DP17 Resource Mobilization Resource Mobilization
<p><b>Decision Point 1: </b> </p><p>The Board adopts the Resource Mobilization Framework developed by the Finance and Audit Committee, attached as Annex 1 of the Report of the Finance and Audit Committee (GF/B13/9), and requests the Finance and Audit Committee to monitor the implementation of the framework, and its role in guiding the replenishment process, and report regularly to the Board.</p><p><b>Decision Point 2:</b> </p><p>The Board requests the Finance and Audit Committee to keep under review the strategy development process led by the Policy and Strategy Committee as it relates to Resource Mobilization and to develop a longer term resource mobilization policy in the light of the approved strategy.</p>
2006-04-28 B13 GF/B13/DP31 Executive Director Nomination Committee Executive Director Nomination Committee
<p><b>Decision Point 1:</b> </p><p>The Board approves the composition of the Executive Director Nomination Committee to be composed of Carol Jacobs, Lieve Fransen, Carsten Staur, Carol Presern, Jimmy Kolker, Peter Van Rooijen, Urbain Olangena Awono and Ren Minghui.</p><p><b>Decision Point 2:</b> </p><p>The Board decides that the Executive Director Nomination Committee shall operate under the following terms of reference:</p><p>1. The Nomination Committee shall assist the Board with the selection of the next Executive Director of the Global Fund under an Action Plan approved by the Board. To that end, it shall:</p><p>- select an executive search firm, based on a competitive process;</p><p>- guide recruitment based on the criteria for selection of the Executive Director that were approved by the Board; and</p><p>- oversee the search process.</p><p>2. The Nomination Committee shall present a list of 5 candidates to the Board, giving reasons for their assessments which should include the extent to which each candidate fulfils the relevant selection criteria and the candidate's ability to perform the duties of the Executive Director as outlined in the Terms of Reference. </p><p>3. The Nomination Committee shall prepare a decision making process for the Board on the selection of candidate at the Fourteenth Board meeting.</p><p>4. Membership in the Committee shall not count towards the two-committee limit set forth in Section 23 of the Board Operating Procedures.</p>
2006-08-16 B13 GF/B13/EDP06 Approval of Phase 2 Funding Recommendations August 2006 Approval of Phase 2 Funding Recommendations August 2006
#
2006-04-28 B13 GF/B13/DP33 Executive Director Recruitment Process Executive Director Recruitment Process
<p><b>Decision Point 1: </b> </p><p>The Board approves the action plan for the recruitment of the Executive Director set forth in Annex 2 to the Report of the Executive Director Transition (GF/B13/14) as revised at the Thirteenth Board meeting.</p><p><b>Decision Point 2:</b> </p><p>The timeline set by the Board for the selection of the new Executive Director is based on the expectation that he or she would be able to take office by January 2007. However, given that this is not certain to happen, the Board requests WHO to extend the contract of Professor Feachem to March 31, 2007. The Board acknowledges Professor Feachem's statement that, notwithstanding the end date of his contract, he is able to leave office at the time his successor is ready to assume it, as determined by the Chair and Vice Chair of the Board.</p>
2006-04-28 B13 GF/B13/DP15 Approval of Audited Financial Statements for 2005 Approval of Audited Financial Statements for 2005
The Board approves the 2005 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young, attached as Annex 7 to the Report of the Finance and Audit Committee (GF/B13/9).
2006-04-28 B13 GF/B13/DP13 Executive Director Recruitment Process Executive Director Recruitment Process
The Board approves the revised Terms of Reference for the Executive Director, attached as Annex 1 to the Report of the Executive Director Transition (GF/B13/14), which shall be used as the basis for the recruitment of a new Executive Director.
2006-04-28 B13 GF/B13/DP16 Approval of the Charter of the Office of the Inspector General, and Approval of the 2006 Budget of the Office of the Inspector General Approval of the Charter of the Office of the Inspector General, and Approval of the 2006 Budget of the Office of the Inspector General
<p><b>Decision Point 1: </b> </p><p>The Board approves the Charter of the Office of the Inspector General, attached as Annex 5 to the Report of the Finance and Audit Committee (GF/B13/9) with the addition of a reference to the Administrative Services Agreement with the World Health Organization (WHO).</p><p>There are no material budgetary implications for this decision.</p><p><b>Decision Point 2: </b> </p><p>The Board approves the 2006 budget in the amount of US$2,015,000 to be used exclusively for the Office of the Inspector General ("OIG"), as set out on page 6 of the Report of the Finance and Audit Committee (GF/B13/9) and as proposed by the Inspector General and recommended by the Finance and Audit Committee. This amount supersedes and replaces the US$823,000 which was allocated to the OIG in the 2006 Secretariat Operating Expenses Budget approved at the Twelfth Board Meeting.</p><p>The budgetary implications of this decision are a maximum of US$1,192,000 in 2006 which would be reduced by any savings achieved on the budget approved for LFA fees and Secretariat expenses.</p>
2006-04-28 B13 GF/B13/DP09 Follow-up to the Internal Oversight Services Report Follow-up to the Internal Oversight Services Report
<p>The Board endorses the findings of the ad hoc Oversight Committee with respect to: </p><p>(a) the management action plan prepared in response to the report of the WHO Office of Internal Oversight Services (the "IOS Report"); and</p><p>(b) work carried out to date by the Global Fund's Deputy Executive Director and the Legal Counsel with respect to determination of accountability for adverse findings described in the IOS Report and the protection of whistleblowers. </p><p>The Board accordingly dissolves the ad hoc Oversight Committee and requests the Secretariat to continue to carry out the processes referred to in points (a) and (b) of this decision, with continued attention to the protection of whistleblowers. The Board requests the Inspector General to continue to oversee the work of the Secretariat in this area and report back to the Board as part of his normal periodic reports to the Board. </p>
2006-04-28 B13 GF/B13/DP12 Approval of Revised Board Operating Procedures and Bylaws (Executive Director clauses) Approval of Revised Board Operating Procedures and Bylaws (Executive Director clauses)
<p><b>Decision Point 1:</b> </p><p><b>The Board amends Article 8 of the Bylaws as follows:</b> </p><p>Article 8. Secretariat</p><p>8.1 Composition</p><p>The Secretariat is responsible for managing the day-to-day operations of the Foundation.</p><p>The Secretariat is headed by an Executive Director, who is selected by the Foundation Board <u>based on merit, in a non-political, open and competitive manner. The Executive Director</u> <strike>and</strike> acts as the chief executive officer of the Foundation <u>and serves for a term of four years, renewable for not more than one additional term of three years</u>.</p><p>The Executive Director is responsible to the Foundation Board for the day-today management of the Foundation, and for specific duties and responsibilities assigned to him <u>or her</u> by the Foundation Board.</p><p>Secretariat staff are selected by the Executive Director, under policies and procedures approved by the Foundation Board. </p><p><b>Decision Point 2: </b> </p><p><b>The Board amends Section 17 of the Board Operating Procedures as follows:</b> </p><p>17. Executive Director</p><p>The Executive Director shall attend all Board Meetings, and shall be responsible for the preparation and distribution of all materials required for the meeting, and for such other duties and responsibilities as may be assigned by the Board or the Chair. The Executive Director shall be appointed by the Board <u>for a term of four years, renewable for not more than one additional term of three years</u> <strike>two year renewable term</strike>.</p>
2006-04-28 B13 GF/B13/DP32 Executive Director Selection Criteria Executive Director Selection Criteria
The Board approves the selection criteria for the recruitment of the Executive Director in Annex 3 to the Report of the Executive Director Transition (GF/B13/14) as revised at the Thirteenth Board meeting.
2006-04-28 B13 GF/B13/DP22 Approval of Round 6 Guidelines and Proposal Form Approval of Round 6 Guidelines and Proposal Form
The Board approves the Guidelines and Proposal Form for the Sixth Call for Proposals (as presented in Annex 4 and Annex 5 of GF/B13/8), as amended at the Thirteenth Board Meeting.
2006-04-28 B13 GF/B13/DP04 Progress on Strategy Development Progress on Strategy Development
<p>The Board acknowledges the progress made on developing options for the strategic issues in Batch 1 as outlined in the Report of the Policy and Strategy Committee (GF/B13/7). In particular, the Board notes the agreed outcomes of the Policy and Strategy Committee set out in Annex 3 to the Report of the Policy and Strategy Committee (GF/B13/7).</p><p> In addition, the Board requests that the development of options continue, and that the Policy and Strategy Committee present to the Board the work on option development for Batches 2 and 3, as well as a draft strategy document, at the Fourteenth Board meeting.</p>
2006-10-16 B13 GF/B13/EDP10 Extension of Deadline for Signing Grant Agreements Extension of Deadline for Signing Grant Agreements
<span>The Board extends the deadline for the signing of a grant agreement for the countries listed in Annex A for three months to 31 December, 2006. </span>
2006-04-28 B13 GF/B13/DP36 Secondment Activity at the Secretariat Secondment Activity at the Secretariat
The Board notes with concern the questions raised by the Ethics Committee on existing Secretariat secondment practice, and requests that the Ethics Committee undertake a review the Secretariat policy on secondments and associated conflict of interest issues and report back to the Board at the Fourteenth Board meeting.
2004-06-30 B08 GF/B08/DP20 Transfer from 2004 Budget Transfer from 2004 Budget
<p>The Board notes and shares the concerns expressed in the report of the Executive Director as to the situation with regard to Portfolio Management staffing, in view of the anticipated rapid acceleration of workload in July - December 2004 and beyond.</p><p>MEFA will call a special meeting of a Finance sub-group in advance of the 7 - 8 October MEFA meeting to further review and analyze the staffing situation and the budget implications for 2004 and 2005. This meeting will also review the 2005 and 2006 draft budget details to ensure that the preparation of the budget is completed in accordance with the agreed schedule and to deliver fully developed proposals to Board members by<br/>October 22, 2004.</p><p>As an exceptional measure, the Board authorizes an increase in the 2004 Secretariat budget of up to $2.0 million, representing + 29 positions, a maximum staffing of 118 positions. This translates into a 2005 commitment of $ 4.8 million (annual basis).</p><p>This will be financed in 2004 by a $ 1.7 million transfer from the 2004 LFA budget and the use of up to $ 300,000 from the contingency provision, after exploring other 2004 savings options.</p>
2004-06-30 B08 GF/B08/DP12 Timeframes for Grant Agreements Timeframes for Grant Agreements
<p><span><b>Decision Point 1:</b> </span></p><p><span>The Board recommends that a maximum time limit is needed for a proposal to result in one or a few grant agreements to set performance incentives for all actors involved in this process. This includes the Secretariat, the TRP, LFAs, CCMs and PRs, with responsibilities to be clearly defined. Based on these specified responsibilities, all actors are accountable for completing the necessary work between Board approval of a proposal and grant agreement signing as swiftly as possible.<br/></span></p><p><span>There are no material budgetary implications for this decision point.<br/></span></p><p><span><b>Decision Point 2:<br/></b> </span></p><p><span>The Board recommends that the normal time from Board approval of a proposal to grant agreement signing should be approximately 6 months. If a grant agreement has not been signed 12 months after Board approval, the proposal should no longer be considered approved unless the Board decides to allow a further exceptional time extension based on information received from the Secretariat and CCMs. This time extension will be limited to a maximum of 3 months.<br/></span></p><p><span>Based on further experiences with Global Fund processes, the Secretariat will provide improved estimates on the time required to complete the work between Board approval and grant signing to MEFA before the November Board meeting. At this time, the Boarf may decide to shorten the maximum time limit specified in decision point 2.<br/></span></p><p><span>The resources allocated to a Board-approved proposal that has no signed grant agreement within the specified time period shall be made available for other priority uses according to the Global Fund financial policies.<br/></span></p><p><span>This policy shall not apply for Rounds 1 and 2.<br/></span></p><p><span>There are no material budgetary implications for this decision point.<br/><br/><b>Decision Point 3:<br/></b></span></p><p><span>The Board recommends that the Secretariat analyze possible implications for proposals approved in Round 3 for which grant agreements have not been signed within the maximum time limit specified.<br/></span></p><p><span></span></p>
2004-06-30 B08 GF/B08/DP8 Legal Status Legal Status
<p><span>The Board authorizes the signing of the Headquarters Agreement based on the text attached as Annex 4a to the Report of the Governance and Partnership Committee.</span></p>
2004-06-30 B08 GF/B08/DP17 Country Coordinating Mechanisms Country Coordinating Mechanisms
<p>The Board adopts the requirements and recommendations as proposed in Annex 3a, and treats all requirements in this document as recommendations, in order to improve the functioning of Country Coordinating Mechanisms as public-private partnerships of all relevant stakeholders.</p> <p>With regards to HIV/AIDS, coordination efforts should be done within the overall framework of the "Three Ones".</p> <p>The Board decided to table Option 1 of Recommendation 9.</p> <p>The Board decided to replace Recommendation 13 with the following:</p> <ul> <li>The Board takes note of the recommendation contained in the reports of GPC, MEFA and TRP concerning the need to strengthen technical assistance and capacity development. Considering the urgency and cross-cutting nature, the Board recommends the formation of a special Ad Hoc Working Group to assess needs and make policy recommendations to facilitate the provision of technical assistance and capacity development for and through Country Coordinating Mechanisms, Principal Recipients, Sub-Recipients, inclusive of all phases of the Fund's grant cycle. The Ad Hoc Working Group will present recommendations for approval at the Ninth Board Meeting.</li> </ul> <p>The Board decided to replace Recommendation 15a with the following:</p> <ul> <li>The Board further directs the Secretariat, in consultation with the TERG, to develop a pilot set of auditable standards for benchmarking the performance of CCMs and report back through the GPC by the Ninth Board Meeting.</li> </ul>
2004-06-30 B08 GF/B08/DP15 Replenishment Mechanism Replenishment Mechanism
<p>The Board adopts the paper describing the operational modalities to implement the process of Voluntary Replenishment (as outlined in Annex 3 of the Report of the Resource Mobilization and Communication Committee (RMCC)).</p>
2004-06-30 B08 GF/B08/DP21 Three Ones Framework Three Ones Framework
<p>The Global Fund strongly endorses the "Three Ones Framework".</p><p>In this context the Board welcomes the recent initiative led by Chairman Thompson, U.S. Ambassador Tobias and European Union leaders to call together key stakeholders -including WHO, UNAIDS, the World Bank, the Global Fund and major donors, to take forward practically the 'Three Ones" agenda.</p><p>We commit the Global Fund, both now and in the future, to work practically and concretely with others to improve and measure coordination and make a success of harmonization as outlined in the "Three Ones Framework".</p><p>Specifically, the Secretariat should explore as part of the CCM indicator framework and other processes, the monitoring of the Global Fund's performance in harmonizing its own processes and procedures with other in-country national frameworks and coordination mechanisms.</p>
2004-06-30 B08 GF/B08/DP4 Voting Rights for Communities Voting Rights for Communities
<p><span>The Board approves, with immediate effect, the amendments to the Bylaws and Board Operating Procedures (as outlined below) that add a constituency represented by a representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria (the "Communities delegation") as a full voting member of the Board.</span></p><p><span>The Board announces its intention to add an additional and balancing donor seat when new donor resources become available which meet an appropriate financial threshold.</span></p><p><span>Amendments:</span></p><p><span>Article 7.1 of the Bylaws is amended as follows:</span></p><p><span>7.1. Composition</span></p><p><span>The Foundation Board shall consist of <u>nineteen voting members and four nonvoting members</u>. Each voting member shall have one vote.</span></p><p><span>Voting members of the Foundation Board shall consist of:</span></p><ul><li><span>Seven representatives from developing countries, one representative based o each of the six World Health Organization ("WHO") regions and one additional representative from Africa.</span></li><li><span> Seven representatives from donors.</span></li><li><span><u>Five</u> representatives from civil society and the private sector (one representativ of a non-governmental organization ("NGO") from a developing country, one representative of an NGO from a developed country, one representative of th private sector, one representative of a private foundation, <u>and one representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria)</u>.</span></li></ul><p><span>The <u>four</u> ex-officio nonvoting members of the Foundation Board shall consist of:</span></p><ul><li><span>One representative from the W HO;One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS");</span></li><li><span>One representative from the trustee; and</span></li><li><span> One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Foundation to the extent required by Swiss law.</span></li></ul><p><span>Members of the Foundation Board ("Board Members") may each appoint one Alternate Member to serve in their stead, under policies and procedures determined by the Foundation Board.</span></p><p><span>The third paragraph of Article 7.6 is amended as follows:</span></p><p><span>7.6 Operations</span></p><p><span>The Foundation Board shall use best efforts to make all decisions by consensus. If all practical efforts by the Foundation Board and the Chair have not led to consensus, any member of the Foundation Board with voting privileges may call for a vote. In order to pass, motions require a two-thirds majority of those present of both: a) the group encompassing the seven donor seats and the two private sector seats and b) the group encompassing the seven developing country seats, the two non-governmental organization seats, <u>and the representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria</u>.</span></p><p><span>Section 10 of the Board Operating Procedures is amended as follows:</span></p><p><span>10. Decision-making</span></p><p><span>The Board shall use best efforts to reach all decisions by consensus. If all practical efforts by the Board and the Chair have not led to consensus, any member of the Board with voting privileges may call for a vote. In order to pass, motions require a two-third majority of those present of both: a) the group encompassing the 7 donor seats and the 2 private sector seats and b) the group encompassing the 7 developing country seats, the 2 non-governmental organization seats, <u>and the representative of an NGO who is person living with HIV/AIDS or from a community living with tuberculosis or malaria</u>. </span></p><p><span>There are no material budgetary implications for this decision point.</span></p>
2004-06-30 B08 GF/B08/DP1 Appointment of the Rapporteur Appointment of the Rapporteur
Dr. Carol Jacobs from the Latin America and Caribbean Constituency is designated as Rapporteur for the Eighth Board Meeting.
2004-06-30 B08 GF/B08/DP5 Phase 2 Funding (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA)) Phase 2 Funding (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA))
<p><span>Decision Point 1: </span></p> <p><span>1.1 The Board decides that special policies and procedures are required in the event o insufficient resources during a certain calendar year to fund all Phase 2 grant renewals. Such a situation of resource constraints would become evident at the final </span><span>Board meeting of the previous year.</span></p> <p><span>1.2 The Board decides that provided funding is available for at least one year of renewals, available resources will be allocated among all grants that satisfy the Global Fund's renewal criteria according to a time-limited partial allocation system.</span></p> <ol type="a"> <li><span>A time-limit for renewed grants should be established by the Board at the final Board meeting of the year prior to the year of renewals. This time limit will be based on conservative estimates of resource needs for renewals as compared to resources available for the calendar year of resource constraints.</span></li> <li><span>Initial amounts committed during the year may be adjusted at the end of the year based on actual resource needs for renewals as compared to resources available.</span></li> </ol> <p><span>There are no material budgetary implications for this decision point.</span></p> <p><span>Decision Point 2:</span></p> <p><span>The Board decides that for subsequent year(s), the following priority system will apply in the event of resource constraints:</span></p> <p><span><u>First funding priority</u>: Unfunded portions of prior year(s) renewals.</span></p> <p><span><u>Second funding priority</u>: Renewals due in the current year. A time limited partial allocation system will be established as necessary (seeDecision Point 1.)</span></p> <p><span><u>Third funding priority</u>: New proposal rounds (as already established in the Comprehensive Funding Policy).</span></p> <p><span>There are no material budgetary implications for this decision point.</span></p> <p><span>Decision Point 3:</span></p> <p><span>The Board recommends that if funding is not available for at least one year of Phase 2 grant renewals during a certain calendar year, special procedures will be decided by the Board at the final Board meeting of the previous year.</span></p> <p><span>There are no material budgetary implications for this decision point.</span></p> <p><span>Decision Point 4:</span></p> <p><span>The Board recognizes the importance of sustaining ongoing treatment, as well as prevention, care and support services.</span></p> <p><span>The Board requests the Secretariat urgently to explore internal mechanisms and to work with partners to develop options for the continuity of services through broader country partnerships associated with common national strategic framework for the three diseases. The Board requests the Secretariat to report back to MEFA, PMPC and the Ethics Committee on these issues in time for the development of recommendations by the Ninth Board Meeting.</span></p> <p><span>Budgetary implications of this decision point:</span></p> <p><span>The additional cost of implementing this decision is approximately US $135,000.</span></p>
2004-06-30 B08 GF/B08/DP2 Approval of the Agenda Approval of the Agenda
<p>The agenda for the Eighth Board Meeting is approved.</p>
2004-06-30 B08 GF/B08/DP13 Protection from Exchange Rate Fluctuation Protection from Exchange Rate Fluctuation
The Board recommends that the option of top-up grants should not be pursued as mechanisms to protect against exchange rate fluctuations.
2004-06-30 B08 GF/B08/DP6 Technical Review Panel: Round 4 Technical Review Panel: Round 4
<p>Decision Point 1:</p> <p>The Board approves for funding the proposals recommended by the Technical Review Panel, and according to the categories listed below, with the clear understanding that budgets requested are upper ceilings rather than final budgets and the Secretariat should report to the Board the results of the negotiations with Principal Recipients on the final budget for acknowledgement (Report of the Technical Review Panel and the Secretariat on Round Four Proposals: Annex II).</p> <ul> <li>Category 1: Recommended proposals with no or minor clarifications, which should be met within 4 weeks and given the final approval by the TRP Chair and/or Vice-Chair.</li> <li>Category 2: Recommended proposals provided clarifications are met within a limited timeframe (the initial reply to TRP clarifications should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant). The TRP Chair and/or Vice-Chair shall give final approval based on consultations with the primary and secondary reviewers</li> <li>Category 3: Not recommended in their present form but are encouraged to resubmit.</li> <li>Category 4: Not recommended for funding.</li> </ul> <p>Decision Point 2:</p> <p>The Board acknowledges the lessons learned by the Secretariat and the TRP during the Round 4 process and requests the PMPC to further consider the Report of the TRP and to recommend specific actions to address the issues raised by the TRP, and to address the length of time TRP members are permitted to serve on the TRP at the Ninth Board Meeting.</p>
2004-06-30 B08 GF/B08/DP19 Continuation of Phase 2 Funding (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA)) Continuation of Phase 2 Funding (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA))
<p><span>Revised Decision Point 4: </span></p> <p>The Board recognizes the importance of sustaining ongoing treatment, as well as prevention, care and support services.</p> <p>The Board requests the Secretariat urgently to explore internal mechanisms and to work with partners to develop options for the continuity of services through broader country partnerships associated with common national strategic framework for the three diseases. The Board requests the Secretariat to report back to MEFA, PMPC and the Ethics Committee on these issues in time for the development of recommendations by the Ninth Board Meeting.</p> <p>Up to the Ninth Board Meeting, Secretariat priority shall be given to addressing issues related to discontinuation of treatment within Global Fund grant programs</p> <p>Budgetary implications of this decision point:</p> <p>The additional cost of implementing this decision is approximately US $67,500.</p> <p>Decision Point 5:</p> <p>With regard to the legal concerns and fiduciary policy constraints raised by some Board Constituencies, the Board decides to revisit the issue of approval authority of the agreed procedure for decision making on Phase 2 renewals.</p> <p>MEFA, in cooperation with the PMPC, is requested to explore options for incorporating in the agreed Phase 2 renewal process provision for the exercise by the Board of an appropriate decision making role that meets legal and fiduciary policy requirements of Board constituencies and make recommendations to the Ninth Board Meeting.</p> <p>As an interim arrangement, the Board authorizes the Secretariat to extend the terms of grants up to six months for those grants where Phase 2 decision is required prior to the Ninth Board Meeting, and to provide bridge funding for such grants as appropriate based on program needs during this extension period. The Board approves an amount of up to USD 30 million to be used for this purpose.<br /><br />Decision Point 6:</p> <p>The Board recognizes the urgent need to allow recipients to change to new, more expensive artemisinin-based combination therapy in line with the latest scientific evidence, following the recommendations of the malaria experts of the Technical Review Panel.</p> <p>As an interim measure, the Board authorizes the Secretariat to commit as necessary up to USD 90 million for the projected costs of reprogramming 28 programs, which would be financed by utilizing resources from the Phase 2 renewal funding of these programs.</p> <p>The Board requests PMPC to consider the issue of reprogramming in the context of changing scientific evidence, and report back to the Ninth Board Meeting.</p>
2004-06-30 B08 GF/B08/DP22 Core Business Model of the Global Fund Core Business Model of the Global Fund
The Board agrees to have a retreat of Board Members and Alternates to discuss the core business model of the Global Fund, to be held in Arusha, Tanzania on Saturday 20 November 2004.
2004-06-30 B08 GF/B08/DP16 Ethics Committee Composition Ethics Committee Composition
<p>The Board resolves to expand the membership of the Ethics Committee from four members to six voting members. Desiring to achieve appropriate balances between geographic representation, gender, and government and civil society participation, 3 members shall come from the voting group encompassing the donor and private sector constituencies and 3 from the recipient, NGO and Communities constituencies.</p><p>The Board resolves that the Ethics Committee shall also appoint one independent, nonvoting expert to advise the Committee.</p>
2004-06-30 B08 GF/B08/DP3 Approval of Report of the Seventh Board Meeting Approval of Report of the Seventh Board Meeting
<p>The report of the Seventh Board Meeting is approved.</p>
2004-06-30 B08 GF/B08/DP7 Technical Review Panel (Report of the Portfolio Management and Procurement Committee) Technical Review Panel (Report of the Portfolio Management and Procurement Committee)
<p>Decision Point 1:</p> <p>The Board exempts the Round 3 proposals from the Angola CCM on malaria and from the Benin CCM on malaria from the requirement that all TRP clarifications for proposals in Category 2 should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant, in light of the evidence presented by the TRP that this timeframe was impossible to meet due to delays caused by the unavailability of TRP reviewers.</p> <p>There are no material budgetary implications for this decision point.</p> <p>Decision Point 2:</p> <p>The Board exempts the incoming Chair of the TRP, Jonathan Broomberg, from the requirement that TRP members leave the TRP after four Rounds of proposal review, in light of the need for continuity in the leadership of the TRP.</p> <p>There are no material budgetary implications for this decision point.</p> <p>Decision Point 3:</p> <p>The Board commends the Technical Review Panel for its dedicated efforts to ensure that Global Fund financing targets only technically sound proposals. Special recognition is given to the outgoing chair of the Technical Review Panel, Michel Kazatchkine, for his leadership, vision, and dedication to the development of the Technical Review Panel.</p> <p>There are no material budgetary implications for this decision point.</p>
2004-06-30 B08 GF/B08/DP10 Eligibility Eligibility
<p>The Board replaces the current eligibility criteria of "co-financing" and "moving over time to an increasing reliance on domestic resources" with a single criterion termed "counterpart financing." The Board adopts the following definition of counterpart financing:</p><ol type="a"><li>Counterpart financing encompasses all domestic resources (including contributions from governments, loans from external sources or private creditors, debt relief proceeds, and private contributions such as from nongovernmental organizations, faith-based organizations, other domestic partners, and user fees) dedicated to the disease program;</li><li>Counterpart financing is in the form of parallel financing.</li></ol><p>The Board requests the Secretariat to only deem eligible proposals from Upper-Middle Income countries that demonstrate 20% counterpart financing, and from Lower-Middle Income countries that demonstrate 10% counterpart financing for the first year of proposed Global Fund grant implementation.</p><p>The Board requests proposals to demonstrate a progressive increase in counterpart financing over the proposed duration of a Global Fund proposal from 20% to 40% for Upper Middle Income countries and from 10% to 20% for Lower-Middle Income countries.</p><p>The Board exempts non-CCM proposals from the counterpart financing requirement.</p><p>The Board will not further define the eligibility criterion "focusing on poor or vulnerable populations" and instead will allow applicants to use their own definitions of poor or vulnerable populations. The Board requests the Secretariat to work with partners such as the World Health Organization, UNAIDS, and the World Bank to further refine this term in order to provide guidance to applicants.</p>
2004-06-30 B08 GF/B08/DP14 Multi-currency Grants and Proposals Multi-currency Grants and Proposals
<p>The Board recommends the following:</p><ul><li>From 2005, proposals submitted to the Global Fund may be denominated in USD as well as in Euro</li><li>Grant agreements may be signed in USD or Euro, depending on a recipient's preference. Disbursements will be made in the denominated currency of the grant agreement.</li><li>The Board requests the Trustee to incorporate in its data processing system for the Global Fund, the capacity to cater for grants denominated in USD as well as in Euro.</li><li>The Board authorizes the Secretariat to incur costs not exceeding USD 150,000, for this purpose. The Secretariat may use the contingency to cover this expenditure.</li><li>The Board mandates the MEFA Committee with the Secretariat to prepare the operational implications for the Ninth Board Meeting.<br/>Budgetary implications of this decision point.</li></ul>
2004-06-30 B08 GF/B08/DP18 Executive Session Executive Session
<p><b>Decision Point 1:</b> </p><p>The Board of The Global Fund to Fight AIDS, Tuberculosis and Malaria decided to renew Professor Richard Feachem's contract as Executive Director of the Global Fund on the same terms and for a period of two years beginning 15 July 2004.</p><p><b>Decision Point 2:<br/></b> </p><p>The Board approved the Terms of Reference for the Executive Director as amended.</p>
2004-06-30 B08 GF/B08/DP23 Recognition of Issuance of Commemorative French Stamp Recognition of Issuance of Commemorative French Stamp
<p>At the occasion of the issue on July 1st of the first stamp dedicated to the Global Fund to Fight AIDS, Tuberculosis and Malaria by the French Post Office, the Board of the Global Fund expresses its profound gratitude to the French Post Office. The issue of this first stamp dedicated to the Global Fund will increase the awareness of the urgency of the fight against these three diseases and on the key role of the Global Fund in this fight.</p><p>A l'occasion de l'émission de le 1er juillet 2004 du premier timbre dédié au Fonds Mondial de Lutte contre le SIDA, la Tuberculose et le Paludisme para la Poste française, le Conseil du Fonds Mondial exprime a la poste française sa profonde gratitude. L'émission de ce premier timbre dédié au Fonds mondial contribuera à accroître a prise de conscience sur l'urgence du combat a mener contre ces trois maladies et sur le rôle clé du Fonds mondial dans ce combat.</p>
2004-06-30 B08 GF/B08/DP9 Conflict of Interest Conflict of Interest
<p>The Ethics and Conflict of Interest Policy is amended by inserting the following as section seven, and re-numbering the policy accordingly:</p><ol><li value="7">Any individual who has served as a Board member, Alternate, a member of a Board committee, or as Chair or Vice Chair of the Technical Review Panel shall not be eligible for employment by the Global Fund Secretariat until one year following their last date of service in such a position. The Ethics Committee may waive this provision as appropriate.</li></ol><p>There are no material budgetary implications for this decision point.</p>
2020-11-11 B44 GF/B44/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 44th Board Meeting (GF/B44/01 – Revision 1) is approved.</p>
2006-11-03 B14 GF/B14/DP13 Dates for the Launch and Approval of Rounds 7 and 8 Dates for the Launch and Approval of Rounds 7 and 8
<ol><li>The Board requests the Secretariat to make the necessary preparations and announce to the public as soon as possible that: <ol type="a"><li> The Secretariat will issue a Call for Proposals for Round 7 by 1 March 2007, and provide for review of those proposals in time for approval at the Sixteenth Board meeting; and</li><li> The Secretariat will issue a Call for Proposals for Round 8 by 1 March 2008, and provide for review of those proposals in time for approval at the last Board Meeting of 2008.</li></ol></li><li>The Board requests the Secretariat to propose at the Sixteenth Board Meeting the appropriate dates for Round 9.</li></ol>
2020-11-11 B44 GF/B44/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Robin Montgomery from the Developed Country NGOs constituency is designated as Rapporteur for the 44th Board Meeting.</p>
2020-11-27 B44 GF/B44/EDP01 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2006-11-03 B14 GF/B14/DP25 Plan for Second Replenishment Plan for Second Replenishment
<p>The Board adopts the recommendations for a Second Voluntary Replenishment of the Global Fund as outlined in Annex 5 to GF/B14/9, Report of the Finance and Audit Committee. </p><p>The Board decides that the Second Voluntary Replenishment will cover a three year period, 2008-2010.</p><p>The Board decides that the Finance and Audit Committee shall approve the agenda for the two voluntary replenishment meetings.</p><p>The Board decides that the next voluntary replenishment structure shall be grounded in the policies of the Four-Year Strategic Plan.</p><p>The Board confirms the nomination of Mr. Kofi Annan, current Secretary-General of the United Nations, as Chair and Mr. Sven Sandström as Vice Chair of the Second Voluntary Replenishment of the Global Fund. The Board expresses its appreciation to both Mr. Annan and Mr. Sandström for their excellent leadership during the First Replenishment and willingness to continue this important service.</p>
2006-11-03 B14 GF/B14/DP37 Confidentiality of Recordings of Executive Sessions Confidentiality of Recordings of Executive Sessions
<p>The Global Fund Board directs the Secretariat to draft a policy for the Global Fund Board and Secretariat concerning the maintenance of confidentiality of any recordings of Executive Sessions of the Global Fund Board, and the circumstances, policies and procedures under which any individual may receive access to these recordings. </p><p>The Board requests the Secretariat to present such draft policy in time for consideration of the next meeting of the Policy and Strategy Committee (PSC), and requests the PSC to present its recommendation for a policy on the "Confidentiality of Recordings of the Executive Sessions of the Board" for approval by the Board at the April 2007 Board Meeting.</p>
2006-11-03 B14 GF/B14/DP08 Third Partnership Forum Third Partnership Forum
<ol start="1" type="1"><li>The Board takes note of the "Partnership Forum 2006 Report" (GF/B14/14) and agrees to use the recommendations contained therein to inform ongoing strategic planning and management of the Global Fund.</li></ol><ol start="2" type="1"><li>The Board agrees to hold the Third Partnership Forum in 2008 and mandates the Policy and Strategy Committee to convene a Partnership Forum Steering Committee to start planning for this event early in 2007.</li></ol><ol start="3" type="1"><li>The format and duration of the Third Partnership Forum should build on the lessons learned from previous Partnership Fora.</li></ol><ol start="4" type="1"><li>The Board approves a budget of US$1,200,000 as an upper limit for the Third Partnership Forum and requests the Finance and Audit Committee to ensure that provision is made for appropriate secretariat staffing levels in the 2007 and 2008 budgets.</li></ol>
2006-11-03 B14 GF/B14/DP32 Transitions Option Project Transitions Option Project
<p>The Board endorses Part 1 of the Report of the Finance and Audit Committee (GF/B14/9), and, accordingly, decides to engage in the necessary preparations to discontinue its present Administrative Services Agreement (ASA) with the World Health Organization after appropriate preparations for administrative independence have been made. </p><p>The Board accordingly requests the FAC to work with the Secretariat to present for approval a detailed plan covering such preparations at the April 2007 Board Meeting. The plan shall include proposed measures to be taken prior to termination of the ASA, their costs, and the timeline over which they are intended to occur, and steps to be taken that would safeguard the interests of staff as outlined in paragraph 11 of GF/B14/9. The plan shall be consistent with the principles set forth in GF/B14/9. The Board will make its final decision at the April 2007 Board meeting.</p>
2006-11-03 B14 GF/B14/DP38 Nomination Committee Nomination Committee
<p>The Board decides to establish a new Nomination Committee to assist with the selection of the next Executive Director of the Global Fund. The members of the Nomination Committee shall be Sheila Dinotshe Tlou, Ren Minghui, Abdalla Abdillahi Miguil, Carole Presern, Melinda Kimble, Masaru Tsuji, Stefano Vella, chaired by Peter van Rooijen, supported by Bobby John. </p><p>The Board decides that the Executive Director shall be selected based on a list of candidates which might include the nominees considered at the Fourteenth Board Meeting in a special Board Meeting to be held in Geneva, before mid-February 2007, and that the Nomination Committee shall propose voting procedures that would allow the Board to make a selection at that session.</p><p>The Board re-affirms the "Selection Criteria for Executive Director" and the "Terms of Reference of the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria" (GF/14/5, Annex 1).</p><p>The Board decides that the Nomination Committee shall submit to the Board a shortlist of five nominees. The Nomination Committee shall provide an indicative ranking, which shall not be binding on the Board, of the nominees based on the extent to which they meet the Selection Criteria. </p><p>The Nomination Committee shall, not later than 1 December 2006, present an Action Plan to the Board for approval by email. The Action Plan shall set forth the powers of the Nomination Committee and include the following:</p><p>-    The actions that the Nomination Committee will carry out and their timing;</p><p>-    A description of the additional search process that is required;</p><p>-    A description of the limited involvement of an executive search firm in the nomination process;</p><p>-    The timeline for submission of a decision making process for the selection of a new Executive Director to the Board for approval.</p><p>- A weighting/ranking of the selection criteria</p>
2006-11-03 B14 GF/B14/DP35 Budget 2007 Budget 2007
The Board approves the 2007 Operating Expense budget in the amount of US$ 104,728,000 as set out in Annex 8 to GF/B14/9 and as recommended by the Finance and Audit Committee and proposed by the Secretariat.
2006-11-03 B14 GF/B14/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Françoise Ndayishimiye from the Communities (NGOs representative of the Communities Living with the Diseases) Constituency is designated as Rapporteur for the Fourteenth Board Meeting.
2006-11-03 B14 GF/B14/DP16 Establishment of a Annual Report on Corporate Key Performance Indicators for the Global Fund Establishment of a Annual Report on Corporate Key Performance Indicators for the Global Fund
<p>The Board requests the Secretariat to report on the core set of Performance Indicators for the Global Fund (formerly the Soft Performance Measures) to the Board during its first meeting of each calendar year. </p><p>The Secretariat shall link the report of these indicators to the report on the Corporate Key Performance Indicators (formerly the Key Performance Indicators for the Executive Director). </p><p>The Board requests the Secretariat to include impact measures as part of the core set of performance indicators as soon as feasible under the guidance of the Technical Evaluation Reference Group. </p><p>The Board also requests the Secretariat to work on including gender in performance and impact measures where feasible and available in recipient country systems under the guidance of the Technical Evaluation Reference Group.</p>
2006-11-03 B14 GF/B14/DP24 Approval of the Terms and Appointment of the Resource Mobilization Task Team Approval of the Terms and Appointment of the Resource Mobilization Task Team
<p>The Board approves the terms of reference of the Resource Mobilization Task Team ("RMTT"), as set forth in GF/B14/9, Revision 2 (the "Terms of Reference"), and appoints Mr Mike Madnick as its Chair. </p><p>The Board requests the Chair of the RMTT in consultation with the Chair and Vice Chair of the Finance and Audit Committee, and the Chair and Vice Chair of the Policy and Strategy Committee, to establish the membership of the Committee, based on the parameters listed in the Terms of Reference. </p><p>The Board requests the RMTT to present a report at the Fifteenth Board Meeting.</p>
2006-11-03 B14 GF/B14/DP28 Request for Continued Funding for SAF-304-G04-H Request for Continued Funding for SAF-304-G04-H
<p>The Board recognizes the importance of encouraging countries to actively seek innovative sustainability strategies.</p><p>In this context, the Board notes:</p><ol start="1" type="a"><li>the commitment of the Government of South Africa to achieve sustainability of the HIV/AIDS program entitled "Strengthening and Expanding the Western Cape HIV/AIDS prevention, treatment and care programs" (the "Program") by the end of the Phase 2 term, therefore not requiring further Global Fund support for these activities beyond the next four years;</li></ol><ol start="2" type="a"><li>the Program is performing well and is A-rated;</li></ol><ol start="3" type="a"><li>the CCM of South Africa and the Principal Recipient of the grant have committed to achieving or exceeding the targets in the proposal within the originally contemplated five-year term and to appropriate increased targets for the sixth year; and</li></ol><ol start="4" type="a"><li>the CCM of South Africa has not requested additional funding for Phase 2 of the grant beyond that requested in the proposal.</li></ol><p>Therefore, the Board authorizes the Secretariat, on an exceptional basis and without setting a precedent, to consider the Request for Continued Funding submitted by the CCM of South Africa for the Round 3 South Africa grant for the Program (Grant Number SAF-304-G04-H) which anticipates a 4-year Phase 2 term. The Board requests the Secretariat to provide by 1 December 2006 a recommendation for continued funding for this grant. Such recommendation shall include a condition for continued funding that the Government of South Africa makes significant counterpart financing contributions to the Program over the next four years.</p>
2006-11-03 B14 GF/B14/DP36 Staffing Impact of Decisions Staffing Impact of Decisions
<p>The Board recognizes that its decision points require clear directions with respect to interpretation, policy and staffing implications, and directs the Secretariat to incorporate additional staffing needs, in addition to budgetary implications in all its decision points. </p><p>The Board furthermore acknowledges that it has a responsibility for the impact on the workload of the Secretariat and Board Committees of decisions that have not been brought to the Board through a Committee process. Therefore, the Board delegates authority to the Chair of the Board Committee with jurisdiction over the matter addressed in that decision point, who shall consult with the Executive Director, to clarify any necessary follow up in relation to interpretation and its policy implications and to make recommendations on its staffing implications.</p><p>The Board requests the Finance and Audit Committee to incorporate in the process of developing a framework that guides review of Secretariat's annual budget and the evaluation of Global Fund's staffing as requested by the Board at its Fourteenth Board Meeting, a process for handling the recommendations on staffing implications in the event that the approved decision point results in a need for additional resources.</p>
2006-11-03 B14 GF/B14/DP07 Recognition of Technical Review Panel Recognition of Technical Review Panel
<p>1. The Board commends the Technical Review Panel for its report and presentation on the Round 6 proposal evaluation process, and its dedicated efforts to ensure that the Global Fund finances only technically sound proposals.</p><p>2. The Board gives special recognition to the outgoing chair of the Technical Review Panel, Dr Jonathan Broomberg, for his leadership, dedication and commitment to the principles of the Global Fund and the work of the Technical Review Panel.</p>
2022-11-14 B47 GF/B47/EDP18 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-11-14 B47 GF/B47/EDP19 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER15 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-10-25 B47 GF/B47/EDP16 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B47/ER13 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-10-18 B47 GF/B47/EDP17 Increasing the Emergency Fund 2020-2022 Increasing the Emergency Fund 2020-2022
<p>The Board reaffirms the importance of responding efficiently and rapidly to emergency situations to ensure the continuity of life-saving health services delivered through Global Fund-supported programs. The Board recognizes the devastating impact that recent natural disasters, climate-related events, and ongoing and protracted conflicts such as those in Pakistan, Ukraine, and Somalia have had on the health and well-being of people supported by Global Fund programs and reaffirms the importance of the Emergency Fund in rapidly responding to such contexts.</p> <p>Therefore, the Board approves the reallocation of USD $ 40 million from Audit and Finance Committee (AFC)-approved portfolio optimization funds to the Emergency Fund.</p>
2022-10-03 B47 GF/B47/EDP15 Appointment of Replacement Members on the Strategy Committee and on the Ethics and Governance Committee Appointment of Replacement Members on the Strategy Committee and on the Ethics and Governance Committee
<p>The Board approves the appointment of:</p> <ol> <li>Harriet Ludwig, representing the Germany Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Rouksana Simjee, to serve in her personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of her successor.</li> </ol>
2022-09-14 B47 GF/B47/EDP14 Confirmation of revision to target definition for KPI 4 (Investment efficiency) Confirmation of revision to target definition for KPI 4 (Investment efficiency)
<p>Based on the recommendation of the Strategy Committee, the Board approves the revision to Key Performance Indicator 4 as presented in GF/B47/ER11.</p>
2006-11-03 B14 GF/B14/DP19 UNITAID Round 6 UNITAID Round 6
<p>The Board welcomes the decision of the UNITAID Board to provide finance for Round 6 to increase the number of patients on treatment. The Board decides to accept a contribution from UNITAID in the amount of US $52,500,000 for Round 6 grants, subject to the execution of appropriate contractual documentation by both parties.</p><p>In addition, the Board:</p><ol><li>acknowledges, without setting any precedent, that the contribution shall be used exclusively for the financing of the purchase of medicines in the treatment areas listed in the UNITAID Board resolution on Round 6 in the amounts specified therein; </li><li>decides that the Secretariat shall employ the contribution in conformity with UNITAID's eligibility requirements and in compliance with existing Global Fund procurement and other policies;</li><li>notes that UNITAID's commitment to improving the price and availability of medicines and diagnostics is consistent with the Global Fund's own endorsement in principle, expressed at its Thirteenth Meeting, of the facilitation of voluntary pooled procurement, subject to the approval of a suitable business plan, and informs the Policy and Strategy Committee's ongoing work on the issue of market dynamics; and</li><li>delegates authority to the Secretariat to negotiate, under the oversight of the PSC, a contribution agreement with UNITAID that reflects the above.</li></ol>
2022-08-24 B47 GF/B47/EDP13 Appointment of the Board Leadership Nomination Committee Membership Appointment of the Board Leadership Nomination Committee Membership
<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B47/ER10, relating to the membership of the Board Leadership Nomination Committee (“Nomination Committee”).</li> <li>Accordingly, the Board appoints the following individuals to serve as members of the Nomination Committee in accordance with the terms of reference of the Nomination Committee approved under electronic decision point GF/B39/EDP08 and set out in Annex 4 to GF/B39/ER07: <ol type="a"> <li>Grace Rwakarema, Chair of the Nomination Committee;</li> <li>Sherwin Charles, Vice-Chair of the Nomination Committee;</li> <li>Cecilia Senoo, Member;</li> <li>Heiko Warnken, Member;</li> <li>Fiu Williame-Igara, Member;</li> <li>Mamadi Yilla, Member; and,</li> <li>Ren Minghui, Member.</li> </ol> </li> </ol>
2006-11-03 B14 GF/B14/DP30 Round 6 Additional Approval Round 6 Additional Approval
<p>The Board approves for funding for an initial two years, subject to paragraph 4 of the decision GF/B14/DP5, all remaining Round 6 proposals recommended for funding by the Technical Review Panel and listed in Annex 2, Rev. 2 to GF/B14/10 Rev. 1 as 'Category 2B' that the Board did not previously approve for funding due to resource constraints. </p> <p>All conditions placed on Round 6 approvals listed in decision GF/B14/DP5 apply to the approvals made under this decision.</p>
2006-11-03 B14 GF/B14/DP09 Establishment of a Rolling Continuation Channel Allowing Country Coordinating Mechanisms to Apply for Continued Funding for Expiring Grants Establishment of a Rolling Continuation Channel Allowing Country Coordinating Mechanisms to Apply for Continued Funding for Expiring Grants
<p>The Board approves the establishment of a funding channel ("rolling continuation channel") that provides an opportunity for Country Coordinating Mechanisms ("CCMs") to apply for continued funding for grants that are reaching the end of their funding terms ("expiring grants") under conditions different from those available for proposals submitted as part of new rounds of financing ("rounds-based channel").</p> <p>The rolling continuation channel shall operate according to the following principles:</p> <ol> <li>The Secretariat shall conduct a review of all grants before the end of their Phase 2 (the "determination of qualification") to determine whether they qualify to apply for continuation of funding through the rolling continuation channel. The Secretariat's determination of qualification shall be final and not subject to appeal.</li> <li>The Secretariat shall establish a standing cross-functional panel (the "qualification panel") to conduct the determination of qualification of grants. This panel will conduct its work several times each year, scheduling determinations of qualification so that grants that do not qualify for the rolling continuation channel have sufficient time to apply through the rounds-based channel.</li> <li>The qualification panel shall base its determination of qualification on the following factors: <ol type="a"> <li>The primary factors shall be the following: <ol type="i"> <li>Strong performance, as determined by the Secretariat having assigned to the grant a performance rating of 'A' in more than half of its reviews of the grant's progress updates over the 18 months immediately preceding the determination of qualification; and</li> <li>Evidence of potential for impact by, for example, demonstration of the grant contributing to a national effort that has had, or has the potential to have in the near future, a measurable impact on the burden of the relevant disease.</li> </ol> </li> <li>In addition, in making a final determination, the qualification panel shall consider the following factors:</li> <ol type="i"> <li>Sustainability, as determined by the extent to which the grant contributes to a national plan which is inclusive of civil society and the private sector and transparently shows the financial contributions made to the plan by major funding sources, including domestic sources; and</li> <li>Whether, in exceptional cases, severe and unexpected changes in circumstances have had a material negative impact on program implementation.</li> </ol> </ol> </li> <li>On the basis of the above factors, the Board expects (based on information provided by the Secretariat) that between a quarter and a third of the grants that expire in a given year would qualify to apply through the rolling continuation channel. The Secretariat will monitor the share of grants that qualify for the rolling continuation channel and report this information to the Board as part of its annual reporting process.</li> <li>Upon completion of each determination of qualification, the qualification panel shall provide feedback to the CCM on the grant's overall performance in a standardized format, and highlight any implementation challenges or sustainability issues that the CCM might address in a subsequent grant proposal. It shall also provide this standardized feedback to the Chair and the Vice Chair of the Technical Review Panel under revised terms of reference and membership(henceforth referred to as "the TRP") to inform consideration by the TRP of a subsequent proposal by that CCM.</li> <li>The determination of qualification shall rely, as much as possible, on existing processes and information, so as to minimize additional work and transaction costs.</li> <li>CCMs that qualify to submit a proposal for continuation of funding through the rolling continuation channel may apply either through the rolling continuation channel or the rounds based channel, but the CCM may not submit proposals covering the same activities through both channels.</li> <li>The process for grant proposals submitted through the rolling continuation channel shall include proposal submission, independent technical review, funding recommendation and if relevant, Board approval, all of which shall occur on a rolling basis.<sup>3</sup> The proposal submission and review process shall be as light as possible, without sacrificing technical rigor.</li> <li>The Secretariat shall modify the proposal requirements and review criteria for the rolling continuation channel as appropriate compared to those for the rounds-based channel. As is the case for proposals for the rounds-based channel, they shall reflect considerations of sustainability and alignment with national strategies and plans.</li> <li>CCMs may submit rolling continuation proposals that allow for the continuation of the broader package of interventions to which the expiring grant was contributing. The TRP shall determine whether a proposal's scope demonstrates a material difference, as defined by the Secretariat, compared to the scope of the grant it seeks to continue. A proposal that the TRP deems materially different from the original one shall not be allowable under the rolling continuation channel.</li> <li>The Secretariat shall propose principles-based guidance in the proposal form or guidelines on the extent to which CCMs may increase the scale of the activities financed by expiring grants in rolling continuation proposals.<sup>5</sup></li> <li>All rolling continuation proposals shall undergo a level of independent technical review as rigorous as that for the rounds-based channel. This review shall be performed by the TRP.</li> <li>The Secretariat shall present to the Board the TRP's funding recommendations not more often than once every three months, unless it is necessary, because of exceptional circumstances, to present a recommendation to the Board more frequently.</li> <li>The TRP shall have the authority to recommend that the Board make its approval of a rolling continuation proposal conditional upon the CCM removing a limited set of specific elements from the proposal.</li> <li>There shall be an appeals process for unsuccessful rolling continuation proposals. The primary grounds for appeal shall be a significant and obvious error made by the TRP regarding information contained in the proposal.<sup>6</sup></li> <li>CCMs may submit proposals under the rolling continuation channel covering a maximum term of six years, in two phases of three years each, with funding for the second phase subject to the approval of the Board based on a mid-point performance review. The Board shall approve rolling continuation of funding proposals for the entire term of the proposal, with a financial commitment for the initial three years. Grants funded under the rolling continuation channel shall undergo assessments at each disbursement similar to those done for grants funded through the rounds-based channel.</li> <li>The Global Fund shall prioritize funding for proposals submitted through the rolling continuation channel below the funding of Phase 2 renewals of proposals submitted through the rounds based channel and funding of Extraordinary Requests for Continued Funding of Treatment under the Continuity of Services Policy, but above the funding of proposals submitted through the rounds-based channel. The Secretariat, in consultation with the Finance and Audit Committee, shall communicate to the Board at the end of a given financial year a projection of the financial resources potentially available for these funding channels for the subsequent year, specifically noting confirmed pledges.</li> </ol> <p>The Board delegates authority to the Portfolio Committee to apply the principles set out in this decision point and (i) approve the proposal form and guidelines for the rolling continuation channel, and (ii) approve the appropriate policy guidance in relation to the appropriate appeals process for unsuccessful rolling continuation proposals, and requests it to do so by end of March 2007.</p> <p>The Board requests the Policy and Strategy Committee to present for approval at the Fifteenth Board meeting the appropriate procedure for the Board to make funding decisions on proposals for rolling continuation funding recommended by the TRP in accordance with the principles set out in this decision point.</p> <p>The Board requests the Finance and Audit Committee to present for approval at the Fifteenth Board meeting appropriate amendments that arise from this decision to each of the following: (i) the Comprehensive Funding Policy approved at the Sixth Board Meeting (and amended at the Thirteenth Board Meeting); and (ii) the decision on prioritization of Phase 2 funding approved at the Eighth Board Meeting (GF/B9/2, p. 9).</p>
2006-11-03 B14 GF/B14/DP02 Waiver of One-Year “Cooling Off” Period Waiver of One-Year “Cooling Off” Period
The Board decides to approve the request of Michel Sidibe for a waiver of the one-year "cooling off" period set forth in Section 7 of the Policy on Ethics and Conflict of Interest for Global Fund Institutions.
2006-11-03 B14 GF/B14/DP31 Upper Middle Income Country Eligibility Upper Middle Income Country Eligibility
The Board requests the Portfolio Committee to consider modifications to the Global Fund policy on eligibility, particularly with regard to the criteria for Upper-Middle Income Countries, and to make a recommendation to the Board by early February 2007, so that the Board may take a vote by e-mail following a Board conference call that is informed by prior submissions from Board delegations on any such recommendations prior to the launch of the Call for Proposals for Round 7.
2006-11-03 B14 GF/B14/DP18 TERG Five Year Evaluation TERG Five Year Evaluation
<p>The Board approves the Five-Year Evaluation plan, and its overall timeframe, budget and implementation arrangements, as presented by the Technical Evaluation Reference Group. The Board requests the Secretariat to seek cost efficiencies through tendering and contract negotiation processes and by building on existing investments by countries and partners.</p><p>The Board requests the Technical Evaluation Reference Group to report on progress of the evaluation at each Board meeting until a final report is delivered and thereafter on the implementation of the recommendations.</p>
2006-11-03 B14 GF/B14/DP14 Grant Consolidation Pilot Project Grant Consolidation Pilot Project
<p>The Board refers to its earlier decision on grant consolidation, taken at its Thirteenth Meeting. To obtain useful experience that could inform the development of policies for grant consolidation, the Board authorizes the Secretariat to modify the application of existing policies to the extent necessary to consolidate grants on a pilot basis (the "Pilot Grants") in multiple countries, which the Secretariat shall select with the consent of the relevant Principal Recipients (PRs) and Country Coordinating Mechanisms (CCMs) and in consultation with other country stakeholders.</p> <p>The purpose of grant consolidation includes streamlining grant management for PRs and the Secretariat, as well as enabling increased alignment with national plans, strategies and systems. The specific objectives of the grant consolidation pilot project are as follows:</p> <ol type="a"> <li>to assess the added value and feasibility of grant consolidation for the Global Fund and for PRs;</li> <li>to identify specific policy and architectural changes that will be required to enable grant consolidation across the Global Fund portfolio (as appropriate) and to inform the development, for the Board's consideration, of strategy and policy recommendations to this end; and</li> <li>to draw operational, policy and architectural lessons from the pilot exercises that could facilitate a broader roll-out of grant consolidation across the Global Fund portfolio and in particular, to identify the criteria for and situations that favor grant consolidation.</li> </ol> <p>Specifically, the Board authorizes the Secretariat, solely in respect to the Pilot Grants, to modify the application of existing policies and procedures so as to achieve objectives that include, but are not limited to the following:</p> <ol type="a"> <li>The consolidation of grants to the same PR into a single grant agreement for the consolidated grant, with aggregated performance targets; </li> <li>The rescheduling of Phase 2 decision dates with respect to the individual grants that are merged into the consolidated grant so as to achieve a single Phase 2 decision date for the entire consolidated grant; and </li> <li>The rescheduling of Phase 1 and Phase 2 end dates with respect to the individual grants that are merged into the consolidated grant so as to achieve single Phase 1 and Phase 2 end dates that apply to the entire consolidated grant.</li> </ol> <p>Any modifications of the application of existing policies and procedures made in connection with Pilot Grants shall be consistent with the Framework Document of the Global Fund.</p> <p>The Board requests the Portfolio Committee to oversee the Pilot Grants and report on the lessons learned that can inform the development of policies for grant consolidation, and update the Board on progress as appropriate.</p> <p>This decision point will expire upon the completion of the terms of the grant agreements of the Pilot Grants.</p>
2006-11-03 B14 GF/B14/DP06 Re-advertisement for the Position of the Executive Director Re-advertisement for the Position of the Executive Director
<p>The Board decides to re-advertise the position of Executive Director, and constitute a Nomination Committee. </p><p>The Nomination Committee shall refine the process for selecting the shortlist of candidates for the new Executive Director and present them to the Board no later than its Fifteenth Board Meeting (April 2007).</p><p>The Board requests the Nomination Committee to recommend to the Board possible changes in the Selection Process and Voting Procedures for deciding amongst the short-listed candidates for Executive Director, based on the experience of the Fourteenth Board Meeting (November 2006) and advise the Board (in consultation with the Chair of the Finance and Audit Committee) of the budgetary implications of this decision.</p>
2006-12-20 B14 GF/B14/EDP04 Extension of Timeframe for Signing Timor Leste Round 5 HIV Grant Agreement Extension of Timeframe for Signing Timor Leste Round 5 HIV Grant Agreement
<span>The Board extends the deadline for the signingof a grant agreement for the Timor Leste Round 5 HIV proposal for three monthsto 16 March 2007.</span>
2006-11-03 B14 GF/B14/DP39 Approval of the Corporate Key Performance Indicators 2007 Approval of the Corporate Key Performance Indicators 2007
The Board approves the 2007 Corporate Key Performance Indicators and associated 2007 targets contained which will also serve as the Key Performance Indicators/Targets for the Executive Director.
2006-11-03 B14 GF/B14/DP11 Continuity of Services Policy Continuity of Services Policy
<p>The Board recognizes that, in exceptional circumstances, there may be a need to provide funding for the continuation of treatment in grants where funding ends. </p> <p>The Board wishes to revise its policy on continuity of services for treatment (as amended at the Twelfth and Thirteenth Board Meetings) to reflect the differing circumstances of grants that end because of suspension, force majeure situations, a decision not to provide Phase 2 funding, or other unforeseen causes ("unanticipated terminations") and grants which reach the end of their term ("anticipated expirations"). </p> <p>The Board accordingly revokes the Continuity of Services decision, as amended at the Thirteenth Board Meeting (GF/B14/2) and replaces it with this decision:</p> <p>The Board adopts the following system for addressing continuity of services following both unanticipated termination and anticipated expiration of grants: </p> <p>i. A recipient (typically a CCM) whose funding has ended may submit an Extraordinary Request for Continued Funding for Treatment.</p> <p>ii. The Extraordinary Request will be limited to expenses directly related to the continuation of courses of treatment (including medicines [which, in the case of discontinuation of anti-retroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on courses of treatment under the existing proposal at the time of the Extraordinary Request. "Courses of treatment" includes treatment that is for a limited duration (such as for tuberculosis), or is life-long (such as for antiretroviral therapy).</p> <p>iii. The Extraordinary Request will be limited to the amount required to provide services directly related to the continuation of courses of treatment for up to two years (taking into account any amount which remains available under the existing grant).</p> <p>iv. The Extraordinary Request shall contain a description of the steps taken to find sustainable sources of financing for the people on courses of treatment, and to ensure the recipients are delivering courses of treatment effectively. To be eligible for funding under this provision, the CCM (or, in the case of non-CCM proposals, the grant applicant) must demonstrate that it has used its best efforts to identify other sources of funding to provide continuity of services, but has been unsuccessful.</p> <p>v. The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval. The Secretariat will take into account performance issues, as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of Global Fund financing.</p> <p>vi. Throughout the process, the Secretariat will encourage CCMs and PRs to actively engage with technical partners to identify mechanisms to ensure continuity of services. </p> <p>vii. In a resource-constrained environment, the Global Fund shall prioritize Extraordinary Requests for Continued Funding for Treatment for anticipated expiration and Extraordinary Requests for Continued Funding for Treatment for unanticipated termination at the same level as Phase 2 renewals.</p> <p>The following additional conditions shall apply in cases of anticipated expiration:</p> <p>viii. CCMs that submit an Extraordinary Request must provide evidence of compliance with Global Fund counterpart financing requirements during the period for which they make the request.</p> <p>ix. In addition to the merit of the request, the primary factor affecting the Secretariat's recommendation to the Board with respect to the amount and duration of funding for the continuity of treatment shall be the income level of the country of the applicant (as defined by the World Bank income classification of the applicant in the year of application of an Extraordinary Request); the Secretariat may also take into account other relevant considerations such as the size of the treatment program (in terms of cost or number of patients).</p>
2006-11-03 B14 GF/B14/DP10 Technical Reviews for the Rolling Continuation Channel Technical Reviews for the Rolling Continuation Channel
<p>The Board refers to its approval of the establishment of a funding channel ("rolling continuation channel") that provides an opportunity for Country Coordinating Mechanisms (CCMs) to apply for continued funding for grants reaching the end of their funding terms under conditions different from those available for proposals submitted as part of new rounds of financing ("rounds-based channel").<sup>1</sup></p> <p>The Board considers that, in order to conduct technical reviews of proposals submitted under the rolling continuation channel, it will be necessary to build additional flexibility into the staffing and procedures of the Technical Review Panel ("TRP"). For that purpose:</p> <p>1. The Board requests the Portfolio Committee to propose amendments of the Terms of Reference of the TRP for approval at the Fifteenth Board Meeting. Such amendments shall reflect the following principles:</p> <p>a. No change shall be made to the current procedures and membership principles of the TRP for the purpose of review of proposals received through the rounds-based channel.</p> <p>b. The Chair and Vice Chair of the TRP shall, acting together, have the authority to convene ad hoc groups for the purpose of reviewing and making recommendations on proposals received through the rolling continuation channel.</p> <p>c. Such ad hoc groups may include TRP members, alternate members, members of the TRP support group, and former members of the TRP. The Chair and Vice Chair of the TRP, acting together, shall determine the appropriate number and composition of reviewers in each group, based on their fields of expertise and the content of the proposals.     </p> <p>2. The Board requests the TRP Chair and Vice Chair to review rolling continuation channel proposals based on the principles set forth in this decision point and decision point "Establishment of a Rolling Continuation Channel" (GF/B14/DP9) if any such proposals are received before the Board has amended the terms of reference of the TRP.</p>
2006-11-03 B14 GF/B14/DP29 Round 6 Lessons Learned Round 6 Lessons Learned
<p>The Board acknowledges the lessons learned by the Technical Review Panel (TRP) and Secretariat during the Round 6 proposals process as presented in the Report of TRP and the Secretariat on Round 6 Proposals (GF/B14/10), and delegates authority to the Portfolio Committee to:</p><p>a. approve appropriate revisions to the Proposal Form and Guidelines for future Rounds by 1 March 2007; and</p><p>b. approve appropriate revisions to the process for screening and clarification of proposals prior to submission to the TRP.</p>
2006-11-03 B14 GF/B14/DP34 Budget Framework Budget Framework
<p>The Board requests the Finance and Audit Committee (FAC) to develop a framework to guide future reviews by the FAC of the Secretariat's annual budget proposals. </p><p>As part of the framework development process, (i) the Board requests the Executive Director, in consultation with the FAC and other Board committees to initiate an external evaluation of the Global Fund's staffing, including its structure and size; and (ii) the FAC will identify appropriate budgetary parameters to assist future budget reviews. </p><p>The Board requests the FAC to take into account the operational implications of the Resource Mobilization Task Team and the Four-Year Strategic Plan.</p><p>The Board requests that the FAC report to the Board on its progress at the April 2007 Board meeting.</p>
2006-11-03 B14 GF/B14/DP04 Approval of Report of the Thirteenth Board Meeting Approval of Report of the Thirteenth Board Meeting
The Report of the Thirteenth Board Meeting (GF/B14/2) is approved, as amended at the Fourteenth Board Meeting.
2006-11-03 B14 GF/B14/DP22 UNITAID MDR TB Initiative UNITAID MDR TB Initiative
<p>The Board acknowledges UNITAID's offer to finance the purchase by the Green Light Committee of the Stop TB Partnership ("GLC") as procurement agent of MDR-TB medicines (the "MDR-TB Contributions"), to eligible programs financed by the Global Fund (the "GF Programs") for scale-up of their existing MDR-TB targets. The Board acknowledges, further, UNITAID's initial approval of USD 7.9 million (the "Initial MDR-TB Funding") to finance MDR-TB Contributions and acknowledges UNITAID's intention to approve additional funding for MDR-TB Contributions (the "Additional Funding") once the Global Fund Secretariat has determined the estimated maximum amount needed for the scale-up of potentially eligible GF Programs through their Phase 2 (the "Maximum MDR-TB Amount"). The Additional Funding shall be equal to the difference between the Maximum MDR-TB Amount and the Initial MDR-TB Funding.</p><p>The Board accepts, in principle, UNITAID's request that the Global Fund assume sole responsibility for (a) the determination of which GF Programs shall receive MDR-TB Contributions; (b) the adjustment of the relevant grant agreements to reflect MDR-TB scale-up; (c) the monitoring of GF Program results linked to MDR-TB scale-up; (d) the authorization of the delivery of shipments of MDR-TB Contributions to GF Programs procured by the GLC based on performance; and (e) the determination at the end of Phase 1 of funding (where applicable) of whether GF Programs receiving MDR-TB Contributions shall continue to receive MDR-TB Contributions during their Phase 2. </p><p>The Board acknowledges that UNITAID's funding is limited to medicines and diagnostics only, and does not include operational costs that enable scale-up in MDR-TB treatment. The Board acknowledges UNITAID's intention, where a GF Program is covered by MDR-TB Contributions and a material increase in expenditure on operational costs is caused by the scale-up in MDR-TB targets, to finance up to the entire purchase price of MDR-TB medicines that the Global Fund is already committed to purchasing, so as to allow the Global Fund to shift expenditure to required operational costs that UNITAID could not finance.</p><p>The Board requests the Secretariat to contact Country Coordinating Mechanisms and Principal Recipients which, based on past performance, appear to have demonstrated the capacity to scale up existing MDR-TB targets, and invite them to apply for MDR-TB contributions, stating in their applications the value of such requested MDR-TB contributions. Based on these applications, the Secretariat shall calculate the Maximum MDR-TB Amount so that the UNITAID Board can approve the Additional Funding.</p><p>Once UNITAID has approved the Additional Funding, the Global Fund Board shall, if appropriate, delegate to the Secretariat the authority to do the following:</p><ol><li>enter into contracts with UNITAID and the GLC to document how MDR-TB Contributions by UNITAID will be financed and made available;</li><li>determine which GF Programs shall receive MDR-TB Contributions ("Approvals"), subject to the following: <ol type="a"><li>the Local Fund Agent shall make recommendations with respect to the capacity of Principal Recipients to implement the proposed scale-up, and the Secretariat shall consider such recommendations prior to any Approvals; </li><li>the Technical Review Panel ("TRP") shall make funding recommendations with respect to applications where the scale-up in MDR-TB targets causes material variations in other objectives of the relevant GF Program; and</li><li>the total value of the MDR-TB Contributions authorized by the Secretariat shall not exceed the Maximum MDR-TB Amount;</li></ol></li><li>negotiate and execute amendments of grant agreements to reflect the approved scale-up and MDR-TB Contributions; and</li><li>monitor the GF Program results linked to MDR-TB scale-up, and authorize the delivery of MDR-TB Contributions procured by the GLC to GF Programs based on performance.</li></ol><p>The Board requests the Secretariat to report back to it on implementation of this decision at the Fifteenth Board meeting.</p>
2006-11-03 B14 GF/B14/DP17 Resource Mobilization Task Team Input into PSC Reflection on Size Resource Mobilization Task Team Input into PSC Reflection on Size
<p>The Board refers to the strategic issue of "Global Fund size" which the Policy and Strategy Committee (PSC) is currently considering. The Board recognizes that significantly increased resources are needed in the fight against the three diseases, including additional contributions to the Global Fund.</p><p>The Board requests the proposed Resource Mobilization Task Team to develop a resource mobilization strategy for how to achieve the following annual target funding levels, and to highlight in each case the associated implications:</p><p>• US$ 4-6 billion per year by 2010; and</p><p>• US$ 8-10 billion per year by 2010.</p><p>The Board further requests the proposed Resource Mobilization Task Team to deliver its findings by 15 February 2007 to inform the PSC's further deliberations on the strategic issue of "Global Fund size".</p>
2006-11-03 B14 GF/B14/DP12 Establishment of Fixed Dates for Rounds Establishment of Fixed Dates for Rounds
<p>The Board notes that the Policy and Strategy Committee discussed (a) establishing fixed dates for the launch and approval of rounds to make progress towards greater alignment of Global Fund processes with country cycles and greater harmonization with partners' actions; and (b) ideas to develop a more flexible system whereby funding by the Global Fund of some grants or proposals might move away from rounds-based timing.</p><p>For those proposals that remain on a rounds-based system, the Board endorses the recommendation of the Policy and Strategy Committee that the Board establish and announce to the public, with significant advance notice, a fixed set of dates for future rounds of funding.</p><p>The Board decides the following:</p><ol start="1" type="1"><li>The Secretariat shall issue a minimum of one Call for Proposals in each calendar year, which it shall issue at approximately the same date(s) each year;</li></ol><ol start="2" type="1"><li>The Global Fund Board shall, with significant advance notice, announce the dates for the next two Calls forProposalsand the dates when the Board foresees it will approve proposals;</li></ol><ol start="3" type="1"><li>The Secretariat shall issue Calls forProposalsat least four months earlier than the due date for such proposals;</li></ol><ol start="4" type="1"><li>The Global Fund Board shall continue to make all decisions regarding the funding of proposals through a round at Board meetings; and</li></ol><ol start="5" type="1"><li>In accordance with the Comprehensive Funding Policy, the Secretariat will announce a forecast of the resources available for the round at the time it issues each Call forProposals.</li></ol><p>The Board requests that at the appropriate times the Secretariat propose the appropriate dates for the next Call for Proposals and for Board approval of such proposals. These dates should take into account the schedules of recipients, partners, donors and the Secretariat.</p>
2006-11-03 B14 GF/B14/DP15 Role of the Global Fund in Market Dynamics Role of the Global Fund in Market Dynamics
<p>The Board endorses the recommendation of the Policy and Strategy Committee, as part of the strategic issue of "Market Dynamics," that the Global Fund assume a deliberate and strategic role in improving impact of grants through influencing market dynamics.</p><p>The Board notes the draft objective and guiding principles for developing the Global Fund's market dynamics strategy set out in the Report of the Policy and Strategy Committee (GF/B14/7).</p><p>The Board requests that the Policy and Strategy Committee further explore the issue and present any additional matters, including any potential modifications to the objective and guiding principles for the Global Fund's market dynamics strategy, for Board consideration at the Fifteenth Board meeting.</p>
2006-11-03 B14 GF/B14/DP05 Approval of Round 6 Approval of Round 6
<p>1. The Board approves for funding for an initial two years, subject to paragraphs 3 and 4 below, the Round 6 proposals recommended for funding by the Technical Review Panel (TRP) and</p> <p>a. listed in Annex 2, Rev. 2 to the Report of the TRP and Secretariat on Round 6 Proposals (GF/B14/10, Rev.1) as 'Category 1' and 'Category 2', and</p> <p>b. listed in Annex 6<a id="_ftnref1" name="_ftnref1"></a>[1] to GF/B14/10 as 'Category 2B' with Composite indices 8 and 6,</p> <p>with the clear understanding that the grant amounts requested in such Annex for "2 Years" are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts.</p> <p>2. The remaining Round 6 proposals recommended for funding by the TRP as 'Category 2B' and listed in Annex 6, to GF/B14/10, will be approved, subject to paragraph 4 below, through Board confirmation by email (or, if appropriate, at a Board meeting), as funds become available under the terms of the Comprehensive Funding Policy (GF/B7/2, p. 6), as amended at the Thirteenth Board meeting (GF/B14/2, p. 25-6) based on the composite ranking of such proposals in compliance with Board's decision entitled 'Prioritization in Resource Constrained Environments' (GF/B8/2, p. 13), but not later than 31 July 2007. In the interim, the Board requests the Secretariat to proceed with the TRP clarifications with respect to those proposals.</p> <p>3. The applicants whose proposals are recommended for funding as 'Category 1' shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than four weeks after notification in writing by the Secretariat to the applicant of the Board's decision.</p> <p>4. The applicants whose proposals are recommended for funding as 'Category 2' and 'Category 2B' shall:</p> <p>a. provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after notification in writing by the Secretariat to the applicant of the Board's decision; and</p> <p>b. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than four months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</p> <p>5. The Board declines to approve for funding those proposals categorized by the TRP as 'Category 3' as indicated in Annex 2 to GF/B14/10, although such applicants are encouraged to resubmit a proposal in a future funding round after major revision of such proposal.</p> <p>6. The Board declines to approve for funding those proposals categorized by the TRP as 'Category 4' as indicated in Annex 2 to GF/B14/10.</p>
2006-11-03 B14 GF/B14/DP27 Phase 2 Decision-Making Policies and Procedures Phase 2 Decision-Making Policies and Procedures
<ol start="1" type="1"> <li>The Board approves the document entitled "Phase 2 Decision-Making Policies and Procedures" included as Annex 3b, version 2 to the Report of the Portfolio Committee (GF/B14/8) and revokes the previous version of this document approved at the Twelfth Board Meeting.</li> </ol> <ol start="2" type="1"> <li>The Board revokes Point 1 of the decision approved at the Tenth Board Meeting entitled "Phase 2 Decisions Process" (GF/B11/2, p. 21).</li> </ol> <ol start="3" type="1"> <li>The Board replaces Point 2 of the decision approved at the Twelfth Board Meeting entitled "Extension of Proposal Completion Dates" (GF/B13/2, p. 27) with the following decision:</li> </ol> <p>The Board decides that in circumstances where the term of a Phase 1 Grant Agreement has been extended in accordance with paragraph 7 of the Phase 2 Decision-Making Policies and Procedures attached as Annex 3b, version 2 to the Report of the Portfolio Committee (GF/B14/8) (a "Phase 1 Extension"), the Secretariat may extend the Phase 2 term of Grant Agreements by up to an equal length of time as the Phase 1 Extension without committing any additional funding.</p>
2006-11-23 B14 GF/B14/EDP01 Approval of Phase 2 Funding Recommendations November 2006 Approval of Phase 2 Funding Recommendations November 2006
#
2022-08-16 B47 GF/B47/EDP10 Eligibility of Venezuela’s Malaria and TB Components for the 2023-2025 Allocation Period Eligibility of Venezuela’s Malaria and TB Components for the 2023-2025 Allocation Period
<p>Based on the recommendation of the Strategy Committee described in [GF/B47/ER08], the Board:</p> <ol> <li>Acknowledges that the Eligibility Policy (GF/B47/03) allows certain non-eligible countries to be recommended to be exceptionally eligible for malaria in line with paragraph 11 of the Policy;</li> <li>Acknowledges that the Eligibility Policy’s treatment of Venezuela’s exceptional tuberculosis (“TB”) eligibility must consider the fact that Venezuela is the only country in the World Bank’s classification system that is temporarily unclassified;</li> <li>Based on the Secretariat and technical partners’ recommendation described in [GF/B47/ER08], approves that Venezuela’s malaria and TB components be made exceptionally eligible for the 2023-2025 Allocation period; and</li> <li>Notes that any components made exceptionally eligible will be governed by the Allocation Methodology 2023-2025 and existing Global Fund policies and processes.</li> </ol>
2022-08-12 B47 GF/B47/EDP11 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-08-12 B47 GF/B47/EDP12 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER09(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-04-08 B44 GF/B44/EDP22 2020 Statutory Financial Statements 2020 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2020 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B44/ER15.</p>
2021-04-08 B44 GF/B44/EDP21 2020 Annual Financial Report 2020 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2020 Annual Financial Report, including the 2020 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B44/ER15.</p>
2021-03-05 B44 GF/B44/EDP17 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER11 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-02-24 B44 GF/B44/EDP16 Revision of Amended and Restated Code of Conduct for Governance Officials Revision of Amended and Restated Code of Conduct for Governance Officials
<ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the revisions to the Amended and Restated Code of Conduct for Governance Officials, as set forth in Annex 1 to GF/B44/ER10.</li> <li>Accordingly, the Board acknowledges that this decision point and the revisions to the Amended and Restated Code of Conduct for Governance Officials shall supersede the approval of the previous Amended and Restated Code of Conduct for Governance Officials, pursuant to decision point GF/B43/EDP05.</li> </ol>
2021-02-19 B44 GF/B44/EDP15 Approval of the Report of the 44th Board Meeting Approval of the Report of the 44th Board Meeting
<p>The Board approves the Report of the 44th Board Meeting, as set forth in GF/B44/18.</p>
2021-02-12 B44 GF/B44/EDP14 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-03-29 B44 GF/B44/EDP20 Renewal of Executive Director Appointment Renewal of Executive Director Appointment
<p>The Board decides to renew the appointment and extend the term of Peter Sands, as the Executive Director of the Global Fund, for an additional four years. In accordance with Article 36.1 of the Operating Procedures of the Board and Committees, the Board has taken such decision with due consideration of performance over his first term, and following discussion of key priorities for the extended term.</p> <p>The Board extends its appreciation and recognition to Mr. Sands for his service during his first term, and expresses support and encouragement to take forward this mandate to implement the organization’s strategic vision in pursuit of the mission.</p>
2020-12-11 B44 GF/B44/EDP06 Revisions for Key Performance Indicators Revisions for Key Performance Indicators
<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revisions for Key Performance Indicators 3, 5, 6a, 6b and 9b as presented in GF/B44/ER04.</li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the 2021 target for Key Performance Indicator 12b as presented in GF/B44/ER04; and</li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the revision of the formula for Key Performance Indicator 7a as presented in GF/B44/ER04. </li> </ol>
2021-03-22 B44 GF/B44/EDP19 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER13 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-12-22 B44 GF/B44/EDP11 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER08 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-12-22 B44 GF/B44/EDP12 Decision on the Secretariat’s Recommendation on Additional Funding to for the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to for the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B44/ER08 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the TRP validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-12-22 B44 GF/B44/EDP13 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B44/ER08 (“Table 3”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>
2020-12-17 B44 GF/B44/EDP09 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B44/ER06 (“Table 2”);</li> <li>Affirms that the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period for the grant listed in Table 2, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component within the grant, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-12-17 B44 GF/B44/EDP08 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-12-10 B44 GF/B44/EDP05 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B44/ER02 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>
2020-12-10 B44 GF/B44/EDP04 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER03 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-12-03 B44 GF/B44/EDP02 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-12-03 B44 GF/B44/EDP03 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <p>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B44/ER02 (“Table 2”);</p> <p>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</p>
2020-12-18 B44 GF/B44/EDP10 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2021-03-30 B44 GF/B44/EDP18 Second Extension of C19RM Timeline and Operational Flexibility for COVID-19 Second Extension of C19RM Timeline and Operational Flexibility for COVID-19
<p>The Board acknowledges its previous decision establishing the Global Fund COVID-19 Response Mechanism (C19RM) and agrees that the COVID-19 pandemic continues to have a devastating impact on global health systems, jeopardizing the fight against HIV, tuberculosis, and malaria and progress towards 2030 goals for the three diseases. Recognizing the acute needs at country-level, and the threat of diversion of resources towards COVID-19, the Board agrees that additional funding to support country responses to COVID-19 is necessary to safeguard the USD 14 billion raised through the 6th replenishment for HIV, tuberculosis, and malaria (HTM) programs. The Board further acknowledges that certain public donors wish to make significant additional pledges to the Global Fund to provide further support for country responses to COVID-19 and that this decision does not preclude further discussion and Board decisions within the Strategy development process on the future role and scope of Global Fund support for pandemic preparedness and response.</p> <p>The Board agrees that C19RM should leverage existing Global Fund processes, controls, and frameworks, while acknowledging that modifications may be necessary to ensure the level of speed and agility necessary for an emergency response. The Board further agrees on the need for greater transparency on the operationalization and implementation of C19RM, to facilitate and ensure an appropriate degree of oversight from, and accountability to, the Board.</p> <p>The Board therefore approves the following:</p> <p>1. Timelines:</p> <ol type="a"> <li>C19RM is a temporary, timebound mechanism established to address the current global emergency related to the COVID-19 pandemic;</li> <li>The Secretariat will, through 31 December 2021, continue to mobilize additional funds from public donors and, pursuant to existing policies, private donors, which will be used to support C19RM;</li> <li>C19RM funds may be awarded through 31 March 2022;</li> <li>C19RM will continue to finance interventions across the 5th and 6th replenishment periods; and</li> <li>While C19RM funding is expected to be used rapidly for emergency needs, the final deadline for use of C19RM funds will be 31 December 2023, to reduce the additional cost and burden associated with establishing and monitoring an independent deadline within core grants.</li> </ol> <p>2. Use of funding:</p> <ol type="a"> <li>C19RM funding will finance interventions consistent with applicable World Health Organization (WHO) guidance, including on COVID-19;</li> <li>C19RM funding must be aligned with national Strategic Preparedness and Response Plans;</li> <li>C19RM funding may be used for the following types of interventions: <ol type="a"> <li>COVID-19 control and containment interventions, including personal protective equipment, diagnostics, treatment, communications and other public measures as specified in WHO guidance;</li> <li>COVID-19-related risk mitigation measures for programs to fight HTM (including, but not limited to, support for COVID-19 interventions needed to safely implement campaigns, community and health facility level HTM programs, and additional delivery and procurement costs for HTM programs where related to addressing COVID-19 disruptions); and</li> <li>iii. Expanded reinforcement of key aspects of health systems, such as laboratory networks, supply chains, and community-led response systems, to address advocacy, services, accountability, and human rights based approaches;</li> </ol> </li> <li>C19RM funds may be used to procure COVID-19 products approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authorities as defined under the Quality Assurance Policy for Pharmaceutical Products and Quality Assurance Policy for Diagnostic Products; and</li> <li>The Secretariat will develop detailed technical guidance on eligible C19RM interventions for countries, in consultation with relevant partners, as described in paragraphs 27.a and 44 of GF/B44/ER12 – Revision 2.</li> </ol> <p>3. Allocations:</p> <ol type="a"> <li>C19RM funding awards will use countries’ 2020-2022 allocations as a starting basis; and</li> <li>C19RM funding awards will be qualitatively adjusted to better reflect countries’ COVID-19 needs using the following factors: (i) COVID-19 burden; (ii) level of disruption to systems of health, including HTM services; (iii) availability of other sources of funding; and (iv) utilization of funds already awarded.</li> </ol> <p>4. Funding requests:</p> <ol type="a"> <li>C19RM funding requests must be endorsed by Country Coordinating Mechanisms;</li> <li>C19RM funding requests must be developed through appropriate, multisectoral consultation, and fully-inclusive decision-making, which must engage communities and civil society, and ensure coordination with the national COVID-19 response coordinator;</li> <li>C19RM funding request development must include consideration of appropriate community, rights, and gender-related interventions, in alignment with the Global Fund’s underlying principles of gender equity and human rights, and funding requests must articulate national HTM program adaptation needs and how these needs will be covered (e.g. through C19RM funding, grant funding, or other sources); and</li> <li>The Board calls on partners to support countries at the country, regional and global levels to develop robust, technically-sound C19RM funding requests.</li> </ol> <p>5. C19RM Funding Request Review and Approval:</p> <ol type="a"> <li>GAC: <ol type="i"> <li>C19RM funding requests will be shared with partners on the Grant Approvals Committee (GAC) for review and input;</li> <li>C19RM funding requests will also be shared with a technical advisory group composed of relevant ACT-Accelerator partners with technical COVID-19 expertise (CTAG) for review and input;</li> <li>iii. The Secretariat will consider input from GAC partners and CTAG in determining C19RM funding awards or recommendations; and</li> <li>The Secretariat will convene regular GAC review of C19RM to discuss awards made, emerging thematic issues relating to C19RM and Global Fund programs, and concerns and observations from partners. CTAG partners will be invited to participate in these reviews.</li> </ol> </li> <li>TRP: <ol type="i"> <li>The TRP will be requested to input into upfront technical guidance relating to HTM adaptations/risk mitigation as referenced in paragraph 2.e above; and</li> <li>The TRP will also be requested to conduct an expedited review of HTM program adaptation/risk mitigation elements of C19RM funding requests that entail material changes to existing Global Fund programs.</li> </ol> </li> <li>Fast-track investments: The Secretariat may award countries up to USD 900 million of C19RM funding on an accelerated basis to support urgent needs for COVID-19 commodities (including personal protective equipment, diagnostics, and therapeutics) and costs relating to the effective deployment of such commodities.</li> <li>Board approval: <ol type="i"> <li>The Board must approve any C19RM awards exceeding USD 35 million, as measured in aggregate by country and not including any funding awarded pursuant to paragraph 5.c above or previously awarded C19RM funding;</li> <li>Commodity orders relating to paragraph 5.d.i above may be placed pending Board approval; and</li> <li>iii. For C19RM awards approved by the Board, the Secretariat will have delegated authority to increase such awards by up to USD 10 million, in order to avoid the need for repeated Board approvals for increases to the same grants. This authority will be limited to increases that scale up interventions previously approved by the Board.</li> </ol> </li> </ol> <p>6. Reporting, Monitoring and Evaluation:</p> <ol type="a"> <li>The Board emphasizes the need for comprehensive reporting, monitoring and evaluation of C19RM investments, while acknowledging the challenges of measuring results within an emergency response to a rapidly evolving pandemic. The Secretariat and TERG will further develop an evaluation approach for C19RM, as described in paragraphs 50 - 56 of GF/B44/ER12 – Revision 2. This approach will be presented to the Strategy Committee at its 16th meeting (July 2021) for review and input;</li> <li>The Board emphasizes the need for enhanced transparency on C19RM. The Secretariat will provide monthly detailed reporting to the Board on C19RM operationalization, as described in paragraph 21 of GF/B44/ER12 - Revision 2. This reporting will also be available on the Global Fund’s external website to increase transparency of investments and support coordination of external support for COVID-19; and</li> <li>The Secretariat will continue to provide updates through regular Board and Committee engagements.</li> </ol> <p>7. Centrally Managed Investments</p> <ol type="a"> <li>Up to 2.5% of C19RM funding may be used for centrally managed investments to address needs that are not well addressed through awards to individual countries, as described in paragraph 57 of GF/B44/ER12 – Revision 2; and</li> <li>The Secretariat will develop any centrally managed investments under this provision in coordination with GAC and CTAG, and will report all such investments to the Board and its relevant Committees.</li> </ol> <p>8. Management and Operating costs</p> <ol type="a"> <li>Up to 3% of C19RM funds may be used by the Secretariat to cover additional management and operating costs relating to C19RM. These costs may include (i) additional Secretariat resources and expertise, (ii) additional assurance costs, (iii) additional costs relating to enhanced reporting and monitoring and evaluation of C19RM investments, and (iv) additional costs to support CCMs;</li> <li>Management and operating costs under this provision are timebound, reflecting the temporary nature of C19RM, and will not form part of the Secretariat’s annual budget for operating expenditures;</li> <li>The Audit and Finance Committee will review the Secretariat’s plan for costs under this provision; and</li> <li>The Secretariat will provide regular reporting on any costs under this provision to the Audit and Finance Committee and the Board.</li> </ol> <p>9. Additional changes:</p> <ol type="a"> <li>The Board will monitor C19RM on an ongoing basis to determine whether any changes are required as the pandemic continues to evolve; and</li> <li>The Secretariat will return to the Board, through its Committees, as relevant, for additional consideration and approval of any further modifications to C19RM.</li> </ol> <p>10. Limited exceptions to Quality Assurance Policies:</p> <ol type="a"> <li>The Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 March 2022.</li> </ol>
2021-04-13 B44 GF/B44/EDP23 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-04-15 B44 GF/B44/EDP24 Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot Second Extension of the Timeline for Including COVID-19 Products in the wambo.org Pilot
<p>The Board:</p> <ol> <li>Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions forCOVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee;</li> <li>Recalls GF/B43/EDP17 where the Board approved the change in the end date of such period to 31 May 2021; and</li> <li>Based on the recommendation of the Strategy Committee, approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org until November 2022 or until the Board approves a future strategy for wambo.org if earlier and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.</li> </ol>
2022-08-12 B47 GF/B47/EDP09 Approval of the Report of the Global Fund 47th Board Meeting Approval of the Report of the Global Fund 47th Board Meeting
<p>The Board approves the Report of the Global Fund 47th Board Meeting, as set forth in GF/B47/22.</p>
2022-07-18 B47 GF/B47/EDP07 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-07-13 B47 GF/B47/EDP08 Appointment of the Ethics Officer Appointment of the Ethics Officer
<p>The Board approves the appointment of Susanne Kuehn to serve as the next Global Fund Ethics Officer for a three-year term which can be renewed no more than once.</p>
2022-06-23 B47 GF/B47/EDP06 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-06-14 B47 GF/B47/EDP05 Revisions to the Board and Committee Operating Procedures Revisions to the Board and Committee Operating Procedures
<p>Based on the recommendation of the EGC, the Board approves the amendments tothe Operating Procedures of the Board and Committees of the Global Fund, as set out in Annex 2 to GF/B47/ER04. The amendments to the BCOP shall enter into force upon the adoption of this decision point.</p>
2022-06-13 B47 GF/B47/EDP04 Revisions to the Charter of the Office of the Inspector General Revisions to the Charter of the Office of the Inspector General
<p>The Board approves a modification to the mandate and functions of the Office of the Inspector General through a change to the Charter of the Office of the Inspector General (the “OIG Charter”), as revised and set forth in Annex 1 to GF/B47/EDP04.</p>
2022-05-23 B47 GF/B47/EDP03 Appointment of the Vice-Chair of the Ethics and Governance Committee Appointment of the Vice-Chair of the Ethics and Governance Committee
<p>The Board approves the appointment of Magda Robalo Correia e Silva as Vice-Chair of the Ethics and Governance Committee, to commence her term on 23 May 2022 and serve for three years or until appointment of her successor (whichever is earlier).</p>
2022-05-26 B47 GF/B47/EDP01 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-05-26 B47 GF/B47/EDP02 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER02(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-05-12 B47 GF/B47/DP08 Leveraging the work of the Standing Committees Leveraging the work of the Standing Committees
<p>Based on the recommendation of the Ethics and Governance Committee (the “EGC”), as presented in GF/B47/06 – Revision 1, the Board:</p> <ol> <li>Acknowledges the changes to the Charter of the Strategy Committee already approved through GF/B46/DP06 and which will be effective as of 31 December 2022;</li> <li>Amends the Charters of the Standing Committees of the Board (“the Charters”), as set forth respectively in Annexes 5, 6 and 7 of GF/B47/06 – Revision 1, which shall each become effective upon the conclusion of the forty-seventh Board meeting; and</li> <li>Acknowledging the specific scope and intent of the changes to the Charters, requests the EGC leadership to determine, after consultation with the Board leadership, Coordinating Group, Standing Committees and Secretariat, as relevant, whether a more complete review of the Charters may be required during the next EGC term.</li> </ol>
2022-05-11 B47 GF/B47/DP05 Allocation Methodology 2023 - 2025 Allocation Methodology 2023 - 2025
<ol> <li>The Board notes:<br /> <ol type="a"> <li>Its decision in May 2019 (GF/B41/DP03) that (i) established the allocation methodology for the 2020 - 2022 allocation period; and (ii) acknowledged the technical parameters for the 2020 - 2022 allocation period; and</li> <li>The decision by the Strategy Committee (the “SC”) in March 2022 GF/SC18/DP05, under authority delegated by the Board, to establish technical parameters for the 2023 – 2025 allocation period (the “Technical Parameters”).</li> </ol> </li> <li>Accordingly, based on the recommendations of the SC, as presented in GF/B47/03, the Board:<br /> <ol type="a"> <li>Approves the allocation methodology presented in Annex 1 to GF/B47/03 (the “Allocation Methodology”);</li> <li>Acknowledges the Technical Parameters for the 2023 – 2025 allocation period, as presented in Annex 2 to GF/B47/03 and</li> <li>Approves that no more than 7.5% of the total sources of funds available for country allocations be used to ensure scale-up, impact and paced reductions, as described in paragraph 4.c of the Allocation Methodology; and</li> </ol> </li> <li>Accordingly, the Board:<br /> <ol type="a"> <li>Requests the SC to review and approve, at its July 2022 meeting, the method by which the Secretariat will apply and report on the qualitative adjustment process; and</li> <li>Acknowledges that the Allocation Methodology and Technical Parameters shall apply for the 2023– 2025 allocation period and supersede the 2020 – 2022 allocation methodology and technical parameters presented in GF/B41/02.</li> </ol> </li> </ol>
2022-05-10 B47 GF/B47/DP01 Approval of the Rapporteur Approval of the Rapporteur
<p>Mišo Pejković from the Eastern Europe and Central Asia Constituency is designated as Rapporteur for the 47th Board Meeting.</p>
2022-05-10 B47 GF/B47/DP03 Approval of the Revised Eligibility Policy Approval of the Revised Eligibility Policy
<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 1 to GF/B47/02 (the “Revised Eligibility Policy”).</li> <li>Accordingly, the Board: <ol type="i"> <li>Acknowledges that this decision point and the Revised Eligibility Policy supersede the decision point GF/B39/DP03 and the previous Eligibility Policy as set forth in Annex 1 to GF/B39/02 (the “Previous Eligibility Policy”); and</li> <li>Notes that, notwithstanding paragraph 2.i of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2020-2022 allocation period.</li> </ol> </li> </ol>
2022-05-11 B47 GF/B47/DP06 Catalytic Investments for the 2023-2025 Allocation Period Catalytic Investments for the 2023-2025 Allocation Period
<p>Based on the recommendation of the Strategy Committee, as presented in GF/B4704 – Revision 1, the Board:</p> <ol> <li>Acknowledges that the total amount of sources of funds for allocation for the 2023-2025 allocation period will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 7th Replenishment;</li> <li>Approves that the total amount of funding for catalytic investments in the 2023-2025 allocation period (“Catalytic Investments”) will be determined by the total amount of sources of funds for allocation for the 2023-2025 allocation period;</li> <li>Approves Catalytic Investments for the 2023 –2025 allocation period, based on the total amount of sources of funds for allocation, as set forth in Table 1 of GF/B47/DP06;</li> <li>Agrees that in the event that sources of funds for allocation for the 2023-2025 allocation period are above the midpoint of the funding range specified for any scenario in Table 1 of GF/B47/DP06, the Secretariat may recommend to the Board to approve additional amounts for Catalytic Investments (up to 50% of the difference in total catalytic funding for the applicable scenario and the next higher funding scenario) to be invested in the priority areas for the next higher funding scenario in Table 1 of GF/B47/DP06;</li> <li>Acknowledging that additional refinements may be required to the catalytic investment amounts for the priorities under the “RSSH/Cross-Cutting” section of Table 1 to GF/B47/DP06, delegates authority to the Strategy Committee to approve, within such RSSH/Cross-Cutting section (with the exclusion of the Emergency Fund priority): (i) a decrease in the amount of any priority by up to 15% and (ii) the inclusion of such decreased amounts within another priority in this group. Any changes made under this paragraph will be approved by the Strategy Committee at its July 2022 meeting, and will be informed by input to be provided by the Secretariat as described in paragraph 6.ii below</li> <li>Approves that the Secretariat will:<br /> <ol type="i"> <li>operationalize Catalytic Investments, considering TRP and TERG recommendations as well as available program and financial performance data from ongoing catalytic investments, and work with partners to ensure that Catalytic Investments have clear objectives, expected outcomes and impact and transparency in the investment decisions on geographic prioritization and country selection;</li> <li>update the Strategy Committee, at its July 2022 meeting, on the status of such operationalization and planned next steps, and report, bi-annually, to the Strategy Committee and Board thereafter on further operationalization;</li> <li>have flexibility, within the total amount of funding for Catalytic Investments, to increase or decrease the amount for any approved priority up to 15% and report to the Strategy Committee on any such changes; and</li> <li>present any increase or decrease of an amount for any approved priority above 15% to the Strategy Committee for approval; and</li> </ol> </li> <li>Agrees that the Secretariat will have delegated authority to increase the amount of funding available for the Emergency Fund, by up to 50% of the amount approved for this priority, using funding approved as available by the Audit and Finance Committee for portfolio optimization, and that paragraph 6.iv above will not apply to increases to the Emergency Fund. Any increase above 50% will be presented to the Board for its urgent, no-objection approval.</li> </ol>
2022-05-12 B47 GF/B47/DP07 Board Leadership Term Board Leadership Term
<p>The Board approves the amendments to the (i) Terms of Reference Chair and Vice-Chair of<br />the Board of the Global Fund, (ii) Bylaws of the Global Fund; and (iii) the Operating Procedures of the Board and Committees of the Global Fund, set out respectively in annexes 1, 2 and 3 to GF/B47/05.</p>
2022-05-10 B47 GF/B47/DP02 Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 47th Board Meeting (GF/B47/01) is approved.</p>
2022-05-10 B47 GF/B47/DP04 Approval of the Eligibility of the 2020-2022 Transition Funding Components for an Additional Allocation Approval of the Eligibility of the 2020-2022 Transition Funding Components for an Additional Allocation
<p>Based on the recommendation of the Strategy Committee, the Board approves the eligibility of the six (6) Transition Funding components from the 2020-2022 allocation period for an additional allocation of Transition Funding for the 2023-2025 allocation period.</p>
2021-05-19 B44 GF/B44/EDP26 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <p>1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER19 (“Table 1”);</p> <p>2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</p> <p>3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</p> <p>4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </p>
2021-04-28 B44 GF/B44/EDP25 Appointment of one Replacement Member on the Audit and Finance Committee, and one Replacement Member on the Ethics and Governance Committee Appointment of one Replacement Member on the Audit and Finance Committee, and one Replacement Member on the Ethics and Governance Committee
<ol> <li>The Board approves the appointment of Mr Mauro Ghirotti, representing the European Commission, Belgium, Italy, Portugal, Spain Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Mr Josephat Kakoma from the Eastern and Southern Africa Constituency, to serve in his personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of his successor. </li> </ol>
2020-12-03 B44 GF/B44/EDP07 Appointment of the Inspector General Appointment of the Inspector General
<p>The Board appoints Tracy Staines to serve as the next Inspector General of the Global Fund for a six-year term to begin not later than 1 January 2021.</p>
2016-11-14 B35 GF/B35/EDP20 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B35/ER16 (“Tables 1a and 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;</li> <li>Approves the additional incremental funding and implementation period recommended for the EHRN regional grant, being an Early Applicant grant, as listed in Table 2 of Section IV to GF/B35/ER16 based on the available funding that the Finance and Operational Performance Committee (the “FOPC”) validated pursuant to GF/FOPC17/DP02;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-08-24 B35 GF/B35/EDP13 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:<br/>1. Approves the incremental funding recommended for each country and regional disease component, and its constituent grants, as listed in Table 1a and 1b, respectively, of Section IV to GF/B35/ER11 (collectively, "Table 1");<br/><br/>2. Acknowledges each country and regional disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Approves the reinvestment of within-allocation efficiencies for the Zambia TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B35/ER11;<br/><br/>4. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for the Philippines TB disease component, being an Early Applicant grant, as listed in Table 3 of Section IV to GF/B35/ER11, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country and regional disease component's constituent grants, (b) is subject to the availability of funding and (c) shall be committed in annual tranches; and<br/><br/>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country and regional disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p><p>This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>
2016-11-01 B35 GF/B35/EDP19 Approval of the Terms of Reference for the 2016 Executive Director Nomination Committee Approval of the Terms of Reference for the 2016 Executive Director Nomination Committee
<p>Based on the recommendation of the Board Chair and Vice-Chair (“Board Leadership”), in consultation with the Ethics and Governance Committee (“EGC”) and the Governance Focal Points Network, the Board:</p> <ol> <li>Notes its responsibilities with regard to the recruitment process of the Executive Director as set out in Article 36 of the Operating Procedures of the Board and Committees <span>of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“BCOP”).</span></li> <li>Notes the consultations of the Board Leadership and the Governance Focal Points Network with the EGC in relation to this process, including with respect to the establishment of the nomination committee referred to in the BCOP and the selection of an executive search firm, Russell Reynolds Associates, to provide support to the said nomination committee in carrying out its mandate.</li> <li>Approves the terms of reference of the 2016 Executive Director Nomination Committee as set out in Annex 1 to GF/B35/ER15.</li> <li>Invites the Board Leadership to submit in due course for Board approval, in accordance with Article 36 of the BCOP, a Chair and the membership of the nomination committee.</li> </ol>
2009-05-06 B19 GF/B19/DP26 Managing the Tension Between Demand and Supply in a Resource-Constrained Environment Managing the Tension Between Demand and Supply in a Resource-Constrained Environment
<p>Based on the updated Demand Scenarios and Resource Forecasts, the Board decides to establish a balanced Working Group with participation by Dr. Peter Godfrey-Faussett, the outgoing Chair of the TRP, to review the current policies that guide both resource mobilization and resource allocation and to develop a framework for managing the tension between resource demand and supply in a resource-constrained environment.</p><p>Upon the recommendation of the Board Chair and Vice-Chair, the Board approves the appointment of the following members of the Working Group:</p><table class="table" dropzone="copy"><tbody><tr><td>Name</td><td>Constituency</td><td> </td></tr><tr><td>1.</td><td>Peter van Rooijen, as Co-Chair</td><td>Developed Country NGO</td></tr><tr><td>2.</td><td>Dr. Sigrun Mögedal, as Co-Chair</td><td>Point 7</td></tr><tr><td>3.</td><td>Javier Hourcade Bellocq</td><td>Communities</td></tr><tr><td>4.</td><td>Dr. Agnes Binagwaho</td><td>Eastern and Southern Africa</td></tr><tr><td>5.</td><td>Simon Bland</td><td>UK/Australia</td></tr><tr><td>6.</td><td>Amb. Patrice Debré</td><td>France/Spain</td></tr><tr><td>7.</td><td>Michelle Moloney-Kitts</td><td>USA</td></tr><tr><td>8.</td><td>Bill Parr</td><td>Western Pacific Region</td></tr><tr><td>9.</td><td>Sujatha Rao</td><td>South East Asia</td></tr><tr><td>10.</td><td>Todd Summers</td><td>Private Foundations</td></tr><tr><td>11.</td><td>Dr. Ernest Messiah</td><td>Latin America and the Caribbean</td></tr><tr><td>12.</td><td>Enrico Vicenti</td><td>Italy</td></tr></tbody></table><p> </p><p>The Working Group is requested to:</p><p>1. provide recommendations for amendments of existing policies regarding prioritization for funding technically sound proposals in a resource-constrained environment, subject to review at the appropriate times;</p><p>2. provide recommendations, if possible, on future resource allocation policies, to be followed-up by the appropriate Board committee(s); and</p><p>3. present options for an increased and urgent resource mobilization effort.</p><p>The Working Group is requested to seek appropriate input during its deliberations, consult with PC, PSC and FAC, and report to the Board before its Twentieth Board Meeting in November 2009. </p>
2009-08-12 B19 GF/B19/EDP10 Approval of Round 8 Funding Recommendations - INCOMPLETE Approval of Round 8 Funding Recommendations - INCOMPLETE
<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite indices 5 and 3 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14.</p>
2009-07-17 B19 GF/B19/EDP09 Appointment of the Chair of the Market Dynamics and Commodities Ad-Hoc Committee Appointment of the Chair of the Market Dynamics and Commodities Ad-Hoc Committee
The Board approves the appointment of Mr. Dai Ellis of the Private Foundations constituency as Chair of the Market Dynamics and Commodities Ad-Hoc Committee.
2009-05-06 B19 GF/B19/DP07 Global Fund Strategy in Relation to Sexual Orientation and Gender Identities Global Fund Strategy in Relation to Sexual Orientation and Gender Identities
The Board approves "The Global Fund Strategy in Relation to Sexual Orientation and Gender Identities (SOGI)" (GF/B19/4 - Attachment 3) and requests the Secretariat to report on progress of implementation of the strategy to the Policy and Strategy Committee at its next meeting.
2009-05-06 B19 GF/B19/DP34 Enhancing the Global Fund’s Response to HIV/AIDS Enhancing the Global Fund’s Response to HIV/AIDS
<p>1. As a leading multi-lateral financier of HIV/AIDS programs globally, the Board recognizes its role as a responsible steward of the Global Fund's investments on behalf of people living with and at risk of HIV and the need to ensure high impact of programs supported by the grants that it approves while achieving maximum value for money.</p><p>2. The Board recognizes that improving prevention efforts is critically important to the fight against HIV/AIDS and that the Global Fund should support countries in implementing HIV prevention strategies that are targeted, evidence-based and consistent with local epidemiology. The Board welcomes the initiative by UNAIDS to form, in an expedited manner, a working group, which may include interested Board constituencies, on assessing evidence and developing practical actions on increasing country adoption of 'combination prevention' strategies to determine relevant actions and the appropriate role for the Global Fund which will be presented to the Board at its Twentieth Meeting for relevant action. </p><p>3. The Board also recognizes that the Global Fund has a responsibility to use its influence to leverage a reduction in stigma, discrimination, criminalization of people due to their sexual orientation or gender identity and HIV+ individuals, travel restrictions and sexual and gender violence.</p><p>4. The Board recognizes that, despite important progress made, there are significant gaps in scaling up coverage of effective HIV prevention, treatment, care and support. In addition, there is an urgent need to improve the quality of care for people living with HIV, reduce the costs of treatment in the long term, and to increase the number of people served through programs supported by the Global Fund. Therefore, the Board:</p><p>i. Recognizes the urgent need to increase resource mobilization efforts, given the need to increase overall HIV treatment and care coverage to achieve the goal of universal access. In addition, acknowledges that increased uptake of innovations in HIV treatment and care may result in initial cost increases, but encourages the technical, programmatic and financial evaluation of these investments. </p><p>ii. Requests the Secretariat to work with partners to project the long-term financial costs of existing commitments and future demand on the Global Fund as a major funder of prevention, treatment, and care, including the potential impact of strategies to improve outcomes and reduce treatment costs. This study should include but not be limited to possible protocol changes. Findings should be presented to the Portfolio and Implementation Committee in order to recommend relevant Board action prior to the Twenty-First Board Meeting.</p><p>iii. Recognizing the value of new technologies to improving quality and cost-efficiency of HIV/AIDS prevention, care and treatment, requests the ad-hoc Market Dynamics Committee, in collaboration with partners, to consider how the Global Fund, its partners, Principal Recipients, and Sub-recipients can accelerate access to and uptake of cost-effective new technologies and optimized HIV treatment regimens, to improve outcomes.</p><p>iv. Requests the Secretariat to urgently work with partners to adopt measures to identify gaps and to further improve the quality of Global Fund supported prevention, treatment, care and support including operational research to identify effective scaling up strategies to improve outcomes. These measures should be reviewed by the Portfolio and Implementation Committee during its review of the Round 10 proposal form and guidelines.</p><p>5. The Board recognizes that prevention of HIV in women and preventing HIV-positive mothers from dying and babies from being infected with HIV is crucial to achieving the goals of universal access and an HIV/AIDS-free generation. Scaling-up access to, and use of effective prevention of mother-to-child transmission (PMTCT) and paediatric HIV care, support, and treatment services - which are integrated with primary, maternal and child health and comprehensive sexual and reproductive health programs - is a critical component of the Global Fund's Gender Equality Strategy. Therefore, the Board requests the Secretariat to conduct a review of the portfolio to identify paediatric HIV high burden countries with low PMTCT and paediatric HIV care, support, and treatment coverage rates and prepare options for the Portfolio and Implementation Committee to use available mechanisms to accelerate transitions to more efficacious ARV regimens for effective PMTCT strategies, which should be reported to the Board at its Twentieth Board Meeting </p><p>6. The Board urges CCMs to consider while formulating future proposals that are targeted, evidence-based and consistent with local epidemiology to (i) re-intensify efforts to prevent HIV including among vulnerable populations; and (ii) to improve the health of HIV-infected pregnant women and children through effective PMTCT and paediatric HIV care and treatment programs to ensure improved responses to high paediatric loss-to-follow-up rates; and that strengthen a family centred care approach. The Board also urges CCMs and Principal Recipients, as needed, to consider reprogramming existing grants on the basis of the above.</p>
2009-07-03 B19 GF/B19/EDP01 Approval of Additional Funding Recommendations (Phase 2) Approval of Additional Funding Recommendations (Phase 2)
<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li><li>The Board approves additional funding for one year for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</li></ol><p>SCHEDULE A <br/>Total US$39,366,472 </p><p>Benin, TB – Round 6 <br/>Grant Number: BEN-607-G06-T <br/>CCM Requested Amount (Total Phase 2): Euro 4,020,433(1) (2) <br/>Approved Funding Amount (Incremental): Euro 3,394,175= US$4,505,767(2) <br/> Recommendation Category: Conditional Go</p><p>Djibouti, HIV – Round 6 <br/>Grant Number: DJB-607-G04-H <br/>CCM Requested Amount (Total Phase 2 in US$): 7,485,768 <br/>Approved Funding Amount (Incremental in US$): 7,485,768 <br/>Recommendation Category: Go </p><p>Djibouti, TB – Round 6 <br/>Grant Number: DJB-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$):2,620,959(1) <br/>Approved Funding Amount (Incremental in US$): 2,415,075 <br/>Recommendation Category: Go </p><p>Senegal, HIV – Round 6 <br/>SNG-607-G05-H <br/>CCM Requested Amount (Total Phase 2): Euro 10,912,515(1) (2) <br/>Euro 9,337,573 = US$12,395,628(2) <br/> Recommendation Category: Go <br/><br/></p><p>Senegal, HIV – Round 6 <br/>Grant Number: SNG-607-G06-H <br/>CCM Requested Amount (Total Phase 2 in US$): Euro 4,166,385(1) (2) <br/>Approved Funding Amount (Incremental in US$): Euro 3,791,386 = US$5,033,065(2) <br/>Go <br/><br/></p><p>Serbia, HIV – Round 6 <br/>Grant Number: SER-607-G03-H <br/>CCM Requested Amount (Total Phase 2 in US$): Euro 4,531,534 (2) <br/>Approved Funding Amount (Incremental in US$): Euro 4,531,534 = US$6,015,611(2) <br/>Recommendation Category: Conditional Go </p><p>Suriname, HIV – Round 5 <br/>Grant Number: SUR-506-G03-H <br/>CCM Requested Amount (Total Phase 2 in US$): 1,800,000 <br/>Approved Funding Amount (Incremental in US$): 1,515,558 <br/>Recommendation Category: Conditional Go </p><p>SCHEDULE B <br/><br/>Côte D’Ivoire, HIV – Round 2 <br/>Grant Number: CIV-202-G05-H <br/>CCM Requested Amount (in US$) : 10,451,388 <br/>Approved Funding Amount (Incremental in US$): 2,950,407 <br/><br/><u><b>Next Steps:</b></u></p><p>The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedules A and B. </p>
2009-05-06 B19 GF/B19/DP30 Partnership Forum 2008 Partnership Forum 2008
<p>a) The Board takes note of the "Partnership Forum 2008 Report" (GF/B19/14) and agrees to use the recommendations contained therein to inform ongoing strategic planning and management of the Global Fund. The Board assigns responsibility to oversee follow-up on the recommendations to its committees as laid out in Attachment 1 to GF/B19/4.</p><p>b) The Board decides to hold the fourth Partnership Forum in the first half of 2011 and approves the following amendment to Article 6.3 of the By-Laws:</p><p><i>By-Laws: Article 6.3 Frequency and notice of meetings</i></p><p><i>The Partnership Forum will meet biennially, at any time during even calendar years <b>every 24 to 30 months.</b></i></p><p><i>Meetings of the Partnership Forum shall be convened by written notice from or on behalf of the Foundation Board.</i></p><p>c) The Board mandates the Policy and Strategy Committee to establish a Partnership Forum Steering Committee to start planning for this event early in 2010.</p><p>d) The format, duration and organization of the fourth Partnership Forum should build on the lessons learned from previous Partnership Fora.</p><p>e) The Board approves a budget of US$ 1,500,000 as an upper limit for the fourth Partnership Forum and requests the Finance and Audit Committee to ensure that provision is made in the 2010 budget for adequate staff resources.</p>
2009-05-06 B19 GF/B19/DP33 Annual Report 2008 Annual Report 2008
The Board approves the Annual Report as presented in GF/B19/11.
2009-05-06 B19 GF/B19/DP14 One-Year Grace Period One-Year Grace Period
<p>The Board decides that the one year "grace period" applicable for income level eligibility determinations for Global Fund funding where a country moves up from one income category to the next does not apply in the case that a country moves from "upper-middle income" to "high income". Therefore, the Board decides to amend paragraph 4 of Part 3 of the document entitled "Income Level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund" (GF/B16/7 Attachment 1, Revision 1) by adding the following paragraph: </p><p>"In line with the general principle that high income countries are not eligible for Global Fund funding, the one-year grace period only applies to countries moving from the "low-income" category to the "lower-middle income" category and for countries moving from the "lower-middle income" category to the "upper-middle income" category. Those countries moving from "upper-middle income" to "high-income" are not eligible for funding."</p>
2009-08-21 B19 GF/B19/EDP12 Decision to Suspend the Rolling Continuation Channel (RCC) until the Twentieh Board Decision to Suspend the Rolling Continuation Channel (RCC) until the Twentieh Board
<p>The Board decides to suspend the Rolling Continuation Channel (RCC) procedure for grant application until the Twentieth Board Meeting, at which time the matter will be reconsidered by the Board, other than as provided below. The Board requests the Secretariat to continue to process, using existing RCC policies:</p><ol><li type="a">all RCC proposals that have previously been submitted; and</li><li type="a">all RCC proposals submitted in response to an invitation:<br/><br/><ol><li type="i">to submit a new proposal as a result of the determination of qualification of a grant for RCC by the Secretariat prior to 1 August 2009; and</li><li type="i">to re-submit a proposal due to receipt of a recommendation from the Technical Review Panel of Category 3A.</li></ol></li></ol>
2009-06-19 B19 GF/B19/EDP05 Extension of Deadline for Wave 5 RCC Extension of Deadline for Wave 5 RCC
The Board extends the deadline for the conclusion of the process for clarification of proposals by the TRP for the RCC Wave 5 China HIV and Benin Malaria proposals to four months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment. This decision does not have material budgetary implications. 
2009-05-06 B19 GF/B19/DP21 Approval of Financial Statements Approval of Financial Statements
The Board approves the 2008 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young as set out in Attachment 1 to the Report of the Finance and Audit Committee (GF/B19/6).
2009-05-06 B19 GF/B19/DP20 Country Coordinating Mechanisms (CCM) Funding Policy Country Coordinating Mechanisms (CCM) Funding Policy
<p>The Board agrees that funding for Country Coordinating Mechanisms (CCMs) should be linked to their core functions as defined in the Global Fund Framework Document and further elaborated in the CCM Guidelines<a id="_ftnref1" name="_ftnref1" target="_self"></a>. The Board recognizes that the role of CCMs has expanded as Global Fund financing for programmes to fight AIDS, tuberculosis and malaria have increased. </p><p>To reduce financial constraints that hinder CCMs from fulfilling their responsibilities, the Board adopts in principle a new funding model for CCMs which allows for increased budget amounts and flexible funding modalities on the basis of the following key objectives:</p><p>i. Meaningful civil society and private sector participation (including access to funding for civil society);</p><p>ii. Enhanced CCM capacity for program oversight;</p><p>iii. Improved incentives to harmonize and align with national structures;</p><p>iv. Improved capacity to implement the Gender Equality Strategy and the Sexual Orientation and Gender Identify Strategy;</p><p>v. Introduction of performance-based funding for CCMs;</p><p>vi. Improved measurability and transparency of CCM performance;</p><p>vii. Enhanced country ownership; and</p><p>viii. Encouraging continued multi-stakeholder donor support to CCMs.</p><p>The Board delegates authority to the Portfolio Committee (PC) to approve at its 12<sup>th</sup> Meeting (September 2009) a revised policy for funding for CCMs based upon:</p><p>i. Linking funding to function;</p><p>ii. Accountability through a robust performance framework;</p><p>iii. Strategic objectives and performance targets expressed in workplans and budgets;</p><p>iv. Different country contexts and needs;</p><p>v. Incorporating CCM best practices; and</p><p>vi. Rigorous oversight mechanisms including Local Fund Agent (LFA) verification as appropriate.</p><p>The current funding model (GF/B16/DP19) continues to apply until PC approval of the fully defined revised policy, which is expected to take effect in January 2010. </p><p>The annual budget for CCM funding will be subject to approval by the Board as part of the regular budgetary process under the oversight of the Finance and Audit Committee (FAC). The financial implications of the proposed CCM funding model are estimated to be approximately US$ 8 million in 2010 (a maximum increase of US$ 2 million over the US$ 6 million CCM budget in 2009) and US$ 12 million in 2011. </p><p>The Board also requests the Secretariat to conduct a review of the CCM Guidelines to clarify the role of CCMs and, as appropriate, to recommend amendments to the CCM Guidelines in time for the </p><p>Twentieth Board Meeting (November 2009). The review should take into consideration the recommendations of the Five Year Evaluation, lessons learned and best practice as identified in various CCM studies. </p><p>In developing the revised funding policy and reviewing the CCM Guidelines the Secretariat shall engage in a broad consultative process.</p><p><a id="_ftn1" name="_ftn1" target="_self"></a></p>
2009-05-06 B19 GF/B19/DP12 Attendance at Restricted Sessions of the Board Attendance at Restricted Sessions of the Board
<p>The Board amends the Board Operating Procedures, Part C, Section 14, as follows:</p><p> […] 14. Restricted Session</p><p>In its discretion, the Board may conduct its business in Restricted Session (Voting Board Members and Alternates only). The Board Chair should exclude non-voting ex-officio Board members from attending a Restricted Session, unless it is deemed by the Board Chair to be appropriate to include such members based on the content of the discussion.</p>
2009-05-06 B19 GF/B19/DP06 Extension of Terms of TERG Members Extension of Terms of TERG Members
The Board notes that the terms of six TERG members were due to expire at the conclusion of the Five-Year Evaluation, in May 2009. The Board decides to extend the terms of these six members of the TERG until the conclusion of the Twentieth Board Meeting. The Board thanks the TERG members for their contribution to the Global Fund and for their willingness to continue their work for this additional period.
2009-05-06 B19 GF/B19/DP19 Flexibilities to Set Grant Start Dates Flexibilities to Set Grant Start Dates
<p>The Board affirms the importance of rapid grant signature and disbursement of approved funds as reflected in the target of 8 months for the 2009 Key Performance Indicator for the average time from Board approval to first disbursement. At the same time, the Board also recognizes the value of aligning disbursements with national cycles.</p><p>The Board delegates to the Secretariat the authority to set the starting date for Grant Agreements up to 18 months after Board approval of a proposal to align with national fiscal and programmatic cycles and support harmonization with existing Global Fund grants and other donor-funded programs. The starting date shall continue to be based on the timing of receipt by the Principal Recipient of the first disbursement of grant funds under a Grant Agreement. </p>
2009-07-03 B19 GF/B19/EDP02 Approval of RCC Funding Recommendations Approval of RCC Funding Recommendations
<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposals recommended for funding by the Technical Review Panel (TRP) as ‘Category 2’ proposals which are listed in Annex 2 to this report. The Board’s approval is for the funding up to the initial three years of each such proposal (indicated as “Total 3 Years” in Annex 1), and is made with the clear understanding that the grant amounts requested are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts.<br/><br/></li><li>The applicants whose proposals are recommended for funding as ‘Recommended Category 2 proposals’ shall:<br/><br/><ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and</li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than:<br/><br/><ol><li type="a">two months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment in cases where no independent budget review is requested by the TRP; and</li><li type="a">five months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarifications and/or adjustment in cases where an independent budget review is requested by the TRP during the clarification of a proposal. <br/><br/></li></ol></li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as ‘Recommended Category 3A’ as indicated in Annex 1, although such applicants are encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the next available wave of Rolling Continuation Channel proposals.<br/><br/></li><li>The Board declines to approve for funding the proposal categorized by the TRP as ‘Recommended Category 3B’ as indicated in Annex 1, although the applicant is strongly encouraged to resubmit the proposal through the Rounds-Based Channel following major revision.<br/><br/></li><li>The Board declines to approve for funding the proposal categorized by the TRP as a ‘Recommended Category 4’ as indicated in Annex 1.</li></ol>
2009-05-06 B19 GF/B19/DP05 Memorandum of Understanding between the Global Fund and the Organization of Islamic Conference Memorandum of Understanding between the Global Fund and the Organization of Islamic Conference
The Board notes the Secretariat's continued focus on strengthening the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the memorandum of understanding with the Organization of Islamic Conference (the "OIC MoU") set out in Attachment 2 of the Policy and Strategy Committee's Report to the Board (GF/B19/4), and requests the Executive Director to finalize and sign the OIC MoU.
2009-05-06 B19 GF/B19/DP23 Delegated Authority for Signature Delegated Authority for Signature
<p>The Board authorizes the Chair and Vice-Chair of the Board and the Executive Director to execute agreements on the Board's behalf. In the event the Executive Director is unavailable to exercise such authority, the Board authorizes each of the Deputy Executive Director, the Director of Country Programs and the Director of Corporate Services individually to execute agreements on the Board's behalf.</p><p>In addition, as necessary and appropriate for the fulfillment of the Executive Director's responsibilities for the day-to-day management of the operations of the Global Fund, the Board authorizes the Executive Director to issue proxies to Secretariat staff to execute agreements on behalf of the Global Fund in accordance with the Financial Rules and Regulations and requests the Executive Director to inform the FAC of his signature authority policy. </p><p>This decision replaces the Board's decision at its Thirteenth Meeting regarding delegated authority to sign agreements.</p>
2009-05-06 B19 GF/B19/DP32 Procedure for the Election of the Chair and Vice-Chair of the Board Procedure for the Election of the Chair and Vice-Chair of the Board
<p>The Board agrees to delay the election of the Board Chair and Vice Chair until no later than 15 July, 2009.</p><p>The Board requests a group representing the entire Implementing Voting Group, with assistance from the Secretariat, to recommend candidate(s) from the Implementing Voting Group before the election vote. Each constituency within the Implementing Voting Group shall appoint a participant for this group.</p><p>The Implementing Voting Group will ensure that its constituency members are fully informed and receive clear explanations in relevant languages of the nomination and election process and will facilitate discussion and agreement on the candidate(s). </p><p>The Board requests the Secretariat, supported by the Implementing Voting Group, to use other opportunities to explain the nomination and election process to delegations, such as at side meetings at the World Health Assembly, as well as efforts to directly inform individual delegations.</p><p>If there is only one recommended candidate for the Chair, the Board shall vote on the election of the Chair and Vice-Chair by electronic vote. If there is more than one recommended candidate, the Board shall vote on the election at a Special Board Meeting in person, combined with other business and with attendance limited to Board Members and Alternates. </p><p>As an interim measure, the Board decides to extend the terms of</p><p>(a) the current Board Chair and Vice-Chair, until the new Board leadership is appointed; and</p><p>(b) the current leadership and membership of the existing committees until the Twentieth Board Meeting after which the new leadership and membership of the committees will be established.</p><p>The Board requests the current Chair and Vice-Chair to constitute the new Market Dynamics Committee with full consultation with all Board members.</p><p>The Board requests the Policy and Strategy Committee (PSC) to review the procedures for nomination and election of the Board Chair and Vice-Chair taking into account lessons learned and report to the Board at its Twenty-First Meeting.</p>
2009-05-06 B19 GF/B19/DP27 AMFm Phase 1 AMFm Phase 1
<p>The Board recalls its decision regarding the Affordable Medicine Facility - malaria ("AMFM") (GF/B18/DP7).</p> <p>The Board notes that it will vote on the AMFm proposals at its Twentieth meeting. The Board understands that the independent evaluation of AMFm Phase 1 is now estimated to be completed in the second half of 2011. </p> <p>The Board decides to maintain the AMFm Ad Hoc Committee as a separate committee of the Board for the duration of the AMFm of the AMFm Phase 1 period with the terms of reference set out in Annex 1 to the Report of the AMFm Committee (GF/B19/7).</p> <p>The Board confirms that the Technical Evaluation Reference Group (TERG) will provide guidance with regard to the technical parameters of the design of the independent evaluation of the AMFm, under the oversight of the AMFm Ad Hoc Committee. Consistent with its previous decisions, the Board confirms that the Secretariat will continue to have responsibility for commissioning of the independent evaluation, under the oversight of the AMFm Ad Hoc Committee.</p> <p>The Board notes pending WHO guidance that fixed-dosed co-formulations (FDCs) are strongly preferable to co-blistered ACTs and may help to delay resistance to artemisinin. The Board also notes that multiple technical issues need to be taken into account to ensure a smooth transition to an exclusive use of FDC ACTs. The Board urges that WHO expedite finalization of this guidance on FDCs and co-blistered ACTs.</p> <p>The Board requests its Chair to delegate to the relevant committee(s) the task of identifying and considering options for the Global Fund, within its mandate as a financing institution, to support countries in expediting the transition to FDCs, taking into consideration the implications for quality, supply, pricing and appropriate use of ACTs, and to report back to the Board at its Twentieth meeting.</p>
2009-07-10 B19 GF/B18/EDP07 Approval of Funding Recommendation - INCOMPLETE Approval of Funding Recommendation - INCOMPLETE
<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 6 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14.</p>
2009-05-06 B19 GF/B19/DP29 Follow-up to the Five Year Evaluation Follow-up to the Five Year Evaluation
<p>Recognizing the continued role of the Technical Evaluation Reference Group (TERG) in the follow-up to the Five Year Evaluation (5YE), as part of the TERG mandate to provide independent advice, assessment and oversight for the Global Fund's work on monitoring and evaluation (M&amp;E), the Board:</p> <p>1. welcomes the findings and recommendations included in the Study Area (SA) 3 Report and in the Synthesis Report of the 5YE, as summarized in the TERG Report (GF/B19/10);</p> <p>2. endorses the TERG's call for action for the Global Fund to work with partners to strengthen country monitoring and evaluation, and information systems for performance and impact, to build analytical capacity in countries and to support development of country-owned impact evaluation platforms;</p> <p>3. requests the Secretariat to articulate a process and timeline for responding to and implementing the recommendations set out in SA3 and the Synthesis Report by 15 June 2009, and to report to the Board at its Twentieth Meeting, through the Policy and Strategy Committee (PSC), on the Secretariat's progress in responding to recommendations contained in the SA1, SA2, SA3 and Synthesis Reports, as well as the TERG recommendations in relation to these reports;</p> <p>4. requests the Chair of the Board, in consultation with Committee Chairs, to set up a small ad-hoc committee by 30 June 2009 with the specific task of assisting the Board, through the PSC, to (i) follow-up on, and formulate the Board's responses to the 5YE recommendations, and (ii) further define the role of the TERG in relation to independent evaluations, the resources required and Board oversight of the process.</p> <p>This decision supersedes the Board Decision (GF/B18/DP21).</p>
2009-09-18 B19 GF/B19/EDP14 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><ol><li>Belarus, TB – Round 6<br/>Grant Number: BLR-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 7,488,285 <br/>Approved Funding Amount (Incremental in US$): 7,468,729 <br/>Recommendation Category: Go<br/><br/></li><li>Bosnia and Herzegovina, TB Round 6 <br/>Grant Number: BIH-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 3,088,672 <br/>Approved Funding Amount (Incremental in US$): 3,088,672 <br/>Recommendation Category: Go<br/><br/></li><li>Burkina Faso, HIV Round 6 <br/>Grant Number: BUR-607-G06-H Euro <br/>CCM Requested Amount (Total Phase 2 in US$): 23,770,535(1) <br/>Approved Funding Amount (Incremental in US$): Euro 19,780,000 = US$ 28,210,236(1) <br/>Recommendation Category: Go<br/><br/></li><li>Iraq, TB Round 6 <br/>Grant Number: IRQ-607-G01-T <br/>CCM Requested Amount (Total Phase 2 in US$): 8,110,000 <br/>Approved Funding Amount (Incremental in US$): 8,056,257 <br/>Recommendation Category: Go<br/><br/></li><li>Moldova, TB Round 6 <br/>Grant Number: MOL-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,871,489 <br/>Approved Funding Amount (Incremental in US$): 5,500,000 <br/>Recommendation Category: Go<br/><br/></li><li>Papua New Guinea, TB Round 6 <br/>Grant Number: PNG-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$): 16,267,739(2) <br/>Approved Funding Amount (Incremental in US$): 14,185,291 <br/>Recommendation Category: Go<br/><br/></li><li>Peru, HIV Round 6<br/>Grant Number: PER-607-G05-H <br/>CCM Requested Amount (Total Phase 2 in US$): 10,847,949 <br/>Approved Funding Amount (Incremental in US$): 9,256,222 <br/>Recommendation Category: Go<br/><br/></li><li>Romania, TB Round 6 <br/>Grant Number: ROM-607-G04-T Euro <br/>CCM Requested Amount (Total Phase 2 in US$): 4,050,099 (1) <br/>Approved Funding Amount (Incremental in US$): Euro 3,555,623 = US$5,071,030(1) <br/>Recommendation Category: Go<br/><br/></li><li>Thailand, TB Round 6 <br/>Grant Number: THA-607-G07-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,319,698 <br/>Approved Funding Amount (Incremental in US$): 4,334,035 <br/>Recommendation Category: Go<br/><br/></li><li>Thailand, TB Round 6 <br/>Grant Number: THA-607-G08-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,342,916 <br/>Approved Funding Amount (Incremental in US$): 4,514,102 <br/>Recommendation Category: Go<br/><br/></li><li>Tunisia, HIV Round 6 <br/>Grant Number: TUN-607-G01-H <br/>CCM Requested Amount (Total Phase 2 in US$): 7,013,846 <br/>Approved Funding Amount (Incremental in US$): 6,614,846 <br/>Recommendation Category: Conditional Go <br/><br/>Total US$96,299,420</li></ol>
2009-05-06 B19 GF/B19/DP15 Correction to Definition of High Disease Burden for Global Fund Financing of Tuberculosis in Upper-Middle Income Countries Correction to Definition of High Disease Burden for Global Fund Financing of Tuberculosis in Upper-Middle Income Countries
<p>The Board decides to correct an error in the definition of high disease burden for Global Fund financing of tuberculosis in Upper-Middle Income Countries by amending paragraph 2 of Part 3 of the document entitled "Income Level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund" (GF/B16/7 Attachment 1, Revision 1) as follows:</p><p>"The country in which the proposal activities are targeted is included on the WHO list of high-burden countries or on the WHO list of countries that account for 97 percent of all new cases attributable to HIV/AIDS." </p>
2009-05-06 B19 GF/B19/DP35 Outgoing Deputy Executive Director Outgoing Deputy Executive Director
<p>We, the Board, express our sincere and deep gratitude to Helen Evans for her service to the Global Fund. Her dedication, fortitude, and ability to handle the many demands made on her with equity, patience and grace, especially during challenging times, is universally admired. Her ability to lead in so many critical areas of the Global Fund speaks volumes to her strength and skills. </p><p>We appreciate her passion, commitment and loyalty to the Global Fund and its mission and her principled leadership and tireless efforts to ensure its success. She will be much missed by the Board and by the Secretariat staff.  </p><p>We wish Helen all the best in her endeavors, and look forward to continuing to work with her in her continuing role as a global health leader dedicated to improving global health.</p>
2009-05-06 B19 GF/B19/DP13 Timing for the Determination of Income Level Eligibility Timing for the Determination of Income Level Eligibility
<p>The Board decides to change the timing of the determination of the income level eligibility for funding from the Global Fund by amending paragraph 4 of Part 3 of the document entitled "Income Level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund" (GF/B16/7 Attachment 1, Revision 1) as follows:</p><p>4. The Secretariat will make income level eligibility determinations on an annual basis following the release of the World Bank Country Income Classifications in July of each year (or following the month of publication if different from July), to be reviewed by the Portfolio Committee at its next meeting. These income level eligibility determinations will be effective for all calls for applications to the Global Fund under all funding channels from 1 January to 31 December for the following calendar year.</p>
2009-05-06 B19 GF/B19/DP10 Terms of Reference for Chair and Vice-Chair of the Board Terms of Reference for Chair and Vice-Chair of the Board
The Board approves the terms of reference for the Chair and Vice-Chair of the Board, as laid out in Attachment 6 of GF/B19/4. The terms of reference shall be used by the Board in its consideration of the candidature of any proposed applicant for the positions as well as the candidates themselves to ensure they are fully aware of what the role(s) involve.
2009-05-06 B19 GF/B19/DP28 AMFm Governance AMFm Governance
<p>On the recommendation of the Board Chair and Vice Chair, the Board makes the following decisions with respect to the AMFm Ad Hoc Committee leadership and membership.</p><p>The Board decides that, in order to enable the new Board leadership to ensure appropriate balance, the leadership and membership of the AMFm Committee shall be renewed at the same time as all the other committees of the Board. The Board clarifies that the membership of the AMFm Committee is 10 voting members, plus representation by WHO, RBM and UNITAID.</p><p>The Board notes that the AMFm Committee Chair is resigning and approves the appointment of Professor Eyitayo Lambo as acting Chair of the AMFm Committee pending renewal of committee leadership and membership. </p><p>The Board notes that UNITAID has requested a role in the governance of AMFm. Recognizing UNITAID as a key partner in support of AMFm, the Board decides, as a one-time exception to the Committee Rules and Procedures and without setting a precedent, to request the Board Chair to invite the UNITAID Board to nominate a suitable representative to serve as Vice-Chair of the AMFm Committee. The appointment of the UNITAID Board representative shall be subject to the approval of the Board Chair and Vice Chair and the AMFm Committee Chair. </p>
2009-05-06 B19 GF/B19/DP17 Technical Review Panel (TRP) Partial Replenishment Technical Review Panel (TRP) Partial Replenishment
<p>The Board approves the appointment of the following:</p><p>1. to strengthen the TRP's cross-cutting expertise with a focus on gender and sexual minorities, Drs Ondina Leal, Tim Brown, Sarah Hawkes, Mabel Bianco and Katya Burns as members of the TRP Support Group;</p><p>2. Mr Tim Brown (HIV), Ms Daphne Toupozis (HIV), Mr Nomathemba Mazelani (HIV), Ms Hanem Zaher (Tuberculosis), Ms Ondina Leal (Cross-Cutting), Ms Mabel Bianco (Cross-Cutting), Mr George Gotsadze (Cross-Cutting) and Mr Tore Rose (Cross-Cutting) as Permanent Members of the TRP to serve up to four Rounds commencing from Round 9; and</p><p>3. in respect of calls for proposals made in 2009, the twelve (12) persons identified as Alternate Members in the Report of the Portfolio Committee (GF/B19/5 - Revision 1). </p><p>each of whom have been recommended by the Portfolio Committee and the Executive Director upon consideration of required technical expertise, as well as geographical distribution and gender balance.</p>
2009-07-03 B19 GF/B18/EDP03 Election of the Chair and Vice Chair of the Board (2009-2011) Election of the Chair and Vice Chair of the Board (2009-2011)
<p>Dr. Tedros Adhanom Ghebreyesus of the Eastern and Southern Africa constituency is elected as Chair of the Board for the period commencing on 6 July 2009 until the adjournment of the first Board meeting of 2011.</p><p>Mr. Ernest Loevinsohn of the Canada-Germany-Switzerland constituency is elected as Vice-Chair of the Board for the period commencing on 6 July 2009 until the adjournment of the first Board meeting of 2011.</p>
2009-05-06 B19 GF/B19/DP11 Allocation of Non-Voting Board Seats Allocation of Non-Voting Board Seats
<ol><li>The Board decides to create one additional non-voting seat on the Board to represent the constituency of key partners (Partners Constituency) whose mission is directly related to the Global Fund and who are not currently represented on the Board. <br/><br/></li><li>The Board decides to invite the Stop TB Partnership, Roll Back Malaria and UNITAID to be the founding members of the Partners Constituency. Any key partner that wishes to be represented on the Global Fund Board through the Partners Constituency should make a formal request to the Board who will determine the appropriateness of their inclusion in the Partners constituency. <br/><br/></li><li>Accordingly, the Board approves the following amendments to the By-laws: <br/><br/>Article 7. Foundation Board <br/><br/>7.1. Composition <br/><br/>The Foundation Board shall consist of twenty voting members and five six nonvoting members. Each voting member shall have one vote. <br/><br/>[…] <br/><br/>The <strike>five</strike><u>six</u> ex-officio nonvoting members of the Foundation Board shall consist of: <br/><br/><ul><li>One representative from the WHO;</li><li>One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS"); </li><li><u> One representative from the Partners constituency; </u></li><li> One representative from the trustee; <strike>and</strike></li><li> One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Foundation to the extent required by Swiss law.; <u>and</u></li><li>The Executive Director of the Foundation. <br/><br/></li></ul></li></ol><li type="1" value="4">The Board requests the PSC to review the purpose, allocation and composition of all non-voting Board seats and report to the Board at its Twenty-Third Meeting. </li>
2009-05-06 B19 GF/B19/DP25 Grant Policy during OIG Investigations and Audits Grant Policy during OIG Investigations and Audits
<p>The Global Fund does not tolerate corruption, fraud, misappropriation or abuse of any kind in relation to its grants. As part of the comprehensive risk management framework, the Board requests the Executive Director to take strong, immediate action in all circumstances where the Inspector General has determined that there is credible and substantive evidence of fraud, abuse, misappropriation or corruption involving Global Fund grants. </p><p>Such action will include the Executive Director restricting the signature of new grants with the nominated principal recipient(s), if the evidence concerns the nominated principal recipient(s), or of all new grants in the country, if the evidence points to country risks.</p><p>Restrictions may also include the suspension of disbursements under existing grants in the affected country or countries, the temporary or permanent debarment of any entity under investigation from receiving grant funding or any other measure deemed appropriate and justified under the circumstances by the Executive Director. </p><p>In such situations, the Executive Director shall ensure that measures imposed balance the impact on the country's health systems, other reliant projects and the continuation of the provision of essential services, against the risks to the Global Fund and adherence to the Global Fund's core ethical values and principles. This balance to be struck should not allow any acceptance of fraud.</p><p>The Secretariat and the OIG will - each based on their respective role and responsibilities - report on restrictions imposed in relation to any grant(s) in such situations, the specific actions required to lift such restrictions, and the status of the situation. This will be done as soon as possible to the Board via an appropriate mechanism as well as on a regular basis through the FAC and at the Board meeting.</p><p>If signature of a new grant with a nominated principal recipient has been restricted, the deadline for signature of a grant agreement shall automatically be extended by a period equal to the period of the restriction in the following limited situations: (i) an OIG investigation or audit by the OIG finds no wrongdoing, or (ii) in the opinion of the Secretariat and OIG, the wrongdoing is not material or the risks to Global Fund grant funds under the new grant are manageable, or (iii) a new principal recipient is identified for the grant under implementation arrangements that address the risks. </p>
2009-08-12 B19 GF/B19/EDP11 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p> The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><ol><li>Egypt, TB – Round 6 <br/>Grant Number: EGY-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 3,541,080 <br/>Approved Funding Amount (Incremental in US$): 4,124,080 <br/>Recommendation Category: Conditional Go<br/><br/></li><li>Guatemala, TB – Round 6 <br/>Grant Number: GUA-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$): 4,098,790 <br/>Approved Funding Amount (Incremental in US$): 3,699,920 <br/>Recommendation Category: Go<br/><br/></li><li>Kazakhstan, TB – Round 6 <br/>Grant Number: KAZ-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 4,400,023<br/> Approved Funding Amount (Incremental in US$): 3,672,383 <br/>Recommendation Category: Go<br/><br/></li><li>Lao PDR, Malaria – Round 6 <br/>Grant Number: LAO-607-G07-M <br/>CCM Requested Amount (Total Phase 2 in US$): 2,109,804 <br/>Approved Funding Amount (Incremental in US$): 1,941,538 <br/>Recommendation Category: Conditional Go<br/><br/></li><li>Liberia, HIV – Round 6 <br/>Grant Number: LBR-607-G04-H CCM <br/>Requested Amount (Total Phase 2 in US$): 20,515,516 <br/>Approved Funding Amount (Incremental in US$): 19,142,000 <br/>Recommendation Category: Go<br/><br/></li><li>Maldives, HIV – Round 6 <br/>Grant Number: MDV-607-G01-H <br/>CCM Requested Amount (Total Phase 2 in US$): 1,905,124 <br/>Approved Funding Amount (Incremental in US$): 1,486,772 <br/>Recommendation Category: Conditional Go<br/><br/></li><li> Mali, Malaria – Round 6 <br/>Grant Number: MAL-607-G05-M <br/>CCM Requested Amount (Total Phase 2 in US$): 11,010,553 <br/>Approved Funding Amount (Incremental in US$): 8,965,242 <br/>Recommendation Category: Go</li></ol><p>Total US$43,031,935</p><p>Next Steps:The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedule A.</p>
2009-09-04 B19 GF/B19/13 Composition of the Ad Hoc Market Dynamic and Commodities Committee Composition of the Ad Hoc Market Dynamic and Commodities Committee
<p>The Board:</p><ol><li>Amends the composition of the Ad Hoc Market Dynamic and Commodities Committee (as set out in GF/B19/4, Attachment 4) as follows:… <br/><br/>Composition: <br/><br/>The proposed membership to include (8) <u>10 </u>representatives of voting Board constituencies + WHO + World Bank <u>UNAIDS </u>+ 2-4 external experts … <br/><br/></li><li>Approves the appointment of the following members to the Ad Hoc Market Dynamic and Commodities Committee.</li></ol> <table class="table"><tbody><tr><td style="cursor: default;"> </td><td style="cursor: default;"><b>Constituency</b> </td><td style="cursor: default;"><b>Name </b> </td><td style="cursor: default;"><b>Role </b> </td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Leadership </b> </td></tr><tr><td style="cursor: default;"> 1</td><td style="cursor: default;">Private Foundations</td><td style="cursor: default;">Dai Ellis Executive Vice President, Access Programs, Clinton HIV/AIDS Initiative </td><td style="cursor: default;">Chair</td></tr><tr><td style="cursor: default;"> 2</td><td style="cursor: default;">UNAIDS</td><td style="cursor: default;">Shanelle Hall Director, Supply Division, UNICEF  </td><td style="cursor: default;">Vice-Chair </td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"> <b>Donor </b></td></tr><tr><td style="cursor: default;"> 3</td><td style="cursor: default;">Private Sector</td><td style="cursor: default;">Ian Boulton Managing Director, TropMed Pharma Consulting </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 4</td><td style="cursor: default;">Point 7</td><td style="cursor: default;">Turid Kongsvik Counselor, Norwegian Permanent Mission to the Council of Europe </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 5</td><td style="cursor: default;">United Kingdom</td><td style="cursor: default;">Saul Walker Senior Policy Adviser (Access to Medicines), DFID, (AIDS expert) </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 6</td><td style="cursor: default;">United States</td><td style="cursor: default;">Mike Hope Senior Pharmacist, Office of HIV/AIDS, USAID</td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Implementer </b> </td></tr><tr><td style="cursor: default;"> 7</td><td style="cursor: default;">Western and Central Africa</td><td style="cursor: default;">Lazare Bansse General Manager, Central Purchasing of Essential and Generic Drugs, Burkina Faso and Permanent Secretary, Association of Central Purchasing of Essential Drugs, Africa</td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 8</td><td style="cursor: default;">Latin America and the Caribbean</td><td style="cursor: default;">Carl Browne Director, Pan Caribbean Partnership Against HIV/AIDS </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 9</td><td style="cursor: default;">Developed Country NGOs</td><td style="cursor: default;">Mohga Kamal-Yanni Senior Health and HIV Policy Advisor, Oxfam </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 10</td><td style="cursor: default;">Eastern Europe</td><td style="cursor: default;">Tonka Varleva, Secretary, National Committee for Prevention of AIDS and STIs, Bulgaria </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 11</td><td style="cursor: default;">Western Pacific </td><td style="cursor: default;">Lin-hua Tang Director, National Institute of Parasitic Disease, China, (malaria expert) </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Non-voting member </b> </td></tr><tr><td style="cursor: default;"> 12</td><td style="cursor: default;">WHO </td><td style="cursor: default;">Rob Matiru Chief of Operations, Global Drug Facility, (TB expert) </td><td style="cursor: default;">Member</td></tr></tbody></table>
2009-05-06 B19 GF/B19/DP03 Approval of Report of the Eighteenth Board Meeting Approval of Report of the Eighteenth Board Meeting
The report of the Eighteenth Board Meeting (GF/B19/2, Revision 2) is approved.
2009-05-06 B19 GF/B19/DP31 Preventing Treatment Disruption Preventing Treatment Disruption
<p>The Board notes with concern increasing reports of threats to HIV/AIDS, tuberculosis (TB), and malaria treatment continuity. For example, recent estimates by the World Bank indicate that antiretroviral treatment to 1.7 million people is under threat, with 15 countries "highly exposed" to the risk of treatment interruption. </p><p>Therefore, the Board requests the Chair and Vice Chair to delegate to the appropriate committee(s) the task of reporting back to the Board at its Twentieth Meeting with an update on this issue, including an analysis - undertaken by the Secretariat in cooperation with partners as a matter of urgency - that indicates which countries receiving Global Fund support for HIV/AIDS, TB and malaria treatment are at risk of treatment disruption in 2009-10. The Board requests that the Secretariat, while continuing its ongoing work to minimize the risk of stock-outs and treatment disruption, report to the appropriate committee(s) on whether or not existing procedures are adequate and propose solutions to minimize the risk of stock-outs and treatment disruption on an ongoing basis. </p><p>The Board also requests the Secretariat to designate a focal point to liaise with specified focal points among relevant partners and affected communities to facilitate communication and respond effectively and collectively to threats to treatment continuity. </p>
2009-05-06 B19 GF/B19/DP22 Collaboration from UNDP in Audit and Investigations Collaboration from UNDP in Audit and Investigations
The Board recognizes the significant improvements in collaboration between UNDP and the Global Fund on audits and investigations relating to grant funds. However, the Board notes that there are still areas where the collaboration could be improved and therefore requests the Chair of the Board, in support of the OIG and Secretariat, to secure greater assurance from the UNDP Board regarding audits and investigations of Global Fund grants where UNDP acts as Principal Recipient, including access to the full text of audit and investigation reports.
2009-07-13 B19 GF/B19/EDP08 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>The Board approves additional funding for the Phase 2 period of the Round 5 Nigeria TB grant (NGA-506-G06-T) as a Conditional Go in the amount of up to US$ 39,617,817, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat.The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><p>Brazil, TB – Round 5 <br/>Grant Number: BRA-506-G01-T <br/>CCM Requested Amount (Total Phase 2 in US$): 2,183,419 <br/>Approved Funding Amount (Incremental in US$): 1,754,028 <br/>Recommendation Category: Go <br/><br/>Brazil, TB – Round 5 <br/>Grant Number: BRA-506-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 11,960,082 <br/>Approved Funding Amount (Incremental in US$): 9,664,550 <br/>Recommendation Category: Conditional Go <br/><br/>China, Malaria – Round 6 <br/>Grant Number: CHN-607-G09-M <br/>CCM Requested Amount (Total Phase 2 in US$): 10,121,428 <br/>Approved Funding Amount (Incremental in US$): 8,471,314 <br/>Recommendation Category: Go <br/><br/>Djibouti, Malaria – Round 6 <br/>Grant Number: DJB-607-G02-M <br/>CCM Requested Amount (Total Phase 2 in US$): 1,190,000 <br/>Approved Funding Amount (Incremental in US$): 958,138 <br/>Recommendation Category: Conditional Go <br/><br/>India, HIV – Round 6 <br/>Grant Number: IDA-607-G10-H <br/>CCM Requested Amount (Total Phase 2 in US$): 22,729,077 <br/>Approved Funding Amount (Incremental in US$): 20,390,449 <br/>Recommendation Category: Go <br/><br/>India, HIV – Round 6 <br/>Grant Number: IDA-607-G11-H <br/>CCM Requested Amount (Total Phase 2 in US$): 145,546,072 <br/>Approved Funding Amount (Incremental in US$): 97,852,982 <br/>Recommendation Category: Conditional Go <br/><br/>Namibia, Malaria – Round 6 <br/>Grant Number: NMB-607-G06-M <br/>CCM Requested Amount (Total Phase 2 in US$): 7,152,683 <br/>Approved Funding Amount (Incremental in US$): 5,015,506 <br/>Recommendation Category: Conditional Go <br/><br/>Paraguay, HIV – Round 6 <br/>Grant Number: PRY-607-G02-H <br/>CCM Requested Amount (Total Phase 2 in US$): 5,749,894 <br/>Approved Funding Amount (Incremental in US$): 5,395,205 <br/>Recommendation Category: o <br/><br/>Tajikistan, TB – Round 6 <br/>Grant Number: TAJ-607-GO6-T <br/>CCM Requested Amount (Total Phase 2 in US$): 7,251,791 <br/>Approved Funding Amount (Incremental in US$): 6,865,442 <br/>Recommendation Category: Go <br/><br/>Ukraine, HIV – Round 6 <br/>Grant Number: UKR-607-G05-H <br/>CCM Requested Amount (Total Phase 2 in US$): 66,026,690 <br/>Approved Funding Amount (Incremental in US$): 63,557,000 <br/>Recommendation Category: Conditional Go <br/><br/>Ukraine, HIV – Round 6 <br/>Grant Number: UKR-607-G06-H <br/>CCM Requested Amount (Total Phase 2 in US$): 42,717,774 <br/>Approved Funding Amount (Incremental in US$): 38,366,000 <br/>Recommendation Category: Conditional Go <br/><br/>Total US$258,290,614</p><p>The Secretariat received comments from Board members on some of the grants. The comments will be taken into account during grant negotiations.</p><p>Next Steps:The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedule A and the Nigeria Round 5 TB grant (NGA-506-G06-T)</p>
2009-05-06 B19 GF/B19/DP24 Credit Suisse Bank Account Credit Suisse Bank Account
<p>The Board recognizes that, as a result of the termination of the Administrative Services Agreement with the World Health Organization, all operating expenses are now required to be paid through the Global Fund's Credit Suisse bank account. The Board decides to rescind its previous decision on the policy for the Credit Suisse bank account (GF/SB1/DP6). The Credit Suisse bank account shall be maintained and used by the Global Fund in accordance with the Global Fund's Financial Rules and Regulations for the following:</p> <p>1. to hold the foundation's capital, of CHF 50,000, as required by Swiss law;</p> <p>2. to pay for all Secretariat operating expenses in accordance with the Board-approved annual budget; and </p> <p>3. to receive private-sector contributions that the Trustee is not able to receive directly and other miscellaneous receipts.</p> <p>The Board requests the Finance and Audit Committee to continue its oversight of the Credit Suisse bank account.</p>
2009-06-26 B19 GF/B19/EDP06 RCC Requalification of Round 3 South Africa Grant number SAF-304-G04-H RCC Requalification of Round 3 South Africa Grant number SAF-304-G04-H
<p>The Board recalls its decision GF/B14/DP/28 in which it authorized the Secretariat, on an exceptional basis, to consider the Request for Continued Funding submitted by the CCM of South Africa for the Round 3 South Africa Grant number SAF-304-G04-H, which anticipated a 4-year Phase 2 term.</p> <p>This decision was based on the commitment of the Government of South Africa at the time to achieve sustainability of the HIV/AIDS program in the Western Cape province and not requiring further Global Fund support for those activities beyond September 2010. The Board decides that due to the change in circumstances surrounding the implementation of the Western Cape HIV/AIDS program, it is willing to consider a further request from the CCM of South Africa for continued support of the program by the Global Fund, and authorizes the Secretariat to consider the grant for qualification under the Rolling Continuation Channel.</p>
2009-05-06 B19 GF/B19/DP08 Review of Board Committee Structure Review of Board Committee Structure
<p>The Board adopts the model for restructuring the Board committees set out in the Report of the Policy and Strategy Committee (GF/B19/4) - the "PSC Report".</p><p>Accordingly, the Board decides:</p><p>1. to create an ad hoc committee of the Board for market dynamics, procurement, and commodities matters (the "Market Dynamics and Commodities Committee" or "MDC") with the terms of reference set out in document GF/B19/4 - Attachment 4 for the period up to the first Board meeting in 2011, when the Board will consider whether to continue the MDC's mandate. Membership in the MDC shall not count towards the two-committee limit set forth in Section 23 of the Board Operating Procedures. This committee will temporarily remove the Portfolio Committee's responsibilities in this area;</p><p>2. to continue the mandate of the AMFm Ad Hoc Committee for the AMFm Phase 1 Period;</p><p>3. to rename the Portfolio Committee the "Portfolio and Implementation Committee" (PIC); and</p><p>4. to approve the amendments to the Committee Rules and Procedures set out in document GF/B19/4 - Attachment 5.</p><p>The Board requests the Board Chair and Vice Chair to review prior Board decisions with a view to clarifying and, if necessary, re-assigning responsibilities among the Committees in line with this decision.</p>
2009-05-06 B19 GF/B19/DP09 Executive Director as Non-Voting Board Member Executive Director as Non-Voting Board Member
<p>The Board decides that the Executive Director shall be an ex-officio non voting member of the Board, with immediate effect, and approves the following Amendments to Articles 7.1 and 7.2 of the Bylaws and Part A, Section 1 of the Board Operating Procedures:</p><p>Bylaws: Articles 7.1 and 7.2</p><p>7.1 Composition</p><p>The Foundation Board shall consist of twenty voting members and five nonvoting members. Each voting member shall have one vote. […] The five ex-officio nonvoting members of the Foundation Board shall consist of:</p><ul><li>One representative from WHO;</li><li>One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS");</li><li>One representative from the trustee; </li><li>One Swiss Citizen with his or her domicile in Switzerland authorized to act of behalf of the Foundation to the extent required by Swiss law.; and</li><li><u>The Executive Director of the Foundation.</u></li></ul><p>7.2 Appointment of Foundation Board Members</p><p>[…] Board Members shall be deemed to act in their capacity as representatives of their respective Governments, organizations, constituencies or other entities. T<u>he Executive Director shall act in his or her capacity as chief executive officer of the Foundation and will serve on the Foundation Board for the duration of his or her term. </u> […]</p><p>Board Operating Procedures: Part A, Section 1</p><p>Board Members</p><p>[…] Board Members serve as the representative of the particular county, organization or other entity, or other constituency holding the Board seat. <u>The Executive Director shall hold an ex-officio seat on the Board as Chief Executive Officer of the Foundation for the duration of his or her term. </u>Except as provided for in Sections A.4 and A.5 below, only properly accredited Board Members have the right to vote and to participate in Board deliberations.</p>
2009-05-06 B19 GF/B19/DP16 Additions to Technical Review Panel (TRP) Leadership and Membership Additions to Technical Review Panel (TRP) Leadership and Membership
<p>Additions to Technical Review Panel (TRP) Leadership and Membership</p><p>The Board decides to amend the Terms of Reference of the Technical Review Panel (TRP) to add a second Vice-Chair and to increase the overall maximum number of Permanent TRP members from 35 to 40 persons. The revised Terms of Reference are set forth in Attachment 1 of the Report of the Portfolio Committee (GF/B19/5 - Revision 1).</p>
2018-05-10 B39 GF/B39/DP10 CCM Evolution: Funding for Near-Term Implementation CCM Evolution: Funding for Near-Term Implementation
<p>The Board:</p> <ol> <li>Recognizes the inherent value and essential function of Country Coordinating Mechanisms (“CCMs”) in the Global Fund architecture and acknowledges the need to evolve CCMs to align with the Global Fund Strategy 2017-2022: Investing to End Epidemics;</li> <li>Recognizes that the Audit and Finance Committee approved USD 50 million as available sources of funds (“Available Funds”) to finance prioritized and costed areas of need on the register of unfunded quality demand, as per GF/AFC04/DP01;</li> <li>Based on the recommendation of the Strategy Committee (“SC”), decides that the amount of USD 3.85 million of such Available Funds be used instead to fund a phased roll-out of the evolution of Country Coordinating Mechanisms (the “CCM Evolution”) in 2018 and 2019 under the CCM Strategic Initiative, consistent with the interventions and activities under the “intermediate” approach, as detailed in GF/B39/04 – Revision 1;</li> <li>Requests the Secretariat (1) to develop a set of draft indicators for consultation with the SC at its July 2018 meeting, including near term (process and output) and longer term (outcome and impact) indicators, and (2) to regularly report to the SC on the operationalization of the CCM Evolution;</li> <li>Directs the SC (1) to utilize the near term results (referenced in part 4 above) as one of the inputs to inform the type of activities and the level of funding for CCM Evolution in the 2020-2022 allocation period, and (2) during the development of the allocation methodology for this period, to discuss the level of funding needed to scale the activities and number of CCMs; and</li> <li>Asks the Board, Secretariat and partners at country level to support the effective implementation of CCM Evolution, and in particular asks the Secretariat to drive the execution of CCM Evolution through consistent engagement of relevant parts of the organization and with an appropriate mix of resources, both staff and financial, from both current and future allocations.</li> </ol>
2018-08-17 B39 GF/B39/EDP09 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP09 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-05-09 B39 GF/B39/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Tamaki Tsukada from the Japan constituency is designated as Rapporteur for the 39th Board Meeting.</p>
2018-09-13 B39 GF/B39/EDP10 Appointment of a New Member to the Strategy Committee Appointment of a New Member to the Strategy Committee
<ol> <li>The Board: <ol type="i"> <li>Recalls its decision (GF/B38/DP05) on the Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws;</li> <li>Notes the requirement of the Operating Procedures of the Board and Committees pursuant to which each constituency of the Board must be represented in at least one Standing Committee of the Board;</li> <li>Notes the Board decision (GF/B39/EDP02) to create an additional non-voting committee seat within the Strategy Committee; and</li> <li>Notes that the Additional Public Donors Constituency is not currently represented on a Standing Committee of the Board.</li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board appoints Kaltham Al-Assam, representing the Additional Public Donors Constituency, as a non-voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</li> </ol>
2018-05-10 B39 GF/B39/DP08 2017 Statutory Financial Statements 2017 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2017 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in GF/B39/06 Annex 2.</p>
2018-05-10 B39 GF/B39/DP07 2017 Annual Financial Report 2017 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore ap proves, the Global Fund’s 2017 Annual Financial Report, which includes the 2017 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in GF/B39/06 Annex 1.</p>
2018-05-09 B39 GF/B39/DP04 Potential Engagement with Non-eligible Countries in Crisis Potential Engagement with Non-eligible Countries in Crisis
<ol> <li>The Board acknowledges that a health crisis may emerge in an ineligible non-high income country that could have an adverse impact on the global response against HIV/AIDS, tuberculosis, and/or malaria, and that the health crisis may be of such a magnitude that the Global Fund should consider providing support; and</li> <li>Based on the recommendation of the Strategy Committee, the Board requests the Secretariat, in consultation with relevant partners, to present potential investment cases meeting the criteria described in GF/B39/03 – Revision 1 to the Strategy Committee for review and recommendation to the Board. Any such proposals shall also include options for how the proposed investment should be funded.</li> </ol>
2018-05-10 B39 GF/B39/DP11 Approval of Risk Appetite Framework Approval of Risk Appetite Framework
<p>The Board:</p> <ol type="i"> <li>Acknowledges the decision of the Strategy Committee concurring with the Risk Appetite Statements for the risks under such committee’s purview, as set forth in the table in Annex 3 to GF/SC06/03 – Revision 2;</li> <li>Acknowledges that the Strategy Committee will further discuss the Human Rights and Gender Inequality, Transition, and Drug and Insecticide Resistance risks at its meeting in July 2018, which will include discussion of the risk management strategy for these risks, including mitigation measures in place and/or planned, and a determination of the appropriateness of setting risk appetite statements for these risks;</li> <li>Further acknowledges the decision of the Audit and Finance Committee concurring with the Risk Appetite Statements for the risks under such committee’s purview, as set forth in the table in Annex 3 to GF/AFC06/16 – Revision 1; and</li> <li>Based upon the recommendation of the Audit and Finance Committee, approves the Risk Appetite Framework, including Risk Appetite, Target Risk levels and the indicative timeframes for achieving Target Risk, as described in the table in Annex 3 to GF/B39/07.</li> </ol>
2012-10-31 B27 GF/B27/EDP04 Approval of Board Processes for Executive Director selection Approval of Board Processes for Executive Director selection
<p>Based on consultations over September and October 2012, the Board approves the framework for candidate engagement and decision-making as proposed by the Board Chair to Board Members on 29 October 2012 as specified in GF/B27/ER3 Revision 1.</p>
2018-07-20 B39 GF/B39/EDP07 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP07 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-10-18 B39 GF/B39/EDP12 Delegation of Signature Authority Delegation of Signature Authority
<ol> <li>The Board hereby delegates to each of the Chair and Vice-Chair of the Board and the Executive Director, individual signature authority on behalf of the Global Fund.</li> <li>The Board hereby authorizes the Executive Director to: <ol type="i"> <li>further delegate his signature authority to Secretariat staff, who may exercise such authority in sole or joint capacities as may be necessary and appropriate for the day-to-day management of the operations of the Global Fund under the direction of the Executive Director and in accordance with the applicable regulations of the Global Fund; and</li> <li>memorialize such delegations of signature authority and any limitations or conditions applicable thereto in proxies and/or signature authority regulations.</li> </ol> </li> <li>The Board hereby affirms the further delegation of individual signature authority, in accordance with the Executive Director’s issuance of proxies and/or signature authority regulations, to each of the Chief of Staff and the Chief Financial Officer of the Global Fund.</li> <li>This decision supersedes the Board’s delegation of signature authority contained in Decision Point GF/B19/DP23 (May 2009).</li> </ol>
2018-05-10 B39 GF/B39/DP09 CCM Evolution: Code of Conduct for CCMs and CCM Policy CCM Evolution: Code of Conduct for CCMs and CCM Policy
<p>The Board:</p> <ol> <li>Notes the recommendation of the Ethics and Governance Committee of a Code of Conduct for Country Coordinating Mechanisms (the “CCM Code”), developed in furtherance of the Ethics and Integrity Framework adopted by the Board at its 32nd Meeting (GF/B32/DP09);</li> <li>Approves the CCM Code, as presented in Annex 4 in GF/B39/04- Revision 1;</li> <li>Based on the recommendation of the Strategy Committee (“SC”), decides that no less than the amount of USD 1,219,700 should be made available over a three year period to fund the implementation and enforcement of the CCM Code, as described in GF/B39/04- Revision 1;</li> <li>Recognizes that the Audit and Finance Committee approved USD 50 million as available sources of funds (“Available Funds”) to finance prioritized and costed areas of need on the register of unfunded quality demand, as per GF/AFC04/DP01, and based on the recommendation of the SC, (i) decides that the amount of USD 1,219,700 of such Available Funds be used instead to fund the implementation and enforcement<br />of the CCM Code, and (ii) decides to add CCMs as a “Strategic Initiative” to the list of catalytic investment priorities presented in Table 1 of GF/B36/04 – Revision 2;</li> <li>Based on the recommendation of the SC, decides to replace the Guidelines and Requirements for Country Coordinating Mechanisms, as approved by the Board under GF/B23/DP17, with the CCM Policy as set out in Annex 3 of GF/B39/04- Revision 1 (the “CCM Policy”); and</li> <li>Delegates authority to the SC to approve amendments to the CCM Policy, and requests the Secretariat to operationalize the CCM Policy and regularly report on its implementation to the SC.</li> </ol>
2018-07-18 B39 GF/B39/EDP06 Approval of the Report of the 39th Board Meeting in Skopje Approval of the Report of the 39th Board Meeting in Skopje
<p>The Board approves the Report of the 39th Board Meeting, as set forth in GF/B39/26 – Revision 2.</p>
2018-10-26 B39 GF/B39/EDP15 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Burundi Malaria, and (ii) Philippines TB, as listed in Table 2 of GF/B39/ER12, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-11-09 B39 GF/B39/EDP18 Revised Terms of Reference for the Chair and Vice-Chair of the Board Revised Terms of Reference for the Chair and Vice-Chair of the Board
<ol> <li><span>The Board approves the revised Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B39/ER15 (the “Terms of Reference”), which shall enter into force upon the commencement of the term of the next Chair and Vice-Chair of the Board.</span></li> <li><span>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</span></li> </ol>
2018-06-13 B39 GF/B39/EDP02 Amendment to the Charter of the Strategy Committee Amendment to the Charter of the Strategy Committee
<ol> <li>The Board: <ol type="i"> <li>Recalls its decision (GF/B38/DP05) on the Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws;</li> <li>Notes the requirement of the Operating Procedures of the Board and Committees pursuant to which each constituency of the Board must be represented in at least one Standing Committee of the Board; and</li> <li>iii. Notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B39/ER02, to create an additional non-voting committee seat within the Strategy Committee.</li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board approves the creation of an additional non-voting seat in the Strategy Committee and, to this effect, amends Section C., article 3, paragraph e. of the Charter of the Strategy Committee, as set forth in Annex 1 to GF/B39/ER02.</li> </ol>
2018-05-09 B39 GF/B39/DP06 Strengthening the Processes for Selection of Committee Leadership and Committee Members Strengthening the Processes for Selection of Committee Leadership and Committee Members
<ol> <li>Notes its commitment to continue to strengthen Global Fund governance processes and requests that the Ethics and Governance Committee (“EGC”) undertakes a review of the existing processes for selection of committee leadership and members, and makes recommendations to the Board on revisions to these selection processes, aiming for a decision at the 40th Board Meeting;</li> <li>Requests that as part of this recommendation, the EGC (i) puts forward principles and concrete actions to underpin and guide the selection processes, including transparency, rotation of constituency representation, relevant experience, institutional memory, and gender equality; (ii) develops standards and processes for due diligence undertaken as part of the selection processes; and (iii) reviews the size and composition of the EGC; and</li> <li>Requests that the EGC seeks feedback broadly from across Board constituencies in formulating its recommendations, including through inviting a representative of civil society to be a participant in EGC deliberations on this review.</li> </ol>
2018-06-15 B39 GF/B39/EDP03 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP03 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-10-26 B39 GF/B39/EDP14 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/ER12 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2012-09-14 B27 GF/B27/DP01 Appointment of Rapporteur Appointment of Rapporteur
Dr Palitha Mahipala from the South East Asia constituency is designated as rapporteur for the Twenty-Seventh Board Meeting.
2012-09-14 B27 GF/B27/DP07 Evolving the Funding Model Evolving the Funding Model
<p>The Board:</p> <ol> <li>Adopts in principle the elements of the new funding model detailed in Annex 1.</li> <li>Requests the SIIC to recommend to the Board at its Twenty-Eighth Meeting the additional elements of the new funding model so as to allow for its implementation beginning in 2013, based on funds available.</li> <li>Requests regular evaluation of the new funding model.</li> <li>Requests the SIIC to continue the work of evolving the business model of the Global Fund beyond the new funding model, enabling the full implementation of the new strategy.</li> </ol>
2012-09-24 B27 GF/B27/EDP01 September 2012 Grant Renewals Funding Recommendations September 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 478,957,450 for the following grants: SNG-S10-G09-H (SNG-H-CNLS) ; SNG-H-ANCS ; SNG-S10-G11-H (SNG-H-DLSI) ; IDA-202-G19-H ; IDA-202-G02-H ; CIV-S10-G10-T ; CIV-S10-G11-T ; ZAN-809-G07-M ; CAM-M-CNM ; NGA-H-NACA ; NGA-H-SFHNG ; NGA-H-ARFH ; NGA-H-CiSHAN ; NGA-H-PPFN ; NGA-T-ARFH ; NGA-T-IHVN ; BUR-810-G10-T ; BUR-810-G11-T ; KGZ-S10-G08-T ; KGZ-910-G07-T ; MOL-T-PCIMU ; MOL-S10-G09-T ; IRQ-T-UNDP ; GMB-T-MRC ; GMB-T-MOH ; LAO-H-GFMOH ; PRY-T-AV</p>
2009-05-06 B19 GF/B19/DP04 Relationship Between the Global Fund and the United Nations (UN) Relationship Between the Global Fund and the United Nations (UN)
<p>The Board reiterates its endorsement of the Global Fund's initiative to obtain a decision of the UN General Assembly granting Observer Status to the Global Fund at the UN General Assembly (Decision Point GF/B18/DP15).</p> <p>The Board notes that the Global Fund would be represented by the Executive Director at the UN General Assembly.</p>
2011-10-31 B24 GF/B24/EDP03 Amended Upper Ceiling Amounts for Bangladesh, Mongolia and Swaziland Round 10 TB Proposals Amended Upper Ceiling Amounts for Bangladesh, Mongolia and Swaziland Round 10 TB Proposals
<p>The Board decides to amend the upper ceiling amounts for the three Round 10 consolidated proposals listed below:</p><table class="table" dropzone="copy"><tbody><tr><td style="cursor: default;">Country/ Disease Component</td><td style="cursor: default;">Amended Phase 1 Upper ceiling (2 years)(US$)</td><td style="cursor: default;">Amended Lifetime Upper ceiling (Up to 5 Years) (US$)</td></tr><tr><td style="cursor: default;">Bangladesh/TB</td><td style="cursor: default;">16,363,126</td><td style="cursor: default;">105,724,068</td></tr><tr><td style="cursor: default;">Mongolia/TB, including cross-cutting HSS</td><td style="cursor: default;">5,763,691</td><td style="cursor: default;"> 9,124,194</td></tr><tr><td style="cursor: default;">Swaziland/TB</td><td style="cursor: default;">12,864,643</td><td style="cursor: default;">39,709,609</td></tr></tbody></table><p>The Board approves the amended upper ceiling amounts specified above for the initial two years.</p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-10-31 B24 GF/B24/EDP06 Setting the Grant Start Date for Cote d’Ivoire HIV Proposal CIV-910-G13-H Setting the Grant Start Date for Cote d’Ivoire HIV Proposal CIV-910-G13-H
<p>The Board sets the Phase 1 Start Date for the Côte d‟Ivoire HIV Grant CIV-910-G13-H at 1 October 2011 and decides that the program implementation period runs for five years from that time, subject to the Board‟s approval of Phase 2 funding and the terms and conditions of the grant agreement. The End Date for the program is 30 September 2016.</p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-09-26 B24 GF/B24/DP01 Appointment of Rapporteur Appointment of Rapporteur
His Excellency Ambassador Patrice Debré from France’s constituency is designated as rapporteur for the Twenty-Fourth Board Meeting.
2011-09-26 B24 GF/B24/DP04 Addressing Funding and Approval Process for Round 11, Second Wave of National Strategy Applications (NSAs) and Health Systems Strengthening Platform (HSFP) Addressing Funding and Approval Process for Round 11, Second Wave of National Strategy Applications (NSAs) and Health Systems Strengthening Platform (HSFP)
<ol> <li>The Board recognizes uncertainties in relation to the expected funding envelope for Round 11, the Second Wave of NSAs and HSFP applications and notes that it has been revised downward to a current estimate of not more than US$0.8 billion, which may not be available until the fourth quarter of 2013.<br /><br /></li> <li>The Board and the Secretariat will examine options for modification of the application, renewal and approval processes for new and existing investments in light of these resource constraints, the recommendations of the High Level Panel and the Global Fund's strategy and reform processes. The Board will communicate the results of those deliberations no later than 1 December 2011. These deliberations will also consider options for reallocation of existing commitments to prioritize high-impact interventions, which could increase resources available for new investments.<br /><br /></li> <li>As a result of the expected delay in availability of resources, the Board extends the application deadline for Round 11, the Second Wave of NSAs and HSFP applications until at least 1 March 2012.</li> </ol>
2011-10-31 B24 GF/B24/EDP07 Delegation of Authority to set Grant Start Dates in Exceptional Circumstances Delegation of Authority to set Grant Start Dates in Exceptional Circumstances
<p>The Board recognizes that Decision Point GF/B19/DP19 entitled “Flexibilities to Set Grant Start Dates” delegates to the Secretariat the authority to set the Start Date for grant agreements up to 18 months after Board approval of a proposal to allow for alignment and harmonization.</p> <p>The Board extends that delegated authority by further authorising the Secretariat to delay a Start Date to allow for exceptional circumstances. The following events are indicative of the standard required to justify „exceptional circumstances‟: natural disasters, sudden outbreaks of disease, sudden or unforeseen outbreaks of civil or political unrest that would severely hinder programmatic start up activities.</p> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-09-26 B24 GF/B24/DP03 High-Level Independent Review Panel High-Level Independent Review Panel
<ol> <li>The Board thanks the High-Level Independent Review Panel (HLP) and its support team for their hard work in delivering to the Board the report titled "Turning the Page from Emergency to Sustainability" dated 19 September 2011 (the "HLP Report").<br /><br /></li> <li>The Board adopts the HLP Report and accepts the underlying analysis, noting that it presents a compelling case for a rapid and urgent transformation of the Global Fund. The HLP acknowledges the achievements of the Global Fund over the past decade, and the importance of ensuring its success.<br /><br /></li> <li>The Board acknowledges that the Global Fund has significant weaknesses of fiduciary control and financial oversight, as identified in the HLP Report, and the Board is determined to take the necessary corrective actions to address these weaknesses. The Board takes note that the Executive Director and the Inspector General also agree with the HLP Report findings.<br /><br /></li> <li>The Board recognizes that implementation of the HLP's recommendations will require a detailed implementation plan, and that this should be informed by best-practice and draw on available experience.<br /><br /></li> <li>To take forward the recommendations of the HLP, the Board decides to execute the following action plan immediately:<br /><br />5.1 - Consistent with Recommendation 6.3 of the HLP Report ("Consolidate the Reform Agenda") the Board Chair and Vice-Chair, with the Secretariat and the Office of the Inspector General (OIG), will develop a single, time-bound and costed Consolidated Transformation Plan which integrates other reform work streams currently underway with recommendations by the HLP into one single plan, which will include prioritized action items, deliverables, timelines, and parties responsible for the delivery of each item in a logical, coherent, manageable, efficient and timely manner;<br /><br />5.2 - A draft of the Consolidated Transformation Plan will be circulated to the full Board for comment by 31 October 2011, and a final draft will be transmitted to the Board by 10 November 2011 for formal adoption at the Twenty-Fifth Board Meeting; and<br /><br />5.3 - The Coordinating Group (see Paragraph 6.3.1.2 below) will be responsible for monitoring, tracking and reporting to the Board on progress of this Consolidated Transformation Plan until all action items are completed.<br /><br /></li> <li> Acknowledging that they will be important components of the Consolidated Transformation Plan that will be approved in November 2011, the Board decides that the following key actions shall commence immediately, with status reports or decision points, as appropriate, being presented at the Twenty-Fifth Board Meeting:<br /><br />6.1 - The Secretariat and OIG will commence implementation of Recommendation 1 of the HLP Report ("Turn the Page from Emergency to Sustainable Response"), in close consultation with the Board Chair, Vice-Chair and Finance and Audit Committee (FAC);<br /><br />6.2 - The Board, Secretariat and OIG will commence implementation of Recommendation 2 of the HLP Report ("Define a Doctrine of Risk and Manage to It"), except Recommendations 2.3.iii.a-b of the HLP Report. The Board will give further consideration to Recommendations 2.3.iii.a-b of the HLP Report, taking into account the clarification provided by the HLP during the Twenty-Fourth Board Meeting;<br /><br />6.3 - The Board Chair and Vice-Chair, as part of their leadership of the Governance Reform process, will integrate Recommendation 3 of the HLP Report ("Strengthen Internal Governance") into the Board Governance Plan they will finalize. To accelerate implementation of the Governance Reform process the Board:<br /><br /> <ul> <li>6.3.1 - Adopts Recommendation 3 of the HLP Report ("Strengthen Internal Governance") with the following modifications to commence from 1 December 2011:<br /><br /> <ul> <li>6.3.1.1 - The existing four standing committees will be replaced by three standing committees titled and composed as follows:<br /><br /> <ul> <li>i. Strategy, Investment and Impact: ten voting members, five from the donor bloc and five from the implementer bloc, with a chair from the donor bloc;<br /><br /></li> <li>ii. Finance and Operational Performance: ten voting members, five from the implementer bloc and five from the donor bloc with a chair from the implementer bloc; and<br /><br /></li> <li>iii. Audit and Ethics - seven members, with four independent members, one of whom will be the Chair;<br /><br /></li> </ul> </li> <li>6.3.1.2 - There will be a Coordinating Group comprised of Board and committee chairs and vice-chairs;<br /><br /></li> <li>6.3.1.3 - The Board leadership will have a casting vote on two of the committees, as follows:<br /><br /> <ul> <li>i. For the Strategy, Investment and Impact Committee, the Chair of the Board will have a casting vote; and<br /><br /></li> <li>ii. For the Finance and Operational Performance Committee, the Vice Chair of the Board will have a casting vote;<br /><br /></li> </ul> </li> <li>6.3.1.4 - The terms of reference of the three committees will include the duties as recommended by the HLP Report and will be further developed under the leadership of the Board Chair and Vice-Chair. Ethics-related matters will be included in the terms of reference of the Audit and Ethics Committee; and<br /><br /></li> <li>6.3.1.5 - To optimize their performance, the committees can include ex-officio members of the Board and will have the ability to delegate operational matters to the Secretariat.<br /><br /></li> </ul> </li> <li>6.3.2 - Requests the Chair and Vice-Chair to seek nominations from Board constituencies for the three Board Member seats of the Audit and Ethics Committee, and to identify three appropriately qualified persons as member-designates. The Board further requests the three member-designates to commence an open and transparent process to identify the four independent members of that committee, for recommendation to the Board for approval at the Twenty-Fifth Board meeting.<br /><br /></li> </ul> 6.4 - The Policy and Strategy Committee (PSC) and its Strategy Development Working Group will include Recommendation 4 of the HLP Report ("Institute a New Grant-Approval Process") into the five-year Strategy that will be finalized and submitted to the Board for approval at the Twenty-Fifth Board Meeting; and<br /><br />6.5 - The Secretariat, in close and regular consultation with the Chair and Vice-Chair of the Board, FAC, PSC and OIG, will implement Recommendation 5 of the HLP Report ("Empower Middle-Management's Decision-Making") and Recommendations 6.1 and 6.2 of the HLP Report ("Measure Outcomes, Not Inputs" and "Focus on Quality and Value, Rather Than Quantity" respectively), and provide a progress report to the Board at the Twenty-Fifth Board Meeting.<br /><br /></li> <li>In implementing these actions and recommendations, the Board expects the Global Fund Secretariat to pursue the overall objectives of aid-effectiveness,1 to stabilize staff levels and to avoid any increase in general administrative overheads without the prior approval of the Board.</li> </ol>
2011-10-19 B24 GF/B24/EDP02 Appointment of Board Chair Appointment of Board Chair
<p>The Board expresses its appreciation to Simon Bland for his leadership as interim Chair of the Board after the resignation of Martin Dinham as Chair due to ill health.</p> <p>Following recommendation of a candidate by the donor constituency as requested by the Board, the Board appoints Simon Bland as Chair of the Board for the period commencing from the date of this decision until the adjournment of the first Board Meeting in 2013.</p> <p>The Board expresses its gratitude for the continued leadership of Dr. Mphu Ramatlapeng as Vice-Chair of the Board, whose term will also end at the adjournment of the first Board Meeting in 2013.</p> <p>This decision has no material budgetary implications for the 2011 operating budget.</p>
2011-10-31 B24 GF/B24/EDP05 Procedure for Rolling Continuation Channel Mid-Term Performance Reviews and Extensions Procedure for Rolling Continuation Channel Mid-Term Performance Reviews and Extensions
<p>The Board decides that for all Rolling Continuation Channel grants which are not consolidated into Single Streams of Funding (“RCC Grants”),</p> <ol> <li>the Phase 2 Decision Making Policies and Procedures (GF/B16/DP16, Document GF/B16/7 Revision 1, Attachment 1, Section 3)(“PDMPP”) shall be applied to RCC Grants, subject to the following: <ol> <li>Paragraph 5 of the PDMPP shall be amended to read as follows: “The Phase 2 decisions will typically be taken on the basis of the reported results of a program as of the end of the 18th month of implementation, or the 24th month in the case of Rolling Continuation Channel (“RCC”) programs, and the Secretariat‟s recommendations that are made up to 23 months, or 30 months in the case of RCCs programs, after the Program Starting Date/Phase 1 Starting Date/ RCC I Starting Date (exceptions could include for situations of force majeure). The decision may be taken earlier in cases of (i) accelerated implementation; or (ii) severe exchange rate fluctuations.”; and</li> <li>The provisions of the PDMPP relating to extensions shall not apply to RCC Grants.</li> </ol> </li> <li>the “Exceptional Extensions” section under paragraph 17 of the Periodic Reviews and Commitments Policy (Annex 2a, version 2, to GF/B20/4 “Report of the Policy and Strategy Committee” and approved under GF/B20/DP31) shall be applied to RCC Grants.</li> <li>the Secretariat may extend the term of Phase 1 of an RCC Grant by up to six months to allow for flexibility in aligning the grant with in-country cycles and/or to facilitate the transition of the grant to a single stream of funding agreement. Any such extension will not alter the overall end date of the Board-approved proposal.</li> </ol> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-09-26 B24 GF/B24/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Fourth Board Meeting (GF/B24/1 Revision 1), as amended to discuss the current funding position, is approved.
2011-10-31 B24 GF/B24/EDP04 Extension of deadline for Round 10 Grant Signatures Extension of deadline for Round 10 Grant Signatures
<p>The Board refers to the following Decision establishing a „Policy on Timeframes for Grant Agreements‟ approved at its Eighth Board meeting:</p> <p>"If a grant agreement has not been signed 12 months after Board approval, the proposal should no longer be considered approved unless the Board decides to allow a further exceptional time extension based on information received from the Secretariat and CCMs. This time extension will be limited to a maximum of 3 months.</p> <p>The Board decides that this policy should apply for Round 3 and subsequent Rounds.”</p> <p>The Board delegates to the Secretariat the authority to allow extensions of up to three months to the signing timeframe for Round 10 proposals on an exceptional basis and only in situations in which there is a strong justification for granting an extension.</p> <p>By 30 April 2012, the Secretariat will provide a report to the Board or its relevant Committee identifying those Round 10 proposals that were granted extensions to the signing deadline, together with the justification for these extensions.</p> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-10-13 B24 GF/B24/EDP01 October 2011 Phase 2 Funding Decision October 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 146,486,654 for the following grants: AFG-809-G07-T ; MDG-405-G07-M ; SRL-809-G10-M ; SRL-809-G11-M ; SRL-809-G12-M ; UGD-708-G07-H</p>
2012-09-14 B27 GF/B27/DP06 Amendments to the Charters of Audit and Ethics Committee and the Finance and Operational Performance Committee Amendments to the Charters of Audit and Ethics Committee and the Finance and Operational Performance Committee
<ol> <li>The Board decides to amend the Charters of the Audit and Ethics Committee (the "AEC") and the Finance and Operational Performance Committee (the "FOPC") to reallocate the advisory and oversight responsibilities related to the external audit of the Global Fund's annual financial statements between the AEC and FOPC, as set forth in Annexes 3 and 4 to GF/B27/07.</li> <li>The AEC and FOPC Charters, as amended and set forth in Annexes 3 and 4 of GF/B27/07, shall be effective as of the date of this decision.</li> </ol>
2012-09-14 B27 GF/B27/DP03 Approval of Report of the Twenty-Sixth Board Meeting Approval of Report of the Twenty-Sixth Board Meeting
The report of the Twenty-Sixth Board Meeting (GF/B27/12 Revision 1) is approved.
2012-10-22 B27 GF/B27/EDP03 October 2012 Grant Renewals Funding Recommendations October 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 636,344,148 for the following grants: BEN-304-G04-M ; BEN-T-PNTUB ; BIH-T-UNDP ; BOL-910-G09-H ; BOL-910- G10-T ; MOL-H-PCIMU ; MOL-809-G06-H ; NIC-910-G07-M ; SLE-H-NAS ; TKM-910-G01-T ; TNZ-809-G13-H ; AZE-910-G05-H ; AZE-910-G06-T ; BAN-T-BRAC ; BAN-T-NTP ; GMB-S10-G07-M (GMB-M-MOH) ; GMB-M-CRS ; GYA-810-G06-T ; IDA-910-G23-M ; IDA-910-G22-M ; SSD-910-G13-S</p>
2012-09-14 B27 GF/B27/DP04 Transitional Arrangements for the Affordable Medicines Facility - malaria Transitional Arrangements for the Affordable Medicines Facility - malaria
<p>The Board refers to its earlier decision regarding the duration of Phase 1 of the Affordable Medicines Facility - malaria ("AMFm") (GF/B22/DP13) and notes that Phase 1 will end on 31 December 2012.</p> <p>The Board recognizes the importance of an orderly transition for those countries that are part of the Phase 1 pilot following its decision expected in November 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line. In order to support an orderly transition towards implementing the outcome of the November decision, the Global Fund will continue to host AMFm during a twelve-month transition period, and the Board will approve the details of the transition in November.</p> <p>In order to support the transition period, the capacity of the Global Fund Secretariat to manage the activities of the AMFm shall be extended by twelve months (until 31 December 2013). The Board requests that the Secretariat include the appropriate budgetary implications of the extended mandate of the AMFm in the 2013 Operating Expenses Budget.</p>
2012-09-14 B27 GF/B27/DP05 Revision to the Policy on Ethics and Conflict of Interest for Global Fund Institutions Revision to the Policy on Ethics and Conflict of Interest for Global Fund Institutions
<p>The Board approves the revised Policy on Ethics and Conflict of Interest for Global Fund Institutions attached as Annex 1 of GF/B27/07 and the revised Declaration of Interest Form attached as Annex 2 of GF/B27/07 as updated to reflect the new Board Committee structure established with the Board's adoption of the Governance Reform at its Twenty-Fifth Meeting.</p>
2012-09-14 B27 GF/B27/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Seventh Board Meeting (GF/B27/1) is approved.
2012-09-24 B27 GF/B27/EDP02 Additional funding for Continuity of Services for the South Sudan Round 5 TB program (SSD-506-G06-T) Additional funding for Continuity of Services for the South Sudan Round 5 TB program (SSD-506-G06-T)
<p>The Board approves additional funding for up to twenty (20) months for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s Continuity of Services form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the Secretariat’s recommendations.</p><p>See attached tabledetailing total recommended funding amount of USD 1,537,483 for the following grant: SSD-506-G06-T</p>
2009-05-06 B19 GF/B19/DP02 Approval of Agenda Approval of Agenda
The agenda for the Nineteenth Board Meeting (GF/B19/1, Revision 3) is approved.
2018-11-05 B39 GF/B39/EDP17 Key Performance Indicator 12b: Availability of Affordable Health Technologies: Affordability Key Performance Indicator 12b: Availability of Affordable Health Technologies: Affordability
<ol> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the 2019 performance target of USD 115 million for Key Performance Indicator 12b as presented in GF/B39/ER14A.</li> </ol>
2009-05-06 B19 GF/B19/DP01 Appointment of Rapporteur Appointment of Rapporteur
H.E. Dr Leslie Ramsammy from the Latin America and Caribbean constituency is designated as Rapporteur for the Nineteenth Board Meeting.
2009-07-03 B19 GF/B19/EDP04 Approval of Funding Recommendations Approval of Funding Recommendations
<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 6 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14. </p>
2023-11-01 B49 GF/B49/EDP08 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-11-13 B49 GF/B49/EDP12 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as <br />listed in Table 1 of GF/B49/ER10 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each  country disease component among its constituent grants, provided that the Technical Review Panel (the <br />“TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2023-08-21 B49 GF/B49/EDP05 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-08-07 B49 GF/B49/EDP04 Approval of the Report of the 49th Board Meeting Approval of the Report of the 49th Board Meeting
<p>The Board approves the Report of the 49th Board Meeting, as set forth in GF/B49/18.</p>
2023-10-17 B49 GF/B49/EDP07 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B49/ER06 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-10-17 B49 GF/B49/EDP06 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-06-30 B49 GF/B49/EDP02 Appointment of Replacement Member on the Strategy Committee Appointment of Replacement Member on the Strategy Committee
<p>The Board approves the appointment of:</p> <ol> <li>Jérôme Salomon, representing the World Health Organization Constituency, as a non-voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of his successor.</li> </ol>
2023-07-19 B49 GF/B49/EDP01 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B49/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-11-13 B49 GF/B49/EDP11 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-06-09 B49 GF/B49/EDP03 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 1 of GF/B49/ER03 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-05-10 B49 GF/B49/DP02 Approval of the Rapporteur Approval of the Rapporteur
<p>Mohamed Chakroun from the Eastern Mediterranean Region is designated as Rapporteur for the 49th Board Meeting.</p>
2023-05-11 B49 GF/B49/DP05 Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Dr. Donald Kaberuka for his leadership as Chair of the Board. Over his time working with the Global Fund, he has driven strong engagement for the Global Fund at the most senior levels, provided strategic direction including during a prolonged period of virtual governance, and demonstrated clear commitment to the work of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Lady Roslyn Morauta for her leadership as Vice-Chair of the Board. She has served the Global Fund with passion and dedication and continues to show her personal conviction for the mission of the Global Fund by her willingness to continue as the incoming Chair of the Board. During her tenure as Vice-Chair, Lady Roslyn Morauta has been an active leader and a strong advocate for the Global Fund and the communities we serve.</p> <p>During their tenure, Dr Kaberuka and Lady Morauta presided over strategy deliberations and decisions that will continue to shape the future of the Global Fund under its new strategy. Together, they have contributed to strengthening relations among Global Fund stakeholders. Their contribution will have a lasting impact on the Global Fund.</p> <p>The Board wishes Dr Kaberuka every success in the future and bestows upon him the honorary title of Chair Emeritus. The Board welcomes Lady Roslyn Morauta into her new role, and looks forward to her tenure, as Chair of the Board.</p>
2023-05-10 B49 GF/B49/DP01 Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 49th Board Meeting (GF/B49/01-Revision 1) is approved.</p>
2023-05-10 B49 GF/B49/DP03 2023-2028 KPI Framework adjustments 2023-2028 KPI Framework adjustments
<p>The Board notes the recommendations of the Audit and Finance Committee (“AFC”) as set forth in GF/AFC21/EDP02, and the Strategy Committee (“SC”) as set forth in GF/SC21A/DP01, and:</p> <ol type="i"> <li>Approves the adjustments to the 2023-2028 Key Performance Indicator (“KPI”) Framework (including each KPI) as set forth in GF/B49/03 Annex 2;</li> <li>Notes that proposed material changes to a KPI (refer to GF/B49/03 Annex 1 for the approach to assessing materiality) will continue to be recommended by the AFC or SC, within their respective allocated responsibilities (each a “Relevant Committee”) (as set forth in Annex 2 section 2.2 of GF/AFC20/09 and Annex 2 section 2.1 of GF/SC20/05 revision 2), for Board approval; and</li> <li>Delegates authority to the Secretariat, in consultation with the Relevant Committee Chair and Vice Chair, to make non-material KPI adjustments, in line with GF/B49/03 Annex 1, and report back to the Relevant Committees and Board on all such changes.</li> </ol>
2023-05-03 B48 GF/B48/EDP13 2022 Annual Financial Report 2022 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2022 Annual Financial Report, including the 2022 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B48/ER12.</p>
2023-05-03 B48 GF/B48/EDP14 2022 Statutory Financial Statements 2022 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2022 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B48/ER12.</p>
2023-05-08 B48 GF/B48/EDP15 Additional Funding from the COVID-19 Response Mechanism Additional Funding from the COVID-19 Response Mechanism
<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B48/ER13 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>
2023-04-27 B48 GF/B48/EDP12 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B48/ER11 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-05-11 B49 GF/B49/DP04 Amended Risk Appetite Statements Amended Risk Appetite Statements
<ol> <li>The Board: <ol type="i"> <li>recalls its ultimate responsibility to the Global Fund’s stakeholders for overseeing the implementation of effective risk management;</li> <li>affirms the Strategy Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as reported to the Audit and Finance Committee; and</li> <li>further affirms the Audit and Finance Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight and integration of the Strategy Committee’s concurrence, as set forth in Annex 1 to GF/AFC21/06 and pursuant to decision point GF/AFC21/DP01.</li> </ol> </li> <li>Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statements, including risk appetite and timeframes to achieve target risk, as set forth in the table in Annex 1 to GF/B49/04, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date, or when earlier achieved.</li> <li>This decision point and the amended Risk Appetite Statements approved by it shall supersede decision point GF/B46/DP05 (November 2021).</li> </ol>
2023-01-27 B48 GF/B48/EDP04 Location of the 49th Board Meeting Location of the 49th Board Meeting
<ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of Viet Nam to host the Global Fund’s 49th Board Meeting on 10-11 May 2023; and</li> <li>Acknowledges the recommendation set forth in GF/B48/ER04.</li> <li>Requests the Global Fund Secretariat to engage with the Government of Viet Nam to agree on any necessary arrangements relating to hosting the Board Meeting in Viet Nam, and invites the Government of Viet Nam to consider conferring privileges and immunities to the Global Fund.</li> </ol> </li> <li>Accordingly, the Board agrees to convene the 49th Board Meeting in Hanoi, Viet Nam.</li> </ol>
2023-11-09 B49 GF/B49/EDP10 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER08 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-11-14 B50 GF/B50/DP02 Approval of the Rapporteur Approval of the Rapporteur
<p>Jean-Bernard Parenteau from the Canada, Switzerland and Australia constituency is designated as Rapporteur for the 50th Board Meeting.</p>
2023-12-19 B50 GF/B50/EDP11 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B50/ER08 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-12-19 B50 GF/B50/EDP09 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B50/ER07 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>
2023-12-19 B50 GF/B50/EDP12 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B50/ER08 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>
2023-12-15 B50 GF/B50/EDP06 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B50/ER05 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2024-01-29 B50 GF/B50/EDP14 Appointment of the Ethics Officer Appointment of the Ethics Officer
<p>The Board approves the appointment of Michelle Beistle to serve as the next Global Fund Ethics Officer for a three-year term which can be renewed no more than once.</p>
2023-12-19 B50 GF/B50/EDP10 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER08 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2024-01-16 B50 GF/B50/EDP13 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country  disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates  any redistribution that constitutes a material change from the program and funding request initially reviewed and  recommended by the TRP. </li> </ol>
2023-12-15 B50 GF/B50/EDP05 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-11-01 B49 GF/B49/EDP09 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B49/ER07 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-12-15 B50 GF/B50/EDP07 Additional Funding from the COVID-19 Response Mechanism Additional Funding from the COVID-19 Response Mechanism
<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through <br />30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards and <br />implemented through 31 December 2025;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of <br />GF/B50/ER06 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding <br />available for each country among its constituent grants, in accordance with previously <br />approved principles under GF/B44/EDP18.</li> </ol>
2023-12-08 B50 GF/B50/EDP03 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER03 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-12-04 B50 GF/B50/EDP01 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2024-02-14 B50 GF/B50/EDP15 Approval of the Report of the 50th Board Meeting Approval of the Report of the 50th Board Meeting
<p>The Board approves the Report of the 50th Board Meeting, as set forth in GF/B50/23.</p>
2023-11-15 B50 GF/B50/DP04 Framework to Guide the Development, Review, Approval and Implementation of Blended Finance Transactions Framework to Guide the Development, Review, Approval and Implementation of Blended Finance Transactions
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the blended finance approach set forth in Annex 1 to GF/B50/04: Framework to Guide the Development, Review, Approval and Implementation of Blended Finance Transactions.</p>
2023-11-14 B50 GF/B50/DP01 Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 50th Board Meeting (GF/B50/01) is approved.</p>
2023-11-15 B50 GF/B50/DP05 2024 Work Plan and Budget Narrative and the 2024 Operating Expenses Budget 2024 Work Plan and Budget Narrative and the 2024 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee (AFC), the Board approves the following:</p> <ol type="a"> <li>the 2024 Work Plan and Budget Narrative, as set forth in GF/B50/02A; and</li> <li>the 2024 Operating Expenses Budget in the amount of US$ 342.2 million (comprising (i) PART A Secretariat Operating Expenses of US$ 277.9 million, which includes US$ 15.9 million for the Office of the Inspector General’s 2024 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US$ 64.4 million), as set forth in GF/B50/02A.</li> </ol>
2023-11-15 B50 GF/B50/DP06 Amended and Restated Global Fund Quality Assurance Policy for Pharmaceutical Products and Amended and Restated Global Fund Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment Amended and Restated Global Fund Quality Assurance Policy for Pharmaceutical Products and Amended and Restated Global Fund Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment
<p>Based on the recommendation of the Strategy Committee, the Board approves:</p> <ol> <li>the Amended and Restated Quality Assurance Policy for Pharmaceutical Products as set forth in Annex 1 to GF/B50/05;</li> <li>the Amended and Restated Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment, as set forth in Annex 2 to GF/B50/05, which replaces in its entirety the former Quality Assurance Policy for Diagnostics Products; and</li> <li>the delegation of authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the two quality assurance policies referenced above, in line with Annex 3 to GF/B50/05 and to report back to the Strategy Committee and Board on all such changes.</li> </ol>
2023-11-14 B50 GF/B50/DP03 Amendments to the Risk Appetite Statements Amendments to the Risk Appetite Statements
<ol> <li>The Board: <ol type="i"> <li>recalls its ultimate responsibility to the Global Fund’s stakeholders for overseeing the implementation of effective risk management;</li> <li>affirms the Strategy Committee’s concurrence with the amended Risk Appetite Statement under such committee’s oversight, as reported to the Audit and Finance Committee; and</li> <li>further affirms the Audit and Finance Committee’s concurrence with the amended Risk Appetite Statement and integration of the Strategy Committee’s concurrence, as set forth in Annex 1 to GF/AFC23/8A – Revision 2 and pursuant to decision point GF/AFC23/DP04.</li> </ol> </li> <li>Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statement, including risk appetite and timeframes to achieve target risk, as set forth in the table in Annex 1 to GF/B50/03, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date, or when earlier achieved.</li> <li>This decision point and the amended Risk Appetite Statement approved by it shall supplement decision point GF/B49/DP04 (May 2023).</li> </ol>
2023-12-19 B50 GF/B50/EDP08 Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-04-20 B48 GF/B48/EDP11 Appointment of the Board Chair and Vice-Chair Appointment of the Board Chair and Vice-Chair
<p>The Board appoints Lady Roslyn Morauta as Chair and Ms. Bience Gawanas as Vice-Chair of the Board to each serve three-year terms, or until the appointment of their respective successors, starting from the adjournment of the 49th Board Meeting on 11 May 2023.</p>
2023-04-14 B48 GF/B48/EDP10 Additional Funding from the COVID-19 Response Mechanism Additional Funding from the COVID-19 Response Mechanism
<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B48/ER09 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants, in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>
2023-03-27 B48 GF/B48/EDP08 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B48/ER08(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2005-12-16 B12 GF/B12/DP01 Appointment of Rapporteur Appointment of Rapporteur
Peter van Rooijen from the Developed Country NGO Constituency is designated as Rapporteur for the Twelfth Board Meeting.
2005-12-16 B12 GF/B12/DP16 Report of the Committee on the Executive Director Report of the Committee on the Executive Director
<p><b>Decision Point 1:</b> </p><p> The Board requests the Chair to launch a process to produce a performance assessment of the Executive Director in time for the Thirteen Board Meeting.</p><p><b>Decision Point 2: </b> </p><p> The Board decides to establish a Committee, composed of the Chairs and Vice Chairs of the Policy and Strategy Committee, Finance and Audit Committee, Portfolio Committee and Ethics Committee, to prepare recommendations for the Thirteenth Board Meeting, which will include updated Terms of Reference for the position of Executive Director. </p><p><b>Decision Point 3: </b> </p><p> The Board decides to amend its By-laws and Board Operating Procedures for the appointment of the Executive Director to be in line with the text appearing below. The Board requests the Chair to work with WHO and the Global Fund's Legal Counsel and outside Swiss counsel to produce draft amendments for adoption at the Thirteen Board Meeting.</p><p>APPOINTMENT OF THE EXECUTIVE DIRECTOR</p><p><b>I. Term and Term Limits: </b> </p><p> The Board decides to amend Article 8.1 of its By-Laws. The Board selects the Executive Director for a period of four (4) years, renewable for a period of three (3) years. The Board will make this selection on a merit-based, non-political and open basis.</p><p><b>I I. Options for Board Decision</b> </p><p>At least six months before the end of the incumbent Executive Director's first term, the Board makes one of three decisions: </p><ol><li> Launch a recruitment procedure, and encourage the Executive Director to let his/her name stand for the post; </li><li> Reappoint the Executive Director, subject to performance appraisal; or</li><li> Launch a recruitment procedure, and do not encourage the Executive Director to let her/his name stand for the post.</li></ol><p>The norm is Option One. In that case, the Board will make public that it has invited the incumbent Executive Director to re-apply for the post.</p><p><b>III. Recruitment/reappointment procedure </b> </p><p>The Board decides to modify its Board Operating Procedures to include a recruitment procedure and a reappointment procedure, as decided in Paragraph 2 above. </p><p>3.1. Recruitment procedure ;</p><ol type="a"><li> At least six months before the end of the term of an incumbent Executive Director, or any other time decided by the Board, the recruitment process will be followed as below. The Board at that time approves updated Terms of Reference, including selection criteria, for the position of Executive Director. </li><li> The Board Chair nominates, and the Board approves, a selection committee.</li><li> The Board launches the recruitment process. </li><li> The selection committee interviews candidates, and presents the best-ranking candidates to the Board for decision. </li></ol><p>3.2. Reappointment procedure </p><p>On the basis of the performance assessments, the Board could decide to reappoint an Executive Director for one additional term of three (3) years, under the conditions in Paragraph One above.</p><p>Under this system, the annual performance assessment of the Executive Director would, of course, continue, in line with normal best practice. All material for the evaluation will be provided to the Board in the first quarter of the calendar year. </p>
2005-12-16 B12 GF/B12/DP07 Secretariat Budget 2006 Secretariat Budget 2006
<p>The Board approves the 2006 operating expense budget in the amount of US$83,200,000 as set out in Annex 1 to the Report of the Finance and Audit Committee (GF/B12/7) and as recommended by the Finance and Audit Committee (FAC) and proposed by the Secretariat. </p><p>The Board notes that the budget includes envisaged cost savings and requests FAC to review actual expenditure and budgetary needs after the first half of 2006 and, if necessary, make further recommendations to the Board at that time.</p>
2006-04-18 B12 GF/B12/EDP06 Approval of Phase 2 Funding Recommendations April 2006 Approval of Phase 2 Funding Recommendations April 2006
#
2006-03-23 B12 GF/B12/EDP02 Election of the Vice Chair of the Board Election of the Vice Chair of the Board
<p>1. Election Procedures for Vice Chair</p><p><span></span></p><p>1.1 The Board takes note of the resignation of Ambassador Michel Kazatchkine as the Vice Chair of the Board and recognizes that, pursuant to Articles 7.3 and 12 of the By-laws, his successor as Vice Chair (who completes his term) must be from the donor group described in Article 7.6 of the By-laws. </p><p>1.2 The Board further notes that, in accordance with Article 18 of the Board Operating Procedures, the election of the Vice Chair of the Board should normally take place at the 13<sup>th</sup> Board meeting.</p><p>1.3 The Board decides that, in this case, an exception to the Board Operating Procedures is appropriate and that the vote to elect the Vice Chair of the Board shall take place by email vote in accordance with Article 7.6 of the Bylaws.</p><p>1.4 The Board notes that the deadline set for the submission of nominations for the position of Vice Chair of the Board is currently 7 April 2006. The Board further notes that the donor group has unanimously supported the nomination of a single candidate for the position of Vice Chair and that such candidate has confirmed her willingness to act as Vice Chair. The Board therefore decides to close the nomination process as of 9 March 2006. </p><p><span></span></p><p>2. Election of Vice Chair</p><p><span></span></p><p>Dr. Lieve Fransen of the European Commission constituency is elected with immediate effect to serve as Vice Chair of the Board for the unexpired term of Ambassador Michel Kazatchkine. </p>
2005-12-16 B12 GF/B12/DP05 Continuity of Services Continuity of Services
<p>The Board recognizes that in exceptional circumstances there may be a need to provide funding for the continuation of treatment in grants where funding ends (whether due to termination, a decision not to provide Phase 2 funding, or a grant reaching the end of its term). The Board recognizes that discussions on whether and how to provide continued funding for treatment will be part of the strategy process. To address exceptional cases that may arise before a comprehensive approach to the issue has been decided, however, the Board replaces the decision at the Ninth Board Meeting on continuity of services (GF/B10/2, Decision Points: Continuity of Services, Decision Point 1) with the following:</p> <p>The Board adopts the following system for addressing continuity of services:</p> <ol type="i"> <li>A recipient (typically a CCM, or, if appropriate, in the case of a non-CCM proposal, the grant applicant) whose funding has ended, has been terminated or is less than four months from the end of its term may submit an Extraordinary Request for Continued Funding for Treatment.</li> <li>The Extraordinary Request will be limited to expenses directly related to the continuation of treatment (including medicines [which, in the case of discontinuation of antiretroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on life-long treatment under the existing proposal at the time of the Extraordinary Request.</li> <li>The Extraordinary Request will be limited to the amount required to provide services directly related to the continuation of treatment for up to two years (taking into account any amount which remains available under the existing grant).</li> <li>The Extraordinary Request shall contain a description of the steps that are being taken to find sustainable sources of financing for the people on treatment, and to ensure that treatment is being delivered effectively. To be eligible for funding under this provision the CCM (or, in the case of non-CCM proposals, the grant applicant) shall demonstrate that it has used its best efforts to identify other sources of funding to provide continuity of services but has been unsuccessful.</li> <li>The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval. The Secretariat will address performance issues as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of grant funds.</li> <li>Throughout the process, the Secretariat will actively engage with technical partners to identify mechanisms to ensure continuity of services.</li> <li>In a resource-constrained environment, Extraordinary Requests for Continued Funding for Treatment shall be treated the same as Phase 2 renewals for the purpose of the decision on prioritization set out in GF/B9/2 page 9, Decision Point 2.</li> </ol> <p>This decision shall expire at the first Board meeting of 2007 unless renewed.</p>
2005-12-16 B12 GF/B12/DP10 Appeals—Round 5 Appeals—Round 5
<p>1. The following proposals will be approved by the Board as Category 2 proposals, based upon the Appeal Panel recommendation, subject to paragraph 2 below and through Board confirmation by e-mail, as funds become available to cover all four proposals under the terms of the Comprehensive Funding Policy: </p><p>i. Equatorial Guinea (Malaria)</p><p>ii. Philippines (Tuberculosis)</p><p>iii. Sudan (HIV/AIDS)</p><p>iv. Sudan (Tuberculosis)</p><p>The Board's approval will be for the amount indicated as "Total 2 years" in Annex 2 to the Report of the Internal Appeal Panel (GF/B12/8) and will be made with the clear understanding that such amounts are upper ceilings rather than the final Phase 1 Grant amounts.</p><p>2. The proposal applicants shall provide an initial reply to the clarifications requested by the Appeal Panel no later than six weeks after notification in writing by the Secretariat to the applicant of the Board's decision. Any further adjustments and clarifications shall be completed within four months from the receipt of the initial reply from the applicant.</p>
2005-12-16 B12 GF/B12/DP15 Conflicts of Interest of Former Employees Conflicts of Interest of Former Employees
The Board decides to extend the Terms of Reference of the Ethics Committee to cover conflicts of interest in relation to former staff members of the Secretariat and requests the Ethics Committee to develop a policy regarding this matter at the Thirteenth Board Meeting.
2005-12-16 B12 GF/B12/DP14 Technical Review Panel Membership Technical Review Panel Membership
<p><b>Decision Point 1:</b> </p><p>Mindful of the current distribution of the geographic diversity of the Technical Review Panel pool, the Board requests the Portfolio Committee to recommend for approval at the 13th Board meeting one additional Alternate Member of the Technical Review Panel for each area of expertise (HIV/AIDS, tuberculosis, malaria and cross-cutting). </p><p><b>Decision Point 2:</b> </p><p>The Board authorizes the Chair and Vice Chair of the Technical Review Panel to add temporarily up to four members, which shall be selected from existing Alternate Members, to the membership of the TRP for a given round of proposals, where appropriate in light of the number of proposals and their distribution among categories.</p>
2006-04-18 B12 GF/B12/EDP07 Appointment of the Chair of the Finance and Audit Committee (FAC) Appointment of the Chair of the Finance and Audit Committee (FAC)
<span>Mr Jerry O’Dwyer of the Point Seven constituency is appointed with immediate effect to serve as Chair of the Finance and Audit Committee.</span>
2005-12-16 B12 GF/B12/DP06 Round 5 Funding Round 5 Funding
<p>1. The Board approves for funding, subject to paragraph 2 below, all remaining Round 5 proposals recommended as eligible for funding by the Technical Review Panel ("TRP") listed in Annex VI to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6) that could not be approved for funding at the Eleventh Board meeting due to resource constraints. </p> <p>The Board's approval is for the amount indicated as 'Total 2 Years' in such Annex, and is made with the clear understanding that such amounts are upper ceilings rather than final Phase 1 Grant amounts. The aggregate amount of funding for the proposals approved by this decision shall not exceed US$343,539,127.</p> <p>2. The Board notes that the Secretariat has previously notified the applicants of the clarifications and adjustments requested by the TRP. These adjustments and clarifications shall be completed within four months from the receipt of the initial reply from the applicant. The Board's approval is conditional on the final approval of the TRP Chair and/or Vice Chair based on consultations with the TRP primary and secondary reviewers.</p>
2006-03-16 B12 GF/B12/EDP04 Approval of Phase 2 Funding Recommendations March 2006 Approval of Phase 2 Funding Recommendations March 2006
#
2005-12-16 B12 GF/B12/DP08 Round 6 Funding Round 6 Funding
<p>The Board requests that the Secretariat make the necessary preparations for a Board decision, including a forecast of resources available, so that a Call for Proposals for Round 6 can be launched and proposals reviewed and approved in 2006. The Secretariat should furthermore work in close collaboration with relevant committees taking into account the established process to develop a strategy for the Global Fund.</p><p>These preparations should ensure the minimum of disruption to countries' ongoing work. </p><p>The Board notes that the mid-term review of the Replenishment process in June 2006 and other resource mobilization efforts are essential for securing adequate funding for Round 6.</p>
2005-12-16 B12 GF/B12/DP17 Report of the Office of Internal Oversight Services Report of the Office of Internal Oversight Services
<p>The Board recognizes the commitment of the Fund management to implement the recommendations and the findings of the WHO Office of Internal Oversight Services report.</p><p>The Board acknowledges its own responsibility to oversee appropriate follow-on measures and ensure that systems and processes for personal and institutional accountability are enforced. </p><p>Therefore, the Board decides to establish an <i>ad hoc</i> Oversight Committee to oversee the following:</p><p>1. On contracts, payments, and recruitment</p><ul type="disc"><li>The Board finds the proposed actions in the Response of the Management appropriate</li><li>The Board requests that the management present an action plan to the Oversight Committee of the Board for review and approval</li><li>The Board requests that the Oversight Committee report to the 13<sup>th</sup>Board meeting</li><li>The Board requests that the Oversight Committee involve the Fund's Inspector General in this process</li></ul><p>2. On involvement of family members of Fund staff</p><ul type="disc"><li>The Board finds the proposed action in the Response of the Management appropriate</li><li>The Board requests that the management present an action plan to the Board's Ethics Committee</li><li>The Board requests that the Ethics Committee review the action plan and report to the 13<sup>th</sup>Board meeting</li></ul><p>3. Furthermore, the Board requests that the Ethics Committee review and make recommendations to strengthen the Fund's conflict of interest policy in light of the deliberations of the 12<sup>th</sup> Board meeting.</p><p>4. The Board requests the Fund's Deputy Executive Director, together with the Fund's Legal Counsel, to prepare appropriate excerpts from the IOS report to be presented to relevant employees with respect to whom there have been adverse findings in the report. Taking into account their responses, Fund management should take measures to determine who is responsible for any improprieties in order to document accountability. In this process, protection of whistleblowers is also essential. </p><p>5. The Board requests the Chair and Vice Chair of the Board to ensure that the IOS report as a whole and the Response of the Management are taken into account in the annual performance evaluation of the Fund's Executive Director. </p><p>6. The Board directs the Executive Director to provide a full report at the 13th Board meeting on steps taken to improve oversight of compliance with existing Global Fund and WHO policies and procedures, including those already developed in response to the Report.</p><p>7. The Board decides that the mandate of the Fund's Inspector General includes oversight of the implementation of this decision point. The Board further requests that, in advance of the 13<sup>th</sup> Board meeting, the Inspector General and the Oversight Committee report to the Board about progress in preparations and implementation called for in this decision point.</p><p>The Board approves the Statement of the Board for public release regarding the report of the IOS of the WHO on allegations of improprieties in the operations of the Global Fund: </p><p><b>Statement</b> </p><p>The Global Fund to Fight AIDS, Tuberculosis, and Malaria has in its first three years of operations achieved significant results that are saving lives. It strives to operate with the highest level of integrity and transparency to ensure that resources provided are properly utilized and focused on providing life-saving services in the fight against AIDS, tuberculosis, and malaria. </p><p>The Board received allegations in July 2005 involving contracting and payments, recruitment of staff, and the involvement of a family member. These allegations concerned activities within the Secretariat in Geneva. </p><p>Acting immediately, the Board Chair and Vice Chair and the Executive Director referred the allegations to the WHO's Office of Internal Oversight Services (IOS)<a id="_ftnref1" name="_ftnref1" target="_self"></a>, which after a substantial review provided a Report to the Board. </p><p>Based on the IOS Report and a review by its Ethics Committee, the Board finds that:</p><ul type="disc"><li>There was no evidence of fraud and misuse of funds.</li><li>There was no evidence of violations of the Policy on Ethics and Conflict of Interest for Global Fund Institutions, though there were actions that created concerns about lack of transparency.</li><li>There were instances of violation of established Global Fund and WHO rules and procedures.</li></ul><p>In response, the Board takes the following actions:</p><ul><li>A new Ad Hoc Committee is established to facilitate Board oversight of corrective measures being taken by Secretariat management.</li><li>The Office of Inspector General will advise the Board on progress made by the Secretariat in implementing recommendations made in the Report and related directives of the Board, as well as to propose additional improvements that might be needed.</li><li>The Executive Director is directed to provide a full report at the next Board meeting (April 2006) on steps taken to improve oversight of compliance with existing Global Fund and WHO policies and procedures, including those already developed in response to the Report.</li></ul><p>In addition to these allegations, the Board also received concerns about Secretariat culture and morale, which it takes seriously. The Global Fund's success depends on the hard work and commitment of its staff. Therefore, the Deputy Executive Director has already been tasked by the Board with responding to these concerns and is now directed to provide a comprehensive progress report at the next Board meeting.</p>
2005-12-16 B12 GF/B12/DP13 Extension of Proposal Completion Dates Extension of Proposal Completion Dates
<p><b>Decision Point 1: </b> </p><p>The Board authorizes the Secretariat to extend the Phase 2 term of Grant Agreements by up to six months, without committing any additional funding, in circumstances where the Principal Recipient is prevented, due to exceptional circumstances, from using the full amount of Grant funds during the Phase 2 term. </p><p><b>Decision Point 2: </b> </p><p>The Board decides that in circumstances where the term of a Phase 1 Grant Agreement has been extended in accordance with paragraph 4 of the Phase 2 Decision-Making Policies and Procedures attached as Annex 1 of the Report of the Portfolio Committee (GF/B12/6) (a "Phase 1 Extension"), the Secretariat may extend the Phase 2 term of Grant Agreements by up to an equal length of time as the Phase 1 Extension without committing any additional funding. </p><p>The Secretariat shall inform the Board immediately upon taking action under Decision Point 1 and 2. </p>
2021-07-22 EB01-2021 GF/EB01-2021/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Dasho Kunzang Wangdi from the South East Asia Constituency is designated as Rapporteur for the Extraordinary Board Meeting.</p>
2021-07-22 EB01-2021 GF/EB01-2021/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the Extraordinary Board Meeting (GF/EB01-2021) is approved.</p>
2021-07-22 EB01-2021 GF/EB01-2021/DP03 Approval of Strategy Framework Approval of Strategy Framework
<ol> <li>The Board notes the broad and inclusive consultations undertaken to inform the development of the next Global Fund Strategy, including the partnership-wide 2020 Open Consultation, 6th Partnership Forums, and extensive Strategy Committee (“SC”) and Board guidance.</li> <li>The Board also notes that the Strategy Narrative will be developed based on the approved Strategy Framework and presented to the Board for approval, based on a recommendation from the SC, at its 46th meeting in November 2021.</li> <li>Accordingly, based on the recommendation of the SC, as presented in GF/EB01-2021/02 – Revision 1, the Board: <ol type="a"> <li>Approves the Strategy Framework presented in Annex 1 to GF/EB01- 2021/02 – Revision 1 for the Global Fund Strategy covering the period 2023-2028; and</li> <li>Requests that the Secretariat develop, for the SC’s recommendation to the Board, the Strategy Narrative to further articulate areas of focus described in the Strategy Framework, based on input received to date through the Strategy development process.</li> </ol> </li> </ol>
2005-12-16 B12 GF/B12/DP04 Update on Strategy Development Update on Strategy Development
The Board acknowledges the progress made on developing the situation assessments and affirms the prioritization of issues and the principles to guide option development outlined in the Report of the Policy and Strategy Committee (GF/B12/5). It requests that the work proceed to the stage of option development and that the Policy and Strategy Committee report on progress at the Thirteenth Board Meeting.
2006-04-05 B12 GF/B12/EDP05 Approval of Bridge Funding Recommendations for Honduras Approval of Bridge Funding Recommendations for Honduras
The Board commits additional funds up to USD 4,125,000 to the Round 1 Honduras HIV/AIDS grant (HND-102-G01-H-00) to cover the program’s funding requirements for the period to 31 July 2006.
2005-12-16 B12 GF/B12/DP12 Phase 2 Decision-Making Policies and Procedures Phase 2 Decision-Making Policies and Procedures
<p>1. The Board may commit funds for Phase 2 renewals (up to the full duration of a proposal) up to the cumulative uncommitted amount pledged through the calendar year of the Board decision.</p><p>2. The Board makes funding decisions for Phase 2 renewals based on its review of Secretariat or Technical Review Panel (TRP) recommendations, according to procedures agreed by the Board.</p><p>3. The Secretariat or TRP will present the Board with its recommendations on the first of every month (notice to Board constituencies of a recommendation shall be effective upon the posting of the recommendation on the Global Fund website; the Secretariat will inform Board constituencies via e-mail when recommendations have been posted). The Board will vote by email on each recommendation on a no-objection basis. Votes must be received by the Secretariat no later than the tenth of the same month.</p><p>4. In exceptional circumstances, the Secretariat may need to take more than 20 months to provide a Phase 2 recommendation to the Board. In such situations, the Secretariat may extend, at no cost, the term of Phase 1 grant agreements by up to six months. The Secretariat shall inform the Board immediately upon taking action under this decision.</p><p>5. If the Secretariat decides to issue a "No Go" recommendation, it shall give notice of that intention and the reasons for it to the relevant CCM and allow that CCM four weeks to comment on the information submitted to it by the Secretariat. </p><p>6. The Secretariat shall review and consider the information provided by the CCM, and then make its recommendation to the Board. The information provided by the CCM shall be made available to the Board.  </p><p>7. A Board decision in favor of a Secretariat or TRP recommendation either:</p><ul><li>commits additional resources in the amount proposed in the recommendation (in the case of recommendations of "Go," "Conditional Go," and "Revised Go"); or</li><li>does not commit any additional resources (in the case of recommendations of "No Go"), thereby discontinuing the proposal after Phase 1.</li></ul><p>8. If the Board does not decide in favor of a Secretariat or TRP recommendation, this would serve to request further clarification on the recommendation and ask the Secretariat or TRP to reassess its recommendation. To facilitate the clarifications process, those Board constituencies that are not ready to decide in favor of a Secretariat or TRP recommendation would provide a written explanation that is made publicly available. The Secretariat or TRP will review its recommendation in light of the questions and comments of those Board constituencies and will then present a second recommendation on the first day of the subsequent month (unless time-constraints make it necessary to wait to the month thereafter). The Board then votes again, on the second Secretariat or TRP recommendation, using the procedures described above.</p><p>9. A Board decision in favor of the second Secretariat or TRP recommendation either:</p><ul><li>Commits additional resources in the amount proposed in the recommendation (in the case of recommendations of "Go," "Conditional Go," and "Revised Go"); or</li><li>Does not commit any additional resources (in the case of recommendations of "No Go"), thereby discontinuing the proposal after Phase 1.</li></ul><p>10. In the event that (i) the Board rejects a first "No Go" recommendation, (ii) the Secretariat issues a second "No Go" recommendation to the Board and (iii) the Board rejects the Secretariat's second "No Go" recommendation, the matter shall be referred to an independent panel, which shall assess the specific areas where the Board and the Secretariat differ on their assessment of the grant and report its conclusions to the Board. </p><p>11. The composition of the Independent Panel will be based on the following principles:</p><ul><li>Size: Two senior members supported by 1-2 contracted analysts, as appropriate;</li><li>Independence: Potential conflict of interest should be taken into consideration in selecting these members;</li><li>Profile of Senior Members: The team of senior members should have a solid understanding of country processes;</li><li>Profile of Analysts: Analysts should have the capability to fully understand GF principles and procedures;</li><li>Identification of Candidates: Pool of pre-qualified candidates for Senior Members and Analysts is identified through partners, including WHO, UNAIDS and the World Bank. A list of these candidates is compiled by the Secretariat and each candidate submits a CV to the file for review. A proposed "reserve list" will be compiled based on this selection process;</li><li>Selection of Panel: The list of tentative candidates will be submitted to the Chair and Vice-Chair of the Board and the Chair and Vice-Chair of the PC. The selection of the Senior Members and Analysts of the independent panel shall be carried out by the Chair and Vice-Chair of the Board in consultation with the Chair and Vice-Chair of the PC;</li><li>Panel members (Senior members and contracted analysts) will be remunerated; and</li><li>The Secretariat will facilitate the process.</li></ul><p>12. The Independent Panel's scope of work will be based on the following principles:</p><ul><li>The objective of the external assessment will be to submit conclusions to the Board based on all information put forth by the CCM, PR, Secretariat and Board constituencies;</li><li>The analysis shall include a chronology of information provided, a typology of the content and an analysis of the source and flow of information;</li><li>The assessment shall take into consideration the different arguments analyzing how they refer to each other, highlighting areas of agreement and disagreement, and defining the areas which have not been previously addressed by the parties involved; and</li><li>The Independent Panel shall report to the Board no later than six weeks after receipt of the relevant information from the Secretariat.</li></ul><p>13. The final decision on making a funding commitment will be made at the next Board meeting. </p><p>14. In circumstances in which insufficient resources remain in Phase 1 to cover financing needs until any Board decision in the Phase 2 procedure can be operationalized, the Board authorizes the Secretariat to extend the terms of the grants by up to six months, and to provide bridge funding for such grants as appropriate. The Board authorizes the Secretariat to commit up to a maximum of one-half of the first year budget contained in the Request for Continued Funding in question for these purposes, which would be financed by utilizing the Phase 2 renewal funding of the proposal. The actual amount committed by the Secretariat would be based primarily on the performance and disbursement patterns in Phase 1.</p><p>15. For proposals for which the Board commits Phase 2 funds, a sufficient amount of assets to cover the full costs of the extension of the Grant Agreement must be deposited with the Trustee or readily available on demand prior to the Secretariat extending a Grant Agreement.</p><p>16. The Technical Reference Group (TERG) will regularly review and report on the soundness of the Phase 2 review and decision process to the Board through the Portfolio Committee. </p><p>17. The Phase 2 decisions will typically be taken based on recommendations that are made 20 months after the Program Starting Date (exceptions could include for situations of force majeure). The decision may be taken earlier in cases of (i) accelerated implementation; or (ii) severe exchange rate fluctuations.</p><p>18. These procedures for the Board commitment of funds for Phase 2 are subject to a time-limited trial period. The Board asks the Portfolio Committee to review these procedures or should adopt an alternative set of procedures. Based on these recommendations the Board will reconsider the procedures at the Thirteenth Board Meeting.</p>
2005-12-16 B12 GF/B12/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twelfth Board Meeting (GF/B12/1, Rev. 3) is approved.
2023-03-27 B48 GF/B48/EDP07 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B48/ER08(“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2023-03-27 B48 GF/B48/EDP09 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B48/ER08 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>
2023-03-24 B48 GF/B48/EDP06 Approval of the Report of the 48th Board Meeting Approval of the Report of the 48th Board Meeting
<p>The Report of the 48th Board Meeting was approved by the Board of the Global Fund via electronic vote on 24th March 2023 (GF/B48/EDP06).</p>
2023-02-13 B48 GF/B48/EDP05 Appointment of Replacement Members on the Strategy Committee and on the Ethics and Governance Committee Appointment of Replacement Members on the Strategy Committee and on the Ethics and Governance Committee
<p>The Board approves the appointment of:</p> <ol> <li>Anne-Claire AMPROU, representing the France Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Ina von Frantzius and Louis da Gama, to serve in their personal capacity as voting members of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of their successors.</li> </ol>
2022-12-16 B48 GF/B48/EDP02 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B48/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-12-16 B48 GF/B48/EDP03 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B48/ER02(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-12-16 B48 GF/B48/EDP01 Revisions to the Honorarium Framework Revisions to the Honorarium Framework
<p>Based on the recommendation of the Ethics and Governance Committee, the Board:</p> <ol> <li>Approves the revisions to the Honorarium Framework of the Global Fund set out in Annex 4 to GF/B48/ER01; and,</li> <li>Notes that the revisions regarding the leadership of the Board’s Standing Committees (“Committee Leaderships”) shall enter into force upon the approval of this decision point, and that Committee Leaderships shall be eligible to receive, from May 2022, the honoraria provided for in the Honorarium Framework as revised pursuant to this decision; and,</li> <li>Notes that the revisions regarding the Independent Evaluation Panel shall enter into force on 1 January 2023.</li> </ol>
2022-11-16 B48 GF/B48/DP05 2023 Work Plan and Budget Narrative and the 2023 Operating Expenses Budget 2023 Work Plan and Budget Narrative and the 2023 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee (AFC), and the recommendation of the Secretariat to supplement the AFC’s recommendation, the Board approves the following:</p> <ol type="i"> <li>the 2023 Work Plan and Budget Narrative, as set forth in GF/B48/02A – Revision 1; and</li> <li>the 2023 Operating Expenses Budget in the amount of US$ 340 million (comprising (i) PART A Secretariat Operating Expenses of US$ 272 million, which includes US$ 16.5 million for the Office of the Inspector General’s 2023 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US$ 68 million), as set forth in GF/B48/02A – Revision 1.</li> </ol>
2022-11-16 B48 GF/B48/DP03 Extension of the COVID-19 Response Mechanism (C19RM) Extension of the COVID-19 Response Mechanism (C19RM)
<ol> <li>The Board acknowledges that C19RM was established to support (i) COVID-19 control and containment interventions, (ii) COVID-19 risk-related mitigation measures for programs to fight HTM, and (iii) expanded reinforcement of key aspects of health systems, and recognizes that C19RM requests and awards through the end of 2021 largely focused on the acute response to the COVID-19 pandemic;</li> <li>The Board acknowledges that the pandemic is evolving, and that recipient priorities are correspondingly shifting towards longer-term investments in health systems’ infrastructure and capacities for pandemic preparedness and response;</li> <li>To facilitate careful planning of such investments, including alignment with potential funding requests for the Seventh Replenishment grant cycle, the Board approves that C19RM funds may be awarded through 30 June 2023, with opportunity for subsequent C19RM portfolio optimization awards;</li> <li>To enable maximization of impact from investments in resilient and sustainable systems for health, the Board approves that any C19RM funds may be implemented through 31 December 2025 and will finance interventions across the Sixth and Seventh Replenishment periods – acknowledging that the Secretariat will continue to ensure rapid deployment of funds and quality implementation notwithstanding this deadline;</li> <li>The Board approves that C19RM funding requests will continue to be developed through appropriate, multi-sectoral consultation and fully inclusive decision-making, which must engage communities and civil society, and which must ensure coordination with the national COVID-19 response coordinating body or provide other evidence of alignment with the national approach to COVID-19 response in the absence of such a coordinating body;</li> <li>The Board approves that the Secretariat may use up to 4.5% of C19RM funds, representing an increase from the prior ceiling of 3%, to cover additional management and operating costs related to extension of C19RM; and</li> <li>The Board agrees that all other parameters of C19RM under GF/B46/EDP06 remain unchanged.</li> </ol>
2022-11-16 B48 GF/B48/DP04 Sources and Uses of Funds for the 2023–2025 Allocation Period Sources and Uses of Funds for the 2023–2025 Allocation Period
<ol> <li>Based on the recommendation of the Audit and Finance Committee (AFC), as presented in GF/B48/03A – Revision 1, the Board approves US$ 12.903 billion as sources of funds for allocation for the 2023-2025 allocation period. The total amount of sources of funds for allocation comprises, in accordance with the Comprehensive Funding Policy set forth in Annex 1 to GF/B36/02 – Revision 1 and approved through decision point GF/B36/DP04: <ol type="i"> <li>US$ 13.678 billion, derived from the announced replenishment results for the Seventh Replenishment, net of adjustments;</li> <li>US$ 0.250 billion of forecasted unutilized funds from the 2020-2022 allocation period; and</li> <li>a deduction of US$ 1.025 billion of forecasted aggregate operating expenses for the 2023-2025 allocation period.</li> </ol> </li> <li>Based on the recommendation of the Secretariat to supplement the recommendation of the Strategy Committee, as presented in GF/B48/03A – Revision 1, the Board approves the use of an additional US$ 0.200 billion for catalytic investments for the 2023-2025 allocation period, bringing the total amount, from sources of funds for allocation, for catalytic investments for the 2023-2025 allocation period to US$ 0.400 billion, to be made available for the priorities and associated costs set forth in Annex 1 of GF/B48/03A- Revision 1, and based on the recommendation of the Secretariat, the Board approves updating the delegated authority to the Secretariat established in paragraph 7 of GF/B47/DP06 so that the Secretariat may increase the amount of funding available for the Emergency Fund by up to an additional US$ 0.020 billion, using funding approved as available by the AFC for portfolio optimization.</li> <li>Additionally, based on the recommendation of the AFC and to help ensure the maximum amount of impact and use of funds over the 2023-2025 allocation period, the Board requests that the Secretariat include an additional US$ 0.625 billion in the amount used to determine country allocations pursuant to the allocation methodology for the 2023-2025 allocation period in accordance with decision point GF/B47/DP05 (Allocation Methodology).</li> <li>Accordingly, the Board approves that the amount of sources of funds for country allocations for the 2023-2025 allocation period is US$ 12.503 billion, to which US$ 0.625 billion will be added prior to determining the country allocation, for a total of US$ 13.128 billion, to be used in accordance with the Allocation Methodology and decision point GF/B47/DP05.</li> </ol>
2022-11-15 B48 GF/B48/DP01 Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 48th Board Meeting (GF/B48/01 - Revision 2) is approved.</p>
2022-11-15 B48 GF/B48/DP02 Approval of the Rapporteur Approval of the Rapporteur
<p>Erika Satterwhite from the Private Sector Constituency is designated as Rapporteur for the 48th Board Meeting.</p>
2022-11-17 B48 GF/B48/DP06 2023-2028 M&E Framework, KPI Framework and Multi-Year Evaluation Calendar 2023-2028 M&E Framework, KPI Framework and Multi-Year Evaluation Calendar
<p>The Board acknowledges and appreciates the extensive work across the partnership to incorporate past lessons into development of an improved holistic approach to Monitoring and Evaluation (M&amp;E) for the new Strategy. The Board notes the recommendations of the Strategy Committee (SC) and Audit and Finance Committee (AFC), as set forth in GF/B48/04 and:</p> <ol type="i"> <li>Endorses the components of the M&amp;E Framework as described in GF/B48/04 Annex 1;</li> <li>Approves the KPI Framework (including each Key Performance Indicator), as set forth in GF/B48/04 Annex 2;</li> <li>Approves the topics for the Multi-Year Evaluation Calendar 2023-2028 as set forth in GF/B48/04 Annex 3; and</li> <li>Delegates authority to the SC to approve changes to the Multi-Year Evaluation Calendar in 2023, following a request by the Chief Evaluation and Learning Officer and advice from the Independent Evaluation Panel.</li> </ol>
2022-11-17 B48 GF/B48/DP07 Advancement of Non-Global Fund-Financed Procurement Utilizing the Pooled Procurement Mechanism and wambo.org Advancement of Non-Global Fund-Financed Procurement Utilizing the Pooled Procurement Mechanism and wambo.org
<p>The Board:</p> <ol> <li>recalls its approval of a pilot for procurement of health and non-health products via wambo.org for eligible buyers using domestic and other non-Global Fund sources of funding as detailed in GF/B37/DP09 and GF/B42/DP05; and its request that the Secretariat include the results of an evaluation of the pilot in the development of a strategy for future advancement of wambo.org to be presented for Board approval no later than November 2022;</li> <li>notes the Technical Evaluation Reference Group (“TERG”) evaluation findings and recommendations concerning the pilot discussed at the 18th meeting of the Strategy Committee; and</li> <li>understands that the Secretariat will explore appropriate solutions for the challenges raised by the TERG evaluation and continue to facilitate access to products through wambo.org, while in parallel working to strengthen the capacities of regional and national procurement channels to ensure value for money and options for access to quality-assured heath products for countries.</li> </ol> <p>Therefore, based on the Strategy Committee’s recommendation and in support of the proposed approach for non-Global Fund financed procurements, as detailed in GF/B48/05, the Board approves:</p> <ol> <li>The Secretariat’s continued operationalization of the current scope of non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for products and services as they become available on wambo.org;</li> <li>Removing any cap related to non-Global Fund-financed orders; and</li> <li>Incorporating reporting on the non-Global Fund-financed procurement mechanism into annual updates to the Board on NextGen Market Shaping implementation</li> </ol>
2006-02-14 B12 GF/B12/EDP03 Approval of Phase 2 Funding Recommendations February 2006 Approval of Phase 2 Funding Recommendations February 2006
#
2005-12-16 B12 GF/B12/DP03 Approval of Report of the Eleventh Board Meeting Approval of Report of the Eleventh Board Meeting
The report of the Eleventh Board Meeting (GF/B12/2) is approved, as amended at the Twelfth Board Meeting.
2005-12-16 B12 GF/B12/DP09 Resource Mobilization Resource Mobilization
The Board requires that resource mobilization and the replenishment process be included as an agenda item at each Board meeting, and that the Finance and Audit Committee will develop a resource mobilization strategy to be discussed at the Thirteenth Board meeting.
2006-01-17 B12 GF/B12/EDP01 Approval of Phase 2 Funding Recommendations January 2006 Approval of Phase 2 Funding Recommendations January 2006
#
2005-12-16 B12 GF/B12/DP11 Phase 2 Decision-Making Policies and Procedures Phase 2 Decision-Making Policies and Procedures
The Board approves the document entitled "Phase 2 Decision-Making Policies and Procedures" included as Annex 1 to the Report of the Portfolio Committee (GF/B12/6) and as amended at the 12th Board Meeting and revokes all previously approved versions of such document. 
2009-05-06 B19 GF/B19/DP18 Quality Assurance Review of the Status of Pharmaceutical Products Other than anti-Retroviral, anti-Malaria and anti-Tuberculosis Medicines Quality Assurance Review of the Status of Pharmaceutical Products Other than anti-Retroviral, anti-Malaria and anti-Tuberculosis Medicines
The Board requests the Portfolio Committee (PC) to oversee the Secretariat's study of the quality assurance status of pharmaceutical products other than anti-retroviral, anti-malaria and anti-tuberculosis medicines. The Secretariat shall present the findings of the first phase of the study to the PC at its 12<sup>th</sup> Meeting in September 2009. Based on these findings, the PC may permit the Secretariat to undertake the later stages of the study to explore the possibility of establishing a quality assurance policy for these products. The Board requests the PC to update the Board on the progress of the study at the Board's first meeting in 2010.
2018-05-09 B39 GF/B39/DP03 Approval of the Revised Eligibility Policy Approval of the Revised Eligibility Policy
<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 1 to GF/B39/02 (the “Revised Eligibility Policy”).</li> <li>Accordingly, the Board: <ol type="i"> <li>Acknowledges that this decision point and the Revised Eligibility Policy supersede the decision point GF/B35/DP07 and the previous Eligibility Policy as set forth in Annex 2 to GF/B35/06 - Revision 1 (the “Previous Eligibility Policy”); and</li> <li>Notes that notwithstanding paragraph 2.i of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2017-2019 allocation period.</li> </ol> </li> </ol>
2018-08-09 B39 GF/B39/EDP08 Terms of Reference of the Board Leadership Nomination Committee and Corresponding Amendments to the Core Governance Documents Terms of Reference of the Board Leadership Nomination Committee and Corresponding Amendments to the Core Governance Documents
<ol> <li>The Board recalls its decision GF/B39/DP12 on the strengthening of the Board Leadership selection process.</li> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Terms of Reference of the Board Leadership Nomination Committee and the corresponding amendments to the Operating Procedures of the Board and Committees of the Global Fund and the Charter of the Ethics and Governance Committee as provided for in Annexes 4, 5, and 6 of GF/B39/ER07.</li> </ol>
2018-07-04 B39 GF/B39/EDP05 Appointment of a New Member to the Strategy Committee Appointment of a New Member to the Strategy Committee
<p>1. The Board approves the appointment of Ambassador Stephanie Seydoux, representing the French Constituency, as a voting member of the Strategy Committee (“SC”) for a term that will expire in May 2020, or until the appointment of her successor.</p>
2010-04-13 B20 GF/B20/EDP16 Approval of Rolling Continuation Channel Wave 8 Proposals Approval of Rolling Continuation Channel Wave 8 Proposals
<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposals recommended for funding by the Technical Review Panel (TRP) as ‘Category 2’ which are listed in Annex 1 to the Report of the TRP and the Secretariat on Funding Recommendation for Wave 8 Rolling Continuation Channel Proposals (the “Wave 8 RCC Report”). The Board approves funding for up to three years for each proposal (indicated as “Total 3 Years” in Annex 1 to the Wave 8 RCC Report). The Board’s approval is made with the clear understanding that the grant amounts requested are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts. For <br/>further clarity, this decision is subject to the revised Comprehensive Funding Policy approved at the Twentieth Board meeting.</li><li>The applicants whose proposals are recommended for funding as ‘Category 2’ shall: <ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and</li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment.</li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as ‘Category 3A’ as indicated in Annex 1 to the Wave 8 RCC Report, however such applicants are strongly encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the final resubmission wave of Rolling Continuation <span style="font-size: 12px; line-height: 1.5;">Channel review.</span></li><li>The Board declines to approve for funding proposals categorized by the TRP as ‘Category 3B’ as indicated in Annex 1 to the Wave 8 RCC Report, however such applicants are encouraged to resubmit the proposal through the Rounds-Based Channel following major revision.</li></ol>
2010-04-16 B20 GF/B20/EDP18 Approval of Phase 2 Funding for Togo Malaria Round 4 Approval of Phase 2 Funding for Togo Malaria Round 4
The Board acknowledges that the special condition upon which the Board approved the Togo Round 4 Malaria grant to the United Nations Development Programme (UNDP) of the delivery at the end of year 3 of a detailed assessment of program progress and performance was fulfilled later than anticipated in the grant agreement. Although the revised timeline for the program assessment has delayed confirmation that the condition has been fulfilled, in recognition of the subsequent improved program performance of the grant the Board decides to retrospectively approve continued funding for years 4 and 5 of the Togo Round 4 Malaria grant (TGO-405-G05-M).
2010-02-11 B20 GF/B20/EDP11 Approval of Funding for Continuity of Services for Bolivia HIV Round 3, Comoros HIV Round 3, and Suriname HIV Round 3 Approval of Funding for Continuity of Services for Bolivia HIV Round 3, Comoros HIV Round 3, and Suriname HIV Round 3
<p>The Board approves additional funding for the Continuity of Services for the proposals listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p><p>See attached tabledetailing total recommended funding amount<sup>6</sup> of US$ 1,579,508 for the following grants: BOL-307-G07-H ; COM-304-G02-H ; SUR-305-G01-H</p>
2009-11-11 B20 GF/B20/DP25 Approval of AMFm Phase 1 Applications Approval of AMFm Phase 1 Applications
<p>The Board approves those AMFm Phase 1 applications recommended for approval by the Technical Review Panel (TRP) as 'Category 1' and 'Category 2', as listed in Annex 1 to the Report of the Technical Review Panel and Secretariat on AMFm Applications (GF/B20/10), subject to paragraphs 2-3 below. The Board's approval is for re-programmed and new grant funding (as the case may be) for a full two<b>-</b>year period for each AMFm Phase 1 application and is not subject to prioritization.</p><p>The applicants whose applications are recommended for approval as 'Category 2' shall:</p><p>a. provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than four weeks after receipt of notification in writing by the Secretariat of the Board's funding decision; and</p><p>b. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than 31 January 2010.</p><p>For those applications recommended for approval as 'Category 2', if the TRP clarification process is not concluded to the satisfaction of the TRP by the deadline stipulated in paragraph b above, the AMFm application in its entirety will be deemed not approved.</p><p>The Board declines to approve for funding those applications recommended by the TRP as 'Category 3' as indicated in Annex 1 in GF/B20/10. </p>
2009-11-11 B20 GF/B20/DP13 Quality Assurance Policy for Pharmaceutical Products Quality Assurance Policy for Pharmaceutical Products
<p>The Board recognizes that, as described in the Portfolio and Implementation Committee's Report to the Board (GF/B20/5), there are challenges with identifying sources for certain essential and long-established multi-source treatments that meet the requirements of the Global Fund's revised Quality Assurance Policy for Pharmaceutical Products ("QA Policy"). In order to avoid disruption to treatment of patients, but without compromising the fundamental quality assurance principles of the QA Policy, the Board therefore decides to revise the QA Policy to expand the eligibility criteria for a risk/benefit review of products by the Expert Review Panel (ERP) by adding the following interim provision at the end of paragraph 13 of the QA Policy: </p><p>"Provided that the criterion in paragraph (ii) above is met, certain multi-source [8] FPPs for malaria and first-line tuberculosis treatment that do not meet the criteria in paragraph (i) above are also eligible for review by the ERP for associated potential risks/benefits in accordance with paragraph 10 of this Policy. The list of ERP-recommended FPPs that is made publicly available will indicate which of the ERP-recommended FPPs were eligible for review as a result of this paragraph. </p><p>Footnote 8: For these purposes, "multi-source" means a pharmaceutical product for which the monograph of the finished dosage form was published in the International, U.S. or U.K. Pharmacopeia before 10 October 2002"</p><p>The Board requests the Market Dynamics and Commodities Committee to review this amendment to the QA Policy, with special attention to the working, transparency and reporting requirements of the ERP review process, and to report to the Board at its last meeting in 2010.</p><p>The Board notes that it will take some time for dossiers for these multi-source FPPs to be prepared and submitted to the next set of ERP reviews and that an interim exception is necessary to avoid disruption in essential treatment. The Board decides that, on an exceptional basis and for the period up to 31 December 2010 only, grant funds may be used to procure certain multi-source FPPs for malaria and first-line tuberculosis treatment, provided that:</p><p>a. there are no other FPPs for that product formulation available (as defined in the QA Policy) that are WHO-prequalified or SRA-authorized or ERP-recommended;</p><p>b. the site at which such FPP is being manufactured must, at the time of the procurement, be in compliance with the relevant GMP standards as verified by the WHO Prequalification Program, or an SRA or a regulatory authority participating in PIC/S; </p><p>c. the FPP has been selected for procurement by relevant UN procurement agencies; and</p><p>d. the notification/confirmation and testing processes described in paragraphs 9 and 31 of the QA Policy will apply to such procurement.</p><p>The Board requests the MDC to consider, as a matter of urgency, contingency plans regarding the recently notified disruption of funding for certain life-saving medicines (e.g. artemisinin intra-rectal and injectable medicines) in situations where no FPPs for such medicines meet the criteria in paragraph 7 of the QA Policy and to make recommendations to the Board at the earliest opportunity.</p>
2009-11-11 B20 GF/B20/DP26 National Strategy Applications First Learning Wave Follow-up National Strategy Applications First Learning Wave Follow-up
<p>The Board:</p> <p>i. acknowledges its previous decisions (GF/B15/DP17 and GF/B18/DP20) concerning the need for and value of a National Strategy Applications ("NSAs") procedure; and</p> <p>ii. recognizes the ongoing learning process with partners from the launch of the First Learning Wave of NSAs ("FLW").</p> <p>Therefore, the Board requests the Secretariat to prepare appropriate in-depth analyses and recommendations, taking into account:</p> <p>i. the feedback from the Technical Review Panel and other relevant partners on the FLW; and</p> <p>ii. the new architecture approved at this Board meeting;</p> <p>for further investment on the basis of NSAs; and present it to the Policy and Strategy Committee for further consideration at its next meeting.</p>
2009-11-11 B20 GF/B20/DP22 Approach for Setting the Office of the Inspector General (OIG) Annual Audit Plan Approach for Setting the Office of the Inspector General (OIG) Annual Audit Plan
The Board notes that the approach adopted by the OIG to develop its annual audit plan is an important strategic matter that reflects the Global Fund's risk management policy. The Board approves the approach for setting the annual OIG audit plan as described in Annex C of the OIG Progress Report (GF/B20/14).
2009-11-11 B20 GF/B20/DP32 Youth Leadership Youth Leadership
<p>The Board emphasizes the urgency of providing more room for youth leadership and involvement in the response to HIV/AIDS, tuberculosis and malaria. The Board recognizes the diversity and special needs of young people and stresses the importance of protecting young people's health and human rights, especially for the 5.4 million young people who are living with HIV and the millions who are at risk, in particular young women and girls; but also those who are marginalized, including but not limited to young sex workers and people who use drugs; lesbian, gay, bisexual and transgender youth; and young migrants. </p><p>The Board asks constituencies and the Secretariat to consider how they can better include young people, facilitate youth-led action at global and national level and ensure that their ideas and perspectives are better reflected in the work of the Global Fund and the Board and report back to the Board within 2 years.</p>
2009-11-11 B20 GF/B20/DP19 Secretariat Office Space Secretariat Office Space
<p>The Board notes the concepts set out in the Letter of Intent (GF/FAC13/20, Annex 2) to be signed with a property developer, and requests the Secretariat to engage in further negotiations for the construction of a building to be leased by the Secretariat. </p><p>The Board notes the importance for the Secretariat to identify a suitable entity that, at the time the Secretariat signs a lease agreement, provides a binding commitment to share the rent for space in this office building, in the case where the building contains more space than what would be necessary to house the Fund at that time. The Board also encourages the Secretariat to minimize the Fund's financial exposure for the costs of the building prior to occupancy, and to provide additional information about interim arrangements between the date of the expiration of the current lease and the expected date of occupancy of the new space. </p><p>The Board requests the Finance and Audit Committee to oversee the arrangements for the Secretariat's future office space.</p>
2009-11-11 B20 GF/B20/DP14 2010 Operating Expense Budget 2010 Operating Expense Budget
The Board approves the 2010 Operating Expenses Budget in the amount of USD 274 million as set out in Annex 1 to the Report of the Finance and Audit Committee (GF/B20/6).
2010-02-11 B20 GF/B20/EDP10 Approval of Phase 2 Funding for February 2010 Approval of Phase 2 Funding for February 2010
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy <span>(GF/B20/DP9).</span><sup>5</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 53,026,371 for the following grants: BTN-607-G03-H ; BTN-607-G04-T ; IND-607-G06-M ; ZIM-509-G10-H ; ZIM-509-G08-T</p>
2009-11-11 B20 GF/B20/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twentieth Board Meeting (GF/B20/1, Revision 2), as amended, is approved.
2009-11-11 B20 GF/B20/DP12 Review of CCM Guidelines Review of CCM Guidelines
<p>The Board delegates authority to the Portfolio and Implementation Committee (PIC) to approve changes to the "Guidelines and Requirements for Country Coordinating Mechanisms". </p><p>However, if the PIC considers that material changes to any of the six CCM eligibility requirements are needed, the PIC will make a recommendation to the Board for approval.</p>
2009-11-11 B20 GF/B20/DP23 Amendments to the Office of the Inspector General (OIG) Charter and Disclosure Policy Amendments to the Office of the Inspector General (OIG) Charter and Disclosure Policy
The Board approves the amendments to the Charter and Terms of Reference of the Office of the Inspector General and the Policy for Disclosure of Reports Issued by the Inspector General as set out in the Annexes 2 and 3 of the Report of the Finance and Audit Committee to the Board (GF/B20/6).
2009-11-11 B20 GF/B20/DP15 Endorsement of the Risk Management Framework Endorsement of the Risk Management Framework
The Board endorses the Risk Management Framework of the Global Fund as set out in Attachment 3 to the Finance and Audit Committee Report to the Board (GF/B20/6).
2009-11-11 B20 GF/B20/DP08 Partners Constituency Committee Membership Partners Constituency Committee Membership
<p>The Board amends the Committee Rules and Procedures, Section C. paragraph 1 a. and b. as follows:</p><p>C. Size</p><p>Committees will be limited to a maximum membership as follows:</p><p>a. Policy and Strategy: 20 members (plus one representative of each of the World Bank, the World Health Organization, the Partners constituency and UNAIDS in a consultative, non-voting role)</p><p>b. Portfolio and Implementation: 12 members (plus one representative of each of UNAIDS, the Partners constituency and the World Health Organization in a consultative, non-voting role).</p>
2009-11-11 B20 GF/B20/DP24 AMFm Implementation AMFm Implementation
<p>The Board refers to its earlier decisions regarding the Affordable Medicine Facility - malaria ("AMFm") and clarifies its intent that the Global Fund will only expand from Phase 1 (the pilot phase) of AMFm to a global scale-up on the basis of evidence gathered during the pilot phase that the initiative is likely to achieve its four stated objectives: (i) increased ACT affordability, (ii) increased ACT availability, (iii) increased ACT use, including among vulnerable groups, and (iv) "crowding out" oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine by gaining market share. The Board further clarifies that it will consider evidence that the AMFm will achieve these four objectives more cost-effectively than other financing models that aim to achieve similar objectives solely or principally through the expansion of public sector services (i.e., public health facilities and community health workers only).</p> <p>The Board requests the AMFm Ad Hoc Committee to review the findings of the independent evaluation of AMFm Phase 1 against the four objectives and to make a recommendation to the Board at its first meeting in 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line in countries participating in the pilot. The Board notes that, in addition, it may decide to extend the pilot phase beyond its first meeting in 2012, if necessary. Any such extension would be subject to available funding and the Board reiterates that AMFm Phase 1 is currently funded as a 24-month program and countries should plan accordingly.</p> <p>The Board decides that, in addition to the AMFm 'identifier', all AMFm co-paid ACTs should bear a logo that is universal for all countries participating in AMFm. During implementation of AMFm Phase 1, based on lessons learned and discussions with participating countries and with due regard to the independent evaluation, other donors should be encouraged and permitted to use the logo on ACTs procured directly by such donors, provided that such ACTs meet the Global Fund's quality assurance policy. The Board requests RBM to work with participating countries, donors and all partners to coordinate the progress towards a universal logo for all quality-assured ACTs.</p> <p>The Board approves the revised AMFm Phase 1 Policy attached as Annex 1 to the Report of the AMFm Ad Hoc Committee to the Board (GF/B20/7).</p>
2010-04-16 B20 GF/B20/EDP17 Approval of Phase 2 Funding for April 2010 Approval of Phase 2 Funding for April 2010
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).</p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount<sup>9</sup> of US$ 55,170,462 for the following grants: BUR-708-G07-M ; SAF-607-G06-H ; TNZ-607-G09-T ; ZAN-607-G05-H</p>
2010-01-28 B20 GF/B20/EDP09 Approval of Phase 2 Funding for January 2010 Approval of Phase 2 Funding for January 2010
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>4</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 56,401,349 for the following grants: CAM-607-G10-M ; MAW-607-G01-H ; HL-607-G08-H ; SLE-607-G04-H</p>
2009-11-11 B20 GF/B20/DP11 Approval of Round 9 Proposals and National Strategy Applications Approval of Round 9 Proposals and National Strategy Applications
<p>1. The Board approves, in principle, all the Round 9 proposals and National Strategy Applications (NSAs) recommended for funding by the Technical Review Panel (TRP).</p> <p>2. The Board approves for funding, subject to Decision GF/B20/DP9, for an initial two years those Round 9 proposals and NSAs recommended for funding by the TRP as 'Category 1' and 'Category 2' as listed in LIST A in GF/B20/18, subject to paragraphs 4 to 5 below.</p> <p>3. The remaining Round 9 proposals and NSAs recommended for funding by the TRP as 'Category 2B' will be approved for funding for an initial two years (subject to Decision GF/B20/DP9) and paragraph 4 and 5 below):</p> <p>a. through Board confirmation by email (or, if appropriate, at the Twenty-First Board Meeting), as funds become available under the terms of the Comprehensive Funding Policy; and</p> <p>b. based on the composite ranking of such proposals in compliance with the Comprehensive Funding Policy.</p> <p>4. The applicants whose proposals are recommended for funding as 'Category 1' (as indicated in Annex 1 of GF/B20/9 and Annex 1 of GF/B20/11) shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than eight weeks after the applicant's receipt of: </p> <p>a. notification in writing from the Secretariat of the Board's decision; or</p> <p>b. the findings of the independent budget review, in cases where the TRP has requested an independent budget review as part of the clarifications process.</p> <p>5. The applicants whose proposals are recommended for funding as 'Category 2', including the subset of proposals identified as 'Category 2B' (as indicated in Annex 1 of GF/B20/9, and Annex 1 of GF/B20/11), shall:</p> <p>a. provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than eight weeks after the applicant's receipt of :</p> <p>i. notification in writing by the Secretariat to the applicant of this Board decision; or</p> <p>ii. the findings of the independent budget review, in cases where the TRP has requested an independent budget review as part of the clarifications process; and</p> <p>b. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</p> <p>6. The Board declines to approve for funding those proposals recommended by the TRP as 'Category 3' as indicated in Annex 1 of GF/B20/9 and Annex 1 of GF/B20/11. These applicants are encouraged to re-submit a proposal in a future funding round after major revision of the proposal. </p> <p>7. The Board declines to approve for funding those proposals recommended by the TRP as 'Category 4', as indicated in Annex 2 of GF/B20/9.</p> <p>8. The Board notes the TRP's request to have additional financial analysis support as part of the clarifications process and requests the Secretariat to make the necessary arrangements. </p>
2010-02-20 B20 GF/B20/EDP13 Approval of Round 9 Proposals (Category 2B) Approval of Round 9 Proposals (Category 2B)
<p>The Board refers to its Decision GF/B20/DP11 regarding approval of Round 9 proposals and approves for funding for an initial two years those Round 9 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals and as listed in the following table. Such approval is subject to the Comprehensive Funding Policy, satisfactory completion by the applicants of the Technical Review Panel (TRP) clarifications as set out in paragraph 5 of Decision GF/B20/DP11 and the measures associated with funding of Round 9 proposals and national strategy applications set out in Decision GF/B20/DP9.</p> <p>See attached tabledetailing total TRP recommended Phase 1 Upper Ceiling (2 years) funding amount of US$ 719,921,434 for the Category 2B grants.</p>
2009-11-11 B20 GF/B20/DP28 Translation and Interpretation of Governance Processes Translation and Interpretation of Governance Processes
<p>The Board stresses the need to ensure that Global Fund governance processes reflect the multi-lingual nature of both the organization and of its Board constituencies. To ensure these processes remain open and transparent to all constituencies it decides to adopt the measures outlined in GF/B20/4 Attachment 4, in an incremental manner, limited initially to two languages in addition to English.</p><p>The Board wishes to emphasize that in implementing this decision a pragmatic approach should be taken, with the provision of any increased interpretation and translation at the Board and committee level being based on a proactive needs assessment of Board and committee members, carried out by the respective Chair and Vice-Chair, prior to committee / Board meetings. </p>
2019-02-21 B40 GF/B40/EDP06 Approval of the Report of the 40th Board Meeting in Geneva Approval of the Report of the 40th Board Meeting in Geneva
<ol> <li>The Board approves the Report of the 40th Board Meeting, as set forth in GF/B40/19.</li> </ol>
2019-04-19 B40 GF/B40/EDP13 Decision on the Secretariat’s Recommendation on additional funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on additional funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER09 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-01-31 B40 GF/B40/EDP04 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B40/ER04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-04-29 B40 GF/B40/EDP14 Revision to the Charter of the Office of the Inspector General Revision to the Charter of the Office of the Inspector General
<p><span>Based on the recommendation of the Audit and Finance Committee, the Board approves the Charter of the Office of the Inspector General, as revised and set forth in Annex 1 to GF/B40/ER10.</span></p>
2019-05-02 B40 GF/B40/EDP15 Appointment of the Board Chair and Vice-Chair Appointment of the Board Chair and Vice-Chair
<p><span>The Board appoints Dr Donald Kaberuka as Chair of the Board and Lady Roslyn Morauta as Vice-Chair of the Board to each serve two-year terms, or until the appointment of their respective successors, starting from the adjournment of the 41<sup>st</sup> Board Meeting on 16 May 2019.</span></p>
2019-02-22 B40 GF/B40/EDP08 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER06 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-05-13 B40 GF/B40/EDP16 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B40/ER12 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-03-22 B40 GF/B40/EDP10 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER10 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2009-11-19 B20 GF/B20/EDP01 Approval of Phase 2 Funding for November 2009 Approval of Phase 2 Funding for November 2009
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>See attached tabledetailing total recommended funding amount of US$ 42,907,127 for the following grants: ZAR-506-G04-T ; ZAR-607-G05-T ; ERT-607-G05-M ; RWN-607-G08-H ; SYR-607-G01-T</p>
2018-11-15 B40 GF/B40/DP04 Private Sector Engagement Private Sector Engagement
<p>The Board:</p> <ol type="a"> <li>Recognizes the foundational concept of the Global Fund as an innovative public private partnership and the importance of the role of the private sector in the Global Fund’s resource mobilization strategy in providing both financial and non-financial resources to increase the scale and effectiveness of the Global Fund’s efforts to fight AIDS, tuberculosis and malaria;</li> <li>Acknowledges the need to expand engagement with the private sector and takes note of the revision, by the Secretariat, of the Framework on Private Sector Engagement (the “Secretariat PSE Framework”) to provide balanced and robust operational policies and procedures which guide the Secretariat’s engagement approach;</li> <li>Notes with appreciation the work undertaken by the Ethics and Governance Committee in overseeing and endorsing the Secretariat PSE Framework, and ensuring that a robust framework, which takes into account risk management and ethical and conflict of interest considerations, is in place to allow the Global Fund to continue to pursue appropriate and impactful engagement with the private sector; and</li> <li>Confirms the importance of the role played by the private sector in the Global Fund’s resource mobilization strategy in providing both financial and non-financial resources to increase the scale and effectiveness of the Global Fund’s efforts to fight AIDS, tuberculosis and malaria.</li> </ol>
2009-12-17 B20 GF/B20/EDP05 Approval of Phase 2 Funding for December 2009 Approval of Phase 2 Funding for December 2009
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>See attached tabledetailing total recommended funding amount of US$ 100, 337, 574 for the following grants: BUL-607-G02-T ; CUB-607-G02-H ; GEO-607-G06-H ; MOL-607-G03-H ; PKS-607-G06-T ; PKS-607-607-T ; PHL-607-G07-M ; TGO-607-G06-M ; TGO-607-G07-T ; VTN-607-G04-H ; VTN-607-G05-T</p>
2010-03-01 B20 GF/B20/EDP14 Membership of Board Committees Membership of Board Committees
The Board approves the membership of the Board Committees as set out in Annex 1 (Revision 1) attached to this decision. The members of each Committee are appointed for the period from the date of this decision until the adjournment of the first Board meeting of 2011.
2009-11-11 B20 GF/B20/DP18 Delegated Authority for the Global Fund Provident Fund Delegated Authority for the Global Fund Provident Fund
The Board delegates its authority to the Finance and Audit Committee to deal with all matters related to the Global Fund Provident Fund.
2009-11-19 B20 GF/B20/EDP02 Approval of Continuity of Services for Haiti TB Round 3 Approval of Continuity of Services for Haiti TB Round 3
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p> <p>See attached tabledetailing total recommended funding amount of 413,096 US$ for the following grant: HTI-304-G04-T</p>
2010-03-11 B20 GF/B20/EDP15 Approval of Phase 2 Funding for March 2010 Approval of Phase 2 Funding for March 2010
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy <span>(GF/B20/DP9).</span><sup>7</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount<sup>8</sup> of US$ 56,930,178 for the following grants: CIV-607-G07-T ; ETH-607-G06-T ; EGY-608-G03-H ; GNB-607-G04-M ; MKD-708-G03-H ; SRL-607-G09-H ; SRL-607-G07-T ; ZIM-509-G09-M</p>
2009-11-11 B20 GF/B20/DP07 Effectively Engaging Implementing Board Constituencies in Governance Processes Effectively Engaging Implementing Board Constituencies in Governance Processes
<p>The Global Fund's constituency based governance model is core to the organization's identity as a public private partnership. The Board reiterates its support for this model and stresses that its effective functioning requires active and informed engagement by all constituencies. </p><p>To further facilitate the engagement of the Board constituencies of the implementing voting group in the Global Fund's governance processes, the Board decides to make available, on an annual basis, funds to these constituencies for communication, meeting, travel and staff costs incurred for intra-constituency functions, as specified in the Board Constituency Funding Policy (GF/B20/4 Annex 3).</p><p>The Board decides that each implementing constituency application in accordance with paragraph 8 of GF/B20/4 Annex 3 should be limited to US$ 80,000 for 2010. Exceptions to this ceiling may be permitted by the Secretariat, in consultation with the Chair of the Policy and Strategy Committee, and within the overall funding ceiling approved by the Board.</p><p>The Board delegates oversight of the Board Constituency Funding Policy to the Policy and Strategy Committee and requests the Secretariat to provide that committee with periodic reports on its impact on constituency participation, particularly in view of possibilities for joint action with UNAIDS and other relevant partners in this area. The first such report to the PSC should be at its first meeting in 2011. </p>
2009-11-11 B20 GF/B20/DP29 Round 3 HIV Grant in Russian Federation Round 3 HIV Grant in Russian Federation
<p>The Board recognizes that:</p><p>i. the Round 3 Russian Federation HIV/AIDS grant to Open Health Institute entitled "Stimulating an Effective National Response to HIV/AIDS in the Russian Federation" (RUS-304-G01-H) (the "OHI Grant") expired on 31 August 2009;</p><p>ii. in addition to provision of treatment services, the OHI Grant has provided support for lifesaving prevention services for populations in the Russian Federation that are vulnerable to HIV/AIDS through the work of non-governmental organizations;</p><p>iii. under the current income eligibility policies of the Global Fund, the Russian Federation is not eligible for funding for HIV/AIDS funding; </p><p>iv. the income eligibility policies of the Global Fund will be reviewed by the Portfolio and Implementation Committee in 2010 for approval by the Board at its second meeting in 2010; and</p><p>v. the Russian Federation has contributed USD$ 225,852,403 to the Global Fund, and has supported other programs for HIV in Russia.</p><p>The Board recognizes the role of the Russian government leadership in developing efficient national policies and providing a long term, sustainable response to HIV, and calls on the Russian Federation to expand investment in these life-saving, evidence-based services to vulnerable populations.</p><p>In recognition of the emergency situation of the lifesaving prevention activities supported by the OHI Grant being discontinued, the Board approves:</p><p>a. an extension, on an extraordinary basis, to 31 December 2011 of the term of the OHI Grant (the "Extension Term"); and</p><p>b. continued emergency funding for lifesaving prevention services in an amount of up to USD$ 24 million for the Extension Term, in order to continue the same activities as currently being implemented under OHI Grant. </p><p>The Board requests that the Secretariat continues discussions with the government of the Russian Federation on the HIV epidemic in Russian and their role as a donor to the Global Fund. </p>
2009-11-11 B20 GF/B20/DP06 Memorandum of Understanding With Roll Back Malaria Memorandum of Understanding With Roll Back Malaria
The Board notes the Secretariat's continued focus on strengthening the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the revised memorandum of understanding with the Roll Back Malaria Partnership (the "RBM MoU") set out in Attachment 3 of the Policy and Strategy Committee's Report to the Board (GF/B20/4), and requests the Executive Director to finalize and sign the RBM MoU.
2009-11-11 B20 GF/B20/DP03 Approval of Report of the Nineteenth Board Meeting Approval of Report of the Nineteenth Board Meeting
The report of the Nineteenth Board Meeting (GF/B20/2, Revision 1) is approved.
2009-11-11 B20 GF/B20/DP21 Reports of the Office of the Inspector General Reports of the Office of the Inspector General
<p>The Board notes the reports of the Office of the Inspector General (OIG), in particular the OIG Report on Lessons Learned (TGF-OIG-09-002), and the Secretariat's response contained in such reports. The Board stresses the need to ensure that the response to the findings and recommendations of the OIG will be prioritized and fed into the overall planning and work of the Global Fund, including grant operations. </p><p>The Board notes that the Secretariat is responsible for monitoring and reporting on the progress made in following up on findings and recommendations of OIG reports to the Finance and Audit Committee (FAC). The OIG, in turn, separately provides assurance on the progress made to the FAC. The Board requests that these reports are provided to the Board at its 21<sup>st</sup> meeting and that the Secretariat also provides a report to the Board describing the process that is followed to address the findings and recommendations of the OIG reports, including (i) a description of the protocols on coordination between the OIG and the Secretariat and (ii) considerations on the roles of implementers, partners, CCMs and LFAs. </p>
2009-12-14 B20 GF/B20/EDP04 Global Fund Privileges and Immunities Global Fund Privileges and Immunities
<p>The Board recognizes the importance of States granting to the Global Fund such privileges and immunities as necessary for the effective exercise of its functions and efficient use of its resources. The Board recommends that States consider granting privileges and immunities to the Global Fund by:</p><ul><li>applying domestic legislation that specifically confers on the Global Fund status, capacities, privileges and immunities equivalent to those enjoyed by <span style="font-size: 12px; line-height: 1.5;">international organizations within their respective legal systems, and/or<br/><br/></span></li><li>adhering to the Agreement on Privileges and Immunities of the Global Fund to Fight AIDS, Tuberculosis, and Malaria set out in Attachment 1 - Revision 1 of the Policy and Strategy Committee’s Report to the Board (GF/B20/4), <span style="font-size: 12px; line-height: 1.5;">pursuant to Article 8 of that Agreement;</span></li></ul><p>and requests the Secretariat to report back to the Board periodically on what measures states have taken in response to this decision.</p>
2009-11-11 B20 GF/B20/DP10 Working Group to Manage the Tension Between Supply and Demand in a Resource-Constrained Environment Working Group to Manage the Tension Between Supply and Demand in a Resource-Constrained Environment
<p>The Board refers to its decision made at the Nineteenth Board Meeting establishing a working group to examine the tension between demand and supply in a resource-constrained environment (GF/B19/DP26) (the "Working Group").</p> <p>The Board commends the Working Group on its recommendations to the Board contained in its report (GF/B20/12) and endorses the broad lines of thought contained in the recommendations contained in the report. In particular, the Board notes that the measures outlined for Area B in the report need to be discussed by the Board and requests the Chair and Vice Chair of the Board to urgently establish the appropriate process, including some recommendations to the Board before the launch of the next Funding Round.</p> <p>The Board requests that this process takes forward the Working Group's effort to improve prioritization for funding amongst proposals. The Board recognizes that significant progress has been made and that further work is necessary to assist the Board to make difficult prioritization decisions.</p> <p>With reference to the Working Group's suggestions on the need for more sophisticated strategies, tools and mechanisms for identifying efficiencies in grant proposals and implementation, the Board requests the Chair and Vice Chair, together with appropriate committees, to make recommendations to the Board at its next meeting.</p> <p>This should specifically address key areas where efficiency gains can and should be made, including a focus on commodity pricing, procurement and supply chain management, optimizing country level collaboration and partnerships, as well as budgeting, planning and implementation processes in line with best practices in efficient and quality service delivery.</p>
2016-10-07 B35 GF/B35/EDP17 Appointment of Independent Committee Member Appointment of Independent Committee Member
1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Ethics and Governance Committee (the "EGC"), as set forth in GF/B35/ER13". <br/><br/>2. Accordingly, the Board approves the appointment of Joan Elise Dubinsky to serve as a non-voting independent member of the EGC with expertise in the area of ethics for a two-year term starting from the June 2016 initial meeting of the EGC, or until the appointment of her successor<br/><br/>3. In accordance with the EGC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to the individual appointed as an independent committee member under this decision point an annual amount of USD 13,500.
2016-06-03 B35 GF/B35/EDP03 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER03 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-04-27 B35 GF/B35/DP09 Challenging Operating Environments Policy Challenging Operating Environments Policy
<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Challenging Operating Environments Policy, as set forth in Annex 1 to GF/B35/03.</p>
2016-04-27 B35 GF/B35/DP10 Allocation Methodology 2017 - 2019 Allocation Methodology 2017 - 2019
<p>1.The Board notes:</p><p>a.Its decisions in September 2012 (GF/B27/DP07) and November 2012 (GF/B28/DP04) that established the principles and framework for the allocation-based funding model (the "Funding Model Principles");</p><p>b.Its decisions in October 2013 (GF/B29/EDP10 and GF/B29/EDP11) and March 2014 (GF/B31/DP06, GF/B31/DP07, GF/B31/DP08, GF/B31/DP09 and GF/B31/DP10) to define certain elements for the 2014 - 2016 allocation period that would be reviewed and refined, as appropriate, prior to the 2017 - 2019 allocation period (the "2014 - 2016 Elements"); and</p><p>c.Decisions by the Strategy, Investment and Impact Committee (the "SIIC") in October 2013, under authority delegated by the Board, to establish technical parameters for the 2014 - 2016 allocation period (GF/SIIC09/DP01) and the process for managing and awarding incentive funding and unfunded quality demand (GF/SIIC09/DP02) (the "Prior SIIC Decisions").</p> <p>2. Accordingly, based on the recommendations of the SIIC, as presented in GF/B35/05 - Revision 1, the Board:</p><p>a. Approves the allocation methodology presented in Annex 1 to GF/B35/05 - Revision 1 (the "Allocation Methodology");</p> <p>b. Acknowledges the technical parameters for the 2017 - 2019 allocation period, as presented in Annex 2 to GF/B35/05 - Revision 1 and approved by the SIIC at its 17<sup>th</sup>meeting in March 2016 (the "Technical Aspects"); and</p> <p>c. Affirms the restatement of core parts of the Funding Model Principles, as presented in Annex 3 to GF/B35/05 - Revision 1 (the "Affirmed Principles").</p> <p>3. Accordingly, the Board:</p><p>a. Requests the Strategy Committee to review and approve, at its June 2016 meeting, the method by which the Secretariat will apply and report on the qualitative-factor adjustment process;</p> <p>b. Requests the Secretariat to present the priorities, activities or initiatives, including associated costs, that could be funded as catalytic investments, for the Strategy Committee to review at its June 2016 meeting and recommend to the Board; and</p> <p>c. Acknowledges that the Allocation Methodology, Technical Aspects and Affirmed Principles shall apply for the 2017 - 2019 allocation period and supersede the Funding Model Principles, 2014 - 2016 Elements and Prior SIIC Decision.</p><p><br/></p>
2016-04-27 B35 GF/B35/DP05 2015 Annual Financial Report 2015 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Annual Financial Report, which includes the 2015 Consolidated Financial Statements that have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 1. </p>
2016-06-10 B35 GF/B35/EDP06 Appointment of a member of the Audit and Finance Committee Appointment of a member of the Audit and Finance Committee
The Board approves the appointment of Sanne Fournier-Wendes to serve as a non-voting member of the Audit and Finance Committee, representing the Partners Constituency, for a two-year term or until the appointment of her successor.
2016-08-03 B35 GF/B35/EDP12 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B35/ER10.
2016-06-09 B35 GF/B35/EDP04 Appointment of Independent Committee Members Appointment of Independent Committee Members
1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Audit and Finance Committee (the "AFC"), as set forth in GF/B35/ER04". 2. Accordingly, the Board approves the appointment of the following individuals to serve as non-voting independent members of the AFC listed below, in the areas of expertise listed by their name: i. Peter Maertens, audit ii. Jean-Michel Ferat, forensic investigation<br/>3. In accordance with the AFC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to each of the individuals serving as independent committee members an annual amount of USD 13,500.<br/>4. The Board notes each independent committee member appointed under this decision point shall begin their term on 9 June 2016 and serve for two years or until the appointment of their respective successor.
2016-04-27 B35 GF/B35/DP11 Change to the Composition of the Partners Constituency Change to the Composition of the Partners Constituency
<p>1. The Board notes that under its previous decision in May 2009 (GF/B19/DP11) to create a non-voting seat on the Board to represent the constituency of key partners whose mission is directly related to the Global Fund and who are not currently represented on the Board (the "Partners Constituency"), any key partner that wishes to be represented on the Global Fund Board through the Partners Constituency should make a formal request to the Board for their inclusion in the Partners constituency.</p> <p>2. The Board also notes that the Partnership for Maternal, Newborn &amp; Child Health ("PMNCH") have fully responded to the criteria for accepting new constituency members, developed by the Partners Constituency, and have received unanimous support from the current Partners Constituency Members to be incorporated into the Constituency.</p> <p>3. Based on the request submitted by the Partners Constituency, as outlined in GF/B35/27, the Board decides to invite the PMNCH to be a member of the Partners Constituency.</p>
2016-04-27 B35 GF/B35/DP07 Revised Eligibility Policy Revised Eligibility Policy
<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 2 to GF/B35/06 - Revision 1 (the "Revised Eligibility Policy").</p> <p>2.Accordingly, the Board: </p> <p>a.Acknowledges this decision point and the Revised Eligibility Policy supersede Board decision point GF/B30/DP05 and the previous Eligibility Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Previous Eligibility Policy"); and</p> <p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period. </p>
2016-04-27 B35 GF/B35/DP01 Appointment of Rapporteur Appointment of Rapporteur
<p>Siula Bulu from the Western Pacific Region constituency is designated as Rapporteur for the 35th Board Meeting.</p>
2016-05-27 B35 GF/B35/EDP02 Appointment of Committee Members Appointment of Committee Members
<p><b><i>1. The Board acknowledges the nominations for membership of the Board's Audit and Finance Committee (the "AFC"), Ethics and Governance Committee (the "EGC"), and Strategy Committee ("SC"), as set forth in GF/B35/ER02".</i></b> </p> <p><b><i>2. Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the Committees listed below, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>a. Audit and Finance Committee</i></b> </p> <p><b><i>i. Gregoire Lacoin, European Commission Constituency;</i></b> </p> <p><b><i>ii. Sylvie Bourdenet, France Constituency;</i></b> </p> <p><b><i>iii. Erika Satterwhite, Private Sector Constituency;</i></b> </p> <p><b><i>iv. Anthony Richard Garnett, United Kingdom Constituency;</i></b> </p> <p><b><i>v. Michael Ruffner, United States Constituency;</i></b> </p> <p><b><i>vi. Soltan Mammadov, Eastern Europe &amp; Central Asia Constituency;</i></b> </p> <p><b><i>vii. Thamer Al Hilfi, Eastern Mediterranean Constituency;</i></b> </p> <p><b><i>viii. Grace Rwakarema, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Sugata Ghosh Dastidar, South East Asia Constituency; and</i></b> </p> <p><b><i>x. Han Mengjie, Western Pacific Region Constituency.</i></b> </p> <p><b><i>b. Strategy Committee</i></b> </p> <p><b><i>i. Philippe Meunier, France Constituency;</i></b> </p> <p><b><i>ii. Heiko Warnken, Germany Constituency;</i></b> </p> <p><b><i>iii. Eiji Hinoshita, Japan Constituency;</i></b> </p> <p><b><i>iv. Lennarth Hjelmaker, Point Seven Constituency;</i></b> </p> <p><b><i>v. Kieran Daly, Private Foundations Constituency;</i></b> </p> <p><b><i>vi. Rico Gustav, Communities Constituency;</i></b> </p> <p><b><i>vii. Jorge Saavedra, Developing Country NGOs Constituency;</i></b> </p> <p><b><i>viii. Vinand Nantulya, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Joel Mayowa, West and Central Africa Constituency; and</i></b> </p> <p><b><i>x. LV Fan, Western Pacific Region Constituency.</i></b> </p> <p><b><i>c. Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>i. Sheikh Mubashar, WHO Constituency; and</i></b> </p> <p><b><i>ii. Melanie Renshaw, Partners Constituency.</i></b> </p> <p><b><i>d. Furthermore, the Board appoints Alexandru Cebotari to serve as a non-voting member of the Audit and Finance Committee</i></b> , <b><i>representing the World Bank, and notes that the remaining non-voting member of the Audit and Finance Committee that will represent one of the non-voting, ex-officio members of the Board will be subsequently appointed.</i></b></p> <p><b><i>3. Additionally, the Board approves the appointment of the following individuals, with their nominating Board constituency listed by their name, to serve in their personal capacity as voting members of the Ethics and Governance Committee:</i></b> </p> <p><b><i>a. Jacques Mader, Canada Switzerland Australia Constituency;</i></b> </p> <p><b><i>b. Sarah Boulton, United Kingdom Constituency;</i></b> </p> <p><b><i>c. Sandy Thurman, United States Constituency;</i></b> </p> <p><b><i>d. Jason Wright, Developed Country NGOs Constituency;</i></b> </p> <p><b><i>e. Archil Talakvadze, Eastern Europe &amp; Central Asia Constituency; and</i></b> </p> <p><b><i>f. Mirta Roses Periago, Latin America and Caribbean Constituency.</i></b> </p><p> <b><i>4. The Board notes each Committee Member appointed under this decision point shall begin their term upon approval of this decision point and serve for two years or until the appointment of their respective successor.</i></b></p>
2016-04-27 B35 GF/B35/DP03 Response to Office of the Inspector General 2015 Annual Opinion and Risk Management Report and Assurance Statement Response to Office of the Inspector General 2015 Annual Opinion and Risk Management Report and Assurance Statement
<p>1.The Board notes its review and discussion of the: </p><p>a.Office of the Inspector General 2015 Annual Opinion on Governance, Risk Management and Internal Controls of the Global Fund, as set forth in GF/B35/11 (the "OIG Annual Opinion"); and</p><p>b.Risk Management Report and Assurance Statement, as set forth in GF/B35/23.</p><p>2.Accordingly, the Board acknowledges that while in-country partnerships are in place and significant initiatives and measures have been implemented to improve programmatic, fiduciary and risk-management processes, immediate and heightened efforts are needed to accelerate progress and advance risk management systems and processes. </p><p>3.The Board requests the Secretariat to:</p><p>a. Present a detailed action plan to advance risk management and internal controls, with measurable and time-bound targets, and a report on progress to the Board in June 2016 through the standing committees that were established under Board decision point GF/B34/EDP07 (the "Standing Committees"); and</p><p>b. In the context of the differentiation initiative, review the business model in high-risk countries and present possible options to the Board after review by the Standing Committees at their second meetings in 2016.</p>
2016-04-27 B35 GF/B35/DP06 2015 Statutory Financial Statements 2015 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 2.</p>
2016-05-24 B35 GF/B35/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER01 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV to GF/B35/ER01 ("Table 2") isshortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09.</li> <li>Approves the reinvestment of within-allocation efficiencies as well as the additional incremental funding and implementation period recommended for Sudan malaria disease component and its constituent grant, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;</li> <li>Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-07-19 B35 GF/B35/EDP10 Exceptional Extension and Funding for Bosnia and Herzegovina HIV and TB Grants (Decision not approved) Exceptional Extension and Funding for Bosnia and Herzegovina HIV and TB Grants (Decision not approved)
<h3>Decision not approved.</h3>
2016-07-14 B35 GF/B35/EDP09 Approval of the Report of the 35th Board Meeting in Abidjan, Côte d’Ivoire Approval of the Report of the 35th Board Meeting in Abidjan, Côte d’Ivoire
The Board approves the Report of the 35th Board Meeting, as set forth in GF/B35/28 - Revision 1.
2016-07-08 B35 GF/B35/EDP07 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/><br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1a of Section IV to GF/B35/ER07 ("Table 1a");<br/><br/>2. Approves the reinvestment of within-allocation efficiencies for the Iran HIV grant and its resultant total program budget, as listed in Table 1b of Section IV to GF/B35/ER07;<br/><br/>3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>4. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for (a) Ghana malaria, (b) Mozambique HIV, (c) Tanzania HIV and (d) Uganda malaria disease components, and each component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br/><br/>7. Approves the additional incremental funding and implementation period recommended for Zimbabwe HIV disease component, being an Early Applicant grant, as listed in Table 3, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br/><br/>8. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>9. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-04-27 B35 GF/B35/DP04 The Global Fund Strategy 2017 – 2022: Investing to End Epidemics The Global Fund Strategy 2017 – 2022: Investing to End Epidemics
<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Global Fund Strategy 2017 - 2022: Investing to End Epidemics, as presented in Annex 1 to GF/B35/02- Revision 1. </p>
2016-10-07 B35 GF/B35/EDP18 Appointment of a Member of the Strategy Committee Appointment of a Member of the Strategy Committee
<ol start="1" type="1"><li>The Board approves the appointment of Ambassador Michèle Boccoz as a voting member of the Strategy Committee for a term that will expire on 26 May 2018, or until the appointment of her successor.</li></ol><p></p>
2016-04-27 B35 GF/B35/DP02 Approval of Agenda Approval of Agenda
The agenda for the 35th Board Meeting (GF/B35/01 - Revision 3) is approved.
2016-06-15 B35 GF/B35/EDP05 2017 – 2022 Strategic Key Performance Indicator Framework 2017 – 2022 Strategic Key Performance Indicator Framework
1. The Board acknowledges the 2017 - 2022 Strategic Key Performance Indicator Framework (the "Strategic KPI Framework"), as presented in Annex 1 to GF/B35/ER05, and the additional methodological work required to set performance targets.<br/>2. Accordingly, the Board approves the Strategic KPI Framework and directs the Secretariat to present the Board with the Strategic KPI Framework's performance targets for approval at the final Board meeting in 2016.
2009-11-11 B20 GF/B20/DP30 Launch of the Next Round of Proposals Launch of the Next Round of Proposals
<p>The Board:</p><p>a. recognizes the continued need for countries to maintain and scale-up their national programs to fight HIV/AIDS, tuberculosis and malaria; and</p><p>b. recognizes the need to improve the effectiveness, simplicity, efficiency, alignment and harmonization and other fundamental aspects of the Global Fund's operating model.</p><p>Therefore the Board requests the Chair and Vice Chair to convene a retreat of the Board in January or early February of 2010 to discuss and determine priority areas for further changes in its operating model and strategic architecture, address key issues such as prioritization for funding amongst proposals; leading to decisions at its next Board meeting and a broader reform agenda timeline, as well as informing substantially the structure of Round 10.</p><p>The Secretariat will call for proposals to launch Round 10 on or about 1 May 2010, with a submission due date of 1 August 2010; and confirmation of this launch will be made at the Board's first meeting in 2010 based primarily on progress on incorporating the new strategic architecture.</p><p>The Board requests the Secretariat and Technical Review Panel (TRP) to review the Round 10 proposals in time for approval at a meeting of the Board (either regular or special) between November 2010 and January 2011, as determined by the Chair and Vice Chair. It would be preferable if the TRP review was completed before the second Replenishment meeting, scheduled for October 2010.</p>
2010-02-20 B20 GF/B20/EDP12 Approval of Round 9 Appeals Approval of Round 9 Appeals
<ol><li>The Board approves the following Round 9 proposals recommended for funding by the Independent Appeal Panel in its report dated 8 February 2010, subject to paragraph 2 below: <ol><li type="i">Pakistan (HIV disease component only) – USD 11,856,124; and</li><li type="i">Ukraine (Tuberculosis) – USD 34,584,205.</li></ol></li><li>These Appeal Panel-recommended Round 9 proposals are approved for funding by the Board as ‘Category 2’ proposals, for an initial two years, under the terms of the Comprehensive Funding Policy and subject to the following: <ol><li type="a">Satisfactory completion by the applicants of the Technical Review Panel <span style="font-size: 12px; line-height: 1.5;">(TRP) clarifications as set out in paragraph 3 below;</span></li><li type="a">the measures associated with funding of Round 9 proposals and national <span style="font-size: 12px; line-height: 1.5;">strategy applications set out in Decision GF/B20/DP9; and</span></li><li type="a">The clear understanding that the amounts indicated are upper ceilings <span style="font-size: 12px; line-height: 1.5;">subject to adjustment through TRP clarifications and grant negotiations, </span><span style="font-size: 12px; line-height: 1.5;">rather than final approved Phase 1 grant amounts.</span></li></ol></li><li>The applicants for the proposals referred to in paragraph 1 above shall: <ol><li type="a">provide an initial detailed written response to the clarifications and adjustments requested by the Independent Appeal Panel not later than six weeks after the receipt of either: <ol><li type="i">notification in writing by the Secretariat to the applicant of this Board <span style="font-size: 12px; line-height: 1.5;">decision; or</span></li><li type="i">the findings of the independent budget review (in the case where the Independent Appeal Panel has requested an independent budget review as part of the clarifications process); and</li></ol></li><li type="a">complete any further clarifications or adjustments, as required by the Chair or <span style="font-size: 12px; line-height: 1.5;">Vice-Chair of the TRP, not later than three months from the Secretariat’s receipt </span><span style="font-size: 12px; line-height: 1.5;">of the applicant’s initial detailed response to the issues raised for clarifications or </span><span style="font-size: 12px; line-height: 1.5;">adjustments (if applicable).</span></li></ol></li><li>The Board notes the Independent Appeal Panel’s request to have additional Financial analysis support as part of the clarifications process and requests the Secretariat to make the necessary arrangements.</li></ol>
2009-11-11 B20 GF/B20/DP31 Architecture Review - Transition Provisions Architecture Review - Transition Provisions
<p>The Board refers to its decision made at the Eighteenth Board Meeting on the Global Fund Architecture (GF/B18/DP19) and recognizes that:</p> <p>i. the Global Fund was established to provide significant additional financing to fight AIDS, tuberculosis and malaria; </p> <p>ii. over time, with the increase in its funding to countries and the resulting multiplicity of funding streams from the Global Fund to Principal Recipients ("PRs"), the funding architecture has become complex; </p> <p>iii. the funding architecture of the Global Fund requires simplification; and</p> <p>iv. the Board has already endorsed the Single Stream of Funding per PR per disease as the foundation for a new funding architecture.</p> <p>Therefore, in order to simplify Global Fund support to current and future implementers of national disease-fighting and health systems strengthening programs, the Board decides as follows:</p> <p>1. The Secretariat shall, at the appropriate time as determined by the Secretariat in collaboration with CCMs:</p> <p>a. consolidate approved grants to one PR supporting a program to fight one of HIV/AIDS, tuberculosis or malaria (which may include any health systems strengthening elements) into one grant agreement (a "Single Stream Agreement") with an initial commitment period of up to three years, by, as appropriate, combining budgets, workplans and targets; and</p> <p>b. align the financial commitment periods for each of the Grant Agreements with different PRs for a particular disease in a country by adjusting the durations and commitment amounts (in accordance with paragraph 2 below).</p> <p>2. In order to facilitate the activities described in paragraph 1 above, the Board delegates to the Secretariat the authority to:</p> <p>a. make reasonable adjustments to: </p> <p>i. the duration of the funding commitment period for the resulting Single Stream Agreement (including both extensions and truncations); </p> <p>ii. the implementation activities contained in the proposals; and </p> <p>iii. the time periods for reaching performance targets contained in proposals; and,</p> <p>b. commit additional funding to the Single Stream Agreement the equivalent of 12 months of grant funds requested in an approved proposal (including a National Strategy Application ("NSA")), but as yet uncommitted (from Phase 2 Renewals or RCC II Renewals) which shall be committed by the Secretariat in accordance with paragraph 3c of the Comprehensive Funding Policy, as presented in Annex 5 Version 2 to GF/B20/12 Report of the Working Group on Managing the Tension Between Demand and Supply in a Resource-Constrained Environment.</p> <p>3. Consolidation of existing grants and alignment of commitment periods of all grants that support a disease program will enable the Secretariat to make recommendations for additional financial commitments under the Periodic Reviews and Commitments Policy attached as Annex 2a Version 2 to GF/B20/4 "Report of the Policy and Strategy Committee", which will be operational not earlier than 1 January 2011. The Board requests the Secretariat to conduct further work on a mechanism to allow for additional funding on the basis of demonstrated strong performance at the time of the requests for and approval of Additional Commitments under the Periodic Reviews and Commitments Policy. In undertaking this work, the Secretariat shall analyze and further describe its feasibility, financial implications and mechanics, and present it to the Policy and Strategy Committee and its next meeting, for its consideration and recommendation to the Board.</p> <p>4. The issue of the Round 10 call for proposals provides an early opportunity for countries to begin transition to the new architecture. To this end, transition to single streams of funding per PR per disease will be possible on a voluntary basis. To facilitate this, the Board delegates authority to the Secretariat to make adjustments to the Round 10 proposal form and guidelines.</p> <p>5. Commencing with Round 11:</p> <p>a. all proposals submitted to the Global Fund shall require the applicant to present a consolidated request for funding incorporating current Global Fund support to the country for the disease, including health systems strengthening support. The consolidated proposal shall identify previously committed and approved funds included within the consolidated request; </p> <p>b. following the approval of a new proposal by the Board, any incremental grant funds for an existing PR shall be included in the PR's existing Single Stream Agreement for that disease, rather than resulting in a new separate Grant Agreement; and</p> <p>c. the Secretariat shall present to the Board for approval, with respect to the proposals recommended for funding by the Technical Review Panel, the amount of the additional financial commitment covering the time remaining in the single stream's then-current commitment period. The revised Comprehensive Funding Policy, as presented in Annex 5 Version 2 to GF/B20/12 "Report of the Working Group on Managing the Tension between Demand and Supply in a Resource-Constrained Environment" shall be applicable to such approvals. All continuing financial commitments to a country's disease-fighting program shall be made in compliance with the Periodic Reviews and Commitments Policy attached as Annex 2a Version 2 to GF/B20/4 "Report of the Policy and Strategy Committee".</p> <p>6. The Rolling Continuation Channel (RCC) procedure for grant application will be discontinued immediately. The Board requests the Secretariat to continue to process all RCC proposals that will be submitted in accordance with existing RCC policies contained in GF/B14/DP9 (Establishment of a Rolling Continuation Channel): GF/B14/DP10 (Technical Reviews for the Rolling Continuation Channel); GF/B15/DP18 (Duration of Grants Eligible for the Rolling Continuation Channel); GF/B15/DP 19 (Board Decision-Making Procedure for the Rolling Continuation Channel); and GF/B16/DP7 (Revision of the Rolling Continuation Channel for Strongly-performing Grants).</p> <p>7. During the period in which the grant portfolio is transitioning to single streams of funding using the methods described in paragraph 1, all funding commitments for grants under the RCC and the Rounds-based Channel (Phase 2 Renewals, RCC proposals and RCC Renewals) and NSA grants, other than incremental requests for funding included in new proposals, shall be considered as "Additional Commitments" in paragraph 9 of the Comprehensive Funding Policy.</p> <p>8. As soon as all of the grants for a particular disease in a country have the characteristics described in paragraph 1 above, the extensions to grant terms available under the Phase 2 Decision-Making Policies and Procedures (GF/B14/8, Annex 3b revision 2, as amended by GF/B15/DP48) and Decision GF/B14/DP27 will no longer be available for the grants for that disease in that country and paragraph 17 of the Periodic Reviews and Commitments Policy attached as Annex 2a Version 2 to GF/B20/4 "Report of the Policy and Strategy Committee", will apply.</p> <p>9. In order to facilitate the implementation of this decision, if a CCM elects to consolidate an approved Round 8, Round 9, Round 10 and/or NSA grant with other existing grants for the same PR:</p> <p>a. as an exception to point 2 of the decision made at the 8<sup>th</sup> Board meeting entitled "Timeframes for Grant Agreements", a Single Stream Agreement must be signed not later than 18 months after Board approval of the funding of the proposal, failing which the Board's approval is no longer valid; and</p> <p>b. as an exception to Decision GF/B19/DP19 entitled "Flexibilities to Set Grant Start Dates", the Secretariat may set the start date for the commitment in the Single Stream Grant Agreement up to 24 months after Board approval.</p> <p>The Board notes that the exceptions in paragraph a and b shall only be available if requested by a CCM in order to give CCMs and PRs the time necessary to consolidate grants and set start dates for alignment purposes.</p> <p>10. The Board recognizes that the new grant architecture has the potential to further empower CCMs in their essential roles of developing programs and funding requests, selecting Principal Recipients, and in overseeing implementation of programs funded by the Global Fund. The Board reaffirms the importance of the minimum eligibility criteria contained in the "Guidelines and Requirements for Country Coordinating Mechanisms." The Board further recognizes that the Portfolio and Implementation Committee (PIC) is currently overseeing a number of CCM strengthening initiatives being implemented by the Secretariat and will undertake a comprehensive revision of the "Guidelines and Requirements for Country Coordinating Mechanisms," taking into account the architecture changes, in time for the second Board meeting in 2010.</p> <p>11. The Board requests the Secretariat to revise the Terms of Reference of the Technical Review Panel, for approval by the Board, prior to the launching of Round 11 in order to give effect to this decision.</p> <p>12. This decision revokes and replaces the Board's previous decisions on Rollout of Grant Consolidation (GF/B16/DP9).</p>
2009-12-31 B20 GF/B20/EDP08 Appointment of Chairs of Committees Appointment of Chairs of Committees
<p>The Board approves the appointment of the following persons as Chairs of the following Committees:</p><ul><li>Dr. Suwit Wibulpolprasert for the Policy and Strategy Committee;</li><li>Mr. Peter van Rooijen for the Finance and Audit Committee;</li><li>Ms. Michele Moloney-Kitts for the Portfolio and Implementation Committee;</li><li>Dr. Bobby John for the Ethics Committee; and</li><li>Dr. Lesley Ramsammy for the Affordable Medicines Facility for Malaria (AMFm) Ad Hoc Committee.</li></ul><p>The Chair of each Committee is appointed for the period from the date of this decision until the adjournment of the first Board meeting of 2011.</p>
2009-11-11 B20 GF/B20/DP09 Measures Associated with Funding of Round 9 Proposals and National Strategy Applications Measures Associated with Funding of Round 9 Proposals and National Strategy Applications
<p>With respect to Round 9 and National Strategy Applications (NSAs), the Board recognizes that:</p> <p>i. currently a large proportion of funding commitments made by the Global Fund are for a three year period, with the entire funding commitment being made at the time of grant signature; </p> <p>ii. it is preferable to make three-year funding commitments in two tranches of an initial two-year period and an additional one-year period;</p> <p>iii. commitment of the additional one-year period can be undertaken in a manner that minimizes funding uncertainty and additional transaction costs; and</p> <p>iv. certain other measures are required to be put into effect in order to fund the current demand for funding. </p> <p>Therefore, the Board decides as follows:</p> <p>1. The Board approves the addition of paragraph 3.c. of the Comprehensive Funding Policy (approved at the Sixth Board Meeting and amended at the Thirteenth Board Meeting and Fifteenth Board Meeting (GF/B15/DP27)) as presented in Annex 5 Version 2 to the Report of the Working Group on Managing the Tension Between Supply and Demand (GF/B20/12).</p> <p>2. Round 9 proposals, National Strategy Applications: </p> <p>a. The Round 9 proposals and National Strategy Applications shall be subject to an overall 10% adjustment for efficiency, resulting in a maximum limit of 90% of the TRP-recommended amount for the first two years of implementation.</p> <p>b The Secretariat shall commit funds for Round 9 and NSAs limited to 90% of the approved funding (an "Initial Commitment") and an anticipated financial commitment for the remaining year of the approved additional funding, to be committed not earlier than 12 months after the starting date of the Initial Commitment, conditional upon the availability of funding (a "Continuing Commitment"). Continuing Commitments shall have the first funding priority under paragraph 8 of the Comprehensive Funding Policy.</p> <p>3. Round 9 and National Strategy Application additional commitments: Approval by the Board of additional commitments for Round 9 proposals and National Strategy Applications shall be subject to a collective maximum limit of US$2,852 million (being 75% of the amounts requested in Round 9 proposals for the third, fourth and fifth year </p> <p>of implementation and 75% of the amounts requested in NSAs for implementation periods beyond the first two years). These limitations, as well as the limitations placed on Round 8 Phase 2 in the decision entitled "Funding Decisions" made at the 18<sup>th</sup> Board meeting (GF/B18/DP13, paragraph 2) shall be increased from 75% to 90% when new resources become available, subject to approval by the Board at that time.</p> <p>4. Due to the measures outlined in this decision, which increase the amount of funding available in 2011, the last sentence of paragraph 4 of Decision GF/B18/DP13 is deleted.</p>
2009-12-17 B20 GF/B20/EDP07 Approval of Phase 2 Funding for Mozambique HIV Round 6 Approval of Phase 2 Funding for Mozambique HIV Round 6
<p>The Board approves additional funding for the Phase 2 period of the Round 6 Mozambique HIV grant (MOZ-607-G05-H) as a Go in the amount of up to US$ 47,292,469, subject to TRP clarifications and conditions within a limited timeframe, and <span style="font-size: 12px; line-height: 1.5;">also subject to possible additional conditions to be cleared by the Secretariat.</span></p><p>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p>
2009-11-11 B20 GF/B20/DP27 Global Fund Partnership Strategy Global Fund Partnership Strategy
The Board approves "The Global Fund Partnership Strategy" (GF/B20/4 - Attachment 2) and requests the Secretariat to report on progress of implementation of the strategy to the Policy and Strategy Committee at its next meeting.
2009-12-17 B20 GF/B20/EDP06 Approval of Funding for Continuity of Services for Cameroon HIV Round 3 Approval of Funding for Continuity of Services for Cameroon HIV Round 3
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p><p>See attached tabledetailing total recommended funding amount of 12, 492,000 Euros = US$ 18,830,441 for the following grant: CMR-304-G01-H</p>
2009-11-11 B20 GF/B20/DP16 In-Kind Non-Health Product Donations In-Kind Non-Health Product Donations
The Board requests the Secretariat to continue to gather information regarding in-kind donations, in particular research into the donation of non-health products and for this purpose authorizes the Secretariat to undertake the facilitation of donations of non-health products to Global Fund grant recipients on a trial basis. The trials shall be in a limited number of countries and will be conducted in line with the guidelines for service donations developed by the Secretariat. Specific attention shall be paid to donations of non-health products by health companies. The Board requests the Secretariat to report to the Finance and Audit Committee, regarding the outcome of the trials, with the aim of making recommendations to the Board, at the Board's second meeting in 2011.
2009-11-11 B20 GF/B20/DP05 Technical Evaluation Reference Group Replenishment Technical Evaluation Reference Group Replenishment
The Board requests the Executive Director to invite Dr Dorothy Kinde-Gazard, Dr Stein-Erik Kruse, Dr Vasanthapuram Kumaraswami, Dr Ruth Levine, Dr Maria Ines Nemes and Dr Wim Van Damme to become members of the Technical Evaluation Reference Group (TERG) for a period of two years, subject to the revision of the TERG Terms of Reference.
2009-11-11 B20 GF/B20/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Eiji Yamamoto from the constituency of Japan is designated as Rapporteur for the Twentieth Board Meeting.
2009-11-19 B20 GF/B20/EDP03 Approval of Phase 2 Funding for Mozambique Malaria Round 9 Approval of Phase 2 Funding for Mozambique Malaria Round 9
<p>The Board approves additional funding for the Phase 2 period of the Round 6 Mozambique Malaria grant (MOZ-607-G06-M) as a Conditional Go in the amount of up to US$ 7,762,108, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p>
2009-11-11 B20 GF/B20/DP04 Joint HSS Platform with GAVI and the World Bank Joint HSS Platform with GAVI and the World Bank
<p>The Board acknowledges the collaborative efforts undertaken by the Global Fund with the World Bank and the Global Alliance for Vaccines and immunizations (GAVI), with technical support and facilitation from the World Health Organization (WHO), to develop a proposal for a common platform for joint Health Systems Strengthening (HSS) funding and programming to respond to country needs and to accelerate achievements in the fight against the three diseases and improve immunization coverage.</p><p>The Board requests the Secretariat, in close consultation with the Policy and Strategy Committee, to continue collaboration with the partner agencies to elaborate in an inclusive manner the operational, financial and policy implications for joint HSS funding and programming based on but not limited to the proposed Option 1 (Single HSS Funding Application) and Option 2 (Funding on the Basis of Jointly Assessed National Health Strategies) described in the Policy and Strategy Committee's Report to the Board (GF/B20/4).</p><p>The Board asks the Secretariat to propose to the PSC, based on consultations at country level with key stakeholders, how a joint HSS platform could be operationalized and funded, for recommendation to the Board at its Twenty-First Meeting.</p>
2009-11-11 B20 GF/B20/DP17 Expansion of Debt2Health Expansion of Debt2Health
<p>The Board notes the progress and positive experience of the pilot phase of the Debt2Health mechanism. The Board decides to incorporate the Debt2Health mechanism as an additional means of resource mobilization for the Global Fund. There will be no limit on the number of creditor and debtor countries that may participate and due diligence on the original purpose of the debt will be undertaken. </p><p>The Board authorizes the Secretariat to amend the Global Fund's Policy for Restricted Financial Contributions to allow restricted contributions from implementing countries for counterpart funds under Debt2Health swaps which are attributed at the country level.</p><p>The Board requests the Secretariat to report to the Board annually on the implementation of Debt2Health.</p>
2009-11-11 B20 GF/B20/DP20 Outgoing Chief Financial Officer Outgoing Chief Financial Officer
<p>We, the Board, express our deep gratitude to Barry Greene for his long service to the Global Fund. We are indebted to him for his dedication and loyalty and the tireless efforts he has made to forward the cause of the Global Fund. We are also grateful for Barry's sense of humour and his ability to maintain congeniality and compassion at all times. His integrity and ability to inspire trust are unrivalled. He represents what is best about the Global Fund. Barry will be much missed by the Board, by the FAC members in particular and by the Secretariat staff. </p><p>We wish Barry all the best, and look forward to continuing to work with him in his new role. <b><i>Go raibh</i></b> <b><i>mile</i></b> <b><i>maith agat</i></b> (Irish for a thousand thank yous)!</p>
2010-04-16 B20 GF/B20/EDP19 Decision to Discontinue Funding for Zambia HIV Round 4 Decision to Discontinue Funding for Zambia HIV Round 4
The Board acknowledges that the special condition upon which the Board approved continued funding to the Zambia Round 4 HIV grant to the Ministry of Finance and National Planning of the Government of Zambia required the Principal Recipient to utilize at least fifty per cent (50%) of the funds disbursed from the Global Fund during Year 3 of the Program Term and that an overall rating of B1 or above would be achieved during Year 3 of the Program Term. In recognition that the special condition was not met, the Board decides to discontinue funding for years 4 and 5 of the Zambia Round 4 HIV grant (ZAM-405-G12-H).
2016-10-06 B35 GF/B35/EDP16 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
The Board:<br/>1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B35/ER12.
2016-07-08 B35 GF/B35/EDP08 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
1. Approves extension of the relevant implementation period for each grant listed in Table 4 of Section IV to GF/B35/ER07.
2016-08-24 B35 GF/B35/EDP14 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:<br/>1. Approves extension of the relevant implementation period for each grant listed in Table 4 of Section IV to GF/B35/ER11.</p><p>This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>
2019-04-19 B40 GF/B40/EDP12 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b of GF/B40/ER09 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-12-19 B40 GF/B40/EDP01 Appointment of a New Member to the Strategy Committee Appointment of a New Member to the Strategy Committee
<ol> <li>The Board approves the appointment of Ms. Katja Roll, representing the German Constituency, as a voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</li> </ol>
2018-11-14 B40 GF/B40/DP03 2019 Work Plan and Budget Narrative and the 2019 Operating Expenses Budget 2019 Work Plan and Budget Narrative and the 2019 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the following:  </p> <ol> <li>2019 Work Plan and Budget Narrative, as set forth in GF/B40/02A; and</li> <li>The 2019 Operating Expenses Budget in the amount of USD 302 million, as set forth in GF/B40/02B (the “2019 OPEX Budget”), which: <ol type="i"> <li>includes USD 15.59 million for the Office of the Inspector General’s 2019 operating expenses; and</li> <li>remains within the total amount of USD 900 million available for operating expenses over the 2017-2019 period.</li> </ol> </li> </ol>
2018-11-14 B40 GF/B40/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 40<sup>th</sup> Board Meeting (GF/B40/01 – Revision 1) is approved.</p>
2005-04-22 B10 GF/B10/DP21 Quality Assurance of Limited and Single Source Pharmaceutical Products Quality Assurance of Limited and Single Source Pharmaceutical Products
<p>The Board decides to change its policy on quality assurance approved at the Third Board Meeting on "option (c)" by replacing the decision on Agenda Item 10(B)(4)(b)(c) with the following and eliminating the last sentence of that decision on the "option (c)" time limit:</p> <ul> <li>Once there are two or more equivalent pharmaceutical products that meet the standards in Option (a) or Option (b), then Option (c) is not applicable. Contracts entered into on or beforeApril 30, 2005with suppliers for products that qualified for purchase under Option (c) may be honoured by the Principal Recipient until they expire. No new purchase contracts or contract extensions for such products will be allowed afterApril 30, 2005.</li> <li>If the Principal Recipient determines that there is only one or no equivalent pharmaceutical product that meets the standards in Option (a) or Option (b) OR if the Principal Recipient determines that the products that meet these standards are unavailable[1] and represents the same to the Global Fund Secretariat, and the Secretariat does not object, then Global Fund resources may be used to procure other equivalent pharmaceutical products, provided that the products are selected in accordance with the following, in order of priority: <ol> <li>(i) the manufacturer has submitted an application for product approval to the WHO Prequalification Program or a stringent regulatory authority AND is manufactured at a site that is compliant with standards of Good Manufacturing Practice (GMP), as certified after inspection by the WHO or a stringent regulatory authority;</li> <li>(ii) the product is manufactured at a GMP-compliant manufacturing site as certified after inspection by the WHO or a stringent regulatory authority. <br /><br />A Principal Recipient shall inform the Global Fund Secretariat if it procures under provisions (i) or (ii), after having followed the above process. In turn, the Secretariat, working with technical partners, shall contract an independent third-party to conduct random quality analysis of products being procured<br /><br />according to these criteria to ensure their quality in the absence of the Option (a) or Option (b) standard. <br /><br />In the event that (a) the submitted application for product approval is no longer under consideration; or (b) the independent third party finds the quality of the product to be unacceptable, then the Principal Recipient shall promptly terminate the contract with the supplying manufacturer.</li> </ol> </li> </ul> <ul> <li>In all cases, products purchased with Global Fund resources are subject to the monitoring product quality standards prescribed by the Fund as specified in Section 6 of the Report of the Third Board Meeting.</li> </ul> <ul> <li>Procurement of products according to criteria (i) or (ii) should be time limited and Principal Recipients should defer to Options (a) or (b) as soon as possible.</li> </ul> <p>The Secretariat will monitor implementation of this decision and report to the Board at the Fourteenth Board meeting.</p>
2005-04-22 B10 GF/B10/DP10 Terms of Reference – Technical Evaluation Reference Group (TERG) Terms of Reference – Technical Evaluation Reference Group (TERG)
The Board approves a revision to the Technical Evaluation Reference Group (TERG) Terms of Reference (ToRs) to respond to the proposed changes in the Board Committee structure. The proposed revised ToRs are attached as Annex 8 to this report. The Board also requests that the TERG Chair present brief independent assessments on performance and status of the Global Fund monitoring and evaluation system to each meeting of the Policy and Strategy Committee and the Board. 
2005-07-25 B10 GF/B10/EDP01 Terms of Reference for the Global Fund Office of Inspector General Terms of Reference for the Global Fund Office of Inspector General
The Board approves the Terms of Reference for the Global Fund Office of Inspector General that are set forth as Annex A of the FAC Report on the Office of Inspector General and the plan for the establishment of the Office of Inspector General that is set forth in Annex B of the FAC Report on the Office of Inspector General.
2005-04-22 B10 GF/B10/DP09 Euro-denominated Grants and Currency Risk Management Euro-denominated Grants and Currency Risk Management
<p>The Global Fund shall take action to minimize its exposure to currency risk through the following transitional policies that set a framework for currency risk management:</p><ol type="a"><li>hedge exposure to currency risk by matching the values[1] of USD assets with USD grant liabilities and Euro assets with Euro grant liabilities to the extent possible using available liquidity, so as to minimize any mismatch within each currency (excess liquidity after matching shall be held in USD and Euro);</li><li>encourage donors to denominate promissory notes only in the grant currencies (USD and Euro); </li><li>if a material currency mismatch remains after these measures, maintain a reserve against commitment authority as a cushion to absorb any potential losses and thus minimize commitments being made in excess of assets available; and </li><li>encourage prospective grant recipients to provide information as to the currency in which they will submit future grant applications.</li></ol><p>The operational implications and practices shall continue to be reviewed by the Secretariat under the guidance of the FAC to present a full recommendation to set the policy and parameters of the currency risk exposure at the Eleventh Board meeting unless insufficient experience warrants extension until the Twelfth Board meeting.</p>
2005-04-22 B10 GF/B10/DP20 Outgoing Chair and Vice Chair of the Board Outgoing Chair and Vice Chair of the Board
<p>We, the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, wish to express our heartfelt gratitude and admiration for the remarkable contribution of our leader, Tommy Thompson, to the improvement of this Board and the cause of global health.</p><p>We, the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, in recognition of the passionate and able work for health and justice of our Vice Chair, Hélène Rossert-Blavier, express our appreciation for her leadership in the Global Fund and wish her well in her personal struggle against disease.</p>
2005-04-22 B10 GF/B10/DP03 Approval of Report of the Ninth Board Meeting Approval of Report of the Ninth Board Meeting
<ul><li>The report of the Ninth Board Meeting is approved.</li></ul>
2005-04-22 B10 GF/B10/DP14 Early Warning and Response System Early Warning and Response System
The Board decides that the Secretariat report to the next meeting of the appropriate committee regarding the implementation of the Early Warning and Response system.
2005-04-22 B10 GF/B10/DP05 Country Coordinating Mechanisms Country Coordinating Mechanisms
<p><b>Decision Point 1</b> </p><p>The Board approves the changes to the CCM Guidelines regarding CCM oversight of implementation, as outlined in GF/B10/7, Annex 3.</p><b>Decision Point 2</b> <br/><p>The Board requests the Secretariat to work closely with partners (multi/bilateral partners, private sector and others) to facilitate and coordinate the provision of resources to support CCM secretariat functioning.</p><p>In countries where partner support for CCMs is not available, the Board approves the use of grant funds to provide CCM support, provided that funding is limited to two-years and meets the terms and conditions set out in Part 2 (para.16) of GF/B10/7. The Board requests the Secretariat to widely communicate this decision point to all stakeholders.</p><b>Decision Point 3</b> <br/><p>The Board approves the revised text of paragraph 19 as outlined in GF/B10/7, Annex 3 (see below).</p><p><b>Revised text of paragraph 19</b> </p><p>Para 19: The Secretariat will take specific steps to collect information on the functioning of CCMs and to disseminate this information. Individual CCM members are free to communicate their views on design or implementation issues with other CCM colleagues or with the Secretariat, on a confidential basis if necessary, to register problems and complaints, and identify weaknesses in CCM functioning as described in the principles of the Fund.<b> At the same time, the Fund Portfolio Managers will ensure that this process contributes to promoting true partnership and trust among the CCM members and between the Fund Portfolio Managers and the CCMs</b>. While respecting confidentiality where confidentiality has been requested, portfolio managers would have the right to inform themselves on the issue through queries to other CCM members, and if necessary tasking the LFA to determine the accuracy of the complaint. <b>The Board requests CCMs to work closely with national authorities within the framework of the Three Ones and harmonization efforts.</b></p>
2005-09-14 B10 GF/B10/EDP02 Extensions and Bridge Funding (Indonesia and Cote d'Ivoire) Extensions and Bridge Funding (Indonesia and Cote d'Ivoire)
<ol><li>The Board decides to commit additional funds equal to U.S.$3,500,000 to the Round 1 Indonesia malaria grant (IND-102-G02-M-00) pending the Phase 2 renewal decision with respect to this grant.<br/><br/></li><li>The Board decides to extend of the term of the Cote D’Ivoire Round 3 HIV Program (Grant No. CIV-304-G02-H) for an additional three months beyond the original eighteen month proposal term.</li></ol>
2005-04-22 B10 GF/B10/DP19 Office of the Inspector General Office of the Inspector General
The Board requests the Finance &amp; Audit Committee to develop, and present for approval by email prior to the 11<sup>th</sup> Board Meeting, terms of reference and a plan for the establishment of a Global Fund Office of the Inspector General, and recommend a candidate for the position of Inspector General for appointment by the Board at the 11<sup>th</sup> Board Meeting.
2005-04-22 B10 GF/B10/DP06 Memorandum of Understanding – Stop TB Memorandum of Understanding – Stop TB
The Board approves the Memorandum of Understanding with the Global Partnership to Stop TB, attached as Annex 4 to the Report of the Governance and Partnership Committee (GF/B10/7), and requests the Secretariat to provide periodic reports on cooperation between the Fund and the Global Partnership to Stop TB under the agreement.
2002-01-28 B01 GF/B01/DP01 Appointment of the Board Chair Appointment of the Board Chair
<p>Dr. Anders Nordström, stepping down as President of the Founding Directors, proposed that Dr. Chrispus Kiyonga presides over the meeting until the first Chair of the Board was elected.</p> <p>As no objections were heard, it was so decided.</p>
2002-01-28 B01 GF/B01/DP05 Interim Administrative Arrangements Interim Administrative Arrangements
<p>It was noted that the draft Global Fund/World Bank agreement had not yet been thoroughly reviewed by the World Bank, and further negotiations would be required. A short, simple agreement for phase one should be quickly drafted and agreed between the World Bank, Secretariat Legal Counsel, and a working group of the Board.</p><p>It was decided that the Chair and Vice Chair establish interim arrangements so that support from WHO would continue.</p><p>It was suggested, and eventually decided that the title of the Working Group on Monitoring and Evaluation be changed to Monitoring, Evaluation, and results-based disbursement.</p><p>Mr. Ritter informed the Board that discussions on establishing a quasi-intergovernmental organization had been initiated with the Swiss Government. The Secretariat is currently waiting for WHO to provide a detailed description of services and costs.</p>
2002-01-28 B01 GF/B01/DP08 Strategic Communication Strategic Communication
<p>One delegation proposed that the Fund consider preparing a letter to potential donors in an effort to raise awareness and request applications to the Fund while another delegation recommended highlighting the communication and advocacy efforts of the Fund. </p><p>The Chair clarified that the letter was intended to update relevant partners to keep their interest up and to inform potential recipient countries and donors. The Chair emphasized that communication is a key element for the Fund. </p><p>Further thinking will be required as to the details of how to implement a longer-term, comprehensive strategy. A working group will be required. </p><p>However, communication on the results of the first Board meeting is still expected, and agreement on key messages will be required. </p><p>The Secretariat will work with Board members to agree on a strategy and messages for this Board meeting. It was so decided.</p>
2002-01-28 B01 GF/B01/DP04 Technical Review Panel: Terms of Reference Technical Review Panel: Terms of Reference
The Chair indicated that all comments on the Terms of Reference of the TRP had been duly noted by the Secretariat, and that a revised version of the TOR paper incorporating the agreed changes would be prepared and used as a basis for initiating the selection process for the Technical Review Panel.
2002-01-28 B01 GF/B01/DP02 Appointment of a rapporteur Appointment of a rapporteur
<p>Dr. Kiyonga proposed Dr. Helene Gayle, Director, HIV/AIDS and TB Program, Bill and Melinda Gates Foundation, as rapporteur for the first Board meeting.</p><p>There were no objections to this proposal, and it was so decided.</p>
2002-01-28 B01 GF/B01/DP03 Quick Start Quick Start
<p>The Chair noted the comments made on the Quick Start (GFATM/B1/Doc.8) paper, and suggested that the Board agree on the principles outlined in the document.</p> <p>He pointed out that these principles had already been built into the Guidelines and Call for Proposals documents, and should be included in revised versions of these two documents that would be presented to the Board for adoption later in the meeting.</p> <p>It was so decided.</p>
2002-01-28 B01 GF/B01/DP07 Committee Appointments Committee Appointments
<p>Appointment of Monitoring, Evaluation and results-based disbursement Committee,</p> <p>Appointment of Recruitment Committee,</p> <p>Appointment of Communication Working Group,</p> <p>Appointment of Technical Review Panel Working Group,</p> <p>Appointment of Trustee Agreement Working Group.</p>
2005-04-22 B10 GF/B10/DP02 Approval of the Agenda Approval of the Agenda
The agenda for the Tenth Board Meeting is approved with modifications. 
2005-04-22 B10 GF/B10/DP12 Phase 2 Renewals Phase 2 Renewals
<p><b>Decision Point 1:</b> </p><p>The Board decides to approve the following procedure for use, should it so decide, in processing proposals pending before it at its 10<sup>th</sup> meeting:</p><p><b>Interim procedure for processing proposals pending before the Board at its 10<sup>th</sup> meeting</b> </p><ol><li>The Board may decide to refer a proposal back to the CCM for further processing as a Revised Request for Continued Funding.</li><li>If the Board refers a proposal for further processing as a Revised Request for Continued Funding, the CCM will be provided with a summary of concerns raised and will be given one opportunity to address these and any other concerns raised during the Phase 2 process.</li><li> The CCM must deliver its Revised Request for Continued Funding to the Secretariat within two months of written notification of the opportunity to resubmit. The Secretariat shall review the Revised Request for Continued Funding solely for financial reasonableness, and shall pass both the submission and its financial comments to the TRP for review within one month of receipt from the CCM. The TRP shall provide a recommendation to the Board within one month of receipt from the Secretariat. </li><li> If the TRP recommends to discontinue funding, the recommendation shall be in the form of notification to the Board, no further funding shall be provided for the proposal and funding of the existing program shall terminate at the completion of its term. </li><li> If the TRP recommends to continue funding, the Board shall vote by e-mail on the TRP recommendation under its no-objection procedure. Votes must be received by the Secretariat no later than the 10th day following notification to the Board (inclusive of the day of notification).</li><li> If the TRP recommendation to continue funding is not approved by the Board, no further funding shall be provided for the proposal and funding of the existing program shall terminate at the completion of its term.</li></ol>
2005-04-22 B10 GF/B10/DP15 Committee Restructuring Committee Restructuring
<p>The Board decides to reorganize the Board Committees by canceling the GPC,</p><p>MEFA, PFSC, PMPC, RMCC and constituting the following three committees:</p><ol><li> The Policy and Strategy Committee (PSC)</li><li> The Portfolio Committee (PC)</li><li> The Finance and Audit Committee (FAC)</li></ol><p><b>Decision Point 2:</b> </p><p>The Board adopts Option 1 with regard to Committee structure and Membership. </p><p><b>Decision Point 3:</b> </p><p>The Board adopts the Committee Rules and Procedures in GF/B10/11, Annex 3, as amended by the Board at its 10<sup>th</sup> meeting.</p><p>The Board adopts the Terms of Reference in GF/B10/11, Annex 2, as amended by the Board at its 10<sup>th</sup> meeting.</p><p><b>Decision Point 4:</b> </p><p>The Board decides to amend Section 23 and Section 25 of the Board Operating Procedures as follows: </p><p><b>23. Size and Membership of Committees</b> </p><p><s>Committees will have a maximum of seventeen members</s>. The Board Chair and Vice Chair, in consultation with the committee chair, <s>and the Executive Director</s>, will propose the constituencies to be included on each committee, based on applications made by constituencies for committee seats, for full Board approval. There will be no more than one member per constituency on any single committee. Each constituency may participate in a maximum of <s>three</s>two committees. Membership on the Ethics Committee shall not count toward this <s>three</s> two-committee limit, nor shall membership on other ad-hoc committees where the Board specifically provides that membership shall not apply toward this limit. Where demand for committee seats exceeds the maximum, priority will be given to ensuring balance.</p><p>Constituencies will designate an individual to represent them on a given committee. While it is preferable that constituencies choose Board Members or Alternate Members to serve on committees, they are free to choose any individual to represent them.<s> While substitutes should be discouraged, committee members will be able to send substitutes as an exception without the approval of the committee chair. Only committee members (or their substitute) will attend committee meetings, unless other individuals are invited to do so by the committee chair</s>. Because committee chairs must chair the committee meeting without prejudice, they may bring an additional representative of the constituency to participate as a member of the committee. Where considered necessary by the committee chair, the vice chair of a particular committee may be permitted to bring an additional representative of the constituency to participate as a member of the committee. </p><p><b>25. Ethics Committee</b> </p><p>The Ethics Committee shall be a permanent committee of the Board. The Ethics Committee shall consist of four members. <s>The Board Vice Chair shall be a member of, and shall Chair, the Ethics Committee</s>.</p><p>The Ethics Committee shall operate under these Board Operating Procedures, the committee guidelines of the Board, and the Ethics Committee procedures and rules, as may be adopted and amended from time to time by the Board. In circumstances where these Ethics Committee procedures and rules conflict with these Board Operating Procedures or the committee guidelines of the Board, the Ethics Committee procedures shall govern.</p>
2005-04-22 B10 GF/B10/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<ul type="disc"><li>Dr. Ren Minghui from the Western Pacific Region (China) Constituency is designated as Rapporteur for the Tenth Board Meeting.</li></ul>
2018-05-09 B39 GF/B39/DP05 Appointment of the Members of the Standing Committees of the Board Appointment of the Members of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Pasqualino Procacci, European Commission, Belgium, Italy, Portugal, Spain;</li> <li>Greg Ferrante, Private Foundations;</li> <li>Michael Ruffner, United States;</li> <li>Chris Taylor, United Kingdom;</li> <li>Gilles Angles, France;</li> <li>Maurine Murenga, Communities;</li> <li>Allan Maleche, Developing Country NGOs;</li> <li>Naveed Kamran Baloch, Eastern Mediterranean Region;</li> <li>Guillermo Birmingham, Latin America and the Caribbean; and</li> <li>Sukhbir Singh, South East Asia.<br /><br />The Board appoints the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /><br /></li> <li>Iris Semini, UNAIDS; and</li> <li>Alexandru Cebotari, World Bank.<br /><br /></li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:<br /> <ol type="i"> <li>Suomi Sakai, Japan;</li> <li>Anders Nordström, Point Seven;</li> <li>Renuka Gadde, Private Sector;</li> <li>David Kihumuro Apuuli, Eastern and Southern Africa;</li> <li>Ana Filipovska, Eastern Europe and Central Asia; and</li> <li>Mohamed Chakroun, Eastern Mediterranean Region.<br /><br /></li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Timothy Poletti, Canada, Switzerland and Australia;</li> <li>Jean-François Pactet, France;</li> <li>Heiko Warnken, Germany;</li> <li>Sarah Boulton, United Kingdom;</li> <li>Mamadi Yilla, United States;</li> <li>Mike Podmore, Developed Country NGOs;</li> <li>Nduku Kilonzo, Eastern and Southern Africa;</li> <li>Violeta Teutu, Eastern Europe and Central Asia;</li> <li>Abdoulaye Ciré Anne, West and Central Africa; and,</li> <li>Ingrid Glastonbury, Western Pacific Region.<br /><br />Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee:<br /><br /></li> <li>Lucica Ditiu, Partners (Stop TB); and</li> <li>Mubashar Sheikh, World Health Organization.<br /><br /></li> </ol> </li> <li>The Board approves the renewal for one additional term of:<br /> <ol type="i"> <li>Jean-Michel Ferat as Independent Member of the Audit and Finance Committee with forensic investigation expertise;</li> <li>Peter Maertens Independent Member of the Audit and Finance Committee with financial audit expertise; and</li> <li>Joan Elise Dubinsky as Independent Member of the Ethics and Governance Committee with ethics expertise.<br /><br /></li> </ol> </li> <li>The Board notes each of the individuals appointed under this decision point shall begin his/her term on 11 May 2018 and serve for two years or until the appointment of his/her successor.</li> </ol>
2018-11-12 B39 GF/B39/EDP20 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease component: (i) Rwanda malaria, as listed in Table 2 of GF/B39/ER16, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-09-24 B39 GF/B39/EDP11 Approval of Funding to Address the Health Crisis in Venezuela Approval of Funding to Address the Health Crisis in Venezuela
<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that is not currently eligible for Global Fund funding, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the extraordinary proposal for funding presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela and the exceptional nature of the funding proposed require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in Annex 1 to GF/B39/ER10 (Annex 1);</li> <li>Accepts that the proposed implementation and management arrangements entail unique risks, as described in GF/B39/ER10 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide USD 5,000,000 to support the procurement of critical health products for Venezuela; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>
2018-05-09 B39 GF/B39/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the 39th Board Meeting (GF/B39/01 – Revision 2) is approved.</p>
2018-07-20 B39 GF/B39/EDP04 Review of the Terms of Reference and Renewal of the Term and Composition of the Privileges and Immunities Advisory Group Review of the Terms of Reference and Renewal of the Term and Composition of the Privileges and Immunities Advisory Group
<p>Based on the recommendation of the Board Chair and Vice-Chair, the Board:</p> <ol> <li>Expresses its appreciation for the work done by the members of the PIAG.</li> <li>Approves the amended terms of reference of the PIAG as set out in Annex 2 to GF/B39/ER04</li> <li>Decides to renew the term of the PIAG for an additional period of three years starting at the conclusion of the 39th Board Meeting and ending on 10 May 2021.</li> <li>Requests the Ethics and Governance Committee to select and appoint the members of the PIAG and to inform the Board of the outcome of the selection process.</li> </ol>
2018-11-02 B39 GF/B39/EDP16 Appointment of the Board Leadership Nomination Committee Membership Appointment of the Board Leadership Nomination Committee Membership
<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B39/ER13, relating to the membership of the Board Leadership Nomination Committee (“Nomination Committee”).</li> <li>Accordingly, the Board appoints the following individuals to serve as members of the Nomination Committee in accordance with the terms of reference of the Nomination Committee approved under electronic decision point GF/B39/EDP08 and set out in Annex 4 to GF/B39/ER07:<br /> <ol type="a">a. Stéphanie Seydoux, Chair of the Nomination Committee;</ol> <ol type="a">b. Vikas Sheel, Vice-Chair of the Nomination Committee;</ol> <ol type="a">c. Paul Schaper, Member;</ol> <ol type="a">d. Rachel Ong, Member;</ol> <ol type="a">e. Sherwin Charles, Member;</ol> <ol type="a">f. Olaitan Tajudeen Ibrahim; Member and,</ol> <ol type="a">g. Minghui Ren, Member.</ol> </li> </ol>
2018-10-18 B39 GF/B39/EDP13 Secretariat Appointments Secretariat Appointments
<p>The Board hereby notes the Executive Director’s appointment of the following senior management officials of the Global Fund:</p> <ol type="i"> <li>Marijke Wijnroks, as Chief of Staff, and</li> <li>Jacques Le Pape, as Chief Financial Officer.</li> </ol>
2018-05-10 B39 GF/B39/DP12 Strengthening the Board Leadership Selection Process Strengthening the Board Leadership Selection Process
<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee (the “EGC”), as set forth in GF/B39/05 – Revision 1, and acknowledges the need to strengthen the current process for selecting the Chair and Vice-Chair of the Board.</li> <li>Based on the recommendation of the EGC, the Board approves, in principle, the revised process for selecting the Chair and Vice-Chair of the Board as detailed in Section II of GF/B39/05- Revision 1 (the “Revised Board Leadership Selection Process”) and the Draft Terms of Reference of the Board Leadership Nomination Committee (the “BLNC ToRs”) as provided for in Annex 7 of GF/B39/05 – Revision 1.</li> <li>The Board requests the Secretariat to finalize the BLNC ToRs and to prepare the necessary revisions to the core governance documents to implement the Revised Board Leadership Selection Process for review by the EGC and recommendation to the Board for approval ahead of the planned 2018 launch of the call for nominations for Board Chair and Vice-Chair.</li> </ol>
2018-05-28 B39 GF/B39/EDP01 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP01 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-11-12 B39 GF/B39/EDP19 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 to GF/B39/ER16 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2005-04-22 B10 GF/B10/DP18 Chair’s Budget Chair’s Budget
The Board approves the budget for the Office of the Chair as presented at the 10<sup>th</sup> Board Meeting.
2005-04-22 B10 GF/B10/DP13 Phase 2: Honduras and Senegal Phase 2: Honduras and Senegal
<p><b>Decision Point 1:</b> </p><p>The Board decides to refer the Honduras Round 1 HIV proposal back to the CCM for further processing as a Revised Request for Continued Funding.</p><p><b>Decision Point 2:</b> </p><p>The Board decides to refer the Senegal Round 1 HIV proposal back to the CCM for further processing as a Revised Request for Continued Funding.</p>
2005-04-22 B10 GF/B10/DP16 Replenishment Conference Replenishment Conference
<p>The Board notes with concern the current shortfall regarding funds availability for Round 5.</p><p>The Board calls upon participants of the Replenishment Conference, and all other potential donors, to take urgent action to ensure that Round 5 is fully funded.</p>
2005-04-22 B10 GF/B10/DP17 Annual Report 2004 Annual Report 2004
<p>The Board approves the draft Annual Report for 2004.</p>
2005-04-22 B10 GF/B10/DP08 2004 Financial Statements and Audit 2004 Financial Statements and Audit
The Board approves the 2004 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young.
2005-04-22 B10 GF/B10/DP11 Phase 2 Decision Process Phase 2 Decision Process
<p><b>Decision Point 1</b> </p><p>The Board acknowledges that, in line with the existing Phase 2 policy, the Secretariat may need to take more than 20 months to provide a Phase 2 recommendation to the Board. It therefore decides that in exceptional circumstances the Secretariat may extend, at no cost, the term of Phase 1 grant agreements by up to six months and decides that the Phase 2 Decision-Making Policies and Procedures document, as set out in Annex 6 to Board Document G/B10/8, shall be amended accordingly. The Secretariat shall inform the Board immediately upon taking action under this decision.</p><p><b>Decision Point 2:</b> </p><p>The Board directs the Chair and Vice Chair of the Board to establish an ad-hoc task force to review the Phase 2 process and report back to the 11<sup>th</sup> Board Meeting. The task force should be comprised of members of the Board, the Technical Review Panel, the Chair of the Technical Evaluation Reference Group and the Secretariat.</p>
2005-04-22 B10 GF/B10/DP22 Title of Chair and Vice-Chair (Emeritus) Title of Chair and Vice-Chair (Emeritus)
Secretary Tommy Thompson and Dr. Hélène Rossert-Blavier, Dr. Chrispus Kiyonga, Mr. Seiji Morimoto and Dr. Suwit Wibulpolprasert are entitled to use the title of Chair and Vice-Chair (Emeritus), respectively, when they deem it necessary to engage in tasks for promotion of the cause of the Global Fund.
2005-04-22 B10 GF/B10/DP04 Election of Chair and Vice Chair 2005-2007 Election of Chair and Vice Chair 2005-2007
<p><b>Decision Point 1:</b> </p><p>Dr. Carol Jacobs of the Latin America and Caribbean constituency is unanimously elected as Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria for the period of 2005-2007.</p><p><b>Decision Point 2:</b> </p><p>Prof. Michel Katzatchkine of the France (Luxemburg, Spain) constituency is unanimously elected as the Vice Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria for the period of 2005-2007.</p>
2005-04-22 B10 GF/B10/DP07 Commencement of the Terms of the Chair and the Vice Chair Commencement of the Terms of the Chair and the Vice Chair
<p>The Board amends Section 18 the Board Operating Procedures as follows:</p><p><b>18. Timing of Elections; Commencement of Terms</b> </p><p>Elections of the Chair and Vice Chair shall take place at the first Board meeting of the year. In the case of a vacancy, elections to fill the vacant slot shall take place at the first Board meeting at which a vacancy exists. The terms of office for Chair and Vice Chair shall commence <u>upon the adjournment of the Board meeting at which the election is held</u> except in the case of elections to fill a vacancy, where terms shall commence immediately upon election.</p>
2008-04-29 B17 GF/B17/DP21 Transition from Administrative Services - Human Resources and Financial Rules Transition from Administrative Services - Human Resources and Financial Rules
<p>The Board refers to its decision (GF/B17/DP20) to accept the World Health Organization's offer to provide human resources services during the period beginning on 1 January 2009 and ending not later than 30 September 2009 (the "Interim Period"). The Board recognizes the importance of full Board ownership of the human resources and related policies and systems ("HR Policy") that shall be in effect at the end of the Interim Period.</p> <p>As the HR Policy must be established prior to the next meeting of the Global Fund's Board, the Board requests the Finance and Audit Committee to invite all interested Board constituencies to participate in preparation of the HR Policy. Following this consultation, the HR Policy shall be submitted to the Board for approval by email on a no-objection basis under the procedure normally applicable to funding commitments set forth in Section 12 of the Board Operating Procedures. The HR Policy shall be consistent with the principles and strategic priorities set out in Annex 4 to the Report of the Finance and Audit Committee (GF/B17/6).</p> <p>In addition, the Board delegates authority to the FAC to approve an interim HR policy applicable to the Interim Period, and rules applicable to the purchasing of services and goods and non-grant financial management, which shall come into effect on 1 January 2009.</p> <p>The Board delegates authority to the Executive Director to take all action, including the execution of legal agreements, required to bring into operation the Global Fund's interim and new administrative frameworks.</p>
2006-04-28 B13 GF/B13/DP25 Phase 2 Decision Making Process Phase 2 Decision Making Process
<p>The Board decides to extend the application of the Phase 2 Decision-Making Policies and Procedures set out in Annex 1 to the Report of the Portfolio Committee to the Twelfth Board Meeting (GF/B12/6) and as amended at the Twelfth Board Meeting, until the Fifteenth Board Meeting.</p> <p>The Board requests the Portfolio Committee to review the Phase 2 Decision-Making Policies and Procedures and develop recommendations for the Board to consider at its Fourteenth meeting.</p>
2008-04-29 B17 GF/B17/DP18 Building the Demand for a Scaled up Malaria Response Building the Demand for a Scaled up Malaria Response
<p>1. The Board acknowledges and commends the call by the UN Secretary General and the Roll Back Malaria (RBM) Partnership to help countries achieve the G8, the World Health Assembly and RBM targets to achieve universal coverage of an essential malaria control intervention package by December 31, 2010. In particular, the Board recognizes the epidemiological rationale set forth by the WHO for a massive scale-up of effective preventive measures to reach these targets. As the largest external financier of malaria programs worldwide, the Board is committed to ensuring that the Global Fund is acting as a key partner, along with others, in this extraordinary public health effort to meet the demand from countries to scale-up their malaria programs.</p><p>2. Given the urgency of the need to devote additional resources and to increase implementation capacities at country level to achieve universal coverage, the Board urges countries to submit ambitious Round 8, Round 9, and Rolling Continuation Channel proposals aimed at scaling up comprehensive malaria control programs (particularly the distribution of long-lasting insecticide treated nets (LLINs) and ACTs) and are linked to broader health systems strengthening.</p><p>3. The Board also urges countries to take advantage of the flexibility offered in Global Fund financing and, if appropriate, to consider revising budgets for existing and new grants and for Phase 2 requests to frontload resources and accelerate implementation and scale-up of LLIN distribution, ACTs and other malaria control interventions.</p><p>4. The Board, recognizing the increased demand from applicants for high quality technical assistance, urges the RBM Partnership to finance and operationalize the Malaria Implementation Support Team to ensure maximum effectiveness of Global Fund resources to achieve universal coverage. </p>
2008-04-29 B17 GF/B17/DP11 Strategic Framework for Collaboration (“Roadmap”) with UNITAID Strategic Framework for Collaboration (“Roadmap”) with UNITAID
<p>The Board refers to its decision (GF/B14/DP23) to request the Policy and Strategy Committee (PSC) to work with the Secretariat and the Finance and Audit Committee to develop a roadmap for future collaboration with UNITAID. The Board approves the proposed framework set out in Attachment 1 of the Report of the PSC (GF/B17/4), and requests the Secretariat under the oversight of the PSC to proceed with collaboration in the five areas described in the proposed framework and provide an update to the PSC at its first meeting in 2009.</p>
2002-04-22 B02 GF/B02/DP05 Country Coordination Mechanisms, Proposals and Eligibility Criteria - Part one Country Coordination Mechanisms, Proposals and Eligibility Criteria - Part one
<ol type="A"><li><u>Country Coordinating Mechanisms: </u><ol><li>The Board approved the principle of sub-regional Country Coordination Mechanisms for small countries, based on the small islands state classification of the United Nations.</li><li>The Board approved the eligibility of sub-national proposals provided that they are consistent with nationally formulated policies and that there is evidence of a legal framework for the sub-national entity stating its autonomy.</li><li>The Board confirmed that regional proposals can be accepted, provided that they clearly add value beyond the national level, include appropriate NGO and other civil society partners, and that they are supported by national Country Coordination Mechanisms."</li><li>Confirming that CCMs should be inclusive, involving members of civil society and the private sector as partners in preparation, approval and implementation of proposals, in accordance with the guidelines of proposals and stressing the importance of improving their effectiveness and capacity, the Board: – recognized the Secretariat as the lead advisor to the TRP and to the Board on CCM confirmation, as necessary;– noted the importance of linking this to the development and leverage of partnerships at the country level.</li></ol></li><li><u>Proposals: </u><ol><li>The Board adopted a three-year approach to balancing the portfolio between regions, diseases and interventions, subject to a mid-term review of balancing after the third round and after ongoing reviews and drawing on existing data from technical partners as well as recommending use of a needs assessment instrument.</li><li>The Board adopted an approach regarding the balance of prevention, care, support and treatment whereby if a given proposal can explain and document that a particular intervention is available through other arrangements it is not necessary that this intervention be a part of the proposal. The most appropriate balance of interventions will differ according to country contexts.</li></ol></li><li><u>Eligibility Criteria: </u><ol><li>The Board reaffirmed the decision that priority be given to proposals from countries in greatest need, as determined by level of poverty and disease burden and that proposals from members of the OECD’s Development Assistance Committee (DAC) are not eligible for funding by the Global Fund.</li><li>The Board confirmed that proposals from eligible countries in lower need situations will be considered for funding, but will be given lower priority and lower overall allocation relative to those with greater need</li><li>The Board decided that proposals from eligible countries whose overall needs are of lower priority but which focus on particularly vulnerable populations will be considered as specified in the above decision.</li><li>The Board decided that multi-year proposals can be approved. The Fund will allocate funds for a two-year period with funding for the third and following years contingent on a satisfactory performance assessment and the Fund’s available resources at that time.</li></ol></li><li><u>Approval guidelines: </u><ol><li>The Board decided that multi-year proposals can be approved. The Fund will allocate funds for a two-year period with funding for the third and following years contingent on a satisfactory performance assessment and the Fund’s available resources at that time.</li><li>The Board endorsed the importance of additionality with regard to resources made available by the Global Fund relative to other sources of funding.The Board agreed that there is a need to further clarify the questions of funding ranges, resource gaps, percentage justification and additionality.</li><li>Noting the desire to ensure economies of scale, to have maximum impact, and not to overburden the operations of the Secretariat and the TRP, the Board agreed to the principle of a lower limit of total requested funds by a single applicant. The Board asked that exceptions to this limit be considered by the TRP on a case-by-case basis.</li><li>It was decided that the Secretariat would continue to work on the development of specific guidelines and report back to the Board at its next meeting.</li></ol></li><li><u>Emergency decision:</u> The Board decided that in the case of complex emergencies – identified by the Secretariat referencing international declarations such as those of the UN Office for the Coordination of Humanitarian Affairs – specific decisions on eligibility in each case should be made by the Executive Director in consultation with the Board to avoid delays in proposal review.</li><li><u>Next steps:</u> Recognizing the need to ensure high quality proposals from countries in greatest need and noting the existing availability of resources from current partners to work with countries at the local level, the Board requested the Secretariat to recommend at its next meeting specific ways for the Global Fund to support countries where capacity to prepare proposals is less strong both by leveraging existing partnerships and possibly catalyzing new processes.</li><li><u>Communication guidelines:</u><br/><ol><li>The Board authorized the Secretariat to share information on the reasoning behind the different decisions taken on proposals only with their authors, other groups that are part of the proposal (e.g. all members of a CCM listed on the CCM certification sheet), and Board Members and their representatives. All others making inquiries about specific proposals would be informed of these guidelines and directed to make their inquiries directly to the proposals’ authors.</li><li>The Board authorized the Secretariat to share information related to the review process so long as proposal-specific deliberations remain confidential</li><li>The Board requested the Secretariat to send a regular e-mail to Board members listing all inquiries made by Board members on information related to the review of specific proposals</li><li>The Board asked the Secretariat to make the arrangements for posting information of the approved proposals on the web site" <br/><br/></li></ol></li></ol>
2002-04-22 B02 GF/B02/DP12 Working Group on Governance Working Group on Governance
The Board requested that representatives from the Private Sector and Italy chair a working group on governance and that the findings of this working group be presented at the Third Board Meeting.
2002-04-22 B02 GF/B02/DP06 Country Coordination Mechanisms, Proposals and Eligibility Criteria - Part two Country Coordination Mechanisms, Proposals and Eligibility Criteria - Part two
<p><u></u>The Board re-emphasized the urgent need for additional funding to fight HIV/AIDS, Tuberculosis and Malaria in countries of greatest need as determined by levels of disease burden and poverty. The Board furthermore stressed the importance of responding to the enormous interest and great need expressed through the submission of 322 proposals from 77 countries (and 7 multi-country proposals) within the deadline.</p><p>The Board indicated that all proposals reviewed by the TRP are considered as proposals in the pipeline, which will follow an expeditious and progressive process for potential approval in the near future. The fact that the Board, at this session, will approve funding for a given number of proposals should not be interpreted as an indication that other submitted proposals will not be approved for funding at a later stage.</p><ol><li>The Board requested the Secretariat to review new and resubmitted proposals to ensure consistency with the specific policy guidelines adopted by the Board at its second Board meeting as well as the Framework document.</li><li>The Board reconfirmed that non-CCM applications were not eligible unless the proposals satisfactorily explained how they met the exceptional circumstances set out in the framework document in this regard. The Board therefore agreed that non-CCM applications from the first round should be removed from category one and placed into category two, and follow the procedure for approval for category two. All decisions regarding categories one and two, as reported in the following section, were taken on the understanding that the categories had been amended in this way.</li><li>The Board gave preliminary approval to fund proposals in the first category recommended by the TRP, provided that: all proposal clarifications and additional information requested are received and reviewed by the Secretariat and endorsed by the Chair and/or Vice-Chair of the TRP; appropriate fiduciary, procurement, monitoring and evaluation (including agreed criteria and reporting guidelines) arrangements are in place in accordance with Board policy directives; appropriate fiduciary, procurement, monitoring and evaluation (including agreed criteria and reporting guidelines) arrangements are in place and approved by the Executive Director. The process of approval will be completed within six weeks on a continuous basis after the applicants received letter of notification from the Secretariat. Grant agreement negotiations for these proposals could then begin on a continuous basis as these proposals fulfill the criteria listed above.</li><li>The Board decided to approve the commitment to fund proposals in the second category recommended by the TRP, provided that clear guidelines to the applicants are provided by the TRP and the following: all proposal clarifications and additional information requested are received and reviewed by the Secretariat, and approved by the Chair and Vice-Chair of the TRP upon consultation of the proposal’s original primary reviewers;- appropriate fiduciary, procurement, monitoring and evaluation (including agreed criteria and reporting guidelines) arrangements are in place in accordance with Board policy directive and are approved by the Executive Director. The process of approval will be completed within six weeks on a continuous basis after the applicants received letter of notification from the Secretariat. These proposals shall finally be approved by the Board, through email, upon notification by the Secretariat that the above conditions have been met. Grant agreement negotiations for these proposals could then begin on a continuous basis as these proposals fulfill the criteria listed above.</li><li>The Board recommended that all proposals in category three need to be resubmitted for a full review by the TRP prior to being resubmitted for Board endorsement.</li><li>The Board decided to merge category 4 and 5. Proposals in this new category will be revised and reformulated using the new guidelines and forms for proposals and reviewed together with newly submitted proposals.</li><li>The Board requested the Secretariat to promptly communicate to applicants of proposals in all categories the additional information needed and/or issues raised by the TRP in order to provide technical guidance, including by relevant partners for an early revision or resubmission of proposals as recommended by the TRP.</li><li>The Board requested the Executive Director to negotiate the Grant Agreements for approved proposals, including detailed budget allocation, disbursement schedule and clear termination clauses as well as specifying the financial and program accountability and procurement mechanisms agreed.</li><li>The Board approved funding for the first two years of each proposal with subsequent years’ funding contingent on: a satisfactory performance assessment, to be completed no later than two years after the first disbursement; the Fund’s available resources at that time.</li><li>The Board authorized the Executive Director, after these conditions have been met, to enter into Grant Agreements and thereafter instruct the Trustee to disburse funds according to agreed disbursement plans and continuous reviews.</li><li>Applicants to the Fund who find that their proposal has not received a fair review by the TRP may appeal through a special procedure for which specific terms of reference will be developed by the Board Sub Working Group.</li></ol><p>The Board took note of the lessons learned and instructed the Secretariat and the TRP sub-working group to take the appropriate actions to revise current procedures and documentation in line with the guidelines developed in the sub-meeting and the revised ToR for the sub-working group.<br/><br/></p>
2002-04-22 B02 GF/B02/DP03 Appointment of a rapporteur Appointment of a rapporteur
The Chair thanked the Foundation representative, Dr. Helene Gayle, for serving as rapporteur during the First Board Meeting and designated the Private Sector representative, Mr. Rajat Gupta, as rapporteur for the Second Board Meeting.
2002-04-22 B02 GF/B02/DP09 Organizational structure, workplan and budget of the Secretariat Organizational structure, workplan and budget of the Secretariat
<ol><li>The Board approved the suggested organizational structure of the Secretariat in principle, stressing the importance of the in-coming Executive Director having a possibility to fine-tune the structure.</li><li>The Board approved the workplan and budget for a five month period (not exceeding USD 9,8 million) and the Board requested the Executive Director to present a revised budget at the Board at the next Board Meeting</li></ol>
2002-04-22 B02 GF/B02/DP08 Phase one agreement Phase one agreement
<ol type="I"><li><u>Guidelines:</u><br/><ol><li>The Board decided to approve the Phase one agreement.</li><li>The Board requested the Secretariat to seek clarity from the Trustee on the management of exchange rate risks as well as the request for different accounts, and that the donors be asked to clarify the intention to earmark funds.</li><li>The Board decided to request the CCMs in consultation with the Secretariat and the Trustee to identify a suitable, independent, credible and experienced partner organization at country level to assure readiness for implementation and adequate programmatic, financial and related standards; and thereafter to oversee the financial accountability and programmatic implementation of the primary recipients (which could be more than one). This organization will not manage or implement the program. Implementation will be the responsibility of the local country partners identified in the proposal by the CCM.</li><li>The Board requested the Secretariat in consultation with the Trustee and other partners to define the standards for the Global Fund on financial accountability and programmatic implementation requirements at the country level, and stressed the importance of linkages to procurement policy.</li><li>The Board agreed to grant the Executive Director authority to enter into agreement with the identified partner organization at country level on the basis of the above CCM process in consultation with the Trustee on accountability standards.</li><li>The country-level arrangements should, if possible, build on already existing structures in country and leverage new private and public partnerships. In addition, the arrangement should aim at increasing local capacity and ensuring local ownership</li><li>The Board will be continuously informed as arrangements with in-country partner organizations are made in each country. </li><li>The Board agreed that, in parallel to the immediate steps described above, the Secretariat in consultation with the Trustee and other partners should develop and specify the Global Fund’s long term fiduciary requirements corresponding to international standards.</li><li>The outcome of the discussions between the Secretariat and the Trustee concerning long-term fiduciary requirements will be reported at the next Board meeting.</li></ol></li><li><u>Monitoring and evaluation:</u><br/><ol><li>The Board endorsed the inclusion of monitoring and evaluation as integral components of the grant agreement negotiations for approved proposals, noting the likely need for additional information on monitoring and evaluation to be provided by applicants.</li><li>The Board requested that monitoring and evaluation revisions to the guidelines for proposals and proposal form be considered by the Sub-working Group on Proposals (former sub-working Group on TRP) with input from the Monitoring &amp; Evaluation and Results-Based Disbursement Working Group (MER).</li></ol></li><li><u>Procurement:</u><br/><ol><li>The Board instructed the Secretariat to solicit additional information on approved applicants' procurement and distribution systems and to review this information prior to the approval of disbursement in accordance with other pre-disbursement arrangements.</li><li>The Board instructed the Executive Director to create a Procurement Task Force – consisting of a limited number of technical experts from multiple sectors, including UN agencies, the private sector and civil society – acting in their personal capacity and selected based on suggestions by and the approval of the Board – and to instruct this Task Force to provide the Board by its third meeting with recommendations on possible procurement policies. The Task Force will be chaired by two members of the Board and invite other Board members to voluntarily participate. The Task Force may draw on other technical expertise as necessary and on an ongoing basis." <br/><br/></li></ol></li></ol>
2002-04-22 B02 GF/B02/DP11 Dates of Third and Fourth Board Meeting Dates of Third and Fourth Board Meeting
<ol><li>The Board decided that the Third Board Meeting be held in Geneva and that it be tentatively scheduled for the middle of September, 2002.</li><li>The Board decided that the Fourth Board Meeting be tentatively scheduled for the middle of November, 2002 and that during this meeting a second round of proposal approvals for 2002 be considered.</li></ol>
2002-04-22 B02 GF/B02/DP01 Adoption of agenda Adoption of agenda
<p>The Board adopted the agenda as presented in document GF/B2/1 with the amendments of “Designation of Rapporteur” as a new, second agenda item and an additional presentation (without discussion) on the process of recruiting the Executive Director in advance of the discussion on the new Executive Director.</p>
2002-04-22 B02 GF/B02/DP07 Appointment of the Executive Director Appointment of the Executive Director
<ol><li>The Board approved the appointment of Richard Feachem for the post of Executive Director for a two-year period. The contract will be renewable. </li><li>The Board requested the Recruitment Committee to agree on performance indicators at the time of the negotiation of the contract of the Executive Director.</li></ol>
2002-04-22 B02 GF/B02/DP04 Approval of Board meeting report Approval of Board meeting report
<p>The Board adopted the minutes of the previous meetings as read with the proviso that the issue of multi-lateral employees to serve on the TRP be considered by the TRP Sub-working Group and brought back for review by the Board at its next meeting. The Board also took note of the longer report as drafted and the amendments suggested by the NGO Community representative to the short version.</p>
2018-12-21 B40 GF/B40/EDP02 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 to GF/B40/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-11-14 B40 GF/B40/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Daniel Graymore from the United Kingdom constituency is designated as Rapporteur for the 40<sup>th</sup> Board Meeting.</p>
2018-12-21 B40 GF/B40/EDP03 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease component: (i) Pakistan malaria, as listed in Table 2 of GF/B40/ER02, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-03-22 B40 GF/B40/EDP09 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B40/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-05-13 B40 GF/B40/EDP17 Decision on the Secretariat’s Recommendation on integration of Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on integration of Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER12 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-02-22 B40 GF/B40/EDP07 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B40/ER06 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> </ol> <p>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>
2019-01-31 B40 GF/B40/EDP05 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER04 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2019-04-01 B40 GF/B40/EDP11 Amendments to the Operating Procedures of the Board and Committees of the Global Fund Amendments to the Operating Procedures of the Board and Committees of the Global Fund
<p>The Board approves the amendments to the Operating Procedures of the Board and Committees of the Global Fund as set forth in Annex 1 to GF/B40/ER08 which shall enter into force upon the approval of this electronic decision point.</p>
2002-04-22 B02 GF/B02/DP10 Administrative Services Agreement with WHO Administrative Services Agreement with WHO
The Board approved the Administrative Services Agreement, with the minor modifications as requested, and authorized the Chairman of the Board to enter into this agreement with WHO.
2002-04-22 B02 GF/B02/DP02 Constituency naming convention Constituency naming convention
Several representatives requested that the labeling of Board members and constituencies be revised to ensure that the full constituency is referenced rather than the resident country of the appointed Board member. 
2008-04-29 B17 GF/B17/DP12 Reattribution of the Five-Year Evaluation Budget Reattribution of the Five-Year Evaluation Budget
The Board approves the reattribution of US$6 million of the Five-Year Evaluation budget from 2007 to 2008.
2008-04-29 B17 GF/B17/DP19 Approval of the Annual Report Approval of the Annual Report
<p>The Board approves the Annual Report as presented in GF/B17/7.</p>
2008-04-29 B17 GF/B17/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Mr. Javier Hourcade Bellocq from the Communities constituency is designated as Rapporteur for the Seventeenth Board Meeting.
2008-04-29 B17 GF/B17/DP08 Approval of 2007 Audited Financial Statements Approval of 2007 Audited Financial Statements
<p>The Board approves the 2007 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young as set out in Attachment 1 to the Report of the Finance and Audit Committee (GF/B17/6).</p><p><b>Annex 1 to Decision Point GF/B17/DP8:</b> </p><p><b>Principles for AMFm Policy Framework, Implementation and Business Plan</b> </p><p>• The timing of the AMFm-launch and implementation in endemic countries should be developed on the basis of the phase-in paper set out as Attachment 3 to the PSC Report (GF/B17/4), to include the following factors:</p><p>- A phased launch starting with a first group of countries to be selected according to criteria developed by the Secretariat and agreed at the 18<sup>th</sup> Board Meeting;</p><p>- Roll-out of the AMFm in these selected countries for an initial phase until a Board decision on full roll-out is reached;</p><p>- Operational research and extensive M&amp;E efforts carried out in these first countries accessing the AMFm to assess the extent to which the AMFm can meet its objectives and provide lessons learned about the design and implementation of the AMFm that would inform a subsequent Board decision on full roll-out;</p><p>- An independent technical evaluation of the roll-out of the AMFm in the selected countries will be commissioned by the Global Fund Secretariat , under the guidance of the appropriate committee, using a set of pre-defined key indicators to be further elaborated and agreed at the Eighteenth Board Meeting to assess potential failures and short-comings("red flags") in the AMFm;</p><p>- At its first meeting in 2010, the Board will consider findings from this evaluation for a decision on whether to expand, accelerate, terminate or suspend the AMFm business line;</p><p>- Expansion from the initial phase to a full roll-out in all eligible countries will occur within a year of launch unless clear failures ("red flags") in the AMFm design are observed.</p><p>• The AMFm should be designed to increase access to ACTs by requiring national roll out plans/strategies that:</p><p>- Emphasize reaching women, children and the poor, </p><p>- Are fully financed, including sources of funding for supporting interventions to enable safe and broad access (notably among those who are currently unable to purchase ACTs because of their low income);</p><p>- Include plans for training, supervision and monitoring of providers, especially to ensure patient safety;</p><p>- Explain how the plan and its interventions link with national malaria control strategies and programs and how AMFm will be coordinated with supporting interventions.</p><p>- Are reviewed and approved by an independent standing technical body that determines that the AMFm roll-out plan is technically sound, with a particular focus on assuring sufficient investment in necessary supporting interventions, prior to provision of co-payment funding</p><p>• The AMFm should pursue responsible negotiations and contracting with manufacturers:</p><p>- Manufacturer sales prices for private sector buyers must not exceed the price available to public sector buyers (currently US$1/dose);</p><p>- Quality standards applied to drugs that qualify for the co-payment must, as a minimum, meet the quality standards outlined in the Global Fund's Quality Assurance policies; and</p><p>- The duration of copayment contracts should not extend beyond the duration of the first phase of roll-out so as to ensure continuation of market competition to reduce prices and encourage market entry of new participants.</p><p>• The AMFm should pursue a responsible funding policy and resource mobilization strategy:</p><p>- The AMFm will not become operational until sufficient funds have been contributed to cover co-payment costs for the full first phase of roll-out;</p><p>- Resources mobilized by the Global Fund Secretariat for the AMFm copayment should be additional to and separate from resources raised for ongoing Global Fund grant making and, must be held in a separate account with the Trustee;</p><p>- Resource mobilization for supporting interventions will be part of ongoing resource mobilization for Global Fund grant making and should be integrated into the Global Fund resource mobilization strategy;</p><p>- No funds can be transferred from the Global Fund's "general" account with the Trustee to support AMFm co-payments;</p><p>- The Global Fund will not make contractual commitments with manufacturers unless the necessary funds are available in the copayment account with the Trustee.</p><p>• The AMFm should work with partners to ensure that:</p><p>- The process for country access, including the development and assessment of roll-out plans, is simple and well-supported;</p><p>- Provider training and supervision emphasizes appropriate use of ACTs; and</p><p>AMFm implementation builds on consultation with the Private Sector in participating countries to ensure the co-payment is passed on through the supply chain.</p>
2008-04-29 B17 GF/B17/DP24 Togo Round 2 HIV Continuity of Services Togo Round 2 HIV Continuity of Services
<p>1. The Board recalls its decision of 17 July 2007 regarding the establishment of continuity of services arrangements for 2,300 patients in Togo following the expiration of the Togo Round 2 HIV grant (TOG-202-G01-H-00). These arrangements will expire in September 2008.</p><p>2. The Board understands that no alternative sources of funding have yet been secured to sustain treatment for these patients and that, unless funding can be secured rapidly, treatment availability for such patients is likely to be interrupted.</p><p>3. The Board decides to the extend the current continuity of services arrangements for the Togo Round 2 HIV grant and approves the use of existing grant funds to procure buffer stocks to cover continued treatment for 2,300 patients for a period of up to six months following the end of the current continuity of services arrangements (i.e. 31 March 2009).</p><p>4. The Board notes with appreciation the efforts of technical and bilateral partners, civil society and the government in preparing Togo's Round 8 application and urges the government to redouble its efforts and the Global Fund's partners to help contribute to meeting the country's urgent needs. </p>
2008-04-29 B17 GF/B17/DP17 Non-Voting Seats for Malaria and Tuberculosis Non-Voting Seats for Malaria and Tuberculosis
Recognizing the need for equitable representation of HIV/AIDS, tuberculosis and malaria within the Global Fund, the Board decides that the follow up work and decisions on the Five Year Evaluation should include action to ensure the effective participation on the Global Fund Board of malaria and tuberculosis constituencies. The Board requests the PSC to discuss the issues and present outcomes at the Board Retreat in October 2008 so that a recommendation can be presented at the Eighteenth Board Meeting in November 2008.
2008-04-29 B17 GF/B17/DP10 Budget Framework for Future Years Budget Framework for Future Years
The Board approves the Budget Framework as set out in Annex 3 to the Report of the Finance and Audit Committee (FAC) (GF/B17/6), which shall guide the formulation and consideration for approval of annual budgets for Operating Expenses of the Global Fund. The Board requests that FAC annually review the Framework, including the parameters, for three years, bearing in mind the desire to achieve economies of scale, and thereafter as needed, and report back to the Board, with recommendations for modifications as necessary. In conjunction with the PSC process that will recommend Secretariat KPIs for 2009, FAC shall explore how best to link the KPIs to the budget. The FAC shall also examine how to enhance its review of expenditure each year. 
2008-04-29 B17 GF/B17/DP15 Memorandum of Understanding with UNAIDS Memorandum of Understanding with UNAIDS
The Board welcomes and supports the Executive Director's initiative to strengthen the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the new memorandum of understanding with UNAIDS (the "UNAIDS MoU"), and requests the Executive Director to finalize and sign the UNAIDS MoU.
2008-04-29 B17 GF/B17/DP22 Transition from Administrative Services - Pension Arrangements Transition from Administrative Services - Pension Arrangements
The Board renews its delegation of authority to the Finance and Audit Committee to approve the Global Fund's cash balance pension fund, and requests the Executive Director to take all necessary action, including the execution of legal agreements, to establish the pension fund following such approval.
2008-04-29 B17 GF/B17/DP07 Amendments to the Continuity of Services Policy Amendments to the Continuity of Services Policy
<p>The Board amends the Continuity of Services Policy (GF/B14/DP11) by amending paragraph v as follows:</p> <p>v. The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval if incremental funding is needed. If incremental funding is not required because there are sufficient funds remaining under the ending grant to cover the Extraordinary Request, the Board authorizes the Secretariat to approve the Request, on the same conditions and subject to the same limitations as set out in this policy. The Secretariat will take into account performance issues, as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of Global Fund financing.</p>
2008-04-29 B17 GF/B17/DP23 Launch of Round 9 Launch of Round 9
<ol><li> The Board, determined to scale up the Global Fund's response to HIV, Tuberculosis and Malaria, decides in principle to announce, after the Seventeenth Board Meeting, that there will be an extra Call for Proposals for funding in 2008.</li><li> The Board requests the Secretariat to prepare to issue a Call for Proposals for Round 9, which shall employ the same proposal form and guidelines as Round 8, on or about 1 October 2008, and to provide for review of those proposals in time for approval at the Nineteenth Board Meeting in April 2009.</li><li> The Board decides that in Round 8 and 9:<ol type="a"><li>Applicants whose initial proposal receives a Category 3 recommendation may resubmit a revised version of the same proposal in the next Round for consideration by the TRP in time for the Board to make a decision at its next Board Meeting.</li><li>When the TRP comments on initial Category 3 proposals, it is encouraged to recommend the types of changes that need to be made to strengthen the proposal for resubmission.</li><li>Within a week of the Board being informed of the TRP's recommendations and comments, each applicant should be informed by the Secretariat of the TRP's recommendation and comments regarding its proposal.</li></ol></li><li> The Board recognizes that this decision point has implications for the Secretariat, the TRP, and applicants. The Secretariat is requested by no later than 15 May 2008 to submit to the Board, for approval by email, a final decision on announcing Round 9, together with a description of resources available and forecasted and proposed changes to existing policies necessary to implement this decision point.</li><li> The Board calls on its members and RBM, along with the STOP TB Partnership and UNAIDS Co-sponsors, to provide support to implementers to develop high-quality proposals and to manage efficient programs, to ensure the effectiveness of Global Fund resources. </li><li> The Board also calls on implementing partnerships, donor countries, and technical partners to prioritize their efforts to develop and agree on a shared approach by which national strategies can be validated, as a basis for the Global Fund to approve funding requests through national strategy applications, and to accelerate the development of robust country-level national strategies. The Board recognizes that national-strategy applications could provide the most sound basis for the scaling-up of programs to prevent, control and treat HIV, tuberculosis and malaria, and could be the most effective way to streamline the ability of country-level partnerships to earn Global Fund resources. </li></ol>
2008-04-29 B17 GF/B17/DP16 Affordable Medicines Facility for Malaria Affordable Medicines Facility for Malaria
<p>The Board refers to its decision (GF/B16/DP14) and the decision of the Board of the Roll Back Malaria ("RBM") Partnership at its meeting on 28-29 November 2007 inviting the Global Fund to take on full responsibility to host and manage the Affordable Medicine Facility - malaria ("AMFm").</p> <p>The Board agrees to have the Secretariat prepare to host and manage the AMFm as a business line within the Global Fund:</p> <ul> <li>based on the AMFm design and business plan set out in the Secretariat Report to the Policy and Strategy Committee (GF/PSC9/03); and</li> <li>subject to final approval at the Eighteenth Board Meeting of a policy framework and implementation plan that incorporates the principles set out in Annex 1 to this Decision Point and offers practical solutions, in consultation with technical partners, to remaining technical issues (including identification of strategies to maximize access to ACTs by the most vulnerable and poorest and ensuring patient safety).</li> </ul> <p>The Board acknowledges the work and recommendations of the RBM Task Force on the AMFm design, as endorsed by the RBM Executive Committee, and joins the RBM Executive Committee in asking the RBM partnership and the AMFm Task Force to continue to contribute to the development of the AMFm and to pursue all options to maximize access (including targeting the poorest through free distribution of ACTs through public and NGO channels).</p> <p>The Board requests that the Secretariat continue to work with the RBM Partnership, UNITAID, endemic countries, and other relevant stakeholders and develop and present to the Board at its Eighteenth Meeting for decision:</p> <ol type="i"> <li>The policy framework and implementation plan for managing the AMFm, including the calendar for phasing in the AMFm and monitoring and evaluation (M&amp;E) arrangements;</li> <li>Recommended arrangements for the ongoing governance of the AMFm;</li> <li>A statement of the resources available for launching the initial phase of the AMFm;</li> <li>The organizational and budgetary requirements for managing the AMFm in its initial phase of operation; and</li> <li>Any required technical changes to the AMFm design and business plan.</li> </ol> <p>To oversee and guide the work by the Secretariat, the Board decides to establish an ad-hoc committee of the Board: the "AMFm Ad-hoc Committee". The ad-hoc committee should include relevant partners, and potential donors, including UNITAID. The Board invites nominations for the members of the AMFm Ad-hoc Committee and requests the submission of nominations to the Board Chair and Vice Chair by no later than May 15, 2008. Membership of the AMFm Ad-hoc Committee shall not apply towards the two-committee limit set out in Section 23 of the Board Operating Procedures.</p> <p>The Board requests the Finance and Audit Committee to work with the AMFm Ad-hoc Committee to review the AMFm design and business plan with regard to 1) the plan's policy and strategy issues relating to finance, 2) implications for the Fund's budget for Operating Expenses, and 3) the Fund fiscal management policies and processes. This review should particularly consider elements of the plan that would involve the Secretariat entering into contractual arrangements with implementers of the AMFm, any additional risk this may pose to the Fund, and how this plan will fit within the forthcoming risk management framework of the Fund and its model as a financing institution, not an implementing agency.</p> <p>The Board calls upon the FAC and the PSC, as part of its ongoing work, to provide analysis on elements of the AMFm policy framework, implementation and business plan that may potentially change the Global Fund framework document and bylaws. In particular, the FAC and the PSC should further review how the various tasks induced by the management of the AMFm should be shared between the Global Fund and its partners. The Board notes the need for extensive consultation with Board members on any proposed substantive change to the Fund's Framework Document of Bylaws.</p>
2008-10-18 B17 GF/B17/EDP08/16 Global Fund Human Resources Policy Framework Global Fund Human Resources Policy Framework
The Board approves the Global Fund Human Resources Framework, as laid out in Annex 1 to Global Fund Human Resources Policy Framework (GF/EDP/08/16), which shall be brought into effect on 1 January 2009.
2008-04-29 B17 GF/B17/DP04 Technical Review Panel Members and Alternate Members Technical Review Panel Members and Alternate Members
<p>The Board approves:</p><p>(a) Dr Fernando Del Castillo (HIV), Dr Ahmed Awad Adeel Adbel-Hameed (Malaria), Dr Omou Younoussa Bah-Sow (Tuberculosis), and Drs Beatriz Ayala-Ostrom, Grace Murindwa, Alison Heywood and Maggie Huff-Rouselle (Cross-Cutting) as Permanent Members of the TRP to serve up to four Rounds commencing from Round 8;</p><p>(b) On an exceptional basis, and to strengthen the TRP's expertise in health systems strengthening (HSS) pending a full replenishment of the TRP Support Group in 2009, two persons currently serving as members of the GAVI Alliance HSS Independent Review Committee, Dr Elsie Le Franc and Dr Bola Oyeledun; and</p><p>(c) In respect of calls for proposals made in 2008, the eighteen (18) persons identified as Alternate Members in the Report of the Portfolio Committee (GF/B17/5, Revision 1),</p><p>each of whom have been recommended by the Portfolio Committee and the Executive Director upon consideration of required technical expertise, as well as geographical distribution and gender balance.</p>
2008-04-29 B17 GF/B17/DP09 Priorities for the Office of the Inspector General Priorities for the Office of the Inspector General
<p>The Board approves the Priorities for the Office of the Inspector General as set out in Attachment 2 and summarized in Annex 2 to the Report of the Finance and Audit Committee (FAC) (GF/B17/6).</p><p>The Board requests the Inspector General to report to the FAC on the action taken in response to any case where mismanagement of Global Fund grant programs has taken place. The Board requests the FAC to review at its meetings any reports received from the Inspector General and action taken in response to such cases, and to propose any further action that the FAC considers necessary, in consultation with other relevant actors in-country.</p>
2008-04-29 B17 GF/B17/DP13 Debt2Health – Exploration of Additional Opportunities Debt2Health – Exploration of Additional Opportunities
The Board recognizes some early success in securing resources through Debt2Health and awaits the first contribution in mid-2008. Although the Board awaits specific data on aspects of the program, the Board supports exploration of additional opportunities. Based on additional data, the Board may consider expansion of the pilot program in the future.
2008-04-29 B17 GF/B17/DP14 Guidance for Board Seat Allocation for Public Donors Guidance for Board Seat Allocation for Public Donors
<p>The Board recognizes the importance of establishing a transparent framework for seat allocation among public donors that attributes rights based principally on levels of contributions, and that helps achieve higher levels and timely payment of contributions.</p><p>In accordance with Article 7.2 of the By-laws, the Board requests the Board Members representing donor constituencies, in consultation with other donors, to determine a framework for donor seat allocation, within the existing eight public donor seats and guided by a threshold, and to report to the Board on their conclusions at the Eighteenth Board Meeting. </p>
2008-04-29 B17 GF/B17/DP20 Transition from Administrative Services - WHO Arrangements Transition from Administrative Services - WHO Arrangements
The Board accepts with gratitude the World Health Organization's offer to provide human resources services, based on WHO's pay scale and rules and regulations, following the discontinuation of the Administrative Services Agreement on December 31, 2008. Global Fund staff shall at that time be directly employed by the Global Fund. The Board requests the Executive Director to negotiate and enter into a legal agreement putting in place this arrangement, not to extend past 30 September 2009, by which time the Global Fund's own arrangements for Human Resources services shall be in place.
2008-04-29 B17 GF/B17/DP06 Delegation of Authority to the Secretariat for Grant Closure Activities Delegation of Authority to the Secretariat for Grant Closure Activities
<p>The Board notes the Secretariat's principles for grant closure set out in Annex 1 of the Portfolio Committee Report (GF/B17/5, <b>Revision 1</b>).</p><p>The Board recognizes that, in the exceptional circumstances of unanticipated terminations, there may be a need for continued funding for programmatic activities in order to ensure the orderly and ethically responsible closure of the grant. The Board endorses the Secretariat's authority, as part of its grant management responsibilities, to approve continued funding for programmatic activities in cases of unanticipated termination from remaining grant funds, based on the Secretariat's grant closure principles, emphasizing that any such funding be time-limited. The Board also acknowledges that, in exceptional cases, funds disbursed prior to the grant end date may not be sufficient to cover grant closure expenses. The Board delegates to the Secretariat the authority to allow disbursements of remaining grant funds for grant closure activities after the grant end date in exceptional circumstances provided the expenses are reasonable and permitted in accordance with the Secretariat's grant closure principles.</p><p>The authorities of the Secretariat referred to above relate to funds remaining under the grant. Board approval continues to be required for any incremental funding that is necessary to finance grant closure expenses that exceed the remaining grant funds.</p><p>The Portfolio Committee will continue to oversee the application of the Secretariat's grant closure policy as part of its on-going responsibility to review regular portfolio updates from the Secretariat. The Secretariat will report to the Portfolio Committee on a regular basis on all unanticipated terminations and suspensions of grants during the preceding reporting period and the arrangements for such grants. These reports will include the specific amounts of funding to be allocated for grant closure, their use and other key issues.</p>
2008-04-29 B17 GF/B17/DP03 Approval of Report of the Sixteenth Board Meeting Approval of Report of the Sixteenth Board Meeting
The report of the Sixteenth Board Meeting (GF/B17/2) is approved.
2008-04-29 B17 GF/B17/DP02 Approval of Agenda Approval of Agenda
The agenda for the Seventeenth Board Meeting (GF/B17/1, Revision 1), as amended, is approved.
2008-04-29 B17 GF/B17/DP05 Amendments to the TRP Terms of Reference Amendments to the TRP Terms of Reference
<p>The Board amends Article 32 of the TRP Terms of Reference [GF/B15/7 Annex 2] as follows:</p><p>32. The TRP shall review each Rounds based proposal as a whole and not separately evaluate elements within a proposal, and recommend some to the Board for funding and not others. However, in reviewing a disease component which contains a cross-cutting HSS section, the TRP may recommend for funding either:</p><p>a. The entire disease component, including the cross-cutting HSS section;</p><p>b. The disease component excluding the cross-cutting HSS section; or</p><p>c. Only the cross-cutting HSS section if the interventions in that section materially contribute to overcoming health systems constraints to improved HIV, tuberculosis and malaria outcomes.</p><p>In addition, tThe TRP can recommend modification or even elimination of weak elements in an otherwise strong proposal where those weak elements are not a key or major aspect of the proposal.</p>
2006-07-10 B13 GF/B13/EDP03 Amendments to Bylaws and Board Operating Procedures Amendments to Bylaws and Board Operating Procedures
<p>The Board amends the Board Operating Procedures by inserting the following text as Section “G” and renumbering the remaining text accordingly:</p><p><span></span></p><p>G. PROCEDURES FOR APPOINTMENT AND ASSESSMENT OF THE EXECUTIVE DIRECTOR</p><p><span></span></p><p>26. Appointment of the Executive Director</p><p><span></span></p><p> No later than six months prior to the end of the term of the incumbent Executive Director, the Board shall, in accordance with Article 8.1 of the Bylaws and this Section of the Board Operating Procedures, decide on a procedure for the appointment of the next Executive Director. </p><p><span></span></p><p> At this time, the Board shall normally launch a competitive recruitment process, publicly inviting applications for the position of Executive Director. Where the incumbent Executive Director has not served more than one term of office, the Board shall invite him or her to re-apply, together with other candidates, for such position and publicly announce such invitation. Where appropriate the Board may launch such a recruitment process without inviting the Executive Director to re-apply for the post or, based on a satisfactory performance appraisal and if the incumbent Executive Director has not served more than one term, extend the appointment of the Executive Director for a further term of three years without the normal recruitment process.</p><p><span></span></p><p>If the Board decides to launch a recruitment process, it shall be assisted by an ad hoc Nomination Committee. At least six months prior to the end of the term of the incumbent Executive Director, or at any other time decided by the Board, the Chair of the Board shall, notwithstanding the otherwise applicable procedures under these Board Operating Procedures and the Committee Rules and Procedures, recommend for Board approval the terms of reference of the Nomination Committee and nominate for Board approval a Chair and the membership of that Committee. Membership in the Nomination Committee shall not count towards the two committee limit referenced in Section 23 of these Board Operating Procedures.</p><p><span></span></p><p> The Chair of the Board may also recommend for Board approval updated terms of reference of the Executive Director and the criteria for his selection. Following approval of the membership of the Nomination Committee, the recruitment process is launched. </p><p><span></span></p><p>The Nomination Committee shall interview and rank candidates, and present the highest ranking candidates to the Board, which shall then select a candidate, consistent with the terms of office of the Executive Director that are stated in Section 17 of these Board Operating Procedures.</p><p><span></span></p><p>The mandate of the Nomination Committee shall expire upon the appointment of the Executive Director.</p><p><span></span></p><p>27. Assessment of the performance of the Executive Director</p><p><span></span></p><p>The Chair of the Board shall ensure that the performance of the Executive Director is assessed each year based on best practices. All documentation related to such assessment shall be provided to the Board not later than the end of the first quarter of the calendar year. </p>
2006-04-28 B13 GF/B13/DP19 Round 5 Appeals Round 5 Appeals
<p>The Board approves for funding, in the amounts indicated, the following Round 5 proposals that were recommended by the Internal Appeal Panel in its Report to the Twelfth Board Meeting (GF/B12/8) and could not be approved for funding at the Twelfth Board meeting due to resource constraints:</p><p>i. Equatorial Guinea (Malaria) -- US$ 12,906,111</p><p>ii. Philippines (Tuberculosis) -- Euro 11,709,434</p><p>iii. Sudan (HIV/AIDS) -- US$29,424,335</p><p>iv. Sudan (Tuberculosis) -- US$6,830,013</p><p>The Board's approval is made with the clear understanding the amount listed for each proposal is an upper ceiling rather than the final Phase 1 Grant amounts.</p>
2006-04-28 B13 GF/B13/DP39 Staff Council Staff Council
The Board acknowledges the formation of the Global Fund Staff Council in November 2005 and notes the intention of the Board Chair, the Vice Chair, and the Staff Council to meet prior to every Board meeting.
2022-04-22 B46 GF/B46/EDP20 2021 Statutory Financial Statements 2021 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2021 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B46/ER15.</p>
2022-04-22 B46 GF/B46/EDP19 2021 Annual Financial Report 2021 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2021 Annual Financial Report, including the 2021 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B46/ER15.</p>
2022-03-30 B46 GF/B46/EDP18 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Multicountry Africa ECSA-HC) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Multicountry Africa ECSA-HC)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$45 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER14; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2022-03-07 B46 GF/B46/EDP17 Increased Funding to the Emergency Fund Increased Funding to the Emergency Fund
<p>The Board expresses its concerns around the devastating effects of the recent invasion of Ukraine; Tropical Cyclone Ana in Mozambique and Malawi; and the conflict in Ethiopia’s northwestern Tigray region and the grave consequences for human lives in these areas. The Board further reaffirms its commitment to responding efficiently and quickly to emergency contexts to ensure the continuity of life-saving health services through Global Fund-supported programs. Therefore, the Board:</p> <ol> <li>Acknowledges that additional funding is required for the Emergency Fund in order to ensure that there is sufficient funding to respond to current and evolving emergency needs;</li> <li>Approves the reallocation of USD 30 million from Audit and Finance Committee-approved portfolio optimization funds to the Emergency Fund.</li> </ol>
2022-03-15 B46 GF/B46/EDP16 Appointment of Independent Committee Members Appointment of Independent Committee Members
<ol> <li>The Board approves the renewal for one additional term of: <ol type="i"> <li>Robert Samels as Independent Member of the Audit and Finance Committee with financial audit expertise;</li> <li>Diana Isiye as Independent Member of the Audit and Finance Committee with forensic investigation expertise; and</li> <li>Mohammad Ali Mubarak Kisubi as Independent Member of the Ethics and Governance Committee with ethics expertise.</li> </ol> </li> <li>The individuals appointed under this decision point will begin their term on 12 May 2022 and serve for two years or until appointment of their respective successors.</li> <li>The Board notes each independent committee member appointed under this decision point is entitled to receive honoraria in accordance with the Global Fund’s Honorarium Framework.</li> </ol>
2022-03-15 B46 GF/B46/EDP14 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B46/ER11 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-03-15 B46 GF/B46/EDP15 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B46/ER11 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>
2022-03-15 B46 GF/B46/EDP13 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER11 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-04-28 B46 GF/B46/EDP23 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed inTable 3 of GF/B46/ER23 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>
2022-02-25 B46 GF/B46/EDP12 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER10; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-12-22 B46 GF/B46/EDP06 Extension of the COVID-19 Response Mechanism and COVID-19 Operational Flexibility Extension of the COVID-19 Response Mechanism and COVID-19 Operational Flexibility
<ol> <li>Based on the rationale provided in GF/B46/ER06, the Board: <ol type="a"> <li>Approves that any additional 6th Replenishment pledges received through 30 September 2022 will be used to support the COVID-19 Response Mechanism (C19RM);</li> <li>Approves that any additional C19RM funds may be awarded through 31 March 2023;</li> <li>Approves to revise the thresholds for Board approval of C19RM awards set out in paragraph 5.d of GF/B44/EDP18 based on the total additional C19RM funding made available, as follows: <ol type="i"> <li>If up to US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 45 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 15 million, where such increases scale-up interventions approved by the Board;</li> <li>If more than US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 55 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 20 million, where such increases scale-up interventions approved by the Board; and</li> <li>Threshold amounts will continue to be measured in aggregate by country, not including any amounts awarded under the fast-track approach or C19RM funds awarded in 2020;</li> </ol> </li> <li>Agrees that all other parameters of C19RM under GF/B44/EDP18 remain unchanged; and</li> <li>Approves that the Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 December 2023.</li> </ol> </li> </ol>
2021-12-21 B46 GF/B46/EDP08 Approval of the Revision for KPI 6e Approval of the Revision for KPI 6e
<p>Based on the recommendation of the Strategy Committee, the Board approves the revision for Key Performance Indicator 6e as presented in GF/B46/ER08.</p>
2021-12-17 B46 GF/B46/EDP07 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Liberia) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Liberia)
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER07; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-12-20 B46 GF/B46/EDP09 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2021-12-20 B46 GF/B46/EDP10 Decision on the Secretariat’s Recommendation on Additional Funding for the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding for the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B46/ER09 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-12-13 B46 GF/B46/EDP04 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-12-02 B46 GF/B46/EDP02 Approval of Additional Funding to Address the Health Crisis in Venezuela Approval of Additional Funding to Address the Health Crisis in Venezuela
<p>The Board:</p> <ol> <li>Expresses continuing concern about the protracted public health crisis in Venezuela, which has been further exacerbated by the COVID-19 pandemic, and continues to adversely impact the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Notes that while the Board exceptionally approved the eligibility of Venezuela’s malaria component under GF/B41/EDP06, resulting in an allocation of US$ 19,800,000 for the 2020-2022 allocation period, Venezuela’s HIV and tuberculosis components were not eligible to receive allocations in the 2020-2022 allocation period;</li> <li>Acknowledges the new proposal for exceptional funding in 2022 and 2023 presented by the Secretariat and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B46/ERXX and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B46/ERXX and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B46/ERXX and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 12,000,000, for the years 2022 and 2023, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>
2021-11-26 B46 GF/B46/EDP03 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Bangladesh) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Bangladesh)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020), as well as increases to C19RM awards previously approved by the Board that either exceed USD 10 million or include interventions not previously approved by the Board;</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER03; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2022-02-11 B46 GF/B46/EDP11 Approval of the Report of the Global Fund 46th Board Meeting Approval of the Report of the Global Fund 46th Board Meeting
<p>The Board approves the Report of the Global Fund 46th Board Meeting, as set forth in GF/B46/22.</p>
2021-11-24 B46 GF/B46/EDP01 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2022-04-28 B46 GF/B46/EDP21 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, aslisted in Table 1 of GF/B46/ER21 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposedPrincipal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by theSecretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shallbe committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for eachcountry disease component among its constituent grants, provided that the Technical Review Panel (the“TRP”) validates any redistribution that constitutes a material change from the program and fundingrequest initially reviewed and recommended by the TRP.</li> </ol>
2022-05-04 B46 GF/B46/EDP26 Appointment of the Chairs, Vice-Chairs and Members of the Standing Committees of the Board Appointment of the Chairs, Vice-Chairs and Members of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of:<br /> <ol type="i"> <li>Edward Ouko as Chair of the Audit and Finance Committee:</li> <li>Sylvie Chantereau as Vice-Chair of the Audit and Finance Committee:</li> <li>Paul Schaper as Chair of the Ethics and Governance Committee</li> <li>Julia Martin as Chair of the Strategy Committee</li> <li>Carolyn Gomes as Vice-Chair of the Strategy Committee</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Revanta Dharmarajah, Developed Country NGOs</li> <li>Andriy Klepikov, Developing Country NGOs</li> <li>Sara Osman, Eastern Mediterranean Region</li> <li>Birgitte Hagelund, European Commission, Belgium, Italy, Portugal and Spain</li> <li>Hiroshi Matsumura, Japan</li> <li>Andreas Karlberg Pettersen, Point Seven</li> <li>Greg Ferrante, Private Foundations</li> <li>Erika Satterwhite, Private Sector</li> <li>Rai Mahimapat Ray, South East Asia</li> <li>Michael Ruffner, the United States of America</li> <li>Daniel Domelevo, West and Central Africa</li> <li>Jiayan Huang, Western Pacific Region</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Aisha Al Kuwari, Additional Public Donors</li> <li>Alexandru Chitic Patapievici, the World Bank</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:<br /> <ol type="i"> <li>Erika Castellanos, Communities</li> <li>Edellin Calixte Randriamiandrisoa, Eastern and Southern Africa</li> <li>Miŝo Pejkovic, Eastern Europe and Central Asia</li> <li>Mohamed Chakroun, Eastern Mediterranean Region</li> <li>Sarah Burwood, France</li> <li>Annette Chammas, Germany</li> <li>Roisin Fegan, the United Kingdom</li> <li>Anthony (Jin) Park, the United States of America</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Timothy Poletti, Canada, Switzerland and Australia</li> <li>Javier Hourcade Bellocq, Communities</li> <li>Gerald Gwinji, Eastern and Southern Africa</li> <li>Tonka Varleva, Eastern Europe and Central Asia</li> <li>Stéphanie Seydoux, France</li> <li>Birgit Pickel, Germany</li> <li>Hampus Holmer, Point Seven</li> <li>Sherwin Charles, Private Sector</li> <li>Sarah Boulton, the United Kingdom</li> <li>Massimo Ghidinelli, Latin America and the Caribbean</li> <li>Djalo Boukou Oumar Mele, West and Central Africa</li> <li>Jim Tulloch, Western Pacific Region</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as non-voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Melanie Renshaw, Partners</li> <li>Victor Bampoe, UNAIDS</li> <li>Mubashar Sheikh, World Health Organization</li> </ol> </li> <li>The Board notes that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group (to be succeeded by the Independent Evaluation Panel pursuant to Board decision GF/B46/DP06) also serve as non-voting members of the Strategy Committee.</li> <li>The Board further notes that each of the individuals named in this decision will commence their term on 13 May 2022 and will serve for two years or until appointment of their successor.</li> </ol>
2011-05-10 B22 GF/B22/EDP18 Additional funding for Continuity of Services to the Round 3 Yemen HIV grant (YEM-307-G05-H) Additional funding for Continuity of Services to the Round 3 Yemen HIV grant (YEM-307-G05-H)
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p><p>See attached tabledetailing total recommended funding amount of US$ 400,572 for the following grant: YEM-307-G05-H </p>
2010-12-15 B22 GF/B22/DP12 Committee Leadership: Chair of the Market Dynamics and Commodities Ad-hoc Committee (MDC) Committee Leadership: Chair of the Market Dynamics and Commodities Ad-hoc Committee (MDC)
The Board approves the appointment of Oliver Sabot from the Private Foundations constituency as Chair of the Market Dynamics and Commodities Ad-hoc Committee (MDC) for the period from the date of this decision until the adjournment of the first Board meeting of 2011 to replace the outgoing Chair, Mr Dai Ellis.
2011-03-24 B22 GF/B22/EDP12 Round 10 Independent Appeals Panel Recommendation Round 10 Independent Appeals Panel Recommendation
<ol><li>The Board approves funding for the Round 10 Ethiopia Tuberculosis proposal for the Phase 1 Period of up to USD 21,107,334, as a „Category 2‟ proposal recommended by the Independent Appeals Panel, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount and subject to satisfactory completion by the applicant of the requirements set out in paragraph 2 below:</li><li>The applicant shall: <ol><li type="a">Provide an initial detailed written response to the clarifications and adjustments requested by the Independent Appeals Panel not later than six weeks after the receipt of the notification in writing by the Secretariat to the applicant of this Board decision; and</li><li type="a">Complete any further clarifications or adjustments, as required by the Chair or Vice-Chair of the Technical Review Panel, not later than three months from the Secretariat‟s receipt of the applicant‟s initial detailed response to the issues raised for clarifications or adjustments.</li></ol></li></ol>
2011-01-31 B22 GF/B22/EDP04 Extend Phase 1 period of the Round 7 Tanzania Malaria grant (TNZ-708-G10-M) Extend Phase 1 period of the Round 7 Tanzania Malaria grant (TNZ-708-G10-M)
<p>The Board decides:</p> <p>1. to revise Conditions 2 and 3 to its Phase 2 approval for the Round 6 Zanzibar HIV (ZAN-607-G05-H) grant as follows:</p> <ul> <li>Condition 2 shall be revised to: “Within 6 months of the signing of the Phase 2 extension the Secretariat will review a repeat LFA On Site Data Verification (OSDV) to determine whether 1) this reconfirms the number of people on ARV treatment at that time, 2) actions recommended from the first OSDV have been implemented and 3) there are appropriate systems in place to ensure quality data.”</li> <li>Condition 3 shall be revised to: “Within 6 months of the signing of the Phase 2 extension the PR shall have completed working with technical agencies on an independent performance review of the Program and provide this independent performance review to the Global Fund. Continuation of funding for years 4 and 5 under the Program is subject to a determination by the Secretariat that the independent performance review demonstrates an efficient use of resources under the Program.”</li> </ul> <p>2. that if Condition 3, as revised, is not fulfilled within the timescale set then the Secretariat is to proceed to terminate the grant.</p>
2011-02-12 B22 GF/B22/EDP06 February 2011 Phase 2 Funding Decision February 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 44,256,536 for the following grants: AGO-708-G04-M ; TCD-708-G03-M ; MOZ-708-G07-T</p>
2011-03-03 B22 GF/B22/EDP10 Amendment of By-Laws and Board Operating Procedures: Appointment of Executive Director Amendment of By-Laws and Board Operating Procedures: Appointment of Executive Director
<p>The Board approves to change:</p> <p>1) Article 8. Secretariat, paragraph 8.1 of the By-Laws to read as follows:</p> <p>8.1 Composition</p> <p>The Secretariat is responsible for managing the day-to-day operations of the Foundation.</p> <p>The Secretariat is headed by an Executive Director, who is selected by the Foundation Board based on merit, in a non-political, open and competitive manner. The Executive Director acts as the chief executive officer of the Foundation and serves for a term of four years<span style="text-decoration: line-through;">, renewable for not more than one additional term of three years.</span></p> <p>The Executive Director is responsible to the Foundation Board for the day-to-day management of the Foundation, and for specific duties and responsibilities assigned to him or her by the Foundation Board.</p> <p>Secretariat staff are selected by the Executive Director, under policies and procedures approved by the Foundation Board.</p> <p>2) Section D. ROLES AND RESPONSIBILITIES, paragraph 17 of the Board Operating Procedures to read as follows:</p> <p>17. Executive Director</p> <p>17.1 The Executive Director shall attend all Board Meetings, and shall be responsible for the preparation and distribution of all materials required for the meeting, and for such other duties and responsibilities as may be assigned by the Board or the Chair. The Executive Director shall be appointed by the Board for a term of four years<span style="text-decoration: line-through;">, renewable for not more than one additional term of three years.</span></p> <p>3) Section G. PROCEDURES FOR APPOINTMENT AND ASSESSMENT OF THE EXECUTIVE DIRECTOR, paragraph 26 of the Board Operating Procedures to read as follows:</p> <p>26. Appointment of the Executive Director</p> <p>26.1 No later than six months prior to the end of the term of the incumbent Executive Director, the Board shall, in accordance with Article 8.1 of the Bylaws and this Section of the Board Operating Procedures, <span style="text-decoration: line-through;">decide on a procedure for the appointment of the next Executive Director.</span></p> <p><span style="text-decoration: line-through;">26.2 At this time, the Board shall normally</span> launch a competitive recruitment process, publicly inviting applications for the position of Executive Director. Where the incumbent Executive Director has not served more than one term of office, the Board <span style="text-decoration: line-through;">shall</span><u>may</u> invite him or her to re-apply, together with other candidates, for such position and publicly announce such invitation<span style="text-decoration: line-through;">. Where appropriate the Board may launch such a recruitment process without inviting the Executive Director to re-apply for the post or,</span> based on a satisfactory performance appraisal <span style="text-decoration: line-through;">and if the incumbent Executive Director has not served more than one term, extend the appointment of the Executive Director for a further term of three years without the normal recruitment process. </span></p> <p><span style="text-decoration: line-through;">26.3</span> 26.2 <span style="text-decoration: line-through;">If</span><u>When</u> the Board decides to launch a recruitment process, it shall be assisted by an ad hoc Nomination Committee. At least six months prior to the end of the term of the incumbent Executive Director, or at any other time decided by the Board, the Chair of the Board shall, notwithstanding the otherwise applicable procedures under these Board Operating Procedures and the Committee Rules and Procedures, recommend for Board approval the terms of reference of the Nomination Committee and nominate for Board approval a Chair and the membership of that Committee. Membership in the Nomination Committee shall not count towards the two committee limit referenced in Section 23 of these Board Operating Procedures.</p> <p><span style="text-decoration: line-through;">26.4</span> 26.3 The Chair of the Board may also recommend for Board approval updated terms of reference of the Executive Director and the criteria for his <u>or her</u> selection. Following approval of the membership of the Nomination Committee, the recruitment process is launched.</p> <p><span style="text-decoration: line-through;">26.5</span> 26.4 The Nomination Committee shall interview and rank candidates, and present the highest ranking candidates to the Board, which shall then select a candidate, consistent with the terms of office of the Executive Director that are stated in Section 17 of these Board Operating Procedures.</p> <p><span style="text-decoration: line-through;">26.6</span> 26.5 The mandate of the Nomination Committee shall expire upon the appointment of the Executive Director.</p>
2010-12-15 B22 GF/B22/DP04 Implementing the new grant architecture for health systems strengthening activities Implementing the new grant architecture for health systems strengthening activities
<p>To provide for a technical change in grant application and management policy so as to align Global Fund funding for crosscutting health systems strengthening actions (HSS) with the Global Fund new architecture as approved by the Board at the Twentieth Board Meeting (GF/B20/DP31), the Board decides as follows:</p> <p>1.  Individual proposals requesting Global Fund funding can address one of the following three components: HIV/AIDS, tuberculosis, or malaria, as well as requests to support related cross-cutting health systems strengthening (focusing on system-wide approaches and actions that significantly benefit more than one of HIV/AIDS, tuberculosis and malaria components) ("cross-cutting HSS component").</p> <p>2.  The Board reiterates that applicants are encouraged, wherever possible, to integrate requests for funding for HSS actions within the relevant disease component(s). Such HSS actions will be assessed by the Technical Review Panel (TRP) as part of its review of that disease component. The Board clarifies that the crosscutting HSS component is for those activities that inherently are more appropriately addressed in a crosscutting or cross-disease manner. When requesting funding for such crosscutting HSS actions applicants are still required to articulate how they address identified health systems constraints to the achievement of improved outcomes in reducing the burden of HIV/AIDS, tuberculosis and malaria.</p> <p>3.  The Board requests the Secretariat to measure, monitor and report - as part of the Key Performance Indicators related to funding for HSS - to the Policy and Strategy Committee (PSC) on funding provided for cross-cutting health systems strengthening proposals.</p> <p>4.  The Board requests the joint Portfolio and Implementation Committee and PSC Eligibility, Cost Sharing and Prioritization Working Group to develop specific criteria for cross-cutting HSS applications as part of the eligibility and prioritization scheme to be approved by the Board in time for the launch of the Round 11 call for proposals.</p> <p>5.  Board policies and decisions that apply to proposals and grants for all three diseases shall apply equally to proposals and grants for the crosscutting HSS component. The Board decision titled "Architecture Review - Transition Provisions" (GF/B20/DP31) shall apply to proposals and grants for the cross-cutting HSS component subject to the amendments outlined in Annex 2 to the PSC's report to the Twenty-Second Board (GF/B22/4).</p> <p>6.  The aspects in the Board decision on Strategic Approach to Health Systems Strengthening (GF/B16/DP10) that relate to funding requests for "cross-cutting HSS actions" (in particular paragraphs 3 and 4) and/or are inconsistent with this decision are revoked</p> <p>7.  This decision does not change the existing scope of Global Fund support to crosscutting HSS activities or create a new funding window for these HSS activities.</p>
2010-12-15 B22 GF/B22/DP23 Comprehensive Funding Policy: Consideration of unqualified portions of multi-year contributions as assets Comprehensive Funding Policy: Consideration of unqualified portions of multi-year contributions as assets
<p>Taking note of Board's decision (GF/B21/EDP20, 10 September 2010) to approve the use of multi-year contribution agreements (MYCAs), preferably on an unconditional basis, as the principal mechanism through which donors should pledge and contribute to the Global Fund, the Board decides that the unqualified portions of MYCAs are considered as assets under the category 'or similar obligations' in Section 4 of the Comprehensive Funding Policy.</p>
2022-04-28 B46 GF/B46/EDP22 Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B46/ER22 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount thatmay be available for the relevant implementation period of each country disease component’s constituentgrants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for eachcountry disease component among its constituent grants, provided that the Technical Review Panel (the“TRP”) validates any redistribution that constitutes a material change from the program and fundingrequest initially reviewed and recommended by the TRP.</li> </ol>
2011-04-12 B22 GF/B22/EDP15 Additional funding to the Round 7 West Bank and Gaza Strip HIV Proposal Additional funding to the Round 7 West Bank and Gaza Strip HIV Proposal
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period of the Round 7 West Bank and Gaza Strip (PSE-708-G01-H) grant as a „Conditional Go‟ in the amount of up to US$ 4,985,587, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).</li> <li>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol>
2010-12-15 B22 GF/B22/DP21 Privileges and immunities Privileges and immunities
<p>The Board acknowledges the serious challenges and risks faced by Global Fund staff in the discharge of their duties in many countries, and reiterates the importance of states granting to the Global Fund such privileges and immunities as are necessary for the effective exercise of its functions and efficient use of its resources (as approved by the Board in its Electronic Decision Point on 14 December 2009 (EDP/09/32).</p> <p>The Board recognizes the measures taken by the Secretariat to secure privileges and immunities for the Global Fund from countries around the world. In this connection, the Board welcomes the signature by the Government of Moldova of the Agreement on Privileges and Immunities of the Global Fund.</p> <p>The Board reiterates the critical need for the Global Fund to pursue its drive to obtain privileges and immunities, and urges relevant stakeholders, including all Board members and their respective constituencies, to support, facilitate and promote the Secretariat's efforts to secure privileges and immunities for the Global Fund with all deliberate speed.</p> <p>The Board requests the Secretariat to update the Board regularly on the status of progress on this matter.</p>
2010-12-15 B22 GF/B22/DP20 Outstanding amounts receivable Outstanding amounts receivable
<p>The Board decides that the names of implementer organizations and the United States Dollar (USD) equivalent of amounts owed to the Global Fund shall be disclosed in the Annual Report.</p><p>The Board further decides that the names of donors and USD equivalent amounts committed to the Global Fund but which are overdue for payment shall also be disclosed in the Annual Report.</p>
2011-05-10 B22 GF/B22/EDP17 Extension of Grant Ending Date For the Round 8 Ghana Malaria Grant (GHN-809-G08-M) Extension of Grant Ending Date For the Round 8 Ghana Malaria Grant (GHN-809-G08-M)
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 18,884,840 for the following grants: KEN-708-G10-H ; TNZ-102-G01-M-00</p>
2011-02-12 B22 GF/B22/EDP08 Funding discontinuation for the Round 6 Mauritania Malaria and TB grants Funding discontinuation for the Round 6 Mauritania Malaria and TB grants
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 6 Mauritania Malaria (MRT-607-G04-M) and TB (MRT-607-G05-T) grants.</p><p><span style="font-size: 12px; line-height: 1.5;">See attached table.</span></p><h5></h5>
2010-12-15 B22 GF/B22/DP03 Approval of the Report of Twenty-First Board Meeting Approval of the Report of Twenty-First Board Meeting
The report of the Twenty-First Board Meeting (GF/B22/2) is approved.
2010-12-15 B22 GF/B22/DP22 Comprehensive Funding Policy: Commitment reserve for grant renewals Comprehensive Funding Policy: Commitment reserve for grant renewals
<p>In order to ensure that funding is available within a replenishment period (or a pre-determined period) for grant renewals, the Board decides that a new commitment reserve be created for this purpose. Under this measure, the amount of assets determined to be available for approval of a new round may be reduced by an amount to be added to this reserve to ensure that funding is available for forecasted grant renewal needs during the subsequent three years.</p><p>The Board amends the Comprehensive Funding Policy<sup>1</sup> by deleting the existing Section 3.d and replacing it as follows:</p><p>"<i>The Board may approve proposals and commit funds for the resulting financial commitments up to the cumulative uncommitted amount of assets that the Board determines will be available at the time the Secretariat commits the funds in the related grant agreements. When making this determination, the Board will set aside the amount of assets required to meet forecasted grant renewal needs in respect of the subsequent three years (a 'Commitment Reserve'), taking into account projections regarding available donor contributions for the same three-year period provided by the Finance and Audit Committee with the support of the Secretariat</i>."</p>
2022-05-05 B46 GF/B46/EDP25 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism
<p>The Board:</p> <ol> <li>Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend tothe Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awardsexceeding US$45 million, as measured in aggregate by country (not including anyfunding awarded for COVID-19 commodities through fast-track investments orC19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 ofGF/B46/ER18; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling offunding available for each country among its constituent grants in accordance with thepreviously approved principles under GF/B44/EDP18.</li> </ol>
2022-05-05 B46 GF/B46/EDP24 Appointment of the External Auditor Appointment of the External Auditor
<p>Based on the recommendation of the Audit and Finance Committee, as set forth in GF/AFC18/DP03, the Board authorizes the appointment of KPMG SA as the Global Fund’s external auditor for a term to cover financial years 2022-2028 to align with the next Global Fund Strategy cycle (2023-2028).</p>
2010-12-15 B22 GF/B22/DP01 Appointment of Rapporteur Appointment of Rapporteur
Mr Simon Bland from the United Kingdom and Australia constituency is designated as rapporteur for the Twenty-Second Board Meeting.
2021-11-10 B46 GF/B46/DP07 2022 Work Plan and Budget Narrative and the 2022 Operating Expenses Budget 2022 Work Plan and Budget Narrative and the 2022 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the:</p> <ol> <li>2022 Work Plan and Budget Narrative, as set forth in GF/B46/02; and</li> <li>2022 Operating Expenses Budget in the amount of US$ 322.2million, as set forth in GF/B46/02 (the “2022 OPEX Budget”), which includes (i) US$ 65.5 million for in-country and external assurance activities, as described in GF/B46/02, and (ii) US$ 14.9 million for the Office of the Inspector General’s 2022 operating expenses.</li> </ol>
2021-11-10 B46 GF/B46/DP04 Global Disease Split for the 2023-2025 Allocation Methodology Global Disease Split for the 2023-2025 Allocation Methodology
<p>Based on its review of the Secretariat’s analysis and recommendations on the global disease split for the 2023-2025 allocation period, and the Strategy Committee’s related deliberations, the Board:</p> <ol> <li>Acknowledges that the total amount of funds available for country allocation (including approved sources of funds for country allocation and any additional funds approved as available for country allocation) will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishments results from the 7th Replenishment;</li> <li>Approves that the apportionment of available country allocation funds across disease components (“Global Disease Split”) for the 2023-2025 allocation period will be determined by the total amount of available funds for country allocation for the 2023-2025 allocation period approved by the Board;</li> <li>Acknowledging the increased share of deaths from tuberculosis among the three diseases, approves the following Global Disease Split for the 2023-2025 allocation period, which increases funding for tuberculosis while preserving funding and potential for scale-up for HIV and malaria: <ol type="a"> <li>Any available funds for country allocation up to and including US$ 12 billion will be apportioned as follows: 50% for HIV/AIDS, 18% for tuberculosis, and 32% for malaria; and</li> <li>Any additional available funds for country allocation above US$ 12 billion will be apportioned as follows: <ol type="i"> <li>i. 45% of such funds will be apportioned to HIV/AIDS;</li> <li>ii. 25% of such funds will be apportioned to tuberculosis; and</li> <li>iii. 30% of such funds will be apportioned to malaria.</li> </ol> </li> </ol> </li> <li>Recognizing the need to further increase funding for tuberculosis and maximize the quality and impact of tuberculosis programs in line with the ambition of the Global Fund Strategy Narrative, requests the Secretariat, partners and committees, as relevant, to propose and implement specific options to address these needs, including: <ol type="a"> <li>Presenting to the Board, at its 47th meeting, a proposal to leverage catalytic investments for the 2023-2025 allocation period to mobilize additional resources to reduce deaths from tuberculosis;</li> <li>Aggressively exploring, on an ongoing basis, evidence-based portfolio optimization and prioritization opportunities in order to more effectively address tuberculosis incidence and mortality in high burden countries;</li> <li>Continuing to pursue and monitor domestic co-financing commitments required to increase overall financing for tuberculosis; and</li> <li>Continuing to pursue innovative finance opportunities to increase funding to tuberculosis in high burden countries.</li> </ol> </li> <li>Requests the Global Fund’s Independent Evaluation Function to commission, in consultation with the Strategy Committee, technical partners and Secretariat, an external evaluation of the Global Fund’s approach to resource allocation to maximize impact, to inform evidence-based decision making on these issues ahead of the 8th replenishment, and to support more effective delivery of the Global Fund Strategy.</li> </ol>
2021-11-10 B46 GF/B46/DP05: Amended Risk Appetite Statements Amended Risk Appetite Statements
<ol> <li>The Board: <ol type="a"> <li>recalls its ultimate responsibility to the Global Fund’s stakeholders for overseeing the implementation of effective risk management;</li> <li>affirms the Strategy Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as set forth in Annex 1 to GF/SC17/14_Rev2 and pursuant to decision point GF/SC17/DP02;</li> <li>further affirms the Audit and Finance Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as set forth in Annex 1 to GF/AFC17/02_Rev2 and pursuant to decision point GF/AFC17/DP02; and</li> <li>instructs the Secretariat to provide greater reporting on emerging risk trends and the effectiveness and results of the assurance measures, including the additional assurances put in place.</li> </ol> </li> <li>Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statements, including risk appetites, target risk levels and timeframes to achieve target risk, as set forth in Annex 1 to GF/B46/06, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date.</li> <li>This decision point and the amended Risk Appetite Statements approved by it shall supersede decision point GF/B39/DP11 (May 2018).</li> </ol>
2011-05-12 B23 GF/B23/DP21 Global Fund Market-Shaping strategy and Market-Shaping Interventions for ARVs Global Fund Market-Shaping strategy and Market-Shaping Interventions for ARVs
<p>Part 1 - Key principles of Market-Shaping Strategy</p> <p>1. The Board acknowledges the critical role of the Global Fund in shaping markets to maximize global access to health products in accordance with the applicable Global Fund quality assurance requirements at affordable and sustainable prices and further emphasizes its desire for the Global Fund to more actively shape the markets for health products to optimize price, quality, design, and sustainable supply.<br /><br />Part 2 - Market-shaping strategy</p> <p>2. The Board approves the market-shaping strategy of the Global Fund set out in Annex 1 to the Report of the Market Dynamics and Commodities Ad-hoc Committee ("MDC") to the Board (GF/B23/9 Revision 1) ("Market-Shaping Strategy"). The Board requests the MDC to oversee the refinement and implementation of the Market-Shaping Strategy, including through relevant non-material changes to Annex 1.<br /><br />Part 3 -Market-shaping interventions for Anti-Retroviral medicines (ARVs)</p> <p>3. The Board approves the strategic interventions for ARVs in accordance with the Market-Shaping Strategy ("Strategic Interventions") as recommended by the MDC and described in Annex 1 to the MDC Report to the Board (GF/B23/9 Revision 1).</p> <p>4. The Board requests the Secretariat to implement the Market-Shaping Strategy and relevant Strategic Interventions under the oversight of the MDC. The Board requests that an implementation framework and appropriate policies and procedures be developed to effectively implement the Strategic Interventions with appropriate consultation. The Board requests the MDC to report back on progress at the Twenty-Fourth Board Meeting.</p> <p>5. Recognizing the risk of supply disruption to pediatric ARVs for certain Global Fund grant programs due to the phase-out of the UNITAID pediatric ARV program, as identified by the MDC and outlined in Table 1 of the MDC Report to the Board (GF/B23/9 Revision 1), the Board requests the Secretariat to prioritize the implementation of the Strategic Interventions set out in Section 5.2.2 of the Market-Shaping Strategy. Further, the Board requests the Secretariat, in consultation with UNITAID and other relevant partners, to facilitate the provision of support to principal recipients to sustain pediatric ARV treatment. The Board further requests the Secretariat to prioritize the execution of the appropriate policy and procedural changes to enable the Secretariat to use the Voluntary Pooled Procurement mechanism ("VPP") to strategically manage demand for pediatric ARVs to ensure the consistent and timely availability of these products purchased through the VPP.</p> <p>6. The Board requests the Secretariat and MDC to provide an update on progress in refining and implementing the Market-Shaping Strategy and the Strategic Intervention for ARVs at the Twenty-Fourth Board Meeting. The Board also requests the MDC to oversee an independent evaluation of the strategy after an appropriate period of implementation.</p> <p>Part 4 - Budgetary Implications</p> <p>7. The Board recognizes that implementation of the proposed Strategic Interventions for ARVs have budgetary implications for the Secretariat‟s operating expenses budget starting in 2011 as described in Table 1 of the MDC Report to the Board (GF/B23/9 Revision 1). The estimated implications for 2011 amount to USD 350,000 for provision of market-shaping tools and implementation of Strategic Interventions, including 4 Full Time Equivalents ("FTEs") starting on or about October 2011.</p> <p>8. The Board requests the Finance and Audit Committee ("FAC") to consider and approve the budgetary implications of this Decision Point within the framework of the 2011 administrative budget review, which is scheduled for June 2011.</p> <p>9. The Board further requests the FAC to consider the budgetary implications of market-shaping strategies including the continued cost of the 4 FTEs for 2012 and later years as part of the regular budgeting cycle.<br />Part 5 - MDC authority to approve implementation of subsequent Strategic Market Interventions</p> <p>10. Recognizing the MDC‟s technical competency, the Board authorizes the MDC to approve the implementation of other Strategic Interventions for health products procured using Global Fund financing, without requiring further approval or authorization from the Board, provided that such Strategic Interventions:</p> <p>a. will not increase the Operating Expenses Budget of the Global Fund beyond the matters referred to in Part 4 above;</p> <p>b. will not contravene, or require an amendment to, a Decision Point or policy approved by the Board; and</p> <p>c. are consistent with the principles set out in the Market-Shaping Strategy.</p> <p>11. The MDC shall notify the Board through the relevant MDC Reports to the Board of:</p> <p>a. any subsequent Strategic Interventions approved by the MDC for implementation in accordance with this Decision Point; and</p> <p>b. the progress of the implementation of such Strategic Interventions, including the phase-out of Strategic Interventions in accordance with the Market-Shaping Strategy.</p> <p>Part 6 - MDC Authority Extends to Any Successor</p> <p>The Board agrees that at its Twenty-Fourth Meeting it will request the Policy and Strategy Committee to recommend a course of action about the continuation of the MDC. Consequently, the Board determines that the authority and responsibilities conferred on the MDC in this Decision Point as applicable, shall apply with such necessary and consequential changes to any successor body or panel that may be approved by the Board to replace the role and responsibilities of the MDC in respect of this Decision Point.</p>
2011-05-12 B23 GF/B23/DP13 Plan for Comprehensive Reform: Implementation of Reforms, Monitoring and Learning Plan for Comprehensive Reform: Implementation of Reforms, Monitoring and Learning
<ol> <li>The Board acknowledges that the Global Fund, as a whole, needs to move forward thoughtfully with the implementation of the overall comprehensive reform agenda, and asks that the Secretariat and incoming Chair and Vice-Chair of the Board take on and advance the operational and governance reforms recommended in the Report of the Comprehensive Working Group (CRWG Report, GF/B23/13).<br /><br /></li> <li>The Board notes that strategic priorities will need to be set in anchoring the operational reforms in the Secretariat‟s current workplan. The Board encourages the Secretariat to engage with the Chair, Vice-Chair, and Finance and Audit Committee (FAC) regarding resource implications for successful implementation of these reforms.<br /><br /></li> <li>The Board acknowledges that consultations with direct implementers have been conducted in Ukraine, Kenya, Thailand, El Salvador and Senegal as part of the comprehensive reform process, and that those inputs should be taken into consideration during the implementation of reforms.<br /><br /></li> <li>The Board acknowledges that it will be accountable for the successful implementation of the comprehensive reform agenda. The Board requests the Executive Director and incoming Chair and Vice-Chair to jointly submit a report at Twenty-Fourth and Twenty-Fifth Board Meeting, which outlines overall progress in relation to the nine reform objectives.</li> </ol>
2011-05-12 B23 GF/B23/DP24 Global Fund Commitment to Transparency Global Fund Commitment to Transparency
<ol> <li>The Board reaffirms the Global Fund‟s strong and continuing commitment to the highest standards of transparency and accountability.<br /><br /></li> <li>The Board further reaffirms the Global Fund‟s commitment to a fully independent and transparent Office of the Inspector General as set forth in the OIG Charter and Terms of Reference.<br /><br /></li> <li>The Board looks forward to receiving the views of the High Level Independent Review Panel on Fiduciary Controls and Oversight Mechanisms on existing arrangements and its recommendations on ways to further improve the fiduciary controls and oversight within the Global Fund.</li> </ol>
2011-05-12 B23 GF/B23/DP09 Plan for Comprehensive Reform: Value for Money Plan for Comprehensive Reform: Value for Money
<ol> <li>The Board recognizes that the Global Fund is well-positioned to drive value for money and should leverage its role as the primary financier of essential health products so as to improve quality, price, design, and sustainable supply. In this context the Board asks the Market Dynamics Committee to propose to the Twenty-Fourth Board meeting expanded uses for the MDC's "toolkit" of interventions- including opt-out mechanisms.<br /><br /></li> <li>When value for money efforts generate savings, the normal consequence is that such savings should stay in countries to scale up efforts against one or more of the three diseases.<br /><br /></li> <li>In order to drive value for money, the Board requests the Secretariat to:<br /><br />i. Take all necessary and appropriate measures to (1) fully implement voluntary pooled procurement (VPP) and (2) aggressively execute the Market Dynamics Committee recommendations.<br /><br />ii. Work with the MDC to determine reference prices to establish maximum levels of Global Fund payments for appropriate products. Reference prices should be set at the lowest accessible competitive price consistent with well-functioning and sustainable markets, recognizing differences according to country income and disease burden.<br /><br />iii. Set limits on how much support the Global Fund will provide in categories of expenditure where there is a risk of overuse or inefficiency ("yellow light" items, e.g., vehicles).<br /><br />iv. Work proactively with Principal Recipients (PRs) and Country Coordinating Mechanisms (CCMs) to use reprogramming within countries to ensure increased use of cost-effective interventions to maximize health impact. The Secretariat should incorporate guidance from technical partners to help guide this reprogramming.<br /><br /></li> <li>In the context of reporting to the Board on the Global Fund's portfolio and its impact on the three diseases, the Secretariat is asked to provide an annual report on its value for money work, including quantified results in terms of savings and additional coverage or impact.</li> </ol>
2011-05-12 B23 GF/B23/DP10 Plan for Comprehensive Reform: Partnerships Plan for Comprehensive Reform: Partnerships
<p>The Board recognizes that the Global Fund, as a financing agency, is both a part of, and heavily dependent on, a partnership model in a range of its strategic functions including to an extent for the success of countries in developing, managing and implementing grants in countries. The Board supports consideration of the recommendations set forth in Parts 5.8-5.10 of the Report of the Comprehensive Working Group GF/B23/13 in the Strategy Process. The Board requests that the Secretariat move on the following two items in the near term, and report on its progress and implementation of these actions at the Twenty-Fourth Board Meeting:</p> <ol> <li>Strengthen country-level mechanisms to build on goodwill-based partnerships through formalized agreements between in-country stakeholders to ensure effective technical cooperation, country support, and capacity building in areas that have been identified as gaps, e.g., in technical, financial, and operational management. <br /><br /></li> <li>Use flexible funding models, where agreed by the Country Coordinating Mechanisms (CCMs) and Principal Recipients (PRs), to utilize existing grant budgets to improve financing of partner support for grant implementation, particularly in bottleneck situations.</li> </ol>
2011-09-15 B23 GF/B23/EDP11 Appointment of Board Chair Appointment of Board Chair
<ol> <li>With profound regret and with deep gratitude for his service to the Global Fund since May 2011, the Board accepts the resignation of Martin Dinham as Chair of the Global Fund Board due to ill health. The Board extends to Mr. Dinham and his family its very best wishes for a timely return to full health.</li> <li>The Board appoints Simon Bland to serve as Chair of the Board on an interim basis until the Board appoints an individual to serve for the remainder of the term for which Mr. Dinham had been appointed.</li> <li>The Board requests and looks forward to the donor group moving expeditiously to recommend a candidate for Board Chair with a target date of 15 October 2011</li> </ol> <p>This decision has no material budgetary implications.</p>
2011-05-12 B23 GF/B23/DP16 Interim measure to address challenges experienced by First Learning Wave grants based on National Strategy Applications for Madagascar and Rwanda Interim measure to address challenges experienced by First Learning Wave grants based on National Strategy Applications for Madagascar and Rwanda
<ol> <li>The Board:<br /><br />i. refers to its decision (GF/B18/DP20) to bring the National Strategy Applications ("NSA") procedure into operation through a phased roll-out beginning with the First Learning Wave ("FLW");<br /><br />ii. notes the specific challenges faced by certain FLW grants in relation to NSA funding continuation, particularly relating to the timing of the rounds-based process for proposal review and approval, which has posed planning difficulties and the possible prospect of significant funding gaps;<br /><br />iii. underscores the nature of the NSA procedure as a response to country requests for more streamlined funding mechanisms and as an expression of the Global Fund‟s commitment to principles of alignment and harmonization embodied in the Paris Declaration on Aid Effectiveness and the Accra Agenda for Action; and<br /><br />iv. reiterates the importance of ensuring that future NSA funding opportunities that may be approved by the Board take into account the lessons learned in the FLW.<br /><br /></li> <li>To provide a long-term solution to the challenges noted above, the Board requests the Policy and Strategy Committee to consider at its meeting in or around October 2011 options, which the Secretariat will develop, for allowing the submission of funding requests through the NSA and Health Systems Funding Platform ("HSFP") modalities in an equitable fashion and at a time suited to country-specific national planning cycles.<br /><br /></li> <li>Such discussions should be conducted in the context of the work on the new Global Fund Strategy 2012-2016 and, specifically, discussions to occur as part of this strategy on the future of Global Fund funding modalities and harmonization between them (including the rounds-based modality, NSAs, and the HSFP, in the context of the Global Fund‟s new architecture).<br /><br /></li> <li>In addition, as an interim and exceptional measure to address the specific challenges faced for the NSA FLW grants for Madagascar (malaria) and Rwanda (HIV and tuberculosis) in having timely and uninterrupted access to funding in a way that does not prejudge future Board decisions on funding modalities, and provided the country in question has not submitted a proposal to address the same disease component through Round 11, the Board decides as follows:<br /><br />i. To allow the Country Coordinating Mechanism of each of Madagascar and Rwanda to seek an extension with bridge funding ("FLW extension funding") under the stipulations included in the Annex to this decision point, for a time-limited period such that the length of this extension period will not cause the combined lifespan of the original grant and the extension period to exceed five years, to provide continuity of funding until either:<br /><br />a. Round 12, or<br /><br />b. the next NSA funding opportunity made available to those countries by the Board, whether concurrent with Round 12 or not.<br /><br /></li> <li>To determine, no later than December 2011, in the context of its discussions on the future of Global Fund funding modalities, whether it will offer an NSA funding opportunity of the type described under 4 i.(b) above.<br /><br /></li> <li>To authorize the Secretariat to make limited exceptions to existing policies and procedures to the extent necessary to implement this decision and within the parameters described in the Annex to this decision point.</li> </ol> <div style="text-align: center;">***</div> <h2>Annex to GF/B23/DP16</h2> <ol> <li>The FLW extension funding in each case will have "Additional Commitments" priority, and the associated funds will be taken from those already included for the FLW grants of Madagascar and Rwanda in the forecast of Additional Commitments as described in Annex 2 of the "Report of the Policy and Strategy Committee‟ GF/B23/4.<br /><br /></li> <li>The maximum total duration of the FLW extension funding in each case will be limited to the duration already forecast for the "Additional Commitments" funds as described in Table 1 of Annex 3 of the "Report of the Policy and Strategy Committee‟ GF/B23/4.<br /><br /></li> <li>The maximum FLW extension funding amount will not be higher than the maximum annual extension amount, as per Table 1 of Annex 3 of the "Report of the Policy and Strategy Committee‟ GF/B23/4 multiplied by the duration of the extension measured in years.<br /><br /></li> <li>The FLW extension funding will be subject to TRP review and Board approval.<br /><br /></li> <li>The procedure to provide FLW extension funding will be as described in Annex 3 of the "Report of the Policy and Strategy Committee‟ GF/B23/4.<br /> </li> <li>All Global Fund policies and procedures, including rules relating to eligibility and cost-sharing, will apply to the FLW extension funding except as otherwise provided herein. The limited exceptions to existing policies and procedures granted in this decision in order to implement it include the timing and format of submission, and the TRP review procedure. Any exceptions needed beyond these will be notified to the Board for its consideration and approval.</li> </ol>
2011-07-11 B23 GF/B23/EDP05 Round 7 Zambia TB grant (ZAM-708-G20-T) Round 7 Zambia TB grant (ZAM-708-G20-T)
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 7 Zambia TB grant (ZAM-708-G20-T).</p><p><span style="font-size: 12px; line-height: 1.5;">See attached table</span></p>
2011-05-12 B23 GF/B23/DP27 Approval of 2010 Financial Statements Approval of 2010 Financial Statements
The Board approves the 2010 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young.
2011-05-12 B23 GF/B23/DP15 Replenishment of TERG Members Replenishment of TERG Members
The Board appoints Dr. Viroj Tangcharoensathien, Dr. Mickey Chopra, Dr. Atsuko Aoyama and Dr. Paulin Basinga as members of the Technical Evaluation Reference Group (TERG) for a period of three years until the end of the first Board meeting in 2014.
2011-07-11 B23 GF/B23/EDP04 July 2011 Phase 2 Funding Decision July 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 15,438,211 for the following grant: BUL-202-G01-H-00</p>
2011-08-13 B23 GF/B23/EDP10 Additional Commitment for the DRC Round 7 HIV grant to the United Nations Development Programme Additional Commitment for the DRC Round 7 HIV grant to the United Nations Development Programme
<p>The Board notes that the conditions for approval of the Additional Commitment for the DRC Round 7 HIV grant to the United Nations Development Programme have not yet been satisfied to a standard which would allow the grant agreement to be signed. However, due to the need to continue to provide services and to prevent potential stock-out of life saving medicines, and in light of the additional risk mitigation measures that the Secretariat proposes to address the risk of weak internal controls at both PR and SR levels, the Board decides to replace the two Board conditions approved in January 2011 (B22/EDP/1) with the following conditions in order to allow the signing of the Phase 2 extension to proceed:</p> <ol> <li>The disbursement of Grant funds by the Global Fund to the Principal Recipient of Grant funds to finance activities to be carried out by Sub-Recipients shall be subject to the delivery by the Principal Recipient to the Global Fund of a report, in form and substance satisfactory to the Global Fund, which shall address the following: <ol> <li>Progress on the implementation of recommendations on issues raised in the OIG audit report regarding SR audits relevant for Round 7 by both the Principal Recipient and Sub-Recipients, and an action plan for the implementation of recommendations that have not yet been implemented;</li> <li>an update on measures taken to strengthen the management and oversight of Sub-Recipients under the grant.</li> </ol> </li> <li>No later than three months after the signing of the Phase 2 grant agreement, the Principal Recipient shall deliver to the Global Fund a report, in form and substance satisfactory to the Global Fund, on the progress on the implementation of recommendations made in the Principal Recipient‟s audit report for 2009, and an action plan for the implementation of recommendations that have not yet been implemented.</li> <li>Prior to disbursement of Grant Funds by the Global Fund for this activity, the PR shall submit to the Global Fund, in form and substance satisfactory to the Global Fund, its strategy to develop community involvement in PMTCT, including an action plan and a detailed budget.</li> </ol> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-05-12 B23 GF/B23/DP17 Revised Country Coordinating Mechanisms Guidelines Revised Country Coordinating Mechanisms Guidelines
<ol> <li>The Board:<br /><br />i. approves the revised Guidelines and Requirements for Country Coordinating Mechanisms ("CCM Guidelines") as set out in Annex 1 of GF/B23/05; and<br /><br />ii. authorizes the Secretariat to update, add or delete electronic links to reference documents within the CCM Guidelines periodically as necessary.<br /><br /></li> <li>The Board notes that the CCM Guidelines will inform the development of a performance framework to be used in the context of CCM funding. The CCM performance framework will be developed under the oversight of the Portfolio and Implementation Committee which will report to the Board on progress relating to the CCM performance framework no later than the Twenty-Fifth Board Meeting.<br /><br /></li> <li>The Board acknowledges that the ongoing review of CCM implementation of the requirements will require additional resources for the Secretariat. Similarly, Secretariat support for CCMs to meet standards for good governance will require additional resources in 2011 and beyond. For 2011, the resource requirements will be covered under extra-budgetary resources. For 2012 and beyond, the annual budgetary requirements will be subject to approval by the Board as part of the regular budgetary process under the oversight of the Finance and Audit Committee.</li> </ol>
2011-05-12 B23 GF/B23/DP22 Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs) Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs)
<ol> <li>In accordance with Board Decision Point GF/B22/DP11, the Board notes that the Market Dynamics and Commodities Ad-hoc Committee ("MDC"), in line with WHO guidance, has presented recommendations to the Board regarding appropriate transition by recipients of Global Fund financing to the use of fixed-dose combinations (FDCs) of artemisinin-based combination therapies (ACTs).<br /><br /></li> <li>The Board determines that once the Secretariat has decided in its discretion that there are at least two FDC Finished Pharmaceutical Products of an ACT Formulation ("FDC ACT") for the treatment of uncomplicated malaria that comply with the Global Fund Quality Assurance Policy for Pharmaceutical Products (as approved by the Board in accordance with Decision Point GF/B22/DP9) ("QA Policy"), and each FDC ACT is considered "available" as defined in Section 8 of the QA Policy,<br />then,<br /><br />(a) the Global Fund shall notify Principal Recipients in writing and on the Global Fund website that it has made such a decision (the date of such notification being the "Notification Date"); and<br /><br />(b) from 90 days after the Notification Date, Global Fund financing for that ACT formulation can only be used to procure FDCs of that ACT formulation.<br /><br /></li> <li>For recipients of Global Fund financing that have not procured FDC ACTs using Global Fund financing prior to the Notification Date, a grace period of up to one year to transition to FDC ACTs can be applied on a case-by-case basis, at the discretion of the Secretariat. The Secretariat, in collaboration with partners, will facilitate the provision of support to recipients of Global Fund financing to conduct an effective and timely transition to FDC ACTs where necessary and appropriate.</li> </ol>
2011-05-12 B23 GF/B23/DP20 Revisions to the Ethics and Conflict of Interest Policy’s Declaration of Interest Form Revisions to the Ethics and Conflict of Interest Policy’s Declaration of Interest Form
<p>The Board decides to replace the Declaration of Interest form attached to the Policy on Ethics and Conflict of Interest for Global Fund Institutions (approved in October 2002 and amended by GF/B18/DP10) with a new Declaration of Interest form as set forth in Annex 2 of the Report of the Ethics Committee (GF/B23/7).</p>
2011-06-11 B23 GF/B23/EDP01 June 2011 Phase 2 Funding Decision June 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 236,241,129 for the following grants: CUB-202–G01-H ; HND-102-G05-M-00 ; IND-809-G09-H ; IND-809-G10-T ; IND-809-G11-T ; IND-809-G12-T ; RWN-809-G10-M ; SER-809-G04-H ; SER-809-G05-H ; SWZ-809-G06-M ; THA-102-G01-H ; THA-809-G10-H ; THA-809-G11-H ; THA-809-G12-H ; THA-809-G13-T</p>
2011-05-12 B23 GF/B23/DP14 Global Fund Strategy Framework 2012-2016 Global Fund Strategy Framework 2012-2016
<p>The Board:</p> <ol> <li>Acknowledges the first draft of the high-level strategy document "A Strategy for the Global Fund 2012-2016" (GF/B23/15, Annex 1), which sets out the preliminary strategic direction of the Global Fund for the next five years;<br /><br /></li> <li>Requests the PSC leadership to appoint a Working Group of the PSC (the "Working Group") to work with the Secretariat, taking into account input from the Twenty-Third Board Meeting, to revise the draft Strategy Framework, prior to consultations with stakeholders, particularly at the Fourth Partnership Forum. The Working Group and Secretariat shall further improve this revised draft Strategy Framework following consultations;<br /><br /></li> <li>Asks the Partnership Forum Steering Committee to design an appropriate and efficient process to enable effective consultation on the draft Strategy Framework at the Fourth Partnership Forum;<br /><br /></li> <li>Asks the Working Group, working with the Secretariat, to ensure appropriate linkages between the action plan of the Board Comprehensive Reform Working Group and the initiatives outlined in the draft Strategy Framework and its Implementation Plan;<br /><br /></li> <li>Asks the Secretariat, working with the Working Group, to host additional necessary regional and technical fora to gather additional input on the draft Strategy Framework, as revised following the Twenty-Third Board Meeting; and<br /><br /></li> <li>Requests the Secretariat to submit the Strategy Framework, together with an implementation plan, through the PSC to the Twenty-Fourth Board Meeting for approval.</li> </ol>
2011-05-12 B23 GF/B23/DP11 Plan for Comprehensive Reform: Business Model Plan for Comprehensive Reform: Business Model
<ol> <li>The Board finds that the Global Fund needs to re-examine its business model. It should move away from a one-size-fits-all approach to a differentiated and calibrated model that allocates oversight resources based upon the risks and resources associated with specific and diverse country contexts. Consistent with this approach, the Board adopts the following three broad principles to guide further development of the business model:<br /><br />i. The Global Fund should actively adapt its business model to place greater importance on disease and health impact and value for money.<br /><br />ii. The Global Fund should improve allocation of resources by adapting its funding modalities and grant management systems to better take into account: (1) performance record of the grant, Principal Recipient (PR), and country; (2) risk presented by the grant, PR, and country; and (3) relative size and role of the Global Fund in-country.<br /><br />iii. The Global Fund should measure the effectiveness of its business model, with particular regard to the health impact on the three diseases and transaction costs.<br /><br /></li> <li>In addition, the Board requests that the Secretariat strengthen two specific reforms to improve the business model, and report on its progress at the Twenty-Fourth Board Meeting:<br /><br />i. Identify ways to reinforce the application of performance-based funding, such as evaluating the current framework, increasing transparency, further developing methodology, and moving towards payment-for-service.<br /><br />ii. Further reinforce the tracking and enforcement of additionality, working with other bodies as appropriate.</li> </ol>
2011-05-12 B23 GF/B23/DP03 Approval of the Report of Twenty-Second Board Meeting Approval of the Report of Twenty-Second Board Meeting
The report of the Twenty-Second Board Meeting (GF/B23/2) is approved.
2011-07-11 B23 GF/B23/EDP07 2011 Budgetary Implications of the Global Fund Reform Agenda 2011 Budgetary Implications of the Global Fund Reform Agenda
<p>The Board authorizes the addition of 25 staff positions, representing US$ 1.8 million in staffing costs, and US$ 4.13 million in non-staffing costs to the approved 2011 Operating Expenses budget to accelerate the implementation of the Reform Agenda, as described in GF/B23/13.</p> <p>The budgetary implications of this decision for the 2011 Operating Expenses Budget are US$ 1.80 million in staff costs (prorated), reflecting an increase of 25 staff positions, and US$ 4.13 million in non-staffing costs.</p>
2011-05-12 B23 GF/B23/DP23 Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund
<ol> <li>The Board refers to its decisions at the Twenty-Second Board Meeting entitled "Review of the Eligibility and Cost Sharing Policy" (GF/B22/DP8), "Measures associated with funding future proposals" (GF/B22/DP25), and "Launch of Round 11, the Second Wave of National Strategy Applications and a Health Systems Funding Platform Pilot" (GF/B22/DP26).<br /><br /></li> <li>The Board approves the document entitled "Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals for Funding from the Global Fund" as set out in Attachment 1 (GF/B23/14) as the new policy governing these matters with the intention that this new policy shall apply to Round 11, the Second Wave of National Strategy Applications, the Health Systems Funding Platform Pilot and future funding opportunities.<br /><br /></li> <li>To give effect to the new Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals for Funding from the Global Fund from Round 11 onwards, the Board decides as follows:<br /><br />a. To revoke the current policy on Income Level and Cost-Sharing Eligibility Criteria for Proposals for Funding from the Global Fund approved during the Sixteenth Board Meeting (GF/B16/DP18, Document GF/B16/7 Revision 1, Attachment 1) as amended at the Nineteenth Board Meeting (GF/B19/D13, GF/B19/DP14, GF/B19/DP15, Document GF/B19/05, Attachment 1); and<br /><br />b. To amend the Comprehensive Funding Policy and Related Board Decisions as approved at the Sixth Board Meeting (as amended at the Thirteenth Board Meeting and by GF/B15/27, GF/B20/DP9, EDP/B21/20 and GF/B22/DP22) by deleting paragraph 8 and replacing paragraph 7 b. of the Comprehensive Funding Policy with the following new sub-paragraph as follows:<br /><br />"7 b. If sufficient resources are not immediately available to approve all TRP-recommended proposals, proposals shall be prioritized in accordance with the Prioritization requirements set out in the "Policy on Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund" (GF/BM23/DP6)."</li> </ol>
2011-06-11 B23 GF/B23/EDP03 Condition Waiver for Uganda Round 6 TB grant (UGD-607-G06-T) Condition Waiver for Uganda Round 6 TB grant (UGD-607-G06-T)
<p>The Board acknowledges that, even though the condition is not fully fulfilled, there is some progress made on the condition upon which the Board approved the Uganda Round 6TB grant to the Ministry of Finance, Planning and Economic Development of the Government of Uganda (UGD-607-G06-T). The Board decides to waive this condition to allow signing of the Phase 2 extension.</p><p>This decision does not have material budgetary implications.</p>
2021-11-08 B46 GF/B46/DP02 Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 46th Board Meeting (GF/B46/01_Rev1) is approved.</p>
2021-11-08 B46 GF/B46/DP01 Approval of the Rapporteur Approval of the Rapporteur
<p>Gabriella Fesus from the European Commission, Belgium, Italy, Portugal, Spain Constituency is designated as Rapporteur for the 46th Board Meeting.</p>
2021-11-10 B46 GF/B46/DP06 Independent Evaluation Function Independent Evaluation Function
<p>The Board notes the recommendation of the Strategy Committee and of the Ethics and Governance Committee, as set forth in GF/B46/05 rev1, with respect to the new independent evaluation model which shall replace the Technical Evaluation Reference Group ("TERG") and decides to approve the creation of the Independent Evaluation Panel, as described in GF/B46/05 rev1.</p> <p>Accordingly, the Board:</p> <ol> <li>Amends the Global Fund Bylaws, as set forth in Annex 1 of GF/B46/05 rev1, effective 31 December 2022;</li> <li>Amends the Charter of the Strategy Committee, as set forth in Annex 2 of GF/B46/05 rev1, effective 31 December 2022;</li> <li>Approves the Terms of Reference of the Independent Evaluation Panel ("IEP"), as set forth in Annex 3 of GF/B46/05 rev1 effective 31 December 2022, which will constitute one structure of the independent evaluation function previously held by the TERG, noting that approval of subsequent non-material modifications to this document are delegated to the Strategy Committee;</li> <li>Requests the Secretariat, under the oversight of the relevant standing Committees, to update any policies, relevant governance documents, charters, terms of reference, agreements or prior decisions needed to align with the documents approved under paragraphs 1, 2 and 3 of this decision point and to manage the orderly transition between the Technical Evaluation Reference Group ("TERG") and the IEP;</li> <li>Requests the Strategy Committee, in fulfilling its oversight role over the independent evaluation function, to consider the effectiveness of the guidance and procedures developed to safeguard both the independence and the learning components of the evaluation function; and</li> <li>Decides to dissolve TERG following the transition period ending 31 December 2022 and instructs the Strategy Committee to develop and oversee transitional arrangement between the IEP and the TERG.</li> </ol>
2021-11-09 B46 GF/B46/DP03 Approval of the Strategy Narrative for the 2023-2028 Global Fund Strategy Approval of the Strategy Narrative for the 2023-2028 Global Fund Strategy
<p>Based on the recommendation of the Strategy Committee, as presented in GF/B46/03_rev1, the Board:</p> <ol> <li>approves the Strategy Narrative for the 2023-2028 Global Fund Strategy in Annex 1 to GF/B46/03_rev1 and requests that the Secretariat develop, for presentation to the Strategy Committee in March 2022 and subsequently the Board in May 2022, an approach for Strategy implementation with a focus on delivering the key changes outlined in the Strategy using all existing levers and identifying where new solutions will be required; and</li> <li>expresses its recognition to the Standing Committees for their work in the context of the development of the Strategy and looks forward to the continuous engagement between the Board, Secretariat and the Standing Committees, in line with their respective mandates, throughout the implementation of the Strategy.</li> </ol>
2011-05-12 B23 GF/B23/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Third Board Meeting (GF/B23/1 Revision 1) is approved.
2011-05-12 B23 GF/B23/DP28 Communication of Losses and Recoveries arising from OIG Audits and Investigations Communication of Losses and Recoveries arising from OIG Audits and Investigations
<p>As outlined in GF/B23/DP24, the Board reiterates its full commitment to transparency, and to the independence of the Office of the Inspector General within the Global Fund.</p> <p>The Board recognizes the need to have clear, consistent and contextualized information regarding the status of losses identified from OIG audits and investigations, as well as the status of efforts to recover losses, which can then be made public.</p> <p>Accordingly, the Board requests the Global Fund Secretariat and the OIG, under the oversight of FAC, to jointly publish before each regular scheduled meeting of the Board, a Losses &amp; Recoveries Report ("Report") containing background information and an updated table in the format outlined in Attachment 1 to GF/B23/6.</p> <p>The Board requests the FAC to:</p> <ul> <li>Oversee the process to create/update this report and table.<br /><br /></li> <li>Ensure requests for clarifications are addressed to their satisfaction.<br /><br /></li> <li>Report to the Board on their oversight of this process.</li> </ul> <p>The table shall only contain information on identified losses when:</p> <ul> <li>The principle of country ownership has been respected by notifying the Country Coordinating Mechanism (CCM) and the entities involved, of the details of the losses claimed, where they have been provided with appropriate time to respond, and this response is incorporated by the OIG in the publicly available reports.<br /><br /></li> <li>The details of losses identified have been submitted to the Global Fund Secretariat and comments have been considered by the OIG.<br /><br /></li> <li>The Global Fund‟s Legal Counsel has made a determination that the Global Fund is entitled to make a claim for recovery against an entity based on the work of the OIG.<br /><br /></li> <li>These figures have been made public, i.e. the OIG has reported a number either through a specific public report or through the OIG Progress report to the Board which will also be made public, or the OIG has notified the FAC in writing.</li> </ul> <p>The usefulness of the application of the Losses &amp; Recoveries Report for information sharing and communication will be reviewed by FAC before the second Global Fund Board meeting of 2012.</p> <p>The Board requests that the High Level Independent Review Panel on Fiduciary Controls and Oversight Mechanisms consider and provide guidance on the issues surrounding the use of a denominator to serve as a communication tool regarding the scale and evolution of losses in Global Fund supported programs, as part of their interim report.</p>
2011-05-12 B23 GF/B23/DP26 Approval of the Public Release of the Investigation Report on Mali Grants Approval of the Public Release of the Investigation Report on Mali Grants
The Board approves the public release of the redacted version of the OIG Report of Investigation of Mali Malaria (Round 4 and 7) and Tuberculosis (Round 1 and 6) (“the Restricted Report”), as set out in GF-OIG-11-002, and authorizes the Inspector General to make the Restricted Report publicly available on the OIG website.
2011-05-12 B23 GF/B23/DP05 Election of Board Chair and Vice-Chair Election of Board Chair and Vice-Chair
<p>The Board appoints Mr. Martin Dinham as Chair of the Board and Dr. Mphu Ramatlapeng as Vice-Chair of the Board for a two-year mandate from the adjournment of the Twenty-Third Board Meeting and until the adjournment of the first Board Meeting in 2013.</p>
2011-09-22 B23 GF/B23/EDP12 September 2011 Phase 2 Funding Decision September 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 149,519,079 for the following grants: BOL-809-G08-M ; DMR-809-G05-M ; DMR-809-G06-M ; ERT-809-G06-H ; KEN-708-G09-H ; MDG-809-G11-H ; MDG-809-G12-H ; MUS-809-G01-H ; MUS-809-G02-H ; MWP-507-G05-M ; SWZ-809-G07-T ; TAJ-809-G07-H ; TAJ-809-G08-M ; TAJ-809-G09-T</p>
2011-07-24 B23 GF/B23/EDP08 Extension of Grant Ending Date For Grant KOS-708-G02-H and Grant Starting and Ending Dates for Grant KOS-911-G03-T Extension of Grant Ending Date For Grant KOS-708-G02-H and Grant Starting and Ending Dates for Grant KOS-911-G03-T
The Board extends the Phase 2 Ending Date of the Kosovo HIV Grant KOS-708-G02-H from 30 September 2013 to 30 June 2014. The Board also changes the Phase 1 Starting Date of the Kosovo TB Grant KOS-911-G03-T from 1 January 2011 to 1 October 2011 and extends the Phase 1 Ending Date from 31 December 2012 to 30 September 2013, and subject to approval of Phase 2 of this Grant, authorizes the extension of the Phase 2 Ending Date from 31 December 2015 to 30 September 2016.
2011-05-12 B23 GF/B23/DP08 Plan for Comprehensive Reform: Fiduciary Controls Plan for Comprehensive Reform: Fiduciary Controls
<ol> <li>The Board recognizes that an effective system of fiduciary control that spans from proposal development through grant implementation is essential to the Global Fund. <br /><br /></li> <li>As such, the Board requests the Secretariat to take the following actions as specified in Part 5.2.i-iv of the Report of the Comprehensive Reform Working Group (CRWG Report) GF/B23/13, and report on its progress and implementation of these actions at the Twenty-Fourth Board Meeting:<br /><br />i. Develop an accountability framework for fiduciary control and risk management;<br /><br />ii. Strengthen the application and enforcement of minimum Principal Recipient requirements;<br /><br />iii. Develop a fully transparent information system and an effective communications strategy; and<br /><br />iv. Develop a calibrated and differentiated response mechanism.<br /><br /></li> <li>Pursuant to Part 5.2.v of the CRWG Report, the Board requests that the Finance and Audit Committee (FAC) review and refine the position and scope of audit and investigation functions, and report on its progress at the Twenty-Fourth Board Meeting.</li> </ol>
2011-05-12 B23 GF/B23/DP01 Appointment of Rapporteur Appointment of Rapporteur
Mr. Maksut Kulzhanov from the Eastern Europe and Central Asia constituency is designated as rapporteur for the Twenty-Third Board Meeting.
2011-05-12 B23 GF/B23/DP29 Approval of the 2010 Annual Report Approval of the 2010 Annual Report
<p>The Board approves the Annual Report as presented in GF/B23/16.</p>
2011-05-12 B23 GF/B23/DP04 High-Level Independent Review Panel High-Level Independent Review Panel
<p>The Board approves the establishment of a High-Level Independent Review Panel on fiduciary controls and oversight mechanisms under the Terms of Reference contained in Annex 1 to the document entitled "High-Level Independent Review Panel on the Fiduciary Controls and Oversight Mechanisms" (GF/B23/21).</p> <p>The Board notes that the estimated cost of the High-Level Independent Review Panel is approximately USD 2.2 million for consultancy fees and costs associated with travel and meetings. The Board delegates the Finance and Audit Committee (FAC) to consider and approve the High-Level Independent Review Panel budget within the framework of the 2011 administrative budget review, which is scheduled for June 2011.</p>
2011-09-22 B23 GF/B23/EDP13 Additional funding for the Continuity of Services to the Ghana Round 5 HIV grant (GHN-506-G06-H) Additional funding for the Continuity of Services to the Ghana Round 5 HIV grant (GHN-506-G06-H)
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the Secretariat‟s recommendation.</p><p><span style="font-size: 12px; line-height: 1.5;">See attached tabledetailing total recommended funding amount of US$16,899,147 for the following grant: GHN-506-G06-H</span></p>
2011-08-13 B23 GF/B23/EDP09 August 2011 Phase 2 Funding Decision August 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 50,244,443 for the following grants: ARM-809-G03-T ; BUR-809-G08-M ; BUR-809-G09-M ; SLV-708-G05-H ; SLV-708-G06-H ; SLV-202-G01-H-00 ; SLV-202-G03-H-00 ; PKS-809-G09-T ; PKS-809-G10-T ; PRY-809-G04-H</p>
2011-05-12 B23 GF/B23/DP25 Exceptional Extension Funding Related to the Timing of the Approval of Round 11 Exceptional Extension Funding Related to the Timing of the Approval of Round 11
<ol> <li>Further to GF/B22/DP25 ("Measures Associated with Funding Proposals"), the Board notes the potential funding gaps faced by certain countries as a result of the decision of the Board to approve Round 11 proposals at the first Board meeting of 2012, instead of at the last Board meeting in 2011.<br /><br /></li> <li>To mitigate the potential adverse impact on service delivery, the Board approves Exceptional Extension Funding to grants that reach the end of their Phase-2 terms under the Rounds Based or the Rolling Continuation funding channels on the basis of the policy contained in the Report of the Finance and Audit Committee GF/B23/6 Annex 1.<br /><br /></li> <li>The Secretariat shall review Exceptional Extension Funding requests and provide a funding recommendation to the Board for approval under the "no objection" voting procedures set forth in Article 12 of the Board Operating Procedures.<br /><br /></li> <li>If incremental funding is not required because there are sufficient funds remaining under the Expiring Grant to cover the Exceptional Extension Funding, the Board authorizes the Secretariat to approve the Request, on the same conditions and subject to the same limitations set out in this policy.</li> </ol>
2011-07-11 B23 GF/B23/EDP06 Round 7 Central African Republic HIV grant (CAF-708-G05-H) Round 7 Central African Republic HIV grant (CAF-708-G05-H)
<p>The Board approves a six-month extension to the Phase 1 period of the Round 7 Central African Republic HIV grant (CAF-708-G05-H), which shall therefore end on 31 December 2011, in order to allow for an enhanced program audit of the grant to take place.</p><p>This decision does not have material budgetary implications.</p>
2011-05-12 B23 GF/B23/DP06 Extension to the Board Committee Membership and Leadership Terms Extension to the Board Committee Membership and Leadership Terms
<ol><li>The Board decides to extend the membership and leadership terms of all the existing standing and ad hoc Board Committees until the appointment of the incoming Board Committee membership and leadership, which shall be no later than the end of the last Board meeting of 2011. <br/><br/></li><li>The Board extends its gratitude to all Committee leaders and members for their continued commitment to the Global Fund.</li></ol>
2010-12-15 B22 GF/B22/DP13 Affordable Medicines Facility – malaria: Duration Phase 1 Affordable Medicines Facility – malaria: Duration Phase 1
<p>The Board refers to its earlier decision regarding the evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm) (GF/B20/DP24), and notes that AMFm Phase 1 is currently funded as a 24-month program.</p> <p>The Board recognizes the shift in the start of the implementation of AMFm Phase 1 and the need to ensure an evaluation that can inform a decision on the future of the AMFm as a business line. Accordingly, the Board decides to extend the implementation period of AMFm Phase 1 by six months and requests the AMFm Ad Hoc Committee to present a recommendation to the Board at its second meeting in 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line.</p> <p>The Board grants the Secretariat the authority to work with relevant countries and Principal Recipients to extend the relevant grants and to make any other consequential amendments to those grants as a result of the extension of AMFm Phase 1. The Board further decides that there are no additional funds earmarked for financing AMFm Phase 1 Supporting Interventions, and countries and Principal Recipients should plan accordingly.</p> <p>In order to support the six month extension, the activities of the AMFm Unit shall be extended by six months. At current budgetary rates, not including the Professional Fees for the Independent Evaluation, an additional US$ 1.6 million will be required in 2012. The six month extension is expected to result in an increase in Professional Fees in 2012 for the Independent Evaluation of US$ 108,000 to cover additional labor costs, inflation and wage increases.</p> <p>The six month extension will likely mean a reduction in 2011 Professional Fees expenditure for the end-point data collection contracts. However, any expenditure saved in 2011 would correspondingly be incurred in 2012. The actual costs of end-point data collection will be known when the contracts for the data collection firms are finalized. The Board notes that this could result in an additional cost or a saving to the estimated US$ 3.9 million budget for the end-point data collection. Any additional cost to the end-point data collection budget will be presented to the Board for approval.</p>
2011-05-12 B23 GF/B23/DP18 Revisions to the Terms of Reference of the Technical Review Panel (TRP) Revisions to the Terms of Reference of the Technical Review Panel (TRP)
<ol><li>The Board delegates to the Portfolio and Implementation Committee the authority to update the Terms of Reference of the TRP to:<br/><br/>i. reflect the Global Fund‟s Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals for Funding from the Global Fund approved at the Twenty-Third Board Meeting.<br/><br/>ii. incorporate value for money principles, clarify language for applicants and eliminate duplications in the review criteria for proposals (Attachment 1 of the Terms of Reference); and<br/><br/>iii. adjust for recommendation categories as specified in the Periodic Reviews and Commitments Policy (Report of the PSC, GF/B20/4 Revision 2, Annex 2a) and other non-material items.<br/><br/></li><li>The revised Terms of Reference will enter into force after the Portfolio and Implementation Committee‟s approval on or about 1 July 2011.<br/><br/></li><li>The Board requests the Portfolio and Implementation Committee to notify the Board of the approved version.</li></ol>
2010-12-15 B22 GF/B22/DP18 Management of foreign exchange in the budget Management of foreign exchange in the budget
<p>The Board acknowledges that a significant percentage of the Operating Expenses Budget is denominated in Swiss Francs (CHF) whereas the budget is presented in United States Dollars (USD) and the reporting currency of the Global Fund is the USD.</p><p>To give greater certainty to the Board at the time of approving the USD budget, the Board decides to give the Secretariat authority to manage foreign exchange transactions in a manner which minimizes the exposure of the budget to volatility in the exchange rate between the USD and the CHF.</p><p>The Board further authorizes the Executive Director to take all necessary steps to manage this exposure.</p><p>The steps taken to manage this exposure will be under the oversight of the Finance and Audit Committee.</p>
2010-12-15 B22 GF/B22/DP06 Board Chair and Vice Chair nomination and election process Board Chair and Vice Chair nomination and election process
<p>The Board approves the following amendments to the Board Chair and Vice-Chair nomination and election process:</p><p>1. The incumbent Board Chair and Vice-Chair shall launch the nomination process three months ahead of the Board meeting at which the election is scheduled to take place.</p><p>2. Any individual nominated by a voting constituency, with the attributes stipulated in the Terms of Reference of the Board Chair and Vice-Chair, may stand for office.</p><p>3. The Board Chair and Vice-Chair shall, upon election, become ex-officio members of the Board during their tenure, independent of any constituency, and shall not hold voting rights.</p><p>These amendments are reflected in the excerpts of the revised By-laws, Board Operating Procedures and Terms of Reference of the Board Chair and Vice-Chair contained in Annex 4, Revision 1 of the PSC's report to the Twenty-Second Board (GF/B22/4).</p>
2004-03-19 B07 GF/B07/DP5 Phase 2 Grant Renewals (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA), Annex 4) Phase 2 Grant Renewals (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA), Annex 4)
<p>The Board approves the following decisions:</p> <p>Decision Point 1</p> <p>Phase 2 grant renewal decisions will be made according to clear criteria for satisfactory grant performance, financial accountability and contextual considerations, subject to Global Fund resource availability. The decision will be based on systematically collected information, which will be made transparently available by the Global Fund through Grant Fact Sheets and Grant Score Cards.</p> <p>Decision Point 2</p> <p>A Request for Continued Funding, up to a maximum of the original approved Proposal less funds spent during the initial grant period (years 1-2)<a id="_ftnref1" name="_ftnref1"></a><sup>[1]</sup>, will be reviewed and may be adjusted for reasonableness. Program objectives for phase 2 are expected to be broadly consistent with the original approved Proposal, with reprogramming subject to review.</p> <p>Decision Point 3</p> <p>The Board delegates the authority to make phase 2 grant commitments to the Secretariat according to the policies and review and decision process set forth in this document. The Board will confirm all decisions to discontinue funding based on reviews by the Secretariat and the TRP. The Secretariat will regularly report on phase 2 grant commitments to MEFA and PMPC. The PMPC Chair will inform the Board at each Board meeting. The Technical Evaluation Reference Group (TERG) will regularly review and report on the soundness of the phase 2 review and decision process to the Board through MEFA.</p> <p>The phase 2 decisions will be taken 20 months after the start date for grant programs with exceptions for force majeur situations. The decision may be taken earlier in cases of (i) accelerated implementation; or (ii) severe exchange rate fluctuations.</p> <p>For Rounds 1 and 2 grants, the start date of each grant program may be adjusted to reflect program realities. This will be achieved through negotiations between the Secretariat and the PR.</p>
2004-04-21 B07 GF/B07/EDP02 Approval and authorization of issuance of the 2003 Annual Report Approval and authorization of issuance of the 2003 Annual Report
<p>The Board approves the 2003 Annual Report for publication and distribution.</p>
2004-03-19 B07 GF/B07/DP13 Report of the Portfolio Management and Procurement Committee Report of the Portfolio Management and Procurement Committee
<p>The Board adopts the following points:</p><p><i><b>TRP Renewal</b> </i></p><p><b>Decision Point 1:</b> </p><p>The Board accepts the list of persons contained in Annex 3 that have been selected by the PMPC and the Executive Director to fill the vacancies on the Technical Review Panel for 3 HIV/AIDS experts, 1 malaria expert, 1 tuberculosis expert, and 4 cross-cutting experts.</p><p><b>Decision Point 2</b> </p><p>The Board accepts the list of persons contained in Annex 4 that have been selected by the PMPC and the Executive Director to comprise the TRP Support Group.</p><p><i><b>Procurement and Supply Management: Pre-qualification of and competition between procurement agents</b> </i></p><p><b>Decision Point 3</b> </p><p>The Board approves the recommendation from the PMPC that it commend the work of the World Health Organization in its work with other partners to develop a system for pre-qualifying procurement agents and report back to the Eighth Board Meeting on the progress in developing such a system.</p><p><b>Decision Point 4</b> </p><p>The Board endorses the PMPC recommendation that it allow recipients that are using procurement agents for health products to select among them using whatever system the recipients wish provided that it is competitively and transparently selected, based on quality, cost, and level of service.</p>
2004-03-19 B07 GF/B07/DP15 Round 3 Appeals Round 3 Appeals
<ul type="disc"><li>The Board endorses the Appeal Panel's recommendation that the following proposals be approved as category 2 proposals, with final approval contingent on the successful completion of the Technical Review Panel clarification process: <ol><li> Suriname HIV/AIDS;</li><li> Yemen HIV/AIDS and</li><li> Multi-Country America Andean Region Malaria. </li></ol></li></ul>
2004-03-19 B07 GF/B07/DP6 Replenishment Mechanism Replenishment Mechanism
<ul> <li>The Board adopts Annex 5 of the Report of Resource Mobilization and Communications Committee (GF/B7/10) on the Voluntary Replenishment Process (as amended) in terms of purpose and scope of the voluntary replenishment, its period and coverage and requests the RMCC to further develop detailed operational modalities to be presented at the Eighth Board meeting.</li> </ul> <p>Amendment (on pages 37-38)</p> <ul> <li>The Fund will ask donors, who participate in the replenishment mechanism, to back all pledges with either cash, or promissory notes, callable on a schedule matching expected Fund disbursements. The minimum threshold for promissory notes would be of $1 million.</li> </ul> <p>Amendment: $10 million is replaced by $1 million</p>
2004-04-27 B07 GF/B07/EDP03 Ratification of the Board leadership's nomination to Committee Leadership Positions (2004-2006) Ratification of the Board leadership's nomination to Committee Leadership Positions (2004-2006)
<p>The Board:</p><ol><li>Having reviewed the Board Chair and Vice-Chair's nominations to Committee Leadership Positions ; <br/><br/></li><li>Ratifies the following nominations ; <br/><br/><ol><li type="a"><u>Resource Mobilization and Communications Committee:</u><br/>Chair: Stu Flavell, Communities Living with the Diseases; <br/>Vice Chair: Jérôme Baconin, France, Spain and Luxembourg. <br/><br/></li><li type="a"><u>Governance and Partnership Committee: </u><br/> Chair: Pasqualino Procacci, Italy;<br/> Vice-Chair: to be determined. </li></ol></li></ol>
2004-03-19 B07 GF/B07/DP1 Appointment of the Rapporteur Appointment of the Rapporteur
<ul type="disc"><li>Mireille Guigaz from the France (Luxemburg, Spain) Constituency is designated as Rapporteur for the Seventh Board Meeting.</li></ul>
2004-03-19 B07 GF/B07/DP10 Prioritization in Resource Constrained Environments (Report of the Portfolio Management and Procurement Committee, Annex 5) Prioritization in Resource Constrained Environments (Report of the Portfolio Management and Procurement Committee, Annex 5)
<p>The Board adopts the following system for prioritizing among TRP-recommended proposals in the event that insufficient resources are immediately available to approve all TRP-recommended proposals. </p> <ol start="1" type="1"> <li>A composite index would be used to assign scores to TRP-recommended proposals, as described below.</li> </ol> <ol start="2" type="1"> <li>For Round 4, the criteria used in this composite index would be poverty and disease burden. The Board requests the PMPC to review the possibility of including an additional criteria for the Fifth and subsequent Rounds around repeated failures and countries that have not previously received funding.</li> </ol> <ol start="3" type="1"> <li>The indicators, values, and scores for the first two criteria are:<br /><br /> <table border="0" class="table" id="b4f51f87-f503-2fa4-092c-e4d1ecbfe5cd"> <tbody> <tr> <td>Criteria</td> <td>Indicator</td> <td>Value</td> <td>Score</td> </tr> <tr> <td rowspan="2">Disease burden</td> <td rowspan="2"> <p>Eligibility criteria for proposals from Upper-Middle Income countries</p> <p>(applied to all proposals)</p> </td> <td>"Very high"</td> <td>4</td> </tr> <tr> <td>Not "very high"</td> <td>1</td> </tr> <tr> <td rowspan="3">Poverty</td> <td rowspan="3">World Bank classification</td> <td>Low Income</td> <td>4</td> </tr> <tr> <td>Lower-Middle Income</td> <td>2</td> </tr> <tr> <td>Upper-Middle Income</td> <td>0</td> </tr> </tbody> </table> </li> <li>In the event that insufficient resources are immediately available to finance all TRP-recommended proposals, TRP-recommended proposals would be financed in the following order: <ol> <li>Proposals in TRP category 1</li> <li>Proposals in TRP category 2.</li> </ol> </li> <li>If category 2 is sub-classified by the TRP into subcategories, these would be financed sequentially, with the proposals in the higher-rated subcategories being financed before those in lower-rated subcategories.</li> </ol> <ol start="6" type="1"> <li>Proposals in the highest-rated category (or subcategory, if category 2 is broken down by the TRP into subcategories) for which insufficient resources are available would be assigned a score in accordance with the above table. They would then be financed in descending order (with the highest scoring proposals receiving priority).</li> </ol> <ol start="7" type="1"> <li>There would be no further subdivision of the groups formed by the combination of the TRP category/subcategory and score would be made.</li> </ol> <ol start="8" type="1"> <li>If insufficient resources are available to immediately finance all TRP-recommended proposals, the Secretariat would be responsible for assigning scores to proposals and would present the Board with these scores at the time of the Board's consideration of the TRP's recommendations.</li> </ol>
2004-03-19 B07 GF/B07/DP8 Executive Session: Decision Executive Session: Decision
<p><b>Decision Point 1</b> </p><p>The Board of the Global Fund agrees to reappoint Dr. Richard Feachem as Executive Director of the Global Fund.</p><p><b>Decision Point 2</b> </p><p>Terms of reference for the Executive Director will be developed and presented for decision at the Eighth Board Meeting.</p><p><b>Decision Point 3</b> </p><p>The Board will establish an annual performance review process for the Executive Director.</p>
2004-04-21 B07 GF/B07/EDP01 Appreciation of the outgoing Vice Chair of the Board, Dr Suwit Wilbulpolprasert Appreciation of the outgoing Vice Chair of the Board, Dr Suwit Wilbulpolprasert
<p>The Board recognizes the valuable contribution of Dr Suwit Wilbulpolprasert from South East Asia in his role as Vice Chair of the Board from January 2003 to March 2004, and extends its appreciation for his leadership, dedication and commitment in supporting the Global Fund and for his major role in developing the Global Fund partnership as a member of the founding Board and as Chair of the Portfolio Management and Procurement Committee.</p><p>The resolution will be recorded in an Annex to the Seventh Board report.</p>
2007-02-09 SB01 GF/SB01/DP03 Selection of the Executive Director Selection of the Executive Director
<p>The Board selects Michel Kazatchkine for the position of Executive Director of the Global Fund and requests the Chair and Vice Chair of the Board to make the necessary arrangements with WHO for the negotiation of the contract and the appointment.</p>
2007-02-09 SB01 GF/SB01/DP05 Decision on the Office of the Inspector General Decision on the Office of the Inspector General
<ol> <li>Bearing in mind its fiduciary responsibilities:<br /><br /> <ol> <li>The Board welcomes and accepts the offer of the World Health Organization (WHO) to assign, with immediate effect, its Director, Office of Internal Oversight Services (lOS) to lead temporarily the Global Fund's Office of the Inspector General (OIG) for a period of four to six months. This arrangement will be reviewed at the Fifteenth Board meeting in April 2007.<br /><br /></li> <li>The Board approves the engagement by the Director, lOS of an external contractor to provide substantive support in accordance with the scope of work outlined in Part 3 of the Joint Report of the Chairs of the Finance and Audit Committee and the Performance Assessment Committee, presented at the Special Board Meeting held on 8-9 February 2007 (GF/SBM1/5), which may be modified by the Chair and Vice Chair based on input from the Director, lOS. <br /><br /></li> <li>The Board is satisfied that these actions will result in the immediate reestablishment of an effective OIG function to fulfill the Global Fund's immediate assurance requirements. <br /><br /></li> </ol> </li> <li>The Board requests the Finance and Audit Committee to submit, at the Fifteenth Board meeting in April 2007, recommendations with respect to clarifying the role, remit and priorities of the OIG, documenting an overall assurance framework for the Global Fund, reviewing and clarifying the reporting lines, relationships and options for resourcing of the OIG and defining an Action Plan, including terms of reference, selection criteria and provision for candidate review by experts in internal audit and other relevant areas, for the recruitment of the next Inspector General.<br /><br /></li> <li>The recruitment process shall be launched upon approval at the Fifteenth Board meeting in April 2007, and shall result in the appointment of a new Inspector General not later than 31 July 2007.</li> </ol>
2007-02-09 SB01 GF/SB01/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Dr Regina Rabinovich from the Private Foundations Constituency is designated as Rapporteur for the First Special Board Meeting.</p>
2007-02-09 SB01 GF/SB01/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the First Special Board Meeting (GF/SB1/1) is approved.</p>
2007-02-09 SB01 GF/SB01/DP04 Selec.tion of the Executive Director (Compensation) Selec.tion of the Executive Director (Compensation)
<p>The Board decides that the compensation of the Executive Director shall correspond to that offered at the appropriate rate of the WHO UG02 grade.</p>
2007-02-09 SB01 GF/SB01/DP06 Credit Suisse Account Credit Suisse Account
<ol> <li>The Board has fully considered the Inspector General's report on the Credit Suisse account, the Secretariat's response and the independent review on the performance of the Office of the Inspector General (OIG). <br /><br /></li> <li>The Board instructs the Secretariat to reduce and maintain the funds in the Credit Suisse account at the minimum level necessary to carry out the functions approved by the Board, which are the following: <br /><br /> <ol> <li>holding the foundation's capital, of CHF 50,000, as required by Swiss law; <br /><br /></li> <li>paying for fees to the Fund's external auditors; <br /><br /></li> <li>receiving private-sector contributions that the Trustee is not able to receive directly, such as proceeds from the Project(RED) campaign, and other miscellaneous receipts, which the Secretariat shall remit immediately upon receipt to the Trustee; <br /><br /></li> <li>paying rent and related charges for the Global Fund's premises in Geneva; <br /><br /></li> <li>paying the rental allowance for the current Executive Director, until 31 March 2007; and <br /><br /></li> <li>paying filing fees in certain jurisdictions for the Global Fund to qualify to receive private, charitable contributions. <br /><br /></li> </ol> </li> <li>The Board requests the Director, Internal Oversight Services of the World Health Organization, in his role as the ad-interim Inspector General of the Global Fund to monitor the transactions of the Credit Suisse account on a continual basis. <br /><br /></li> <li>The Board takes note that the Secretariat has voluntarily suspended the use of the credit cards connected with this account since September 2006 and instructs the Secretariat to cancel the credit cards with immediate effect. <br /><br /></li> <li>The Board endorses the recommendations for improvement in controls contained in the report of the Inspector General, notes Secretariat agreement with these recommendations, and directs the Secretariat to complete their implementation as soon as possible. <br /><br /></li> <li>The ad-interim Inspector General and the new Inspector General should follow up on the full implementation of the improvements to the controls and report back to the Board at the Fifteenth Board Meeting (April 2007) and Sixteenth Board Meeting (November 2007), respectively. <br /><br /></li> <li>The Board requests the ad-interim Inspector General, to conduct an independent analysis of the remaining issues raised by the Inspector General's report and the Secretariat response, and advise the Board whether further action is required, not later than the Fifteenth Board Meeting in April 2007.</li> </ol>
2017-05-04 B37 GF/B37/DP11 Health Situation in Venezuela Health Situation in Venezuela
<ol> <li>The Board expresses: <ol type="a"> <li>Continued concern about the resurgence of malaria, shortages of critical commodities for HIV and TB, and broader health crisis in Venezuela and its impact on the region; and</li> <li>Appreciation for the engagement of communities, civil society groups, PAHO, UNAIDS, WHO and others and their efforts to raise awareness and explore solutions for this situation.</li> </ol> </li> <li>The Board discussed the situation at length, noting Venezuela is currently not eligible for Global Fund financing, and calls for a coordinated regional response to the health crisis in Venezuela and that addresses the impact on the region incorporating relevant partners, donors and financers.</li> <li>Under such circumstances, in the context of a regional response, the Global Fund will continue to engage and, if possible, support the regional response</li> <li>The Board directs the Strategy Committee and the Secretariat to discuss exceptional circumstances in non-eligible countries as part of the ongoing review of the Eligibility Policy.</li> </ol>
2017-11-17 B37 GF/B37/EDP07 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>1.1 Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 1,117,868,607 and € 108,755,207, this includes allocation funding as well as US$ 27,873,561 of catalytic investments for matching funds.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B37/EDP07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP;</li> </ol>
2004-03-19 B07 GF/B07/DP11 Appointment of Technical Evaluation Reference Group (TERG) Appointment of Technical Evaluation Reference Group (TERG)
<ul type="disc"><li>The Board confirms the shortlist of nominations for the Technical Evaluation Reference Group (TERG) as presented by the Selection Committee.</li></ul><ul type="disc"><li>The Board invites the Japan delegation to submit nominations for the TERG to be considered by the MEFA Committee.</li></ul>
2017-05-03 B37 GF/B37/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Ambassador Deborah Birx from the United States constituency is designated as Rapporteur for the 37th Board Meeting.</p>
2004-03-19 B07 GF/B07/DP12 Additional MEFA Items (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA)) Additional MEFA Items (Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA))
<p><b><i>Protecting Grants from the Impact of Exchange Rate Fluctuations</i></b> </p><p><b>Decision Point 1</b> </p><p>That in cases where a funding shortfall caused by an adverse currency fluctuation is jeopardizing the viability of the grant supported program, the CCM may apply for Phase 2 funding on an accelerated basis in order to permit the program to continue uninterrupted without curtailing program activity.</p><p><b>Decision Point 2</b> </p><p>That the Secretariat evaluate the implications of the Global Fund offering top-up grants and multi-currency denominated grants as further means of protecting grants from the impact of exchange rate fluctuations and to present its analysis and recommendations to the Board in June 2004.</p><p><b>Decision Point 3</b> </p><p>To mandate the Secretariat and the MEFA Committee to study possible stabilization mechanisms, including topping-up grants and multi-currency grants, aimed at protecting grants from the impact of exchange rate fluctuations. The MEFA Committee will present its analysis and recommendations to the Board at the Eighth Board Meeting.</p><p><b><i>Criteria for Considering Promissory Notes as Assets</i></b> </p><p><b>Decision Point 4</b> </p><p>That the Global Fund shall consider as assets for the purposes of entering into grant agreements, promissory notes or similar obligations issued by the government of a sovereign state (or its designated depository) which shall be non-negotiable, non-interest bearing and payable at par value to the account of the Fund in the designated depository on demand or in accordance with an encashment schedule agreed between the contributor and the Secretariat.</p>
2004-03-19 B07 GF/B07/DP14 Report of the Governance and Partnership Committee Report of the Governance and Partnership Committee
<p>Additional Safeguard Policy</p> <p>Decision Point 1</p> <p>The Board adopts the paper on the Additional Safeguard Policy as outlined in Annex 4.</p> <p>The Board requests the Secretariat to include additional operating principals/procedures to address non-performance of PRs in appropriately rapid disbursement of Global Fund grant funds to sub-recipients.</p> <p>Grant Agreements</p> <p>Decision Point 2</p> <p>The Board requests the Governance and Partnership Committee, in consultation with its other appropriate bodies, to develop a standard template grant agreement containing clear and detailed definition of role, obligations and competence of main actors in grant disbursement process (i.e. CCM, LFA, PR, Global Fund Secretariat) and to elaborate procedures for ensuring timely, sound and unhindered implementation of grant agreements for consideration by the Board at its Eighth Meeting.</p> <p>Study of Board Governance and the Role and Composition of Board Committees</p> <p>Decision Point 3</p> <p>The Board mandates a study of, and recommendations regarding, the structures, role and composition of any Board committees. The findings and recommendations of the study should be presented, via the Governance and Partnership Committee with options, to the Board at the Ninth Board Meeting.</p> <p>Conflict of Interest</p> <p>Decision Point 4</p> <p>The Board adopts the revised version of the Policy on Ethics and Conflict of Interest for Global Fund Institutions as outlined in Annex 5 with the exception of the changes on Post-Board employment should be referred back to the committee (Section 7 GF/B7/7 page 6).</p> <p>Decision Point 5</p> <p>The Board requests the GPC to address the conditions under which the Communities delegation can become a voting member of the Board and report back with decision points to the Eighth Board Meeting.</p> <p>Board Member Terms</p> <p>Decision Point 6:</p> <p>The Board adopts the proposed amendment to Article A. Paragraph 1 of the Board Operating Procedures as underlined below:</p> <p>Board Members terms shall begin at the opening of the first Board meeting in a given year, and end at the opening of the first Board meeting in the second calendar year following the commencement of their term.</p>
2007-04-27 B15 GF/B15/DP05 Adoption of the Resource Mobilization Strategy Adoption of the Resource Mobilization Strategy
<p>The Board adopts the Resource Mobilization Strategy contained in the Report of the Policy and Strategy Committee (GF/B15/6), Annex 3, which is based on the recommendation of the Task Team on Resource Mobilization, and commits, where possible, to assisting the Secretariat in executing the strategy to achieve the agreed targets. </p><p>The Board requests the Finance and Audit Committee (FAC) to actively monitor the progress against the targets, as stated in the strategy, expected to be achieved as a result of the significant budgetary increase. First year progress against these targets should be fully reviewed by the FAC prior to the Eighteenth Board meeting. Further budget recommendations to support resource mobilization efforts will be presented at the Eighteenth Board meeting dependant on the performance review. </p>
2007-04-27 B15 GF/B15/DP36 Disclosure of TRP Review Forms and Non-Approved Proposals Disclosure of TRP Review Forms and Non-Approved Proposals
<p>The Board amends Section II, paragraph 1 of the Documents Policy approved at the Third Board Meeting as follows:</p> <p>"B. Disclosure Categories</p> <ol> <li>Records Posted on the Web Site of the Fund: <ol type="a"> <li>Minutes of each Board meeting, together with the full text of all decisions approved by the Board and accompanying documents.</li> <li>List of current Members of the Board, Alternates, Members of Board delegations, Members of the Technical Review Panel, Membership of all Committees, Expert Committees and other Advisory Panels.</li> <li>Current Rules and Procedures of the Board, Technical Review Panel, Committees, and any other Fund body.</li> <li>Annual Report of the Fund.</li> <li>Approved Budget of the Fund.</li> <li>Proposal Applications for Approved Proposals, and commencing from Round 7, all eligible proposal applications.</li> <li>Core Documents, as defined in the Board Operating Procedures."</li> </ol> </li> </ol>
2007-04-27 B15 GF/B15/DP20 Amendment to Section 12 of the Board Operating Procedures Amendment to Section 12 of the Board Operating Procedures
<p>To allow RCC funding decisions to be made on a 'no-objection' basis, the Board amends Section 12 of the Board Operating Procedures as follows:</p><p><i>"<b>12. No-Objection Process</b></i></p><p><i>Notwithstanding Sections 10 and 11, decisions by the Board to provide funding for approved proposals beyond the initial funding commitment or for proposals requesting continued funding for grants that are reaching the end of their funding terms may be made on a no-objection basis under the following process.</i></p><p><i>As directed by the Board, the Secretariat shall issue a request for decision action on each funding commitment for which a Board decision is required, and shall notify the Board accordingly. Unless four Board members of one of the voting groups described in Section 10 object to the requested decision within a time period specified by the Board following the date of notification, the requested decision shall be deemed approved by the Board."</i></p>
2007-04-27 B15 GF/B15/DP34 Approval of Revised Process and Responsibilities for Annual Performance Evaluation of ED Approval of Revised Process and Responsibilities for Annual Performance Evaluation of ED
The Board approves the revised process and responsibilities for the annual performance evaluation of the Executive Director as outlined in the Report of the Performance Assessment Committee (GF/B15/10).
2007-04-27 B15 GF/B15/DP48 Amendment to the Phase 2 Decision-Making Policies and Procedures Amendment to the Phase 2 Decision-Making Policies and Procedures
<p>The Board decides to amend the Phase 2 Decision-Making Policies and Procedures approved at the Fourteenth Board Meeting (Annex 3b Version 2 to the Report of the Portfolio Committee (GF/B14/8)) by:</p><ol type="a"><li>adding the words "or the TRP" after the word "Secretariat" in the first sentence of paragraph 2;</li><li>deleting the words "("Revised Go")" in paragraph 2 and adding the words "Revised Request" after the word "CCM" in the fifth line of the paragraph; </li><li>amending paragraphs 4, 9 and 10 as follows:<br/> "4. A Board decision in favor of a Secretariat or TRP recommendation either: <ul><li>commits additional resources in the amount proposed in the recommendation (in the case of recommendations of "Go,"and"Conditional Go,); or</li><li>does not commit any additional resources (in the case of recommendations of "No Go"), thereby discontinuing the proposal after Phase 1.</li></ul><br/>9. If the Board does not decide in favor of a Secretariat or TRP recommendation of "Go" or, "Conditional Go", the Secretariat or TRP shall reassess its recommendation. To facilitate the reassessment process, those Board constituencies that object to a Secretariat or TRP recommendation shall provide a written explanation that is made available to all Board members and the Secretariat. The Secretariat or TRP will review its recommendation in light of such explanations and will then present a second recommendation on the first day of the subsequent month (unless time-constraints make it necessary to wait to the month thereafter). The Secretariat shall then request the Board to vote on the second Secretariat or TRP recommendation, using the procedures described above. In the event that the Board rejects a second recommendation of "Go", or "Conditional Go", the matter will be referred to the next Board meeting.<br/><br/> 10. If the Board does not decide in favor of a "No Go" recommendation from the Secretariat, the Secretariat shall reassess its recommendation. To facilitate the reassessment process, those Board constituencies that object to such recommendation shall provide a written explanation that is made available to all Board members and the Secretariat. The Secretariat will review its recommendation in light of such explanations and will either: (i) present a revised recommendation of "Go" or "Conditional Go" and then request that the Board vote on the revised recommendation (or in the case of a Revised Go Request submit to the TRP), using the procedures described above; or (ii) if the Secretariat wishes to maintain its recommendation for a "No Go", it shall refer the matter to an Independent Review Panel, which shall assess the specific areas where the Board and the Secretariat differ on their assessment of the grant and report its conclusions to the Board."<br/><br/> and</li><li> adding the following paragraph as paragraph 11 (and renumber the remaining paragraphs accordingly):<br/><br/> "11. If the Board does not decide in favor of a "No Go" recommendation from the TRP, the TRP shall reassess its recommendation. To facilitate the reassessment process, those Board constituencies that object to such recommendation shall provide a written explanation that is made available to all Board members and the TRP. The TRP will review its recommendation in light of such explanations and will either: (i) present a revised recommendation of "Go" or "Conditional Go" and then request that the Board vote on the revised recommendation, using the procedures described above; or (ii) if the TRP wishes to maintain its recommendation for a "No Go", the matter will be referred to the next Board meeting for final decision."</li></ol>
2007-04-27 B15 GF/B15/DP37 Approval of Revised Terms of Reference of the Technical Review Panel Approval of Revised Terms of Reference of the Technical Review Panel
The Board approves the Terms of Reference of the Technical Review Panel (TRP) as set out in Annex 2 of the Report of the Portfolio Committee (GF/B15/7).
2007-04-27 B15 GF/B15/DP40 Continuation of Board Role in Phase 2 Decision-Making Policies and Procedures Continuation of Board Role in Phase 2 Decision-Making Policies and Procedures
The Board decides to extend the application of the Phase 2 Decision-Making Policies and Procedures set out in Annex 3b Version 2 to the Report of the Portfolio Committee to the Fourteenth Board Meeting (GF/B14/8) beyond the time-limited trial period that is specified therein and delete the final paragraph of such document.
2007-04-27 B15 GF/B15/DP33 Approval of Revised Competency Model Approval of Revised Competency Model
The Board approves the revised Competency Model and associated behaviors that will be used to assess how the Executive Director has set about achieving the various performance targets as detailed in Attachment 1 to the Report of the Performance Assessment Committee (GF/B15/10).
2004-03-19 B07 GF/B07/DP4 Election of the Vice Chair Election of the Vice Chair
Hélène Rossert-Blavier of the Developed Country NGOs is unanimously elected as Vice Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria for the unexpired term of the outgoing Vice Chair. 
2007-04-27 B15 GF/B15/DP26 Approval of 2006 Audited Financial Statements Approval of 2006 Audited Financial Statements
The Board approves the 2006 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young, attached as Annex 3 to the Report of the Finance and Audit Committee (GF/B15/8).
2007-04-27 B15 GF/B15/DP04 Approval of Report of the Fourteenth Board Meeting Approval of Report of the Fourteenth Board Meeting
The Report of the Fourteenth Board Meeting (GF/B15/2) is approved.
2007-04-27 B15 GF/B15/DP49 Procedure for Funding Decision Beyond Initial Financial Commitment of Approved Rolling Continuation Channel Proposals Procedure for Funding Decision Beyond Initial Financial Commitment of Approved Rolling Continuation Channel Proposals
The Board requests the Portfolio Committee to present for approval, no later than the Seventeenth Board Meeting, a procedure for the Board to make funding decisions beyond the initial financial commitment of approved Rolling Continuation Channel proposals. The Board further requests that, in developing such procedure, the Portfolio Committee take into consideration the principles, policies and procedures applicable to Phase-2 funding decisions of rounds-based proposals.
2007-04-27 B15 GF/B15/DP09 Reporting on the Status of the Portfolio Reporting on the Status of the Portfolio
<p>The Board requests the Secretariat to provide an analysis of the Global Fund's grant portfolio at the Board's first meeting of each calendar year, as part of the Secretariat's yearly reporting to the Board on the core set of Performance Indicators for the Global Fund.<sup>1</sup></p><p>This analysis shall include, for example, where feasible and available in recipient country systems, elements such as value for money of Global Fund-financed interventions, the quality of treatment, prevention and care interventions provided through Global Fund-supported programs, the balance of interventions within each disease, the integration of relevant scientific innovations, and gender.</p>
2007-04-27 B15 GF/B15/DP18 Duration of Grants Eligible for Qualification for the Rolling Continuation Channel Duration of Grants Eligible for Qualification for the Rolling Continuation Channel
The Board decides that grants from the fourth and subsequent Rounds that have a term of less than five years shall be ineligible for qualification for the Rolling Continuation Channel. The Board and Secretariat will communicate with Country Coordinating Mechanisms<sup>1</sup> in a timely manner regarding this policy.
2004-03-19 B07 GF/B07/DP7 Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA) Report of the Monitoring, Evaluation, Finance and Audit Committee (MEFA)
<p>Audited Financial Statements 2003</p> <p>Decision Point 1</p> <p>The Board approves the 2003 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young.</p> <p>From the 2004 audit, any Board member can contact the MEFA Committee to bring to the Board an item that the auditor should analyze.</p> <p>Performance on Operating Expense Budget &amp; Work Plan</p> <p>Decision Point 2</p> <p>The Board mandates MEFA to propose a policy regarding the timeframe from approval to signature of Grant Agreements.</p> <p>2004 Operating Expense Budget &amp; Work Plan</p> <p>Decision Point 3</p> <p>The Board approves the 2004 Operating Expense Budget in the amount of</p> <p>US$ 52,668,000 as set out in Annex 10 of the Monitoring, Evaluation, Finance &amp; Audit (MEFA) Report GF/B7/8.</p> <p>Decision Point 4</p> <p>The Board approves that, with regard to Secretariat flexibility to transfer</p> <p>budget between functions and expense types within the overall budget, the following rules shall apply :</p> <ol type="a"> <li>Maintain the separation between the budget for LFA Fees and that for Secretariat Expenses. No transfers are allowed between these two items.</li> <li>Within the budget for Secretariat Expenses, allow transfers between the following five groups of functions (Portfolio Management and TRP; Strategy, Evaluation and Program Support; External Relations; Executive Director and Board Relations; and Operations) subject to the approval of MEFA.</li> <li>Within the budget for each functional grouping, allow unlimited transfers between expense lines.</li> <li>That MEFA shall review and, if considered necessary, adjust this policy in the light of experience during 2004.</li> <li>MEFA shall have the final approval authority for the use of contingency funds.</li> </ol> <p>Decision Point 5</p> <p>Each recommendation submitted to the Board for adoption will include an annex to inform the Board of its budgetary implications.</p> <p>Decision Point 6</p> <p>The Board instructs the Secretariat to conduct, under MEFA oversight, an analysis of Secretariat staffing levels and skills mix, including a mix of fixed and temporary staff and the profile of salaries and benefits, to inform the preparation of the 2005 budget, and that this analysis together with the Secretariat recommendations for the profile of a mature Secretariat for Global Fund operations, be submitted to the Ninth Board meeting together with the 2005 budget for approval.</p>
2004-03-19 B07 GF/B07/DP3 Approval of Report of the Sixth Board Meeting Approval of Report of the Sixth Board Meeting
<ul> <li>The report of the Sixth Board Meeting is approved. </li> </ul>
2004-03-19 B07 GF/B07/DP2 Approval of the Agenda Approval of the Agenda
<ul> <li>The agenda for the Seventh Board Meeting is approved with the following amendments:</li> </ul> <div style="margin-left: 2em;"> <ul> <li>Prioritization in Resource Constrained Environments is moved to Friday 19 March</li> </ul> </div> <div style="margin-left: 2em;"> <ul> <li>A closed Executive Session will held at the end of the first day (18<sup>th</sup>March) as well as the beginning of the second day (19<sup>th</sup>March)</li> </ul> </div> <div style="margin-left: 2em;"> <ul> <li>The approval of the Annual Report has been removed from the agenda. Approval will occur via email in the beginning of April 2004.</li> </ul> </div>
2004-03-19 B07 GF/B07/DP9 3x5 Initiative 3x5 Initiative
The Board supports the 3x5 initiative launched by WHO and UNAIDS. Its success will be vital to the goals of the Global Fund. We wish to ensure that WHO and UNAIDS are fully supported to play their part in contributing to these goals, which have been endorsed in various international forums. This should be mainly implemented at the country and regional level.
2007-04-27 B15 GF/B15/DP38 Approval of Technical Review Panel Members and Alternate Members for Round 7 Approval of Technical Review Panel Members and Alternate Members for Round 7
The Board approves as Permanent Members and Alternate Members of the Technical Review Panel (TRP) the list of persons as indicated in Annex 3 the Report of the Portfolio Committee (GF/B15/7) who have been recommended by the Portfolio Committee and the Executive Director from the TRP Support Group approved at the Thirteenth Board meeting, upon consideration of required technical expertise, as well as geographical distribution and gender balance.
2017-09-08 B37 GF/B37/EDP02 Decision on the Secretariat’s Recommendation on Reinvestment of Funding from the 2014-2016 Allocation to Burkina Faso Across Country Disease Components Decision on the Secretariat’s Recommendation on Reinvestment of Funding from the 2014-2016 Allocation to Burkina Faso Across Country Disease Components
<p>The Board:</p> <ol> <li>Approves the reinvestment of funds from the TB-HIV grant BFA-C-IPC and the RSSH grant BFA-S-PADS to the malaria grant BFA-M-PADS, as listed in Table 1 of Section IV to GF/B36/ER01 (“Table 1”);</li> <li>Affirms the reinvestment of funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of the grant BFA-M-PADS, (b) decreases the upper-ceiling amount that may be available for the relevant implementation period(s) of the TB/HIV grant BFA-C-IPC and RSSH grant BFA-S-PADS, (c) is subject to the availability of funding, and (d) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-05-03 B37 GF/B37/DP03 Board Chair and Vice-Chair Terms of Reference Board Chair and Vice-Chair Terms of Reference
<ol> <li>The Board approves the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B37/22- Revision 1 (the “Terms of Reference”), which shall enter into force upon the conclusion of the 37th Board Meeting in May 2017.</li> <li>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</li> </ol>
2017-05-04 B37 GF/B37/DP12 Amended and Restated Global Fund Quality Assurance Policy for Diagnostic Products Amended and Restated Global Fund Quality Assurance Policy for Diagnostic Products
<p>Based on the recommendation of the Strategy Committee, the Board approves the amended and restated Global Fund Quality Assurance Policy for Diagnostic Products, as set forth in Annex 1 to GF/B37/06.</p>
2011-04-29 B22 GF/B22/EDP16 Extension of Grant Ending Date For the Round 8 Ghana Malaria Grant (GHN-809-G08-M) Extension of Grant Ending Date For the Round 8 Ghana Malaria Grant (GHN-809-G08-M)
The Board extends the Phase 1 Ending Date of the Ghana Malaria Grant GHN-809-G08-M from 31 December 2011 to 31 December 2012, and subject to approval of Phase 2 of this Grant, authorises the extension of the Phase 2 Ending Date from 31 December 2014 to 31 December 2015.
2010-12-15 B22 GF/B22/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Second Board Meeting (GF/B22/1, Revision 1), as amended, is approved.
2010-12-15 B22 GF/B22/DP07 Technical Evaluation and Reference Group (TERG) – Related matters Technical Evaluation and Reference Group (TERG) – Related matters
<p>1. The Board acknowledges the work of the sub-committee of the Policy and Strategy Committee (PSC) on the follow-up to the Five-Year Evaluation and on the future of the TERG, starting in May 2009. The Board also thanks the TERG for its involvement in this reflection.</p><p>2. To ensure that the TERG moves forward with sufficient resources, expertise, independence and credibility in advising the Board and its committees on monitoring and evaluation matters, the Board approves the revised Terms of Reference, membership and procedures for the Technical Evaluation Reference Group (as set out in Annex 5 to the PSC Report to the Twenty-Second Board (GF/B22/4).</p><p>3. The Board notes that Dr Ruth Levine resigned from the TERG in April 2010. The Board also notes that the terms of Dr Lola Dare and Dr Atsuko Aoyama on the TERG are due to expire, and decides to extend the terms of these two members of the TERG until the end of February 2011.</p><p>4. The Board requests the Secretariat and the PSC to launch the process of nominations for new members of the TERG with the aim of having a complete TERG to be approved electronically by the Board by the end of February 2011.</p><p>5. The Board requests the TERG to include in its 2011 annual report to the Board an assessment of its own independence and of the independence of the TERG support team within existing administrative arrangements and to make recommendations for change, if appropriate.</p>
2010-12-15 B22 GF/B22/DP08 Review of the Eligibility and Cost Sharing Policy Review of the Eligibility and Cost Sharing Policy
<p>The Board refers to its decision at the Sixteenth Board Meeting to review the Income Level and Cost Sharing Criteria for determining eligibility for funding (GF/B16/DP18). </p> <p>The Board acknowledges the progress made by the joint Portfolio Implementation Committee (PIC) and Policy and Strategy Committee (PSC) working group (the 'Joint PIC-PSC Working Group') in reviewing such criteria and the prioritization rules which are to be applied where there are insufficient resources to finance all proposals approved for funding ('Prioritization Rules'). </p> <p>The Board recognizes the complexities of the review and acknowledges that further analysis needs to be undertaken by the Joint PIC-PSC Working Group to present more clearly defined options for the PSC and PIC to consider at a joint meeting in March 2011.</p> <p>The Board requests the PSC and PIC to present recommendations to the Board at the Twenty-Third Board Meeting regarding the outcome of its review of the Income Level and Cost-Sharing Criteria and Prioritization Rules. </p>
2010-12-15 B22 GF/B22/DP17 Committee Leadership: Chair of the Ethics Committee Committee Leadership: Chair of the Ethics Committee
The Board approves the appointment of Karlo Boras from the Developing Country NGO constituency as Chair of the Ethics Committee for the period from the date of this decision until the adjournment of the first Board meeting of 2011 to replace the outgoing Chair, Dr Bobby John.
2010-12-15 B22 GF/B22/DP26 Launch of Round 11, the Second Wave of National Strategy Applications and a Health Systems Funding Platform Pilot Launch of Round 11, the Second Wave of National Strategy Applications and a Health Systems Funding Platform Pilot
<p>The Board refers to its decision at the Twenty-Second Board Meeting entitled "Measures Associated with Round 10 and Future Funding Opportunities".</p> <p>The Board acknowledges its responsibility to take a decision on eligibility, cost-sharing and prioritization at its Twenty-Third Board Meeting in order to launch Round 11, Second Wave of National Strategy Applications (NSAs) and Health Systems Funding Platform pilot (HSFP) as follows:</p> <p>Launch of Round 11</p> <p>a.  The Board requests the Secretariat to make a call for proposals on 15 August 2011, with a submission due date of 15 December 2011.</p> <p>b.  The Board acknowledges that the Portfolio and Implementation Committee will approve the proposal forms and guidelines for Round 11, which will incorporate requirements for transitioning to the new Global Fund grant architecture and reflect the eligibility, cost sharing and prioritization requirements arising from Board decisions taken by the Board in May 2011.</p> <p>c.   The Board requests that Round 11 proposals be reviewed by the Technical Review Panel in time for approval at the first Board Meeting of 2012.</p> <p>Second wave of National Strategy Applications</p> <p>The Board refers its decision GF/B21/DP4 to initiate the second funding opportunity for National Strategy Applications (NSA)("the Second Wave") and now approves the launch of the Second Wave of NSA under the following timeline:</p> <p>a.  The Board requests the Secretariat to initiate the Second Wave of NSA in January 2011.</p> <p>b.  Notwithstanding this launch date, Board decisions concerning new requirements on eligibility, cost sharing and prioritization will apply to the Second Wave of NSA.</p> <p>c.   The Board requests that Second Wave of NSA proposals be reviewed by the Technical Review Panel (TRP) in time for approval at the first Board Meeting of 2012.</p> <p>Health Systems Funding Platform Pilot (HSFP)</p> <p>The Board refers to its decision at the Twenty-First Board Meeting GF/B21/DP5, such that the Board could approve funding requests emanating from a pilot in four to five countries at the same time that it approves Round 11 proposals.</p> <p>The Board notes that, at its 14<sup>th</sup> meeting in October 2010, under delegated authority of the Board, the Policy and Strategy Committee approved the design of the pilot for the approach identified as 'Track 2 option 2' of the HSFP.</p> <p>Accordingly, the Board approves the launch of the HSFP pilot as follows:</p> <p>a.  The Board requests the Secretariat to initiate the HSFP pilot on or about January 2011.</p> <p>b.  Notwithstanding this launch date, Board decisions concerning new requirements on eligibility, cost sharing and prioritization will apply to the HSFP pilot. </p> <p>c.   The Board acknowledges that the Portfolio and Implementation Committee will approve the proposal form and guidelines for the HSFP pilot.</p> <p>d.  The Board requests that HSFP pilot proposals be reviewed by the TRP in time for approval at the first Board meeting of 2012.</p> <p>Launch of Funding opportunities beyond 2011: </p> <p>The Board refers to its decision at its Fourteenth Board Meeting entitled "Establishment of Fixed Dates for Rounds" (GF/B14/DP12) to announce to the public, with significant advance notice, future Rounds of funding.</p> <p>Accordingly, the Board decides to launch Round 12 (and other funding opportunities<sup>1</sup>) within the Third Replenishment period, i.e. no later than 31 December 2013. Based on the availability of assets, the Board may decide to make this call for proposals well in advance of 31 December 2013 with the goal of making funding decisions during 2013 and acknowledges the value this would have in supporting the urgent need for continued scale-up in the fight against the three diseases.</p>
2010-12-15 B22 GF/B22/DP24 Use of innovative promissory notes by private foundations Use of innovative promissory notes by private foundations
<p>The Board: </p> <p>1. Refers to its decision entitled "Multi-Year Contributions and Promissory Notes from Private Donors" taken by electronic vote on 13 September 2010 (EDP/B21/20) to permit the use of promissory notes by private donors when providing contributions to the Global Fund. </p> <p>2. Acknowledges the potential for the Global Fund to mobilize additional resources from private foundations through the use of innovative long-term promissory notes, while being mindful of the associated opportunity costs.</p> <p>3. Notes that the forms of contribution instruments provided by donors should not conflict with the principles and requirements set forth in the Comprehensive Funding Policy (CFP), including the conditions under which instruments may be characterized as assets for the purpose of determining commitment authority. </p> <p>4. Notes the practice of the Global Fund of accepting promissory notes with encashment schedules for annual payments over the next succeeding three years, which is in line with grant disbursement profile and thereby ensures that the Global Fund will continue to meet grant disbursement needs. </p> <p>5. Decides that, for an initial period of three years, and upon the approval of the Finance and Audit Committee, the Global Fund may accept promissory notes issued by private foundations available for encashment only at the end of terms exceeding three years ("Long-Term Promissory Notes"). However, the acceptance of Long-Term Promissory Notes is contingent upon the compliance of such instruments with the requirements of the CFP and the right of the Global Fund to automatic early encashment where the Global Fund requires cash to meet grant disbursement needs. </p> <p>6. Decides that contributions to the Global Fund through Long-Term Promissory Notes shall be limited to those from private foundations. </p> <p>7. Requests the Secretariat to establish a minimum cash policy in order to ensure a requirement of a minimum cash threshold equal to six months of projected disbursements at any given time, as may be amended from time to time by the Finance and Audit Committee. The minimum cash threshold requirement established by the Secretariat would underpin the early encashment provisions of the long-term promissory notes to allow for payment at any point at which the cash available to the Global Fund to fund disbursements falls below the required minimum cash threshold.</p>
2010-12-15 B22 GF/B22/DP15 Enhancing Global Fund support to maternal, newborn and child health Enhancing Global Fund support to maternal, newborn and child health
<p>The Board:</p> <p>1. Notes the paper presented by the Secretariat on potential options and implications for enhancing Global Fund contributions to maternal and newborn and child health (GF/B22/DP4, Annex 3), consistent with its previous decision entitled "Exploring Options for Optimizing Synergies with Maternal and Child Health." (GF/B21/DP20);</p> <p>2. Encourages countries, where applicable, to strengthen the MNCH content of their Global Fund-supported investments, maximizing existing flexibilities for integrated programming as noted in the previous Decision Point;</p> <p>3. Requests the Secretariat to develop, under the oversight of PIC and in collaboration with partners, clear guidance (including indicators) for countries on strengthening the MNCH content of their HIV/AIDS, tuberculosis, malaria, and health systems strengthening portfolios. As part of this work, the Secretariat will detail the operational and budgetary implications of rolling out the guidance; and</p> <p>4. Acknowledges the need to define longer-term possibilities for increased engagement by the Global Fund in MNCH, as part of the Strategy Development Process. </p>
2011-01-31 B22 GF/B22/EDP05 Extension of time required to fulfill a „condition‟ in the Phase 2 term of the Round 6 Kenya Tuberculosis grant (KEN-607-G08-T) Extension of time required to fulfill a „condition‟ in the Phase 2 term of the Round 6 Kenya Tuberculosis grant (KEN-607-G08-T)
The Board acknowledges that additional time is required for the Phase 1 implementation period for the Tanzania Round 7 Malaria grant (TNZ-708-G10-M) in order to allow the grant to be consolidated with the Round 9 grant into a Single Stream of Funding and to ensure that AMFm activities are not interrupted during this time. The Board therefore approves the extension of the Phase 1 period for the Round 7 malaria grant (TNZ-708-G10-M) by an additional 3 months until 31 March 2011 without committing additional funding for the Phase 1 period.
2011-01-22 B22 GF/B22/EDP03 Extension of time required to fulfill two „conditions‟ in the Phase 2 term of the Round 6 Zanzibar HIV grant (ZAN-607-G05-H) Extension of time required to fulfill two „conditions‟ in the Phase 2 term of the Round 6 Zanzibar HIV grant (ZAN-607-G05-H)
<p>The Board:</p><ol><li>Refers to condition number 5 in its decision approving as a „Conditional Go‟ the Phase 2 of the Kenya Round 6 TB grant (KEN-607-G08-T) (“Condition 5”) which states that: “Not later than 30 September 2010, the Principal Recipient must finalize and submit to the Global Fund the reports for the audits of the Financial Management Agent and the Procurement Consortium,” and</li><li>Decides to extend the deadline in Condition 5 from 30 September 2010 to 31 March 2011.</li></ol>
2010-12-15 B22 GF/B22/DP14 Recognizing the contributions of Ambassador Richard C Holbrooke Recognizing the contributions of Ambassador Richard C Holbrooke
<p>The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria expresses its shock and deep sorrow at the untimely death of Ambassador Richard C. Holbrooke.</p><p>In his position as the United States Ambassador to the United Nations and later as the founding President of the Global Business Coalition against AIDS, Ambassador Holbrooke played a ground-breaking role in ensuring that the world accepted HIV and AIDS as a threat to international security and global business as well as being a humanitarian catastrophe. He was one of the drivers behind the allocation of large, additional resources to fight HIV and AIDS and was a tireless advocate for the engagement of the private sector in the fight against the pandemic and for testing and prevention as a crucial part of this struggle. </p><p>The fight against HIV and AIDS has lost one of its most influential and passionate ambassadors. Richard Holbrooke will be missed by all who knew him and the millions who benefitted from his work.</p><p>The members of the Board and the staff of the Global Fund send our thoughts to Ambassador Holbrooke's wife, their children and grandchildren.</p>
2010-12-15 B22 GF/B22/DP19 2011 Operating Expenses Budget 2011 Operating Expenses Budget
<p>The Board approves the 2011 Operating Expenses Budget in the amount of US$ 324.7 million as set out in Annex 1 to the Report of the Finance and Audit Committee (FAC) to the Twenty-Second Board (GF/B22/6), based on the exchange rate applicable on the date of release of the Report of the FAC.</p><p>Following approval of the budget, the Secretariat shall enter into a forward contract with a reputable bank. In the event that the exchange rate determined on the date of signature of the forward contract results in a change in the budget, the Secretariat shall notify the Board of such change. The new amount shall thus be deemed to be the approved Operating Expenses Budget for 2011. </p><p>The use of any amount in the US$ 3.0 million contingency within the OIG budget for 2011 is conditional upon the advance approval of the FAC.</p>
2011-01-31 B22 GF/B22/EDP01 January 2011 Phase 2 Funding Decision January 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 140,505,542 for the following grants: ZAR-708-G06-H ; ETH-708-G08-H ; GNB-708-G05-H ; HND-102-G04-H-00 ; MDG -708-G10-M ; MLW-708-G06-T ; MON-102-G01-T-00 ; MON-202-G02-H-00 ; RWN-304-G03-M ; STP-708-G03-M ; TNZ-708-G10-M</p>
2011-01-31 B22 GF/B22/EDP02 Commitment of additional funding for Prevention of Mother to Child Transmission (PMTCT) activities during the Phase 2 term of the Round 6 South Africa HIV grant (SAF-607-G06-H) Commitment of additional funding for Prevention of Mother to Child Transmission (PMTCT) activities during the Phase 2 term of the Round 6 South Africa HIV grant (SAF-607-G06-H)
The Board approves additional funding up to US$ 13,055,416 for the Phase 2 period of the Round 6 South Africa HIV grant (SAF-607-G06-H) to improve the quality and scale of PMTCT activities, subject to Technical Review Panel (TRP) clarifications and conditions within a limited timeframe. The Board approves the revised Phase 2 incremental amount up to US$ 37,951,822 which includes an additional sum of US$ 13,055,416 allocated for PMTCT activities. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its risk management function.
2011-02-15 B22 GF/B22/EDP09 Extension to the grant signing deadline for Round 9 “Category 2B” proposals Extension to the grant signing deadline for Round 9 “Category 2B” proposals
<p>The Board extends the deadline for the signing of grant documentation for the proposals listed in Table 1 for three months to 20 May 2011.</p><p>Table 1: Extension of grant signing deadline for four grants in three countries</p><table class="table" dropzone="copy"><tbody><tr><td style="cursor: default;">No </td><td style="cursor: default;"> Country, Disease, Round</td><td style="cursor: default;"> Grant information</td><td style="cursor: default;">Deadline for signature </td></tr><tr><td style="cursor: default;"> 1</td><td style="cursor: default;">Central African Republic, TB, Round 9</td><td style="cursor: default;"><p>Principal Recipient: Ministry of Public Health, Population and the fight against HIV/AIDS</p><p>Total approved amount: Euros 20,972,227 over five years</p><p>Phase 1 approved upper ceiling: Euros 8,961,795</p></td><td style="cursor: default;">20 May 2011</td></tr><tr><td style="cursor: default;"> 2</td><td style="cursor: default;">Nigeria, TB, MDR-TB Component, Round 9</td><td style="cursor: default;"><p> Principal Recipient: IHVN</p><p>Total amount: US$ 113,332,101 over five years</p><p>Phase 1 (total): US$ 31,515,160</p><p>Phase 1 (MDR TB component): US$ 9,002,945</p></td><td style="cursor: default;">20 May 2011</td></tr><tr><td style="cursor: default;"> 3</td><td style="cursor: default;">Democratic Republic of Congo, Round 9 TB/HSS <br/>(2 grants)</td><td style="cursor: default;"><p>Principal Recipients: i) Ministry of Health and ii) CARITAS</p><p>Total amount (over 5 years): US$ 275,383,647</p><p>Phase 1: US$ 100,261,325</p></td><td style="cursor: default;">20 May 2011</td></tr></tbody></table>
2011-02-12 B22 GF/B22/EDP07 Board Approval of Additional Funding for the Round 7 Afghanistan HIV Grant (AFG-708-G04-H) Board Approval of Additional Funding for the Round 7 Afghanistan HIV Grant (AFG-708-G04-H)
<p>The Board approves additional incremental funding up to US$ 30,000 for the Phase 2 period of the Round 7 Afghanistan HIV grant (AFG-708-G04-H) with conditions stipulated in its B21/EDP/27 decision of 19 November 2010. The Board approves the revised Phase 2 incremental amount up to US$ 513,579.</p>
2010-12-15 B22 GF/B22/DP05 Health Systems Funding Platform: Pilot for funding requests based on jointly assessed national health strategies Health Systems Funding Platform: Pilot for funding requests based on jointly assessed national health strategies
<p>The Board:</p> <p>1.  Notes that further to the Board decision on the Health Systems Funding Platform (GF/B21/DP5) the Policy and Strategy Committee (PSC) has approved, in principle, the design of a pilot for 4 to 5 countries for Track 2 Option 2 (the "Pilot");</p> <p>2.  Clarifies that the Pilot shall be conducted in accordance with the Board decision on "Implementing the new grant architecture for health systems strengthening activities" taken at its Twenty-Second Meeting; and</p> <p>3.  Authorizes the Secretariat to make exceptions to existing policies and procedures to the extent necessary and within the parameters described in the paper titled 'Health Systems Funding Platform - Pilot for funding requests based on jointly assessed national health strategies' (GF/PSC14/04) as presented at the 14<sup>th</sup> PSC to implement the Pilot.</p> <p>The Board notes that any exceptions to existing policies and procedures made in connection with the Pilot shall be consistent with the Framework Document of the Global Fund, including the principle that the Global Fund supports activities that help health systems overcome constraints to the achievement of improved outcomes in reducing the burden of HIV/AIDS, tuberculosis and malaria.</p>
2010-12-15 B22 GF/B22/DP25 Measures associated with funding future proposals Measures associated with funding future proposals
<p>The Board agrees to adopt the measures outlined below in order to enable the launching of funding opportunities described in GF/B22/DP26. </p> <p>The Global Fund Strategy Development Process and Reform Agenda</p> <p>The Board acknowledges the processes underway for development of a new strategy and the agenda for creating a more efficient and effective Global Fund. Nothing in these decisions seeks to prejudge or prejudice the outcomes from these processes.</p> <p>Eligibility, cost sharing and prioritization</p> <p>The Board affirms the importance and urgency of the ongoing review of the Global Fund's eligibility criteria, cost sharing and prioritization requirements and that the Board will make a decision on these matters at its first meeting in 2011 (GF/B22/DP8). The Board now decides that the revised requirements on eligibility, cost sharing and prioritization, to be approved at the Twenty-Third Board Meeting, shall apply for all funding opportunities described in GF/B22/DP26. </p> <p>Assessment of the impact of program interruption at the May 2011 Board Meeting</p> <p>The Board requests the Secretariat to undertake an analysis of the potential impact of program implementation being interrupted as a consequence of the timing of funding decisions on Round 11 being at the first meeting of 2012 rather than at the end of 2011 and to report its findings to the Finance and Audit Committee (FAC) and the Portfolio Implementation Committee.</p> <p>Based on this analysis, the FAC will make a recommendation to the Board on any necessary measures to mitigate the impact of identified cases of program interruption. Consequent to this the Board will decide, at its meeting in May 2011, whether to extend the provisions relating to Funding of Additional Commitments, as described below for Round 10, to also apply to Round 9 with a view to:</p> <ul> <li>Making available resources to mitigate the impact of program interruption arising from the timing of Round 11; and</li> <li>Making available resources to contribute towards the demand including from the Second Wave of NSAs and the Health Systems Funding Platform Pilot.</li> </ul> <p>Funding of Additional Commitments for Round 10</p> <p>The Board refers to its decision at the Twentieth Board Meeting (GF/B20/DP9) to make funding commitments in respect of Additional Commitments in two tranches of an initial two-year period and an additional one year period.</p> <p>The Board now decides in respect of Additional Commitments, arising from Round 10 Proposals only, to make such commitments in three tranches of one year each. This measure is being adopted on an exceptional basis in order to enable a more effective and even commitment of resources within the Third Replenishment term and as an exception to the provisions of paragraph 3.c of the Comprehensive Funding Policy.</p> <p>The Board requests the Secretariat to implement this decision in a manner that minimizes funding uncertainty and transaction costs. </p> <p>Increase in Current Ceilings on Additional Commitments for Round 8 and Round 9 Proposals and the First Learning Wave of National Strategy Applications</p> <p>The Board decisions to increase the limits on Round 8, Round 9 and First Learning Wave of National Strategy Application proposals from 75% to 90%. In doing so, the Board refers to its decision at the Eighteenth Board Meeting (GF/B18/DP13) and its decision at the Twentieth Board Meeting (GF/B20/DP9) which provided for the limits described in these decisions to be increased from 75% to 90% when new resources become available, subject to Board approval.</p> <p>Application of Performance Based Funding</p> <p>The Board acknowledges the importance of implementing Performance Based Funding as a core principle of the Global Fund.</p> <p>In this context, the Board requests the Secretariat to strengthen its application of Performance Based Funding principles having regard to utilization of funds and performance of existing grants. Accordingly the Board requests the Secretariat to consider reductions in Additional Commitments, where appropriate for reasons of performance, and to work with CCMs and Principal Recipients in order to adjust performance targets in light of the revised lifetime budgets; this will result in overall savings that will then be available for approval of new funding opportunities.</p>
2010-12-15 B22 GF/B22/DP28 Re-appointment of the Executive Director Re-appointment of the Executive Director
In accordance with Section 26 of the Board Operating Procedures and based on the satisfactory performance appraisal of Professor Michel Kazatchkine in the role of the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Board decides to extend his appointment for a further term of three years from the end of his current term till the end of the month of the first Board meeting in 2014.
2011-04-01 B22 GF/B22/EDP13 Membership of the Ethics Committee Membership of the Ethics Committee
The Board approves the appointment of the Latin America and Caribbean Constituency as a member of the Ethics Committee until the adjournment of the Twenty-Third Board Meeting.
2010-12-15 B22 GF/B22/DP16 Global Fund Strategy Development Process Global Fund Strategy Development Process
<p>The Board recognizes that the Global Fund should be guided by a strategy that reflects the principles in the Global Fund's Framework Document. The work on developing the next strategy should be based on the six broad objectives discussed at the Global Fund Board Retreat on 10 - 11 December 2010 and outlined in the Chair's summary of the Board Retreat (GF/B22/19) and the final report of the Board Retreat.</p><p>The Board decides that the next strategy will cover the period up to the end of 2016, with a mid-point review in 2014. </p><p>The strategy will be a concise, high level document setting out the broad strategic direction of the Global Fund (the "Strategy Document"), with further details captured in an accompanying implementation plan (the "Implementation Plan"). The strategy will take into account the action plan of the reform working group.</p><p>The Policy and Strategy Committee (PSC) will steer the strategy development work and make recommendations to the Board. The Secretariat will be actively involved in the development of and deliberations on the strategy, and will also ensure that any necessary content development work is carried out. </p><p>The Board requests the PSC to develop a complete draft of the Strategy Document including objectives, targets, and strategic initiatives for discussion at the Board meeting in May 2011. The Secretariat shall then develop the Implementation Plan for the strategy. The PSC shall seek appropriate input on the strategy at the Fourth Partnership Forum (in consultation with the Partnership Forum Steering Committee, which shall advise on the nature of such input). The final Strategy Document and its Implementation Plan shall be approved at the Board meeting at the end of 2011.</p>
2010-12-15 B22 GF/B22/DP27 Approval of Round 10 Proposals Approval of Round 10 Proposals
<p>1.  The Board approves all the Round 10 proposals recommended for funding by the Technical Review Panel (TRP) as "Category 1", "Category 2" and "Category 2B", subject to the below provisions. </p><p>2.  The Board approves for funding for an initial two years all those Round 10 proposals recommended for funding by the TRP as "Category 1", "Category 2" and "Category 2B" as listed in Annex 1 of GF/B22/13, subject to paragraphs 3, 4 and 5 below. This includes all Round 10 proposals focusing on Most-at-Risk Populations for HIV/AIDS, which have been submitted under the dedicated reserve referred to in its decision entitled "Prioritization for funding amongst Round 10 TRP-recommended Proposals" GF/B21/DP18 and recommended for funding by the TRP. </p><p>3.  The applicants whose proposals are recommended for funding as 'Category 1' (as indicated in Annex 1 of GF/B22/13) shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than eight weeks after the applicant's receipt of notification in writing from the Secretariat of the Board's decision.</p><p>4.  The applicants whose proposals are recommended for funding as 'Category 2', including the subset of proposals identified as 'Category 2B' (as indicated in Annex 1 of GF/B22/13), shall:</p><p>a.  provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after the applicant's receipt of notification in writing by the Secretariat of this Board decision; and</p><p>b.  conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment. </p><p>5.  As required under the Income Level and Cost Sharing Policy, the lifetime grant amount of approved Round 10 proposals that will be implemented in Upper-Middle Income Countries ("UMI Proposals") shall be subject to a collective maximum limit of 10 percent of the lifetime grant amount of all Round 10 approved proposals. The Board notes that this limit will be applied at the time of approving additional commitments for approved Round 10 UMI Proposals. </p><p>6.  The Board declines to approve for funding those proposals recommended by the TRP as 'Category 3', as indicated in Annex 1 of GF/B22/13. These applicants are encouraged to re-submit a proposal in a future funding round after major revision of the proposal. </p><p>7.  The Board declines to approve for funding those proposals recommended by the TRP as 'Category 4', as indicated in Annex 1 of GF/B22/13. </p><p>8.  The Board notes the TRP's request to have additional financial analysis support as part of the clarifications process and requests the Secretariat to make the necessary arrangements.</p><p>9.  Prior to the signing of a grant, the Secretariat will provide confirmation that, as far as can be determined based on data available to the Secretariat, the grant budget is in accord with value for money considerations including unit costs.</p>
2017-10-06 B37 GF/B37/EDP04 Selection of the Global Fund Executive Director: Contingency Voting Procedures Selection of the Global Fund Executive Director: Contingency Voting Procedures
<p>Decision Point GF/B37/EDP04: Approval of Contingency Voting Procedures</p> <ol> <li>The Board recalls: <ol type="a"> <li>its approval at the 36th Board Meeting of the voting procedure for the selection of the Executive Director, as set forth as part of the Summary of Voting Process in Annex 2 to GF/B36/07 (the “Summary of Voting Process”); and</li> <li>the contingency procedures in the event of ties/deadlock, described in section 3 of the Summary of Voting Process, to be proposed for Board approval in advance of any voting.</li> </ol> </li> <li>As contemplated in the Summary of Voting Process, the Board approves the following contingency procedures: <ol type="a"> <li>In the event of a tie during weighted voting cycles: <ol type="i"> <li>the more-preferred candidate will be allowed to proceed (i.e., the candidate with the higher number of first and second place points will move forward);</li> <li>if the tie persists after applying paragraph 2.a.i of this decision point, the Board shall repeat the voting cycle; and</li> <li>except in the cycle with the final two candidates, if the tie continues to persist, both candidates will be removed from consideration.</li> </ol> </li> <li>In the event of deadlock in the final affirmative vote (i.e., if the final candidate is not selected with an affirmative two-thirds majority vote of each of the donor and implementer groups), the voting thresholds for the selection of the final candidate will be gradually lowered as follows, so that the final candidate will be appointed to the position of Executive Director with the approval of a: <ol type="i"> <li>Qualified Two-Thirds Majority vote: Two-Thirds Majority of the full Board and Simple Majority (i.e., over one-half) in each of the donor and implementer groups;</li> <li>Simple Two-Thirds Majority vote: Two-Thirds Majority by the full Board, without regard to groups, if the final candidate is not selected through the Qualified Two-Thirds Majority vote described in (i) above; or</li> <li>Simple Majority vote: Over 50% of the vote by the full Board, without regard to groups, if the final candidate is not selected through the Simple Two-Thirds Majority vote described in (ii) above.</li> </ol> </li> </ol> </li> </ol>
2017-05-03 B37 GF/B37/DP07 Administration Agreement with the World Bank Administration Agreement with the World Bank
<ol> <li>The Board: <ol type="a"> <li>Notes the proposed Administration Agreement between the World Bank and the Global Fund for the Performance Based Funding project in the Democratic Republic of Congo, as presented in GF/B37/03- Revision 1 (the “Administration Agreement”);</li> <li>Acknowledges the Administration Agreement does not provide the Global Fund the right of access to books, records, personnel or sites relating to the Performance Based Funding project, including as required under the Board-approved Charter of the Office of the Inspector General; and</li> <li>Acknowledges that, accordingly, the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, on the funds disbursed under the Administration Agreement.</li> </ol> </li> <li>Based on the recommendation of the Audit and Finance Committee, the Board authorizes the Secretariat to enter into the Administration Agreement with the World Bank for the Performance Based Funding project in the Democratic Republic of Congo in accordance with the financial and programmatic terms presented in GF/B37/03-Revision 1.</li> <li>However, the Board confirms that this decision does not set a precedent for future investments with development partners or for existing relationships with partners and requests the Secretariat develop a framework to guide future consideration of such investments for presentation to and review by the Audit and Finance Committee, in consultation with the Strategy Committee, for recommendation to the Board.</li> </ol>
2017-05-03 B37 GF/B37/DP08 Approval of Revisions to the Amended and Restated Global Fund Policy for Restricted Financial Contributions Approval of Revisions to the Amended and Restated Global Fund Policy for Restricted Financial Contributions
<ol> <li>Based on the recommendations of the Audit and Finance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as revised and set forth in Annex 1 to GF/B37/04 (the “Amended and Restated Policy”).</li> <li>The Amended and Restated Policy shall supersede the prior version of the Policy as approved by the Board in November 2014 under decision point GF/B32/DP13.</li> </ol>
2017-05-03 B37 GF/B37/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the 37th Board Meeting (GF/B37/01- Revision 4) is approved.</p>
2017-05-04 B37 GF/B37/DP09 Wambo.org: Progress Update and Steps for Advancement Wambo.org: Progress Update and Steps for Advancement
<ol> <li>The Board acknowledges the progress update on wambo.org presented by the Secretariat and notes the proposal contained in the paper “Wambo.org: Progress Update and Steps for Advancement”, as set forth in GF/B37/07 – Revision 2, to pilot a limited number of transactions by current Principal Recipients (“PRs”) using domestic funding via wambo.org.</li> <li>Based on the recommendation of the Strategy Committee, the Board approves the piloting of a limited number of transactions (at a maximum ten in total) by current PRs using domestic funding via wambo.org.</li> <li>Accordingly, the Board: <ol type="i"> <li>requests that the Secretariat: (i) provide to the Strategy Committee, by its next meeting, clearly defined draft indicators of success for the pilot; and (ii) report regularly to the Strategy Committee on the operationalization of this pilot, including any lessons learned from such transactions in light of the long-term perspective for wambo.org; and</li> <li>delegates to the Strategy Committee the authority to approve further transactions with domestic funding through wambo.org on a pilot basis, with the objective to provide input into further strategic and operational planning for wambo.org.</li> </ol> </li> </ol>
2017-10-13 B37 GF/B37/EDP06 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>1.2 Set forth below is the Secretariat’s recommendation to approve grant extensions.</p> <p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B37/ER04.</li> </ol>
2017-10-13 B37 GF/B37/EDP05 Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Period
<p>1.1 Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,051,987,870 and € 105,315,127.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B37/ER04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches;</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP; and</li> <li>For country disease components specifically noted in Table 1, notes that the final upper-ceiling for such country disease components may be adjusted to reflect a redistribution of funding across country disease components for the applicant, provided that (a) any redistribution of funding is invested in activities validated by the TRP, and (b) the final upper-ceilings for such country disease components will be subject to Board approval.</li> </ol>
2017-09-18 B37 GF/B37/EDP03 Appointment of Members to the Audit and Finance Committee and the Strategy Committee Appointment of Members to the Audit and Finance Committee and the Strategy Committee
<p>The Board:</p> <ol> <li>Approves the appointment of Madame Perrine Bonvalet-Doring, representing the French Constituency, as a voting member of the Audit and Finance Committee (“AFC”);</li> <li>Ambassador Anders Nordström, representing the Point Seven Constituency, as a voting member of the Strategy Committee (“SC”); and</li> <li>Doctor Manabu Sumi, representing the Japan Constituency, as a voting member of the SC,</li> </ol> <p>Each for a term that will expire in May 2018, or until the appointment of their successors</p>
2017-05-03 B37 GF/B37/DP05 2016 Annual Financial Report 2016 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Annual Financial Report, which includes the 2016 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in GF/B37/02 Annex 1.</p>
2017-05-04 B37 GF/B37/DP14 Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Mr. Norbert Hauser for his leadership as Chair of the Board. Over his time working with the Global Fund, he has shown a high degree of personal commitment, willingness to devote his time and energy, and passion for the work of the Global Fund. During his tenure, Norbert has presided over significant and complex deliberations and decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Aida Kurtović for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and continues to show her personal conviction for the mission of the Global Fund by focusing her efforts as the incoming Chair of the Board. During her tenure as Vice-Chair, Aida has been an active driver of relationship building and collaborations that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board delivered the enhanced governance structure, strengthened ties across Global Fund stakeholders, and helped to guide and direct external relations.</p> <p>The Board wishes Norbert every success in the future and bestows upon him the honorary title of Chair Emeritus. The Board welcomes Aida into her new role, and looks forward to her tenure, as Chair of the Board.</p>
2017-05-04 B37 GF/B37/DP10 Appointment of the 2017 Executive Director Nomination Committee Membership Appointment of the 2017 Executive Director Nomination Committee Membership
<ol> <li>The Board acknowledges the nomination of members for the 2017 Executive Director Nomination Committee (the “Nomination Committee”).</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as members of the Nomination Committee as described below, in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B36/EDP11 and set out in Annex 1 to GF/B36/ER10: <ol type="a"> <li>Michèle Boccoz, Chair of the Nomination Committee;</li> <li>Vinand Nantulya, Vice- Chair of the Nomination Committee;</li> <li>Ala Alwan, Member;</li> <li>Sarah Boulton, Member, EGC Member;</li> <li>Joanne Carter, Member;</li> <li>Julie Essiam, Member;</li> <li>William Steiger, Member;</li> <li>Peter Felix, Independent Member</li> <li>Reinhard Tittel-Gronefeld, Independent Member</li> </ol> </li> <li>The Board requests the Nomination Committee to start the 2017 recruitment process for the next Executive Director.</li> </ol>
2017-05-04 B37 GF/B37/DP13 Recognition of Dr. Mark Dybul Recognition of Dr. Mark Dybul
<p>At the end of his term, the Board wishes to sincerely thank Mark Dybul for the exceptional leadership, vision, and passion he displayed throughout his tenure as Executive Director.</p> <p>Through his tireless, humble, far-sighted efforts to expand and maximize the impact of the Global Fund partnership, Dr. Dybul has inspired all partners to go farther than many thought possible: two successful Replenishments; implementation of a new funding model; shifting operations and attitudes to embrace a strong focus on impact; strengthening partnerships to deliver our mission; supporting the Board in devising a new Strategy; and developing forward-looking initiatives to better promote sustainability and innovation.</p> <p>The Board additionally recognizes Dr. Dybul’s role in enhancing the relationship between the Board and the Secretariat. Through strengthening this relationship, he has helped the Global Fund remain targeted on achieving its mission and focused on best serving those affected by the three diseases.</p> <p>The Board wishes Dr. Dybul every success in the future.</p>
2017-08-14 B37 GF/B37/EDP01 Approval of the Report of the 37th Board Meeting in Kigali, Rwanda Approval of the Report of the 37th Board Meeting in Kigali, Rwanda
<p>Approval of the Report of the 37th Board Meeting in Kigali, Rwanda </p>
2017-05-03 B37 GF/B37/DP04: Appointment of the Board Chair and Vice-Chair Appointment of the Board Chair and Vice-Chair
<p>The Board appoints Aida Kurtović as Chair of the Board and Ambassador John Simon as ViceChair of the Board to each serve two-year terms, or until the appointment of their respective successors, starting from the adjournment of the 37th Board Meeting.</p>
2017-05-03 B37 GF/B37/DP06 2016 Statutory Financial Statements 2016 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in GF/B37/02 Annex 2.</p>
2011-04-12 B22 GF/B22/EDP14 April 2011 Phase 2 Funding Decision April 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 64,134,199 for the following grants: BRN-202-G05-M-00 ; ETH-708-G07-H ; GYA-708-G04-M ; SUR-708-G04-M ; SWZ-708-G05-H</p>
2010-12-15 B22 GF/B22/DP10 Quality Assurance Policy for diagnostic products Quality Assurance Policy for diagnostic products
<p>The Board approves the quality assurance policy for diagnostic products ("QA Policy for Diagnostics"), as set out in Annex 2 to the Report of the Market Dynamics and Commodities Ad-hoc Committee to the Board (GF/B22/11, Revision 1). </p> <p>The Board requests the Secretariat to work with the World Health Organisation (WHO) towards concluding an agreement under which WHO will manage the technical evaluation of diagnostic products, including, as relevant, the establishment of an Expert Review Panel for Diagnostics, as described in the QA Policy for Diagnostics.</p> <p>The Board further requests the Secretariat to work with WHO to explore measures to ensure principal recipients procure appropriately performing malaria rapid diagnostic tests (RDTs) and the MDC to report back by the Twenty-Fourth Board Meeting. </p>
2011-03-14 B22 GF/B22/EDP11 Exceptional Extension to the Round 10 Submission Deadline Exceptional Extension to the Round 10 Submission Deadline
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)<sup>[1]</sup>.</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 69,047,796 for the following grants: CAM-708-G12-T ; KGZ-708-G05-H ; NIC-708-G04-M ; SUD-708-G10-M ; TMP-709-G05-M</p>
2010-12-15 B22 GF/B22/DP09 Amendment to the Quality Assurance Policy for pharmaceutical products Amendment to the Quality Assurance Policy for pharmaceutical products
<p>The Board approves the amendment and restatement of the Quality Assurance Policy for Pharmaceutical Products as set out in Annex 1 to the report of the Market Dynamics and Commodities Ad-hoc Committee (MDC) to the Board (GF/B22/11, Revision 1) (the QA Policy).</p> <p>The Board requests the Secretariat to explain to grant recipients in writing the implications of the termination of the Interim Exception and the changes to the eligibility criteria for the review of Finished Pharmaceutical Products by the Expert Review Panel (ERP) as specified in the QA Policy.</p> <p>The Board requests the World Health Organisation (WHO) to consider evaluating products under the WHO Prequalification Programme in circumstances where the relevant product may only have a limited geographical relevance.</p> <p>The Board confirms that, as requested by the Board at its Twenty-First Board Meeting (GF/B21/DP16), the MDC has reviewed the updated Expert Review Panel (ERP) process to deal with exceptional cases, and considers it to be satisfactory.</p>
2010-12-15 B22 GF/B22/DP11 Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs) Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs)
<p>The Board notes that World Health Organisation (WHO) guidance<a id="_ftnref1" name="_ftnref1"></a>[1] states that fixed-dose combination formulations (FDCs) of artemisinin-based combination therapies (ACTs) are strongly preferred to co-blistered formulations.</p> <p>The Board requests the Market Dynamics and Commodities Ad-hoc Committee (MDC) to present recommendations to the Board at the Twenty-Third Board Meeting regarding appropriate transition by recipients of Global Fund financing to the use of FDCs of ACTs.</p> <p>The Board also requests the MDC to analyze additional measures to accelerate the transition to FDCs of HIV/AIDS and tuberculosis medicines and to present its recommendations to the Board at its Twenty-Fourth Meeting.</p> <p><a id="_ftn1" name="_ftn1"></a>[1] WHO Guidelines for the Treatment of Malaria Second Edition (2010). http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf</p>
2011-05-12 B23 GF/B23/DP12 Plan for Comprehensive Reform: Governance Plan for Comprehensive Reform: Governance
<ol> <li>The Board recognizes that addressing governance challenges will enhance the impact and management of the Fund, enable the Board and Secretariat to effectively pursue the Plan for Comprehensive Reform (PCR), as set forth in the Report of the Comprehensive Working Group (CRWG Report, GF/B23/13), and facilitate the next Global Fund strategy.<br /><br /></li> <li>The Board requests that the incoming Chair and Vice-Chair, working with committees and Secretariat as appropriate, lead and oversee a process for governance reforms, as set out in Parts 5.14-5.17 of the CRWG Report (GF/B23/13). Reforms will be presented for Board approval at the Twenty-Fourth and Twenty-Fifth Board Meetings.</li> </ol>
2011-05-12 B23 GF/B23/DP07 Report of the Comprehensive Reform Working Group Report of the Comprehensive Reform Working Group
<p>The Board embraces the Report of the Comprehensive Reform Working Group (CRWG Report GF/B23/13) and fully supports the need for continuous reform. The Board also endorses the broad direction of the Plan for Comprehensive Reform (PCR), as included in Annex 1 to the CRWG Report (GF/B23/13), and specifically recognizes its enumerated reform objectives.</p>
2011-05-12 B23 GF/B23/DP19 Revisions to the Whistle-blowing Policies Revisions to the Whistle-blowing Policies
<p>The Board decides to replace the Whistle-blowing Policy for the Secretariat and Governance Bodies of the Global Fund and the In-country Whistle-blowing Policy for the Global Fund (approved at the Thirteenth Board meeting) with the new Whistle-blowing Policy and Procedures as set forth in Annex 1 of the Report of the Ethics Committee (GF/B23/7).</p>
2015-07-24 B33 GF/B33/EDP12 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Afghanistan (AFG-M-UNDP), Botswana (BWA-M-BMOH), Comoros (COM-T-ASCOBEF), Congo (Democratic Republic) (COD-H-CORDAID, COD-H-SANRU, COD-H-MOH, COD-T-CARITAS, COD-H-MCOD-T-MOH), Somalia (SOM-T-WV) and Swaziland (SWZ-H-CANGO, SWZ-H-NERCHA).</p>
2015-06-30 B33 GF/B33/EDP07 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER05 – Revision 1 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-H-MOH), Bulgaria (BGR-T-MOH), Burkina Faso (BFA-T-PADS, BFA-H-SPCNLS, BFA-C-IPC), Cambodia (KHM-M-UNOPS), Cape Verde (CPV-M-CCSSIDA), Côte d'Ivoire (CIV-M-PNLP), Eritrea (ERI-T-MOH, ERI-H-MOH), Ethiopia (ETH-H-HAPCO, ETH-T-FMOH), Fiji (FJI-T-MHMS), Ghana (GHA-H-ADRA, GHA-H-PPAG, GHA-H-MOH, GHA-H-GAC, GHA-T-MOH), Mauritius (MUS-H-NAS, MUS-H-PILS), Multicountry Western Pacific (QMJ-C-UNDP, QMJ-M-UNDP), Nicaragua (NIC-H-INSS), Niger (NER-H-CISLS), Pakistan (PAK-T-NTP, PAK-T-MC), Russian Federation (RUS-H-OHI), Rwanda (RWA-T-MOH, RWA-H-MOH), Solomon Islands (SLB-M-MHMS, SLB-T-MHMS), Sudan (SDN-H-UNDP), Swaziland (SWZ-T-NERCHA) and Tanzania (TZA-C-STC).</p>
2015-11-13 B33 GF/B33/EDP28 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:<br/><br/>1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER18.</p><p><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b> <br/></p>
2015-10-12 B33 GF/B33/EDP22 Decision on the Secretariat’s Recommendation on waiver of the Board condition for Congo HIV grant Decision on the Secretariat’s Recommendation on waiver of the Board condition for Congo HIV grant
<p>The Board:</p> <ol> <li>Approves waiver of the Board condition imposed in the Congo HIV grant (COG-911-G06-H) restricting the “use of funds to finance activities other than (i) the procurement of Health Products and Pharmaceuticals and (ii) other activities deemed essential in the framework of the program,” and</li> <li>Approves disbursement of grant funds to the principal recipient the Secretariat Executif Permanent/Comité National de Lutte contre le SIDA (SEP /CNLS) to conduct activities essential to the implementation of the HIV program.</li> </ol>
2015-03-31 B33 GF/B33/DP03 Appointment of the Chair and Vice-Chair of the Board Appointment of the Chair and Vice-Chair of the Board
The Board appoints Norbert Hauser as Chair of the Board and Aida Kurtovic as Vice -Chair of the Board to each serve a term starting from the adjournment of the Thirty-Third Board Meeting on 1 April 2015 and until the adjournment of the first in person Board Meeting in 2017.
2015-07-07 B33 GF/B33/EDP10 Approval of the Report of the Thirty-Third Board Meeting Approval of the Report of the Thirty-Third Board Meeting
<p>The Board approves the Report of the Thirty-Third Board Meeting, as set forth in GF/B33/24.</p>
2015-05-15 B33 GF/B33/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER01;</li> <li>Approves the reinvestment of newly identified existing funds for the Ukraine TB/HIV program and its constituent grants and its resultant total program budget, as listed in Table 2 of Annex 1 to GF/B33/ER01;</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</p> <p>Annex: Armenia TB - Ministry of Health of the Republic of Armenia (ARM-T-MOH), Bhutan - TB - Ministry of Health of Bhutan (BTN-T-MOH), Costa Rica - HIV - Humanist Institute for Cooperation (HIVOS) (CRI-H-HIVOS), Eritrea - Malaria - Ministry of Health of Eritrea (ERI-M-MOH), Iraq - TB - UNDP (IRQ-T-UNDP), UKR-C-AUA, UKR-C-AUN, UKR-C-UCDC.</p>
2015-07-24 B33 GF/B33/EDP13 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER07.</li> </ol> <p>Annex: Abidjan-Lagos Corridor Organization (MAW-607-G01-H), Djibouti (DJB-613-G05-H), Guinea-Bissau (GNB-M-UNDP), Kosovo (KOS-711-G04-H), Nigeria (NGA-T-IHVN), Pakistan (PKS-M-DOMC PKS-T-NTP).</p>
2015-06-05 B33 GF/B33/EDP05 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER03.</li> </ol> <p>Annex: Malawi (MLW-H-NAC), Multi Country Americas REDCA+ HIV Grant (MAR-H-SICSA).</p>
2015-06-29 B33 GF/B33/EDP09 Terms of Reference of the Ethics Officer (Decision not approved) Terms of Reference of the Ethics Officer (Decision not approved)
<p>#</p>
2015-09-14 B33 GF/B33/EDP17 Strategy Development Process — Alignment of Strategy Cycle (Decision not approved) Strategy Development Process — Alignment of Strategy Cycle (Decision not approved)
<ol> <li>Based on the recommendations of the Strategy, Investment and Impact Committee, as set forth in GF/B33/ER10, the Board decides the Global Fund’s strategy should cover a period that aligns the start of each strategy cycle to the start of a replenishment and allocation period.</li> <li>Accordingly, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022, with a mid-point review of progress and implementation alongside replenishment.</li> </ol>
2015-11-13 B33 GF/B33/EDP29 Decision on the Secretariat’s Recommendation on Policy Exceptions for Processing HIV and TB Funding Applications from Certain Countries in the Middle East Region Decision on the Secretariat’s Recommendation on Policy Exceptions for Processing HIV and TB Funding Applications from Certain Countries in the Middle East Region
1. Acknowledges the current political context and challenging implementation environment in Iraq, Palestine, Syria and Yemen due to ongoing conflicts; and<br/><br/>2. Accordingly, approves the following policy exceptions for processing HIV and TB funding applications from these countries to access relevant 2014-2016 funding allocations:<br/><br/>• Waiver of the CCM eligibility requirements;<br/>• Waiver of the counterpart financing requirement; and<br/>• Waiver of the "willingness-to-pay" requirement<br/><br/><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b>
2015-03-31 B33 GF/B33/DP05 2014 Statutory Financial Statements 2014 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2014 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in Annex 2 to GF/B33/03 - Revision 1. </p>
2015-04-01 B33 GF/B33/DP09 Ethics and Integrity: Reporting and Location Arrangements for the Ethics Officer Ethics and Integrity: Reporting and Location Arrangements for the Ethics Officer
<ol> <li>The Board approves a reporting arrangement for the Ethics Officer as follows: <ol type="a"> <li>The Ethics Officer will report on its activities directly to the Board through the Committee responsible for ethics matters (the "Committee").</li> <li>The Ethics Officer will provide regular advice and support: <ol type="i"> <li>To the Executive Director on ethical matters pertaining to the Secretariat's activities, including issues related to grant recipients, CCMs, third-party providers (e.g., LFAs and suppliers) and staff. Based on the Ethics Officer's advice, the Executive Director will determine and implement appropriate remedial actions.</li> <li>To the Committee on all other ethical matters not included in paragraph 1(b)(i) above. Based on the Ethics Officer's advice, the Committee will determine appropriate remedial actions.</li> </ol> </li> <li>The Ethics Officer will be located within the Office of the Inspector General for administrative purposes only. </li> </ol> </li> </ol>
2015-04-01 B33 GF/B33/DP10 Ethics and Integrity: Second Stage Policy Proposals Ethics and Integrity: Second Stage Policy Proposals
<ol> <li>The Board acknowledges the Audit and Ethics Committee's second stage policy proposals as set forth in document GF/B33/15 - Revision.</li> <li>Accordingly, the Board: <ol type="a"> <li>Approves the Code of Ethical Conduct for Governance Officials contained in Annex A to GF/B33/15 - Revision 2; and</li> <li>Notes that the Code of Ethical Conduct for Governance Officials will be reviewed following appointment of the Ethics Officer. This review will be conducted by the Board Leadership in collaboration with the Committee responsible for ethics matters (the "Committee"). The findings of the review will be presented to the Board for discussion and potential revisions to the Code of Ethical Conduct as applicable.</li> </ol> </li> <li>In addition, the Board: <ol type="a"> <li>Notes the Board's decision to approve the reporting arrangements for the Ethics Officer described in GF/B33/DP09;</li> <li>Endorses, in principle, the Terms of Reference of the Ethics Officer contained in Annex B to GF/B33/15 - Revision 2; and</li> <li>Requests that the Terms of Reference of the Ethics Officer be further developed by the Board Leadership in collaboration with the Committee, with the support of the Office of the Inspector General, through a comprehensive consultation process and submitted to the Board through the Committee for approval by June 2015.</li> </ol> </li> <li>Following approval by the Board of the Terms of Reference of the Ethics Officer in June 2015, the recruitment process will be launched.</li> </ol>
2015-06-04 B33 GF/B33/EDP03 Appointment of Member of the Strategy, Investment and Impact Committee Appointment of Member of the Strategy, Investment and Impact Committee
<p>The Board approves the appointment of Ms. Sandra Roelofs as a voting member of the Strategy, Investment and Impact Committee (the “SIIC)”) for a term that will expire on 9 March 2016, or until the appointment of her successor.</p>
2015-03-31 B33 GF/B33/DP07 Remaining Targets for the 2014 - 2016 Corporate Key Performance Indicator Framework Remaining Targets for the 2014 - 2016 Corporate Key Performance Indicator Framework
<ol> <li>The Board: <ol type="a"> <li>Notes additional analysis was required to finalize the performance targets for the updated 2014 - 2016 Global Fund Corporate Key Performance Indicator Framework (the "KPI Framework") that was approved in November 2014 (GF/B32/DP10); and</li> <li>Acknowledges the Secretariat's presentation of 2014 performance assessments and updates, as well as updated performance targets, for the KPI Framework, as set forth in GF/B33/04B.</li> </ol> </li> <li>Accordingly, the Board approves the updated performance targets for Key Performance Indicators 6, 12 and 16, as presented in GF/B33/04B.</li> </ol>
2015-06-11 B33 GF/B33/EDP06 Appointment of a new Vice-Chair of the Finance and Operational Performance Committee Appointment of a new Vice-Chair of the Finance and Operational Performance Committee
<p>The Board approves the appointment of Mr. Michael Ruffner as the non-voting, neutral Vice-Chair of the Finance and Operational Performance Committee (the "FOPC") for the remainder of his predecessor's term.</p>
2015-10-08 B33 GF/B33/EDP19 Appointment of Member of the Finance and Operational Performance Committee Appointment of Member of the Finance and Operational Performance Committee
<p>The Board approves the appointment of Eiji Hinoshita as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor. </p>
2015-04-01 B33 GF/B33/DP08 Policy on Co-infections and Co-morbidities Policy on Co-infections and Co-morbidities
<ol> <li>The Board acknowledges its approval of an interim measure for the financing of Hepatitis C virus treatment until the approval of a broader policy on co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria (GF/B32/DP07).</li> <li>Based on the recommendations of the Strategy, Investment and Impact Committee, the Board approves the framework for financing co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, as set forth in GF/B33/11.</li> <li>Accordingly, the Board notes this decision point supersedes GF/B32/DP07.</li> </ol>
2015-03-31 B33 GF/B33/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the Thirty-Third Board Meeting (GF/B33/01 - Revision 2) is approved.</p>
2015-06-05 B33 GF/B33/EDP04 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER03 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-M-MOH), Ethiopia (ETH-S-FMOH, ETH-M-FMOH), Gambia (GMB-H-NAS, GMB-H-ActionAid), Guinea (GIN-M-CRS), Lao (People Democratic Republic) (LAO-T-GFMOH), Mozambique (MOZ-M-MOH, MOZ-M-WV, MOZ-H-MOH, MOZ-T-MOH, MOZ-C-FDC), Papua New Guinea (PNG-H-OSHF), Philippines (PHL-H-SC), Sao Tome &amp; Principe (STP-T-UNDP), Senegal (SEN-H-ANCS, SEN-H-CNLS), Somalia (SOM-H-UNICEF, SOM-M-UNICEF), South Sudan (SSD-T-UNDP), Tanzania (TZA-H-MOF, TZA-T-MOF), Uganda (UGA-S-MoFPED, UGA-S-TASO, UGA-C-TASO, UGA-H-MoFPED, UGA-T-MoFPED), Viet Nam (VNM-H-VAAC, VNM-H-VUSTA, VNM-T-NTP) and Yemen (YEM-M-NMCP).</p>
2013-05-31 B28 GF/B28/EDP23 Discontinuation of Funding for the Guinea-Bissau HSS Grant (GNB-809-G09-S) Discontinuation of Funding for the Guinea-Bissau HSS Grant (GNB-809-G09-S)
<p>The Board:</p><p>The Board declines approval of additional funding for the next implementation period for the Round 8 Guinea-Bissau HSS Grant (GNB-809-G09-S).</p><p>Table 3: Secretariat’s Recommendations for Discontinuation of Funding for Renewals</p><p>See attached table.</p>
2012-11-15 B28 GF/B28/DP08 Recognition of Debrework Zewdie Recognition of Debrework Zewdie
<p>The Board notes that this meeting will be the last involving participation by Debrework Zewdie as Deputy General Manager.</p><p>The Board therefore thanks Debrework for her wonderful service to the Global Fund. In her work as Deputy General Manager and Head of the Strategy, Investment and Impact Division, she has demonstrated enormous commitment and passion for the mission of the Global Fund. The Board acknowledges the numerous contributions Debrework has made to the organization and, in particular, the Board praises her leadership in reforming the grant renewals process.</p><p>The Board wishes Debrework every success in the future as she continues to work towards improving global health.</p>
2013-03-15 B28 GF/B28/EDP14 Decision on the Secretariat’s Funding Recommendations Decision on the Secretariat’s Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 39,383,839 for the following grants: BIH-910-G03-H ; PKS-911-G13-H ; PKS-911-G14-H ; NMB-202-G03-M-00</p>
2013-03-15 B28 GF/B28/EDP11 Appointment of Global Fund Board Chair and Vice-Chair Appointment of Global Fund Board Chair and Vice-Chair
<p>The Board appoints Dr Nafsiah Mboi as Chair of the Board and Madame Mireille Guigaz as Vice-Chair of the Board for a two-year mandate from the adjournment of the Twenty-Ninth Board Meeting and until the adjournment of the first Board Meeting in 2015</p>
2012-11-15 B28 GF/B28/DP03 Approval of Report of the Twenty-Seventh Board Meeting Approval of Report of the Twenty-Seventh Board Meeting
The report of the Twenty-Seventh Board Meeting (GF/B28/11) is approved.
2012-12-14 B28 GF/B28/EDP06 Decision on December 2012 Grant Renewals Funding Recommendations Decision on December 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 269,567,949 for the following grants: BEL-910-G02-H ; BEN-H-SEIBsa ; BEN-H-PlanBen ; BEN-H-PNLS ; CAM-S-PRMOH ; CMR-910-G07-M ; CMR-910-G08-M ; CMR-910-G09-T ; COM-910-G04-H ; GNB-M-MOH ; MAC-910-G02-H ; MEX-910-G01-H ; PKS-910-G11-T ; PKS-910-G12-T ; SRL-911-G13-H ; SRL-911-G14-H ; SUR-910-G05-T ; VTN-910-G08-T</p>
2013-06-14 B28 GF/B28/EDP25 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of USD 27,531,616 for the following grants: Chad newly approved but as yet unsigned malaria grant under the Transitional Funding Mechanism ; PNG-612-G07-T ; KEN-S11-G11-T ; KEN-S11-G12-T</p>
2013-05-31 B28 GF/B28/EDP22 Decision on the Secretariat’s Grant Renewals Funding Recommendations Decision on the Secretariat’s Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.<br />Table 1: The Secretariat’s Funding Recommendations for Renewals</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 262,191,837 for the following grants: NMB-202-G01-H ; NMB-202-G07-H ; IDA-T-CTD ; IDA-T-IUALTD ; IDA-T-WVI</p>
2015-05-15 B33 GF/B33/EDP02 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 3 of Annex 1 to GF/B33/ER01.</li> </ol> <p>This decision does not have material budgetary implications for the 2014 Operating Expenses Budget.</p> <p>Annex: Cameroon (CMR-011-G10-H), Cameroon (CMR-011-G11-H), Indonesia (IND-M-MOH), Sudan (SUD-011-G15-H), Thailand (THA-H-DDC).</p>
2013-06-14 B28 GF/B28/EDP26 Decision on the Secretariat’s Funding Recommendations for grant renewals Decision on the Secretariat’s Funding Recommendations for grant renewals
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 3 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Program Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li><li> Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 3 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 125,959,401 for the following grants: MOZ-911-G11-M ; MOZ-911-G12-M ; TNZ-911-G14-S ; ECU-910-G08-T ; ECU-910-G09-T</p>
2013-03-19 B28 GF/B28/EDP16 Revised Charter of the Office of the Inspector General and Terms of Reference for the Inspector General Revised Charter of the Office of the Inspector General and Terms of Reference for the Inspector General
<p>Based on the recommendations of the Audit and Ethics Committee and information presented in the Electronic Report to the Board dated 12 March 2013 and titled “Revised Charter of the Office and the Inspector General and Terms of Reference for the Inspector General” (“B28/ER/12”), the Board:</p> <ol> <li>Approves the revised Charter of the Office of the Inspector General, as set forth in Annex 1 to B28/ER/12 (the “Charter”);</li> <li>Approves the Terms of Reference for the Inspector General (the “TOR”), as set forth in Annex 2 B28/ER/12 (the “TOR”); and</li> <li>Notes the Charter and TOR shall be effective as of the date of this decision.</li> </ol>
2013-04-02 B28 GF/B28/EDP17 Decision on the Secretariat’s Funding Recommendations Decision on the Secretariat’s Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 26,899,613 for the following grants: NEP-T-NTC ; HTI-911-G08-T ; COG-810-G02-T</p>
2012-12-13 B28 GF/B28/EDP04 Terms of Reference of Chair and Vice-Chair of Global Fund Board Terms of Reference of Chair and Vice-Chair of Global Fund Board
<p>The Board approves the revised Terms of Reference for the Chair and Vice-Chair of the Board of the Global Fund, as set forth in B28/ER/04 (the "Revised Terms of Reference"), which supersede the existing Terms of Reference for the Chair and Vice Chair of the Board, as last amended in December 2010 (GF/B22/DP6).</p> <p>The Board shall utilize the Revised Terms of Reference in the nomination and election of the next Chair and Vice-Chair of the Board.</p>
2013-05-24 B28 GF/B28/EDP21 Approval of the Global Fund’s 2012 Consolidated Financial Statements Approval of the Global Fund’s 2012 Consolidated Financial Statements
<p>The Board:</p><p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2012 Consolidated Financial Statements, which have been audited by Ernst &amp; Young, as set forth in Annex 1 to B28/ER/16.</p>
2015-09-21 B33 GF/B33/EDP18 Approval of the Governance Performance Assessment Framework Approval of the Governance Performance Assessment Framework
<ol> <li>Based on the recommendation of the Transitional Governance Committee, the Board approves the Governance Performance Assessment Framework, as set forth in Annex 1 to GF/B33/ER11 (the “Framework”).</li> <li>The Board agrees with the approach for partially implementing the Framework in 2015, as described in GF/B33/ER11, and acknowledges that full implementation of the Framework will start in 2016.</li> </ol>
2015-07-17 B33 GF/B33/EDP11 Location of the Thirty-Fourth Board Meeting, 16-17 November 2015 Location of the Thirty-Fourth Board Meeting, 16-17 November 2015
The Board decides to convene the Thirty-Fourth Board Meeting in Geneva, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.
2015-11-27 B33 GF/B33/EDP27 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B33/ER18 (collectively, "Table 1");<br/>2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the additional funding for the Zimbabwe HIV Program and its resultant total program budget, as listed in Table 1c of Section IV to GF/B33/ER18;<br/>4. Approves the reinvestment of within-allocation efficiencies for the Bangladesh malaria and Cote d'Ivoire malaria grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER18;<br/>5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.<br/>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.
2015-11-12 B33 GF/B33/EDP30 Appointment of Member of the Strategy, Investment and Impact Committee Appointment of Member of the Strategy, Investment and Impact Committee
<p>The Board approves the appointment of Ambassador Lennarth Hjelmaker as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor. </p>
2012-12-13 B28 GF/B28/EDP03 2013 Operating Expenses Budget 2013 Operating Expenses Budget
<p>The Board approves the 2013 Operating Expenses Budget, as set forth in GF/B28/ER03-Annex 1, in the amount of USD 301.2 million (USD 297.2 million recurring plus USD 4.0 million non-recurring costs), which includes USD 21.1 million budgeted for the Office of the Inspector General.</p> <p>Following approval of this decision, the Secretariat may enter into a forward contract to manage the 2013 Operating Expenses Budget's exposure to currency risk in accordance with GF/B22/DP18. If the exchange rate determined on the date of signature of the forward contract results in a foreign-exchange adjustment to the budget amount approved by the Board, the adjusted amount shall be communicated to the Board and deemed the approved 2013 Operating Expenses Budget. In the absence of hedging, monitoring of the 2013 Operating Expenses Budget will be measured at the exchange rate used to prepare the budget.</p>
2015-10-19 B33 GF/B33/EDP24 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER15.</li> </ol> <p>Annex: Kyrgyzstan (KGZ-H-UNDP)</p>
2015-09-11 B33 GF/B33/EDP16 Decision on the Secretariat’s Recommendation on Grant Extension Decision on the Secretariat’s Recommendation on Grant Extension
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER09.</li> </ol> <p>Annex: Liberia (LBR-T-MOH), Madagascar (MDG-809-G11-H, MDG-809-G12-H), Syria (SYR-011-G02-H).</p>
2015-03-31 B33 GF/B33/DP01 Appointment of Rapporteur Appointment of Rapporteur
Professor Christian Otu Onyebuchi Chukwu from the West and Central Africa constituency is designated as Rapporteur for the Thirty-Third Board Meeting.
2007-11-13 B16 GF/B16/DP05 Round 7 Lessons Learned Round 7 Lessons Learned
The Board acknowledges the lessons learned by the TRP and Secretariat during the Round 7 proposals process as presented in the Report of Technical Review Panel and the Secretariat on Round 7 Proposals (GF/B16/5), and requests the Portfolio Committee to include appropriate revisions to the Proposal Form and Guidelines for Round 8 by 1 March 2008.
2007-11-13 B16 GF/B16/DP20 Budget 2008 Budget 2008
The Board approves the 2008 Operating Expense budget in the amount of US$ 176,610,000 as set out in Annex 1 to the Report of the Finance and Audit Committee GF/B16/8 and proposed by the Secretariat. 
2007-11-13 B16 GF/B16/DP13 Amendment of Assessment Process for Key Performance Indicators Amendment of Assessment Process for Key Performance Indicators
<p>The Board amends the Key Performance Indicator ("KPI") assessment process approved in GF/B15/DP34 as follows:</p> <p>(a) KPIs for the following year shall be developed and approved by the Policy and Strategy Committee ("PSC"). The PSC shall present the approved KPIs at the last Board meeting of each calendar year.</p> <p>(b) KPIs for 2008 shall exceptionally be reviewed at the PSC's meeting in the first quarter of 2008.</p> <p>All other requirements and timelines set forth in decision GF/B15/DP34 remain unchanged. The PSC shall accordingly assess results achieved against KPIs during the previous year and report on them at the first Board meeting of each calendar year.</p>
2007-11-13 B16 GF/B16/DP12 Timing of the Partnership Forum Timing of the Partnership Forum
<p>The Board amends the first sentence of Article 6.3 of the By-laws as follows:</p><p>"The Partnership Forum will meet biennially, at any time during even calendar years".</p>
2007-11-13 B16 GF/B16/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Mr Luis Riera Figueras from the European Commission (Belgium, Finland, Portugal) constituency is designated as Rapporteur for the Sixteenth Board Meeting.
2008-04-12 B16 GF/B16/EDP05 Approval of Funding Recommendations (Phase 2 and RCC Bridge Interim Funding) Approval of Funding Recommendations (Phase 2 and RCC Bridge Interim Funding)
<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.<br/><br/>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/></li><li>The Board approves the use of undisbursed grant funds under grant number IND-102-G01-T-00 listed in Schedule B to finance continuation of program activities under the Rolling Continuation Interim Bridge Funding policy, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on an understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendations set forth in the Qualification Score Card.<br/><br/><br/>SCHEDULE A (Phase 2 Recommendations)<br/><br/>Ghana, HIV – Round 5<br/>Grant Number(s) GHN-506-G06-H<br/>CCM Requested Amount (Total Phase 2 in US$): 65,468,580<br/>Approved Funding Amount (Incremental in US$): 65,468,580<br/>Recommendation Category: Go<br/><br/>Ghana, TB – Round 5<br/>Grant Number(s) GHN-506-G05-T<br/>CCM Requested Amount (Total Phase 2 in US$): 17,916,308(1)<br/>Approved Funding Amount (Incremental in US$): 16,924,238<br/>Recommendation Category: Go<br/><br/>Kenya, Malaria – Round 4<br/>Grant Number(s) KEN-405-G06-M<br/>CCM Requested Amount (Total Phase 2 in US$): 104,346,797<br/>Approved Funding Amount (Incremental in US$): 80,423,329<br/>Recommendation Category: Conditional Go<br/><br/>Kyrgyzstan, Malaria – Round 5<br/>Grant Number(s) KGZ-506-G03-M<br/>CCM Requested Amount (Total Phase 2 in US$): 1,733,735<br/>Approved Funding Amount (Incremental in US$): 1,733,735<br/>Recommendation Category: Go<br/><br/>Uganda, Malaria – Round 4<br/>Grant Number(s): UGD-405-G05-M<br/>CCM Requested Amount (Total Phase 2 in US$): 91,614,931<br/>Approved Funding Amount (Incremental in US$): 71,034,989<br/>Recommendation <br/>Category: Conditional Go<br/><br/>Zambia, HIV – Round 4<br/>Grant Number(s): ZAM-405-G12-H<br/>CCM Requested Amount (Total Phase 2 in US$): 21,687,283<br/>Approved Funding Amount (Incremental in US$): 13,390,445<br/>Recommendation<br/>Category: Conditional Go<br/><br/><br/>SCHEDULE B (RCC Interim Bridge Funding Recommendation)<br/><br/>Indonesia, TB – Round 1<br/>Grant Number(s): IND-102-G01-T-00<br/>Duration of Funding: 10 months<br/>CCM Requested Amount (Incremental in US$): 0<br/>Approved Funding Amount (Incremental in US$) 0</li></ol>
2007-11-13 B16 GF/B16/DP22 Policy for Disclosure of Reports Issued by The Inspector General Policy for Disclosure of Reports Issued by The Inspector General
The Board approves the Policy for Disclosure of Reports Issued by the Inspector General, set out in Annex 3 to the Report of the Finance and Audit Committee GF/B16/8.
2007-11-13 B16 GF/B16/DP08 Revision of the Rolling Continuation Channel for Strongly-performing Grants Revision of the Rolling Continuation Channel for Strongly-performing Grants
<p>The Board refers to its decision at the Fourteenth Board Meeting (GF/B14/DP7) to establish the Rolling Continuation Channel as an alternative funding channel for strongly-performing grants that are reaching the end of their funding terms ("expiring grants").</p> <p>As an interim measure, pending the implementation of the outcomes of the review of the Rolling Continuation Channel architecture, the Board:</p> <ol> <li>Decides to revise the Rolling Continuation Channel policy and procedures in regard to the role of the TRP and the avenues for recourse available to a CCM whose proposal is not recommended for funding after the first submission of a Rolling Continuation Channel proposal by: <ol type="a"> <li>amending paragraph 12 of the decision point (GF/B14/DP9) entitled 'Establishment of a Rolling Continuation Channel' ("RCC decision point") as follows:<br /><br />12. All rolling continuation proposals shall undergo an independent technical review by the TRP. Such review shall ensure that only technically appropriate interventions are funded, with consideration to the fact that the proposal is intended to ensure continued funding for expiring grants that have met the qualification requirements set out in paragraph 3 above.</li> <li>amending paragraphs 7 and 8 of the Board Decision-Making Procedure for the Rolling Continuation Channel (GF/B15/DP19) as follows:<br /><br />7. The effect of a Board decision to approve a TRP recommendation shall be as follows:<br /><br />a. If the Board approves a TRP recommendations to fund a RCC proposal, that decision will constitute an approval of the entire term of such RCC proposal, with a financial commitment for the initial three (3) years of the RCC proposal, with funding for the second phase subject to the approval of the Board based on a mid-term review;<br /><br />b. If, after an initial submission of a given proposal under the RCC, the Board approves a TRP recommendation that the CCM resubmit a revised version of this proposal in the next wave of RCC proposals, the CCM shall have the option to:<br /><br />i. revise its proposal based on the issues identified by the TRP during the initial review of the proposal, and submit the revised proposal in the next wave of Rolling Continuation Channel proposals ("revised proposal"); or<br />ii. file an appeal as described in paragraph c. below<br /><br />If the CCM submits a revised proposal, the procedure described in paragraphs 2-6 above will be followed.<br /><br />c. If the Board approves a TRP recommendation not to fund a proposal, the CCM may file an appeal of the decision not to approve the proposal in accordance with the Global Fund's Rules and Procedures for Appeals as the final avenue for recourse for the unsuccessful RCC proposal.<br /><br />8. If the Board decides not to approve a TRP recommendation to fund, the decision making process that applies following a Board objection to a TRP funding recommendation under the Phase 2 Decision-Making Policies and Procedures, as amended from time to time, will be followed. If the Board objects to a TRP recommendation not to fund, then the matter will be referred to the Board at its next Board meeting.</li> </ol> </li> <li>Amends the description of 'Category 3' recommended proposals set out in Part 2 of Attachment 1 to the Terms of Reference of the Technical Review Panel by splitting 'Category 3' into two parts as follows<br /><br />Category 3a: (Applicable only upon initial submission) Not recommended for funding based on technical merit but strongly encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the next wave of Rolling Continuation Channel proposals.<br /><br />Category 3b: (Applicable only upon re-submission) Not recommended for funding based on technical merit but encouraged to resubmit through the Rounds-Based Channel following major revision</li> <li>Approves all 'Category 3' recommendations in the Wave 1 TRP Report as if such recommendations were designated 'Category 3a' and requests the Secretariat to notify the relevant CCMs promptly of this decision and the option to resubmit in time for the third wave of RCC proposals</li> <li>Delegates authority to the Secretariat to modify the Rolling Continuation Channel application forms and guidelines to give effect to these modified principles</li> <li>Approves the procedure for providing additional funding ("Rolling Continuation Channel Bridge Funding") for expiring grants as set out in Attachment 1 to Annex 3 of document GF/B16/6.</li> </ol>
2007-11-13 B16 GF/B16/DP11 Approval of Guidelines on Constituency Processes Approval of Guidelines on Constituency Processes
The Board approves the Guidelines on Constituency Processes, as detailed in Annex 2 of paper GF/B16/6, and requests that Board Members, Alternate Board Members and Focal Points, along with the Secretariat, ensure these guidelines are shared widely within their respective constituencies, and recommended as a guide to strengthen internal constituency processes.
2007-11-13 B16 GF/B16/DP21 Transition from Administrative Services Arrangement Transition from Administrative Services Arrangement
<p>The Board decides that the Global Fund shall discontinue the Administrative Services Agreement with the World Health Organization not later than December 31, 2008 (the "End Date"). Administrative and employment arrangements that will be in effect after that date shall be determined in accordance with the principles, processes and timelines that are described in Annex 2 to the Report of the Finance and Audit Committee GF/B16/8. </p><p>Pursuant to the above, the Board requests the Secretariat to propose a new cash balance pension scheme that shall provide safeguards for the interests of staff, to which Global Fund staff can be affiliated beginning on the date of termination of the WHO Administrative Services Agreement (the "GF Pension Fund"), and delegates authority to the Finance and Audit Committee to approve it by its March 2008 meeting.</p><p>The Secretariat shall notify the United Nations Joint Staff Pension Fund through the WHO that the Global Fund wishes to negotiate a transfer agreement between the UNJSPF and the GF Pension Fund, for submission to the July 2008 session of the UNJSPF Board.</p><p>The Board takes note of the need to further clarify the relationship and partnership with the WHO and the UN system after a discontinuation of the administrative services agreement with WHO, based on a true public/private identity as an efficient and attractive financing instrument and the role of the UN, including its normative role and function. It requests that a draft policy statement on the relationship and partnership with the WHO and the UN system, linked to the broader PSC review of partnership relations, is presented at the 17th Board Meeting.</p>
2007-11-13 B16 GF/B16/DP09 Roll-Out of Grant Consolidation Roll-Out of Grant Consolidation
<p>The Board refers to its decision<a id="_ftnref1" name="_ftnref1"></a>1 to authorize the Secretariat to modify the application of existing policies to the extent necessary to consolidate grants on a pilot basis. Noting the update on the Secretariat's progress set out in the Policy and Strategy Committee document GF/PSC8/06, the Board reaffirms its commitment to achieving simplification and cost-efficiency in managing grants, and alignment with country systems, while maintaining adherence to the principle of performance-based funding. The Board accordingly delegates to the Secretariat the authority to:</p> <ol start="1" type="1"> <li>work with countries, on a voluntary basis, to consolidate existing and new grants where doing so would be consistent with the principles listed above;</li> <li>exercise flexibility in the application of existing policies, including but not limited to the Phase 2 Decision-Making and the Rolling Continuation Channel policies and procedures,<a id="_ftnref2" name="_ftnref2" target="_self"></a>where necessary, revising requirements that could inhibit grant consolidation; and</li> <li>approve bridge funding, in limited cases and for a period of no longer than nine months, by employing Phase 2 funds not yet approved by the Board, where necessary to allow for the alignment of end dates of grants that are being consolidated, provided that the amount of such bridge funding is reported to the Board on each occasion that it is approved.</li> </ol> <p>The Board requests the Portfolio Committee to ensure that application forms and guidelines allow for the submission of consolidated applications through the Rounds-Based Channel and Rolling Continuation Channel.</p> <p><a id="_ftn1" name="_ftn1"></a></p>
2007-11-13 B16 GF/B16/DP19 Guidelines on the Purpose, Structure, Composition and Funding of Country Coordinating Mechanisms and Requirements for Grant Eligibility Guidelines on the Purpose, Structure, Composition and Funding of Country Coordinating Mechanisms and Requirements for Grant Eligibility
<p>The Board approves the "Guidelines on the Purpose, Structure, Composition and Funding of Country Coordinating Mechanisms and Requirements for Grant Eligibility" ("CCM Guidelines") as outlined in Attachment 1, Section 1 of GF/B16/7 (Revision 1). </p><p>In the context of DP/B15/14 the Board requests the Portfolio Committee to continue to review the representation and participation of civil society and private sector on CCMs and delegates to the Portfolio Committee the authority to modify the CCM Guidelines to make membership of key affected populations and other civil society and private sector representatives on the CCM a requirement if the Portfolio Committee deems it appropriate based on its review.</p><p>The Board approves an allocation of US$ 5,961,000 for CCM funding for the period ending on 31 December 2008. The Board emphasizes that this funding must be used in accordance with the CCM funding policy and is a maximum only. The Board requests that the Secretariat include the expected annual CCM funding maximum as part of the annual budget for the Secretariat that is reviewed by the Finance and Audit Committee and approved by the Board at the last Board Meeting of each calendar year, by adding a separate line item within the operating costs in the same manner as the LFA oversight cost.</p><p>The Board delegates to the Portfolio Committee the responsibility for overseeing the implementation of the CCM funding policy and grants to the Portfolio Committee the authority to make such modifications to the CCM Guidelines as may be necessary to operationalize the funding policy. The Portfolio Committee will provide updates on any such modifications in its periodic reports to the Board.</p><p>The Board also requests the Portfolio Committee to work with the Secretariat to identify future alternative models of CCM funding taking into consideration (i) the intended purpose and role of CCMs, (ii) differing country contexts, (iii) the need for meaningful participation by civil society representatives, and (iv) the need to strengthen and support the capacity and resources of CCMs to conduct grant oversight and (v) harmonization with other national bodies. If appropriate based on the outcome of this work, the Portfolio Committee shall recommend modifications to the CCM composition functioning and financing for decision by the Board at its Eighteenth Meeting.</p>
2007-11-13 B16 GF/B16/DP16 Flexibility in Phase 2 Timing Flexibility in Phase 2 Timing
The Board decides to amend the Phase 2 Decision Making Policies and Procedures by adding a new paragraph 19 to the Phase 2 Decision-Making Policy and Procedures as set out in Attachment 1, Section 3 of GF/B16/7.
2007-11-13 B16 GF/B16/DP07 Use of Bridge Funding as a Short-Term Measure to Address Architectural Limitations of the Rolling Continuation Channel Use of Bridge Funding as a Short-Term Measure to Address Architectural Limitations of the Rolling Continuation Channel
<p>The Board takes note of the challenges in operationalizing the Rolling Continuation Channel ("RCC")<a id="_ftnref1" name="_ftnref1">1</a> as set out in the Policy and Strategy Committee document GF/PSC8/05. The Board further notes that the Policy and Strategy Committee has requested the Secretariat to analyze further and develop a Quarterly Application Schedule architecture. It is expected that such long-term architecture changes will be presented to the Board for decision at the Seventeenth Board Meeting.</p><p>As an interim measure to address the specific challenges faced in operationalizing the RCC, the Board approves the procedure for providing additional funding for affected well-performing grants for a time-limited period as set out in Annex 1 (entitled "Interim Bridge Funding for Expiring Grants") to the Report of the Policy and Strategy Committee (GF/B16/6). This interim measure shall apply for relevant grants that fail to qualify for the RCC during the period from initial implementation of the RCC until the adoption by the Board, and full operationalization by the Secretariat, of long-term architectural changes which will address such RCC implementation challenges and that would otherwise experience a funding gap as a direct result of such failure to qualify for the RCC. </p>
2007-11-13 B16 GF/B16/DP03 Approval of Report of the Fifteenth Board Meeting Approval of Report of the Fifteenth Board Meeting
The report of the Fifteenth Board Meeting (GF/B16/2) is approved, as amended at the Sixteenth Board meeting.
2007-11-13 B16 GF/B16/DP06 Eligibility for Qualification for the Rolling Continuation Channel in Cases of Accelerated Implementation Eligibility for Qualification for the Rolling Continuation Channel in Cases of Accelerated Implementation
<p>The Board decides that the Secretariat may provide an exception from the decision that grants from the fourth and subsequent Rounds that have a term of less than five years are ineligible for qualification for the Rolling Continuation Channel ("RCC") (GF/B15/DP18) in cases where a Country Coordinating Mechanism ("CCM") <a id="_ftnref1" name="_ftnref1" target="_self"></a>has applied for a grant of five years and the grant term is reduced at the request of the CCM due to accelerated implementation of the program funded by the grant.</p>
2007-11-13 B16 GF/B16/DP17 Interim Quality Assurance Policy for Multi-Source Products Interim Quality Assurance Policy for Multi-Source Products
<p>The Board requests the Portfolio Committee to conduct a review of the Global Fund's quality assurance policy for drugs, taking into account alignment with relevant partners' quality assurance policies, concerns about safety, stability and efficacy of drugs, and market dynamics, and report back to the Board at its Eighteenth Meeting.</p><p>Concerns have been raised about the risk of quality assurance problems with drugs previously covered by the Global Fund's Quality Assurance Policy for Single and Limited Source Products ("Single Source QA Policy") that have recently been re-categorized as multi-source products (GF/B16/7 Revision 1). As an interim measure to address this risk pending the outcome of the review of quality assurance policy, the Board decides that any drugs for the treatment of HIV/AIDS, TB and malaria for which the formula has been published <a id="_ftnref1" name="_ftnref1" target="_self"></a>since the Third Board Meeting (10 October 2002) shall be subject to the Single Source QA Policy.</p><p><a id="_ftn1" name="_ftn1" target="_self"></a></p>
2008-02-28 B16 GF/B16/EDP03 Approval of Appeal Panel Funding Recommendations. Approval of Appeal Panel Funding Recommendations.
<p>The Board approved for funding for an initial two years in the amounts indicated and subject to paragraph 2 below, the following Round 7 proposals that were recommended for funding by the Independent Appeal Panel in its report dated 8 February 2008:</p><ul><li>Azerbaijan (Malaria) – Euro 2,544,154; <br/><br/></li><li>Cambodia (Tuberculosis) – USD 8,707,480; and<br/><br/></li><li>Zambia (Tuberculosis) – USD 4,112,419.</li></ul><p>With the clear understanding that the amounts indicated are upper ceilings subject to Technical Review Panel (TRP) clarifications and grant negotiations, rather than final approved grant amounts.</p><p>The applicants referred to in paragraph 1 above shall:</p><ul><li>provide an initial detailed written response to the clarifications and adjustments requested by the Independent Appeal Panel by not later than six weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and</li><li>conclude the clarification process, as indicated by the written approval of the Chair or Vice Chair of the TRP not later than three months from the Secretariat’s receipt of the applicants initial detailed response to the issues raised for clarifications or adjustments.</li></ul>
2007-11-13 B16 GF/B16/DP24 Board Action on the Right to Travel of People living with HIV Board Action on the Right to Travel of People living with HIV
The Global Fund to Fight AIDS, Tuberculosis and Malaria will not hold Board or Committee Meetings in countries that restrict short-term entry of people living with HIV/AIDS and/or require prospective HIV-positive visitors to declare their HIV status on visa application forms or other documentation required for entry into the country.
2007-11-13 B16 GF/B16/DP25 Acknowledgement of the UNAIDS Commitment to Create a Task Team on Travel Restrictions Acknowledgement of the UNAIDS Commitment to Create a Task Team on Travel Restrictions
<p>Following GF/B16/DP24 the Board strongly encourages all countries to move rapidly towards elimination of travel/entry restrictions, including waivers, for people living with HIV. The Board acknowledges the UNAIDS commitment to create a Task Team with the aim of eliminating policies and practices that restrict travel for HIV positive people.</p>
2008-02-11 B16 GF/B16/EDP02 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<ol><li>The Board approves additional funding for the Phase 2 period for the proposal listed in Schedule A in the amount indicated for the proposal, with the clear understanding that the amount approved is an upper ceiling rather than the final funding amount, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for the proposal consistent with the recommendations set forth in its Grant Scorecard.The Board reaffirms that the maximum funding amount for Phase 2 of the proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/></li><li>The Board approves additional funding for the Phase 2 period of the Round 4 Togo Malaria grant (TGO-405-G05-M) as a ‘Conditional Go’ in the amount of up to US$4,628,947 subject to TRP clarifications within a limited timeframe and to conditions to be cleared by the Secretariat.The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/>SCHEDULE A<br/><br/>Rwanda, Malaria – Round 5<br/>Grant Number: RWN-506-G06-M<br/>CCM Requested Amount (Total Phase 2 in US$) 11,508,591<br/>Approved Funding Amount (Incremental in US$) 11,508,591<br/>Recommendation Category: Conditional Go</li></ol>
2007-11-13 B16 GF/B16/DP18 Income level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund Income level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund
<p>The Board decides to revise the current eligibility criteria for proposals for funding and approves the income level and cost-sharing eligibility criteria for Global Fund funding as set out in Attachment 1, Section 2 of GF/B16/7. The Board delegates to the Portfolio Committee the responsibility to oversee the implementation of the Income Level and Cost-Sharing Eligibility Criteria and to make decisions to facilitate such implementation within the parameters of the policy. The Board further requests technical partners to work with the PC to review how the availability of data for concentrated epidemics in HIV/AIDS will impact access to Global Fund financing. </p><p>The Board decides to review the Income Level and Cost-Sharing Criteria in three years' time. </p>
2015-04-01 B33 GF/B33/DP11 Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<ol><li>The Board expresses its deep appreciation to Dr Nafsiah Mboi for her leadership as Chair of the Board. She has served the Global Fund with a high degree of personal commitment and passion. During her tenure, Ibu Naf has presided over significant deliberations and decisions that will continue to shape the future of the Global Fund. </li><li>The Board also expresses sincere gratitude to Ambassador Mireille Guigaz for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mireille has been an active driver of discussions and initiatives that will have a lasting impact on the Global Fund. </li><li>Their stewardship of the Board through the launch of a new funding model, an ethics and integrity initiative, and the approval of a governance plan for impact have pointed the Global Fund towards continued success and efficiency in achieving its mission. </li><li>The Board wishes Ibu Naf and Mireille every success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively. </li></ol>
2015-10-29 B33 GF/B33/EDP25 Appointment of Member of the Strategy, Investment and Impact Committee Appointment of Member of the Strategy, Investment and Impact Committee
<p>The Board approves the appointment of Dr Suriya Wongkongkathep as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor.</p>
2015-09-11 B33 GF/B33/EDP15 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER09 (“Table 1”);</li> <li>Approves the reinvestment of newly identified existing funds for the Burkina Faso TB/HIV grant (BFA-H-SPCNLS) and its resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER09;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Belize (BLZ-C-UNDP), Burkina Faso (BFA-S-PADS, BFA-M-PADS), Cambodia (KHM-H-NCHADS, KHM-S-PRMOH), Center for Health and Policy Studies (QMZ-T-PAS), Elimination 8 - SADC (QPA-M-E8S), Guinea (GIN-H-CNLS, GIN-H-PSI), India (IDA-M-NVBDCP, IDA-M-CARITAS, IDA-H-NACO, IDA-H-IHAA, IDA-H-PLAN, IDA-H-SAATHII, IDA-T-CTD, IDA-T-IUATLD, IDA-T-WV), Kenya AIDS NGOs Consortium Regional (QPB-H-KANCO), Kenya (KEN-M-TNT, KEN-M-AMREF, KEN-H-KRCS, KEN-H-TNT, KEN-T-AMREF, KEN-T-TNT), Korea (Democratic People’s Republic) (PRK-T-UNICEF), Lao (People’s Democratic Republic) (LAO-M-GFMOH), South Sudan (SSD-H-UNDP), Sri Lanka (LKA-T-MOH), Sudan (SDN-S-FMOH), Suriname (SUR-C-MOH), Tajikistan (TJK-H-UNDP), Togo (TGO-H-PMT, TGO-T-PMT), Zanzibar (QNB-M-MOH).</p>
2015-03-31 B33 GF/B33/DP06 Appointment of External Auditor Appointment of External Auditor
<p>The Board appoints Ernst &amp; Young SA as the Global Fund's external auditor for the 2015 fiscal year.</p>
2015-03-31 B33 GF/B33/DP04 Annual Financial Report 2014 Annual Financial Report 2014
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's Annual Financial Report 2014, which includes the 2014 Consolidated Financial Statements that have been audited by Ernst &amp; Young SA, as set forth in Annex 1 to GF/B33/03 - Revision 1.</p>
2015-10-19 B33 GF/B33/EDP23 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV of GF/B33/ER15 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex:</p> <p>Dominican Republic (DOM-H-CONAVIH, DOM-H-IDCP0, Lao (People's Democratic Republic) (LAO-S-GFMOH), Malawi (MWI-M-MOH, MWI-M-WVM, MWI-C-MOH)<br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /></p>
2015-07-30 B33 GF/B33/EDP14 Terms of Reference of the Ethics Officer Terms of Reference of the Ethics Officer
<ul> <li>Based on the recommendation of the Board Leadership, the Board: <ol type="a"> <li>Approves the Terms of Reference of the Ethics Officer, as set forth in Annex 1 to document GF/B33/ER08; and</li> <li>Notes that the Terms of Reference of the Ethics Officer supersede the Board’s earlier decisions regarding the reporting arrangement for the Ethics Officer (GF/B33/DP09)</li> </ol> </li> <li>Accordingly, the Board instructs the Secretariat to launch the recruitment process for the Ethics Officer, who will be jointly selected by the Audit and Ethics Committee (AEC) and the Executive Director, and appointed by the Board on a no-objection basis for a three-year term that may be renewed no more than once.</li> <li>The Board requests the AEC and Finance and Operational Performance Committee to determine the future budgetary implications of this function as part of the standard Operating Expenses budget approval process, with particular consideration given to methods for maximizing value for money.</li> </ul>
2015-11-10 B33 GF/B33/EDP26 Global Fund Strategy Cycle Global Fund Strategy Cycle
<ol><li>Based on the recommendations of the Strategy, Investment and Impact Committee (the "SIIC"), as set forth in GF/B33/ER17, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022 (the "2017 - 2022 Strategy"), with a mid-point review of progress and implementation. </li><li>The Board notes the importance of coherence between the strategy, allocation and replenishment, as well as the need to provide advanced articulation of the Global Fund's strategy and objectives to guide implementation planning, facilitate advocacy efforts and support mobilization of resources.</li><li>Accordingly, the Board directs the SIIC, or its successor committee, to develop a timeline for developing and finalizing the strategy that will commence immediately after the 2017 - 2022 Strategy as part of the mid-point review of the 2017 - 2022 Strategy. </li></ol><p><br/></p>
2015-10-12 B33 GF/B33/EDP21 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER14.</li> </ol> <p>Annex:</p> <p>Angola (AGO-M-MOH), Sri Lanka (SRL-607-G07-T, SRL-809-G10-M)</p>
2015-06-30 B33 GF/B33/EDP08 # #
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER05 – Revision 1.</li> </ol> <p>Annex: Guatemala (GUA-610-G04-T), Haiti (HTI-102-G09-H), India (IDA-T-CTD), Lao (PDR) (LAO-708-G09-M), Nepal (NEP-H-SCF, NEP-M-SCF), Syria (SYR-607-G01-T), Zanzibar (ZAN-T-MOHSW).</p>
2015-10-12 B33 GF/B33/EDP20 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex:</p> <p>Azerbaijan (AZE-T-MOH), Bangladesh (BGD-H-NASP, BGD-H-SC, BGD-H-ICDDRB), Cape Verde (CPV-C-CCSSIDA), Comoros (COM-M-PNLP), Haiti (HTI-C-PSI), Lao (People's Democratic Republic) (LAO-H-GFMOH), Panama (PAN-C-UNDP), Sri Lanka (LKA-M-MOH), Zanzibar (QNB-C-MOH).<br /><br />Regional grants: Abidjan-Lagos Corridor Organization (OCAL) (QPF-H-ALCO), African Network for the Care of Children Affected by HIV/AIDS (ANECCA) (QPA-H-ANECCA), ECSA-HC Uganda Supranational National Reference Laboratory (QPA-T-ECSA), Humanist Institute for Cooperation with Developing Countries, Southern Africa (HIVOS) (QPA-H-HIVOS), Removal of Legal Barriers (RLB) (QPA-H-UNDP).</p>
2007-11-13 B16 GF/B16/DP10 Strategic Approach to Health Systems Strengthening Strategic Approach to Health Systems Strengthening
<p>The Board refers to the principles set forth in its decision GF/B15/DP6 and reaffirms that the Global Fund should continue to support the strengthening of public, private and community health systems by investing in activities that help health systems overcome constraints to the achievement of improved outcomes in reducing the burden of HIV/AIDS, tuberculosis and malaria ("ATM").</p> <p>The Board decides that the Global Fund shall provide funding for health systems strengthening ("HSS") actions within the overall framework of funding technically sound proposals focused on the three diseases and that such funding shall be based on the following principles:</p> <ol> <li>The Global Fund shall allow broad flexibility regarding HSS actions eligible for funding, such that they can contribute to system-wide effects and other programs can benefit. With this principle in mind, the Global Fund shall develop guidance with few prescriptions for applications for HSS funding, which may take the form of the following: <ol type="a"> <li>the specification of categories of HSS actions that the Global Fund recommends applicants consider when developing applications for funding;</li> <li>the specification of principles to guide applicants in deciding which categories of HSS actions to apply for; and</li> <li>the specification of any category of HSS actions that may not be financed by the Global Fund.</li> </ol> </li> <li>The Global Fund shall encourage applicants, wherever possible, to integrate requests for funding for HSS actions within the relevant disease component(s). Such HSS actions will be assessed by the Technical Review Panel ("TRP") as part of its review of that disease component.</li> <li>Recognizing that some HSS actions ("cross-cutting HSS actions") may significantly benefit more than one disease, the Global Fund shall allow applicants to request funding for such HSS actions by completing a distinct but complementary section (a "cross-cutting HSS section") within a disease component, provided that: <ol type="a"> <li>An application shall not contain more than one cross-cutting HSS section.</li> <li>Where cross-cutting HSS actions are proposed, the applicant shall articulate how they address identified health systems constraints to the achievement of improved ATM outcomes.</li> </ol> </li> <li>In reviewing a disease component which contains a cross-cutting HSS section, the TRP may recommend for funding either: <ol type="a"> <li>The entire disease component, including the cross-cutting HSS section;</li> <li>The disease component excluding the cross-cutting HSS section; or</li> <li>Only the cross-cutting HSS section if the interventions in that section materially contribute to overcoming health systems constraints to improved ATM outcomes.</li> </ol> </li> <li>The Global Fund shall also: <ol type="a"> <li>Recommend that proposals containing material HSS actions be based on the results of a recent assessment (the coverage of which need not be limited to ATM) identifying health systems constraints to the achievement of improved outcomes in reducing the burden of HIV/AIDS, tuberculosis and malaria; and</li> <li>Recommend that applications provide evidence of the involvement of relevant HSS stakeholders in the Country Coordinating Mechanism - including at least one non-government in-country representative with a focus on HSS and one government representative with responsibility for HSS planning.</li> </ol> </li> </ol> <p>The Board requests the Portfolio Committee to modify future application forms and guidelines (including for the Rolling Continuation Channel), effective from 1 March 2008, to incorporate the above principles and propose for approval at the Seventeenth Board Meeting any modifications to the Terms of Reference of the TRP (including with respect to the composition of the TRP) that are required in light of the strategic approach reflected in this decision point</p> <p>The Board requests the Secretariat to provide to the TRP information on the principles that are set forth in this decision. The Board also requests the Secretariat to communicate clearly, working closely with relevant partners, to country stakeholders the Global Fund's amended strategic approach to HSS - including the flexibilities inherent within it.</p> <p>The Board requests the Secretariat and the TRP to review the results of the Round 8 proposals with regard to HSS actions, and to report to the Eighteenth Board Meeting on the impact of this decision on the application and review process. The report should discuss the quality of proposals that include HSS actions, the proportion recommended by the TRP for approval, and the extent to which applicants have articulated how cross-cutting HSS actions address identified health systems constraints to the achievement of improved ATM outcomes.</p>
2008-03-13 B16 GF/B16/EDP04 Approval of Funding Recommendations (Phase 2 and Extension) Approval of Funding Recommendations (Phase 2 and Extension)
<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.<br/><br/>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/></li><li>The Board approves a 3-month extension to the deadline for the satisfaction of the following condition in the Yemen Round 3 HIV Grant Score Card[1]:<br/><br/>Within 12 months of Board approval of continued funding, the Principal Recipient shall provide evidence to the Global Fund that it has met at least 80% of the targets for that period contained in the proposal for each of the following indicators:<br/><br/>Number of PLWHA receiving antiretroviral combination therapy; <br/>Number of people receiving VCT; <br/>Number of high risk vulnerable persons reached with IEC activities; <br/>Number of staff trained in behavioral surveillance; and Number of service deliverers trained in IEC, BCC community outreach, VCT, STD, ART, care and support. Should these targets not be met by September 2008, all further funding of this proposal shall cease.<br/><br/>The revised deadline to meet the condition is set at 31 December 2008.<br/><br/><br/>SCHEDULE A<br/><br/>Kosovo, TB – Round 4<br/>Grant Number(s): KOS-405-G01-T<br/>CCM Requested Amount (Total Phase 2 in US$): 1,830,050<br/>Approved Funding Amount (Incremental in US$): 1,830,050<br/>Recommendation Category: Go<br/><br/>Macedonia, TB – Round 5<br/>Grant Number(s): MKD-506-G02-T<br/>CCM Requested Amount (Total Phase 2 in US$): 1,628,608<br/>Approved Funding Amount (Incremental in US$): 1,628,608<br/>Recommendation Category: Go<br/><br/>Malawi, Malaria – Round 2<br/>Grant Number(s): MLW-202-G02-M<br/>CCM Requested Amount (Total Phase 2 in US$): 19,674,096(1)<br/>Approved Funding Amount (Incremental in US$): 18,816,000<br/>Recommendation Category: Conditional Go<br/><br/>Tajikistan, Malaria – Round 5<br/>Grant Number(s): TAJ-506-G04-M<br/>CCM Requested Amount (Total Phase 2 in US$): 2,611,509<br/>Approved Funding Amount (Incremental in US$): 2,611,509<br/>Recommendation Category: Go</li></ol>
2007-11-13 B16 GF/B16/DP26 Scaling Up a Gender-Sensitive Response to HIV/AIDS, Tuberculosis, and Malaria by the Global Fund Scaling Up a Gender-Sensitive Response to HIV/AIDS, Tuberculosis, and Malaria by the Global Fund
<p>The Board recognizes the importance of addressing gender issues, with a particular focus on the vulnerabilities of women and girls and sexual minorities, in the fight against the three diseases, more substantially into the Global Fund's policies and operations. </p><p>The Board authorizes the Secretariat as a matter of priority to immediately appoint senior level "Champions for Gender Equality", with appropriate support, who will:</p><p>a. Work with technical partners and relevant constituencies to develop a gender strategy.</p><p>b. As an immediate priority, provide guidance to the Portfolio Committee on revisions to the Guidelines for Proposals for Round 8 to encourage applicants to submit proposals that address gender issues, with a particular reference to the vulnerability of women and girls and sexual minorities.</p><p>The Board requests the Policy and Strategy Committee to review the Gender Strategy and present it to the Board for approval at the Seventeenth Board meeting.</p>
2007-11-13 B16 GF/B16/DP15 Delegated Authority to Portfolio Committee to Approve Guidelines and Proposal Forms Delegated Authority to Portfolio Committee to Approve Guidelines and Proposal Forms
The Board delegates to the Portfolio Committee the authority to approve the guidelines and proposal forms for each future funding opportunity under both the Rounds-Based Channel and the Rolling Continuation Channel. 
2007-11-13 B16 GF/B16/DP02 Approval of Agenda Approval of Agenda
The agenda for the Sixteenth Board Meeting (GF/B16/1 Revision 2) is approved.
2007-11-13 B16 GF/B16/DP14 Hosting of the Affordable Medicines Facility - malaria Hosting of the Affordable Medicines Facility - malaria
<p>The Board acknowledges the letter from the Roll Back Malaria ("RBM") Partnership, dated August 16, 2007 requesting the Global Fund to consider hosting the Affordable Medicines Facility - malaria ("AMFm").</p><p>Based on the information provided to date, the Board supports in principle:</p><ul type="disc"><li>the objectives and principles of AMFm; and</li><li>the idea of investigating with no presumptive decision the appropriateness of hosting the AMFm as a Global Fund business line, considering the complementarities and synergies of the Global Fund's objectives and business model with many design elements of the AMFm.</li></ul><p>To facilitate a final Board decision on hosting the AMFm, the Board requests the Secretariat, under the oversight of the PSC, to develop and present to the Board at its Seventeenth Meeting a report and a possible business model and plan for hosting the AMFm within the Global Fund, taking into account operational and architectural considerations and consultations with the RBM Taskforce, UNITAID, key recipient countries and other relevant stakeholders. The intended mechanism should seek to increase broad access to ACTs especially among those at highest risk.</p>
2007-12-13 B16 GF/B16/EDP01 Approval of Funding Recommendation (Phase 2, Extension, and Continuity of Services) Approval of Funding Recommendation (Phase 2, Extension, and Continuity of Services)
<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.<br/><br/>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/>SCHEDULE A (Phase 2 Decision)<br/><br/>Rwanda, HSS – Round 4<br/>Grant Number(s): RWN-505-G05-S<br/>CCM Requested Amount (Total Phase 2 in US$) 19,622,213<br/>Approved Funding Amount (Incremental in US$) 19,622,213<br/>Recommendation Category: Go2. <br/><br/>South Africa, HIV/TB – Round 2<br/>Grant Number(s): SAF-202-G05-C-00<br/>CCM Requested Amount (Total Phase 2 in US$) 17,563,541(1)<br/>Approved Funding Amount (Incremental in US$) 15,986,220<br/>Recommendation Category: Conditional Go3. <br/><br/>Swaziland, HIV – Round 4<br/>Grant Number(s): SWZ-405-G04-H<br/>CCM Requested Amount (Total Phase 2 in US$) 34,273,541(1)<br/>Approved Funding Amount (Incremental in US$) 29,442,921<br/>Recommendation Category: <br/>Conditional Go<br/><br/></li><li>The Board approves Exceptional Extension Funding for the proposal listed in Schedule B in the amount and period indicated for the proposal, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount.<br/><br/>SCHEDULE B (Exceptional Extension Funding Decision)<br/><br/>Burundi, Malaria – Round 2<br/>Grant Number(s): BRN-202-G05-M<br/>Duration of Funding: 5 months<br/>CCM Requested Amount (in US$) 3,492,712<br/>Approved Funding Amount (Incremental in US$) 1,267,367<br/><br/></li><li>The Board approves the use of undisbursed grant funds under grant number TMP-304-G02-T to finance the continuity of services listed in Schedule C and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on an understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.<br/><br/>SCHEDULE C (Continuity of Services Decision)<br/><br/>Timor Leste, TB – Round 3<br/>Grant Number(s): TMP-304-G02-T<br/>CCM Requested Amount (in US$) 36,560<br/>Approved Funding Amount (Incremental in US$) 0</li></ol>
2007-11-13 B16 GF/B16/DP23 Development of the Global Fund Assurance Framework and Development of a Risk Management Framework. Development of the Global Fund Assurance Framework and Development of a Risk Management Framework.
<p>The Board thanks the Inspector General ad interim for his work on the development of the Global Fund Assurance Framework, and requests the incoming Inspector General to further develop the Assurance Framework for approval at the Seventeenth Board Meeting.</p><p>The Board requests the Secretariat to develop a Risk Management Framework in collaboration with the incoming Inspector General for review by the FAC in March 2008 (subject to the priorities to be established). </p><p>The Board requests the incoming Inspector General to develop a list of priorities for consideration by the Finance and Audit Committee for inclusion in the 2008 work plan of the Office of the Inspector General that will be presented to the Seventeenth Board Meeting. </p>
2012-12-06 B28 GF/B28/EDP05 Decision on November 2012 Grant Renewals Funding Recommendations Decision on November 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 339,631,976 for the following grants: IDA-910-H ; IDA-910-G21-H ; IDA-910-G24-H ; IDA-405-G05-H ; IDA-405-G06-H ; IND-910-G15-H ; IND-H-NAC ; IND-H-MOH ; IND-809-G09-H ; LSO-810-G08-T</p>
2012-11-15 B28 GF/B28/DP05 Evolving the Funding Model (Part Three) Evolving the Funding Model (Part Three)
<p>Referring to its previous decision Evolving the Funding Model (GF/B27/DP7) and GF/B28/DP4, the Board decides to launch the transition to the new funding model immediately by taking the following steps:</p> <ol> <li><u>Transition to the Full Implementation of the New Funding Model</u>: The Board decides to invest a portion of currently available uncommitted assets, to be determined by the Finance and Operational Performance Committee (FOPC) before the end of 2012, in a transition phase to test elements of the new funding model.<br /> </li> <li><u>Participation</u>:<a id="_ftnref1" name="_ftnref1" href="#_ftn1"><sup>1</sup></a> The Secretariat would invite countries to participate in the Transition Phase, considering those that are:<br /><br /> <ol type="a"> <li>Significantly "underfunded" over the 2013-2014 period;<br /><br /></li> <li>At risk of service interruptions;<br /> </li> <li>Positioned to achieve rapid impact; and<br /><br /></li> <li>Diverse in areas including, but not limited to size, geography, capacity and proposal modalities (including non-CCM and regional applicants), such that lessons learned can be derived from all aspects of the funding model, including funding for underserved and most-at-risk populations (MARPs).<a id="_ftnref2" name="_ftnref2" href="#_ftn2" target="_self"><sup>2<br /><br /></sup></a>The Secretariat will report quarterly to the Strategy, Investment and Impact Committee (SIIC) on the identity of countries participating in the Transition Phase. Countries, including those not invited to participate in the Transition Phase, are nonetheless encouraged to work on developing strong national strategies, reflecting full expressions of demand, and beginning Country Dialogues and iterative processes to encourage Concept Notes to be ready to allow for funding, based on the replenishment, to begin in early 2014.<br /> </li> </ol> </li> <li><u>Disease Split</u>: As previously agreed by the Board (GF/B27/DP7), to apportion resources to the Country Bands for this transition period, the Board will first split the total projected resources between the three diseases based on the historical distribution of the Global Fund's portfolio: 52% for HIV, 32% for malaria, and 16% for tuberculosis.<br /> </li> <li><u>Allocating Funding to Eligible Countries in the Transition Phase</u>: The Secretariat will determine an indicative funding range for each participating country based on the principles approved by the Board for indicative funding ranges in GF/B28/DP4 as adjusted by qualitative criteria<a id="_ftnref3" name="_ftnref3" href="#_ftn3"></a> and informed by the extent to which each country is "underfunded". The SIIC will assess the indicators used in the allocation formula prior to the commencement of the Transition Phase.<br /><br /></li> <li><u>Channeling Funding During the Transition Phase</u>: The primary vehicle for investing the additional funding during the transition phase will be existing grants. <br /> </li> <li><u>Use of Concept Note and Incentive Funding in the Transition Phase</u>: A subset of participating countries will receive an invitation to participate in the Concept Note process outlined in GF/B27/DP7, and as such will have an opportunity to access incentive funding in addition to the indicative range amounts per country. The incentive funding available to these countries will be limited to a ceiling established by the Secretariat at the time the transition is launched. <br /><br /></li> <li><u>Strategic Investment Frameworks, Minimum Standards and Investment Guidance</u>: The guidance package the Secretariat will make available to Country Coordinating Mechanisms (CCMs) in the transition phase will include Strategic Investment Frameworks and Minimum Standards. <br /> </li> <li><u>Independent Technical Review of Funding Requests</u>: To optimize learning, during this transition, the Secretariat and the Technical Review Panel (TRP) will jointly identify entry points for the TRP to review and provide feedback and recommendations on funding requests. As part of the transition to the full implementation of the new funding model, the composition and modalities of the TRP may change from current practice during the transition phase.<br /><br /></li> <li><u>Board Approval of Investments during the Transition Phase</u>: During the transition phase, the Board will approve electronically the investments negotiated by the Secretariat and recommended by the TRP, on the basis of the Board's "no-objection" process for approving funding decisions for renewals and continuations of existing grants.<br /><br /></li> <li><u>Existing Policies and Procedures</u>: The Board authorizes the Secretariat, under the oversight of the FOPC and SIIC, to make temporary exceptions to, or apply restrictions contained in, existing policies and procedures to the extent necessary to implement the transition phase of the new funding model. <br /><br /></li> <li><u>Assessing the Effectiveness of the Transition:</u> The SIIC will have responsibility for assessing the effectiveness of the Transition, based on a monitoring and evaluation plan presented by the Secretariat, in consultation with the Technical Evaluation Reference Group. The SIIC will report to the Board regarding the effectiveness and lessons learned from the Transition.</li> </ol> <div style="text-align: center;">***</div> <p><u>Notes:</u></p> <p><a id="_ftn1" name="_ftn1" href="#_ftnref1"></a>1) Participation in the transition phase will not preclude access to new financing when the new funding model is implemented in full.</p> <p><a id="_ftn2" name="_ftn2" href="#_ftnref2"></a>2) For the purposes of the transition to the new funding model, "MARPs" will be defined as subpopulations, applying to HIV/AIDS, malaria and tuberculosis, within a defined and recognized epidemiological context:</p> <p>2.1) That have significantly higher levels of risk, mortality and/or morbidity;</p> <p>2.2) Whose access to or uptake of relevant services is significantly lower than the rest of the population; and</p> <p>2.3) Who are culturally and/or politically disenfranchised and therefore face barriers to gaining access to services.</p> <p>2.4) The qualitative criteria will include external financing, "willingness to pay", absorptive capacity, performance of current and previous Global Fund grants and risk.</p>
2012-12-14 B28 GF/B28/EDP07 Decision on additional funding for the Madagascar Round 9 Malaria grants (MDG-910-G16-M; MDG-910-G17-M; MDG-910-G18-M; MDG-910-G19-M) Decision on additional funding for the Madagascar Round 9 Malaria grants (MDG-910-G16-M; MDG-910-G17-M; MDG-910-G18-M; MDG-910-G19-M)
<p>The Board:</p> <p>Approves additional funding for the Phase 2 period of the Madagascar Round 9 Malaria grants (MDG-910-G16-M; MDG-910-G17-M; MDG-910-G18-M; MDG-910-G19-M) in the amount listed in Table 2 subject to TRP clarifications and conditions within a limited timeframe, and any additional conditions to be cleared by the Secretariat. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</p> <p>See attached tabledetailing total recommended funding amount of USD 61,957,049 for the following grants: MDG-910-G16-M ; MDG-910-G17-M ; MDG-910-G18-M ; MDG-910-G19-M</p>
2013-06-14 B28 GF/B28/EDP24 Decision on the Secretariat’s Funding Recommendations for Early Applicants Decision on the Secretariat’s Funding Recommendations for Early Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the early-applicant grants in Table 1 (the “Total Incremental Funding Recommendation”). The Total Incremental Funding Recommendation increases the upper-ceiling amount available for commitment for the relevant implementation period and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of USD 622,110,305 for the following grants: Myanmar/HIV/AIDS ; Myanmar/Tuberculosis ; Myanmar/Malaria ; El Salvador/HIV/AIDS ; Zimbabwe/HIV/AIDS</p>
2012-03-14 B25 GF/B25/EDP15 Extension of Grant Signing Deadline for Niger Round 10 - Tuberculosis Proposal Extension of Grant Signing Deadline for Niger Round 10 - Tuberculosis Proposal
The Board decides to extend the deadline for the signing of the Niger Round 10 Tuberculosis Proposal until such time as the Secretariat has established appropriate safeguards and implementation arrangements for the related grants. The Secretariat will report back to the Board or its relevant Committee when the grant is signed.
2011-12-19 B25 GF/B25/EDP04 Extension of timeline for a completion of condition for the Malawi Round 7 Malaria (MLW-708-G05-M) grant. Extension of timeline for a completion of condition for the Malawi Round 7 Malaria (MLW-708-G05-M) grant.
<p>The Board decides to extend the timeline for the completion of the condition requiring the Principal Recipient to deliver a detailed and costed Action Plan to address and improve the diagnosis of suspected malaria cases and reduce the current trends in over prescription of ACTs <span style="font-size: 12px; line-height: 1.5;">at health facility level from 21 October 2011 to 21 January 2012.</span></p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses <span style="font-size: 12px; line-height: 1.5;">Budget.</span></p>
2011-11-22 B25 GF/B25/DP14 Appointment of Committee Leadership Appointment of Committee Leadership
<ol><li>The Board approves the appointment of Todd Summers and Shaun Mellors respectively as Chair and Vice-Chair of the Strategy, Investment and Impact Committee to serve two-year terms, or until the appointment of their respective successors;<br/><br/></li><li>The Board approves the appointment of Viorel Soltan and John Monahan respectively as Chair and Vice-Chair of the Finance and Operational Performance Committee to serve two-year terms, or until the appointment of their respective successors; and<br/><br/></li><li>The Board approves the appointment of Brian Brink, Claude Rubinowicz and Karlo Boras to serve as members of the Audit and Ethics Committee, occupying those Committee seats reserved for Board constituencies, and Brian Brink as Vice-Chair of the Audit and Ethics Committee to serve two-year terms, or until the appointment of their respective successors. The remaining four seats on the Audit and Ethics Committee reserved for independent members, including that of the Committee Chair, shall be filled by the Board in due course based on the nominations received from the Coordinating Group.</li></ol>
2011-11-22 B25 GF/B25/DP12 Approval of Voluntary Dispute Resolution Process Approval of Voluntary Dispute Resolution Process
The Board approves the adoption of a Voluntary Dispute Resolution Process as described in GF/FAC17/23 to provide Principal Recipients of Grant funds with a non-binding alternative to arbitration to resolve disputes related to OIG final audit or inspection reports.
2011-12-19 B25 GF/B25/EDP03 Approval of an exception to the standard methodology under the Continuity of Services Policy for quantification of eligible patients for the Mauritania Round 5 HIV Grant (MRT-506-G03-H) grant. Approval of an exception to the standard methodology under the Continuity of Services Policy for quantification of eligible patients for the Mauritania Round 5 HIV Grant (MRT-506-G03-H) grant.
<p>The Board notes the decision of the Phase 2 Panel to provisionally approve funding of a ceiling amount of USD 3,547,057 for two years for Continuity of Services for the Mauritania Round 5 HIV (MRT-506-G03-H) grant. The Board further notes that while incremental funding is not required due to sufficient funds within the expired grant, the Phase 2 Panel has approved Continuity of Services subject to approval by the Board of an exception to the standard methodology under the Continuity of Services Policy for quantification of eligible patients. Based upon the information presented by the Secretariat, the Board approves the proposed exception so as to permit financing for continuation of life-saving treatment for the <span style="font-size: 12px; line-height: 1.5;">1,631 patients receiving treatment as of the Ending Date of the Grant.</span></p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-11-22 B25 GF/B25/DP05 The Global Fund Strategy 2012-2016 The Global Fund Strategy 2012-2016
<p>The Board refers to its decision on the Global Fund Strategy 2012-2016 Framework (GF/B23/DP14) and:</p> <ol> <li>Approves the Global Fund Strategy Framework 2012-2016 (GF/B25/7/a) (the "Strategy Framework"), endorses in principle the Strategic Actions articulated in the Global Fund Strategy 2012-2016 (GF/B25/7/b) (the "Strategy Document"), and affirms its vision of a more vibrant and engaged institution working more closely with countries to achieve impact;<br /><br /></li> <li>Requests the Secretariat to commence work to implement the strategy as set forth in the Strategy Framework and the Strategy Document; and<br /><br /></li> <li>Requests the Strategy, Investment and Impact Committee to:<br /><br />i. oversee the implementation of the strategy;<br /><br />ii. review and recommend as appropriate any related changes in policy or operations that require Board discussion or approval (or refer other changes as appropriate to the Coordinating Group for attention by other committees); and<br /><br />iii. provide the Board with a progress update on the implementation of the Strategic Actions at the Twenty-Seventh Board Meeting, and regularly thereafter.</li> </ol>
2011-11-22 B25 GF/B25/DP09 The Global Fund Evaluation Strategy 2012-2016 The Global Fund Evaluation Strategy 2012-2016
<p>The Board:</p> <ol> <li>Approves the Global Fund Evaluation Strategy 2012-2016 (as set out in Annex 1 to the Report of the Policy and Strategy Committee (GF/B25/12));<br /><br /></li> <li>Acknowledges that the Global Fund Evaluation Strategy 2012-2016 may require additional revisions in order to ensure consistency with the final Global Fund Strategy 2012-2016, as approved under GF/B25/DP5, and requests that the Secretariat, working together with the TERG, update the Global Fund Evaluation Strategy 2012-2016 as may be required;<br /><br /></li> <li>Requests the TERG to develop an annual implementation plan for the Global Fund Evaluation Strategy 2012-2016; and<br /><br /></li> <li>Requests the TERG, through the new Strategy, Investment and Impact Committee, to submit a revised Global Fund Evaluation Strategy 2012-2016 and the first annual implementation plan to the Twenty-Sixth Board Meeting for approval, and to submit subsequent annual implementation plans thereafter.</li> </ol>
2012-02-12 B25 GF/B25/EDP11 Discontinuation of Funding for the Gabon Round 8 HIV (GAB-809-G05-H) and the Multi-Country Africa RCC Malaria (MAF-202-G01-M-00) Discontinuation of Funding for the Gabon Round 8 HIV (GAB-809-G05-H) and the Multi-Country Africa RCC Malaria (MAF-202-G01-M-00)
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 8 Gabon HIV (GAB-809-G05-H) and the Multi-Country Africa RCC Malaria (MAF-202-G01-M-00) <span style="font-size: 12px; line-height: 1.5;">proposals.</span></p><p>See attached table.</p>
2012-01-26 B25 GF/B25/EDP22 Implementation of the 55% floor for funding for Low Income Countries Implementation of the 55% floor for funding for Low Income Countries
<p>Consistent with the Board’s November 2011 decision titled ‘Modification of Grant Renewals and Transition to New Funding’ (GF/B25/DP16) as it applies to grant renewals:</p> <ol> <li>While the Secretariat works on scenarios to model the impact of the 55% rule, and the most effective measures for implementation, grant renewal invitation letters issued to Country Coordinating Mechanisms will have ceilings of 90% for Low Income Countries and Low-Lower Middle Income Countries, and 75% for all other country income level categories;</li> <li>New ceilings will apply to all grant renewal invitation letters issued on or after 1 January 2012; and</li> <li>The letters will explain the reasons for these (in some cases) new ceilings, and will also mention that the ceilings may be adjusted later.</li> </ol>
2011-11-22 B25 GF/B25/DP04 Approval of Report of the Twenty-Fourth Board Meeting Approval of Report of the Twenty-Fourth Board Meeting
The report of the Twenty-Fourth Board Meeting (GF/B25/11) is approved.
2012-01-06 B25 GF/B25/EDP05 Committee Membership Committee Membership
<p>The Board:</p><ol><li>Expresses its gratitude to the out-going Committee Chairs and Vice-Chairs for their leadership and service to the Global Fund.<br/><br/></li><li>Notes the nominations presented by the Board Chair and Vice-Chair for membership of the Finance and Operational Performance Committee and the Strategy, Investment and Impact Committee, each identified through reference to the key competencies and responsibilities required for membership in such Committees.<br/><br/></li><li>Approves the appointment of the following individuals as representatives of their respective constituencies to the Finance and Operational Performance Committee to serve as Committee Members for two-year terms, or until the appointment of their respective successors:<br/><br/><ul><li>Pasqualino Procacci, Italy and Spain</li><li>Ann Lion, Private Sector</li><li>Tom Hunstad, Point Seven</li><li>Carlton Evans, United Kingdom and Australia</li><li>Jan Paehler, European Commission</li><li>Allan Ragi, Developing Country NGOs </li><li>Juliette Bynoe-Sutherland, Latin America and the Caribbean</li><li>Joseph Niangue, West and Central Africa</li><li>Bal Suvedi, South East Asia<br/><br/></li></ul></li><li>Approves the appointment of the following individuals as non-voting, ex-officio members of the Finance and Operational Performance Committee to serve for two-year terms, or until the appointment of their respective successors:<br/><br/><ul><li>Denis Broun, Partners</li><li>Veronique Bishop, World Bank<br/><br/></li></ul></li><li>Approves the appointment of the following individuals as representatives of their respective constituencies to the Strategy, Investment, and Impact Committee to serve as Committee Members for two-year terms, or until the appointment of their respective successors:<br/><br/><ul><li>David Stevenson, Germany (Canada, Switzerland)</li><li>Mireille Guigaz, France</li><li>Masaki Noke, Japan</li><li>Julia Martin, USA</li><li>Kieran Daly, Private Foundations</li><li>Joanne Carter, Developed Country NGOs</li><li>Lucy Cheshire, Communities</li><li>Narciso Matos, East and Southern Africa</li><li>Ren Minghui, Western Pacific Region</li><li>Maksut Kulzhanov, Eastern Europe and Central Asia<br/><br/></li></ul></li><li>Approves the appointment of the following individuals as non-voting, ex-officio members of the Strategy, Investment, and Impact Committee to serve for two-year terms, or until the appointment of their respective successors: <br/><br/><ul><li>Bernard Schwartlander, UNAIDS</li><li>Winnie Mpanju-Shumbusho, WHO<br/><br/></li></ul></li><li>Delegates to the Board Chair and Vice-Chair the authority to fill, in consultation with the Chair and Vice-Chair of the Finance and Operational Performance Committee, the current vacancy on that committee through appointment of a suitably qualified representative of the Eastern Mediterranean constituency, to serve as a Committee Member for the remaining period of the two year term for the currently vacant seat. </li></ol>
2011-11-22 B25 GF/B25/DP16 Modification of Grant Renewals and Transition to New Funding Modification of Grant Renewals and Transition to New Funding
<p>The Board:</p> <ol> <li>In light of current resource constraints, adopts the measures identified in Annex 1 in order to make available resources to provide for continuation of essential prevention, treatment and/or care services by current grantees.</li> <li>Agrees to establish a Transitional Funding Mechanism as described in Annex 2 in order to provide this continuation funding.</li> <li>Decides to convert Round 11 into a new funding opportunity consistent with the new Global Fund 2012-2016 Strategy, with a view towards funding proposals under the new model beginning in early 2014. Round 11 proposals that are updated as appropriate may form the basis for an application for the next funding opportunity.</li> <li>Directs the Secretariat to work with countries and partners to develop full expressions of demand for programs for the three diseases and related health systems and civil society strengthening investments that are consistent with the new strategic approach envisioned in the new Strategy with such information to be available for the Mid-Term Replenishment.</li> <li>Urgently requests donors to consider measures to increase and accelerate funding, and implementing country governments, especially those from middle-income countries, to increase funding for the three diseases and related health investments.</li> <li>Delegates to the Board Chair, in consultation with the Vice-Chair, authority to make or delegate any additional decisions necessary to implement the above. The Board Chair shall report to the Board on any such decisions taken.</li> </ol> <p>Annex 1: Financial Measures</p> <ol> <li>Effective 1 January 2012, a revised application and approval process for renewals will be employed to ensure strategic investments, as described in “Options for Modification of the Application, Renewal and Approval Processes for New and Existing Investments,” (GF/B25/8).</li> <li>Effective 1 January 2012, the following eligibility criteria for renewals applications will become effective: <ol type="a"> <li>Group of 20 (G-20) upper middle income countries with less than an extreme disease burden will no longer be eligible for renewals of grants; and</li> <li>The counterpart financing and focus of proposal requirements under the Policy on Eligibility, Counterpart Financing and Prioritization will apply.</li> </ol> </li> <li>Transitional measures as described in GF/B25/8 will be made available to countries impacted by the above changes to eligibility.</li> <li>The one-year Grace Period provision for changes in country income classification will be rescinded for both new proposals and grant renewals.</li> <li>The TRP will support the renewals process by providing independent technical expertise to the Secretariat panel making recommendations on grant renewals.</li> <li>The total funding approved for grant renewals for Low Income Countries will be no less than 55% of any annual funding window.</li> <li>Additional Commitments (as defined in the Comprehensive Funding Policy) longer than one year shall be committed in annual tranches for renewals of existing grants.</li> </ol> <p>Annex 2: Transitional Funding Mechanism</p> <p>Scope:</p> <ol> <li>Grantees may apply for up to two years of funding for continuation of essential prevention, treatment and/or care programs currently financed by the Global Fund that will otherwise face disruption between 1 January 2012 and 31 March 2014.</li> <li>The Secretariat, in consultation with partners and the TRP, will develop guidance on components of “essential prevention, treatment and/or care.”</li> <li>Applicants must show that there are no alternative sources of funding available to fund the activities proposed.</li> <li>The Policy on Eligibility, Counterpart Financing and Prioritization will apply.</li> <li>Applications will be due 31 March 2012.</li> <li>Second Wave NSA applications will also be subject to the criteria above.</li> <li>The Health Systems Funding Platform will be suspended until the new funding model is operational.</li> </ol> <p>Review and Approval Process</p> <ol> <li>The TRP will assess applications for the Transitional Funding Mechanism in accordance with the criteria in its Terms of Reference and will also determine whether applicants demonstrate a risk of “disruption of essential prevention, treatment and/or care” services and that the activities cannot be funded by alternative sources of funding.</li> <li>The Board or an appropriate committee, as determined by the Board Chair, will endorse the TRP‟s recommendations, and provide guidance on prioritization if demand exceeds supply.</li> <li>Applications will be approved on a rolling basis. Funds may be committed in staggered commitments so as to minimize disruption of activities.</li> </ol> <p>Implementation</p> <ol> <li>If programs face disruption before funds become available under the Transitional Funding Mechanism, the Secretariat (under the direction of the Board Chair) will develop a bridge funding mechanism to cover the disruption for the minimum amount and time necessary.</li> </ol>
2012-04-13 B25 GF/B25/EDP16 Decision on April 2012 Grant Renewals Funding Recommendations Decision on April 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period<sup>[1]</sup> for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by <span style="font-size: 12px; line-height: 1.5;">recipients under the grant.</span></li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 313,697,746 for the following grants: AFG-809-G09-M ; AFG-809-G10-M ; PRK-810-G01-M ; ZAR-810-G09-M ; MAL-809-G08-H ; ZIM-809-G11-H ; ZIM-809-G12-T </p>
2011-11-22 B25 GF/B25/DP07 Governance Reform Governance Reform
<p>The Board notes that:</p> <ul> <li>A. The Board Chair and Board Vice-Chair were requested by the Board to lead and oversee a governance reform initiative based on recommendations from the Comprehensive Reform Working Group at the Twenty-Third Board meeting. Drawing from an extensive consultation process, in September 2011 the Chair and Vice-Chair provided the Board with a summary of the emerging governance reform recommendations. These governance recommendations were further complemented by the release of the findings and recommendations of the High-Level Independent Review Panel.<br /><br /></li> <li>B. On the basis of these recommendations, a number of governance reform decisions were undertaken by the Board at its Twenty-Fourth meeting, including the replacement of the four standing committees with three new standing committees and establishment of a Coordinating Group comprised of Board and Committee chairs and vice-chairs.</li> </ul> <p>To further transform the governance of the Global Fund, the Board decides as follows:</p> <ol> <li>The Board approves the revised Bylaws of the Global Fund as set out in Attachment 1 to the paper titled "Governance Reforms‟, GF/B25/5 ("the Board Governance Paper"), which shall supersede the existing Bylaws of the Global Fund as last amended by the Board on 2 March 2011(GF/B22/EDP/10).<br /><br /></li> <li>The Board approves a Charter for each of the new standing Committees of the Board, namely:<br /><br />a. the Strategy, Investment and Impact Committee (as set out at Attachment 2 to the Board Governance Paper);<br /><br />b. the Finance and Operational Performance Committee (as set out at Attachment 3 to the Board Governance Paper); and<br /><br />c. the Audit and Ethics Committee (as set out at Attachment 4 to the Board Governance Paper).<br />These Charters shall supersede the standing committees‟ terms of reference as last amended at the Nineteenth Board Meeting (GF/B19/DP8) and ad hoc committees‟ terms of reference.<br /><br /></li> <li>The Board approves the Terms of Reference for the Coordinating Group as set out at Attachment 5 of the Board Governance Paper.<br /><br /></li> <li>The Board approves the Operating Procedures of the Board and Committees of the Global Fund (as set out at Attachment 6, Revision 1 of the Board Governance Paper), which shall supersede both the Board Operating Procedures as last amended on 2 March 2011 (GF/B22/EDP/10) and the Committee Rules and Procedures as last amended at the Twentieth Board Meeting.<br /><br /></li> <li>The Board authorizes the Secretariat to undertake any necessary consequential modifications to existing policies, processes and procedures in order to reflect the amendments to the governance materials of the Global Fund as set out in this decision point.<br /><br /></li> <li>The amendments to the governance materials of the Global Fund as set out in this decision point shall have immediate effect.</li> </ol> <p>The Board notes that this decision point concludes the first phase of the governance reform program initiated in May 2011.</p> <p>The Board requests the Board Chair and Board Vice-Chair to proceed to propose further governance reforms as appropriate and present findings and recommendations for decision at the first Board meeting of the 2012 calendar year.</p>
2011-12-19 B25 GF/B25/EDP02 December 2011 Phase 2 Funding Decision December 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$282,752,190 for the following grants: BLR-809-G03-H ; BRN-809-G07-H ; IND-809-G13-M ; IND-809-G14-M ; KAZ-809-G04-T ; NIC-809-G06-H ; PHL-202-G09-M ; PHL-202-G11-T ; SOM-809-G06-H ; ZIM-809-G14-S ; ZIM-809-G13-M</p>
2012-01-26 B25 GF/B25/EDP20 Application of G-20 rule to the Transitional Funding Mechanism Application of G-20 rule to the Transitional Funding Mechanism
<p>Consistent with the Board's November 2011 decision titled 'Modification of Grant Renewals and Transition to New Funding' (GF/B25/DP16) as it applies to grant renewals, Group of 20 Upper Middle Income Countries with less than an extreme disease burden will not be eligible for funding under the Transitional Funding Mechanism.</p>
2011-11-22 B25 GF/B25/DP03 Approval of Report of the Twenty-Third Board Meeting Approval of Report of the Twenty-Third Board Meeting
The report of the Twenty-Third Board Meeting (GF/B25/10) is approved.
2014-11-20 B32 GF/B32/DP05 Approving the Governance Plan for Impact Approving the Governance Plan for Impact
<ol> <li>The Board acknowledges the:</li> <ol type="a"> <li>Observations, options and survey results presented in the advisory report issued by the Office of the Inspector General (the “OIG”) on the effectiveness and efficiency of Global Fund governance, as set forth in GF-OIG-14-008 (the “OIG Advisory Report, Governance Review”);</li> <li>Analysis and recommendations presented in the Governance Plan for Impact prepared by the 2014 Ad-Hoc Working Group on Governance, as set forth in GF/B32/08 – Revision 2 (the “Governance Plan”); and</li> <li>Related discussions and deliberations during the Board Retreat held in Montreux, Switzerland on 16 – 18 November 2014.</li> </ol> <li>Accordingly, the Board notes the recommendations on governance function contained in the Governance Plan and approves:</li> <ol type="a"> <li>The finalization of an enhanced governance structure, to be presented at the November 2015 Board meeting, comprised of the Board, Coordinating Group and the following re-configured standing committees:</li> <ol type="i"> <li>Audit and Finance;</li> <li>Ethics and Governance; and</li> <li>Strategy and Operations.</li> </ol> <li>Measures to transition the current governance structure to the enhanced governance structure, by the beginning of April 2016, which consists of:</li> <ol type="i"> <li>Establishment of the Transitional Governance Committee, under the terms of reference set forth in Annex 2 to the Governance Plan;</li> <li>Modified responsibilities for the Coordinating Group, as reflected in its amended terms of reference, as set forth in Annex 4 to the Governance Plan; and</li> <li>Maintaining the current allocation of responsibilities among the three standing committees (i.e., Audit and Ethics, Finance and Operational Performance, Strategy, Investment and Impact) until the enhanced governance structure is in place.</li> </ol> <li>Amended terms of reference for the Chair and Vice-Chair of the Board, as set forth in Annex 5 to the Governance Plan, to reflect the allocation of their shared and individual responsibilities.</li> </ol> <li>With respect to cross-cutting activities, the Board approves the recommendations set forth in the Governance Plan regarding the following:</li> <ol type="a"> <li>The Model for managing cross-cutting activities, as depicted in Figure 5 of the Governance Plan;</li> <li>Responsibilities for risk management;</li> <li>Assessment of organizational performance; and</li> <li>Reaffirmation of the Partnership Forum with a refocused scope, as outlined in the proposed amendments to the By-laws set forth in Annex 6 to the Governance Plan.</li> </ol> <li>Furthermore, the Board approves the recommendations set forth in the Governance Plan for the following areas:</li> <ol type="a"> <li>Transparency of Board and committee votes, including revisions to the Operating Procedures of the Board and Committees set forth in Annex 7 to the Governance Plan;</li> <li>Institutional memory management;</li> <li>Elevating the implementer voice; and</li> <li>Lifecycle management practices as well as constituency management, which shall be overseen by the Transitional Governance Committee described in paragraph 2.b.i of this decision point.</li> </ol> <li>In relation to the topic of legal status, the Board decides, noting the unique legal status of the Global Fund, to utilize the transition measures to, and eventual implementation of, the enhanced governance structure outlined in the Governance Plan to facilitate the Board’s understanding and determination of the set of norms and standards the Global Fund strives to comply with in its governance and operations.</li> <li>The Board authorizes the Secretariat, in coordination with the Transitional Governance Committee, to amend, restate or develop the relevant governance documents to reflect the implications of this decision point. Such amended, restated or developed governance documents shall be presented to the Board for approval. In doing so, the Secretariat will also propose additional modifications to rules, procedures or structures established under this decision point, which may be required for its implementation, for further approval by the Board.</li> <li>This decision point and its related modifications to governance documents shall take immediate effect upon the date the Board approves this decision point.</li> </ol> <p>Finally, the Board notes this decision point marks the conclusion of the work and mandate of the 2014 Ad-Hoc Working Group on Governance, and extends its gratitude and appreciation to the 2014 Ad-Hoc Working Group on Governance, as well as the Office of the Inspector General, for their efforts to produce analysis, observations, options and recommendations to guide the Board in furthering the effectiveness and efficiency of governance matters.</p>
2011-12-06 B25 GF/B25/EDP01 November 2011 Phase 2 Funding Decision November 2011 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 475,214,596 for the following grants: CAF-708-G05-H ; DMR-202-G01-H ; MR-202-G04-H ; GMB-809-G05-H ; GMB-809-G06-H ; LSO-809-G06-H ; MLW-102-G01-H ; PNG-809-G04-M ; PNG-809-G05-M ; PNG-809-G06-M ; TP-809-G04-T ; TNZ-809-G11-M ; TNZ-809-G12-H ; TGO-809-G08-H ; TGO-809-G09-H ; UGD-708-G08-M ; UZB-809-G05-T ; PSE-809-G02-T</p>
2011-11-22 B25 GF/B25/DP06 Approval of the Consolidated Transformation Plan Approval of the Consolidated Transformation Plan
<ol> <li>To transform the Global Fund into a more efficient and effective organization, the Board approves the Consolidated Transformation Plan presented in the Board paper titled "Consolidated Transformation Plan" (GF/B25/4, Revision 1 and Attachment 1, Revision 1) to address and implement the recommendations of the High-Level Independent Panel (the "HLP") that were adopted at the Twenty-Fourth Board Meeting and to integrate the Plan for Comprehensive Reform which was endorsed at the Twenty-Third Board Meeting. The Consolidated Transformation Plan sets objectives, deliverables and timelines to transform through the following elements:<br /><br /> <ul> <li>a. Transforming Resource Allocation, Investment, Results Measurement and Evaluation;<br /><br /></li> <li>b. Transforming Risk Management;<br /><br /></li> <li>c. Transforming Grant Management including working with partners;<br /><br /></li> <li>d. Transforming Secretariat Organization, Management and Culture;<br /><br /></li> <li>e. Transforming Board Governance; and<br /><br /></li> <li>f. Transforming Resource Mobilization.<br /><br /></li> </ul> </li> <li>The Board requests the Secretariat, the OIG and the Board Chair and Vice Chair to proceed with implementation, and to provide a comprehensive progress update at the two regular Board meetings in the 2012 calendar year.<br /><br /></li> <li>A review to evaluate the success of the Consolidated Transformation Plan and identify any adjustments that may be required will be conducted after one year of full implementation. The results of this review shall be presented to the Board at its first regular meeting in the 2013 calendar year.<br /><br /></li> <li>The budgetary implications of the Consolidated Transformation Plan will be part of the 2012 Operating Expenses Budget. The Board requests the Secretariat to provide, by 31 January 2012, a detailed costing of the Consolidated Transformation Plan based on the estimated funds, based on the principles of cost neutrality, specifying from which de-prioritized activities the resources will come.</li> </ol>
2012-01-26 B25 GF/B25/EDP21 Application of NGO Rule to the Transitional Funding Mechanism Application of NGO Rule to the Transitional Funding Mechanism
<p>Notwithstanding the effect of Decision 1 (GF/B25/EDP20 applied post factum) above, paragraph 11 of the Global Fund's 'Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals' (GF/B23/14), which allows NGOs from Upper Middle Income Countries not listed on the OECD's DAC list of ODA recipients to apply for HIV/AIDS funding, shall remain applicable to the Transitional Funding Mechanism.</p>
2011-11-22 B25 GF/B25/DP13 The Global Fund Medium-Term Human Resources Strategy The Global Fund Medium-Term Human Resources Strategy
<p>The Board approves the Global Fund Medium-Term Human Resources Strategy as described in GF/FAC17/17.</p>
2011-05-12 B23 GF/B23/DP30 Outgoing Chair and Vice-Chair of the Board Outgoing Chair and Vice-Chair of the Board
<p>The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria expresses its deep appreciation to Dr. Tedros Adhanom Ghebreyesus for his leadership as Chair of the Board. He has served the Global Fund with a high degree of commitment and passion. During his tenure, Dr. Ghebreyesus has guided the Board to address significant challenges and to make important decisions for the future of the Global Fund. He has led with commitment and determination the development of a comprehensive reform agenda, which will lead to a more efficient and effective Global Fund.</p> <p>The Board also expresses its sincere gratitude to Dr. Ernest Loevinsohn who has served with distinction as Vice-Chair. He has been instrumental in managing difficult issues and has played a significant role in coordinating important initiatives spearheaded by the Board leadership.</p>
2011-06-11 B23 GF/B23/EDP02 Round 7 Haiti HIV grant (HTI-708-G06-HIV) Round 7 Haiti HIV grant (HTI-708-G06-HIV)
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 7 Haiti HIV grant (HTI-708-G06-HIV)</p><p><span style="font-size: 12px; line-height: 1.5;">See attached table</span></p>
2012-02-02 B25 GF/B25/EDP08 Authorization of the General Manager of the Global Fund Authorization of the General Manager of the Global Fund
<p>The Board:</p><ol><li>Acknowledges the decision of Board Leadership, acting on the request of the Board and pursuant to a consultative process, to select and appoint Gabriel Jaramillo to the temporary position of General Manager of the Global Fund for a one-year term beginning 1 February 2012.</li><li>Decides that the General Manager will throughout his term exercise all of the powers and <span style="font-size: 12px; line-height: 1.5;">functions of the Executive Director, including the power to execute agreements on behalf of </span><span style="font-size: 12px; line-height: 1.5;">the Global Fund. The General Manager will report to the Board in relation to all his </span><span style="font-size: 12px; line-height: 1.5;">functions and for the management of the Secretariat.</span></li><li>Requests Board Leadership to oversee the activities of the General Manager, undertake periodic assessments of his performance, and report accordingly to the Board.</li><li>Requests the Secretariat to undertake any administrative actions necessary to facilitate the formal engagement of Gabriel Jaramillo as General Manager.</li></ol>
2011-11-22 B25 GF/B25/DP10 Review of the Corporate Performance Framework Review of the Corporate Performance Framework
<p>The Board:</p> <ol> <li>Refers to the Policy and Strategy Committee's endorsement of the findings of the Independent Review of the Key Performance Indicator (KPI) Framework (GF/PSC16/07), and requests the Secretariat to revise the KPI Framework in light of that Independent Review, the High-Level Panel recommendations (approved under GF/B24/DP3), and the Global Fund Strategy 2012-2016 (as approved under GF/B25/DP5);<br /><br /></li> <li>Requests the Secretariat to submit the revised KPI Framework to the Board for a decision to approve any revisions; and<br /><br /></li> <li>Requests the Secretariat to allocate sufficient resources under the KPI Framework to allow appropriate reporting to Board Committees relating to the KPIs under their oversight function.</li> </ol>
2012-03-08 B25 GF/B25/EDP12 Transitional Funding Mechanism Arrangements for RUS-506-G05 Transitional Funding Mechanism Arrangements for RUS-506-G05
<ol> <li>The Board approves, on an exceptional basis, the following specific arrangements for the RUS-506-G05-H grant (“Grant”): <ol type="a"> <li>An application may be submitted for funding under the Bridge Funding Mechanism in the context of the Transitional Funding Mechanism (“BFM”), as well as to the Transitional Funding Mechanism (“TFM”);</li> <li>In assessing the TFM application, the relevant period for considering whether there has been a disruption of essential prevention, treatment and/or care programs financed by the Global Fund shall be 31 August 2011 to 31 March 2014 (inclusive); and</li> <li>In accordance with Decision Point GF/B25/DP16, the Secretariat shall provide appropriate BFM arrangements for the Grant up to 31 December 2012, when TFM funding is expected to come into effect.</li> </ol> </li> </ol>
2011-11-22 B25 GF/B25/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Fifth Board Meeting (GF/B25/1) is approved.
2011-11-22 B25 GF/B25/DP11 TRP Membership TRP Membership
<ol> <li>The Board refers to its decision on "TRP Recruitment 2010-2012" (B21/EDP/18) appointing the membership of the Technical Review Panel (TRP) Support Group, comprising the pool of experts from which TRP membership will be replenished in the event of TRP vacancies as they may arise. The Board also notes that each of the TRP Support Group members (as presented in Annex 1 of the Report B21/EDP/18) have been recommended by the Portfolio and Implementation Committee and the Executive Director of the Global Fund Secretariat. The Board authorizes the TRP Chair and TRP Vice-Chairs to appoint replacements for vacancies in the Permanent TRP and Alternate members from members of the TRP Support Group.<br /><br /></li> <li>The Board authorizes the TRP Chair and TRP Vice-Chairs to add members to the TRP as required for a given round of proposals. Such additional members shall be selected from Alternate Members, and where necessary due to member unavailability, from former TRP Members.<br /><br /></li> <li>When additional members are added to the TRP, the TRP leadership shall report such additions to the relevant Board Committee.<br /><br /></li> <li>The Terms of Reference of the TRP shall be amended accordingly.</li> </ol>
2011-11-22 B25 GF/B25/DP01 Appointment of Rapporteur Appointment of Rapporteur
Mr. Alvaro Bermejo from the Developed Country NGO constituency is designated as rapporteur for the Twenty-Fifth Board Meeting.
2012-04-13 B25 GF/B25/EDP17 Decision on additional funding for the Continuity of Services to the Albania Round 5 HIV program (ALB-506-G01-H). Decision on additional funding for the Continuity of Services to the Albania Round 5 HIV program (ALB-506-G01-H).
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s COS form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the Secretariat’s recommendations.</p><p>See attached tabledetailing total recommended funding amount of US$419,941 for the following grant: ALB-506-G01-H</p>
2012-02-12 B25 GF/B25/EDP10 Additional funding for the Continuity of Services to the South Sudan Round 4 grant ( SSD-405-G05-H) Additional funding for the Continuity of Services to the South Sudan Round 4 grant ( SSD-405-G05-H)
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s COS form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements <span style="font-size: 12px; line-height: 1.5;">for such proposal consistent with the recommendations set forth in the Secretariat’s COS form.</span></p><p>See attached tabledetailing total recommended funding amount of US$8,317,359 for the following grant: SSD-405-G05-H</p>
2011-11-22 B25 GF/B25/DP08 TERG Replenishment TERG Replenishment
<p>The Board decides to extend the terms of current TERG members Minister Dorothée Kinde Gazard, Prof. Wim Van Damme, Mr. Stein-Erik Kruse, Dr. Kumaraswami Vasanthapuram, and Dr. Lixia Wang until the completion of the recruitment and selection of new TERG members, as required under the TERG Terms of Reference (GF/B22/4, Annex 5).</p>
2011-11-22 B25 GF/B25/DP15 2012 Operating Expenses Budget 2012 Operating Expenses Budget
<ol><li>The Board approves a budget ceiling for the 2012 Operating Expenses Budget in the amount of US$ 369.9 million, as set out in Attachment 1 to the Report of the Finance and Audit Committee ("FAC") to the Twenty-Fifth Board Meeting (GF/B25/14), based on the exchange rate outlined in Attachment 1 of the Report of the FAC (GF/B25/14) and subject to the Secretariat providing a budget paper to be presented to the Finance and Operational Performance Committee and shared with the Board before the end of the calendar year 2011.<br/><br/></li><li>The Secretariat shall enter into a forward contract with a reputable bank and shall notify the Board of the budget amount at the exchange rate determined on the date of the signature of the forward contract in a paper submitted to the Board. The new amount shall thus be deemed to be the approved Operating Expenses Budget for 2012.<br/><br/></li><li>The use of any amount in the US$ 3.0 million contingency within the OIG budget for 2012 is conditional upon the advance approval of the Finance and Operational Performance Committee on the recommendation of the Audit and Ethics Committee.</li></ol>
2012-03-11 B25 GF/B25/EDP14 Discontinuation of Funding for the Guyana HSS grant (GYA-809-G05-S) Discontinuation of Funding for the Guyana HSS grant (GYA-809-G05-S)
<p>The Board declines approval of additional funding for the next implementation period for them Round 8 Guyana HSS (GYA-809-G05-S) grant.</p><p>See attached table.</p>
2012-03-11 B25 GF/B25/EDP13 March 2012 Grant Renewals Funding Decision March 2012 Grant Renewals Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period<sup>[1]</sup> for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 157,073, 590 for the following grants: BAN-M-NMCP ; BAN-M-BRAC ; TCD-810-G04-H ; TCD-810-G05-H ; TCD-810-G06-H ; ZAR-809-G10-H ; ZAR-810-G11-H ; ZAR-810-G12-H</p>
2012-02-12 B25 GF/B25/EDP09 February 2012 Phase 2 Funding Decision February 2012 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the <span style="font-size: 12px; line-height: 1.5;">amounts indicated for each proposal, with the clear understanding that the amounts </span><span style="font-size: 12px; line-height: 1.5;">approved are upper ceilings rather than final funding amounts, and based on an </span><span style="font-size: 12px; line-height: 1.5;">understanding that the Secretariat shall pursue on-going implementation arrangements for </span><span style="font-size: 12px; line-height: 1.5;">each proposal consistent with the recommendations set forth in its Grant Score </span><span style="font-size: 12px; line-height: 1.5;">Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification </span><span style="font-size: 12px; line-height: 1.5;">of Grant Renewals and Transition to New Funding (GF/B25/DP16).</span><sup style="font-family: inherit; font-style: inherit; font-weight: inherit;">[1]</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 1,654,675 for the following grant: KGZ-811-G09-M</p>
2012-01-20 B25 GF/B25/EDP07 Funding ceilings contained in November 2011 Phase 2 Funding decision for Zimbabwe grants ZIM-809-G14-S and ZIM-809-G13-M Funding ceilings contained in November 2011 Phase 2 Funding decision for Zimbabwe grants ZIM-809-G14-S and ZIM-809-G13-M
<p>Referring to its earlier decision on 19 December 2011 (B25/EDP/02), the Board:</p> <ol> <li>Notes that a transcription error was made in the reporting of the amounts requested and the Secretariat’s recommendation for incremental funding for the Phase 2 period for the Zimbabwe grants numbered ZIM-809-G14-S and ZIM-809-G13-M listed in decision point B25/EDP/02;</li> <li>Decides to amend its funding decision for the two Zimbabwe grants numbered ZIM-809-G14-S and ZIM-809-G13-M, by replacing the earlier approved amounts with the corrected funding amounts as set out in Table 1, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each of affected proposals shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$282,752,190 for the following grants: BLR-809-G03-H ; BRN-809-G07-H ; IND-809-G13-M ; IND-809-G14-M ; KAZ-809-G04-T ; NIC-809-G06-H ; PHL-202-G09-M ; PHL-202-G11-T ; SOM-809-G06-H ; ZIM-809-G14-S ; ZIM-809-G13-M</p>
2012-04-16 B25 GF/B25/EDP18 Appointment of Independent Members of the Audit and Ethics Committee Appointment of Independent Members of the Audit and Ethics Committee
<p>The Board notes that:</p> <ol> <li>In September 2011, the Board decided (GF/B24/DP3, entitled “High Level Independent Review Panel”) to form an Audit and Ethics Committee (“AEC”) comprised of seven members, four of whom would be independent of any constituency of the Board.<br /><br /></li> <li>In November 2011, the Board mandated the Coordinating Group (GF/B25/DP14, entitled “Appointment of Committee Leadership”) to provide nominations to the Board to fill the four independent member seats on the AEC, with one of those seats being for the Chair of the AEC.<br /><br /></li> <li>The Coordinating Group’s 27 March 2012 “Electronic Report” to the Board on the nominations process (GF/B25/ER11) recommended that the Board increase the number of independent AEC members from four persons to five in order to ensure that the AEC will have an appropriate level of expertise in its financial audit function, in addition to the three other necessary disciplines of forensic investigation, ethics, and legal and dispute resolution.</li> </ol> <p>The Board:</p> <ol> <li>Approves the increase in independent members of the AEC from four persons to five, to bring the full membership of the committee to eight.<br /><br /></li> <li>Amends the Charter of the Audit and Ethics Committee and the Board and Committee Operating Procedures in the manner set forth below with immediate effect:<br /><br /> <ol> <li>Amendments to the Charter of the Audit and Ethics Committee:<br /><br /> <ol> <li>the word “four” is deleted in each of paragraphs 3.i, 6 and 7, and is replaced with “five”; and<br /><br /></li> <li>a new paragraph is inserted immediately following paragraph 4, containing the following text: “In instances in which the Committee is unable to take a decision, the AEC Chair shall, in consultation with the AEC Vice-Chair, exercise an additional vote in order to resolve such impasse.”<br /><br /></li> </ol> </li> <li>Amendments to the Board and Committee Operating Procedures:<br /><br /> <ol> <li>Table 3.b of Annex 1 (“Expected Minimum Key Competencies and Responsibilities of Members of each of the Standing Committees of the Board”), is amended by striking out the whole of the text in bulleted item 1 in column three of that table (“Key Competencies of Audit and Ethics Committee Members”); and<br /><br /></li> <li>replacing it with the following text: “At least two voting members with financial audit experience, with professional accreditation in financial accounting (Committee Chair should be selected from amongst the independent members who hold professional accreditation in financial accounting)”.<br /><br /></li> <li>The word “four” is deleted in paragraph 44.1.3 and is replaced with “five.”<br /><br /></li> </ol> </li> </ol> </li> <li>Approves the appointment of the following individuals as independent members of the AEC to serve for two-year terms from the date of effect of this decision, or until the appointment of their respective successors:<br /><br /> <ol> <li>Graham Joscelyne (Financial audit competency) as member and Chair of the AEC</li> <li>Gabor Amon (Forensic investigation competency) as member of the AEC</li> <li>Veronica Charlesworth (Financial audit competency) as member of the AEC</li> <li>Wendy Harrison (Ethics competency) as member of the AEC</li> <li>Barry Metzger (Legal/dispute resolution competency) as member of the AEC<br /><br /></li> </ol> </li> <li>Acknowledges that the Finance and Operational Performance Committee will bring to the November 2012 Board meeting a comprehensive remuneration and honorarium strategy across the Global Fund’s governance and advisory entities, which will include a recommendation on the appropriate honorarium for independent members of the AEC having regard to their role and fiduciary obligations.<br /><br /></li> <li>Approves an honorarium for the period April to December 2012 of US$ 14,000 for the independent Chair of the AEC, and US$ 9,000 for other independent members of the AEC. The Board notes that the FOPC’s recommendations in November 2012 may include a recommendation to retroactively increase the honorarium of independent members of the AEC.<br /><br /></li> <li>Requests the Audit and Ethics Committee to provide recommendations into the Phase 2 Governance Reform process on revised “Criteria for Independent Members of the Audit and Ethics Committee” that takes into account lessons learned during the process of constituting the committee.</li> </ol>
2012-01-20 B25 GF/B25/EDP06 January 2012 Phase 2 Funding Decision January 2012 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p><span style="font-size: 12px; line-height: 1.5;">See attached tabledetailing total recommended funding amount of US$ 146,478,569 for the following grants: BRN-809-G08-H ; ZAR-809-G07-M ; ZAR-810-G08-M ; ECU-809-G04-M ; ECU-809-G05-M ; PER-809-G06-T ; PER-809-G07-T</span></p>
2012-04-26 B25 GF/B25/EDP19 Exception to the Quality Assurance Policy for Pharmaceutical Products for the Procurement of Ritonavir 100mg in Cuba Exception to the Quality Assurance Policy for Pharmaceutical Products for the Procurement of Ritonavir 100mg in Cuba
<p>The Board refers to the Quality Assurance Policy for Pharmaceutical Products (the “QA Policy”) (as last approved and amended in GF/B22/DP9), and the requirement set forth therein that Global Fund grant funds may only be used to purchase Finished Pharmaceutical Products which comply with the QA Policy.</p> <p>The Board grants an exception to the quality standards set forth in the QA Policy such that sufficient quantities of ritonavir 100mg may be procured under existing Global Fund grants in Cuba to avoid a treatment disruption.</p> <p>This exception is valid until a source of ritonavir 100mg that is compliant with the quality standards of the QA Policy is available for the Global Fund Cuba programs, and if such a source becomes available and a procurement of ritonavir 100mg can be made from that source in time to avoid a treatment disruption in Cuba, that procurement should be made and this exception should not be applied.</p> <p>The Secretariat shall take appropriate measures to minimize and address any quality risks associated with the procurement authorized by this decision, including:</p> <ol> <li>Requiring that, at a minimum, the manufacturing site of the ritonavir 100mg procured must, at the time of the procurement, be in compliance with Good Manufacturing Practices as verified by the WHO Prequalification Programme, a Stringent Drug Regulatory Authority, or a regulatory authority participating in the Pharmaceutical Inspection Cooperation Scheme; and</li> <li>Applying the notification/confirmation and systematic quality control testing as described in paragraphs 9 and 31 of the QA Policy to such procurement.</li> </ol>
2014-11-21 B32 GF/B32/DP11 Approval of the Risk Management Policy Approval of the Risk Management Policy
<ol> <li>The Board acknowledges multiple operational tools are utilized and updated by the Secretariat to execute the Global Fund's approach to risk management, as outlined in the Enterprise Risk Management Framework set forth in Annex 1 to GF/B32/13. </li> <li>Accordingly, based on the recommendation of the Finance and Operational Performance Committee, the Board approves the Risk Management Policy, as set forth in Annex 3 to GF/B32/13 (the "Policy").</li> <li>The Policy shall supersede the Risk Management Framework adopted by the Board in November 2009 at its Twentieth Meeting (GF/B20/DP15) and become effective as of the date of this decision. </li> </ol>
2007-04-27 B15 GF/B15/DP15 Market Dynamics and Voluntary Pooled Procurement Market Dynamics and Voluntary Pooled Procurement
<p>The Board refers to its decision at the Thirteenth Board Meeting (GF/B14/2, p.13) to approve, in principle, the recommendation that the Global Fund facilitate the provision of voluntary pooled procurement for recipients of grants, subject to the development and Board approval of a suitable feasibility and business plan. It also refers to its decision at the Fourteenth Board Meeting (GF/B14/DP15) that the Global Fund assumes a deliberate and strategic role in improving the impact of grants by influencing market dynamics.</p> <p>The Board adopts the Objective and Guiding Principles for the Global Fund's Market Dynamics Strategy, as set out in the Report of the Policy and Strategy Committee (GF/B15/6), as amended at the Fifteenth Board meeting.</p> <p>The Board decides to endorse the following strategic model ("the Model") for voluntary pooled procurement, as a first element of its strategy on market dynamics, and notes additional elements to this strategy may follow.</p> <ol> <li>The Secretariat shall rapidly strengthen its existing Price Reporting Mechanism ("PRM"), with the objective of enhancing the completeness and quality of self-reported data as an essential foundation of sound market dynamics and procurement practices. In particular, the Secretariat shall more strictly enforce compliance with the existing requirement that recipients report procurement information (including prices paid) for the relevant health products, and subject the data reported in the PRM to periodic audit by an external agent with appropriate qualifications.</li> <li>The Secretariat shall establish a pooled-purchasing service<sup>1</sup> (the "Pooled Service"). <ol type="i"> <li>The Pooled Service shall cover a set of target products and be operated by one or more global or regional procurement agent(s) (the "Procurement Agent") that the Secretariat shall select following a transparent, competitive tender process. The Secretariat shall direct the Procurement Agent to seek to award contracts for a given product to several suppliers, where possible and appropriate in view of considerations of market dynamics.</li> <li>Participants in the Pooled Service must agree to have the Global Fund Trustee make direct payment to the Procurement Agent for purchases. The Procurement Agent will input in the PRM all required information in relation to purchases made through the Pooled Service.</li> <li>Use of the Pooled Service shall be voluntary except for PRs that, in the determination of the Secretariat, have demonstrated inadequate capacity to procure effectively and efficiently, which the Secretariat, if appropriate, may in each case require to procure through the Pooled Service.</li> </ol> </li> <li>The Secretariat shall enter into contracts with global, regional or national providers of procurement capacity-building services and supply-chain-management assistance (the "Capacity-Building Providers"), which it shall select following transparent, competitive tender processes. These services shall be available, on a voluntary basis, to any PR using the Pooled Service. In addition, to further support the development of the national capacity to conduct procurement effectively and efficiently, the Secretariat shall make available the services provided by the Capacity-Building Providers to other relevant entities in those countries with Global Fund grants whose PR procures through the Pooled Service (at their own cost).</li> </ol> <p>Payment for services of the Procurement Agent pertaining to purchases made through the Pooled Service with funds provided by the Global Fund, and payment for services provided to PRs by the Capacity-Building Providers shall, if not otherwise covered by the relevant PRs, be made out of grant funds and not out of the Secretariat's operating budget.</p> <p>The Board delegates authority to the Secretariat to implement the Model, in conformity with the Guiding Principles for market dynamics, in a phased approach that shall initially cover a small number of target product categories, which the Secretariat shall select based on further, careful analysis, taking into account the Global Fund's comparative advantage and the work already done by different partners.</p> <p>The Board expects the Secretariat to refine the operational implementation of the Model based on lessons learned over time and other considerations, and to report back to the Policy and Strategy Committee on possible strategic refinements or revisions to the model (including the possible use of price ceilings and other incentives) that might prove helpful to better achieving the Objective in conformity with the Guiding Principles.</p> <p>The Board also requests the Secretariat to report on progress at the Sixteenth Board Meeting. Noting the limited progress to date on improving the PRM, the Board specifically requests the Secretariat to include in its report an analysis of the status of the current PRM (including rates of, and challenges to, compliance by PRs) and specific measures taken to improve compliance with reporting requirements and the data reliability of the PRM.</p>
2014-12-08 B32 GF/B32/EDP02 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER01.</li> </ul>
2015-02-13 B32 GF/B32/EDP10 Decision on the Secretariat’s Recommendation on a Grant Extension Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER07 - Revision 1.</li> </ul> <p>.Annex Table 2: Papua New Guinea (PNG-012-G09-H)</p>
2012-11-15 B28 GF/B28/DP07 Appointment of Executive Director Appointment of Executive Director
<p>The Board:</p> <ol> <li>Selects Mark Dybul to serve as the next Executive Director of the Global Fund for a four-year term beginning on or around 4 February 2013.<br /> </li> <li>Requests the Board Chair and Vice-Chair to facilitate the appointment of Mark Dybul to the position of Executive Director.</li> </ol>
2013-03-15 B28 GF/B28/EDP15 Decision on additional funding for the Rwanda SSF Tuberculosis grant (RWN-T-MOH). Decision on additional funding for the Rwanda SSF Tuberculosis grant (RWN-T-MOH).
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period of the Rwanda SSF Tuberculosis grant (RWN-T-MOH) in the amount listed in Table 2, subject to relevant clarifications and conditions imposed by TRP. Approval is granted based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for the Phase 2 period and that on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 22,054,804 for the following grant: RWN-T-MOH</p>
2013-06-14 B28 GF/B28/EDP27 Decision on additional funding for the Rwanda SSF HIV grant (RWN-HMOH) Decision on additional funding for the Rwanda SSF HIV grant (RWN-HMOH)
<p>The Board:</p> <p>Approves additional funding for the Phase 2 period of the Rwanda SSF HIV grant (RWN-H-MOH) in the amount listed in Table 4, subject to relevant clarifications and conditions stipulated by the TRP. The amount approved represents the upper ceiling rather than the final funding amount for the Phase 2 period and on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that continued funding for the grant shall be committed in annual tranches (GF/B25/DP16, para 7 of Annex 1).</p> <p>See attached tabledetailing total recommended funding amount of USD 150,684,607 for the following grant: RWN-H-MOH</p>
2012-11-15 B28 GF/B28/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Eighth Board Meeting (GF/B28/1) is approved.
2012-11-15 B28 GF/B28/DP01 Appointment of Rapporteur Appointment of Rapporteur
Jan Paehler from the European Commission constituency (Belgium, Finland, Portugal, Italy and Spain) is designated as Rapporteur for the Twenty-Eighth Board Meeting.
2012-12-13 B28 GF/B28/EDP02 Strategic Investment in Monitoring and Evaluation Strategic Investment in Monitoring and Evaluation
<p>The Board notes:</p><ol><li>the importance of strengthened national data systems to ensure effective program implementation; demonstrate impact; and guide the optimal use of limited resources;</li><li>the High-Level Independent Review Panel's recommendation to focus on outcomes rather than inputs and to improve in-country data quality; and</li><li>the concerns cited in the Five-Year Evaluation and by the Technical Review Panel regarding the need to strengthen in-country data systems and capacity.</li></ol><p>The Board approves a strategic investment of up to US$ 10 million of incremental Grant funds to strengthen national data systems to measure impact in 20 priority countries established by the Global Fund. The amount of the additional Grant funds committed to each country shall be determined on the basis of joint country and partner data quality assessments.</p>
2013-02-25 B28 GF/B28/EDP10 Reference not in use Reference not in use
<p>The EDP number (GF/B28/EDP10) is not in use.</p>
2013-04-26 B28 GF/B28/EDP18 Appointment to Replace Out-Going SIIC Member. Appointment to Replace Out-Going SIIC Member.
<p>The Board:</p> <ol> <li>Approves the appointment of the following individual to the SIIC, to replace one out-going member:<br />a. Koichi Aiboshi, representing Japan.</li> <li>Notes that Mr. Koichi Aiboshi shall serve on the SIIC until the end of his predecessor’s term.</li> </ol>
2015-01-16 B32 GF/B32/EDP06 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER06.</li> </ul> <p>Annex: Congo (Democratic Republic) (ZAR-911-G13-T, ZAR-911-G14-T, ZAR-H-SANRU, ZAR-H-CORDAID), Sudan (SUD-011-G16-M, SUD-011-G15-H), Tanzania (TNZ-809-G13-H)</p>
2013-03-15 B28 GF/B28/EDP13 2013 Inspector General Ad-Hoc Nominations Committee 2013 Inspector General Ad-Hoc Nominations Committee
<p>The Board:</p> <ol> <li>Establishes a seven member ad hoc nominations committee to assist the Board with its appointment of the next Inspector General (“IG AHNC”) according to the Terms of Reference set out at Annex 1 to this Decision Point with the following membership:<br /><br />• Gabor AMON<br />• Wendy HARRISON<br />• Aida KURTOVIC<br />• Galina MIKHLIN-OLIVER<br />• Jan PAEHLER<br />• Navin RUGHOONUNUN<br />• Timothy ZIEMER<br /><br /></li> <li>Requests the Audit and Ethics Committee, working in collaboration with Legal Counsel of the Global Fund, and the Interim Inspector General, to present for Board approval by not later than 5 March 2013:<br /><br />a. revised Terms of Reference for the role of Inspector General; and<br /><br />b. a revised Charter for the Office of the Inspector General.<br /><br /></li> <li>Requests the Audit and Ethics Committee to develop, and apply to candidates shortlisted by the AHNC, an appropriate conflict of interest assessment process to ensure that the Board will receive from the AHNC only the names of candidates who are without any conflict of interest for the role.<br /><br /></li> <li>Requests the AHNC to incorporate the AEC’s final recommendations into the AHNC’s decision making and present to the Board the AHNC’s recommendation on the strongest candidate(s) for the role of Inspector General, and the reasons for its recommendation, by 10 June 2013.</li> </ol>
2013-02-04 B28 GF/B28/EDP09 Decision on 3-month Extensions to Phase 1 for Ecuador Round 9 HIV and TB grants (ECU-910-G06-H, ECU-910-G07-H, ECU-910-G08-T, ECU-910-G09-T) Decision on 3-month Extensions to Phase 1 for Ecuador Round 9 HIV and TB grants (ECU-910-G06-H, ECU-910-G07-H, ECU-910-G08-T, ECU-910-G09-T)
<p>The Board:</p><ol><li>Approves additional 3-month extensions to Phase 1 ending dates for Ecuador Round 9 HIV and TB grants (ECU-910-G06-H, ECU-910-G08-T) following the “Resubmission Request” recommendation2. Additional funding is not provided for these grant extensions while the CCM submits a revised Request for Renewal.</li><li>Approves 3-month extensions to Phase 1 ending dates with funding for the grants listed in Table 2 in the amounts indicated for each grant, following the “Resubmission Request” recommendation. Additional Funding will be provided to the grants implemented by Civil Society Principal Recipients in order to prevent disruption of programmatic activities while the CCM submits a revised Request for Renewal.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 482,472 for the following grants: ECU-910-G07-H ; ECU-910-G09-T</p>
2012-11-30 B28 GF/B28/EDP01 Extensions for South Africa HIV/AIDS Grants Extensions for South Africa HIV/AIDS Grants
<p>The Board:</p><ol><li>Approves extension of the current implementation periods of SAF-910-G09-H, SAF-H-NACOSA, SAF-304-G04-H, and SAF-H-NDOH to 30 September 2013; and</li><li>Approves the commitment of up to USD 26,831,949 in additional funding from the indicative amounts of grant funds available, but not yet approved or committed, for the next implementation periods to fund extensions for SAF-910-G09-H, SAF-H-NACOSA and SAF-H-NDOH, as set forth in Table 1.</li></ol>
2013-06-14 B28 GF/B28/EDP28 Discontinuation of funding for the Congo malaria grants (COG-810-G03-M and COG-810-G04-M) Discontinuation of funding for the Congo malaria grants (COG-810-G03-M and COG-810-G04-M)
<p>The Board:</p><p>Declines approval of additional funding for the next implementation period for the Round 8 Congo malaria grants (COG-810-G03-M and COG-810-G04-M).</p><p><span style="font-size: 12px; line-height: 1.5;">See attached table.</span></p>
2013-05-03 B28 GF/B28/EDP20 Decision on the Secretariat’s Grant Renewals Funding Recommendations Decision on the Secretariat’s Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Notes the consolidation of Pakistan’s Round 8 (PKS-809-G09-T) and Round 9 (PKS-910-G11-T) tuberculosis grants (the “Constituent Grants”) into one Single Stream of Funding (“SSF”) grant with the National Tuberculosis Control Program as Principal Recipient and a total budget amount for the implementation period comprised of the sum of the Board-approved budgets of the Constituent Grants, as set forth in Table 2; and</li> <li>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the interim-applicant SSF grant in Table 2 (the “Additional Amount”), which will be in addition to the total budget amount of the Constituent Grants for the implementation period. The Additional Funding increases the upper-ceiling amount available for commitment rather than the final funding amount for the implementation period and is subject to the provision that continued funding for the SSF grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 8,000,000 for the following grant: PKS-T-NTP</p>
2012-11-15 B28 GF/B28/DP06 Integration of the Lessons from the Affordable Medicines Facility - malaria Integration of the Lessons from the Affordable Medicines Facility - malaria
<p>The Board refers to its decision (GF/B20/DP24) to review the findings of the Independent Evaluation of the Affordable Medicines Facility - malaria (AMFm) Phase 1 and make a recommendation on whether to "expand, accelerate, modify, terminate or suspend the AMFm business line" in pilot countries.</p> <p>The Board:</p> <ol> <li>notes the findings of the Independent Evaluation ("IE"), as detailed in the Strategy, Investment and Impact Committee ("SIIC") Report to the Board (GF/B28/04), on the effectiveness of the AMFm in the eight pilot programs and, in particular, notes the results regarding the "upstream" success parameters recommended in 2010 by the Technical Evaluation Reference Group ("TERG").<br /><br /></li> <li>recognizes that the successes of the AMFm are due to the co-payment system, consisting of price negotiations with manufacturers and direct co-payments from the Global Fund to manufacturers on behalf of approved first-line buyers, and the use of supporting interventions.<br /><br /> </li> <li>notes that the results of the IE and the TERG's interpretation of those findings indicate there is sufficient evidence to approve a modified approach to support countries in achieving the Roll Back Malaria targets of universal coverage of malaria treatment if coupled with efforts to improve access to diagnostic testing.<br /><br /></li> <li>recognizes the importance of ensuring access to affordable diagnostic testing and treatment for malaria and the role of the private sector in delivering this access.<br /><br /></li> <li>notes the role of the Global Fund in helping to ensure sustainable affordable pricing for health commodities through innovative strategies and initiatives, including through engagement of the private sector.<br /><br /></li> <li>thanks countries, partners, donors and manufacturers for their participation and support in AMFm.</li> </ol> <p>The Board decides to modify the existing AMFm business line by integrating the lessons learned from the operations and resourcing of Phase 1 of the AMFm into Global Fund grant management and financial processes by:</p> <ol> <li>requesting the Secretariat to establish and operationalize a co-payment system through which the Global Fund will make direct payments to manufacturers on behalf of in-country buyers and at negotiated prices for countries which request the use of approved grant funds for a private sector subsidy to achieve their malaria case management targets and utilize supporting interventions; and<br /><br /></li> <li>Acknowledging the need for an assessment by technical partners of the feasibility to include diagnostic testing into the co-payment system, which would inform the operationalization of the co-payment system.</li> </ol> <p><u>2013 Transition by AMFm Pilot Countries to Full Integration</u>:</p> <p>The Board:</p> <ol> <li>notes that the integration of a co-payment system into Global Fund grant management and financial processes will mean that, following a responsible Transition, co-payments for anti-malarial drugs will no longer be available through a separate funding mechanism hosted by the Global Fund.<br /><br /></li> <li>decides that, during the Transition in 2013 to operationalizing the integration of a co-payment system, the pilot countries will have a defined funding allocation to support private sector co-payments, subject to availability of dedicated resources for such payments, and that each country will determine the parameters, such as the use of demand levers, under which that funding is utilized.<br /><br /></li> <li>requests the Secretariat to report to the FOPC and SIIC prior to the end of 2012 on the outcome of resource mobilization efforts undertaken to finance the co-payments for the Transition.<br /><br /></li> <li>authorizes the Secretariat to deploy remaining resources from malaria grants in Phase 1 for supporting interventions, which is separate from co-payment funds.</li> </ol>
2012-11-15 B28 GF/B28/DP04 Evolving the Funding Model (Part Two) Evolving the Funding Model (Part Two)
<p>Building on its previous decision Evolving the Funding Model (GF/B27/DP7), the Board decides the following:</p> <ol> <li>Allocation Period: Every three years,aligned with the replenishment cycle, the Secretariat shall (i) identify the amount of resources available for allocation to the Country Bands, and (ii) update the country-specific information required to use the allocation formula described below.<br /><br /></li> <li>Implementation of Grants: While the allocation period will be aligned with the replenishment cycle, the planning and implementation of grants will be aligned with country planning cycles. The standard period of Global Fund financing for an applicant will be three years, subject to flexibility where deemed appropriate by the Secretariat<a id="_ftnref1" name="_ftnref1" href="#_ftn1"><sup>1</sup></a>.<br /><br /></li> <li>Establishment of Country Bands: The Board approves the following approach to determine the composition and structure of Country Bands (groups of countries) for the purposes of allocating resources:<br /><br /> <ol type="a"> <li><u>Principles for Determining Country Bands</u>: The Board approves the following principles for determining Country Bands to ensure focus is placed on countries with the highest disease burden and least ability to pay:<br /><br /> <ol type="i"> <li>Sufficient Critical Mass: Each Country Band should have a large enough number of countries and sufficient resources to enable flexibility within it;<br /><br /></li> <li>Logical Coherence within Each band: As the incentive funding introduces a need for comparison between applications, countries in each Country Band should be roughly comparable;<br /><br /></li> <li>Bands Should Not Be Disease-Specific: Each country should only be part of one Country Band; and<br /><br /></li> <li>Simplicity: The system of Country Bands should be easy to communicate and implement.<br /><br /></li> </ol> </li> <li><u>Composition Criteria for Country Bands</u>: Countries will be allotted to Country Bands based on a composite score generated based on a combination of a country's (i) Gross National Income (GNI) per capita and (ii) disease burden. The principles for these criteria are as follows:<br /><br /> <ol type="i"> <li>Transparency: The factors for "ability to pay" and disease burden should be objective and use widely accepted and available data;<br /><br /></li> <li>Proportionality: To adjust funding to population size, the disease-burden measure should take into account the scale of affected persons (in terms of absolute numbers, not percentages) by the three diseases in each country; and<br /><br /></li> <li>Comprehensiveness: To avoid putting a country in more than one Country Band, the burden metrics for each of the three diseases in a country should be aggregated into a composite disease-burden measure.<br /><br /></li> </ol> </li> <li><u>Number of Country Bands:</u> Based on these composition criteria, eligible countries<a id="_ftnref3" name="_ftnref3" href="#_ftn3"><sup>2</sup></a> will be placed in one of four Country Bands based on a combination of: (i) higher or lower disease burden; and (ii) higher or lower income (GNI per capita). One of these Country Bands, corresponding to higher income (GNI per capita) and lower disease burden, will include countries that should finance strategies, projects or plans targeted at most-at-risk populations (MARPs); however, countries in this band with generalized epidemics will not be restricted to MARPs related funding.<a id="_ftnref3" name="_ftnref3" href="#_ftn3" target="_self"><sup>3</sup></a>.<br /><br /></li> <li><u>Revising the Bands:</u> Prior to each allocation period, the Board may revisit the composition of the Bands, based on recommendations from the SIIC.<br /><br /></li> </ol> </li> <li>Allocation of Available Funding to Each Country Band: As outlined in GF/B27/DP7, the Board will undertake, on a regular basis, a strategic allocation of resources to Country Bands, and this will serve as the primary pool for funding grants. Such allocation will be based on a forecast of available resources approved by the Finance and Operational Performance Committee (FOPC). The Board approves the following approach to the allocation methodology and formula:<br /><br /> <ol type="a"> <li><u>Principles for Allocating Funding to Country Bands</u>: The Board agrees on the following principles for allocating funding to Country Bands:<br /><br /> <ol type="i"> <li>Strategic Focus: Focus funding on countries with the highest needs and least ability to pay;<br /><br /></li> <li>Simplicity: The methodology should be easy to communicate to implementers and other stakeholders;<br /><br /></li> <li>Transparency: The allocation methodology should use objective and widely accepted and available data;<br /><br /></li> <li>Global Reach:  The funding distribution should remain global;<br /><br /></li> <li>Comprehensive Scope:  Taking committed and uncommitted assets into account; and<br /><br /></li> <li>Flexibility: The output of the allocation formula is a guiding number, to be adjusted by pre-determined qualitative criteria.<br /><br /></li> </ol> </li> <li><u>Allocation Formula</u>: The formula for apportioning funding to Country Bands will be based on each country's "ability to pay" (measured by GNI per capita) and disease burden. The SIIC will assess the indicators used in the formula prior to each allocation period, and approve changes deemed appropriate. The specific construction of the formula shall follow the principles below:<br /><br /> <ol type="i"> <li>Proportionality:  The disease split implied by the allocation formula at the country should be based on each country's share of global disease burden and its ability to pay, applied to each of the three diseases;<br /><br /></li> <li>Flexibility: The system should feature flexibility in how to apportion funding between the three diseases and health and community systems strengthening (HCSS) at the country level;<br /><br /></li> <li>Sensitivity: Qualitative factors will adjust the initial figures derived from the allocation formula to account for the specific circumstances in each country the allocation formula might not capture; and<br /><br /></li> <li>Calibrated Eligibility: Not all countries are eligible for all three diseases, as reflected in current Global Fund policy.<br /><br /></li> </ol> </li> <li><u>Disease Split</u>: As previously agreed by the Board (GF/B27/DP7), to apportion resources to the Country Bands at the start of each allocation period, the Board will first split the total projected resources for a given allocation period between the three diseases. As the Board previously agreed (GF/B27/DP7), the Secretariat will under the oversight of the SIIC develop a measure that can be used to estimate disease burden and financial demand across all three diseases for approval by the Board no later than September 2013.<br /><br /></li> <li><u>Apportionment to Country Bands</u>: After making the global disease split described in GF/B27/DP7, the Board will then apportion to each Band a share of the total funding available for the chosen period. These shares will be calculated by adding up the shares produced by the allocation formula for all of the countries in each Band, adjusted for major sources of external financing and, if necessary, a transitional provision to ensure the Global Fund's financial commitments in some countries do not fall below a minimum required level<a id="_ftnref4" name="_ftnref4" href="#_ftn4"><sup>4</sup></a> over the allocation period. For countries in the band with lower disease burden and higher income, this aggregation of shares will be based on a separate methodology that is currently under development by the Secretariat which recognizes the particular needs of countries in this band including multi-country grants, regional grants, small island states and MARPs. The Secretariat will present this methodology to the SIIC for approval. Although countries' initial funding ranges will be dependent on the outcome of the Global Fund replenishment, countries will be encouraged to apply to the Global Fund for their full quality demand.<br /><br /></li> <li><u>New Resources:</u> Any resources that become available during an allocation period in addition to the initially allocated funding can be used by the Secretariat to (i) increase the amount of funding available in the Country Bands, (ii) fund "unfunded quality demand" (see paragraph 6), or (iii) propose to the SIIC to use some of these resources to fund special initiatives as described in GF/B27/DP7.<br /><br /></li> </ol> </li> <li>Indicative and Incentive Funding: As part of its allocation, the Board will divide the total amount of resources allocated to each Country Band into indicative and incentive funding: <br /><br /> <ol type="a"> <li><u>Purpose of</u><u>Indicative</u><u> Funding</u>: Indicative funding should ensure predictability for applicants, and should defend the Global Fund's aggregate investments in ways that go beyond the Continuity of Essential Services.<br /><br /></li> <li><u>Purpose of Incentive Funding</u>: As the Board previously agreed (GF/B27/DP7), a portion of funds will be used to establish a funding stream to incentivize high impact, well-performing programs and the submission of robust, ambitious requests based on national strategic plans or investment cases. The apportionment of funding to this stream will be substantial so as to ensure sufficient funds are available to motivate full expressions of quality demand<br /><br /></li> <li><u>Determining the Division Between Indicative and Incentive Funding</u>: The Board will decide the required resource levels to meet the applicants' prioritized needs through the indicative funding ranges for the allocation period, and apportion to the incentive funding the difference between prioritized needs and the amount of available assets identified at the time of the allocation. In this way, additional resources mobilized during the given replenishment period may be apportioned to incentive funding. Additional principles to guide the division between indicative and incentive funding, including a final definition of prioritized needs, will be approved by the Board at its Twenty-Ninth Meeting, based on recommendations of the SIIC.<br /><br /></li> <li><u>Access to Funding</u>: The access to funding process will be based on country dialogue and reviews where the Global Fund is part of joint country-led processes, including within the CCMs and with other relevant partners, and will result in the development of a Concept Note.<br /><br /> <ol type="i"> <li><u>Access to Indicative Funding</u>: The determination of indicative funding ranges will be supplemented by qualitative factors including, but not limited to, the following:<br /><br /> <ol> <li>Major sources of external financing;</li> <li>Minimum funding levels;</li> <li>Willingness to pay;</li> <li>Past program performance and absorptive capacity;</li> <li>Risk; and</li> <li>Increasing rates of new infections in lower prevalence countries.<br /><br /></li> </ol> </li> <li><u>Access to Incentive Funding</u>: The Secretariat will develop the process and methodology for awarding incentive funding. Prior to the full implementation of the new funding model, the Secretariat will present to the SIIC for approval this methodology, which shall conform to the following principles: <br /><br /> <ol> <li>Ambition: Additional funding should foster quality expressions of full demand to address the totality of the response to a disease;</li> <li>Strategic Focus:  Additional funding should reward robust National Strategies and investment cases, and well-performing programs with a potential for increased, quantifiable impact;</li> <li>Alignment: The processes for awarding additional funding should ensure that applicants can access funding aligned to national planning cycles, by avoiding unintended incentives to apply either early or late in an allocation period</li> <li>Sustainability:  Additional funding should leverage contributions from other sources, including domestic budgets</li> <li>Simplicity:  The processes for awarding additional funding must minimize complexity and transaction costs for implementers, and avoid disruptions to grant-making; and</li> <li>Co-investment or Willingness to Pay:  Additional funding should also leverage financing from Governments in implementing countries.<br /><br /></li> </ol> </li> </ol> </li> </ol> </li> <li>Managing Unfunded Quality Demand: Since quality demand by countries could exceed the level of resources available, the Secretariat will maintain a register of unfunded quality demand. The Global Fund will prioritize this demand for future funding should additional resources become available, as well as invite other donors to finance this demand directly:<br /><br /> <ol type="a"> <li><u>Prioritizing and Awarding Financing to Unfunded Quality Demand</u>: The Secretariat will determine how to prioritize and award financing to unfunded quality demand and will present this methodology to the SIIC, as appropriate, for approval prior to the full implementation of the new funding model. This methodology for prioritizing and awarding financing to unfunded quality demand shall conform to the same set of principles as set forth in paragraph 5.d.ii above.</li> </ol> </li> </ol> <div>***</div> <p><u>Notes:</u></p> <div> <div id="ftn1"> <p><u><a id="_ftn1" name="_ftn1" href="#_ftnref1"></a></u></p> <p>1) Justifications for variations from the three-year standard will be provided to the Board as part of the Secretariat's grant approval requests.</p> </div> <div id="ftn2"> <p><a id="_ftn2" name="_ftn2" href="#_ftnref2"></a>2) Country eligibility will follow existing criteria approved by the Board in the Policy and Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund (Twenty-Third Board Meeting Documents, attachment to GF/B23/14), GF/B25/DP16 and B25/ER/05.</p> </div> <div id="ftn3"> <p><a id="_ftn3" name="_ftn3" href="#_ftnref3"></a>3) It is anticipated that some countries will have MARPs-related epidemics for one disease, and not for others.</p> </div> <div id="ftn4"> <p><a id="_ftn4" name="_ftn4" href="#_ftnref4"></a>4) Based on a recommendation from the Secretariat, the FOPC and SIIC, as appropriate, will define this "minimum required level" before the first full allocation period under the new funding model.</p> </div> </div>
2013-03-15 B28 GF/B28/EDP13 Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee Member Appointments Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee Member Appointments
<p>The Board:</p> <ol> <li>Approves the appointment of the following individuals to the Finance and Operational Performance Committee, to replace two out-going members:<br /><br />a. Matthew Flomo, representing West and Central Africa; and<br /><br />b. Reinhard Tittel-Gronefeld, representing Germany.<br /><br /></li> <li>Approves the appointment of the following individual to the Strategy, Investment and Impact Committee, to replace one out-going member:<br /><br />a. Marat Turkeyev, representing Eastern Europe and Central Asia<br /><br /></li> <li>Notes that each of the members appointed by this decision shall serve until the end of their predecessor’s term.</li> </ol>
2013-05-03 B28 GF/B28/EDP19 Decision on the Secretariat’s Grant Renewals Funding Recommendations Decision on the Secretariat’s Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 319,497,728 for the following grants: COL-911-G04-H ; ETH-911-G11-S ; GNB-910-G11-T ; TNZ-M-MOFEA ; GHN-809-G08-M ; GHN-M-MOH ; UKR-911-G07-T ; MCP-911-G01-H</p>
2013-02-04 B28 GF/B28/EDP08 Decision on January 2013 Grant Renewals Funding Recommendations Decision on January 2013 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat in consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 187,471,224 for the following grants: VTN-S10-G09-H ; HTI-811-G07-M ; MLW-911-G08-M ; TGO-910-G10-M ; TGO-910-G11-M ; KEN-S11-G11-T ; KEN-S11-G12-T ; MON-S-MOH</p>
2014-11-20 B32 GF/B32/DP01 Appointment of Rapporteur Appointment of Rapporteur
Mr. Paul Schaper from the Private Sector constituency is designated as Rapporteur for the Thirty-Second Board Meeting.
2014-11-21 B32 GF/B32/DP09 Ethics and Integrity Initiative: First Stage Policy Proposals Ethics and Integrity Initiative: First Stage Policy Proposals
<ol> <li>The Board acknowledges the Audit and Ethics Committee’s recommendation of policy principles arising from the First Stage of the Ethics and Integrity Initiative, as set forth in GF/B32/18 – Revision 1.</li> <li>Accordingly, the Board approves:</li> <ol type="a"> <li>The Ethics and Integrity Framework contained in Annex A to GF/B32/18 – Revision 1; and</li> <li>The proposal for creation of a dedicated and independent ethics function led by an Ethics Officer, as described in Annex B to GF/B32/18 – Revision 1.</li> </ol> <li>The Board furthermore requests the Audit and Ethics Committee to develop the following for the Board’s approval at its Thirty-Third Meeting:</li> <ol type="a"> <li>A Terms of Reference, reporting line and resourcing for the Global Fund ethics function, developed in consultation with the Finance and Operational Performance Committee; and</li> <li>A Code of Ethical Conduct for Governance Officials, developed in consultation with all Board constituencies, and based on the Global Fund’s core ethical values and the principles contained in Annex C to GF/B32/18 – Revision 1.</li> </ol> </ol>
2014-11-21 B32 GF/B32/DP12 Applying Risk Differentiation Applying Risk Differentiation
<ol><li>Based on the recommendation of the Finance and Operational Performance Committee, the Board adopts the risk differentiation framework presented in paragraphs 34 through 37 of GF/B32/14. </li><li>The Board directs the Secretariat to operationalize this risk differentiation framework and report on its implementation at each Board Meeting. Furthermore, the Secretariat shall conduct annual reviews to update the risk differentiation framework as appropriate, and report to the Board once a year on the outcome of such reviews. </li></ol>
2015-02-09 B32 GF/B32/EDP07 Approval of the Report of the Thirty-Second Board Meeting Approval of the Report of the Thirty-Second Board Meeting
<p>The Board approves the Report of the Thirty-Second Board Meeting (GF/B32/29 - Revision 1).</p>
2015-03-28 B32 GF/B32/EDP15 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex to GF/B32/ER14 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>See Details: Annex including table of recommendation on Additional Funding from the 2014 Allocation- Afghanistan (HSS and Tuberculosis - AFG-T-UNDP, AFG-T-MOPH), Ghana (Malaria - GHN-M-MOH, GHN-M-AGAMal), Multi-country Africa - SADC (HIV/AIDS - QML-H-SADC), Pakistan (Malaria - PAK-M-SC, PAK-M-DOMC), Paraguay (HIV/AIDS - PRY-H-CIRD), South Sudan (Malaria - SSD-M-PSI), Sudan (Malaria - SUD-M-UNDP).</p>
2014-12-08 B32 GF/B32/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2015-02-13 B32 GF/B32/EDP09 Reference not in use Reference not in use
<p>The EDP number (GF/B32/EDP09) is not in use.</p>
2014-11-21 B32 GF/B32/DP13 Approval of the Amended and Restated Global Fund Policy for Restricted Financial Contributions Approval of the Amended and Restated Global Fund Policy for Restricted Financial Contributions
<ol> <li>Based on the recommendations of the Finance and Operational Performance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as set forth in Annex 1 to GF/B32/20 (the “Amended and Restated Policy”).</li> <li>The Amended and Restated Policy shall supersede the prior version of the Policy for Restricted Financial Contributions (GF/B15/DP29) and be effective as of 22 November 2014, and shall not alter the characterization of any sources of funds that have been factored into the 2014 allocation of resources.</li> </ol>
2015-02-27 B32 GF/B32/EDP11 Appointment of Member of the Finance and Operational Performance Committee Appointment of Member of the Finance and Operational Performance Committee
<p>The Board approves the appointment of Ms. Beatrijs Stikkers as a voting member of the Finance and Operational Performance Committee (the "FOPC") for a term that will expire on 1 May 2016, or until the appointment of her successor.</p>
2014-11-21 B32 GF/B32/DP07 Global Fund Financing of Hepatitis C Treatment Global Fund Financing of Hepatitis C Treatment
<ol> <li>The Board acknowledges the Strategy, Investment and Impact Committee’s (the “SIIC”) plan to develop recommendations for Board consideration at its March 2015 meeting on the Global Fund’s role in funding treatment of co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, and directs the Secretariat to engage and collaborate with partners to support the SIIC’s development of such recommendations.</li> <li>As an interim measure until there is an outcome to those deliberations, where there is a currently approved budget for Hepatitis C virus (“HCV”) treatment within an existing Global Fund grant, the Global Fund may continue to fund such treatment up to the approved budget amount, as set forth in GF/B32/22, and may otherwise permit continuation of Global Fund funded HCV treatment programs during this interim period with new grants in these countries up to previously approved budgeted levels.</li> <li>The Board encourages partners to finance broader and additional HCV treatment needs, including those identified within Global Fund grant programs.</li> <li>The Board acknowledges the close working relationship and collaboration among the Global Fund, UNITAID and other partners on market-shaping activities, including the expansion of access to HCV treatments.</li> </ol>
2014-11-20 B32 GF/B32/DP04 Communication on Status of Recoveries Communication on Status of Recoveries
<ol> <li>As outlined in GF/B23/DP24 and reiterated in GF/B23/DP28, the Board continues to work with a full commitment to transparency and to endeavor to uphold the independence of the Office of the Inspector General (the “OIG”) within the Global Fund. In order to further promote this independence, the Board decides to supersede GF/B23/DP28 in its entirety with this decision point (GF/B32/DP04).</li> <li>The Board recognizes the need to have clear, consistent and contextualized information regarding the status of recoveries related to non-compliant expenditures identified within grant programs financed by Global Fund resources.</li> <li>With respect to non-compliant expenditures identified from OIG audits and investigations, the Board requests the Global Fund Secretariat to prepare a Recoveries Report (the “Report”) for the periods ending 30 June and 31 December of each year. The Report will detail, among other items: <ol type="a"> <li>the amounts reported by the OIG as being non-compliant and/or as constituting financial loss;</li> <li>the amounts deemed recoverable by the Secretariat based on the OIG’s findings, including an explanation of the method and process employed for the determination of such amounts; and</li> <li>progress on outstanding recovery actions, including a description of the context within which recovery-related processes are being handled by the Secretariat and any lessons learned.</li> </ol> </li> <li>The Board requests the AEC to: <ol type="a"> <li>review the Report;</li> <li>engage with the Finance and Operational Performance Committee (the “FOPC”) on matters within the FOPC’s mandate that relate to the process of developing and updating the Report; and</li> <li>present any recommended amendments to this decision point to the Board for approval.</li> </ol> </li> <li>Following the review of the Report by the AEC, the Secretariat shall submit the Report to the Board.</li> <li>Furthermore, the Board directs the Secretariat to develop, for AEC approval, a methodology and format for future reporting within the Report, which describes measures taken with respect to recoverable amounts identified in the due course of grant management operations.</li> </ol> <p>The Board requests the OIG to report independently on the Secretariat’s progress on matters related to recoveries as part of the OIG’s Report to the Board or as otherwise determined by the AEC.</p>
2015-03-06 B32 GF/B32/EDP12 Terms of Reference of the Privileges and Immunities Advisory Group Terms of Reference of the Privileges and Immunities Advisory Group
<ol> <li>The Board notes its decision to establish a dedicated group of donor and implementer representatives to identify strategies and advocate for the acquisition of privileges and immunities for the Global Fund (GF/B32/DP06).</li> <li>Accordingly, the Board approves the terms of reference of the Privileges and Immunities Advisory Group as set forth in Annex 1 to GF/B32/ER12.</li> </ol>
2014-11-21 B32 GF/B32/DP08 Market Dynamics Oversight Market Dynamics Oversight
<ol> <li>Based on the joint recommendation of the Strategy, Investment and Impact Committee (the “SIIC”) and the Finance and Operational Performance Committee (the “FOPC”), as outlined in GF/B32/23, the Board:</li> <ol type="a"> <li>Affirms its commitment to optimizing the performance and impact of investments in health products and devices, through the review and updating of the Market Shaping Strategy (Annex 1 to GF/B23/09 - Revision 1) as well as oversight of its implementation and operationalization;</li> <li>Decides the Market Dynamics Advisory Group (the “MDAG”) will cease as of the date of this decision, and that no advisory body shall be created or utilized to support the Board and its Committees in their responsibilities over market-dynamics matters;</li> <li>Acknowledges the Secretariat’s responsibility to develop, update and implement strategic policies and initiatives on market-dynamics matters in collaboration with partners with relevant expertise;</li> <li>Decides that the overall responsibilities for oversight and monitoring of market-dynamics matters, which include strategic and operational components, shall rest with the FOPC and SIIC as follows: <ol type="i"> <li>The SIIC shall be responsible for guiding and overseeing the development and updating of strategic policies related to market-dynamics matters, such as the Market Shaping Strategy for recommendation to the Board by its November 2015 meeting; and</li> <li>The FOPC shall be responsible for oversight of the implementation of strategic policies, including the financial and operational aspects of related sourcing and procurement initiatives.</li> </ol> </li> </ol> <li>Accordingly, the Board approves the amendments and restatements of the following governance documents, which shall become effective as of the date of this decision: <ol type="a"> <li>Bylaws, as set forth in Annex 1 to GF/B32/23;</li> <li>Charter of the Finance and Operational Performance Committee, as set forth in Annex 2 to GF/B32/23; and</li> <li>Charter of the Strategy, Investment and Impact Committee, as set forth in Annex 3 to GF/B32/23.</li> </ol> </li> <li>The Board directs the FOPC and SIIC, in collaboration with the Secretariat, to develop procedures and mechanisms on reporting and engagement to facilitate the FOPC and SIIC in the discharge of their responsibilities, including establishment of methods for how the committees will communicate, as a whole and through focal points, and ways to enlist experts that can provide technical support when appropriate. Such procedures and mechanisms will be in place and communicated among the members of the FOPC and SIIC by the end of the 2014 calendar year.</li> </ol>
2014-12-18 B32 GF/B32/EDP03 Appointment of Inspector General Appointment of Inspector General
<ol> <li>The Board appoints Mr. Mouhamadou Diagne to serve as the next Inspector General of the Global Fund for a six-year term to begin not later than 30 June 2015.</li> <li>The Board authorizes the Global Fund to enter into a contract of employment with Mouhamadou Diagne for an annual salary that is above CHF 245,000 and does not exceed CHF 310,000, and requests the Board Chair to facilitate that process.</li> </ol>
2014-12-22 B32 GF/B32/EDP04 Membership of the Transitional Governance Committee Membership of the Transitional Governance Committee
<ol> <li>The Board notes its decision to establish the Transitional Governance Committee (GF/B32/DP05) under terms of reference set forth in Annex 1 to GF/B32/ER05 (the “Terms of Reference”) and acknowledges the recommendations on membership of the Transitional Governance Committee presented in GF/B32/ER05.</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve on the Transitional Governance Committee for a term that will expire upon the conclusion of the Transitional Governance Committee’s mandate, as outlined in the Terms of Reference: <ol type="a"> <li>Ton Coenen;</li> <li>Marina Hue;</li> <li>Jimmy Kolker;</li> <li>Jorge Saavedra;</li> <li>Viorel Soltan; and</li> <li>Carsten Staur.</li> </ol> </li> <li>The Board acknowledges that members of the Transitional Governance Committee shall serve in their independent, personal capacity. As such, membership on the Transitional Governance Committee shall not apply towards the rule that each Board constituency may participate in a maximum of two committees.</li> </ol>
2015-03-18 B32 GF/B32/EDP14 Decision on the Secretariat’s recommendation on grant extensions Decision on the Secretariat’s recommendation on grant extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B32/ER13.</li> </ol> <p>See Details: Annex including table of recommendation on grant extensions- Bolivia (BOL-809-G08-M), Kyrgyzstan (KGZ-S10-G08-T)).</p>
2014-11-20 B32 GF/B32/DP03 2015 Corporate Work Plan, Budget Narrative and Operating Expenses Budget 2015 Corporate Work Plan, Budget Narrative and Operating Expenses Budget
<ol> <li>Based on the recommendation of the Finance and Operational Performance Committee (the “FOPC”), the Board approves the following: <ol type="a"> <li>Corporate Work Plan and Budget Narrative 2015, as set forth in GF/B32/04; and</li> <li>2015 Operating Expenses Budget in the amount of USD 299.8 million, as set forth in GF/B32/03 (the “2015 OPEX Budget”), which includes USD 16.4 million for the Office of the Inspector General’s 2015 operating expenses based on the recommendation of the Audit and Ethics Committee.</li> </ol> </li> <li>As previously decided by the Board (GF/B22/DP18), the Secretariat will manage the 2015 OPEX Budget’s exposure to foreign-exchange rate volatility and include in its periodic reporting to the FOPC on budget matters any measures taken to minimize such exposure.</li> </ol>
2015-01-16 B32 GF/B32/EDP05 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bangladesh (BGD-M-BRAC, BGD-M-NMCP, BGD-T-BRAC, BGD-T-NTP), Cameroon (CMR-M-MOH), Nigeria (NGA-M-NMEP, NGA-M-SFH), Philippines (PHL-T-PBSP), Rwanda (RWA-M-MOH), Zimbabwe (ZWE-M-MOHCC, ZWE-TB-MOHCC)</p>
2014-11-21 B32 GF/B32/DP10 Approval of the Global Fund Corporate KPI Framework 2014-2016 Approval of the Global Fund Corporate KPI Framework 2014-2016
<ol> <li>The Board :</li> <ol type="a"> <li>Notes the Global Fund Corporate Key Performance Indicator Framework for 2014-2016 (the “KPI Framework”), which was approved in November 2013 (GF/B30/DP07), required additional methodological work during 2014 to finalize certain indicators; and</li> <li>Recognizes the work by the Secretariat to complete the methodology of the KPI Framework in consultation with the relevant committees of the Board.</li> </ol> <li>Accordingly, the Board approves the updated KPI Framework, currently available performance targets for 2015, and the plan to present the remaining 2015 performance targets for approval at the Thirty-Third Board Meeting, as set forth in GF/B32/24.a – Revision 2.</li> </ol>
2015-03-18 B32 GF/B32/EDP13 Decision on the Secretariat’s recommendations on additional funding from the 2014 Allocation Decision on the Secretariat’s recommendations on additional funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B32/ER13 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>See Details: Annex including table of recommendations on additional funding from the 2014 Allocation- Democratic People’s Republic of Korea (Malaria), Islamic Republic of Iran (HIV/AIDS), Republic of Honduras (Malaria), Republic of Moldova (Tuberculosis), Romania (Tuberculosis), Suriname (Malaria).</p>
2014-11-21 B32 GF/B32/DP06 Privileges and Immunities Privileges and Immunities
<ol> <li>The Board acknowledges: <ol type="a"> <li>The absence of privileges and immunities exposes the Global Fund’s resources, staff and mission to serious risks and challenges;</li> <li>The importance of States, particularly implementing country governments, to accord privileges and immunities to the Global Fund through either applying domestic legislation or executing the Board-endorsed multilateral Agreement on Privileges and Immunities; and</li> <li>The Secretariat’s efforts to require host-country grantees to take all appropriate and necessary actions to ensure the Global Fund is accorded privileges and immunities within three years from the effective date of a Framework Agreement signed between the Global Fund and host-country grantees.</li> </ol> </li> <li>To further ensure progress in protecting the Global Fund through privileges and immunities, the Board requests: <ol type="a"> <li>The Secretariat to dedicate required resources for the acquisition of privileges and immunities for the Global Fund;</li> <li>The Finance and Operational Performance Committee and the Audit and Ethics Committee to oversee jointly the acquisition of privileges and immunities for the Global Fund, and report to the Board on an annual basis on implementing and donor countries that have and have not provided such protection to the Global Fund; and</li> <li>The Board Leadership to constitute a dedicated group of donor and implementer representatives to identify strategies and advocate for the acquisition of privileges and immunities for the Global Fund.</li> </ol> </li> </ol>
2015-02-13 B32 GF/B32/EDP08 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER07 - Revision 1;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex Table 1: Guyana (GYA-304-G01-H), Papua New Guinea (PNG-M-PSI, PNG-M-RAM, PNG-T-WVI)</p>
2014-11-20 B32 GF/B32/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the Thirty-Second Board Meeting (GF/B32/01) is approved.</p>
2023-12-15 B50 GF/B50/EDP04 Reactivation of the Privileges and Immunities Advisory Group and Revisions to its Terms of Reference Reactivation of the Privileges and Immunities Advisory Group and Revisions to its Terms of Reference
<p>Based on the recommendation of the Ethics and Governance Committee (EGC), the Board:</p> <ol> <li>Approves the reactivation of the Privileges and Immunities Advisory Group (PIAG), as set out in Annex 1 to GF/B50/ER04.</li> <li>Approves the revisions to the PIAG’s terms of reference, as set out in Annex 1 to GF/B50/ER04.</li> <li>Delegates to the EGC the authority to select and appoint members to the PIAG, and to extend the term of the group or dissolve it after its initial 3-year term.</li> </ol>
2007-04-27 B15 GF/B15/DP31 Debt2Health Mechanism Debt2Health Mechanism
<p>1. The Board acknowledges the potential for additional resources for the Global Fund from debt conversions and authorizes the Secretariat to implement a two year pilot phase (2007-2009) of the Debt2Health mechanism in up to four beneficiary countries. </p><p>2. The Board authorizes the Secretariat for the purposes of the implementation of Debt2Health to accept restricted contributions from counterpart funds which are attributed at the country level. </p><p>3. The Board requests the Secretariat to implement and monitor the Debt2Health pilot phase and to report on the results and lessons learned to the Finance and Audit Committee on a regular basis. </p>
2007-04-27 B15 GF/B15/DP19 Board Decision-Making Procedure for the Rolling Continuation Channel Board Decision-Making Procedure for the Rolling Continuation Channel
<p>The Board has approved the establishment of a funding channel (the "Rolling Continuation Channel" or "RCC")<sup>1</sup> that provides an opportunity for Country Coordinating Mechanisms ("CCMs")<sup>2</sup> to apply for continued funding for high-performing grants that are reaching the end of their funding terms ("expiring grants") under conditions different from those available for proposals submitted as part of new rounds of financing ("rounds-based channel"). The Board approves the following procedure for the Board to make funding decisions for proposals submitted under the Rolling Continuation Channel that the Secretariat has qualified as eligible for the RCC.</p> <p>1. The Board will consider proposals for RCC funding not more than once every three months, unless the Secretariat determines it is necessary because of exceptional circumstances to present a recommendation to the Board more frequently.</p> <p>2. The Board will make funding decisions for proposals for RCC funding based on the recommendations of the Technical Review Panel ("TRP"), which will take into account performance data provided by the Secretariat. The TRP will make recommendations to the Board for funding of RCC proposals in accordance with the Terms of Reference of the TRP.</p> <p>3. The Secretariat will post the TRP's recommendations and supporting documents on the Global Fund website with password protection, will inform Board constituencies via e-mail when it has posted these recommendations, and will provide to them a voting form that will list the recommendations. Notice to Board constituencies of the vote on the TRP's recommendations will be effective upon the transmission of the voting form. For the purposes of Article 7.6 of the By-laws, all Board members will be deemed to be participating in the vote when such notice becomes effective.</p> <p>4. The Board will vote on the TRP recommendations on RCC funding by e-mail on a "no-objection" basis, in accordance with Section 12 of the Board Operating Procedures and Article 7.6 of the By-laws. Consistent with Board practice for funding decisions made under the rounds-based channel, the Board will consider the totality of the TRP's recommendations.</p> <p>5. However, if a Board member objects to an individual recommendation from the TRP, he or she will provide to the Secretariat a written explanation of the reasons for such objection. The Secretariat will then promptly make available such explanation to all other Board members and the TRP.</p> <p>6. For the purposes of Section 12 of the Board Operating Procedures, the time period within which the Secretariat must receive objections in order for them to be counted is ten (10) calendar days after notice of the vote is effective. </p> <p>7. If the Board approves the TRP recommendations, that decision will constitute an approval of the entire term of each RCC proposal recommended for funding by the TRP, with a financial commitment for the initial three (3) years of the RCC proposal, with funding for the second phase subject to the approval of the Board based on a mid-term performance review. </p> <p>8. If the Board decides not to approve a TRP recommendation, the decision-making process that applies following a Board objection to a TRP recommendation under the Phase-2 Decision-Making Policies and Procedures<sup>3</sup>, as amended from time to time<sup>4</sup>, will be followed.</p> <p>9. Funding recommendations with respect to RCC proposals that have successfully been appealed, in accordance with the Global Fund's Rules and Procedures for Appeals, will come before the Board for decision, in accordance with such Rules and Procedures for Appeals.</p>
2017-02-16 B36 GF/B36/EDP08 Appointment of a Member to the Ethics and Governance Committee Appointment of a Member to the Ethics and Governance Committee
<p>The Board approves the appointment of Ana Filipovska as a voting member of the Ethics and Governance Committee (the “EGC”) for a term that will expire in May 2018, or until the appointment of her successor.</p>
2016-11-16 B36 GF/B36/DP05 Sources and Uses of Funds for the 2017 – 2019 Allocation Period Sources and Uses of Funds for the 2017 – 2019 Allocation Period
<p>1. Based on the recommendation of the Audit and Finance Committee (the "AFC"), as<br />presented in GF/B36/03, the Board decides the amount of sources of funds for allocation<br />for the 2017 - 2019 allocation period is USD 11.1 billion and comprised of the following<br />amounts:<br /><br />a. USD 10.0 billion, derived from the announced replenishment results of the Fifth<br />Replenishment (2017 - 2019) net of certain adjustments and qualifying deductions, in<br />accordance with the Amended and Restated Comprehensive Funding Policy set forth<br />in Annex 1 to GF/B36/02 - Revision 1; and<br /><br />b. USD 1.1 billion, the forecasted unutilized funds from the 2014 - 2016 allocation period<br />presented by the AFC and the Strategy Committee (the "SC") for inclusion in the<br />sources of funds for allocation for the 2017 - 2019 allocation period following<br />deliberations at the committees' October 2016 meetings.<br /><br />2. Based on the recommendation of the SC, as presented in GF/B36/03, the Board approves<br />USD 0.8 billion for the 2017 - 2019 allocation period's catalytic investments.<br /><br />3. Accordingly, the Board decides the amount of sources of funds for country allocations for<br />the 2017 - 2019 allocation period is USD 10.3 billion, of which USD 0.8 billion is to ensure<br />scale up, impact and paced reductions according to the allocation methodology approved<br />by the Board in April 2016 under decision point GF/B35/DP10.</p>
2016-11-16 B36 GF/B36/DP08 Corporate Work Plan and Budget Narrative 2017 and the 2017 Operating Expenses Budget Corporate Work Plan and Budget Narrative 2017 and the 2017 Operating Expenses Budget
<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves<br />the following:<br /><br />a. Corporate Work Plan and Budget Narrative 2017, as set forth in GF/B36/05B; and<br /><br />b. 2017 Operating Expenses Budget in the amount of USD 300.0 million, as set forth<br />in GF/B36/05A, which includes USD 17.1 million for the Office of the Inspector<br />General's 2017 operating expenses.</p>
2016-12-19 B36 GF/B36/EDP03 Review of the Employee Grievance and Dispute Resolution System Review of the Employee Grievance and Dispute Resolution System
<p>1. The Board acknowledges the work carried out by the Secretariat to review the Global Fund's employee grievance and dispute resolution system, as well as the decisions reached by the Management Executive Committee (MEC) to strengthen internal components of this system (GF/B36/ER03).<br /><br />2. Regarding mechanisms for final resolution of employee grievances, the Board notes the review carried out by the Secretariat on the recognition of the jurisdiction of the International Labour Organization Administrative Tribunal (ILOAT), as compared with other available mechanisms.<br /><br />3. Noting the outcome of this review, and upon recommendation from the Audit and Finance Committee (AFC), the Board requests that the Secretariat continue its work in this area, specifically to (i) further explore available mechanisms for final resolution of employee disputes; and (ii) review the feasibility of implementing alternatives to the current system within the Global Fund's context. The Staff Council will be consulted as part of this exercise.<br /><br />4. Provided an alternative model is identified which is both feasible and considered by MEC to present advantages over the current ILOAT model, the Board requests that the Secretariat develop such an alternative model and present it to the AFC for review and decision at its October 2017 meeting. As part of its presentation to the AFC, the Secretariat will include an analysis of the projected costs of any proposed alternative model, as compared with the current ILOAT model.</p>
2016-11-16 B36 GF/B36/DP01 Appointment of Rapporteur Appointment of Rapporteur
Carsten Staur from the Point Seven constituency is designated as Rapporteur for the 36th Board Meeting.
2016-11-16 B36 GF/B36/DP06 Catalytic Investments for the 2017 – 2019 Allocation Period Catalytic Investments for the 2017 – 2019 Allocation Period
<p>1. The Board notes that up to USD 800 million is available for catalytic investments, subject<br />to the amount of sources of funds for allocation, in accordance with the allocation<br />methodology approved in April 2016 under decision point GF/B35/DP10 and set forth in<br />Annex 1 to GF/B35/05 - Revision 1.<br /><br />2. Based on the recommendation of the Strategy Committee (the "SC") and the amount of<br />sources of funds for allocation recommended by the Audit and Finance Committee (the<br />"AFC") in GF/B36/03, the Board decides USD 800 million will be available for catalytic<br />investments over the 2017 - 2019 allocation period for the priorities and associated costs<br />presented in Table 1 of GF/B36/04 - Revision 2, of which no portion will be moved to<br />further balance scale up, impact and paced reductions through country allocations.<br /><br />3. The Board notes the Secretariat will have flexibility to operationalize catalytic investments,<br />update the SC and Board on such operationalization, and present any reallocations of the<br />associated costs among the approved priorities for the SC's approval.<br /><br />4. The Board asks the Secretariat to provide the SC with a scope of effort and expected<br />outcomes at the start of all strategic initiatives and to seek SC approval during<br />implementation if there is a substantial change to the relevant strategic initiative's scope.</p>
2016-11-16 B36 GF/B36/DP10 Location of the 37th Board Meeting Location of the 37th Board Meeting
1. The Board welcomes the invitation of the Government of Rwanda to host the Global Fund's<br/>37th Board Meeting on 03-04 May 2017.<br/><br/>2. Accordingly, the Board agrees to convene the 37th Board Meeting in Kigali, Rwanda.
2016-11-16 B36 GF/B36/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the 36th Board Meeting (GF/B36/01) is approved.</p>
2012-05-11 B26 GF/B26/DP07 Modification of Rules Governing Grant Renewals Modification of Rules Governing Grant Renewals
<p>The Board:</p> <blockquote> <p>1. Refers to its decision on the Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16) which, among other adopted measures, required that the total funding approved for grant renewals for Low Income Countries be no less than 55% of any annual funding window (the “55% Rule”);</p> </blockquote> <blockquote> <p>2. Acknowledges that the 55% Rule is intended to drive resources toward the places with the greatest need and least ability to address the three epidemics, and that existing policies, including the Policy on Eligibility, Counterpart Financing and Prioritization, already shape the Global Fund portfolio by directing resources and requiring middle-income implementing countries to contribute financial resources to the response;</p> </blockquote> <blockquote> <p>3. Notes unintended consequences of the 55% Rule and some negative impact on achievement of the targets of the Global Fund Strategy and on vital programs targeted for the poorest people in lower middle-income countries; and</p> </blockquote> <blockquote> <p>4. Directs the Secretariat to develop further analysis of the 55% Rule in consultation with the Strategy, Investment, and Impact Committee at its next meeting, with a recommendation to the Board before its November meeting. Until that time, the Board decides to freeze the implementation of the 75% ceiling on grant renewals funding for Lower-Middle Income Countries and above (including on the four approved grant renewals affected by its implementation).</p> </blockquote>
2017-04-21 B36 GF/B36/EDP11 Approval of the Terms of Reference for the 2017 Executive Director Nomination Committee Approval of the Terms of Reference for the 2017 Executive Director Nomination Committee
<ol> <li>Based on the recommendation of the Chair and Vice-Chair of the Board (the “Board Leadership”), in consultation with the Ethics and Governance Committee (the “EGC”), the Board: <ol type="a"> <li>Notes its responsibilities with regard to the recruitment process of the Executive Director as set out in Article 36 of the Operating Procedures of the Board and Committees of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“BCOP”);</li> <li>Notes the consultations of the Board Leadership and the EGC in relation to this process, including with respect to the establishment of the nomination committee referred to in the BCOP and the selection of an executive search firm, in accordance with Global Fund procurement regulations, to provide support to the nomination committee in carrying out its mandate; and</li> <li>Approves the terms of reference of the 2017 Executive Director Nomination Committee, as set out in Annex 1 to GF/B36/ER10.</li> </ol> </li> <li>The Board requests the Board Leadership to submit a Chair, Vice-Chair and the membership of the nomination committee to the Board for approval.</li> </ol>
2016-12-07 B36 GF/B36/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board: <br /><br />1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1A and 1B of Section IV to GF/B36/ER01 ("Table 1A" and "Table 1B"); <br /><br />2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1A and 1B, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies; <br /><br />3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and <br /><br />4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. <br /><br />This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>
2016-11-16 B36 GF/B36/DP09 Performance Targets for the 2017 – 2022 Strategic Key Performance Indicator Framework Performance Targets for the 2017 – 2022 Strategic Key Performance Indicator Framework
1. The Board notes the additional analysis by the Secretariat to develop performance<br/>targets for the 2017-2022 Strategic Key Performance Indicator (the "KPI") Framework<br/>approved by the Board in June 2016 under the decision point GF/B35/EDP05 and set<br/>forth in Annex 1 to GF/B35/ER05 (the "Strategic KPI Framework").<br/><br/>2. To support the efforts of the Global Fund and partners to implement the 2017-2022<br/>Global Fund Strategy and achieve maximum impact, the Board requests:<br/><br/>a. Board constituencies to submit statements, questions, concerns or suggested<br/>revisions regarding the performance targets, including how country-level<br/>information or estimates will be considered, to the Secretariat by 30 November<br/>2016 followed by the Secretariat's response by 9 December 2016 to be<br/>communicated to all constituencies;<br/><br/>b. The Chairs and Vice-Chairs of the Audit and Finance Committee (the "AFC")<br/>and the Strategy Committee (the "SC") to determine, in accordance with the<br/>respective mandates of the AFC and SC, the performance targets to be<br/>addressed by each committee; and<br/><br/>c. The Chairs and Vice-Chairs of the AFC and the SC to establish a joint-committee<br/>advisory group (the "Advisory Group") by 9 December 2016 that will work with<br/>the Secretariat to present revised performance targets for the Strategic KPI<br/>Framework, based on country-level estimates where relevant and available in<br/>alignment with the principle of country ownership, to the AFC and SC for<br/>recommendation to the Board by the first week of March 2017.<br/><br/>3. The Advisory Group will:<br/><br/>a. Be comprised of four individuals selected from implementer constituencies and<br/>four individuals selected from donor constituencies and two representatives of<br/>the Technical Partners, in consultation with the Chairs and Vice-Chairs of the<br/>AFC and SC, to work with the Secretariat to present revised performance targets<br/>for the Strategic KPI Framework;<br/><br/>b. Consult with the Technical Review Panel and Technical Evaluation Reference<br/>Group;<br/><br/>c. Consider statements, questions, concerns or suggested revisions by Board<br/>constituencies, as well as responses provided by the Secretariat, to advise the<br/>Secretariat on presenting the AFC and SC with revised performance targets for<br/>the Strategic KPI Framework; and<br/><br/>d. Be dissolved upon the Board's approval of performance targets for the Strategic<br/>KPI Framework.<br/><br/>
2016-12-21 B36 GF/B36/EDP05 Decision on the Secretariat’s Recommendation on Financing Unfunded Quality Demand from the 2014 – 2016 Allocation Period Decision on the Secretariat’s Recommendation on Financing Unfunded Quality Demand from the 2014 – 2016 Allocation Period
<p>The Board:<br /><br />1. Notes the Secretariat's review of the items on the 2014 - 2016 allocation period's unfunded quality demand ("UQD") register, as described GF/B36/ER04;<br /><br />2. Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Bangladesh TB, (ii) Central African Republic TB/HIV, (iii) Myanmar TB, (iv) Philippines TB, and (v) Viet Nam TB, as listed in Table 4 of Section IV to GF/B36/ER04, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br /><br />3. Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br /><br />4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>
2016-12-21 B36 GF/B36/EDP04 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:<br /><br />1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a, 1b and 1c of Section IV to GF/B36/ER04 ("Table 1a", "Table 1b" and "Table 1c");<br /><br />2. Notes the incremental funding approved for APN+, as set forth in Table 1c, is conditioned on the fulfilment of certain time-bound requirements, as described in GF/B36/ER04, and that the Secretariat will inform the Board of the final grant outcome following the relevant deadlines outlined in GF/B36/ER04.<br /><br />3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a, 1b and 1c, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br /><br />4. Approves the reinvestment of within-allocation efficiencies for the Solomon Islands TB and South Africa TB/HIV grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B36/ER04;<br /><br />5. Acknowledges the original grant duration, as expressed by either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 3 of Section IV ("Table 3") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br /><br />6. Approves the additional incremental funding and/or implementation period recommended for (a) Iraq TB and (b) Zimbabwe malaria, and each component's constituent grants, as listed in Table 3, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br /><br />7. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 30 June 2017 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br /><br />8. Approves the additional incremental funding and implementation period recommended for disease components (i) EMMIE malaria, (ii) Myanmar malaria, (iii) Myanmar TB/HIV and (iv) RAI malaria, being Early Applicant grants, as listed in Table 3, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br /><br />9. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants,<br />GF/B36/ER04 (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br /><br />10. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p> <p> </p>
2016-11-16 B36 GF/B36/DP03 Continuing Resource Mobilization Efforts Throughout the Replenishment Cycle Continuing Resource Mobilization Efforts Throughout the Replenishment Cycle
<p>The Board:<br /><br />1. Notes the successful launch of the Global Fund Fifth Replenishment (2017-2019) and the<br />importance of continuing to actively engage to mobilize increased resources throughout<br />the Replenishment cycle; and<br /><br />2. Requests that the Secretariat, under the oversight of the Audit and Finance Committee,<br />develop an ambitious action plan for attracting additional resources which may include<br />providing additional pledging opportunities for donors and maintains visibility of both<br />unfunded quality demand and progress in achieving impact, to be shared with the Board<br />at its 37th Meeting, and subsequently reported on by the Audit and Finance Committee<br />to the Board on a regular basis.</p>
2017-02-08 B36 GF/B36/EDP07 Approval of the Report of the 36th Board Meeting Approval of the Report of the 36th Board Meeting
<p>(Board meeting report document available below)</p>
2016-11-16 B36 GF/B36/DP04 Approval of the Amended and Restated Comprehensive Funding Policy Approval of the Amended and Restated Comprehensive Funding Policy
<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves<br />the Amended and Restated Comprehensive Funding Policy, as set forth in Annex 1 to<br />GF/B36/02 - Revision 1.</p>
2017-03-20 B36 GF/B36/EDP09 Performance Targets for the 2017-2022 Strategic Key Performance Indicator Framework Performance Targets for the 2017-2022 Strategic Key Performance Indicator Framework
<ol> <li>The Board notes the additional analysis to develop performance targets for the 2017 – 2022 Strategic Key Performance Indicator (the “KPI”) Framework approved by the Board in June 2016 under decision point GF/B35/EDP05 and set forth in Annex 1 to GF/B35/ER05 (the “Strategic KPI Framework”).</li> <li>Based on the recommendation of the Audit and Finance Committee and the Strategy Committee, as set forth in GF/B36/ER08A and GF/B36/ER08B, the Board: <ol type="a"> <li>Approves the performance targets where proposals are complete;</li> <li>Approves the proposed interim indicator proposals for KPIs 5 and 9c; and</li> <li>Agrees with postponing its review and approval of performance targets for KPIs 6a, 6b and 6e until the final Board meeting of 2017.</li> </ol> </li> </ol>
2016-11-16 B36 GF/B36/DP07 Executive Director Selection Process Executive Director Selection Process
<p>1. The Board notes:<br /><br />a. Its November 2016 approval (GF/B35/EDP19) of the terms of reference of the 2016<br />Executive Director Nomination Committee (the "Nomination Committee"), as set<br />forth in Annex 1 to GF/B35/ER15; and<br /><br />b. Consultations between the Ethics and Governance Committee and the Chair and<br />Vice-Chair of the Board with respect to the terms of reference of the Executive<br />Director, voting procedures for the selection of the next Executive Director, and<br />anticipated timelines for recruiting the next Executive Director, as outlined in<br />GF/B36/07.<br /><br />2. Accordingly, the Board approves:<br /><br />a. The revised terms of reference of the Executive Director, as presented in Annex 1 to<br />GF/B36/07, which shall supersede the terms of reference approved by the Board<br />under decision point GF/B26/EDP08 and set forth in Annex 1 to GF/B26/ER05;<br />and<br /><br />b. The voting procedure for the selection of the Executive Director, as presented in<br />Annex 2 to GF/B36/07, which shall supersede any prior versions of voting<br />procedures adopted for the selection of any direct report of the Board.</p>
2017-01-30 B36 GF/B36/EDP06 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B36/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Approves the additional funding for the South Africa TB/HIV program and its resultant total program budget, as listed in Table 1;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2012-05-11 B26 GF/B26/DP04 Decision-Making Authority on Adjustments within the Operating Expenses Budget Decision-Making Authority on Adjustments within the Operating Expenses Budget
<p>1. The Board affirms the Finance and Operational Performance Committee (the “FOPC”) is authorized to approve operating expenditures that do not result in an increase in the amount of the Board-approved operating expenses budget for any financial year.</p><p>2. The FOPC is authorized to establish a framework to determine when decision-making authority on adjustments, reallocations or additions to the operating expenses budget may be taken by the Secretariat or FOPC provided that:</p><blockquote><p>a. such decision does not result in an increase in the operating expenses budget approved by the Board for the relevant financial year;</p></blockquote><blockquote><p>b. the FOPC shall consult with the Secretariat to develop appropriate criteria and thresholds within such criteria to establish this decision-making framework; and</p></blockquote><blockquote><p>c. decisions taken by the Secretariat shall be reported to the FOPC and decisions taken by the FOPC shall be reported to the full Board.</p></blockquote>
2012-05-31 B26 GF/B26/EDP03 Additional Funding for the Ethiopia Round 8 Malaria Grant (ETH-809-G10-M) Additional Funding for the Ethiopia Round 8 Malaria Grant (ETH-809-G10-M)
<p>The Board approves additional funding for the Phase 2 period of the Ethiopia Round 8 Malaria grant (ETH-809-G10-M) as a ‘Conditional Go’ in the amount of up to US$ 114,264,421 subject to Technical Review Panel clarifications and conditions within a limited timeframe, and any additional conditions to be cleared by the Secretariat. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</p>
2015-11-17 B34 GF/B34/DP08 Approval of the amended and restated Market Shaping Strategy Approval of the amended and restated Market Shaping Strategy
<p>1. Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the amended and restated Market Shaping Strategy, as set forth in Annex 1 to GF/B34/17 - Revision 1 (the "Amended and Restated Market Shaping Strategy").</p> <p>2. This decision point and the Amended and Restated Market Shaping Strategy supersede Board decision point GF/B23/DP21 and the previous Market Shaping Strategy set forth in Annex 1 to GF/B23/09 - Revision 1.</p>
2012-05-11 B26 GF/B26/DP08 Launch of the Selection Process for the next Executive Director Launch of the Selection Process for the next Executive Director
<p>The Board:</p> <blockquote> <p>1. Establishes an ad hoc nominations committee (‘AHNC’) to assist the Board with its selection of the next Executive Director.</p> </blockquote> <blockquote> <p>2. Notes the constituency nominations for members of the AHNC, and appoints the following individuals as members, each serving in his or her personal capacity:</p> </blockquote> <blockquote> <blockquote> <p>Don Baxter<br />Agnes Binagwaho<br />Karlo Boras<br />Nils Daulaire<br />Mireille Guigaz<br />Masaki Noke</p> </blockquote> </blockquote> <blockquote> <p>3. Requests the AHNC to initiate the selection process in accordance with its Terms of Reference, including the timely appointment of three non-constituency affiliated members to facilitate the work of the AHNC.</p> </blockquote>
2012-06-20 B26 GF/B26/EDP05 June 2012 Bridge Funding Recommendations June 2012 Bridge Funding Recommendations
<p>The Board:</p> <ol> <li>Approves bridge funding for the grants listed in Table 2 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts and are approved for the continuation of essential programs up to the period of the Transitional Funding Mechanism (GF/B25/DP16 Annex 2).</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 1,745,524 for the following grants: RUS-304-G01-H ; RUS-506-G05-H</p>
2012-07-30 B26 GF/B26/EDP09 July 2012 Grant Renewals Funding Recommendations July 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 130,325,572 for the following grants: BLR-304-G01-H ; BRN-910-G09-M ; BRN-910-G10-M ; CPV-810-G01-H ; CPV-810-G02-H ; PRK-810-G02-T ; SLV-910-G08 ; SLV-910-G07-T ; ERT-910-G07-M ; FJI-T-MOH ; LSO-809-G07-H ; MDG-810-G13-T ; MDG-810-G14-T ; MNT-910-G03-H ; NIC-202-G05-T-00 ; PRY-910-G06-S ; SER-910-G06-T ; SER-910-G07-T ; SLB-810-G01-T ; SWZ-809-G08-S ; TAJ-304-G02-T</p>
2012-08-20 B26 GF/B26/EDP10 Additional Funding for the Ghana Round 8 HIV Grants (GHN-809-G09-H; GHN-809-G10-H; GHN-809-G11-H; and GHN-809-G12-H) Additional Funding for the Ghana Round 8 HIV Grants (GHN-809-G09-H; GHN-809-G10-H; GHN-809-G11-H; and GHN-809-G12-H)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period of the Ghana Round 8 HIV grants (GHN-809-G09-H; GHN-809-G10-H; GHN-809-G11-H; and GHN-809-G12-H) as a ‘Conditional Go’ in the amount of US$ 43,524,540 subject to Technical Review Panel (‘TRP’) clarifications and conditions within a limited timeframe, and any additional conditions to be cleared by the Secretariat. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of these grants shall be the amount approved by this decision and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grants.</li> </ol>
2012-05-11 B26 GF/B26/DP06 Accelerating Implementation of the Global Fund Strategy Accelerating Implementation of the Global Fund Strategy
<p>1. Given the new and encouraging financial forecasts presented to the Global Fund’s Board at its Twenty-Sixth Meeting in Geneva in May 2012, the Board decides to accelerate the implementation of the new Global Fund Strategy ‘Investing for Impact’ by opening new funding opportunities starting in late September 2012 to allow for Board funding decisions to be made no later than the end of April 2013.</p> <p>2. The Secretariat, under the guidance of the Strategy, Investment and Impact Committee (‘SIIC’), will design in consultation with countries, partners and other stakeholders, the elements of the new funding models, including the structure and parameters of the new ‘iterative process’, options for distribution of funds available, and other elements, and the SIIC will bring its recommendation to a special Board meeting in September 2012.</p> <p>3. The Finance and Operational Performance Committee will work with the Secretariat to test the resource forecasting model on a monthly basis and confirm the resource forecast in September 2012.</p> <p>4. As soon as possible, and under the oversight of the SIIC, the Secretariat will work with countries and partners to develop estimates of demand for programs for the three diseases and related health systems and civil society strengthening investments that are consistent with the new strategic approach and take into account existing resources available in country, by September to inform the Board and other stakeholders and to aid replenishment.</p> <p>5. The new funding models will be developed in line with the new Strategy and the principles articulated in the Framework Document that the ‘Fund will base its work on programs that reflect national ownership and respect country-led formulation and implementation processes’.</p> <p>6. It is envisaged that this will :</p> <blockquote> <p>a. create a specific opportunity for countries to assess the gap between national coverage levels for the 3 diseases and actual need;</p> </blockquote> <blockquote> <p>b. permit the establishment of multiple funding opportunities per year and have a mechanism that allows for high quality, grant ready proposals to be financed as funding becomes available ;<br />Accelerating Implementation of the Global Fund Strategy</p> </blockquote> <blockquote> <p>c. ensure a comprehensive and specific analysis of complementarity among funders; and</p> </blockquote> <blockquote> <p>d. increase the sustainability of Global Fund supported programs.</p> </blockquote>
2012-05-11 B26 GF/B26/DP01 Appointment of Rapporteur Appointment of Rapporteur
Dr. Reinhard Tittel-Gronefeld from the Germany (Canada, Switzerland) constituency is designated as rapporteur for the Twenty-Sixth Board Meeting.
2012-08-24 B26 GF/B26/EDP11 Approval of Transitional Funding Mechanism Proposals Approval of Transitional Funding Mechanism Proposals
<ol> <li> <p>The Board endorses the Technical Review Panel (TRP) Recommendation Categories for the Transitional Funding Mechanism (TFM) as set forth in the GF/B26/ER 07.</p> </li> <li> <p>The Board approves all TFM proposals recommended for funding by the TRP as Categories 1, 2, and 3 as indicated in Annex 1 of GF/B26/ER 07, subject to all applicable clarifications or conditions outlined in TRP review forms. The aggregate total of the maximum upper ceilings of funding for Category 1, 2 and 3 TFM proposals is US$ 419.8 million.</p> </li> <li> <p>Applicants whose proposals are recommended for funding as "Category 3" shall:</p> <ol type="a"> <li> <p>provide an initial detailed written response to the requested TRP clarifications no later than four (4) weeks after the applicant's receipt of notification in writing by the Secretariat of this Board decision; and</p> </li> <li> <p>conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than eight (8) weeks after the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</p> </li> </ol> </li> <li> <p>The Board conditionally approves all TFM proposals which are recommended for funding by the TRP as "Category 4" as indicated in Annex 1 of GF/B26/ER 07 subject to review and approval by the TRP of the revised TFM proposals. The Board notes that applicants whose proposals are recommended for funding as "Category 4" submitted proposals in need of substantial revision despite risks of disruption of essential prevention, treatment and/or care services during the TFM eligibility period of 1 January 2012 and 31 March 2014. The aggregate total of the maximum upper ceilings of funding for Category 4 TFM proposals is US$ 91.2 million.</p> </li> <li> <p>Applicants whose proposals are recommended for funding as "Category 4" shall:</p> <ol type="a"> <li> <p>submit a revised proposal, based on the parameters set out in the applicants' TRP review form; and</p> </li> <li> <p>complete the revised proposal review process, including anyclarification which the TRP may require, within the timeframe stipulated in the TRP review form resulting from such a review.</p> </li> </ol> </li> <li> <p>The Secretariat will notify the Board of the outcomes of all Category 4 proposals.</p> </li> <li> <p>The Board declines to approve for funding those proposals recommended by the TRP as "Category 5." These proposals are eligible to appeal this decision subject to the grounds and process for appeals as stipulated in the 'Rules Governing the Global Fund's Appeal Mechanism for Applications not Approved for Funding'.</p> </li> <li> <p>The Board notes that many applicants will face disruption during the second half of 2013 or in 2014, the latter stages of the TFM eligibility period. There may be circumstances where there are advantages to signing a TFM grant closer to the date of disruption, including circumstances created by the Board's decision to accelerate the implementation of the Global Fund Strategy (GF/B26/DP6). As such, the Board decides that TFM grants may be signed beyond the currently required 12-month period after Board approval of a proposal (GF/B8 Timeframes for Grant Agreements, Decision Point 2) and may have start dates that are beyond 15 or 18 months after Board approval, as applicable, in accordance with their respective disruption dates.</p> </li> <li> <p>The Board's approval of proposals is made with the clear understanding that the proposal amounts recommended for funding by the TRP, as set forth in Annex 1 - GF/B26/ER 07, are maximum upper ceilings rather than final approved grant amounts and are subject to reduction upon successful completion of TRP clarifications, TRP reviews of revised proposals, and grant negotiations.</p> </li> </ol>
2012-05-11 B26 GF/B26/DP03 Approval of Report of the Twenty-Fifth Board Meeting Approval of Report of the Twenty-Fifth Board Meeting
The report of the Twenty-Fifth Board Meeting (GF/B25/08 Revision 1) is approved.
2012-06-27 B26 GF/B26/EDP07 Authorization for Chief Financial Officer Salary Authorization for Chief Financial Officer Salary
<p>In accordance with the Board-adopted Global Fund Human Resources Policy Framework (GF/EDP/08/16 – Annex 1), any staff salary above CHF 245,000 requires Board approval. The Board authorizes the Secretariat to enter into a contract of employment with a new Chief Financial Officer within the Grade 09 level with an annual salary above CHF 245,000 and below the ceiling for Grade 09 salaries of CHF 349,800.</p>
2012-08-13 B26 GF/B26/EDP12 August 2012 Phase 2 Funding Decision August 2012 Phase 2 Funding Decision
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 99,032,607 for the following grants: BAN-202-G11-H-00 ; BAN-202-G12-H-00 ; BAN-202-G13-H-00 ; LBR-810-GO7-H ; SUD-T-UNDP</p>
2012-07-06 B26 GF/B26/EDP08 Approval of Revised Terms of Reference of the Executive Director Approval of Revised Terms of Reference of the Executive Director
<p>The Board approves revised Terms of Reference for the Executive Director as set out in Annex 1 to Electronic Report B26/ER/05, which shall be used as the basis for the recruitment of a new Executive Director.</p>
2012-06-20 B26 GF/B26/EDP04 June 2012 Grant Renewals Funding Recommendations June 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 81,836,373 for the following grants: COL-809-G02-M ; COL-809-G03-M ; ARM-809-G04-S ; ARM-202-G05-H-00 ; ARM-202-G06-H00 ; DMR-309-G07-T ; TUN-810-G02-T ; TUN-810-G03-T ; BUL-809-G03-T ; RUS-304-G02-T ; IRN-810-G04-H ; TCD-810-G07-T ; CIV-809-G08-M ; CIV-809-G09-M ; AFG-809-G08-M</p>
2012-05-31 B26 GF/B26/EDP01 Approval of the 2011 Consolidated Financial Statements and Annual Report Approval of the 2011 Consolidated Financial Statements and Annual Report
The Board approves the Global Fund’s 2011 Annual Report and 2011 Consolidated Financial Statements, which have been audited by Ernst &amp; Young Ltd.
2012-08-13 B26 GF/B26/EDP13 Increase in Incremental Funding of the Colombia Malaria Grant (COL-809-G02-M) Increase in Incremental Funding of the Colombia Malaria Grant (COL-809-G02-M)
<p>The Board approves additional incremental funding up to EUR 1,075,944 for the Phase 2 period of the Colombia malaria grant (COL-809-G02-M) with conditions stipulated in its B26/EDP/04 decision of 20 June 2012.</p>
2012-05-31 B26 GF/B26/EDP02 May 2012 Grant Renewals Funding Recommendations May 2012 Grant Renewals Funding Recommendations
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 420,336,975 for the following grants: COM-810-G03-M ; ETH-202-G03-H-00 ; HTI-102-G09-H ; NGA-809-G11-M ; NGA-809-G13-M ; NGA-809-G14-M ; UZB-809-G04-M ; ZAM-809-G21-H ; ZAM-809-G22-H ; ZAM-809-G23-H</p>
2012-05-11 B26 GF/B26/DP05 Delegation of Authority to Secretariat for Grant Operations Delegation of Authority to Secretariat for Grant Operations
<ol> <li>The Board notes that: <ol type="a"> <li>it has previously made decisions restricting the timeframe for signing grant agreements, placing parameters around the flexibility to set grant start dates, limiting the ability to extend the total length of a grant, and detailing the process for Phase 2 and Periodic Reviews;</li> <li>the principles surrounding these decisions remain valid and support the Global Fund’s mandate to efficiently and effectively provide funding to programs while ensuring that only strategic, cost-effective investments are made; and</li> <li>while the general principles remain valid, there is a need to allow for additional flexibilities, where necessary, to ensure the Secretariat is able to independently respond to grant specific needs while managing day-to-day grant management operations.</li> </ol> </li> <li>In order to address certain operational constraints and increase the efficiency and effectiveness of the Secretariat in grant management operations, the Board <ol type="a"> <li>further delegates to the Secretariat, in line with the authorities provided under GF/B24/EDP/4, the authority to approve extensions of up to three months to the signing timeframe for future approved proposals on an exceptional case-by-case basis and only in situations in which there is a strong justification for granting an extension;</li> <li>extends the authorities provided under GF/B24/EDP/7 by delegating to the Secretariat the authority to make exceptions, due to operational needs, to the general principle that grant start dates should not be set beyond 15 months, or 18 months, as applicable, after Board approval of a proposal; so long as no exception results in a grant start date being set beyond 22 months after Board approval of a proposal;</li> <li>delegates to the Secretariat the authority to make exceptions, due to compelling circumstances, to the existing policy which only allows for a maximum extension period of six months to the total length of a grant’s implementation period, at the end of a program; so long as any extension does not lengthen the total implementation period by more than twelve additional months; and</li> <li>delegates to the Secretariat the authority to, on an exceptional case-by-case basis: <ol type="i"> <li>provide additional no-cost extensions to the current grant implementation period during the renewals process, based on specific grant related circumstances, to allow for continued grant implementation; and Delegation of Authority to Secretariat for Grant Operations</li> <li>amend conditions upon which the Board has conditioned the approval of incremental funding where necessary to account for changes in circumstances; so long as measures are available to effectively mitigate the risk addressed in the condition.</li> </ol> </li> </ol> </li> <li>In order to ensure proper oversight, the Secretariat must limit the ability to approve the use of the delegations of authority granted above to the appropriate panel or committee of senior managers within the Secretariat</li> <li>The Board requests that the Secretariat prepare a report twice a year detailing any exceptions or extensions approved in connection with this decision point and submit such report to the Strategy, Investment and Impact Committee (the “SIIC”) for review. The first such report will be submitted to the SIIC prior to its first meeting in 2013.</li> </ol>
2012-05-11 B26 GF/B26/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-Sixth Board Meeting (GF/B26/01) is approved.
2012-06-24 B26 GF/B26/EDP06 Approval for the Re-launch of the Mozambique Round 8 Health Systems Strengthening (HSS) Grant (MOZ-809-G08-S) Approval for the Re-launch of the Mozambique Round 8 Health Systems Strengthening (HSS) Grant (MOZ-809-G08-S)
<ol><li>The Board refers to the Mozambique Round 8 Health Systems Strengthening grant (MOZ-809-G08-S) which has not begun implementation more than 24 months from the original Board approval of the proposal.</li><li>Noting that the Country Coordinating Mechanism has requested a material re-programming of the program, the Board approves the grant to be re-launched with additional funding of up to USD 5,653,933 and with one additional year of implementation, subject to the approval of the Technical Review Panel (‘TRP’) to the re-programming and any clarifications which the TRP may require, so that the program will be implemented for a total of three years from the date of the re-launch.</li></ol>
2017-04-04 B36 GF/B36/EDP10 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Acknowledges the original grant duration, as expressed by either the implementation or budgeted period, of Nigeria malaria and its constituent grants, as described in GF/B36/ER09, was shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09 when approved by the Board in January 2015 under GF/B32/EDP05;</li> <li>Approves the redistribution of funding available to Nigeria malaria, and its constituent grants, under the Board’s approval of additional funding in January 2015 (GF/B32/EDP05) as well as the additional implementation period recommended for Nigeria malaria, and its constituent grants, as listed in Tables 1a and 1b of GF/B36/ER09 and described in GF/B36/ER09, paragraph 1.4;</li> <li>Acknowledges Nigeria malaria’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding available for Nigeria malaria under GF/B32/EDP05 and this decision (a) remains the upper-ceiling amount that may be available for the relevant implementation period of each constituent grant, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-12-08 B36 GF/B36/EDP02 Recommendation on Revisions to the Constituency Funding Policy Recommendation on Revisions to the Constituency Funding Policy
<ol> <li>The Board recalls its approval in November 2009 of the Board Constituency Funding Policy (GF/B20/DP7), as set forth in Annex 3 to GF/B20/4 (the "Existing Policy"), which makes funds available to Board constituencies of the Implementer Voting Group to facilitate engagement in the Global Fund's governance processes;</li> <li>Based on the recommendations presented in GF/B36/ER02, the Board approves the revised Board Constituency Support Policy, as set forth in Annex 1 to GF/B36/ER02 (the "Revised Policy").</li> <li>Accordingly, the Board: <ol type="a"> <li>Notes this decision point and the Revised Policy, which supersede the Board decision point GF/B20/DP7 and the Existing Policy, respectively;</li> <li>Delegates oversight of the Revised Policy to the Ethics and Governance Committee (the "EGC");</li> <li>Delegates to the EGC the authority to determine the Overall Funding Ceiling under the Revised Policy up to a threshold of an annual average of 1.5 million USD over the three-year period of the Funding Cycle;</li> <li>Notes that under the Revised Policy the estimated annual average of the Overall Funding Ceiling for the Funding Cycle 2017-2019 is 1.2 million USD; and</li> <li>Requests the Secretariat to provide the EGC with an annual report on the implementation of the Revised Policy.</li> </ol> </li> </ol> <p>Budgetary implications of the decision for Funding Cycle 2017-2019: an estimated annual average of 1,200,000 USD with be included in the OPEX budget for each year of the 2017-2019 Funding Cycle to support activities covered under the Revised Policy. (This annual average represents an increase of 200,000 USD over amounts approved in 2015 and 2016 OPEX budgets with respect to constituency funding. For 2017, this increase will be accommodated within the OPEX approved at the November 2016 Board Meeting).</p> <p>The Overall Funding Ceiling for future periods (from 2020 forward) will be approved by the EGC in line with the delegated authority from the Board outlined in clause 3c of this decision point.</p>
2013-11-07 B30 GF/B30/DP03 Approval of Report of the Twenty-Ninth Board Meeting Approval of Report of the Twenty-Ninth Board Meeting
<p>The report of the Twenty-Ninth Board Meeting (GF/B30/2) is approved.</p>
2021-10-19 B45 GF/B45/EDP22 Decision on the Secretariat’s Recommendation on Additional Funding for the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding for the 2020-2022 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B45/ER19 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-10-19 B45 GF/B45/EDP23 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B45/ER02 (“Table 3”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>
2021-10-19 B45 GF/B45/EDP21 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B45/ER19 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-08-18 B45 GF/B45/EDP12 Increases to the COVID-19 Response Mechanism’s (C19RM) Fast-track Investment Ceiling Increases to the COVID-19 Response Mechanism’s (C19RM) Fast-track Investment Ceiling
<p>Based on the rationale provided in GF/B45/ER11, the Board delegates authority to the Audit and Finance Committee (the “AFC”) to increase the overall ceiling amount to be made available through the C19RM Fast-track investment channel established under paragraph 5.c of GF/B44/EDP18. The AFC may increase the C19RM Fast-track investment ceiling by up to a further USD 700 million, based on additional funds approved as available by the AFC. </p> <p>Budgetary implications (included in, or additional to, OPEX budget): No material budget implications are envisioned. Any incremental management and operating costs directly attributable to the proposed expansion of the C19RM’s fast-track ceiling amount will continue to be covered from funds made available for C19RM, pursuant to GF/B44/EDP18.</p>
2021-10-04 B45 GF/B45/EDP19 Appointment of Replacement Members on the Audit and Finance Committee and the Strategy Committee Appointment of Replacement Members on the Audit and Finance Committee and the Strategy Committee
<ol> <li>The Board approves the appointment of Florence Perez, representing the France Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> <li>The Board approves the appointment of Andriy Klepikov, representing the Developing Country NGOs Constituency, as a voting member of the Strategy Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Hampus Holmer, representing the Point 7 Constituency, as a voting member of the Strategy Committee for a term that will expire in May 2022, or until the appointment of his successor</li> </ol>
2021-09-30 B45 GF/B45/EDP18 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Central African Republic) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Central African Republic)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER17; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-09-02 B45 GF/B45/EDP17 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Mali, Mozambique and South Africa) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Mali, Mozambique and South Africa)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding  US$35  million,  as  measured  in  aggregate  by  country  (not  including  any  funding  awarded  for  COVID-19  commodities  through fast-track  investments  or C19RM funding awarded in 2020);</li> <li>Approves  the  funding  recommended for  each  country,  as  listed in  Table  1  of  GF/B44/ER16; and</li> <li>Delegates  to  the  Secretariat  authority  to  redistribute  the  overall  upper-ceiling  of  funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-08-05 B45 GF/B45/EDP13 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Burkina Faso, Côte d'Ivoire and Rwanda) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Burkina Faso, Côte d'Ivoire and Rwanda)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER10; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18. </li> </ol>
2021-08-10 B45 GF/B45/EDP11 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation (Armenia, Eswatini, Guatemala and Multicountry Southern Africa TIMS) Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation (Armenia, Eswatini, Guatemala and Multicountry Southern Africa TIMS)
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B45/ER10 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-08-19 B45 GF/B45/EDP16 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Myanmar and Ukraine) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Myanmar and Ukraine)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER15; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18. </li> </ol>
2021-07-20 B45 GF/B45/EDP08 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Ghana and Kenya) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Ghana and Kenya)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER07; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-08-13 B45 GF/B45/EDP14 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Indonesia and Nigeria) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Indonesia and Nigeria)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER13; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-08-20 B45 GF/B45/EDP15 Appointment of Replacement Chair of the Strategy Committee Appointment of Replacement Chair of the Strategy Committee
<p>The Board approves the appointment of Carolyn Gomes as Chair of the Strategy Committee for a term that will expire in May 2022, or until the appointment of her successor.</p>
2021-07-13 B45 GF/B45/EDP05 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p style="text-align: justify;" class="Default">The Board:</p> <ol> <li class="Default" style="text-align: justify;"><span style="font-size: 11.0pt; color: windowtext;">Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B45/ER05 (“Table 1”); </span></li> <li class="Default" style="text-align: justify;"><span style="font-size: 11.0pt; color: windowtext;">Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies; </span></li> <li class="Default" style="text-align: justify;"><span style="font-size: 11.0pt; color: windowtext;">Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and </span></li> <li class="Default" style="text-align: justify;"><span style="font-size: 11.0pt; color: windowtext;">Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </span></li> </ol>
2021-07-01 B45 GF/B45/EDP04 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Uganda) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Uganda)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding USD 35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER04; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-06-17 B45 GF/B45/EDP03 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of GF/B45/ER03 (“Tables 1a and 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2021-07-09 B45 GF/B45/EDP06 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Ethiopia and Malawi) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Ethiopia and Malawi)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding USD 35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER06; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-06-04 B45 GF/B45/EDP01 Approval of Revised Definitions, Metric Adjustments and Targets for KPIs Approval of Revised Definitions, Metric Adjustments and Targets for KPIs
<p>a) Based on the recommendation of the Strategy Committee, the Board approves the revisions for Key Performance Indicators 2, 5c, 6e, 9c and 11 as presented in GF/B45/ER01.</p> <p>b) Based on the recommendation of the Audit and Finance Committee, the Board approves the revision for Key Performance Indicator 7a as presented in GF/B45/ER01.</p>
2021-07-27 B45 GF/B45/EDP09 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Sudan and Tanzania) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Sudan and Tanzania)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER08; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-10-21 B45 GF/B45/EDP24 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Cameroon and DRC) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Cameroon and DRC)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID 19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B45/ER20; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-10-19 B45 GF/B45/EDP25 Extension of terms of the Board Chair and Vice-Chair Extension of terms of the Board Chair and Vice-Chair
<p>In response to the continued exceptional circumstances related to the current Covid-19 pandemic, the Board:</p> <ol> <li>Extends its recognition to Dr Donald Kaberuka, Chair of the Board, and Lady Roslyn Morauta, Vice-Chair of the Board, for their service since May 2019;</li> <li>Thanks the Ethics and Governance Committee for their recommendation and notes the analysis and review process preceding this decision; and</li> <li>Extends the terms of Dr Donald Kaberuka, as Chair of the Board, and Lady Roslyn Morauta, as Vice-Chair of the Board, to the adjournment of the first Board Meeting in 2023.</li> </ol>
2021-11-03 B45 GF/B45/EDP26 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Russian Federation and Zimbabwe) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Russian Federation and Zimbabwe)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER21; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18. </li> </ol>
2014-02-28 B30 GF/B30/EDP08 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants) Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for thegrants listed in Table 2 in the amounts indicated for each grant, based on theunderstanding that the amounts approved are upper ceilings rather than finalfunding amounts for that period and that on-going implementation arrangementsfor each grant shall be pursued by the Secretariat consistent with theprinciples of the recommendations set forth in the related documentation submittedto the Board and in accordance with Global Fund policies. Approval is alsosubject to the availability of funding and to the provision that funding forrenewals of existing grants shall be committed in annual tranches (GF/B25/DP16,paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the nextimplementation period of each grant shall be the sum of the amount set out inTable 1 below for each listed grant and the amount of any funds approved forthe prior implementation period which have not been utilized during thatperiod, either as undisbursed funds or cash balances held by recipients underthe grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 89,129,143 for the followinggrants: COG-911-G06-H, COG-911-G05-H (Congo), LSO-H-MoFDP, LSO-813-G09-H (Lesotho), MOZ-708-G07-T (Mozambique)and MAT-011-G01-H (Multicountry Americas - REDTRASEX).</p>
2013-12-20 B30 GF/B30/EDP05 Decision on the Secretariat’s Early Applicant Funding Recommendation Decision on the Secretariat’s Early Applicant Funding Recommendation
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model(GF/B28/DP5), funding in the amount listed for the early-applicant grants in Table 1 (the “Total Incremental Funding Recommendation”). The Total Incremental Funding<br />Recommendation increases the upper-ceiling amount available for commitment for the relevant implementation period and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 100,000,000 for the following grant: Malaria - Regional Artemisinin Resistance Initiative (Cambodia, Lao PDR, Myanmar, Thailand and Viet Nam)</p>
2013-11-08 B30 GF/B30/DP06 2014 Operating Expenses Budget Approval Process 2014 Operating Expenses Budget Approval Process
<ol> <li>The Board delegates to theFinance and Operational Performance Committee (the “FOPC”) authority to approvean interim operating expenses budget for the first quarter of the 2014 fiscalyear (the “Q1 2014 Budget”), subject to the following:<br /><br /> <ol type="a"> <li>The Q1 2014 Budget will notexceed the first-quarter amount of the 2013 operating expenses budget; and<br /><br /></li> <li>The full 2014 operatingexpenses budget will be presented to the Board for approval at the Thirty-FirstBoard Meeting in February 2014.<br /><br /></li> </ol> </li> <li>This decision’s impact onthe 2014 operating expenses budget will not exceed USD 77.4 million.</li> </ol>
2013-11-22 B30 GF/B30/EDP02 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 30,831,682 for the following grants: BEN-T-PNTUB ; DMR-309-G07-T ; MON-H-MOH ; MWP-708-G06-H ; NIC-202-G05-T ; TGO-809-G08-H ; TGO-809-G09-H ; VTN-910-G08-T</p>
2013-12-20 B30 GF/B30/EDP04 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Incremental Funding under the New Funding Model” column), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches</p> <p>See attached tabledetailing total recommended funding amount of US$ 2,248,918 for the following grants: EGY-607-G02-T ; SUR-708-G04-M</p>
2014-02-28 B30 GF/B30/EDP07 Decision on the Secretariat’s Funding Recommendations for Early Applicants Decision on the Secretariat’s Funding Recommendations for Early Applicants
<p>The Board:</p> <p>Approves,in accordance with its decision to launch the transition to the New FundingModel (GF/B28/DP5), funding in the amount listed for the early-applicant grantsin Table 1 (the “Total Incremental Funding Recommendation”). The TotalIncremental Funding Recommendation increases the upper-ceiling amount availablefor commitment for the relevant implementation period and is subject to theavailability of funding and to the provision that the approved funding for eachgrant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 55,629,879. for thefollowing: Eurasian Harm Reduction Network (EHRN) (HIV/ AIDS), The RegionalMalaria Elimination Initiative in Mesoamerica and Hispaniola - EMMIE (Malaria)and Philippines (TB).</p>
2013-11-08 B30 GF/B30/DP05 Revision of the Policy on Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund Revision of the Policy on Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund
<ol> <li>The Board approves the amended policy on “Eligibility Criteria,Counterpart Financing Requirements and Prioritization of Proposals for Fundingfrom the Global Fund”<sup>[1]</sup>as set out in GF/B30/6 – Revision 1, Attachment 1 (the “Amended Policy”). TheAmended Policy, “The Global Fund Eligibility and Counterpart Financing Policy,”is effective upon the date of this decision and applies to all subsequenteligibility determinations.<br /><br /></li> <li>The Board requests the Strategy, Investment and Impact Committee and the Secretariat to initiate a process that by the end of 2014 will provide options and recommendations to the Board to refine the Global Fund’s approach to transitioning countries. This approach shall include consideration of appropriate public health indicators to measure progress in sustaining and enhancing gains against the three diseases.</li> </ol> <p> </p>
2013-11-07 B30 GF/B30/DP04 Revision to the Whistle-blower Policy Revision to the Whistle-blower Policy
<p>The Board decides to replace the Whistle-blowing Policy and Procedures for the Global Fund to Fight AIDS, Tuberculosis and Malaria (approved at the Twenty-Third Board Meeting) with the revised Whistle-blowing Policy and Procedures, as set forth in Annex 1 of the Report of the Audit and Ethics Committee (GF/B30/12 Revision 1).</p>
2013-11-08 B30 GF/B30/DP08 Appointment of Committee Leadership Appointment of Committee Leadership
<ol><li>The Board approves theappointment of:<br/><br/><ol type="a"><li>Claude Rubinowicz as Vice-Chair of the Audit and Ethics Committee;<br/><br/></li><li>Soltan Mammadov and Jason Lawrence as Chair and Vice-Chair,respectively, of the Finance and Operational Performance Committee; and<br/><br/></li><li>David Stevenson and Anita Asiimwe as Chair and Vice-Chair, respectively,of the Strategy, Investment and Impact Committee.<br/><br/></li></ol></li><li>The Board notes each Committee Chair andVice-Chair appointed under this decision shall begin their term on 1 March 2014and serve for two years or until the appointment of their successor.</li></ol>
2014-01-14 B30 GF/B30/EDP06 Appointment of Board Constituency representative to the Audit and Ethics Committee Appointment of Board Constituency representative to the Audit and Ethics Committee
<ol> <li>In accordance with paragraph 15.2 of the Global Fund’s Board and Committee Operating Procedures (‘Operating Procedures’) and after the approval of the Coordinating Group on 13 January 2014, the Board leadership decides to appoint Marc de Santis from the Canada/Switzerland constituency to serve as a member of the Audit and Ethics Committee (‘AEC’) to fill a current vacancy.<br /><br /></li> <li>Mr de Santis shall serve on the AEC for a two year term or until the appointment of his successor. This appointment is effective on 14 January 2014.</li> </ol>
2013-11-08 B30 GF/B30/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the Thirtieth Board Meeting (GF/B30/1) is approved.</p>
2013-11-22 B30 GF/B30/EDP01 Decision on the Secretariat’s Funding Recommendations for Grant Renewals Decision on the Secretariat’s Funding Recommendations for Grant Renewals
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 46,371,589 for the following grants: <span>ERT-H-MOH ; </span>ERT-T-MOH ; IRN-M-UNDP ; TLS-H-MOH</p>
2013-11-08 B30 GF/B30/DP07 The Global Fund Corporate Key Performance Indicator Framework for 2014-2016 The Global Fund Corporate Key Performance Indicator Framework for 2014-2016
<ol> <li>The Board:<br /><br /> <ol type="a"> <li>Notes and approves theGlobal Fund Key Performance Indicator Framework for 2014-2016 (the “KPIFramework”), as set forth in GF/B30/7 – Revision 1;<br /><br /></li> <li>Directs the Secretariat toreport annual key-performance-indicator results to the Board Committees and tothe Board, and where available, interim results will be made available throughthe routine information dashboard;<br /><br /></li> <li>Acknowledges that furthermethodological work is required to extend the scope of specified indicators, asdescribed in GF/B30/7 – Revision 1, and requests the Secretariat to submitindicator revisions to the Board for approval, with a complete KPI framework,including baselines for each measure, finalized by June 2014 (subject to agreedexceptions set forth in Annex 2 to GF/B30/7 – Revision 1);<br /><br /></li> <li>Directs the Secretariat tocomplement indicator results with sex and age dis-aggregated data wherefeasible; and<br /><br /></li> <li>Requests the Secretariat toregularly review performance targets to drive effectiveness and efficiency andsubmit any proposed changes to the Board for approval.<br /><br /></li> </ol> </li> <li>Budgetary implications of this decision will beincluded in the operating expenses budget of the Secretariat.</li> </ol>
2014-02-28 B30 GF/B30/EDP09 Decision on the Secretariat’s Funding Recommendations for Interim Applicants Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <ol> <li>Approves, in accordance with its decision to launchthe transition to the New Funding Model (GF/B28/DP5), incremental funding inthe amount listed for the interim-applicant grants in Table 3 (the “RecommendedIncremental Funding under the New Funding Model”), which will be in addition tothe relevant grants’ total budget amounts that the Board has already approvedfor the implementation period. The Recommended Incremental Funding under theNew Funding Model increases the upper-ceiling amount available for commitmentrather than representing the final funding amount for the relevantimplementation period, and is subject to the availability of funding and to theprovision that the approved funding for the relevant grants shall be committedin annual tranches.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 3,000,000 for the followinggrants: CAM-708-G12-T (Cambodia) and MLW-708-G05-M (Malawi).</p>
2013-11-07 B30 GF/B30/DP01 Appointment of Rapporteur Appointment of Rapporteur
Mr. David Stevenson from the Canada and Switzerland constituency is designated as Rapporteur for the Thirtieth Board Meeting.
2013-12-20 B30 GF/B30/EDP03 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants) Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 300,584,953 for the following grants: COL-011-G05-T ; COL-011-G06-T ; GUA-M-MSPAS ; KAZ-H-RAC ; KEN-011-G13-M ; KEN-011-G14-M ; MMM-011-G01-H ; PER-011-G08-H ; STP-011-G05-H ; SLE-M-CRSSL ; SLE-M-MOHS ; SOM-T-WV ; TNZ-405-G06-H ; TNZ-809-G13-H ; VTN-011-G10-S ; YEM-911-G07-T ; ZIM-M-UNDP</p>
2021-11-10 B45 GF/B45/EDP27 Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Indonesia) Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism (Indonesia)
<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020), as well as increases  to C19RM awards previously approved by the Board that either exceed USD 10 million or include interventions not previously approved by the Board;</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B45/ER22; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>
2021-07-21 B45 GF/B45/EDP07 Approval of the Report of the Global Fund 45th Board Meeting Approval of the Report of the Global Fund 45th Board Meeting
<p>The Board approves the Report of the 45th Board Meeting, as set forth in GF/B45/22.</p>
2021-10-12 B45 GF/B45/EDP20 Approval of the Report of the Global Fund Extraordinary Board Meeting (22 July 2021) Approval of the Report of the Global Fund Extraordinary Board Meeting (22 July 2021)
<p>The Board approves the Report of the Extraordinary Board Meeting, as set forth in GF/EBM01-2021/03.</p>
2016-02-11 B34 GF/B34/EDP11 Location of the 36th Board Meeting Location of the 36th Board Meeting
<p>1. The Board acknowledges that the meeting facilities needed to accommodate the 36th Board Meeting on the scheduled dates of 16-17 November 2016 will not be available in Geneva, Switzerland.</p><p>2. Accordingly, the Board agrees to convene the 36th Board Meeting in Montreux, Switzerland, as an exception to article B.6.1. of the Operating Procedures of the Board and Committees.</p>
2021-06-01 B45 GF/B45/EDP02 Revisions to the Terms of Reference of the Ethics Officer Revisions to the Terms of Reference of the Ethics Officer
<ol> <li>The Board recalls its ultimate ownership over the Ethics and Integrity Framework and its authority to appoint the next Global Fund Ethics Officer.</li> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves revisions to the Terms of Reference of the Ethics Officer, as set forth in Annex 1 to document GF/B45/ER02.</li> <li>The Board acknowledges that this decision point and the revisions to the Terms of Reference of the Ethics Officer shall supersede the approval of the previous Terms of Reference of the Ethics Officer, as set forth in Annex 1 to GF/B33/ER08 and pursuant to decision point GF/B33/EDP14 (July 2015).</li> <li>Accordingly, the Board instructs the Secretariat to launch the recruitment process to engage the next Global Fund Ethics Officer for appointment by the Board on a no-objection basis, following the joint recommendation of the EGC and the Executive Director.</li> </ol>
2015-11-16 B34 GF/B34/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the 34 <sup>th</sup> Board Meeting (GF/B34/01 - Revision 1) is approved.</p>
2016-03-24 B34 GF/B34/EDP16 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER12 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2006-04-28 B13 GF/B13/DP20 Launch of Round 6 Launch of Round 6
<p>The Board decides to launch Round 6 today.</p><p>The Sixth Call for Proposals, including the Guidelines for Proposals approved at this Board meeting, shall be issued by the Secretariat no later than thirty days after the date of this decision.</p><p>Round 6 proposals will be approved at the Fourteenth Board Meeting. </p><p>The Board requests the Finance and Audit Committee to present an estimate of resources available for Round 6 at the Fourteenth Board Meeting (based on the Comprehensive Funding Policy, as amended at the Thirteenth Board Meeting).</p><p> The Board has taken account of the various forecasts of assets presented at this Board meeting (GF/B13/11 Revision 1). The Board, noting the limited level of currently confirmed pledges for 2007, makes an urgent appeal to current and potential donors to expedite and increase their pledges for 2006 and 2007 so that Round 6 can be funded.</p>
2006-10-16 B13 GF/B13/EDP11 Approval of Phase 2 Funding Recommendations October 2006 Approval of Phase 2 Funding Recommendations October 2006
#
2006-08-07 B13 GF/B13/EDP04 Interim Continuation of Funding Policy Interim Continuation of Funding Policy
<p>The Board approves the following temporary measure for providing exceptional, time-limited funding (“Exceptional Extension Funding”) to grants that reach the end of their Phase-2 term (“Expiring Grants”). </p><p><span></span></p><ul><li>The Country Coordinating Mechanism (CCM) or, if appropriate, in the case of a non-CCM proposal, the grant applicant that has oversight over the Expiring Grant shall normally make the application for Exceptional Extension Funding of an Expiring Grant.<br/><br/></li><li><span></span> Eligibility for Exceptional Extension Funding will be based on the following criteria: <ul><li>The application for Exceptional Extension Funding must meet the eligibility criteria that apply to new proposals, including, but not limited to, country eligibility criteria and the requirements for CCMs approved by the Global Fund Board;</li><li>The applicant must not have received approval from the Global Fund Board for a new grant that fully continues the activities of the Expiring Grant; </li><li>The application must not seek to continue a grant that the Global Fund Secretariat has rated “C” in either of its last two disbursement requests prior to application.<br/><br/></li></ul></li><li><span></span> The Global Fund Board may provide Exceptional Extension Funding over a period that shall not extend beyond 30 November 2007. </li><li><span></span> The maximum Exceptional Extension Funding the Global Fund Board may grant under this decision shall be determined as follows: <ul><li>the number of months in the period over which the Global Fund Board is to provide Exceptional Extension Funding,</li><li>multiplied by: the average monthly amount the Principal Recipient (PR) is expected to spend during Phase 2 of the Program, based on the financial information set forth in the Program Budget contained in the grant agreement that covers the Expiring Grant,</li><li>less: any funds disbursed to the PR under the Expiring Grant agreement that are expected to be unspent or uncommitted at the end of Phase 2 of that grant and which can be employed during the Exceptional Extension Funding period, and any funds available under the Expiring Grant agreement that are expected to remain undisbursed at the end of Phase 2 of that grant and which can be made available during the Exceptional Extension Funding period.<br/><br/></li></ul></li><li><span></span> In the event the Global Fund Board approves additional funding to cover the same activities as those covered by the Exceptional Extension Funding (such as in a successful Round 6 application), the Secretariat shall adjust either funding so as to avoid duplicative financing of those activities.<br/><br/></li><li><span></span> Applicants can submit a “request for Exceptional Extension Funding” up to six months prior to the end of the term of the Expiring Grant. The Global Fund Secretariat will review the request, and provide a funding recommendation to the Global Fund Board for its approval under the “no-objection” voting procedure set forth in Section 12 of the Board Operating Procedures. </li></ul><p><span></span></p><p>The Global Fund Board shall not approve Exceptional Extension Funding under this decision once the Board has approved, and the Secretariat has brought into operation, the long-term continuation of funding policy that is currently under development.</p>
2006-04-28 B13 GF/B13/DP03 Approval of Report of the Twelfth Board Meeting Approval of Report of the Twelfth Board Meeting
The Report of the Twelfth Board Meeting (GF/B13/2) is approved, as amended at the Thirteenth Board Meeting.
2006-04-28 B13 GF/B13/DP38 Delegation of Authority to Sign Agreements Delegation of Authority to Sign Agreements
<p>1. The Board authorizes the Chair and Vice Chair of the Board and the Executive Director to execute agreements on the Board's behalf. As necessary and appropriate to maintain continuity of Secretariat operations, in the event the Executive Director is unavailable to exercise such authority, the Board authorizes each of the Deputy Executive Director, the Chief of Operations and the Senior Director, Business Services to execute agreements on the Board's behalf.</p> <p>2. The Board revokes the decision made at the 6<sup>th</sup> Board meeting regarding the Board's delegation of authority to execute agreements (GF/B7/2 p. 22).</p>
2020-03-10 B42 GF/B42/EDP04 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER04 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-05-04 B42 GF/B42/EDP12 Approval of dates and format of the 6th Partnership Forums Approval of dates and format of the 6th Partnership Forums
<p>The Global Fund Board, on 4 May 2020, decided on initial dates and locations for the 6th Partnership Forums for the development of the next Global Fund Strategy and, due to the evolving nature of the COVID-19 pandemic, delegated authority to its Strategy Committee to approve subsequent changes to 6th Partnership Forum locations and dates. On 5 October 2020, at its 14th meeting, the Strategy Committee decided to hold virtual Partnership Forums on the following revised dates:</p> <ol type="i"> <li>Partnership Forum I, 9-11 February, 2021: Eastern Europe and Central Asia &amp; Latin America and the Caribbean;</li> <li>Partnership Forum II, 17-19 February, 2021: Africa and MENA I;</li> <li>Partnership Forum III, 3-5 March, 2021: East Asia Pacific, South West Asia and MENA II.</li> </ol>
2020-04-09 B42 GF/B42/EDP11 Additional Support for Country Responses to COVID-19 Additional Support for Country Responses to COVID-19
<p>The Board agrees that the COVID-19 pandemic poses a global public health emergency and that failure to control the pandemic threatens to derail the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and strengthen systems for health. The Board acknowledges that without immediate action, health facilities, communities and geographies served by Global Fund programs will be severely impacted. As a major actor in global health, the Global Fund is uniquely positioned to deliver rapid support to countries developing responses to control the COVID-19 pandemic. In light of the urgency of the situation, and the need to take swift and decisive action with partners to control the impact of COVID-19 on the Global Fund mission and country health systems, the Board:</p> <ol> <li>Approves the creation of a temporary COVID-19 response mechanism (C19RM) to provide additional support for country responses to the pandemic and to ensure the continuity of the fight against HIV, tuberculosis, and malaria. C19RM will: <ol type="a"> <li>Support the rapid deployment of funds to support implementer countries’ COVID-19 responses, using expedited decision-making approaches determined by the Secretariat and coordinated with partners;</li> <li>Finance interventions consistent with World Health Organization (WHO) guidance on COVID-19 and national Strategic Preparedness and Response Plans, including: <ol type="i"> <li>COVID-19 control and containment interventions, including personal protective equipment, diagnostics, treatment, communications and other public measures as specified in WHO guidance;</li> <li>COVID-19-related risk mitigation measures for programs to fight HIV/AIDS, tuberculosis, and malaria; and</li> <li>Expanded reinforcement of key aspects of health systems, such as laboratory networks, supply chains, and community-led response systems, to address advocacy, services, accountability, and human-rights based approaches;</li> </ol> </li> <li>Finance interventions across the 5th and 6th replenishment periods;</li> <li>Be administered within the established internal control framework of the Global Fund; and</li> <li>Be additional to amounts approved by the Global Fund for programming towards COVID-19 interventions under existing grants.</li> </ol> </li> <li>Approves initial funding for C19RM of up to USD 500 million, comprised of: <ol type="a"> <li>USD 180 million from the USD 300 million of available funds approved by the Audit and Finance Committee on 16 March 2020 under GF/AFC12/DP01; and</li> <li>Up to USD 320 million of additional funds approved as available by the AFC under section E.6 of the Amended and Restated Comprehensive Funding Policy.</li> </ol> </li> <li>Agrees that C19RM funds may be used to procure COVID-19 products approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authorities as defined under the Quality Assurance Policy for Pharmaceutical Products and Quality Assurance Policy for Diagnostic Products.</li> <li>Agrees that C19RM is a Board-approved initiative for which the Global Fund may mobilize additional resources from private and public donors, in accordance with existing policy.</li> <li>Agrees that the Secretariat may approve requests for C19RM funds for an initial six-month period through 30 September 2020, and that C19RM funds may be used through 30 June 2021. These dates may be extended by the Board, based on updated information on needs as the pandemic evolves.</li> <li>Requests the Secretariat to further operationalize the investment and management modalities for C19RM, including working with partners to deliver critical technical assistance, ensuring the appropriate involvement of Country Coordinating Mechanisms and alignment with the Global Fund’s underlying principles of gender equity and human rights, and providing the flexibility to take rapid action, including at global and regional level, in close collaboration with WHO and other critical partners, and provide regular reporting to the Board on the operationalization of C19RM, including on any investments made with C19RM funds.</li> </ol>
2006-06-21 B13 GF/B13/EDP02 Approval of Phase 2 Funding Recommendations June 2006 Approval of Phase 2 Funding Recommendations June 2006
#
2019-11-14 B42 GF/B42/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Mary Isaac from the Latin American and Caribbean constituency is designated as Rapporteur for the 42nd Board Meeting</p>
2019-11-14 B42 GF/B42/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 42nd Board Meeting (GF/B42/01-Revision 1) is approved.</p>
2020-02-14 B42 GF/B42/EDP03 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER03 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-05-11 B42 GF/B42/EDP13 Appointment of the Chair of the Ethics and Governance Committee (EGC) for the 2020-2022 term Appointment of the Chair of the Ethics and Governance Committee (EGC) for the 2020-2022 term
<ol> <li>The Board approves the appointment of Magda Robalo Correia e Silva as Chair of the Ethics and Governance Committee.</li> <li>The Board notes that the Chair of the Ethics and Governance Committee appointed under this decision point shall begin her term on 16 May 2020 and serve for two years or until the appointment of her successor.</li> </ol>
2020-02-05 B42 GF/B42/EDP02 Approval of the Report of the Global Fund 42nd Board Meeting Approval of the Report of the Global Fund 42nd Board Meeting
<p>The Board approves the Report of the 42nd Board Meeting, as set forth in GF/B42/ER22.</p>
2019-11-14 B42 GF/B42/DP05 Evolving the wambo.org pilot for non-Global Fund-financed orders Evolving the wambo.org pilot for non-Global Fund-financed orders
<ol> <li>Based on the recommendation of the Strategy Committee as presented in GF/B42/04- Revision 1, the Board:<br /><br /> <ol type="i"> <li>reaffirms the importance of wambo.org and supports evolving the wambo.org pilot approved by the Board pursuant to GF/B37/DP09, as the number of transactions was increased pursuant to GF/SC09/DP01, to further its development and advancement;</li> <li>decides that, in connection with the evolution of the wambo.org pilot, wambo.org may be made available for non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for all products, services and functionalities as they become available on wambo.org, subject, if applicable, to agreement by the product catalogue owners, as described in GF/B42/04- Revision 1, up to a cap of USD 50 million of transactions within the above scope from the date of this Decision Point; and</li> <li>instructs the Secretariat to undertake consultations early in 2020, an evaluation of the wambo.org pilot in 2022 and bi-annual reporting on progress of the wambo.org pilot to the Strategy Committee.<br /><br /></li> </ol> </li> <li>The Board delegates to the Strategy Committee the authority to: <ol type="i"> <li>approve a higher cap for transactions within the scope of Section 1(ii) above on a pilot basis prior to the consultations in 2020; and</li> <li>establish the future parameters of the wambo.org pilot within the scope of Section 1(ii) above, based on the outcome of the 2020 consultations.</li> </ol> </li> <li>The Board requests the Secretariat to include the results of the evaluation referred to in Section 1(iii) in the development of a strategy for future advancement of wambo.org to be presented for Board approval at the conclusion of the wambo.org pilot for non-Global Fund-financed orders no later than November 2022.</li> </ol>
2020-03-12 B42 GF/B42/EDP05 Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of: <ol type="i"> <li>Michael Ruffner as Chair of the Audit and Finance Committee;</li> <li>Edward Ouko as Vice-Chair of the Audit and Finance Committee;</li> <li>Suomi Sakai as Vice-Chair of the Ethics and Governance Committee;</li> <li>Rico Gustav as Chair of the Strategy Committee; and</li> <li>Gunilla Carlsson as Vice-Chair of the Strategy Committee.</li> </ol> </li> <li>The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 16 May 2020 and serve for two years or until the appointment of their successor.</li> </ol>
2019-11-14 B42 GF/B42/DP06 Revisions to the selection process of the members of the Board Standing Committees and to the Charters of the Board Standing Committees Revisions to the selection process of the members of the Board Standing Committees and to the Charters of the Board Standing Committees
<p>The Board, cognizant of the overarching desire of fostering the further participation of constituencies across the Board Standing Committees, and mindful that the composition of the Board Standing Committees should reflect the broad partnership that brings together representatives from donor and implementer governments, communities, civil society, the private sector, the private foundations and the technical partners:</p> <ol> <li>Expresses its sincere appreciation for the comprehensive work done by the Ethics and Governance Committee (“EGC”) over the course of the last year in relation to the strengthening the process for the selection of committee members.</li> <li>Decides that the Board Leadership shall consider the principles set out below when submitting the list of proposed members for committee membership pursuant to article 43.3 of the Board and Committees Operating Procedures as of the next selection process of the members of the Board Standing Committees:<br /><br /> <ol type="i"> <li>Each voting constituency should be represented in the Strategy Committee (“SC”) and the Audit and Finance Committee (“AFC”) for at least one term within a three two-year terms cycle;</li> <li>Each voting constituency should be represented, in any given term, in at least, the SC or the AFC;</li> <li>For the above committees, the implementer group representation should include government and civil society/communities;</li> <li>Each voting constituency should have the opportunity to have an individual nominated by it serving in their personal capacity in the EGC within a three two-year terms cycle;</li> <li>In setting out the list of proposed members, the Board Leadership shall consider experience, competency, continuity and gender balance.<br /><br /></li> </ol> </li> <li>Decides to amend article 4 of the Charter of the EGC by deleting the words “according to a pre-established rotation of membership of constituencies”; the revised article 4 of the EGC Charter, as amended, shall therefore read as follows: “Nomination and appointment of Committee Members shall be according to the Operating Procedures of the Board and Committees”.</li> <li>Decides to amend article 3.a. the Charter of the SC and article 3.a. of the Charter of the AFC by, in each case, increasing the number of voting representatives of constituencies from the implementer group by one; the revised article 3.a. of the Charter of the SC and article 3.a. of the Charter of the AFC, as amended, shall therefore read as follows: “Six voting representatives of constituencies from the implementer group”.</li> <li>Decides to amend article 3.b. of the Charter of the SC and article 3.b. of the Charter of the AFC by increasing the number of voting representatives of constituencies from the donor group by one in each case; the revised article 3.b. of the Charter of the SC and article 3.b. of the Charter of the AFC, as amended, shall therefore read as follows: “Six voting representatives of constituencies from the donor group”.</li> <li>The amendments to the EGC Charter, the AFC Charter and the SC Charter set out in paragraphs 3 to 5 of this decision point shall enter into force upon the expiry of the term of the current EGC, the AFC and SC in May 2020.</li> </ol>
2019-12-23 B42 GF/B42/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-04-09 B42 GF/B42/EDP08 2019 Statutory Financial Statements 2019 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2019 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B42/ER07.</p>
2020-04-09 B42 GF/B42/EDP10 Operational Flexibilities to Ensure Continued Operations during COVID-19 Operational Flexibilities to Ensure Continued Operations during COVID-19
<p>The Board acknowledges the severe negative impact COVID-19 is having on country health systems and Global Fund programs to fight the three diseases. The Board agrees with the need for temporary flexibilities to ensure the continued delivery of the Global Fund’s core mission during a prolonged period of disruption.</p> <p>Based on the recommendation of the Secretariat, as presented in GF/B42/ER09 – Revision 1, the Board approves the following:</p> <ol> <li>In order to account for delays in the supply chain due to COVID-19 disruptions, the Secretariat may allow additional flexibility for the deadline for delivery of goods and services under Global Fund programs to be funded from the 2017-2019 allocation period, up to a maximum of 180 days after the implementation period end date;</li> <li>In order to ensure swift deployment of portfolio optimization funds, the Secretariat may approve the increase of grant amounts to integrate awards of portfolio optimization funds approved by the Secretariat in line with the Strategy Committee-approved prioritization framework, where such funds have been approved as available by the AFC, with subsequent reporting to the Board; and</li> <li>In order to mitigate risks of disruption to the supply of health products in-country, the Secretariat may grant limited exceptions to the Quality Assurance Policies, to waive the requirement for pre-shipment sampling and testing for Expert Review Panel-approved products, vector control products, and condoms, where such testing may delay the delivery of products to countries.</li> </ol> <p>The Secretariat may apply the temporary flexibilities described in paragraphs 2 and 3 above for an initial six-month period, subject to renewal by the Board. The Secretariat may apply the flexibility described in paragraph 1 through 30 June 2021.</p>
2006-04-28 B13 GF/B13/DP29 Phase 2 Nigeria Grants (NGA-102-G01-H-00; NGA-102-G03-H-00) Phase 2 Nigeria Grants (NGA-102-G01-H-00; NGA-102-G03-H-00)
<p><b>Decision Point 1:</b> </p><p>The Board declines to approve additional funding for the Phase 2 period of the Nigeria Grant number NGA-102-G01-H-00 (Expansion of Prevention of Mother to Child Centers of Excellence). </p><p><b>Decision Point 2:</b> </p><p>The Board declines to approve additional funding for the Phase 2 period of the Nigeria Grant number NGA-102-G03-H-00 (Program for the expansion of anti-retroviral therapy in Nigeria).</p>
2006-04-28 B13 GF/B13/DP24 Length of term for the Technical Review Panel Chair Length of term for the Technical Review Panel Chair
The Board decides that the Technical Review Panel Chair may serve as Chair for no more than two rounds. The normal term limit of four rounds for TRP members may be extended for two rounds in the event that a member is approved as Chair.
2006-07-17 B13 GF/B13/EDP05 Approval of Phase 2 Funding Recommendations July 2006 Approval of Phase 2 Funding Recommendations July 2006
#
2006-04-28 B13 GF/B13/DP23 Appointment of TRP Members and Support Group Appointment of TRP Members and Support Group
<p>The Board approves:</p><p>a) Dr. Blaise Genton as a new Technical Review Panel (TRP) member to fill the vacancy of a Malaria expert commencing from Round 6;</p><p>b) In respect of Round 6, seventeen (17) Alternate Member positions in total, and specifically in respect of the 2006 TRP replenishment process, those persons recommended by the Portfolio Committee and the Executive Director from the Support Group to fill the fourteen (14) Round 6 TRP Alternate Member position vacancies (as presented in Table 1 of Annex 7 of GF/B13/8); and</p><p>c) A Technical Review Panel Support Group (as presented in Table 1 of Annex 7 of GF/B13/8), comprising the group of experts from which TRP membership will be replenished in the event of TRP member vacancies as they may arise.</p>
2006-09-28 B13 GF/B13/EDP09 Approval of Phase 2 Funding Recommendations September 2006 Approval of Phase 2 Funding Recommendations September 2006
#
2006-04-28 B13 GF/B13/DP06 Earlier Initiation of TRP Clarifications and LFA Assessments Earlier Initiation of TRP Clarifications and LFA Assessments
The Board endorses the recommendation of the Policy and Strategy Committee, as part of the strategic issue of "Optimizing Grant Performance", that the Technical Review Panel (TRP) clarification and Local Fund Agent assessment processes begin prior to Board approval of the proposals submitted by the Country Coordinating Mechanisms ("CCMs"). The Board therefore requests the Portfolio Committee to recommend for approval to the Board specific conditions for the application of this decision in time for it to apply to the next round of proposals. These conditions shall include, but not be limited to, a statement to the CCM by the Secretariat that a TRP recommendation shall only result in the Global Fund awarding a grant if the recommendation is approved by the Board, which retains the sole authority to make such approvals.
2006-04-28 B13 GF/B13/DP02 Appointment of the Rapporteur Appointment of the Rapporteur
Mr. Carsten Staur from the Point Seven Constituency is designated as Rapporteur for the Thirteenth Board Meeting.
2006-04-28 B13 GF/B13/DP14 Comprehensive Funding Policy Comprehensive Funding Policy
<p>The Board amends paragraphs (a) and (c) of decision point 3 under the Comprehensive Funding Policy approved at the Sixth Board Meeting as follows:</p> <p>3. Proposals are approved for the entire term of the proposal (up to five years) with a financial commitment for the initial two years with the possibility of renewal for up to an additional three years, with the following conditions:</p> <p>a. The Board may approve proposals and commit funds for two years up to the cumulative uncommitted amount of assets <span style="text-decoration: line-through;">pledged through the calendar year of the Board decision</span> <u>that the Board determines will be available at the time of signing the related grant agreements in accordance with 3(b)</u>;</p> <p>b. A sufficient amount of assets to meet the full cost of two years of implementation of approved grants must be deposited with the Trustee or readily available on demand prior to the Secretariat signing a grant agreement;</p> <p>c. Based on successful implementation of a grant, funding beyond its first 2 years receives priority over the funding of new proposals. <u>A sufficient amount of assets to meet the cost of such additional funding for the grant must be deposited with the Trustee or readily available on demand prior to the Secretariat signing an amendment to the grant agreement committing such additional funding</u>;</p> <p>d. No funds for appeals should be reserved. Successful appeals should be funded immediately if resources are available or as soon as new resources become available.</p>
2006-09-13 B13 GF/B13/EDP08 Approval of Funding Recommendations for Kosovo Round 4 Tuberculosis Grant Approval of Funding Recommendations for Kosovo Round 4 Tuberculosis Grant
<span>The Board authorizes the Secretariat to change the Program Starting Date of the Kosovo Round 4 TB grant (KOS-405-G01-T) from 1 July 2005 to 1 April 2006. </span>
2006-04-28 B13 GF/B13/DP18 Replenishment Replenishment
The Board recognizes the importance of the replenishment in ensuring sustainable and predictable funding, and its role in increasing the Global Fund's donor base. The Board requests the Finance and Audit Committee to continue its oversight role of the process and to guide the Mid Term Replenishment.
2006-04-28 B13 GF/B13/DP28 Local Fund Agents Local Fund Agents
<p>The Board takes note of the fact that the term of existing contracts with LFAs is coming to an end in October/November 2006 and that it will soon be necessary to enter into new ones. </p><p>The Board expresses its desire that contracting arrangements with LFAs reflect the outcome of the strategy development process, as well as the outcomes of the ongoing work of the Portfolio Committee in this area. </p><p>To that end, the Board requests the Secretariat to explore and make contractual arrangements that advance that goal. </p>
2006-04-28 B13 GF/B13/DP10 Executive Director Performance Review 2005 Executive Director Performance Review 2005
The Board takes note of the Report on Performance by the Executive Director (GF/B13/5), including performance against Key Performance Indicators in 2005, and expresses its satisfaction with the results achieved.
2006-04-28 B13 GF/B13/DP35 Lobbying Policy Lobbying Policy
The Board approves the "Code of Conduct for Contacts with Members of the Global Fund Involved in Funding Decisions" set forth as Annex 2 to the Report of the Ethics Committee (GF/B13/6) and decides that this code of conduct shall be put on the Global Fund website and that a copy shall be sent to all Country Coordinating Mechanisms and Principal Recipients with all funding application materials. The Board decides that the Code of conduct shall also apply with regard to the selection of the Executive Director of the Global Fund. The Board further decides that all violations of this Code of Conduct shall be reported promptly to the Ethics Committee for action, which may include, among other things, placing funding in jeopardy by reporting all violations of the code as part of the information used in the funding decision.
2006-04-28 B13 GF/B13/DP05 Facilitating Pooled Procurement Facilitating Pooled Procurement
The Board endorses, in principle, the recommendation of the Policy and Strategy Committee, as part of the strategic issue of "Optimizing Grant Performance", that the Global Fund facilitate the provision of voluntary pooled procurement for recipients of grants subject to the development and Board approval of a suitable feasibility and business plan. To that end, the Board requests that the Policy and Strategy Committee further explore possible strategic models for and implications of including Global Fund facilitation of the provision of pooled procurement, and report to the Board on progress at the Fourteenth Board meeting. 
2006-04-28 B13 GF/B13/DP34 Whistle-blowing Policy Whistle-blowing Policy
<p>The Board approves the Whistle-blowing policies set forth in Annex 1A and 1B in the Report of the Ethics Committee (GF/B13/6), as amended below, and encourages the Office of Inspector General to implement these policies as soon as practical.</p><p>Footnote 3 in the Whistle-blowing policy for the Secretariat and Governance Bodies of The Global Fund to Fight AIDS, Tuberculosis and Malaria (Annex 1A) is amended to read as follows:</p><p>This section shall not apply to Secretariat staff until such time as the World Health Organization determines that the Policy may be implemented under WHO rules and takes all administrative steps to facilitate its implementation.</p>
2006-04-28 B13 GF/B13/DP27 Grant Consolidation Grant Consolidation
The Board supports in principle the concept of Grant Consolidation and requests that the Portfolio Committee explores the implications of, and possible models for grant consolidation, and to prepare a report and recommendation to the Board at the Fifteenth Board meeting.
2006-04-28 B13 GF/B13/DP21 Revised Eligibility Criteria for Round 6 Revised Eligibility Criteria for Round 6
<p>The Board decides that for Round 6, proposals from applicants whose economies are classified by the World Bank as "upper-middle income" may become eligible if the applicant falls under the "small island economy" exception to the International Development Association lending eligibility requirements, regardless of national disease burden.</p><p>This decision does not affect the applicability of counterpart financing and other eligibility requirements.</p><p>The Board requests the Portfolio Committee to review eligibility criteria for upper-middle income countries for Round 7 and provide recommendations at the Fourteenth Board Meeting.</p>
2006-04-28 B13 GF/B13/DP30 Assessment of Executive Director Assessment of Executive Director
<p>The Board reaffirms its commitment to the performance measurement system for the Executive Director adopted at the Ninth Board Meeting in Arusha and requests the Chair and the Vice-Chair to appoint a Performance Assessment Committee, consisting of four Board Members (or Alternates) which is tasked with:</p> <ul> <li>concluding the 2005 Performance Report of the Executive Director in the context of the adapted procedure agreed for 2005, the Management Response to the IOS Report and the Report of the Oversight Committee;</li> <li>implementing the full performance measurement system in respect of the Executive Director's performance objectives and targets for 2006, with particular attention to establishing a revised list of competencies against which performance will be measured;</li> <li>compiling an interim report for the Board to be presented at the Fourteenth Board meeting in November 2006; and</li> <li>compiling a final report for the Board to be presented at the Board meeting scheduled for April 2007.</li> </ul>
2006-04-28 B13 GF/B13/DP26 Funding for Green Light Committee Activities Funding for Green Light Committee Activities
<p>The Board recognizes the essential service provided by the Green Light Committee as a unique entity that ensures the quality of multi-drug resistant tuberculosis control programs. The Board reaffirms its decision taken at the Third Board Meeting, which requires recipients of Global Fund grants to procure second-line anti-tuberculosis drugs through the Green Light Committee, and recognizes that the Green Light Committee provides a package of services for multi-drug resistant tuberculosis control treatment that cannot be disaggregated. The Board urges the Green Light Committee to develop a proactive resource-mobilization effort to attract other donor funding.</p><p>The Board decides that applicants: </p><ol start="1" type="i"><li>applying for grants with multi-drug resistant tuberculosis control components in Round 6 and beyond; or</li><li>submitting a Request for Continued Funding for grants with multi-drug resistant tuberculosis control components as of January 2007,</li></ol><p>must include a cost-sharing element for Green Light Committee services. To limit transaction costs, this will be defined by the Secretariat in consultation with the Green Light Committee as a flat rate per grant per year that will not exceed US$ 50,000 per grant per year. This figure is subject to review by the Portfolio Committee. </p><p>The Board requests the Secretariat to explore mechanisms to apply these cost-sharing principles for Green Light Committee services to programs funded by grants in Rounds 1 through 5 that are not already covered by paragraph (a) (ii) of this decision and report back to the Board at the Fourteenth Board Meeting.</p>
2006-05-15 B13 GF/B13/EDP01 Approval of Phase 2 Funding Recommendations May 2006 Approval of Phase 2 Funding Recommendations May 2006
#
2006-04-28 B13 GF/B13/DP37 Chair of the Ethics Committee Chair of the Ethics Committee
<p>The Board accepts the resignation of Ms Anandi Yuvaraj from the position of Chair of the Ethics Committee. </p><p>The Board accepts the resignation of the Latin American and Caribbean constituency from the Ethics Committee, and approves its replacement by the Eastern and Southern Africa constituency.</p><p>The Board appoints Professor Sheila Dinotshe Tlou of the Eastern and Southern Africa constituency as Chair of the Ethics Committee.</p>
2020-04-15 B42 GF/B42/EDP09 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER08 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-03-18 B42 GF/B42/EDP06 Appointment of a Replacement Member on the Strategy Committee Appointment of a Replacement Member on the Strategy Committee
<p>The Board approves the appointment of Ms Reem Ghanim Al-Sulaiti, representing the Additional Public Donors Constituency, as a non-voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</p>
2020-05-11 B42 GF/B42/EDP14 Appointment of the Members of the Standing Committees of the Board Appointment of the Members of the Standing Committees of the Board
<p>1. The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:</p> <ol type="i"> <li>Arun Thangaraj, Canada, Switzerland and Australia;</li> <li>Maurine Murenga, Communities;</li> <li>Revanta Dharmarajah, Developed Country NGO;</li> <li>Sara Mohammed, Eastern Mediterranean Region;</li> <li>Malefia Dereje, Eastern and Southern Africa;</li> <li>Pasqualino Procacci, European Commission, Belgium, Italy, Portugal, Spain;</li> <li>Gilles Angles, France;</li> <li>Guillermo Birmingham, Latin America and the Caribbean;</li> <li>Greg Ferrante, Private Foundations;</li> <li>Sherwin Charles, Private Sector;</li> <li>Bharati Das, South East Asia; and</li> <li>Chris Taylor, United Kingdom.</li> </ol> <p>The Board appoints the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:</p> <ol start="13" type="i"> <li>Heesun Shin, Additional Public Donors; and</li> <li>Alexandru Chitic Patapievici, World Bank.</li> </ol> <p>2. The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:</p> <ol type="i"> <li>Alexander Schulze, Canada, Switzerland and Australia;</li> <li>Berry Nibogora, Developing Country NGO</li> <li>Mohamed Chakroun, Eastern Mediterranean Region;</li> <li>Rudolph Maziya, Eastern and Southern Africa;</li> <li>Anders Nordström, Point Seven;</li> <li>Renuka Gadde, Private Sector;</li> <li>Sandra Thurman, United States; and</li> <li>Pascal Niamba, West and Central Africa.</li> </ol> <p>3. The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:</p> <ol type="i"> <li>J. Carolyn Gomes, Developing Country NGO;</li> <li>Nataliya Nizova, Eastern Europe and Central Asia;</li> <li>Nduku Kilonzo, Eastern and Southern Africa;</li> <li>Stéphanie Seydoux, France;</li> <li>Birgit Pickel, Germany;</li> <li>Naoki Akahane, Japan;</li> <li>Marja Esveld, Point Seven;</li> <li>Kieran Daly, Private Foundations;</li> <li>Suriya Wongkongkathep, South East Asia;</li> <li>Mamadi Yilla, United States</li> <li>Oumar Djalo Boukou, West and Central Africa; and</li> <li>Jim Tulloch, Western Pacific Region.</li> </ol> <p>Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee:</p> <ol start="13" type="i"> <li>Lucica Ditiu, Partners (Stop TB);</li> <li>Victor Bampoe, UNAIDS; and</li> <li>Mubashar Sheikh, World Health Organization.</li> </ol> <p>4. The Board notes each of the individuals appointed under this decision point shall begin his/her term on 16 May 2020 and serve for two years or until the appointment of his/her successor.</p>
2016-02-10 B34 GF/B34/EDP09 Approval of the Report of the 34th Board Meeting Approval of the Report of the 34th Board Meeting
<p>The Board approves the Report of the 34th Board Meeting, as set forth in GF/B34/25.</p>
2015-11-17 B34 GF/B34/DP07 Enhanced Governance Structure Enhanced Governance Structure
<ol> <li> <p>Based on the recommendations of the Transitional Governance Committee (the "TGC"), presented in GF/B34/18 - Revision 1, the Board:</p> a. Approves, in principle, the establishment of the following three standing committees (the "Standing Committees") and each Standing Committee's respective purpose, functions, and composition: <br />i. Audit and Finance Committee to exercise the powers and perform the functions set forth in the draft charter presented in Annex 1 to GF/B34/18 - Revision 1; <br />ii. Ethics and Governance Committee to exercise the powers and perform the functions set forth in the draft charter presented in Annex 2 to GF/B34/18 - Revision 1; <br />iii. Strategy Committee to exercise the powers and perform the functions set forth in the draft charter presented in Annex 3 to GF/B34/18 - Revision 1; <br /><br />b. Endorses, in principle, the draft: <br />i. Amended and restated Terms of Reference of the Coordinating Group, as set forth in Annex 4 to GF/B34/18 - Revision 1; <br />ii. Amended and restated Bylaws, as set forth in Annex 5 to GF/B34/18 - Revision 1; and <br />iii. Amended and restated Operating Procedures of the Board and Committees, as set forth in Annex 6, revision 1, to GF/B34/18 - Revision 1; and <br /><br />c. Notes that the Standing Committees shall replace the Audit and Ethics Committee, Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee upon the conclusion of the first Board meeting in 2016. <br /><br /></li> <li> <p>Accordingly, the Board requests the TGC (i) consider all potential refinements, suggested by the Board, to the charters and other core governance documents referenced in paragraph 1 above and (ii) propose final versions to the Board for approval as soon as possible to enable the Chair and Vice-Chair of the Board to launch the process for the Board to appoint the Chairs and Vice-Chairs, as well as membership, of the Standing Committees, by no later than the first Board meeting in 2016.</p> </li> </ol>
2016-03-04 B34 GF/B34/EDP14 Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board
<p>1. The Board approves the appointment of:</p> <p>a. Greg J. Ferrante as Chair of the Audit and Finance Committee;</p> <p>b. Beatrijs Stikkers as Vice-Chair of the Audit and Finance Committee;</p> <p>c. Mohamed Salah Ben Ammar as Chair of the Ethics and Governance Committee;</p> <p>d. Jan Paehler as Vice-Chair of the Ethics and Governance Committee;</p> <p>e. Dorothée Kinde-Gazard as Chair of the Strategy Committee; and</p> <p>f. Julia Martin as Vice-Chair of the Strategy Committee.</p> <p>2. The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 1 May 2016 and serve for two years or until the appointment of their successor.</p>
2015-12-23 B34 GF/B34/EDP02 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p><ol><li><i></i> Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B34/ER02 (collectively, "Table 1");</li><li><i></i> Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li><li><i></i> Approves the reinvestment of within-allocation efficiencies for the Zanzibar TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER02;</li><li><i></i> Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li><li><i></i> Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li></ol>
2016-03-14 B34 GF/B34/EDP20 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p><p><br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER14.</p>
2015-11-16 B34 GF/B34/DP04 Strategic Framework 2017 - 2022 Strategic Framework 2017 - 2022
<p>1. Based on the recommendation of the Strategy, Investment and Impact Committee (the "SIIC"), the Board approves the Strategic Framework 2017 - 2022, as set forth in Annex 1 to GF/B34/11, and notes the next steps of presenting further details in a final strategy narrative and on implementation planning.</p> <p>2. As such, the Board requests the Secretariat to submit the final strategy narrative through the SIIC for Board approval at the first Board meeting in 2016, taking into consideration lessons from implementing the current strategy, recommendations from the Strategic Review 2015, and additional input collected throughout the strategy development process.</p>
2015-11-16 B34 GF/B34/DP03 Strategic Review 2015 Strategic Review 2015
<p>1. Based on the recommendation of the Strategy, Investment and Impact Committee (the "SIIC"), the Board:</p> <p>a. Acknowledges the results and recommendations of the Strategic Review 2015 commissioned by the Technical Evaluation Reference Group (the "TERG"), as presented in GF/B34/10;</p> <p>b. Requests the Secretariat to consider the TERG's recommendations as it prepares the final strategy narrative that will be presented for the SIIC to review and recommend to the Board for approval by the first Board meeting in 2016; and</p> <p>c. Requests the Secretariat to provide the SIIC with its response to the TERG's recommendations in relation to the current strategic period.</p> <p>2. The Board also notes its appreciation for the TERG and its evaluation team for their work to commission and produce the Strategic Review 2015.</p>
2015-11-17 B34 GF/B34/DP06 Global Fund Board’s commitment on Replenishment Global Fund Board’s commitment on Replenishment
<ol><li><p>The Board:</p><p>a. Expresses its strong commitment to the Global Fund Fifth Replenishment (2017-2019) aimed at raising the appropriate levels of funding for implementation of the "Investing to End Epidemics" Strategy; </p><p>b. Recognizes the importance of the preparatory meeting that will take place in Tokyo in December 2015; and</p> c. Acknowledges the challenging environment for mobilizing resources, the need to continue maximizing the Global Fund's results and impact, and the initiative to maximize absorption capacity. <br/><br/></li><li>Accordingly the Board will: <br/><br/> a. Explore options to enhance its active engagement in contributing towards a successful outcome of the Replenishment, including the broadening of the donor base; and <br/><br/> b. Seek the support of high-level individual(s) who, in collaboration with the Board leadership and Secretariat, will advocate on its behalf for a successful Global Fund Replenishment.</li></ol>
2016-01-27 B34 GF/B34/EDP08 Appointment of the Ethics Officer Appointment of the Ethics Officer
<p>1. The Board: <br /> a. Notes its approval of the Terms of Reference of the Ethics Officer (the "Terms of Reference") (GF/B33/EDP14); <br /> b. Notes the requirement set forth in the Terms of Reference whereby the Audit and Ethics Committee ("AEC") and the Executive Director are to jointly select the Ethics Officer, for appointment by the Board on a no-objection basis; <br /> c. Notes the AEC's delegation of authority to Claude Rubinowicz and Wendy Harrison to jointly select, with the Executive Director, the Ethics Officer for recommendation to the Board (GF/AEC12/EDP02); <br /> d. Recognizes the work of the AEC, the Executive Director and the Secretariat to select a suitable candidate for this position; and <br /> e. Accepts the joint recommendation of the AEC and the Executive Director, as set forth in document GF/B34/ER07.</p> <p>2. Accordingly, the Board: <br /> a. Approves the appointment of Nick Jackson to the position of Global Fund Ethics Officer for a three-year term which can be renewed no more than once; and <br /> b. Authorizes the Secretariat to enter into a contract of employment with Nick Jackson for an annual salary subject to the Amended and Restated Global Fund Human Resources Policy Framework, and requests the Secretariat to proceed with that process pursuant to standard Human Resources procedures. <br /><br /></p>
2016-01-13 B34 GF/B34/EDP04 Approval of 2016 Targets for the 2014 – 2016 Corporate Key Performance Indicator Framework Approval of 2016 Targets for the 2014 – 2016 Corporate Key Performance Indicator Framework
<p>1. The Board:</p> <p>a. Acknowledges the Secretariat's presentation of the mid-2015 performance assessments for the 2014-2016 Corporate Key Performance Indicator Framework, as set forth in GF/B34/08; and</p> <p>b. Notes the Secretariat's response to requests by the Board at its November 2015 meeting for additional analysis on certain indicators, including proposed management actions to improve performance, as set forth in GF/B34/ER03 - Annex 1.</p> <p>2. Accordingly, the Board:</p> <p>a. Approves the 2016 performance targets presented in GF/B34/ER03 - Annex 1; noting the revisions to the 2016 performance targets for KPI 7 (Access to Funding) and KPI 10 (Value for Money); and</p> <p>b. Directs the Secretariat to implement its proposed management actions, continue to identify lessons that can inform the next Corporate Key Performance Indicator Framework, and update the committees and the Board at their first meetings in 2016.</p>
2016-02-22 B34 GF/B34/EDP13 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
The Board: <br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER09.
2015-11-17 B34 GF/B34/DP05 2016 Corporate Work Plan and Operating Expenses Budget 2016 Corporate Work Plan and Operating Expenses Budget
<p>1. Based on the recommendation of the Finance and Operational Performance Committee (the "FOPC"), the Board approves the following: </p><p>a. Corporate Work Plan and Budget Narrative 2016, as set forth in GF/B34/13; and</p><p>b. 2016 Operating Expenses Budget up to the amount of USD 305.0 million, as set forth in GF/B34/14 (the "2016 OPEX Budget"), which includes USD 16.3 million for the Office of the Inspector General's 2016 operating expenses based on the recommendation of the Audit and Ethics Committee</p><p>2. The Board requests the Secretariat to include in its periodic reporting to the FOPC on budget matters:</p><p>a. The foreign-exchange impact on the 2016 OPEX Budget, as requested by the Board in 2010 (GF/B22/DP18), tracked against budget rate;</p><p>b. Budgetary variations by type of expenses; and</p><p>c. Progress updates on the priority projects and activities outlined in the 2016 OPEX Budget. </p><p>3. The Board notes operating expenses over the 2014 - 2016 period, including the 2016 OPEX Budget, remain within the USD 900 million reserved for operating expenses at the time the Board approved the resources available for allocation over the 2014 - 2016 period</p><p> <br/><br/></p>
2016-01-28 B34 GF/B34/EDP07 Enhanced Governance Structure Enhanced Governance Structure
<p>1. Based on the recommendations of the Transitional Governance Committee (the "TGC"), as presented in GF/B34/ER06, the Board approves:</p> <p>a. The establishment of the following three standing committees (the "Standing Committees"):</p> <p>i. Audit and Finance Committee</p> <p>ii. Ethics and Governance Committee;</p> <p>iii. Strategy Committee;</p> <p>b. The following core governance documents, which shall each become effective upon the conclusion of the first Board meeting in 2016:</p> <p>i. Charter of the Audit and Finance Committee, as set forth in Annex 1 to GF/B34/ER06;</p> <p>ii. Charter of the Ethics and Governance Committee, as set forth in Annex 2 to GF/B34/ER06;</p> <p>iii. Charter of the Strategy Committee, as set forth in Annex 3 to GF/B34/ER06;</p> <p>iv. Terms of Reference of the Coordinating Group, as amended and restated in Annex 4 to GF/B34/ER06;</p> <p>v. Bylaws, as amended and restated in Annex 5 to GF/B34/ER06; and</p> <p>vi. Operating Procedures of the Board and Committees, as amended and restated in Annex 6 to GF/B34/ER06.</p> <p>2. The Board acknowledges the Standing Committees shall replace the Audit and Ethics Committee, Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee upon the conclusion of the first Board meeting in 2016.</p> <p>3. Accordingly, the Board requests the:</p> <p>a. Chair and Vice-Chair of the Board to launch the process for the Board to appoint the Chairs and Vice-Chairs, as well as membership, of the Standing Committees, by no later than the first Board meeting in 2016; and</p> <p>b. Secretariat, under the oversight of the Coordinating Group, to update any policies or prior decisions needed to align with the core governance documents approved under paragraph 1 of this decision point</p>
2016-01-18 B34 GF/B34/EDP06 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B34/ER03 (collectively, "Table 1");<br/>2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the reinvestment of within-allocation efficiencies for the Bangladesh TB and Thailand TB/HIV grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER03;<br/>4. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2015-12-07 B34 GF/B34/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p> The Board:</p><p>1. Acknowledges that there are ongoing audit and investigation by the Office of the Inspector General ("OIG") on existing Nigeria grants, which, as of the date of this decision point, has revealed evidence pointing to: (1) serious weakness in financial, supply-chain, non-health product procurement and programmatic management in individual grants at both Principal Recipient and sub-recipient levels and, despite the uncompromising efforts of the Secretariat, such weakness in certain instances has manifested in fraud and misappropriation of grant funds, and (2) country risks across the Nigeria portfolio of the Global Fund;</p><p>2. Considers that Nigeria is the most populous country in Africa and its high disease burden of HIV and TB has important impact on the global epidemics and that disengaging Nigeria or halting the launch of the new grants to Nigeria to deliver the proposed targets in the TB/HIV concept note is not a preferred option at this stage if the Global Fund is to fulfil its mission;</p><p>3. Approves the incremental funding recommended for each disease component, and its constituent grants, as listed in Table 1 of Section IV of GF/B34/ER01 ("Table 1"), provided that the Secretariat (1) pursues a full recovery, as it has done for other Nigeria recoveries and as supported by evidence, of the amounts derived from the confirmed findings and recommendations of the OIG in accordance with the Global Fund policies, (2) continues its efforts to enforce risk-mitigating mechanisms currently in place and other enhanced measures planned for new grants, and (3) duly implements all additional risk-mitigating actions agreed between the Secretariat and the OIG for the Nigeria portfolio;</p><p>4. Acknowledges that each grant approved under this decision will be implemented by the proposed Principal Recipients listed in Table 1 or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with this decision point and other Global Fund policies;</p><p>5. Affirms that the incremental funding approved under this decision (1) increases the upper-ceiling amount that may be available for the relevant implementation period of each grant listed in Table 1, (2) is subject to the availability of funding, and (3) shall be committed in annual tranches;</p><p>6. Acknowledges that while Nigeria, through the TB/HIV concept note, has requested to access its 2014 Allocation fully, the funding recommended in Table 1 does not exhaust such allocation so as to preserve flexibility to address uncertainties and potential needs associated with a differentiated approach and OIG findings for implementing the TB and HIV programs, and accordingly that the Secretariat through a separate report to the Board may recommend further funding for Nigeria's TB and HIV programs from the country's remaining allocation; and</p><p>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and related funding request initially reviewed and recommended by the TRP.</p>
2016-02-11 B34 GF/B34/EDP10 Location of the 35th Board Meeting Location of the 35th Board Meeting
<p>1. The Board:</p> <p>a. Welcomes the invitation of the government of Côte d'Ivoire to host the Global Fund's 35th Board Meeting on 26-27 April 2016; and</p> <p>b. Acknowledges the recommendation of the Secretariat set forth in GF/B34/ER08.</p> <p>2. Accordingly, the Board agrees to convene the 35th Board Meeting in Côte d'Ivoire.</p><p><b><i></i></b> </p>
2015-12-23 B34 GF/B34/EDP03 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
The Board: <br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER02.
2016-03-14 B34 GF/B34/EDP19 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/><br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER14 ("Table 1");<br/><br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV to GF/B34/ER14 ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09.<br/><br/>4. Approves the reinvestment of within-allocation efficiencies for the Congo (Democratic Republic) malaria grant and its resultant total program budget, as listed in Table 2;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for Mozambique malaria disease component and its constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-04-07 B34 GF/B34/EDP18 Appointment of External Auditor Appointment of External Auditor
<p>Based on the Audit and Ethics Committee recommendation, set forth in GF/B34/ER13, the Board authorizes the appointment of KPMG SA as the Global Fund's external auditor for an initial three year term beginning with the 2016 fiscal year.</p>
2015-11-16 B34 GF/B34/DP01 Appointment of Rapporteur Appointment of Rapporteur
Mr Kieran Daly from the Private Foundations constituency is designated as Rapporteur for the 34th Board Meeting.
2016-03-24 B34 GF/B34/EDP17 Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions
The Board:<br/>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B34/ER12.
2016-04-21 B34 GF/B34/EDP21 Operating Procedures of the Board and Committees Operating Procedures of the Board and Committees
<p>1. The Board notes its January 2016 approval (GF/B34/EDP07) of the amended and restated Operating Procedures of the Board and Committees, which become effective upon the conclusion of the 35th Board Meeting in April 2016.<br /><br />2. Based on the recommendation of the Transitional Governance Committee, the Board approves the amendments to Articles 15, 16, 20, 22 and 36 of the Operating Procedures of the Board and Committees, as set forth in Annex 1 to GF/B34/ER15 (the "Amended Provisions"), which become effective upon the date of this decision and will be incorporated into the amended and restated Operating Procedures of the Board and Committees.</p>
2019-11-14 B42 GF/B42/DP04 2020 Work Plan and Budget Narrative and the 2020 Operating Expenses Budget 2020 Work Plan and Budget Narrative and the 2020 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the following:</p> <ol> <li>2020 Work Plan and Budget Narrative, as set forth in GF/B42/03A; and</li> <li>the 2020 Operating Expenses Budget in the amount of US$ 305 million, as set forth in GF/B42/03B (the “2020 OPEX Budget”), which includes US$ 15.24 million for the Office of the Inspector General’s 2020 operating expenses.</li> </ol>
2019-11-14 B42 GF/B42/DP03 Sources and Uses of Funds for the 2020-2022 Allocation Period Sources and Uses of Funds for the 2020-2022 Allocation Period
<ol> <li>Based on the recommendation of the Audit and Finance Committee (the “AFC”), as presented in GF/B42/02, the Board decides the amount of sources of funds for allocation for the 2020-2022 allocation period is USD 13.00 billion, comprised of the following amounts, in accordance with the Comprehensive Funding Policy set forth in Annex 1 to GF/B36/02 – Revision 1 and approved through decision point GF/B36/DP04:<br /><br /> <ol type="i"> <li>USD 13.25 billion, derived from the announced replenishment results of the Sixth Replenishment (2020-2022), net of certain adjustments; and</li> <li>USD 0.65 billion of forecasted unutilized funds from the 2017-2019 allocation period;</li> <li>to which a reduction of USD 0.90 billion of forecasted aggregate operating expenses for the 2020-2022 allocation period is applied.<br /><br /></li> </ol> </li> <li>Based on the recommendation of the Secretariat, made in accordance with its delegated authority from the Board pursuant to decision point GF/B41/DP04, and after consultation with the Strategy Committee, the Board approves the use of an additional USD 0.09 billion for the 2020-2022 allocation period’s catalytic investments, bringing the total amount for catalytic investments for the 2020-2022 allocation period to USD 0.89 billion, to be made available for the priorities and associated costs set forth in Annex 1 of GF/B42/02.</li> <li>Additionally, based on the recommendation of the AFC and to help ensure the maximum amount of impact and use of funds over the 2020-2022 allocation period, the Board requests that the Secretariat include an additional USD 0.60 billion in the amount used to determine country allocations pursuant to the Allocation Methodology for the 2020-2022 Allocation Period as approved pursuant to GF/B41/DP03 (the “Allocation Methodology”).</li> <li>Accordingly, the Board decides the amount of sources of funds for country allocation for the 2020-2022 allocation period is USD 12.11 billion, to which USD 0.60 billion will be added prior to determining the country allocation, to be used in accordance with the Allocation Methodology and decision point GF/B41/DP03.</li> </ol>
2020-04-09 B42 GF/B42/EDP07 2019 Annual Financial Report 2019 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2019 Annual Financial Report, including the 2019 Consolidated Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B42/ER07.</p>
2002-10-10 B03 GF/B03/DP02 Approval of the Rapporteur Approval of the Rapporteur
The Chair thanked the Private Sector representative, Mr Rajat Gupta, for serving as Rapporteur during the Second Board Meeting and proposed Dr Christoph Benn, Member for the Developed Country NGOs, as Rapporteur for the Third Board Meeting. This proposal was unanimously accepted. 
2002-10-10 B03 GF/B03/DP15 Measures Related to Procurement and Supply Management (Product Selection, Quality Assurance, Procurement and Pricing, Budgeting and Finance, Monitoring and Evaluation) Measures Related to Procurement and Supply Management (Product Selection, Quality Assurance, Procurement and Pricing, Budgeting and Finance, Monitoring and Evaluation)
<p>The Global Fund Board decided on the following measures related to procurement and supply management:</p> <p>A. PRODUCT SELECTION AND RATIONAL USE</p> <p><u>1. List of medicines to be procured</u></p> <p>Fund resources may be used only to procure medicines which appear in current national, institutional or World Health Organization (WHO) standard treatment guidelines (STGs) or essential medicines lists (EMLs). The relevant STG or EML should be included in the proposal submitted to the Fund. Unlisted products may be procured only with appropriate and specific rationale presented in the proposal, as judged by the Technical Review Panel (TRP).</p> <p><u>2. Plans for preventive, diagnostic and other public health products</u></p> <p>Proposals for purchase of medications must be accompanied in the proposal by a plan of enabling diagnostics and other major categories of supplies related to the provision of these medications.</p> <p><u>3. Adherence, drug resistance and monitoring adverse effects</u></p> <p>a) It is strongly recommended to Recipients that they implement mechanisms to encourage adherence to treatment (including but not limited to Fixed Dose Combinations (FDCs), once-a-day formulations, blister packs, and peer education and support), to monitor and contain resistance, and to monitor adverse drug reactions (ADRs) according to existing international guidelines and, if necessary, drawing on budgeted requests for financial support from the Fund.</p> <p>b) To help contain resistance to second-line TB drugs and consistent with the policies of other international funding sources, all procurement of medications to treat Multi Drug Resistant TB (MDR-TB) must be conducted through the Green Light Committee (GLC). [http://www.who.int/gtb/policyrd/DOTSplus.htm]</p> <p>B. QUALITY ASSURANCE</p> <p><u>4. Compliance with quality standards</u></p> <p>a) For any medicinal product to be eligible for purchase with Fund resources, its compliance with quality standards must be assured. For multi-source, off-patent products with available dosage from public pharmacopoeial quality standards, verification of product compliance with standards would be conducted in accordance with the existing national procedures of the Recipient’s country.</p> <p>b) Provided products are accepted by the national drug regulatory agency (NDRA)of the Recipient country (see 5 below), to be eligible for purchase with Fund resources any single or limited source product (that is, a medicinal product for which there are not publicly available quality assurance standards, analytic methods, and reference standards) must (a) have been found to be acceptable by the WHO-initiated UN Pilot Procurement Quality and Sourcing Project, or (b) have been authorized for consumption in its country by a stringent regulatory authority, [For the purposes of this policy a stringent drug regulatory authority is defined as a regulatory authority in one of the 28 countries which is either a PIC/S and/or ICH member] or (c) have been authorized by the national drug regulatory authority in the Recipient’s country. Option (c) is applicable only until December 31, 2004, after which suppliers must comply with one of the two standards as set out in (a) and (b) and in all cases are subject to monitoring product quality standards prescribed by the Fund as in 6.1.</p> <p><u>5. National drug registration</u></p> <p>a) Products procured with Fund resources are subject to authorization by the National Drug Regulatory Authority (NDRA) in the country in which they will be used, following its standard practices for drug registration for pharmaceutical products. For products that have passed the UN Pilot Procurement Quality and Sourcing Project review, as described in above, NDRAs are encouraged to expedite registration by accepting WHO pre-qualification inspection and supporting dossiers in lieu of national requirements.</p> <p>b) For products which have been authorized by stringent drug regulatory authorities, NDRAs are encouraged to expedite registration by accepting in lieu of national requirements the Executive Summary of the Common Technical Document (CTD) or Summary parts for quality, safety and efficacy together with all necessary information to perform quality control testing of products and necessary reference standards.</p> <p><u>6. Monitoring product quality</u></p> <p>a) Recipients, their procurement agents, or NDRA’s must systematically draw random samples of pharmaceutical products purchased with Fund resources for quality control testing to monitor compliance with quality standards. Testing may be budgeted in proposals, to be funded by the Fund. For multi-source off-patent products with available public standards, samples should be sent to WHO-recognized laboratories in cases where the NDRA have no capacity for this testing.</p> <p>b) For single- or limited-source products without public standards and pre-qualified by UN Pilot Procurement Quality and Sourcing Project, samples should be sent to WHO-recognized laboratories already participating in the WHO pre-qualification project in case the NDRA has no capacity. For single- or limited-source products that have been pre-qualified on the basis of authorization by a regulatory authority in an ICH and/or PIC/S member, testing shall be done by a laboratory identified by the purchaser as stated in the purchase contract. The laboratory should be a WHO-recognized laboratory, or a laboratory in ICH and/or PIC/S countries in case the country does not have identified laboratory capacity.</p> <p>C. PROCUREMENT AND PRICING</p> <p><u>7. Procurement practices</u></p> <p>The Fund will require that, as a minimum, Recipient procurement offices and any contracted agencies/services adhere to the Interagency Operational Principles for Good Pharmaceutical Procurement. [Operational Principles for Good Pharmaceutical Procurement (Interagency document). WHO, Geneva, 1999. WHO/EDM/PAR/99.5. www.who.int/medicines/library/par/who-edm-par-99-5/who-edm-par-99-5.htm] Where practices differ from the Interagency Guidelines, Recipients or their agents must demonstrate to the LFA comparable systems for competitive bidding within a group of pre-qualified suppliers, transparency and accountability to their practices, and their application of necessary quality assurance mechanisms. Recipients should also demonstrate the existence of a full set of contractual documentation to govern each transaction.</p> <p><u>8. Procurement responsibilities</u></p> <p>a) The Recipient is responsible for all procurement, with the use of contracted local, regional or international procurement agents being at the discretion of the Recipient. The exception to this would be for those product categories for which local procurement capacity is insufficient, as judged by the Procurement and Supply Management Assessment. For such product categories, Recipients would be required to use established regional or international procurement services and will be informed by the Fund on which mechanisms are available. </p> <p>b) Even for product categories for which Recipients have procurement capacity, the use of capable regional and global procurement services is encouraged wherever pooling of demand lowers prices for products of assured quality.</p> <p><u>9. Monitoring supplier performance</u></p> <p>Recipients are responsible for monitoring the performance of suppliers with respect to product and service quality and for submitting that information electronically for web publication through a mechanism established by or identified by the Fund. Reporting guidelines for supplier performance should be specified by the LFA, according to guidelines provided by the Secretariat of the Fund.</p> <p><u>10. Lowest possible price</u></p> <p>a) The Fund requests Recipients to use Good Procurement Practices, which includes competitive purchasing from qualified manufacturers and suppliers, as outlined in section B of these recommendations, to attain the lowest price of products. The Fund encourages Recipients to comply with national laws and applicable international obligations in the field of intellectual property including the flexibilities provided in the TRIPS agreement and referred to in the Doha declaration in a manner that achieves the lowest possible price for products of assured quality.</p> <p>b) The Fund encourages the voluntary efforts of pharmaceutical companies to expand current tiered or preferential pricing arrangements, among other mechanisms, to promote differential pricing.</p> <p>c) Disclosure of information on prices paid for purchases by Fund Recipients is a matter of principle and will facilitate a process leading to lower prices. The Fund will ensure that information on prices paid on products of assured quality with the same conditions (e.g., including other goods or services included in the contract) is made publicly available. The disclosure of this information will be pursued by the Fund. A methodology for assuring this transparency will be presented to the Board by January 2003.</p> <p>d) In the cases of this policy, price refers to DDU costs – delivered duty unpaid. The approach taken may be to publicly list average, minimum, maximum, and mode prices and/or prices for individual companies and/or Recipients. This choice requires further consideration by the Fund to identify or develop standard methods to ensure to the extent possible that price information is based on a consistent set of definitions. It is understood that price comparisons are indicative and must include special “add ons”/conditions included in the price and that actual prices will vary.</p> <p><u>[...]</u></p> <p>E. BUDGETING AND FINANCE</p> <p><u>17. Direct payment to suppliers upon delivery</u></p> <p>Prompt payment in compliance with the terms of payment of the contractual provisions encourages timely delivery of products and reduces transaction costs. Direct payment to suppliers by the Trustee, on confirmation of delivery, will be allowable upon request of the Secretariat if, as confirmed by the LFA, such payment arrangements are expected to reduce costs and to be consistent with necessary accounting requirements.</p> <p><u>18. Exemption from duties, tariffs and taxes</u></p> <p>a) The Fund strongly encourages the relevant national authorities in the Primary Recipient’s country to exempt from duties and taxes all public health products financed by the Fund to NGOs, groups of NGOs, or national authorities, or any other PRs.</p> <p>b) In any case, Fund resources may not be used to pay duties, tariffs, local or national taxes on public health products procured with Fund resources. If payment of such fees is required by relevant national authorities, such payment is the responsibility of the Recipient.</p> <p><u>19. Additionality of Fund resources and contribution to sustainability</u></p> <p>a) The Fund encourages Recipients to manage and to apply Fund resources as part of a sustainable long-term plan for local public health financing. Recipients will be required to declare in the original proposal to the Fund other international financing and product donation programs being utilized by Recipients. Ongoing indicators must show the magnitude of product financing supported by domestic versus international financing.</p> <p>b) Programs which include consumer cost recovery mechanisms are eligible for funding by the Fund when such programs are part of a pre-existing healthcare financing policy, which should be specified in the proposal to the Fund; in these cases, the budget request to the Fund must not duplicate costs to be reimbursed by consumers.</p> <p><u>[...]</u></p> <p><u>21. Prices used for budgeting proposals</u></p> <p>a) For budget requests for pharmaceutical products, proposals to the Fund must use the lessor of current procurement prices, firm offers from suppliers, or existing public price information sources specified by the Secretariat in the Guidelines for Proposals. A rationale for budgeting using prices other than those specified above should be described in the proposal. All prices should be expressed in standard trade terminology to allow transparent comparison.</p> <p>b) During implementation, these budgeted prices will not act as a defined reimbursable ceiling or floor to the full cost of products paid by the Recipient, provided that products are of assured quality and that procurement practices adhere to the policies of the Recipient and Fund.</p> <p>F. MONITORING AND EVALUATION</p> <p><u>22. Monitoring the performance of procurement and supply systems</u></p> <p>a) Prior to disbursement, Recipients must prepare a plan for monitoring the performance and sustainability of procurement and supply management systems. The monitoring plan should include tracking of procurement prices, distribution costs, additionality of Fund resources to domestic and other international sources, and other measures of procurement and supply system performance and sustainability. Indicators for monitoring should be agreed with the Fund and included in the Grant Agreement. The Secretariat of the Fund will make available a menu of existing international indicators with agreed methodology to support this process.</p> <p>b) Baseline data for agreed “core” indicators must be gathered before Fund-supported services and products may be delivered. The baseline survey should be done prior to the Grant Agreement as part of the Procurement and Supply Management assessments undertaken by the LFA.</p> <p><u>23. The Board also approved several follow-up items to be considered by the Portfolio and Procurement Committee (Reference numbers refer to the Report of the Task Force on Procurement and Supply Management) :</u></p> <p>a. Reference 2.1: Diagnostics and other major categories related to provision of medications;</p> <p>b. Reference 4.2.c): A study of the degree of intensity, the frequency, monitoring, and how frequent the testing and monitoring should be done, along with the costs involved;</p> <p>c. Reference 6.1: A study of :</p> <p>• the need to decide on how to make a judgment on NDRA capacity to proceed with analysis of multi-source products, and if required make a recommendation on this topic to the Board;</p> <p>• the potential conflicts of interest involved when products are manufactured in a state-owned laboratory and the Principal Recipient is a public entity;</p> <p>• the potential conflicts of interest involved when products are manufactured or purchased in a state-owned structure and the state is responsible for quality;</p> <p>d. Reference 8.1: Review the feasibility and options for partnering relevant global bidding mechanisms;</p> <p>e. Reference 8.2: Review the feasibility or necessity of global or regional procurement or bidding mechanisms for product categories for which such mechanisms do not currently exist. The Fund will not, in any case, take on such procurement responsibilities itself;</p> <p>f. Reference Annex IV, p. 7: Review specific recommendations on capacity building;</p> <p>g. Reference 10.1: Perform a feasibility study, including a full cost analysis, to develop a pricing reporting mechanism as outlined in the pricing section that will require that information on prices paid by Recipients is made publicly available through existing international pharmaceutical pricing services or be made public by the Fund. This includes determining who will publish the pricing information. Taking into account that it is a difficult matter, the Portfolio Management and Procurement Committee will study the best way of achieving this objective;</p> <p>h. Reference 12: Study and make recommendations regarding the issue of domestic production;</p> <p>i. Reference 18.1: Study the impact of the policy on duties, tariffs, and taxes, including specifically the impact on NGOs, and make appropriate recommendations to the January 2003 Board meeting; </p> <p>j. Explore the necessity for the continuation for a special Procurement and Supply Management Task Force and review the memberships of such a Task Force.</p>
2002-10-10 B03 GF/B03/DP10 Approval of Policy on Ethics and Conflict of Interest Approval of Policy on Ethics and Conflict of Interest
<p>The Board will recognize and accept that all constituencies have interests and that these may lead to potential, actual and perceived conflicts of interest. Article 14 of the By-Laws makes provision for a policy on this matter to be established. To ensure fairness in the Board’s decision-making and to protect the Fund’s interests, the Board adopts the Policy on Ethics and Conflict of Interest, which applies to all Board members and other interested persons (including, but not limited to, alternates, members of any Committee, expert panel, Technical Review Panel, and employees of the Secretariat including the Executive Director). This policy is based on clear definitions of potential areas of conflict, a duty to disclose, and a mechanism for managing conflicts as they arise.</p><p>The Policy on Ethics and Conflict of Interest is adopted subject to refinement as appropriate based on legal review, and applies to all activities from here on including consideration of Round 2 proposals. This policy currently applies to both personal and institutional conflicts. Subsequent review should focus attention on institutional conflicts, and the differentiation between personal and institutional conflicts of interest.</p>
2002-10-10 B03 GF/B03/DP03 Approval of Second Board Meeting Report Approval of Second Board Meeting Report
<ol> <li>The Report of the 2nd Meeting of the Board held 22-24 April 2002 was approved, noting the following correction:“Dr Kiyonga, Chair of the Board, opened the session and thanked the United Nations Secretary-General for hosting The Global Fund session and for his ongoing support to the Fund. The Secretary-General, Mr. Kofi Annan, gave a speech to welcome the Fund’s Board members, delegates and representatives and to reaffirm the global commitment to fight HIV/AIDS, tuberculosis, and malaria. Following his remarks, comments were made by the following delegates: Mr. Rajat Gupta (Private Sector), Minister of Health Girolamo Sirchia (Italy), Dr. Huang Jiefu (Vice-Minister, Ministry of Health, China) Mr. Gordon Conway (Rockefeller Foundation), Secretary Tommy Thompson (United States), Mr. John Junor (Jamaica), Ms Milly Katana (NGOs), and a representative of the South East Asia Region.</li> <li>The references to the delegation of the Gates Foundation should be changed to Private Foundations. In addition it should be noted that the section on new Board Members is inaccurate since the appointment of Professor Lucas as the Board Member for West and Central Africa was only officially made on 1 May 2002, after the Board meeting.</li> <li>The current practice will continue that minutes will be distributed via email to Board Members for review and comment. Thereafter a revised version will be sent by email to Board Members. These final minutes will be ratified by the Board at their next meeting. The fact of formally ratifying the minutes at a Board meeting does not preclude action being taken on those minutes between Board meetings. Any changes to this process should be the subject of a formal Board decision.</li> <li>It was emphasized that should any changes to the approval process of the draft Board minutes be requested, they should be made while being careful not to delay the work of the Secretariat.</li> </ol>
2002-10-10 B03 GF/B03/DP05 Board and Committee Roles and Functions Board and Committee Roles and Functions
<ol><li>The Board reconfirms its role as stated in Article 14 of the Bylaws.</li><li> Committee matters:<br/><ol><li>Committees will be established according to need with defined terms of reference and deliverables.</li><li>All committees will be reviewed at each Board meeting for decisions on continuation and/or modification.</li><li>There will initially be four (4) committees: <ol type="A"><li>Monitoring, Evaluation, Finance and Audit: Reviewing Fund progress with a view to managing performance including: <ol type="A"><li type="i">financial budget oversight and the mechanisms for accomplishing it (e.g. external audit);</li><li type="i">updates on programmatic progress in beneficiary countries, including its impact on reducing disease burden;</li><li type="i">results based disbursement and overall performance of the Fund at a global level.</li></ol></li><li>Portfolio Management and Procurement: <ol type="A"><li type="i">includes previous and ongoing work of the Proposals Working Group such as TRP review guidelines</li><li type="i">the proposals appeal process (recourse mechanism)</li><li type="i">policies related to grants management;• policies on procurement and supply management.</li></ol></li><li>Resource Mobilization: <ol type="A"><li type="i">supporting the development of projections of resource needs;</li><li type="i">supporting the development of strategies to achieve mobilization targets, especially through cooperative work of Board members and constituencies.</li></ol></li><li>Governance and Partnerships: <ol type="A"><li type="i">focus on making the bodies of the Fund work effectively, including Board processes and structure;</li><li type="i">personnel policies;</li><li type="i">policies on interactions among Board, TRP, Secretariat and Partnership Forum;</li><li type="i">CCM partnership (including a tool on minimum standards of “good practice” for CCM processes, building on experiences from the first two rounds and partner organizations, and evaluating the CCM process and practices, with this work beginning immediately) and policies related to expanding partnerships at the global level.</li></ol></li></ol></li></ol></li><li>In consultation with the Executive Director, the committees should develop Terms of Reference and circulate these to the Board for approval.</li></ol>
2002-10-10 B03 GF/B03/DP08 Board Meeting Room Credentials Principles Board Meeting Room Credentials Principles
The status quo will be retained, namely that five members (the Board member and four others) of each constituency should be allowed in the Board meeting room. There will be video transmission of Board proceedings to a controlled-access room occupied by the additional delegation and Secretariat members who do not have access to the main Board meeting room.
2002-10-10 B03 GF/B03/DP01 Approval of the Agenda Approval of the Agenda
The Board adopted the meeting agenda with the provision that the topic on communication be included under the Global Partnerships Agenda item and CCM issues be discussed during the item on the Report of the Proposals Working Group. The issue of introducing agenda topics will be addressed under the item on the Report of the Governance Working Group. 
2002-10-10 B03 GF/B03/DP13 Approval of MEFA Decisions Approval of MEFA Decisions
<ol><li>The Global Fund Board decided to adopt the decision points requested by the Working Group on Monitoring and Evaluation and ask the M.E.F.A Committee to report back to the Board on progress on their implementation at the meeting of the Board in January, 2003. <ol><li type="a">The Board instructed the Secretariat to prepare annual action plans for monitoring and evaluation of the Global Fund’s performance, and instruct the M.E.F.A. Committee to present a plan appropriate to its mandate as agreed by the Board;</li><li type="a">The Board endorsed the principles of transparency, consultation with stakeholders and coordination of monitoring and evaluation efforts to facilitate optimal use of existing partner capacity, while satisfying the needs of major donors and their internal auditing requirements;</li><li type="a">The Board reaffirmed the importance of linking results to an appropriate disbursement schedule and annual results reviews, and instructed the Secretariat to include results-reporting templates in grant agreements with PRs, ensuring PRs clearly understand the concept of Results Based Disbursement;</li><li type="a">The Board instructed the Secretariat to operationalize an approach for results reviews, which includes a provision for annual results reviews, review criteria, and a strengthening of information systems making this reporting feasible;</li><li type="a">The Board instructed the Secretariat to clarify the role and responsibilities of CCMs, PRs, LFAs and the Fund Secretariat regarding monitoring and reporting within the context of the fiduciary architecture of the Global Fund;</li><li type="a">The Board instructed the Secretariat to define quality assurance in the context of the Fund’s mission, and identify mechanisms for ensuring data quality;</li><li type="a">The Board endorsed the need to set budgetary parameters for monitoring and evaluation at the Fund level and to reconfirm the need for grant proposals to include budgets for monitoring and evaluation.</li></ol></li><li>The Board directs the M.E.F.A. Committee to review the recommendation that there be an independent secretariat in the field of monitoring and evaluation and to report on this matter to the January, 2003 Board meeting</li><li>The Board directs the M.E.F.A. Committee to consider the need for periodic focused external audits of the performance of the Global Fund, or aspects of the Global Fund, and to bring recommendations to the Board in January 2003.</li></ol>
2002-10-10 B03 GF/B03/DP06 Committee Membership Principles Committee Membership Principles
<ol><li>There should be a balance between chairs from developed and developing countries. There should be one chair per committee. The committee chair shall appoint a vice chair of the committee.</li><li>Committee chairs will preferably be either Board members or alternates. The Board will also approve any vice chairs who are appointed by committee chairs. The Board Chair/Vice Chair will select the committee chairs and submit these names to the full Board for approval. The Board will also approve any vice chairs who are appointed by committee chairs.</li><li>The Board Chair/Vice Chair will be able to designate or replace committee chairs when necessary as, for example, when a committee chair is no longer available, or is not adequately fulfilling the role. The Board will approve the change of any committee chair.</li><li>Committees will have a minimum of six and a maximum of twelve members.</li><li>The Board Chair/Vice Chair, in consultation with the committee chair and the ED, will propose the constituencies to be included on each committee, based on applications made by constituencies for committee seats, for full Board approval. There will be no more than one member per constituency on any single committee.Each constituency may participate in a maximum of three committees. Where demand for committee seats exceeds the maximum, priority will be given to ensuring the balance of donors, recipient countries, NGOs, private sector and foundations.</li><li>Constituencies will designate an individual to represent them on a given committee. While it is preferable that constituencies choose Board members or alternates to serve on committees, they are free to choose any individual to represent them.</li><li>While substitutes should be discouraged, committee members will be able to send substitutes as an exception without the approval of the committee chair.</li><li>Only committee members (or their substitute) will attend committee meetings, unless other individuals are invited to do so by the committee chair.</li><li>Expert input should be provided at the discretion of committees and in consultation with the Executive Director and may take the form of a panel of independent experts. The committee chair and vice chair, in conjunction with the ED, will then choose the panel of independent experts from the list of nominations submitted by the committee. The Board will not need to approve the specific list of individuals selected. These independent experts will be subject to the agreed conflict of interest provisions. When Board committees have designated an expert panel, the expert panel will be able to meet with the full committee, or (at the committee’s discretion) independently, with only the committee chair and/or vice-chair); in either case, Board/constituency members who are not members of the committee will not attend these expert panel meetings, unless invited to do so by the committee. The committee will provide terms of reference for expert panels.</li></ol>
2002-10-10 B03 GF/B03/DP11 Approval of the Documents Policy Approval of the Documents Policy
The Board adopts The Global Fund Documents Policy, subject to refinement as appropriate based on legal review. As outlined in the policy, the Board will operate under a principle of maximum transparency and openness; subject to the restrictions outlined in the policy, the Board will make public all documents and records. As outlined in the policy, the Fund and the Board will not release any document or otherwise disclose information which is for discussion (“deliberative“) or “pre-decisional“ in order to encourage dialogue among Board members and other units of the Fund. As outlined in the policy, deliberative information will only be shared with the members of constituencies who need to provide input to the Board member. As outlined in the policy, all Board decisions, actions, or other final statements will be made public under the general principle of openness and transparency.As outlined in the policy, in extremely limited and sensitive circumstances, such as personnel actions, business proprietary information, or resource mobilization and other strategies, the Fund will not release information to the public.
2002-10-10 B03 GF/B03/DP04 Commission of an Additional Legal Opinion on Delegation of Authority Commission of an Additional Legal Opinion on Delegation of Authority
At the request of the Board, and to address concerns regarding this delegation of authority, it was decided to commission a separate legal opinion to ensure that the by-laws allow for appropriate decision-making authority to be granted to the Chair and Vice-Chair between Board meetings.
2002-10-10 B03 GF/B03/DP07 Board Membership and Participation Principles Board Membership and Participation Principles
<ol><li>The status quo will be retained, namely that constituencies will be able to change the alternate as needed and, as stated in the Board Operating Procedures, should confirm the appointment preferably at least two weeks prior to a scheduled Board meeting. If abused the Board should revisit the policy on alternate Board members.</li><li>Other members of a delegation shall only have the right to speak or participate directly in the deliberations of the Board when doing so at the request of and in place of the Board Member of their delegation and the Chair should be informed of this in advance. Only one individual from a constituency, including the Board Members/Alternate, may speak per agenda item. Alternate Members may speak during debates or cast votes, when replacing the Board Member.</li><li>While the Board Chair/Vice Chair is presiding, his/her alternate (or any member of his/her delegation as stipulated by the Board Chair/Vice Chair) from the Board Chair/Vice Chair’s constituency will be permitted to participate in the discussion. However, but the Board Chair/Vice Chair will retain the single vote of the constituency.</li></ol>
2002-10-10 B03 GF/B03/DP12 Attribution of Committee Leadership Seats Attribution of Committee Leadership Seats
<p>With reference to Section 2.3.2, the Board decided to appoint the following constituencies to Chair the four Committees: - Governance and Partnership : Italy; Resource Mobilization: East and Southern Africa; Portfolio Management and Procurement: South East Asia; Monitoring, Evaluation, Finance and Audit: Point Seven or USA (to be decided). </p><p>Individual nominees from these constituencies will be submitted to the Chair for review and submission to the Board for approval.</p>
2002-10-10 B03 GF/B03/DP09 Board Meeting Principles Board Meeting Principles
<ol><li>The Board will have three regular in-person meetings per year, two to be held in Geneva and one to be held in a recipient country (with optional visits, as appropriate, to programs supported by the Global Fund before or after the meeting). The location of the recipient country of Board meetings will rotate appropriately between regions. Meetings will generally be kept to two days in length. Committees will normally meet before and/or after the Board meetings, at the discretion of the committee chair and depending on their program of work. When deciding on the location of meetings, due consideration will be given to ensuring that delegations are not faced with any difficulties in visiting the selected country, especially as regards visa requirements.</li><li>The Board Chair/Vice Chair are empowered to make decisions on matters within their discretion between Board meetings . These decisions will be presented to the Board at its next meeting. (Legal advice will be sought on whether the implementation of this decision requires a change to Article 17 of the By-Laws). The Board will review and may modify or reverse these decisions during the next Board meeting. If, in exceptional circumstances, the ED and Board Chair/Vice Chair determine that a pending issue requires Board input, and the issue cannot wait until the next Board meeting, the Board Chair/Vice Chair will consult with Board members. (Such Board input will, wherever possible, take the form of consultations that inform the decision of the Board Chair/Vice Chair, rather than formal Board decisions).</li><li>The Board Chair/Vice Chair will be able to call an in-person emergency Board meeting, in extraordinary circumstances only (e.g. major financial, legal and/or ethical issues, loss of confidence in leadership), and only with support of at least one-third of the members of the Board. Any Board member, or the ED, will be able to suggest the need for an emergency meeting to the Board Chair/Vice Chair. The Board Chair/Vice Chair will have reasonable discretion, as required under the circumstances, to change the normal procedural guidelines for Board meetings for an emergency Board meetings (e.g., provision for delegations, translation services, etc.).</li><li>The Secretariat and Board Chair/Vice Chair will develop the Board meeting agenda, which will be approved by the Board at the beginning of each meeting.</li><li>The Secretariat will prepare synthesized options, recommendations, and supporting rationale (maximum of ten to fifteen pages per agenda item) and distribute it three weeks in advance of the Board meeting. Items requiring decision will be clearly identified and prioritized.</li><li>The Governance and Partnership Committee should develop a few basic, enforceable procedural rules for consideration by the Board at the January Board meeting</li></ol>
2002-10-10 B03 GF/B03/DP14 Adoption of the report and recommendations of the Working Group on Proposals Adoption of the report and recommendations of the Working Group on Proposals
<p>The Board decided to adopt the report and recommendations of the Working Group on Proposals. The decision points are to: ratify the expansion of the TRP from 17 to 22 members on an experimental basis; The Board decided to revise the TRP review approach so that it strengthens the transparency and consistency of the process while maintaining the independence and flexibility of the TRP. Specifically, the TRP will score all proposals and present them to the Board classified according to four categories, namely:Category 1: Recommended for funding with no or minor modifications; Category 2: Recommended for funding provided clarifications are met within a limited timeframe (e.g. 6 weeks); Category 3: Not recommended for funding in its present form but strongly encouraged to resubmit; Category 4: Not recommended for funding.</p><p>The Board agreed that WHO/UNAIDS and other technical partners will verify data, compile statistics and provide written answers to the TRP on an agreed set of questions relating to all proposals going to the TRP.</p><p>The Board agree that the Secretariat will provide, rationales for non-eligible proposals, executive Summaries and standardized TRP reporting forms for all reviewed proposals, full texts of recommended proposals on request, and statistics on all received proposals (countries, diseases, poverty indicators etc.) to the Board prior to the next Board meeting in January 2003:</p><p>The Board strongly encouraged the Global Fund’s partners (e.g. local civil society and others) with in-country presence to increase their support and assistance to CCMs during all phases of the process.</p><p>The Board requested the Committee on Portfolio Management and Procurement to identify the most needy and poorest countries and ensure they are not systematically excluded; to consider the need for, and make recommendations about, a recourse mechanism (appeal procedure) for countries; to improve the information sharing between the Fund’s stakeholders; to provide guidance on operational research to the TRP;to set clearer boundaries for financial support by the Fund, including eligibility, priorities and Round budgets; to review the functioning of the TRP, including how membership is selected and expanded and how it is renewed after two Rounds; to regard Recommendation 2, evaluating whether there are conflicts of interest for technical experts to CCMs who may be benefiting from Global Fund applications on which they are providing assistance, or who may otherwise be assisting the TRP with its deliberations; to define how to deal more effectively with non-technical and non-disease specific elements of the TRP review such as broader developmental and health systems issues;</p><p>The Board requested the Committee on Portfolio Management and Procurement to expand the partnership between various actors (including TRSG, WHO, UNAIDS), at all levels including technical assistance that can be provided by national and international NGO’s "<br/><br/></p>
2016-02-22 B34 GF/B34/EDP12 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER09 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the reinvestment of within-allocation efficiencies for the South Sudan TB grant and the resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER09;<br/>4. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-03-04 B34 GF/B34/EDP15 Appointment of a member of the Finance and Operational Performance Committee Appointment of a member of the Finance and Operational Performance Committee
<p>The Board approves the appointment of Dr. HAN Mengjie as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor.</p>
2021-05-11 B45 GF/B45/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Birgit Pickel from the Germany Constituency is designated as Rapporteur for the 45th Board Meeting.</p>
2021-05-11 B45 GF/B45/DP03 Operating Expenses for the 2020-2022 Allocation Period Operating Expenses for the 2020-2022 Allocation Period
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the increase of forecasted aggregate operating expenses available for the 2020-2022 allocation period by US$ 30 million, in order to facilitate the implementation of critical activities in 2022; such that the amount made available for operating expenses for the 2020-2022 allocation cycle shall be US$ 930 million.</p>
2021-05-11 B45 GF/B45/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 45th Board Meeting (GF/B45/01) is approved.</p>
2005-09-29 B11 GF/B11/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Dr. Helene D. Gayle from the Private Foundations Constituency is designated as Rapporteur for the Eleventh Board Meeting.
2005-09-29 B11 GF/B11/DP13 Round 5 Funding Decisions Round 5 Funding Decisions
<p>1. The Board approves for funding, subject to paragraphs 3 and 4 below, the proposals recommended by the Technical Review Panel ("TRP") and as listed in Annex VI to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6) as:</p><ul><li>"Recommended 1 Proposals";</li><li>"Recommended 2A Proposals with Composite index 8"; and</li><li>"Recommended 2A Proposals with Composite index 6".</li></ul><p>The Board's approval is for the amount indicated as "Total 2 Years" in such Annex, and is made with the clear understanding that such amounts are upper ceilings rather than final Phase 1 Grant amounts.</p><p>2. The remaining proposals recommended for funding by the TRP as "Category 2" will be approved, subject to paragraph 4 below, through Board confirmation by e-mail, as funds become available under the terms of the Comprehensive Funding Policy, but no later than June 30, 2006. Approval will be based on their composite ranking, following the Prioritization in Resource Constrained Environments principles (approved by the Board at its 7th meeting).</p><p>3. The proposal applicants in Category 1 shall provide any adjustments or clarifications requested by the TRP no later than four weeks after notification in writing by the Secretariat to the applicant of the Board's decision. The Board's approval is conditional on the final approval of the TRP Chair and/or Vice Chair. This process shall proceed immediately after the 11th Board meeting.</p><p>4. The proposal applicants in Category 2 shall provide an initial reply to the clarifications requested by the TRP no later than six weeks after notification in writing by the Secretariat to the applicant of the Board's decision. Any further adjustments and clarifications shall be completed within four months from the receipt of the initial reply from the applicant. The Board's approval is conditional on the final approval of the TRP Chair and/or Vice Chair based on consultations with the TRP primary and secondary reviewers. This process shall proceed immediately after the 11th Board meeting.</p><p>5. The Board declines to approve for funding the proposals indicated as Category 3 in Annex II to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6), but the applicants are encouraged to re-submit a proposal for any possible future rounds of funding.</p><p>6. The Board declines to approve for funding the proposals indicated as Category 4 in Annex II to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6).</p><p>7. The situation and progress in the approvals process for Round 5 proposals will be further considered, if necessary, at the Thirteenth Board Meeting</p>
2005-09-29 B11 GF/B11/DP05 Report of the Ethics Committee: Whistleblowing Policy Report of the Ethics Committee: Whistleblowing Policy
The Board requests the Ethics Committee, in coordination with the Office of Inspector General, to explore the development of a whistleblowing policy, and appropriate structures for its oversight and implementation for consideration by the Board at its Twelfth Board meeting.
2005-09-29 B11 GF/B11/DP15 Ethics - Lobbying Ethics - Lobbying
The Board requests the Ethics Committee to recommend options regarding the establishment of a policy on lobbying with respect to funding decisions by the Thirteenth Board Meeting.
2005-09-29 B11 GF/B11/DP19 Budget for the Quality Assurance of Limited and Single-Source Products Board Decision Budget for the Quality Assurance of Limited and Single-Source Products Board Decision
<p>The Board approves an addition to the 2005 budget of US$ 380,000 for the estimated costs of implementing the quality assurance policy for single and limited source pharmaceutical products. This amount is an upper limit pending experience of the extent to which random testing is required.</p><p>The Board notes that the Secretariat will continue to engage with WHO and other partners in order to optimize the process. The Finance and Audit Committee shall review the 2006 cost estimates in conjunction with the 2006 Secretariat budget process, and shall review the actual costs of implementation towards the end of 2006 and adjust the budget accordingly if warranted.</p>
2005-09-29 B11 GF/B11/DP20 Secretariat Office Premises Secretariat Office Premises
The Board requests that the Secretariat shall focus on the current move to rented offices (BIBC) with a view to expanding within, while continuing to pursue the Swiss (FIPOI) loan option and to explore low cost commercial financing alternatives for a Secretariat office premises, with no commitment to rent elsewhere or to purchase without prior authorization from the Board.
2005-12-01 B11 GF/B11/EDP01 Round 1 Sri Lanka Malaria Grants –request for no-cost extension to Proposal Completion Date Round 1 Sri Lanka Malaria Grants –request for no-cost extension to Proposal Completion Date
The Board decides to extend of the term of the two Sri Lanka Round 1 Malaria Programs (Grant No. SRL-102-G01-M-00 and SRL-102-G02-M-00) by an additional six months beyond the original five year proposal term at no additional cost and provided that targets are maintained at the levels originally set in the proposal.
2005-09-29 B11 GF/B11/DP22 Transition from WHO Transition from WHO
<p>The Board takes note of the Secretariat's work to date in exploring alternative options to WHO for contracting certain administrative services, undertaken against the objective of "delivering a plan by November 2005 for transition to a fully independent entity" (Executive Director's performance objectives, Arusha, November 2004).</p><p>Having regard to the Finance and Audit Committee's request for clarification of the Board's intent with respect to a possible transition from current administrative arrangements with WHO, the Board requests the Secretariat to continue its analysis of advantages and disadvantages of alternative arrangements, including their costs, and report back, providing a proposed implementation plan if appropriate, at the Thirteenth Board meeting.</p>
2005-09-29 B11 GF/B11/DP06 NGO Access to Resources NGO Access to Resources
The Board directs the Portfolio Committee, in its discussions of the findings of the TRP report at the next Portfolio Committee meeting, to prepare recommendations to improve NGO access to the Global Fund resources in Round 6, for consideration at the 13'h Board Meeting.
2005-09-29 B11 GF/B11/DP10 Phase 2 Decision: Senegal Phase 2 Decision: Senegal
<p>The Board approves additional funding for the Phase 2 period of the Senegal grant (SNG-102-G01-H-OO) in the amount of USD 5,714,285, conditional on satisfaction of the conditions set forth in the Report of the Technical Review Panel on Honduras Round 1 HIV/AIDS Grant and Senegal Round 1 HIV/AIDS Grant Phase 2 Renewals (GF/B11/15, Revision 2). The Board specifies that the approved amount is an upper ceiling rather than a final funding amount, and that the final amount shall reflect the conditions and the responses to the clarifications requested by the Technical Review Panel.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p>
2005-09-29 B11 GF/B11/DP25 Acknowledgment of the Report on the Secretariat and Request for a Human Resources Plan Acknowledgment of the Report on the Secretariat and Request for a Human Resources Plan
<p>The Board welcomes the Report on the Secretariat and thanks the Executive Director, Deputy Executive Director and the staff for their dedication in improving the Global Fund's work.</p><p>Considering the issues raised in the Report, the Board requests the Secretariat to continue its efforts in the development and implementation of a human resources plan.</p>
2005-09-29 B11 GF/B11/DP23 Replenishment Report Replenishment Report
The Board takes note of the Report of the Replenishment (GF/B11/5) and requests the Finance and Audit Committee, as the lead committee, to review its contents and make recommendations resulting from such review to the Board as appropriate. The Board also invites the Portfolio Committee and the Policy and Strategy Committee to review the same Report and provide any recommendations or other input resulting from such review to the Finance and Audit Committee.
2005-09-29 B11 GF/B11/DP11 Phase 2 Decision: Honduras Phase 2 Decision: Honduras
<p>The Board approves additional funding for the Phase 2 period of the Honduras grant HND-102-G01-H-OO) in the amount of USD 14,273,782. The Board specifies that the approved amount is an upper ceiling rather than a final funding amount, and that the final amount shall reflect the conditions to this approval and the responses to the clarifications requested by the Technical Review Panel, described below. This approval is subject to the satisfaction of each of the following conditions:</p><ol type="a"><li> The Program shall continue activities under Objective 3 ("To Strengthen Integral Treatment Services for People Living with HIV/AIDS") as described in the Honduras CCM's Revised Request for Continued Funding.</li><li> The Program shall continue activities under Objectives 1 and 2 ("To Promote and Defend the Human Rights of People Living with HIV/AIDS" and "To Promote Conduct Change and the Adoption of Healthy Practices to arrest the Spread of HIV") as described in the Honduras CCM's Revised Request for Continued Funding conditioned on satisfaction of the requirements under section D.</li><li> The CCM shall submit to the Global Fund a summary proposal, with a detailed workplan and budget, showing how the Program will be revised to reflect the conditions described above in clauses (a) and (b) of this decision. The CCM's summary proposal, together with the workplan and budget, is subject to the approval of the TRP prior to the execution of Phase 2 documentation.</li><li> The CCM shall provide clarification, satisfactory to the Global Fund, of each of the issues outlined in Part 1, Section 6 and 7 of the Report of the Technical Review Panel on Honduras Round 1 HIV/AIDS Grant and Senegal Round 1 HIV/AIDS Grant Phase 2 Renewals (GF/B10/15, Revision 2). Such clarifications are subject to the approval of the TRP prior to the signing of Phase 2 documentation.</li></ol><p>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of (i) the amount approved by this decision and (ii) any funds available under the existing grant agreement, including bridge funding, that have not been disbursed by the Global Fund.</p>
2005-09-29 B11 GF/B11/DP17 Global Fund Strategy Global Fund Strategy
The Board endorses the recommended framework of strategic themes and approach to strategy development outlined in the Policy and Strategy Committee Report GF/B11/7. It requests that the work proceed and that the Policy and Strategy Committee report on progress at the Twelfth Board meeting.
2005-09-29 B11 GF/B11/DP26 Board Calendar 2006 Board Calendar 2006
<p>The Board adopts Option 2 of GF/B11/17 (as amended and set out below) as an indicative Global Fund calendar for 2006.</p><table class="table" dropzone="copy"><tbody><tr><th style="cursor: default;" scope="col" rowspan="1" colspan="4"><b> Board Calendar 2006 (Option 2) </b> </th></tr><tr><td style="cursor: default;"> January</td><td style="cursor: default;"> </td><td style="cursor: default;"> </td><td> </td></tr><tr><td style="cursor: default;"> February</td><td style="cursor: default;"> </td><td style="cursor: default;"> </td><td style="cursor: default;"> </td></tr><tr><td style="cursor: default;" rowspan="3" colspan="1"> March </td><td style="cursor: default;"> 14-15</td><td style="cursor: default;"> Portfolio Committee Meeting (TBC)</td><td style="cursor: default;"> Geneva </td></tr><tr><td style="cursor: default;"> 16-17</td><td style="cursor: default;"> Policy and Strategy Committee Meeting (TBC)</td><td style="cursor: default;"> Geneva </td></tr><tr><td style="cursor: default;"> 22-23</td><td style="cursor: default;"> Finance and Audit Committee Meeting (TBC)</td><td style="cursor: default;"> Geneva </td></tr><tr><td style="cursor: default;" rowspan="2" colspan="1"> April </td><td style="cursor: default;"> 7</td><td style="cursor: default;"> Board documents to be sent to the Board (13<sup>th</sup> Board meeting)</td><td style="cursor: default;"> </td></tr><tr><td style="cursor: default;"> 26-28</td><td style="cursor: default;"> 13<sup>th</sup> Board meeting</td><td style="cursor: default;"> Geneva</td></tr><tr><td style="cursor: default;"> May</td><td style="cursor: default;"> 13-20 </td><td style="cursor: default;"> Eastern Europe and Central Asia AIDS Conference </td><td style="cursor: default;"> Moscow </td></tr><tr><td style="cursor: default;"> May/June </td><td style="cursor: default;"> TBD </td><td style="cursor: default;"> Partnership Forum (TBC) </td><td> TBD </td></tr><tr><td style="cursor: default;"> June </td><td style="cursor: default;"> TBD </td><td style="cursor: default;"> Mid Term Replenishment </td><td> TBD </td></tr><tr><td style="cursor: default;"> July </td><td> 3-21 </td><td style="cursor: default;"> Committee Meetings </td><td> </td></tr><tr><td style="cursor: default;"> August </td><td> 13-18 </td><td style="cursor: default;"> XVI International AIDS Conference </td><td> Toronto </td></tr><tr><td style="cursor: default;"> September </td><td style="cursor: default;"> 27 </td><td style="cursor: default;"> Board documents to be sent to the Board (14<sup>th</sup> Board meeting)</td><td> </td></tr><tr><td style="cursor: default;" rowspan="2" colspan="1"> October </td><td style="cursor: default;"> 16-18</td><td style="cursor: default;"> Site Visits: Jamaica, Cuba, Guatemala, Honduras </td><td> LAC </td></tr><tr><td style="cursor: default;"> 18-20 </td><td style="cursor: default;"> 14<sup>th</sup> Board meeting</td><td style="cursor: default;"> Mexico</td></tr><tr><td style="cursor: default;"> November</td><td> </td><td style="cursor: default;"> </td><td> </td></tr><tr><td style="cursor: default;"> December</td><td style="cursor: default;"> </td><td style="cursor: default;"> </td><td> </td></tr></tbody></table>
2005-09-29 B11 GF/B11/DP16 Contract of the Executive Director Contract of the Executive Director
<p>The Board requests the Chair of the Board to create a committee to propose recommendations, at the Twelfth Board meeting, regarding:</p><p>• a process leading to the appointment or reappointment of an Executive Director in July 2006; and</p><p>• the term of office and number of permitted terms of the Executive Director.</p>
2005-09-29 B11 GF/B11/DP09 Additional Donor Seat Additional Donor Seat
<p>The Board approves, with immediate effect, the following amendments to the Bylaws and Board Operating Procedures that add a constituency represented by a donor (or donors) as a voting member of the Board:</p><p><b>Article 7.1 of the Bylaws is amended as follows:</b> </p><p>7.1 Composition</p><p>The Foundation Board shall consist of <strike>nineteen</strike> <strike></strike><u>twenty</u> voting members and four nonvoting members. Each voting member shall have one vote.</p><p>Voting members of the Foundation Board shall consist of:</p><ul><li> Seven representatives from developing countries, one representative based on each of the six World Health Organization ("WHO") regions and one additional representative from Africa.</li><li><strike>Seven</strike> <u>Eight</u> representatives from donors.</li><li> Five representatives from civil society and the private sector (one representative of a non-governmental organization ("NGO") from a developing country, one representative of an NGO from a developed country, one representative of the private sector, one representative of a private foundation, and one representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria).</li></ul><p>The four ex-officio nonvoting members of the Foundation Board shall consist of:</p><ul><li> One representative from the WHO;</li><li> One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS");</li><li>One representative from the trustee; and</li><li>One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Foundation to the extent required by Swiss law.</li></ul><p>Members of the Foundation Board ("Board Members") may each appoint one Alternate Member to serve in their stead, under policies and procedures determined by the Foundation Board.</p><p><b>The third paragraph of Article 7.6 of the Bylaws is amended as follows</b> </p><p>7.6 Operations</p><p>The Foundation Board shall use best efforts to make all decisions by consensus. If all practical efforts by the Foundation Board and the Chair have not led to consensus, any member of the Foundation Board with voting privileges may call for a vote. In order to pass, motions require a two-thirds majority of those present of both: a) the group encompassing the <strike>seven</strike><u>eight</u> donor seats and the two private sector seats and b) the group encompassing the seven developing country seats, the two non-governmental organization seats, and the representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria.</p><p><b>The first paragraph of Article 10 of the Board Operating Procedures is amended as follows:</b> </p><p>10. Decision-making</p><p>The Board shall use best efforts to reach all decisions by consensus. If all practical efforts by the Board and the Chair have not led to consensus, any member of the Board with voting privileges may call for a vote. In order to pass, motions require a two-thirds majority of those present of both: a) the group encompassing the <strike>Seven</strike> <u>Eight</u> donor seats and the 2 private sector seats and b) the group encompassing the 7 developing country seats, the 2 non­ governmental organization seats, and the representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria.</p><p><b>The Board notes that the donor constituencies have decided to allocate the additional donor constituency at this time to the United Kingdom of Great Britain and Northern Ireland, and Australia.</b> </p>
2005-09-29 B11 GF/B11/DP21 PricewaterhouseCoopers Fiscal Management Study PricewaterhouseCoopers Fiscal Management Study
The Board takes note of the recommendations of the PriceWaterhouseCoopers study and requests that the Finance and Audit Committee keep these recommendations under review and report further to the Board as necessary.
2005-09-29 B11 GF/B11/DP14 Appointment of the Inspector General Appointment of the Inspector General
The Board approves the recommendation of the selection sub-group in relation to the appointment of the Inspector General and requests Heidrick &amp; Struggles to conclude negotiations with the selected candidate as soon as possible.
2005-12-01 B11 GF/B11/EDP03 Allocation of Committee Seat Allocation of Committee Seat
The Board decides to add the United Kingdom of Great Britain and Northern Ireland and Australia constituency to the membership of the Portfolio Committee.
2005-09-29 B11 GF/B11/DP04 Global Task Team Global Task Team
<p>In accordance with the performance based and result oriented interventions of the Global Fund, the Board endorses the recommendations of the Global Task Team on Improving AIDS Coordination among Multilateral Institutions and International Donors.</p><p>The Board asks for a report from the Policy and Strategy Committee integrated with its normal report on progress on how the Global Fund will implement the recommendations.</p>
2017-02-27 BR2017 GF/BR2017/DP01 Appointment of Rapporteur Appointment of Rapporteur
<p>Owen Ryan from the Developed Country NGO constituency is designated as Rapporteur for the February 2017 Board Retreat.</p>
2010-04-30 B21 GF/B21/DP05 Health Systems Funding Platform Health Systems Funding Platform
<p>The Board affirms the critical importance of strong health systems to achieve the Global Fund's mandate to fight AIDS, tuberculosis and malaria.</p><p>The Board endorses an incremental approach to coordinated health systems strengthening investments under Track 1 and Track 2 as presented by the Secretariat in GF/PSC13/03 in collaboration with partners.</p><p>The Board requests the Secretariat to continue rapid implementation of Track 1.</p><p>The Board requests the Secretariat to continue, based on consultations at country level, implementation of Track 2 Option 1 through the development of a joint proposal form with GAVI as described in GF/PSC13/03. The joint proposal form would be approved by the PIC (as per current policy) for use as soon as possible, no later than Round 11. Any funding proposals using this new joint proposal form would be subject to TRP review and Board approval processes.</p><p>The Board requests further work on Track 2 Option 2 such that funding requests emanating from a pilot in 4-5 countries could be approved by the Board at the same time as it approves Round 11. The Board requests that in the interim, its Policy and Strategy Committee review and approve the pilot's design at its meeting in late 2010. </p><p>The Board requests the Secretariat to increase dialogue with partners, and develop a communications strategy and mechanisms for building health systems capacity at country level as part of the implementation and to regularly provide updates to the PSC.</p><p>The Board endorses the current scope of Global Fund HSS support as the scope for Global Fund HSS support within the Platform. This will help to achieve outcomes for the three diseases and improve progress towards achieving MDGs 4, 5 and 6.</p><p>The Board requests TERG to oversee the independent evaluation of the Joint Platform.</p>
2010-04-30 B21 GF/B21/DP18 Creation of a dedicated reserve for Most at Risk Populations for HIV/AIDS for Round 10 Creation of a dedicated reserve for Most at Risk Populations for HIV/AIDS for Round 10
<p>1. The Board decides that for Round 10 a dedicated reserve of resources for proposals from applicants who decide to submit a proposal which focuses only on most-at-risk populations for HIV/AIDS will be established. It is anticipated that this will lead to discussions on future eligibility and strategy. </p><p>2. The Board strongly recommends that proposals coming from 'lower-middle' and 'upper-middle' income applicants clearly demonstrate increasing government contribution over the proposal lifetime to ensure sustainability of the proposal interventions in the long-term and a possible exit strategy from requiring Global Fund financing. The TRP shall take this into consideration when recommending proposals for funding. </p><p>3. The following conditions will apply to the funding stream described in paragraph 1 above:</p><p>(a) US $75 million will be made available for the period of the initial commitment for all these proposals;</p><p>(b) The totality of the five years of all these proposals cannot exceed US $200 million;</p><p>(c) Applicants can request up to US $5 million for the initial commitment and US $12.5 million over the proposal lifetime;</p><p>(d) Existing income eligibility and cost-sharing requirements shall apply for these applicants;</p><p>(e) Applicants must opt at the time of submission of their Round 10 proposal to apply under this stream and may not submit another proposal for Round 10 for the same disease component;</p><p>(f) Applicants may not submit a separate health systems strengthening cross-cutting part under this funding stream;</p><p>(g) The prioritization for funding amongst these Round 10 TRP-recommended proposals is described in the Annex to this decision point; and</p><p>(h) In the event that a recommended proposal is not able to be funded under this funding stream due to the fact that maximum resources allocated have been exhausted, these proposals will be subject to the prioritization provisions set out GF/B21/DP17. </p><p>Annex:</p><p>8. The system for prioritizing among Round 10 TRP-recommended proposals under this funding stream, in the event that there are insufficient resources available to approve all TRP-recommended proposals, is as follows:</p><ol start="1" type="a"><li>The Secretariat is responsible for assigning a score to all TRP-recommended components of proposals in accordance with the composite index described in paragraph b. below and is to present the Board with these scores at the time of the Board's consideration of the TRP's recommendations. They are then financed in descending order (with the highest scoring proposals receiving priority).</li></ol><p>b. A composite index, based on two criteria, is used to assign scores to each TRP-recommended component of a proposal as described below.</p><table class="table" dropzone="copy"><tbody><tr><td><b>Criteria</b> </td><td><b>Indicator</b> </td><td><b>Value</b> </td><td><b>Score</b> </td></tr><tr><td>TRP Recommendation</td><td>TRP Recommendation Category</td><td>Category 1</td><td>4</td></tr><tr><td>Category 2</td><td>4</td><td> </td><td> </td></tr><tr><td>Category 2B</td><td>3</td><td> </td><td> </td></tr><tr><td rowspan="4"><p>Disease</p><p>Burden</p></td><td rowspan="4">Specific disease burden criteria set forth in paragraph c. below  </td><td>4</td><td> </td></tr><tr><td>3</td><td> </td></tr><tr><td>1</td><td> </td></tr></tbody></table> <ol start="3" type="a"><li>The specific disease burden indicator, value and score which will be used to assign scores for HIV/AIDS disease burden are:</li></ol><table class="table" dropzone="copy"><tbody><tr><td><b>Indicator</b> </td><td><b>Value</b> </td><td><b>Score</b> </td></tr><tr><td rowspan="3">HIV prevalence in vulnerable populations*</td><td>MARP <a id="_ftnref1" name="_ftnref1" draggable="false">[1]</a> prevalence ≥10%</td><td>4</td></tr><tr><td>MARP prevalence ≥5% and &lt;10%</td><td>3</td></tr><tr><td>MARPS &lt;5% OR no data</td><td>1</td></tr></tbody></table> <p>*Source of data: WHO and UNAIDS</p><ol start="4" type="a"><li>If an applicant requests funds for more than one most at risk populations then scores will be allocated for each target population according to the indicator and values described above and the scores will be averaged. The average will then be rounded to the nearest score.</li></ol><p><a id="_ftn1" name="_ftn1">[1]</a> MARP: Most at risk populations</p>
2010-10-15 B21 GF/B21/EDP23 The Secretariat’s request to the Board not to commit additional funding for the Phase 2 term of Round 6 Zanzibar HIV grant (ZAN-607-G06-H) The Secretariat’s request to the Board not to commit additional funding for the Phase 2 term of Round 6 Zanzibar HIV grant (ZAN-607-G06-H)
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 6 Zanzibar HIV grant (ZAN-607-G06-H)</p><p>See attached table.</p>
2010-08-15 B21 GF/B21/EDP16 Approval of Equatorial Guinea Continuity of Services request (GNQ-405-G01-H) Approval of Equatorial Guinea Continuity of Services request (GNQ-405-G01-H)
The Board acknowledges that, while Equatorial Guinea is classified as high income country according to the World Bank income classification and therefore no longer eligible for Global Fund support, the CCM requires additional time to mobilize resources for the Continuity of Services (CoS) for the 2,330 patients currently on life-saving treatment. The Board therefore approves the funding from the Phase 2 undisbursed funds of the Equatorial Guinea Round 4 HIV grant in the amount of USD 765,674, for the one year period from 1 July 2010 until 30 June 2011, with the understanding that not later than 31 December 2010, the CCM will submit to the Global Fund a transition plan identifying how the patients on treatment will be funded from government and other sources after the end of the one year period approved for CoS.
2010-07-15 B21 GF/B21/EDP07 Extension of the Phase 2 term and additional funds for the Republic of Suriname (SUR-404-G02-M) Extension of the Phase 2 term and additional funds for the Republic of Suriname (SUR-404-G02-M)
<p>The Board acknowledges that, due to circumstances which were mainly beyond the control of the CCM, the PR has not been given adequate opportunity to prepare for the orderly close out of the Program. Although the criteria for Rolling Continuation Channel (RCC) Bridge Funding do not apply to the circumstances of this grant, the Board approves, as an exception, additional funding amounting to US$ 254,559 and additional time for the PR to implement the grant up to 31 October 2010.</p><p>See attached tabledetailing total recommended funding amount of US$ 254,559 for the following grant: SUR-404-G02-M </p>
2010-04-30 B21 GF/B21/DP17 Prioritization Criteria for Round 10 Proposals Prioritization Criteria for Round 10 Proposals
<p>The Board decides that, for Round 10 only, the prioritization provisions of the Comprehensive Funding Policy described in Article 8 will be replaced with the provisions set out in the Annex to this decision point.</p><p>The Board requests that, at the time of issuing the Call for Round 10 proposals, the Secretariat communicate clearly to applicants the new prioritization mechanism that will apply for Round 10.</p><p>The Board requests (i) the Portfolio and Implementation Committee to consider an exceptional bridge funding mechanism as proposed by the Policy and Strategy Committee for possible approval at the Twenty-Second Board Meeting; and (ii) the Technical Review Panel (TRP) to review data on significant under-spending of existing grants as part of its formal recommendation process (such data to be provided by the Secretariat).</p><p>Further, the Board requests that, as part of the Eligibility and Cost Sharing Review being jointly carried out by the Policy and Strategy Committee and the Portfolio Implementation Committee, the following long-term strategic issues be considered; long-term implications of existing financial commitments of grant agreements; appropriate cost sharing and graduation guidance; and optimal allocation of future resources.</p><p>Annex:</p><p>8. The system for prioritizing among Round 10 TRP-recommended proposals, in the event that there are insufficient resources available to approve all TRP-recommended proposals, is as follows:</p><ol start="1" type="a"><li>The Secretariat is responsible for assigning a score to all TRP-recommended components of proposals in accordance with the composite index described in paragraph (b) below and is to present the Board with these scores at the time of the Board's consideration of the TRP's recommendations. They are then financed in descending order (with the highest scoring proposals receiving priority).</li></ol><p>b. A composite index, based on three criteria, is used to assign scores to each TRP-recommended component of a proposal as described below. </p><table class="table" dropzone="copy"><tbody><tr><td><b>Criteria</b> </td><td style="cursor: default;"><b>Indicator</b> </td><td><b>Value</b> </td><td><b>Score</b> </td></tr><tr><td>TRP Recommendation</td><td style="cursor: default;">TRP Recommendation Category</td><td>Category 1</td><td>4</td></tr><tr><td>Category 2</td><td style="cursor: default;">4</td><td> </td><td> </td></tr><tr><td>Category 2B</td><td>3</td><td> </td><td> </td></tr><tr><td rowspan="4"><p>Disease</p><p>Burden</p></td><td rowspan="4">Specific disease burden criteria set forth in paragraph c below  </td><td>4</td><td> </td></tr><tr><td>3</td><td> </td></tr><tr><td>2</td><td> </td></tr><tr><td>1</td><td> </td></tr><tr><td>Poverty </td><td style="cursor: default;"><p>World Bank</p><p>Classification</p></td><td>Low Income</td><td>4 </td></tr><tr><td>Lower-Middle Income</td><td style="cursor: default;">2</td><td> </td><td> </td></tr><tr><td>Upper-Middle Income</td><td>0</td><td> </td><td> </td></tr></tbody></table> <ol start="3" type="a"><li>The specific disease burden indicators, values and scores which will be used to assign scores for disease burden are:</li></ol><p>i. For HIV/AIDS:</p><table class="table" dropzone="copy"><tbody><tr><td><b>Indicator</b> </td><td><b>Value</b> </td><td><b>Score</b> </td></tr><tr><td rowspan="4" style="cursor: default;">HIV prevalence in the general population and/or in vulnerable populations*</td><td>HIV national prevalence ≥ 2%</td><td>4</td></tr><tr><td>HIV national prevalence ≥ 1% and &lt;2% OR MARP <a id="_ftnref1" name="_ftnref1" draggable="false">[1]</a> prevalence ≥10%</td><td>3</td></tr><tr><td>HIV national prevalence ≥ 0.5% and &lt;1% OR MARP prevalence ≥5% and &lt;10%</td><td>2</td></tr><tr><td>HIV national prevalence &lt; 0.5% and MARPS &lt;5% OR no data</td><td>1</td></tr></tbody></table> <p>*Source of data: WHO and UNAIDS</p><p>ii. For Tuberculosis</p><table class="table" dropzone="copy"><tbody><tr><td style="cursor: default;"><b>Indicator</b> </td><td><b>Value</b> </td><td><b>Score</b> </td></tr><tr><td rowspan="4">Combination of tuberculosis notification rate per 100,000 population (all forms including relapses); and WHO list of high burden countries (TB, TB/HIV or MDR-TB) **</td><td><p>TB Notification rate per 100,000 population ≥ 146)</p><p><b>OR</b> </p><p>TB Notification rate per 100,000 population ≥83 and &lt;146 and high TB burden, high TB/HIV burden, or high MDR-TB burden country</p></td><td>4</td></tr><tr><td><p>TB Notification rate per 100,000 population ≥83 and &lt;146</p><p><b>OR</b> </p><p>TB Notification rate per 100,000 population ≥38 and &lt;83 and high TB burden, high TB/HIV burden, or high MDR-TB burden country</p></td><td>3</td></tr><tr><td><p>TB Notification rate per 100,000 population ≥38 and &lt;83</p><p><b>OR</b> </p><p>TB Notification rate per 100,000 population &lt; 38 and high TB burden, high TB/HIV burden, or high MDR-TB burden country</p></td><td>2</td></tr><tr><td>TB Notification rate per 100,000 population &lt; 38</td><td>1</td></tr></tbody></table> <p>** Source of data: WHO</p><p>iii. For Malaria <a id="_ftnref2" name="_ftnref2" target="_self">[2]</a></p><table class="table" dropzone="copy"><tbody><tr><td><b>Indicator</b> </td><td><b>Value</b> </td><td><b>Score</b> </td></tr><tr><td rowspan="4">Combination of mortality rate per 1,000 persons at risk of malaria; morbidity rate per 1,000 persons at risk of malaria; and contribution to global deaths attributable to malaria***</td><td><p>Mortality rate ≥ 0.75 and morbidity rate ≥ 10</p><p><b>OR</b> </p><p>Contribution to global deaths ≥ 1%</p></td><td>4</td></tr><tr><td><p>Mortality rate ≥ 0.75 and morbidity rate &lt;10 <b>OR</b></p><p>Mortality rate ≥ 0.1 and &lt;0.75 regardless of morbidity rate</p><p><b>OR</b> </p><p>Contribution to global deaths ≥ 0.25% and &lt;1%</p></td><td>3</td></tr><tr><td><p>Mortality rate &lt;0.1 and morbidity rate ≥1</p><p><b>OR</b> </p><p>Contribution to global deaths ≥ 0.01% and &lt; 0.25%</p></td><td>2</td></tr><tr><td><p>Mortality rate &lt;0.1 and morbidity rate &lt;1</p><p><b>OR</b> </p><p>Contribution to global deaths &lt; 0.01%</p></td><td>1</td></tr></tbody></table> <p>*** Source of data: WHO</p><p><a id="_ftn1" name="_ftn1">[1]</a> MARP: Most at risk populations</p><p><a id="_ftn2" name="_ftn2">[2]</a> (i) It is recommended to use burden estimates for earlier years (2000) in order not to penalize countries that have demonstrated progress; and</p><p>(ii) In the case that a proposal is submitted from a sub-national Applicant it will be scored according to incidence and mortality rates for those specific areas (and the contribution of those areas to the global burden).</p>
2010-11-25 B21 GF/B21/EDP28 Increase to the 2010 Budget of the Office of the Inspector General Increase to the 2010 Budget of the Office of the Inspector General
<p>The Board decides to approve an increase of US $1,923,339 to the 2010 Budget of the Office of the Inspector General bringing the total budget of the Office of the Inspector General for 2010 to $12,227,621.</p><p>The increase in the budget for the Office of the Inspector General will be absorbed from within the existing 2010 Operating Expenses Budget.</p>
2010-05-07 B21 GF/B21/EDP01 Criteria for Exceptions to the Salary Threshold Criteria for Exceptions to the Salary Threshold
<p>The Board refers to GF/B21/DP10 and decides that in cases where an exception is sought to the threshold, the Remuneration Group shall consider approval based on written justification provided by the Executive Director as specified below:</p> <ol> <li>An explanation as to how the selection of the Grade and positioning in the band of the proposed salary has been established according to the Global Fund‘s remuneration policy and procedures.</li> <li>A comprehensive rationale as to why this exceptional salary is deemed necessary and appropriate based on the candidate‘s professional qualifications, experience, comparison with the market or other specific qualifications. The rationale may also include, as necessary, managerial considerations that relate to the specific needs of the Secretariat.</li> <li>An explanation of the efforts that have been undertaken to identify qualified alternative candidates that may have accepted a salary below the threshold or justify why such efforts were not deemed possible and/or appropriate.</li> <li>A risk assessment addressing the potential negative impact of approval of the salary, including the risk of setting a precedent, creating a trend towards a general increase in the levels of remuneration and the potential reputational risks for the Global Fund.</li> </ol>
2017-02-27 BR2017 GF/BR2017/DP03 Executive Director Selection Process Executive Director Selection Process
<ol> <li>The Board notes: <ol type="a"> <li>its gratitude for the work of the 2016 Executive Director Nomination Committee in leading the 2016-2017 selection process of the Executive Director of the Global Fund (“2016-2017 Selection Process”); and</li> <li>its discussions during the February 2017 Board Retreat with respect to the 2016 – 2017 Selection Process, including the importance of refining the process for identifying, and presenting to the Board, the short-listed candidates for Executive Director taking into account the need to balance transparency and confidentiality considerations throughout the recruitment process.</li> </ol> </li> <li>As such, to facilitate the launch of the new recruitment process for the Executive Director of the Global Fund, the Board requests the Board Leadership, in consultation with the Ethics and Governance Committee (the “EGC”) to review, and propose to the Board, by no later than the EGC’s March 2017 meeting, revisions to the terms of reference of the Executive Director Nomination Committee.</li> <li>Upon completion of the steps outlined in paragraph 2 above, the Board shall appoint the members of the 2017 Executive Director Nomination Committee and launch the new recruitment process for the Executive Director.</li> </ol>
2010-05-14 B21 GF/B21/EDP02 May 2010 Phase 2 Funding Decision May 2010 Phase 2 Funding Decision
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>1</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attachedtable detailing totalrecommended funding amount of US$ 34,025,556 for the following grants: KEN-607-G08-T ; SLE-708-G05-M ; SOM-708-G05-T</p>
2010-12-10 B21 GF/B21/EDP29 Phase 2 December 2010 Phase 2 December 2010
<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>1</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 133,171,860 for the following grants: CUB-708-G03-T ; YEM-708-G06-M ; NEP-708-G07-M ; NEP-708-G09-H ; NEP-708-G10-H ; NEP-708-G11-H ; TMP-708-G04-T ; VTN-708-G06-M ; ETH-708-G09-H ; MLW-708-G05-M ; KAZ-708-GO3-H ; SUD-708-G11-T</p>
2010-10-31 B21 GF/B21/EDP25 Extension of Timeline: Procedure for Appointment of Executive Director Extension of Timeline: Procedure for Appointment of Executive Director
In order to allow adequate time for further in-person consultations during the Executive Session of the Twenty-Second Board Meeting, the Board agrees, on an exceptional basis, to postpone, by approximately six weeks, the deadline for reaching a decision on the next steps pertaining to the Executive Director's term of office.
2010-04-30 B21 GF/B21/DP03 Approval of Report of the Twentieth Board Meeting Approval of Report of the Twentieth Board Meeting
The report of the Twentieth Board Meeting (GF/B21/2) is approved as amended at the Twenty-First Board Meeting.
2010-04-30 B21 GF/B21/DP04 Next National Strategy Application Funding Opportunity Next National Strategy Application Funding Opportunity
<p>The Board:</p> <p>1. notes the progress achieved in the implementation of the First Learning Wave ("FLW") of National Strategy Application ("NSAs");</p> <p>2. acknowledges the analysis of lessons of the FLW and the recommendations for further investment on the basis of NSAs presented in GF/PSC13/02, which respond to the Board's decision GF/B20/DP26 requesting these; and</p> <p>3. refers to its decision GF/B18/DP20 to bring the NSA procedure into operation through a phased roll-out.</p> <p>The Board requests the Secretariat to initiate a next NSA funding opportunity on a schedule that enables funding decisions to be made at the Board meeting in the fourth quarter of 2011, subject to availability of funding. The TRP-recommended applications emanating from this NSA submission opportunity shall be treated at least in the same manner as other proposals being simultaneously considered for new funding (see Section 9 of the Comprehensive Funding Policy).</p> <p>In addition, the Board requests the Secretariat to:</p> <p>1. ensure the next NSA funding opportunity builds on the lessons learned in the FLW;</p> <p>2. plan for the next NSA funding opportunity to include an incrementally larger number of countries than the FLW;</p> <p>3.focus on applications based on a national disease strategy that has been jointly assessed using a credible, joint assessment approach for national disease strategies that accords with the fundamental principles supported by the Policy and Strategy Committee (GF/B16/06):</p> <p>i.  country ownership;</p> <p>   ii.  independence;</p> <p>iii.  consistency;</p> <p>iv.  adequate expertise;</p> <p>v.  transparency; and</p> <p>vi.  multi-stakeholder involvement;</p> <p>4. further encourage meaningful multi-stakeholder involvement in the development of the national strategy;</p> <p>5. ensure the application and grant management processes for the next NSA funding opportunity are consistent with the new Global Fund grant architecture (as described in GF/B20/DP31 and GF/PSC12/02);</p> <p>6. draw lessons from the next NSA funding opportunity to inform a future broader roll-out of the NSA procedure; and</p> <p>7. periodically update the Board through the PSC on the possible financial implications of the next NSA funding opportunity, and consult with the PIC on implementation.</p> <p>The Board authorizes the Secretariat to make exceptions to existing policies and procedures to the extent necessary to implement the next NSA funding opportunity, under the same conditions as those for the FLW, as stated in GF/B18/DP20. The principles in that decision shall also apply to the next NSA funding opportunity, with the exception of the principle regarding the funding period, which will be based on the Global Fund new architecture.</p>
2010-09-21 B21 GF/B21/EDP21 September Phase 2 decision to commit additional funding for the proposals listed in Schedule A September Phase 2 decision to commit additional funding for the proposals listed in Schedule A
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>5</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 96,900,486 for the following grants: MAR-708-G01-H ; BRN-708-G06-T ; ZE-708-G04-M ; AZE-708-G03-T ; LAO-708-G10-T ; KOS-708-G02-H ; RWN-708-G09-H</p>
2017-02-27 BR2017 GF/BR2017/DP05 Amendment to the Board Leadership Terms of Reference Amendment to the Board Leadership Terms of Reference
<ol> <li>The Board notes the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as originally approved through GF/B19/DP10, and as last amended through GF/B32/DP05 (the “Board Leadership Terms of Reference”).</li> <li>In connection with the upcoming launch of the call for nominations for the next Chair and Vice-Chair of the Board, the Board decides to amend and restate Section IV of the Board Leadership Terms of Reference and include the following new Section V in the Board Leadership Terms of Reference: <br /> <ol start="4" type="i"> <li>TIME COMMITMENT <ol> <li>Depending on how the Chair and the Vice-Chair divide the responsibilities between them, the Board Chair should be prepared and able to dedicate an average of 40-50% of an individual’s working time to Global Fund matters, while the Vice Chair should anticipate an average of 25-40% to the same. This commitment may not be uniformly distributed throughout the calendar year. For example, Board, Committee and Coordinating Group meetings, as well as periods before and after such meetings, may require the Board Chair and Vice-Chair to commit full capacity to Global Fund matters for several consecutive days.</li> <li>The time commitment for the Board Chair and Vice-Chair is highly dependent on the Replenishment and Strategy cycles of the Global Fund. In years where there will be either a Replenishment or the development of the Strategy for the upcoming period, it is anticipated that the time commitment of the Board Chair and Vice-Chair would be higher. The Board Chair and Vice-Chair should also be prepared and able to commit additional time in exceptional circumstances.</li> <li>The Board Chair and Vice-Chair shall communicate regularly with Committee Chairs and Vice-Chairs, Board Members, the Secretariat, partners and other stakeholders between Board Meetings. Additionally, the Board Chair and Vice-Chair should be prepared and willing to travel as representatives of the Global Fund, in some cases to locations with security, economic and infrastructural challenges.</li> </ol> </li> <li>HONORARIUM <ol> <li>An honorarium may be provided to the Board Chair and/or Vice-Chair for service in accordance with an honorarium framework as may be approved, or as separately approved on an individual basis, by the Board.”</li> </ol> </li> </ol> </li> <li>The Board decides an annual honorarium in the amount of US$ 40,000 and US$ 30,000 will be available for the next Board Chair and Vice-Chair, respectively.</li> </ol>
2017-02-27 BR2017 GF/BR2017/DP02 Approval of Agenda Approval of Agenda
<p>The agenda for the February 2017 Board Retreat (GF/BR2017/01- Revision 5) is approved.</p>
2017-02-27 BR2017 GF/BR2017/DP04 Interim Executive Director Interim Executive Director
<p>The Board appoints Marijke Wijnroks to serve as Interim Executive Director of the Global Fund, effective as of 01 June 2017 until the commencement of the term of the new Executive Director of the Global Fund.</p>
2010-07-15 B21 GF/B21/EDP06 July 2010 Phase 2 Funding Decision July 2010 Phase 2 Funding Decision
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>3</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p> </p> <p>See attached tabledetailing total recommended funding amount of US$ 20,127,403 for the following grants: LBR-708-G06-T ; GIN-607-G04-H</p>
2005-09-29 B11 GF/B11/DP07 Round 5: Report of the Technical Review Panel Round 5: Report of the Technical Review Panel
<p><b>Decision Point 1:</b> </p><p>The Board notes that, as requested by the Board, the Technical Review Panel graded a sub-set of Category 2 proposals in Category 2B. This allows for a situation in which there are insufficient funds to meet the commitments required to fund all the Category 1 and 2 proposals recommended by the Technical Review Panel in Round 5. The Technical Review Panel defined Category 2B proposals as relatively weak Category 2 proposals, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation. The Technical Review Panel took no account of the applicant country's income level, nor of burden of disease nor of any factors other than technical merit and feasibility in grading a proposal as Category 2B.</p><p><b>Decision Point 2:</b> </p><p>The Board requests the Portfolio Committee to take note of the lessons learned, and the issues arising out of the technical Review of Round 5 proposals as well as the recommendations of the TRP (contained in GF/B11/6) and work on these, including:</p><ol><li>revising the Proposal Form and Guidelines for Proposals for future rounds; and</li><li>revising the process for screening and clarification of proposals prior to submission to the TRP with concrete recommendations for improvement and follow up for presentation at the Thirteenth Board meeting.</li></ol>
2005-09-29 B11 GF/B11/DP12 Phase 2 Task Force Phase 2 Task Force
<p><b>Decision Point 1:</b> </p><p>The Board endorses the recommendations of the Phase 2 Task Force (contained in GF/B11/10) with regard to the process to be followed for Phase 2 "no go" recommendations by the Secretariat, currently set forth in the "Phase 2 Decision Making Policies and Procedures" (Annex 6 to GF/B10/8), as amended. Specifically, it decides in principle that the following steps shall be introduced into the Phase 2 procedure once the recommendations referenced in Decision Point 2 below have been approved by the Board at its 12th Meeting:</p><ol type="a"><li>a) Where the Secretariat would otherwise issue a "no go" recommendation with respect to a grant, it shall give notice of that intention and the reasons for it to the relevant CCM, and allow that CCM four weeks to comment on the information submitted to it by the Secretariat, which shall consider it before submitting a recommendation to the Board.</li><li>b) In the event that (i) the Board rejects a first Secretariat "no go" recommendation, (ii) the Secretariat issues a second "no go" recommendation to the Board and (iii) the Board rejects the Secretariat's second "no go" recommendation, the matter shall be referred to an independent panel which shall assess the specific areas where the Board and the Secretariat differ on their assessment of the grant and report its conclusions to the Board.</li></ol><p>The budgetary implications for this decision are approximately USD 120,000 (depending on the composition and functioning of the independent panels).</p><p><b>Decision Point 2:</b> </p><p>In anticipation of a full review of the Phase 2 policies and procedures in 2006, the Board requests the Portfolio Committee to make recommendations with respect to the composition and functioning of the independent panels that are referred to in Decision Point 1 above, and to present amended Phase 2 Policies and Procedures reflecting the process described in Decision Point 1 to the Board for approval at its 12th Meeting.</p>
2005-09-29 B11 GF/B11/DP18 Partnership Forum Partnership Forum
<p>The Board:</p><ol type="a"><li>Calls for the 2nd Global Partnership Forum to be held before the end of July 2006;</li><li>Requests the Policy and Strategy Committee to establish a Partnership Forum Steering Committee under the leadership of Dr. Brian Brink to work with the Policy and Strategy Committee and Secretariat on the preparation of the Partnership Forum; Dr. Brink is accepting nominations from representatives of Board constituencies that are interested in serving on the steering committee, which is expected to have 6-8 members;</li><li>Asks the Secretariat to explore suitable dates and locations for the 2nd Partnership Forum for review and decision by the Policy and Strategy Committee as soon as possible;</li><li>Requests that the Steering Committee conduct an evaluation of the Partnership Forum to assess the effectiveness of this forum, including the budgetary implications, to suggest options for improving it, or alternatives for achieving similar objectives through other means;</li><li>Requests the Steering Committee, through the Policy and Strategy Committee, to provide an update on progress at the Twelfth Board Meeting.</li></ol>
2007-04-27 B15 GF/B15/DP54 Reporting Hotline to Support Whistle-Blowing Policy for Secretariat Reporting Hotline to Support Whistle-Blowing Policy for Secretariat
The Board requests the Office of the Inspector-General to implement an independent, confidential and technically robust reporting hotline to support the Whistle-blowing Policy for Secretariat and Governance Bodies of the Global Fund and In-Country Whistle-blowing Policy, as a matter of urgency.
2007-04-27 B15 GF/B15/DP35 High Level Principles for Upper-Middle Income Economy Eligibility for HIV/AIDS Proposals High Level Principles for Upper-Middle Income Economy Eligibility for HIV/AIDS Proposals
<p>The Board requests the Portfolio Committee to recommend to the Board at the Sixteenth Board meeting changes to the requirements with respect to the eligibility of applicants from upper-middle income economies<sup> </sup> for HIV/AIDS grants based on the following principles:</p><ol type="a"><li> An applicant would be eligible if:<ol type="i"><li> the epidemic in the country targeted in the proposal is of such magnitude that it has measurable impact on population demographics such as life expectancy<sup> </sup> and significant additional external resources are required to adequately address the epidemic; or</li><li>. the epidemic in a vulnerable population<sup> </sup> in the country targeted in the proposal is of such a nature and/or magnitude that there is risk of accelerated spread within that vulnerable population<sup> </sup> and significant additional external resources are required to adequately address the epidemic.</li></ol></li><li> Applicants with higher income levels should contribute through appropriate levels of counterpart financing and domestic investments.</li><li> Applicants must be included in the list of Official Development Assistance recipients published by the Organization for Economic Cooperation and Development (OECD) Development Assistance Committee.</li></ol>
2007-04-27 B15 GF/B15/DP43 Budget for Support to Chair and Vice Chair Budget for Support to Chair and Vice Chair
The Board approves a budget for US$400,000 in 2007 for support services to the Chair and Vice Chair of the Board.
2007-04-27 B15 GF/B15/DP12 Election of Vice Chair of the Board Election of Vice Chair of the Board
Ms Elisabeth Mataka of the Developing Country NGO constituency is elected as Vice Chair of the Board for the period commencing upon the adjournment of the Fifteenth Board meeting until the adjournment of the first Board meeting of 2009.
2007-04-27 B15 GF/B15/DP11 Election of Chair of the Board Election of Chair of the Board
Mr. Rajat Gupta of the Private Sector constituency is elected as Chair of the Board for the period commencing upon the adjournment of the Fifteenth Board meeting until the adjournment of the first Board meeting of 2009.
2007-04-27 B15 GF/B15/DP32 Report by the Performance Assessment Committee Report by the Performance Assessment Committee
The Board takes note of the end of year report by the Performance Assessment Committee (PAC) on the Corporate Key Performance Indicators (KPIs) 2006. It is fully satisfied with the indicators for which targets were met or exceeded. While it notes that there is a material shortfall in four KPIs, the Board accepts the reasons given as to why these targets were not met. Overall, the Board regards the results achieved in 2006 as a reflection of the performance based culture of the Global Fund and is pleased with the significant progress achieved in embedding this culture throughout all Global Fund activities.
2007-04-27 B15 GF/B15/DP46 Analysis of Discontinued Grants Analysis of Discontinued Grants
The Board requests the Secretariat to prepare for the Seventeenth Board Meeting, in consultation with its partners, an analysis of those grants that have been discontinued to identify any systemic weaknesses that led to that decision and recommend steps to address those weaknesses.
2007-04-27 B15 GF/B15/DP51 Funding of Country Coordinating Mechanisms Funding of Country Coordinating Mechanisms
<p>As a temporary measure, the Board decides that the two-year limit on funding for Country Coordinating Mechanisms contained in GF/B11/2, p. 12, Decision Point 2 (the "CCM Funding Decision") shall not apply to CCMs whose funding expires prior to 31 December 2007. In such circumstances, the Board authorizes the continued payment of grant funds to the CCM, provided that the funding:</p><p>- complies with the requirements of the CCM Funding Decision, other than the otherwise applicable two-year limit;</p><p>- is disbursed at a similar rate as that at which funding was disbursed during the preceding two-year funding period; and</p><p>- expires not later than (i) the ending date of the proposal term of a grant that the CCM is overseeing; and (ii) 31 December 2007, whichever is earlier.</p>
2007-04-27 B15 GF/B15/DP41 Amendment to the By-Laws and Board Operating Procedures Amendment to the By-Laws and Board Operating Procedures
<p>1. The Board approves the following amendments to the fourth paragraph of Article 7.6 of the Bylaws: </p><p>Notwithstanding the foregoing, the Board may decide to take action on a no-objection basis. On such basis, and subject to procedures set by the Board, a motion shall be deemed approved unless four Board members of one of the voting groups described above objects to the motion<b>.</b>, except that a motion not to renew funding for a proposal beyond the initial funding commitment shall be deemed approved unless four Board members of each of the voting groups described above object to the motion. </p><p>2. The Board approves the following amendments to Article 12 of the Board Operating Procedures:</p><p>"<b>Article 12. No-Objection Process for Approving Funding </b></p><p>Notwithstanding Sections 10 and 11, decisions by the Board to provide funding for approved proposals beyond the initial funding commitment or proposals requesting continued funding for grants that are reaching the end of their funding terms may be made on a no-objection basis under the following process.</p><p>As directed by the Board, the Secretariat shall issue a request for decision on each funding commitment for which a Board decision is required, and shall notify the Board accordingly. Unless four Board members of one of one of the voting groups described in Section 10 object to the requested decision within a time period specified by the Board following the date of notification the requested decision shall be deemed approved by the Board, except that a requested decision not to renew funding of a proposal beyond the initial funding commitment shall be deemed approved by the Board unless four Board members of each of the voting groups described in Section 10 object to the recommendation within a time period specified by the Board following the date of notification."</p>
2007-04-27 B15 GF/B15/DP07 Modified Application Process for Supporting Country Programs Modified Application Process for Supporting Country Programs
<p>The Board reaffirms its commitment to the principles of alignment and harmonization - in particular to further alignment of the Global Fund with national strategies, systems, and structures, and further harmonization with the procedures of international partners, as a means to achieving increased impact.</p><p>To provide greater support for country programs, the Board decides, in principle, to establish new procedures that will allow applicants to submit national strategies for HIV/AIDS, tuberculosis or malaria for Global Fund financing under conditions that differ in some respects from existing application requirements ("National-Strategy Applications").</p><p>The Board endorses the following principles for National-Strategy Applications<sup>1</sup>:</p><ul><li>National-Strategy Applications must be based on inclusive, costed, comprehensive and prioritized national strategies (which include a workplan and budget) that have undergone a rigorous technical certification by an independent review mechanism ("IRM")<sup>2</sup>;</li></ul><ul><li>National-Strategy Applications shall comprise the certified national strategy and minimal additional information, which should include a specification of financial contributions to the national strategy received from existing sources, the amount of funding requested from the Global Fund, and the results to which this funding is expected to contribute;</li></ul><ul><li>The IRM that certifies national strategies shall meet certain conditions - to be defined and endorsed by the Board at a later stage - such as appropriate technical expertise and the capacity to carry out certifications functions rapidly, efficiently and transparently;</li></ul><ul><li>The IRM shall assess the technical soundness and feasibility of national strategies based on rigorous criteria that will be developed jointly with relevant partners, so the outcome of the certification is useful beyond the Global Fund's own specific needs. The Global Fund shall contribute to the development of the criteria the standards the Board requires for the certification to fulfill the Global Fund's core principles, including but not limited to programmatic and financial accountability; and</li></ul><ul><li>The implementation of National-Strategy Applications should be consistent with the core principles of the Global Fund, including performance-based funding, financial and programmatic accountability, and additionality.</li></ul><p>The Board requests the Policy and Strategy Committee to recommend to the Board for approval at its Sixteenth Meeting a plan and policies for bringing into operation a National-Strategy Applications procedure, based on the principles set forth in this decision. Such recommendations shall also address</p><p>the role of Country Coordinating Mechanisms and the Technical Review Panel, the inclusion of non-governmental entities in the National-Strategy Applications process, and the possibility of more frequent funding decisions for National-Strategy Applications, which the Board believes could provide benefits in terms of alignment and harmonization. The Policy and Strategy Committee shall also identify any modifications to existing Global Fund policies that would be necessary in order to bring into operation the National-Strategy Applications procedure.</p><p>In the spirit of the underlying principles of the Global Task Team and the Paris Declaration, the Board calls upon all partners to develop a shared certification approach for national strategies and to allow, where relevant, the use of certified strategies as the basis for applications for funding.</p>
2007-04-27 B15 GF/B15/DP08 Use of Existing Flexibilities, and Flexibility in the Timing of Phase-2 Reviews Use of Existing Flexibilities, and Flexibility in the Timing of Phase-2 Reviews
<p>The Board reaffirms its commitment to the principles of alignment and harmonization - in particular to further alignment of the Global Fund with national strategies, systems, and structures, and further harmonization with the procedures of international partners, as a means to achieving increased impact.</p><p>The Board recognizes that there is much flexibility in the current policy framework of the Global Fund that can and should be further exercised to enable increased alignment and harmonization. Thus, the Board encourages the Secretariat, Country Coordinating Mechanisms (CCMs)<sup>1</sup> and Principal Recipients to communicate and fully exercise - as relevant and appropriate - these existing flexibilities. </p><p>In addition, the Board decides, in principle, to allow CCMs to request greater flexibility, for grants to operate in alignment with the implementation of national programs, in the timing of, and the performance period covered by, the Phase-2 review, for the purpose of enabling greater alignment with national cycles and harmonization with other donors' evaluation efforts. The Secretariat shall only allow this flexibility where relevant and appropriate, based on a set of conditions to be determined and agreed by the Board. The Board shall vote on any requests for bridge funding in cases in which such funding would be necessary to avoid interruption of program activities prior to the beginning of Phase 2. The Board requests the Portfolio Committee to propose appropriate modifications to existing Board policies to enable the Secretariat to exercise this flexibility, including by specifying the conditions under which the Board would allow CCMs to request this flexibility and the specific timing parameters for the Phase-2 review, and to present these to the Board for approval at its Sixteenth Meeting.</p>
2007-04-27 B15 GF/B15/DP29 Global Fund Policy for Restricted Financial Contributions Global Fund Policy for Restricted Financial Contributions
<p><b>1. Guiding Principles</b> </p><p>The Board acknowledges the need to accommodate restricted financial contributions in order to fully realize the Global Fund's mission of mobilizing significant additional resources for the fight against AIDS, tuberculosis and malaria, and authorizes the Secretariat to mobilize and accept such contributions which represent additional new funding in accordance with the following guiding principles:</p><ol type="a"><li> Restricted financial contributions to the Global Fund shall be limited to those from private donors and a limited number of public mechanisms approved in advance by the Board for this purpose; The Global Fund shall not accommodate restrictions on contributions through Official Development Assistance, thereby ensuring that the majority of contributions to the Global Fund remain unrestricted. </li><li> Restricted financial contributions shall be used solely for the purpose of supporting grants approved by the Board and activities of the Secretariat in line with the recipient-driven, Board-determined priorities of the Global Fund; and</li><li> Restricted financial contributions shall not result in unreasonable transaction costs for the Global Fund, substantial changes to Global Fund systems and processes, or the responsibilities of the Trustee, or any deviation from Global Fund rules and procedures. The Secretariat shall maintain the accounting records necessary to record restrictions attached to contributions and to identify the expenditure that satisfies such restrictions.</li></ol><p>For these purposes "restricted financial contributions" (sometimes referred to as "targeted funding" or "earmarked funding") has the meaning assigned by accounting standards applicable to contribution income, i.e. contributions which have been provided by a donor with specific restrictions on how they may be used by a recipient.</p><p><b>2.</b> <b>Restricted Financial Contributions for Grant Activities</b> </p><p>The Board authorizes the Secretariat to mobilize and accept contributions which are restricted to broad categories of expenses such as by disease and region (e.g. AIDS grants in Africa), to specific grants and/or to the procurement of specific goods and services, provided that:</p><ol type="a"><li> such restricted financial contributions comply with the Guiding Principles outlined in paragraph 1 above;</li><li> such restricted financial contributions are made through the Global Fund;</li><li> the total amount of restricted financial contributions is less than the total sum of Global Fund financing committed to any grant or activity receiving restricted financial contributions, ensuring that the programmatic results of such grants or activities are attributable, not just to the restricted financial contributions, but to contributions from all Global Fund donors. </li></ol><p><b>3.</b> <b>Restricted Financial Contributions for Secretariat Activities</b> </p><p>The Board authorizes the Secretariat to mobilize and accept restricted financial contributions for use to pay for Secretariat activities. Such restricted financial contributions may be made either directly to the Global Fund or to third parties in payment for liabilities of the Global Fund, provided that such contributions comply with the Guiding Principles outlined in paragraph 1 above.</p><p><b>4.</b> <b>Oversight</b> </p><p>The Board requests the Secretariat to provide the Finance and Audit Committee with progress updates on the implementation of this Restricted Financial Contributions Policy, including (a) a report on the results of mobilizing restricted financial contributions and (b) identification of new public mechanisms for inclusion in the Policy. </p><p>The Board delegates to the Finance and Audit Committee the authority to approve new public mechanisms proposed by the Secretariat for inclusion in the Restricted Financial Contributions Policy, and acknowledges UNITAID as the first such approved public mechanism. </p><p>The Board further requests the Finance and Audit Committee to consider new developments as they arise and to propose any changes to the Policy deemed appropriate by the Finance and Audit Committee for adoption by the Board.</p>
2007-04-27 B15 GF/B15/DP17 Development of a Roadmap for Future Collaboration with UNITAID Development of a Roadmap for Future Collaboration with UNITAID
<p>The Board refers to its decision (GF/B14/DP23) to request the Policy and Strategy Committee (PSC) to work with the Secretariat and the Finance and Audit Committee (FAC) to develop a roadmap for future collaboration with the UNITAID Board and Secretariat, and present it for approval by the Board at its Fifteenth Meeting. The Board notes that it was not possible for the PSC to present such a roadmap at the Fifteenth Board Meeting, for a number of reasons explained in the Report of the PSC (GF/B15/6), and requests the PSC<sup>1</sup> to continue to work with the Secretariat and the FAC to develop the roadmap with UNITAID, with a view to presenting it for approval by the Board at its Sixteenth Meeting.</p>
2007-04-27 B15 GF/B15/DP44 Committee Terms of Reference Committee Terms of Reference
<p>1. The Board requests the incoming Chair and Vice Chair of the Board to review and amend membership of the Portfolio Committee and Finance and Audit Committee in line with the original balance of membership foreseen when the committees were restructured at the Tenth Board Meeting.</p><p>2. The Board adopts the amended Terms of Reference for the Portfolio Committee as detailed in Annex 3 and of the Ethics Committee as detailed in Annex 4 to the Report on Committees (GF/B15/12).</p>
2007-04-27 B15 GF/B15/DP06 Global Fund Strategic Approach to Health-Systems Strengthening Global Fund Strategic Approach to Health-Systems Strengthening
<p>The Board refers to the Framework Document of the Global Fund, which states that the Global Fund will support programs that "address the three diseases in ways that will contribute to strengthening health systems," and "the Fund will support proposals which…support the substantial scaling up and increased coverage of proven and effective interventions, which strengthen systems for working: within the health sector; across government departments; and with communities." The Board reaffirms the importance of strong public and private health systems to accomplishing the Global Fund's mission to mitigate the impact of HIV/AIDS, tuberculosis and malaria in countries in need. The Board also recognizes that health systems capacity constraints have proven to be significant bottlenecks to Global Fund grant implementation, and that the Global Fund has, since its inception, provided significant support to a broad range of activities to strengthen health systems.</p><p>The Board decides that the Global Fund, as a financing instrument, should continue to support the strengthening of public and private health systems, and reaffirms its strategic approach in this regard, which consists of investing in activities to help health systems overcome constraints to the achievement of improved outcomes in reducing the burden of HIV/AIDS, tuberculosis and malaria. The Board also recognizes that the Global Fund is not the sole, or even primary, financier of such activities, and close coordination in strategic direction and implementation at the country level in this area is essential. </p><p>With this approach in mind, the Board asks the Policy and Strategy Committee (PSC) to consider the following issues, and, in coordination with the Portfolio Committee, make recommendations to the Board for decision at its Sixteenth Meeting:</p><ul><li>Whether the Board should continue to fund "Health-Systems Strengthening" (HSS) interventions exclusively within disease components or, in addition, establish a separate HSS component for proposals to the Global Fund;</li></ul><ul><li>The appropriate parameters for allowable HSS activities;</li></ul><ul><li>The possible use and nature of conditionality for applying for HSS funding; and</li></ul><ul><li>The possible use and nature of ceilings for HSS funding.</li></ul><p>The Board requests the World Health Organization to identify or convene a suitable forum before the Sixteenth Board meeting to provide input on HSS as related to the Global Fund and other partners, taking into account the work already done by the Portfolio Committee. </p>
2007-04-27 B15 GF/B15/DP27 Amendments to the Comprehensive Funding Policy following Establishment of the Rolling Continuation Channel Amendments to the Comprehensive Funding Policy following Establishment of the Rolling Continuation Channel
<ol> <li>The Board approves the amendments to the Comprehensive Funding Policy, as amended at the Thirteenth Board Meeting, as presented in Annex 5 to the Report of the Finance and Audit Committee (GF/B15/8).</li> <li>The Board revokes the following decisions: <ol type="a"> <li>The decisions made at the Seventh Board Meeting regarding prioritization of funding in resource-constrained environments (GF/B8/2 p. 13-14);</li> <li>The decision made at the Seventh Board Meeting regarding the criteria for considering promissory notes as assets (GF/B8/2, p. 16, decision point 6); and</li> <li>The decision points 1 and 2 entitled "Phase 2 Funding" made at the Eighth Board Meeting regarding prioritization of Phase 2 funding (GF/B9/2 p. 9-10).</li> </ol> </li> </ol>
2007-04-27 B15 GF/B15/DP45 Additional Mechanism for New Technologies Additional Mechanism for New Technologies
<p>The Board requests the Chair to assign to a committee of the Board the task of investigating the feasibility of an additional mechanism for providing special funding to allow rapid access to new technologies to diagnose, prevent or treat one of the three diseases. This could involve reprogramming or additional funding to existing grantees and /or an extraordinary funding round to allow countries without current grants access to new funding.</p><p>The committee should report back to the Board on the results of this review at the Seventeenth Board meeting. It can, at its discretion, include in that report a recommendation for a specific mechanism for Board consideration and possible approval. </p>
2007-04-27 B15 GF/B15/DP47 Outgoing Chair and Vice Chair of the Board Outgoing Chair and Vice Chair of the Board
<p>We thank our Chair, Dr. Carol Jacobs, for her leadership as our Board Chair. She faced many difficult issues and transition during her tenure, and managed them all with compassion and commitment to those the Global Fund serves.</p><p>We thank our Vice Chair, Dr. Lieve Fransen, for her service as our vice chair. She helped as well to manage many challenges, and played a particularly important role in coordinating the work of the Board committees. And finally, we wish to acknowledge and thank Alies Jordan and Enrico Mollica, who supported the Chair and Vice Chair in performing their duties with skill, grace, and good humor.</p>
2007-04-27 B15 GF/B15/DP23 Global Fund Assurance Framework Global Fund Assurance Framework
The Board notes the work already conducted by the Finance and Audit Committee to develop an overall assurance framework for the Global Fund and acknowledges that such effort involves considerations that extend beyond the OIG. The Board requests that the Finance and Audit Committee continue to develop its recommendation for documenting the overall assurance framework of the Global Fund in consultation with the Policy and Strategy Committee, the Secretariat and the Inspector General for presentation to the Board for its approval at the Sixteenth Board Meeting.
2007-04-27 B15 GF/B15/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Mr. Alexander Konuzin from the Eastern Europe constituency is appointed as Rapporteur for the Fifteenth Board Meeting.
2007-04-27 B15 GF/B15/DP02 Outgoing Executive Director Outgoing Executive Director
We, the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria, wish to express our heartfelt thanks and appreciation to Professor Sir Richard Feachem for his tremendous service as our founding Executive Director. He has helped lead a Secretariat of the Global Fund from vision to reality. There is no greater measure of success than the estimated 1.25 million lives saved because of Global Fund-supported grants. We thank him for his tremendous service and wish him continued success as a global leader committed to improving the health and wellbeing of the world's poorest citizens.
2007-04-27 B15 GF/B15/DP03 Approval of Agenda Approval of Agenda
The agenda for the Fifteenth Board Meeting (GF/B15/1, Revision 3), as amended at the Fifteenth Board Meeting, is approved.
2005-09-29 B11 GF/B11/DP02 Approval of the Agenda Approval of the Agenda
The agenda for the Eleventh Board Meeting is approved.
2005-09-29 B11 GF/B11/DP08 Health Systems Strengthening Health Systems Strengthening
The Board directs the Portfolio Committee to present to the Thirteenth Board Meeting their recommendations, on a stand-alone basis, for resolving the technical problems that occurred in Round 5 concerning Health Systems Strengthening issues, in order to improve future guidelines.
2005-09-29 B11 GF/B11/DP03 Approval of Report of the Tenth Board Meeting Approval of Report of the Tenth Board Meeting
The report of the Tenth Board Meeting (GF/B11/2, Amendment) is approved as amended at the Eleventh Board Meeting.
2005-09-29 B11 GF/B11/DP24 Revised Request for Continued Funding for South Africa Round 1 HIV and TB Proposal (Grant Number SAF-102-G02-C-OO) Revised Request for Continued Funding for South Africa Round 1 HIV and TB Proposal (Grant Number SAF-102-G02-C-OO)
<p><b>Decision Point 1:</b> </p><p>The Board notes the discrepancy between the perceptions of performance of the Secretariat and the sub-recipient of the South Africa Round 1 HIV and TB proposal (SAF-102-G02-C-OO). In this connection, it decides that the goal of reducing the incidence of HIV infection among South African adolescents shall be the basis for further funding.</p><p>The Board approves the following procedure for further consideration of the proposal:</p><ol><li> The Board refers the proposal back to the CCM for further processing as a Revised Request for Continued Funding.</li><li> The Revised Request for Continued Funding shall address the concerns raised during the Phase 2 process, with particular reference to the need:<ol type="a"><li> to focus on elements of the existing grant that have performed well towards reducing the incidence of HIV infection;</li><li> to adjust the funding requests accordingly;</li><li> to revise financial and accounting procedures; and</li><li> to ensure an effective governance structure and CCM oversight.</li></ol></li><li> The CCM shall deliver its Revised Request for Continued Funding to the Secretariat not later than October 31, 2005. Failure by the CCM to comply with this deadline shall result in no further consideration of Phase 2 funding.</li><li> The Secretariat shall, upon receipt, transmit the Revised Request for Continued Funding to the Technical Review Panel {TRP). Not later than November 21, the TRP shall provide a recommendation to the Board for full or partial funding, or discontinuation.</li><li> If the TRP recommends discontinuing funding, the recommendation shall be in the form of a notification to the Board, no further funding shall be provided for the proposal and funding of the existing program shall terminate at the completion of its term.</li><li> If the TRP recommends continued funding, the recommendation on the Revised Request for Continued Funding shall be presented for a vote at the Twelfth Board Meeting.</li><li> If the TRP recommendation to continue funding is not approved by the Board, no further funding shall be provided for the proposal and funding of the existing program shall terminate at the completion of its term.</li></ol><p><b>Decision Point 2:</b> </p><p>The Board approves additional bridge funding of not more than US$1,000,000 per month, paid on a monthly basis, for Grant Number SAF-102-G02-C-OO until a final decision on further funding is made.</p>
2005-12-01 B11 GF/B11/EDP02 Round 5 Nigeria Tuberculosis Component – correction of two-year funding amount. Round 5 Nigeria Tuberculosis Component – correction of two-year funding amount.
The Board decides to correct the Round 5 funding decision taken by the Board at the 11<sup>th</sup> Board Meeting by replacing the total two-year budget amount of US$19,217,311 for the Round 5 Nigeria tuberculosis component in Annex VI to the Report of the Technical Review Panel and the Secretariat on Round 5 Proposals with the amount of US$25,570,097.
2007-04-27 B15 GF/B15/DP16 Size of the Global Fund Size of the Global Fund
<p>The Board notes that UNAIDS, the Stop TB Partnership and Roll Back Malaria have estimated that the global resource needs regarding the three diseases are approximately US$ 28-31 billion per year in 2008-2010.</p><p>The Board recognizes that adequate resources are critical in fighting the three diseases, and that contributions must come from several sources -- national and international, multilateral and bilateral, governmental and non-governmental. The Board believes that, as a major financing mechanism for HIV/AIDS, tuberculosis and malaria, the Global Fund has a critical role to play in this effort. The Board also recognizes that some funders provide significant resources through other channels. </p><p>The Global Fund's 2007 Resource Needs report currently projects a level of demand to the Global Fund of US$ 6 billion per year in 2010, which would represent a tripling in the size of the Global Fund.</p><p>The Board recognizes that, if its partners and stakeholders in developed and developing countries scale up their efforts to strengthen and improve the quality of demand from country partnerships, such demand could potentially reach the level of US$ 8 billion by 2010. Meeting concrete expressions of demand in the above range will require major, additional resource mobilization from public and private sources, and innovative financing mechanisms. The Board, therefore, also calls on its partners, stakeholders and the Secretariat to take concrete steps to encourage demand at these levels, and to work with the Board and Secretariat to mobilize the resources necessary to meet increased demand expressed in the submission of quality proposals to the Global Fund. </p><p>The Board further acknowledges that reaching the target will require continued demonstration of good performance, effectiveness and rapid disbursement by the Global Fund and its grantees.</p>
2007-04-27 B15 GF/B15/DP50 Re-tendering of Local Fund Agent Contracts Re-tendering of Local Fund Agent Contracts
<p>The Board urges the Secretariat to develop and implement a grant-associated risk assessment framework as soon as possible, noting that the Local Fund Agents (LFAs) are an inherent part of the Fund's assurance framework.</p><p>The Board directs the Secretariat to re-tender LFA contracts on a 4-year basis, with contracts subject to the right of the Secretariat to cancel such contracts based on a mid-term performance review of the LFA, to be initiated between month 18 and 24 of the contract. </p><p>The Board provides the following recommendations, as indicated in the Report of the Portfolio Committee (GF/B15/7), on key principles to guide the Secretariat in the process of re-tendering:</p><ol type="i"><li>LFAs should act in a timely, open and reliable manner in order to be responsive to program needs;</li><li>LFAs themselves should be subject to more rigorous performance assessment (including through the use of penalties);</li><li>There needs to be a balance between the requirement for knowledge of local circumstances and the need to avoid potential conflicts of interest;</li><li>LFAs must be able to monitor financial management performance and program performance, and link the two components;</li><li>The Portfolio Committee (PC) cautioned against building up new institutions or architecture in-country;</li><li>The tender process should provide open space to encourage a diversity of participants, including civil society, possibly setting up a process to encourage consortia applications; and</li><li>While recognizing that LFAs need a diversity of skills, there is a need for clear lines of accountability so country program implementers and the Secretariat can deal with a single reporting entity.</li></ol><p>The Board recognizes the urgent need for protocols to be developed to guide LFA communication with CCMs, PRs and technical operations partners in-country.</p><p>The Board also affirms that the PC's recommendation that the re-tendering process proceed in a way that optimizes, to the extent possible, the Global Fund's partnerships, with key technical agencies, such as UNAIDS and WHO.</p><p>The Board recognizes that the primary responsibility for sub-recipient (SR) oversight resides with the Principal Recipient.</p><p>However, the Board directs that the Terms of Reference of LFAs shall include the assessment of the systems and procedures that PRs possess for the oversight of SRs, which shall include both initial capacity assessments and ongoing implementation oversight. The LFA's fulfilment of this function shall be an element in the Secretariat's ongoing evaluation of LFA performance, including at the mid-term review. </p>
2007-04-27 B15 GF/B15/DP14 Strengthening the Role of Civil Society and the Private Sector in the Global Fund’s Work Strengthening the Role of Civil Society and the Private Sector in the Global Fund’s Work
<p>The Board believes that civil society and the private sector can, and should, play a critical role at all levels of the architecture and within every step of the processes of the Global Fund, at both the institutional and country levels. This includes their critical roles in the development of policy and strategy and in resource mobilization at the Global Fund Board level, and in the development of proposals and the implementation and oversight of grants at the country level. The Board further expresses its desire for strengthened and scaled-up civil-society and private-sector involvement at both the country and Board levels, while recognizing the respective strengths and roles of the two sectors.</p><p>With this goal in mind - and also reaffirming the importance of effective Country Coordinating Mechanisms (CCMs)<sup>1</sup> in ensuring strong country-level development of proposals and oversight of grants - the Board recognizes the need to further enable civil society and the private sector to play their critical roles, facilitated by the following:</p><ul><li>The routine inclusion, in proposals for Global Fund financing, of both government and non-government Principal Recipients (PRs) for Global Fund grants ("dual-track financing"). The Board recommends the submission of proposals with both government and non-government PRs. If a proposal does not include both government and non-government PRs, it should contain an explanation of the reason for this;</li></ul><ul><li>The routine inclusion, in proposals for Global Fund financing, of requests for funding of relevant measures to strengthen the community systems necessary for the effective implementation of Global Fund grants;</li></ul><ul><li>The effective representation and meaningful participation of vulnerable groups (as defined in the context of each particular country) on CCMs; and</li></ul><ul><li>Simplified CCM access to funding to support their effective administrative functioning, for the life of a grant that the CCM is overseeing when needed, and increased transparency by CCMs about how they plan to ensure access by civil society to such funding.</li></ul><p>The Board requests the Secretariat to take the necessary actions and collaborate with partners to achieve the above outcomes, working with the relevant Board committee(s), where necessary. </p><p>In particular, the Board requests the Policy and Strategy Committee to agree on a suitable definition of the term "civil society", by building on existing work to that effect. </p><p>In addition, the Board requests the Portfolio Committee (PC) to do the following:</p><ul><li>Modify future proposal forms and guidelines (starting with those for Round 8) to encourage the use of dual-track financing and the inclusion of funding requests for strengthening community systems in proposals;</li><li>Propose means to increase the representation of vulnerable groups on CCMs, such as by revising the relevant, current recommendation on the composition of CCMs;</li><li>Propose guidance to CCMs regarding types of civil-society and private-sector representatives that could be most relevant to the work of CCMs;</li><li>Propose appropriate modifications to the policy or guidance on the funding for CCM activities;</li><li>Propose guidance on increasing the capacity of the Technical Review Panel in the area of civil society and the private sector; and</li><li>Report on progress at the Sixteenth Board Meeting.</li></ul><p>Regarding dual-track financing, the Board notes the following:</p><ul><li>The possible benefits achieved through dual-track financing include increased absorption capacity (from taking full advantage of the implementation capacity of all domestic sectors, both governmental and non-governmental), accelerated implementation and performance of grants, and the strengthening of weaker sectors; and</li><li>CCMs, PRs and the Secretariat should implement dual-track financing according to the following principles:<ul><li>The implementation should be consistent with alignment and harmonization of efforts to fight the three diseases;</li><li>It should be consistent with national strategies to fight the three diseases, or there should be a justification stated when this is not the case;</li><li>It should seek to minimize transaction costs and demands on CCMs, PRs and the Secretariat;</li><li>It should apply equally the same expectations of accountability, transparency and responsibility to government and non-government PRs; and</li><li>It should seek to be consistent with national plans for human resources for health.</li></ul></li></ul>
2007-04-27 B15 GF/B15/DP13 TERG Membership Rotation Procedure TERG Membership Rotation Procedure
<p>The Board approves the following amendments to paragraph 6 of the Terms of Reference, Membership and Procedures of the Technical Evaluation Reference Group approved at the Tenth Board Meeting (GF/B10/8, Annex 8):</p> <ol> <li>Each Board member of the Global Fund may nominate candidates who match the profile and qualifications defined in paragraph 7 (up to 4 candidates per board member). The names of candidates will be submitted to the Policy and Strategy Committee with the appropriate information and documentation through the Secretariat. The PS Committee with the support of the Fund Secretariat, will recommend a proposed list of appointees to the selection committee which is comprised of the Chair or Vice Chair of the PS Committee, <u>the Chair of the TERG,</u> the Committee M&amp;E focal point and the Executive Director of the Global Fund <u>or his/her designee</u>. The final proposed list will be forwarded to the Board of the Global Fund for decision. The confirmed appointees will be invited to become members of the TERG by the Executive Director of the Global Fund. The M&amp;E focal point member of the PS committee as well as the chairs of the monitoring and evaluation reference panels of UNAIDS, Roll back Malaria, and Stop TB shall be ex-officio members of the TERG. In addition to the regular TERG membership, additional experts may be invited to participate as the need arises.</li> </ol>
2007-04-27 B15 GF/B15/DP52 Approval of Annual Report Approval of Annual Report
The Board approves the Annual Report as presented in GF/B15/13.
2007-04-27 B15 GF/B15/DP22 Disclosure of Reports of the Office of the Inspector General Disclosure of Reports of the Office of the Inspector General
<p>The Board notes the initial work undertaken by the Finance and Audit Committee (FAC) to develop a policy for disclosure of reports issued by the Inspector General. The Board notes that the FAC has established a sub-group, composed of the World Bank delegate, the United States delegate and the Inspector General <i>ad interim,</i> supported by the Chief Financial Officer and the Legal Counsel, to continue development of the OIG disclosure policy, in consultation with Deloitte. The Board requests that the FAC, after consultation with the Policy and Strategy Committee, to present its recommendations for the OIG disclosure policy to the Board for approval at the Sixteenth Board Meeting.</p><p>The Board decides that, prior to Board approval of such policy, the Chair, the Vice Chair and the Chair of the FAC, after consulting the Inspector General and the Legal Counsel, shall have the authority to determine public disclosure of OIG reports after they have been made available. </p>
2007-04-27 B15 GF/B15/DP28 Transition from the Administrative Service Agreement with the World Health Organization Transition from the Administrative Service Agreement with the World Health Organization
<p>1. The Board notes the progress made to date, and authorizes the Secretariat, under the oversight of the Finance and Audit Committee, to proceed with the negotiation and costing of the remaining alternative administrative arrangements as described in detail in the Report of the Finance and Audit Committee to the Fourteenth Board meeting (GF/B14/9).</p><p>2. The Board authorizes the Secretariat to pursue the most beneficial arrangement for providing pension services to the staff. The Board recognizes the need to provide support to these negotiations. </p><p>3. The Board requests the FAC to present the final fully costed implementation plan for decision of the Board at the Sixteenth Board Meeting.</p>
2007-04-27 B15 GF/B15/DP30 Potential Funding by UNITAID to Third Party Procurement Mechanisms Potential Funding by UNITAID to Third Party Procurement Mechanisms
The Board acknowledges that, in developing a roadmap for future collaboration with UNITAID, the Policy and Strategy Committee, working together with the Secretariat and the Finance and Audit Committee, may consider the possibility of UNITAID providing direct funding to third party procurement mechanisms to support Global Fund grants. The Board notes that the roadmap, including the contribution structure and funds-flow mechanism, will be presented to the Board for its approval.
2007-04-27 B15 GF/B15/DP39 Approval of Changes to the Composition of the Appeal Panel Approval of Changes to the Composition of the Appeal Panel
<p>The Board decides that the following criteria apply to the Appeal Panel which reviews appeals of funding decisions with respect to the Rounds-based and Rolling Continuation Channels:</p><p>a. the Appeal Panel shall be comprised of five experts, including three nominated by the Stop TB Partnership, Roll Back Malaria Partnership and UNAIDS, in close collaboration with WHO tuberculosis, HIV/AIDS and malaria departments (collectively, the "Independent Members") and two who are TRP members;</p><p>b. the Independent Members may serve on the Appeal Panel for two consecutive years; and</p><p>c. commencing from Round 8, employees of the United Nations and its specialized agencies are ineligible to serve as members of the Appeal Panel.</p>
2007-04-27 B15 GF/B15/DP42 Amendment to the By-Laws and Board Operating Procedures Amendment to the By-Laws and Board Operating Procedures
<p>1. The Board approves the following amendments to the fourth paragraph of Article 7.6 of the Bylaws: </p><p>Notwithstanding the foregoing, the Board may decide to take action on a no-objection basis. On such basis, and subject to procedures set by the Board, a motion shall be deemed approved unless four Board members of one of the voting groups described above objects to the motion, except that a motion not to make a renew funding for a proposal beyond the initial funding commitment shall be deemed approved unless four Board members of each of the voting groups described above object to the motion. </p><p>2. The Board approves the following amendments to Article 12 of the Board Operating Procedures:</p><p>"<b>Article 12. No-Objection Process for Approving Funding </b></p><p>Notwithstanding Sections 10 and 11, decisions by the Board to provide funding for approved proposals beyond the initial funding commitment or proposals requesting continued funding for grants that are reaching the end of their funding terms may be made on a no-objection basis under the following process.</p><p>As directed by the Board, the Secretariat shall issue a request for decision on each funding commitment for which a Board decision is required, and shall notify the Board accordingly. Unless four Board members of one of one of the voting groups described in Section 10 object to the requested decision within a time period specified by the Board following the date of notification the requested decision shall be deemed approved by the Board, except that a requested decision not to make a renew funding of a proposal beyond the initial funding commitment shall be deemed approved by the Board unless four Board members of each of the voting groups described in Section 10 object to the recommendation within a time period specified by the Board following the date of notification."</p>
2007-04-27 B15 GF/B15/DP21 Independent Analysis of Credit Suisse Account Independent Analysis of Credit Suisse Account
<p>During the First Special Board Meeting in February 2007, the Board requested that the Inspector General <i>ad interim</i> conduct an independent analysis of the remaining issues raised by the Inspector General's Report on the Credit Suisse Bank Account and the Management Response to the OIG Report on the Audit of Credit Suisse Bank Account Transactions, and advise the Board whether further action is required. In addition, the Board requested that Deloitte &amp; Touche complete the draft <i>Review of the Office of the Inspector General</i> (the "Deloitte Report"). The Board has received the report of ORNA Corporate Integrity AG, retained by the Inspector General <i>ad interim</i> to conduct the requested independent analysis, and the Deloitte Report. </p><p>The Board notes with approval the conclusions of the ORNA Report that no fraud or misappropriation of funds occurred. It is satisfied that this report provides the review, analysis and conclusions necessary to bring this matter to a close. The Board requests the Inspector General <i>ad interim</i> to prepare a comprehensive account (including, as appropriate, original documents) of the findings and recommendations of the Deloitte Report, the OIG Report, the Management Response, and the ORNA Report. The comprehensive account should be drafted with the expectation that it be released publicly, in consultation with the Chair and Vice Chair of the Board and the Executive Director, not later than May 31, 2007. The Board requests the Secretariat to prepare a response to the recommendations in the ORNA Report and report to the Finance and Audit Committee on its response to, and implementation of, these recommendations. </p>
2007-04-27 B15 GF/B15/DP53 Policy on Ethics and Conflict of Interest for Global Fund Institutions Policy on Ethics and Conflict of Interest for Global Fund Institutions
<p>The Board amends the Policy on Ethics and Conflict of Interest for Global Fund Institutions by inserting the following as section 8, and re-numbering the policy accordingly: </p><p>"8. <b>Uncompensated Involvement of an Associated Person </b></p><p>An Associated Person of any employee of the Secretariat shall not be engaged to carry out work without compensation either on or outside the Global Fund premises." </p>
2007-04-27 B15 GF/B15/DP25 Inspector General Reporting Lines Inspector General Reporting Lines
<p>The Board takes note of the document entitled "Draft Options for Inspector General's Reporting Lines" that is appended to the Report of the Finance and Audit Committee (GF/B15/8) (Addendum 1) as Attachment 4, and adopts option 2 as set out in such report. The Board clarifies that the Inspector General will report independently and confidentially to the Board, while maintaining the administrative reporting line to the Executive Director.</p> <p>The Board requests that the Inspector General Selection Panel (established by GF/B15/DP24) prepare appropriate revisions to the current Terms of Reference of the Inspector General and the OIG Charter to reflect this decision for presentation to the Finance and Audit Committee not later than 31 May 2007. The Board delegates to the Finance and Audit Committee the authority to approve the revised Terms of Reference of the Inspector General and the Office of the Inspector General Charter and requests that the Finance and Audit Committee notify the Board of the revised Terms of Reference of the Inspector General and the OIG Charter promptly after such approval.</p>
2007-04-27 B15 GF/B15/DP24 Recruitment Process for the Inspector General Recruitment Process for the Inspector General
<ol start="1" type="1"><li>The Board takes note of the options for sourcing candidates for the position of the Inspector General as described in the draft Action Plan for Recruitment of a New Inspector General (the "Draft Action Plan") that is appended to the Report of the Finance and Audit Committee (GF/B15/8), Addendum 1, as Attachment 2, and decides to adopt a combination of option 1 and 2 as set out therein.</li></ol><ol start="2" type="1"><li>The Board approves, in principle, the process and responsibilities for selection of the new Inspector General set out in the draft Revised Action Plan, as modified and set forth in Attachment 3 to GF/B15/8 (Addendum 1), and the desired role and personal competencies of the Inspector General that are listed in the draft Action Plan.</li></ol><ol start="3" type="1"><li>The Board decides to establish a Selection Panel to lead the recruitment process. The composition of the Selection Panel shall include two representatives of Board delegations, the Inspector General<i>ad interim </i> and an external advisor,supported by a member of the human resources staff of the Secretariat. The Chair and the Vice Chair of the Board shall appoint the two Board representatives and the external adviser to the Selection Panel. The Inspector General ad interim shall be the chair of the Selection Panel.</li></ol><ol start="4" type="1"><li>The Selection Panel shall be constituted not later than 11 May 2007. The Board requests that the Selection Panel take all necessary steps to agree a final action plan and an expeditious and appropriate timescale for the selection process and transmit them to the Board for information as soon as possible.</li></ol><ol start="5" type="1"><li>The Board decides to establish a special Sub-committee of the Board to interview not more than three candidates recommended as suitable by the Selection Panel and to select the new Inspector General from among these candidates. The Sub-committee shall consist of the Vice Chair of the Board and two other Board Members who have not participated in the Selection Panel. Notwithstanding Article 23 of the Board Operating Procedures, the Chair and the Vice Chair of the Board shall appoint the two Board Members of the Sub-committee. The Sub-committee shall notify the Board of its selection of the new Inspector General promptly after the selection has been made.</li></ol>
2010-04-30 B21 GF/B21/DP15 Approval of the 2009 Annual Report Approval of the 2009 Annual Report
<p>The Board approves the Annual Report as presented in GF/B21/14. </p><p>The Board decides that, starting with the Annual Report for 2010, the Annual Report will include appropriate information on donor contributions to the Global Fund.</p>
2010-10-15 B21 GF/B21/EDP22 October Phase 2 decision to commit additional funding for the proposals listed in Schedule A October Phase 2 decision to commit additional funding for the proposals listed in Schedule A
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>6</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of USD 88,178,595 for the following grants<span>: </span>IDA-708-G13-H ; IDA-708-G14-H ; IDA-708-G15-H ; CAM-708-G11-H ; MLW-708-G07-H ; UGD-607-G06-T ; DMR-708-G03-T ; SNG-708-G08-T</p>
2010-08-04 B21 GF/B21/EDP11 Exceptional Extension to the Round 10 Submission Deadline Exceptional Extension to the Round 10 Submission Deadline
<p>The Board approves, on an exceptional basis, a two week extension of the Round 10 proposal submission deadline (i.e. to 3 September 2010) for the following Country Coordinating Mechanisms, whose Rolling Continuation Channel (RCC) proposals were not approved for funding as part of the Final RCC Resubmission Wave, to submit a Round 10 proposal for HIV/AIDS:</p><ul><li>Burundi;</li><li>Tanzania; and</li><li>Togo.</li></ul>
2010-09-10 B21 GF/B21/EDP20 Multi-Year Contributions and Promissory Notes from Private Donors Multi-Year Contributions and Promissory Notes from Private Donors
<p>The Board refers to its decision at its Twenty-First Meeting, which requested the Finance and Audit Committee (FAC) to conduct a review of the Global Fund Comprehensive Funding Policy (CFP) (GF/B21/DP13). It also notes the issues raised in the report of the FAC Working Group on the Review of the Comprehensive Funding Policy (GF/FAC15/08) and its associated annexes.</p> <p>The Board notes the importance of increasing the level of assurance and predictability of donor funding to the Global Fund, promoting inter-donor equity and ensuring that donor funding is used as effectively as possible for the benefit of people in need. In this context, the Board notes the need for formalization of donor commitments made through the replenishment process.</p> <p>The Board decides that in order to increase the level of assurance and predictability of donor commitments following the announcement of pledges, while taking into consideration the budgetary systems of individual donors, the Secretariat should seek to conclude multi-year contribution agreements between individual donors and the Global Fund. The Board agrees that such multi-year contribution agreements should, as appropriate, be developed on the basis of the principles outlined in GF/FAC15/08 Annex 3.</p> <p>The Board notes that the conclusion of multi-year contribution agreements does not require amendment to the CFP. However, the FAC and the Working Group will pursue the review of the CFP to ensure donor funding is used as effectively as possible for the benefit of people in need, while maintaining appropriate levels of financial assurance. The FAC will present any recommended changes thereto, beyond those set out below, to the Board for decision at its Twenty-Second Meeting.</p> <p>The Board notes Annex 5 to GF/FAC15/08, entitled "The CFP and Promissory Notes from Private Donors", and decides to replace paragraph 4 of the CFP as follows:</p> <p>The Global Fund shall consider as assets for the purposes of entering into grant agreements the following: cash; promissory notes or similar obligations issued by the government of a sovereign state (or its designated depository); and, subject to approval by the Finance and Audit Committee, promissory notes or similar obligations issued by private donors. For these purposes, promissory notes and similar obligations shall be non-negotiable, non-interest bearing and payable at par value to the account of the Global Fund in the designated depository on demand or in accordance with an encashment schedule agreed on between the contributor and the Secretariat.</p>
2008-11-08 B18 GF/B18/DP12 Building and Sustaining a Response that Halves Tuberculosis (TB) Mortality and Prevalence Building and Sustaining a Response that Halves Tuberculosis (TB) Mortality and Prevalence
<p>1. The Board acknowledges and commends the Stop TB Partnership's Global Plan to Stop TB 2006-2015 (the "Global Plan"), which aims to halve current tuberculosis prevalence and death rates by 2015. As the largest external financier of tuberculosis programs worldwide, the Global Fund is committed to ensuring that it is a key partner in supporting the implementation of the Global Plan.</p><p>2. The Board recognizes that almost 40% of the estimated 9.2 million new tuberculosis infections per year worldwide are not detected/diagnosed, posing a major risk to an increased transmission of tuberculosis. Therefore, the Board encourages applicants to the Global Fund and implementers of tuberculosis programs to develop innovative actions to accelerate case detection and effective treatment of these cases. This will require investment to: increase the speed and precision of tuberculosis diagnosis using new tools; strengthen in-country monitoring and evaluation (M&amp;E) and surveillance systems; increase community based responses. The Board specifically urges use of the dual track financing and other mechanisms to expand funded, well-trained community-based services for case detection and Directly Observed Treatment Short-Course (DOTS) provision.</p><p>3. The Board recognizes that the slow progress in implementing core TB-HIV collaborative services is a risk to achieving successful outcomes under current and future Global Fund tuberculosis and HIV grants. Given the large gap in tuberculosis screening in HIV settings and vice versa, the Board emphasizes that all applicants should include and implement significant, robust tuberculosis interventions in their HIV/AIDS proposals and HIV/AIDS interventions in their tuberculosis proposals. The Board requests the Secretariat to review the guidelines for phase 2 requests to require that, in respect of continued funding for tuberculosis or HIV grants, CCMs explain their plans for scale up to universal TB-HIV collaborative services and explicitly articulate what TB-HIV activities, funding, and indicators will be included in each proposal.</p><p>4. Noting the upcoming Ministerial meeting on MDR-TB in Beijing, the Board of the Global Fund urges substantive proposals be submitted to support MDR- and XDR-TB plans and that countries make use of budget and planning flexibilities to ensure programs utilize emerging technologies. The Board recognizes that the first line in reducing the risk of MDR-and XDR-TB is through effective DOTS treatment programs with high cure rates. In addition to expanding quality DOTS to prevent MDR-TB, a successful response will necessarily include a major scale up of drug susceptibility testing for all people suspected of having drug-resistant tuberculosis and effective treatment of these cases by expanding community-based DOTS-Plus programs. As such, the Board urges applicants to scale up laboratory capacity, and community-based management of MDR- and XDR-TB cases. </p><p>5. Recognizing that, according to the Global Plan to Stop TB, there is a gap between estimated needs and available resources, the Board urges countries to undertake a comprehensive situational gap analysis and to submit ambitious proposals that are appropriate to the specific country context through future funding Rounds, or the Rolling Continuation Channel, or national strategy applications, which requests for funding are particularly aimed at achieving major and rapid expansion of case detection with high cure rates, universal coverage of TB-HIV collaborative services, as well as scaling up laboratory and care capacities to expand DOTS and to address MDR- and XDR-TB, and at strengthening M&amp;E and surveillance systems. The Board also urges CCMs and Principal Recipients to take advantage of the flexibility offered in Global Fund financing and, if appropriate, to consider revising budgets for existing and new grants and for Phase 2 requests. In any funding request (whether a new application or under the Phase 2 process) applicants should demonstrate that they have sufficient capacity in these areas or show their plans for doing so.</p>
2008-11-08 B18 GF/B18/DP02 Approval of Agenda Approval of Agenda
The agenda for the Eighteenth Board Meeting (GF/B18/1, Revision 2) is approved.
2008-11-20 B18 GF/B18/EDP02 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><ol><li>Afghanistan, Malaria – Round 5<br/>Grant Number: AFG-506-G03-M<br/>CCM Requested Amount (Total Phase 2 in US$): 15,043,320 (1)<br/>Approved Funding Amount (Incremental in US$): 13,751,426<br/>Recommendation Category: Go<br/><br/></li><li>Cambodia, HSS – Round 5<br/>Grant Number: CAM-506-G08-S<br/>CCM Requested Amount (Total Phase 2 in US$): 3,207,184 (1)<br/>Approved Funding Amount (Incremental in US$):3,174,142<br/>Recommendation Category Conditional: Go<br/><br/></li><li>Congo, HIV – Round 5<br/>Grant Number: COG-506-G01-H<br/>CCM Requested Amount (Total Phase 2 in US$): 33,495,657 US$ <br/>Approved Funding Amount (Incremental in US$):30,545,082 (2) = Euro 23,822,400<br/>Recommendation Category: Go<br/><br/></li><li>Haiti, HIV – Round 5<br/>Grant Number: HTI-506-G05-H<br/>CCM Requested Amount (Total Phase 2 in US$): 32,721,252 (1) <br/>Approved Funding Amount (Incremental in US$):30,222,919<br/>Recommendation Category: Go</li></ol>
2009-04-14 B18 GF/B18/EDP09 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. </p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A</p><ol><li>Rwanda, TB, Round 6<br/>Grant Number(s) RWN-606-G07-T <br/> CCM Requested Amount (Total Phase 2 in US$ or Euro) $4,745,610<br/>Approved Funding Amount (Incremental in US$) $4,745,610<br/>Recommendation Category Conditional Go<br/><br/></li><li>Tajikistan, HIV, Round 6<br/>Grant Number(s) TAJ-607-G05-H<br/>CCM Requested Amount (Total Phase 2 in US$ or Euro) $6,486,107<br/>Approved Funding Amount (Incremental in US$) $6,486,107<br/>Recommendation Category Go</li></ol>
2008-10-31 B18 GF/B18/EDP01 Extension of Deadline for Grant Agreements Extension of Deadline for Grant Agreements
<p>The Board extends the deadline for the signing of a grant agreement for the proposals listed in Annex A for three months to 12 February 2009.</p><ol><li>Cuba (Tuberculosis)<br/>Principal Recipient: United Nations Development Program (UNDP)<br/>Total amount: US$ 7,871,598 over five years<br/>Phase 1: US$ 5,455,745<br/><br/></li><li>Nepal (HIV/AIDS)<br/>Principal Recipient(s):Undetermined (nominated Principal Recipients under LFA assessment)<br/>Total Amount: US$ 36,620,119 over five years<br/>Phase 1: US$ 12,321,512<br/><br/></li><li>Sudan Northern Sector (Malaria)<br/>Principal Recipient: United Nations Development Program (UNDP)<br/>Total Amount: US $94,762,531 over five years<br/>Phase 1: US $38,296,873<br/><br/></li><li>Chad (Malaria)<br/>Principal Recipient: United Nations Development Program (UNDP)<br/>Total Amount: US$ 27,497,966 over five years<br/>Phase 1: US$ 10,477,631<br/><br/></li><li>Democratic Republic of East Timor (Tuberculosis)<br/>Principal Recipient: Ministry of Health (MOH)<br/>Total Amount: US$ 7,011,931 over five years<br/>Phase 1: US$ 2,895,449<br/><br/></li><li>Democratic Republic of East Timor (Malaria)<br/>Principal Recipient: Ministry of Health (MOH)<br/>Total Amount: US$ 10,105,038 over five years<br/>Phase 1: US$ 6,866,605</li></ol>
2009-01-30 B18 GF/B18/EDP04 Amendment to GF/B18/DP3 Board Decision paragraph on the New Rolling Continuation Channel (RCC) Amendment to GF/B18/DP3 Board Decision paragraph on the New Rolling Continuation Channel (RCC)
<p>The Board amends numbered paragraph 3 of its decision point GF/B18/DP13 as follows:</p> <ol> <li>New Rolling Continuation Channel (RCC): The first phase of RCC proposals (RCC 1) approved by the Board in response to RCC invitations sent after the date of this decision shall be subject to a limit of 140% of the amount of <span style="text-decoration: line-through;">incremental funding approved</span><u>the budget</u> for the Phase 2 period of the relevant expiring grant (indicated in the Grant Score Card, section B.2. as “Global Fund Recommendation” for the “Total Phase 2 Amount”). If new resources become available, this limit may be reviewed and revised or removed.</li> </ol> <p>This decision shall take effect immediately and shall apply to all RCC proposals submitted to the Global Fund in response to invitations sent after 1 December 2008.</p>
2008-11-08 B18 GF/B18/DP04 Mid-Term Review of Second Voluntary Replenishment Mid-Term Review of Second Voluntary Replenishment
<p>The Board adopts the recommendation for a Mid-term Review of the Second Voluntary Replenishment of the Global Fund.</p><p>The Board decides that the Mid-term Review of the Second Voluntary Replenishment shall take place in advance of the Nineteenth Board Meeting scheduled for May 2009.</p>
2009-04-22 B18 GF/B18/EDP10 Approval of Round 8 Funding Recommendations Approval of Round 8 Funding Recommendations
<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 8 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14. </p><p>CATEGORY 2B PROPOSALS WITH COMPOSITE INDEX 8</p><ol><li>Burkina Faso, TB: <br/>Phase 1 Upper ceiling: Euro 12,045,997 <br/> Lifetime Upper ceiling: Euro 27,167,685<br/><br/></li><li>Chad, TB: <br/> Phase 1 Upper ceiling: Euro 3,427,453 <br/> Lifetime Upper ceiling: Euro 5,385,007<br/><br/></li><li>Burundi, HIV: <br/> Phase 1 Upper ceiling: USD 41,315,145 <br/> Lifetime Upper ceiling: USD 159,105,087<br/><br/></li><li>Nigeria, Malaria: <br/>Phase 1 Upper ceiling: USD 334,351,033 <br/> Lifetime Upper ceiling: USD 599,810,494<br/><br/></li><li>Sudan,Northern, TB:<br/>Phase 1 Upper ceiling: USD17,979,663 <br/> Lifetime Upper ceiling:USD58,048,795<br/><br/></li><li>Zimbabwe, TB: <br/>Phase1 Upper ceiling: USD 29,538,652<br/> Lifetime Upper ceiling: USD 58,298,297</li></ol>
2008-11-08 B18 GF/B18/DP23 Policy on Grant Signature where there are Pending OIG Investigations Policy on Grant Signature where there are Pending OIG Investigations
<p>The Board strongly affirms in principle the following decision point and requests the Finance and Audit Committee (FAC) to review this text, in particular to ensure that this policy is limited to circumstances in which the Inspector General has determined that there is prima facie evidence of fraud, abuse, misappropriation or corruption. The FAC should report back to the Board at its Nineteenth Meeting with a final decision point, or confirmation that the policy has been incorporated into the Global Fund's risk management framework.</p><ol><li> Consistent with the principles of transparency and performance-based funding, the Board decides that grant signature of a Board-approved grant proposal that nominates a Principal Recipient of a grant that is currently under investigation by the Office of the Inspector General of the Global Fund ("OIG") in relation to a grant in the same country shall not proceed until such time as the investigation is completed and the investigation findings either demonstrate that risks of continued Global Fund financing through such Principal Recipient are manageable, or all material investigation recommendations have been certified as resolved by the Inspector General of the Global Fund, or the CCM appoints a new Principal Recipient that does not raise issues of concern with respect to effective and transparent management of the proposal. Investigations in this circumstance are those related to potential fraud, abuse, misappropriation, corruption or mismanagement of funds.</li><li> Where the Principal Recipient under investigation is different from the Principal Recipient that is nominated under the newly-approved proposal, but the Board, the OIG, or the Secretariat is concerned that there could be a significant link between the Principal Recipients, or a material connection between the nominated Principal Recipient and the facts that are being investigated, the provisions of paragraph one, above, shall apply until such concerns are resolved. The OIG shall seek to clarify factual issues giving rise to such concerns as promptly as possible.</li><li> Should a Sub-Recipient be under investigation by the OIG, the Secretariat will place similar limits on further engagement with the Sub-recipient during grant signature with the Principal Recipient, pending the outcome of the OIG's investigation and recommendations.</li><li> If investigation findings do not demonstrate that risks of continued Global Fund financing through such Principal Recipient are manageable or the investigation recommendations cannot be certified as fully resolved by the Inspector General of the Global Fund in accordance with the policy on the timeframe for signature of grant agreements, the approval of the grant will be considered terminated without the possibility of a time extension. </li><li> If the grant under investigation is terminated, a new grant proposal to the same Principal Recipient, or to a new Principal Recipient where concerns arising under paragraph two, above, remain unresolved, may proceed to grant signature only if the following conditions are met:<ol type="a"><li> The Additional Safeguards Policy (ASP) is applied and specific conditions are developed addressing relevant aspects of the OIG's investigation; and</li><li> The OIG certifies that the conditions that led to termination in the previous grant are adequately addressed in the new grant agreement.</li></ol></li><li> If the grant under investigation is not terminated, but the Board, OIG or Secretariat determines that material risks remain, in addition to addressing conditions for continuation of the existing grant, the ASP shall be applied to new grants to the same Principal Recipient, or to a new Principal Recipient where concerns arising under paragraph two, above, remain unresolved.</li></ol>
2009-03-05 B18 GF/B18/EDP06 Approval of RCC Wave 5 Funding Recommendations Approval of RCC Wave 5 Funding Recommendations
<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposals recommended for funding by the Technical Review Panel (TRP) as ‘Category 1’ and ‘Category 2’ proposals which are listed in Annex 2 to this report. The Board’s approval is for the funding up to the initial three years of each such proposal (indicated as “Total 3 Years” in Annex 2), and is made with the clear understanding that the grant amounts requested are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts. <br/><br/></li><li>The applicants whose proposals are recommended for funding as ‘Recommended Category 2 proposals’ shall: <br/><br/><ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and <br/><br/></li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment. <br/><br/></li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as ‘Recommended Category 3A’ as indicated in Annex 2, although such applicants are encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the next available wave of Rolling Continuation Channel proposals. <br/><br/></li><li>The Board declines to approve for funding the proposal categorized by the TRP as ‘Recommended Category 3B’ as indicated in Annex 2, although the applicant is strongly encouraged to resubmit the proposal through the Rounds-Based Channel following major revision. </li></ol>
2003-06-06 B05 GF/B05/DP13 Partnership Agreements Partnership Agreements
<p>The Board endorsed the Memoranda of Understanding with UNAIDS and the IADB, and the letter of agreement with the ILO, and requested the Secretariat to provide periodic reports on cooperation between the Fund and these partners.</p>
2003-06-06 B05 GF/B05/DP10 Resource Mobilisation Strategy: International Conference to Support the Global Fund Resource Mobilisation Strategy: International Conference to Support the Global Fund
<p>The Board:</p> <p>1. Approved the principle of a regular funding mechanism for the Global Fund.</p> <p>2. Requested the secretariat, with Resource Mobilization Committee input, to develop the outline into a detailed proposal with an action plan to be adopted by the Board at its Sixth Board Meeting in October 2003.</p>
2003-06-06 B05 GF/B05/DP03 Approval of Agenda Approval of Agenda
<p>The Agenda is adopted with the following amendments: Fiduciary Arrangements will be presented before Monitoring and Evaluation Strategy on Day 1; Day 2 will begin at 8:00 a.m.; delete tracking study from the agenda.</p>
2003-06-06 B05 GF/B05/DP11 CCMs CCMs
<p>The Board endorsed the document - Guidelines on the Purpose, Structure, and Composition of the Country Coordinating Mechanisms - (Annex 3 of the Report of the Governance and Partnership Committee), and:</p> <ol> <li>Approved the guidelines on CCMs as presented.</li> <li>Requested the Governance and Partnership Committee to continue to monitor the issue of CCMs.</li> <li>Requested the Secretariat to report back on the case studies when the findings of these studies become available.</li> </ol>
2003-06-06 B05 GF/B05/DP09 By-Laws and Board Operating Procedures By-Laws and Board Operating Procedures
<p>The Board approved the following changes to the Bylaws:</p> <p>1. Article 20: Representation</p> <p>The Chair and Vice Chair (for matters which are within the responsibility of the Foundation Board) and the Executive Director (for matters which are delegated to him/her) are entitled to represent the Foundation in all dealings with third parties.</p> <p>(Option 2) Between Board meetings, the Chair and the Vice Chair acting together, are empowered to take on behalf of the Foundation any decision within the responsibility of the foundation which they consider must be taken urgently without recourse to other procedures as provided in the Bylaws and the Board Operating Procedures. In case no consensus is reached between the Chair and the Vice Chair, the Chair shall take the decision.</p> <p>2. Article 12: The Chair and the Vice Chair of the Board</p> <p>(Option 1)The Foundation Board members will select the Chair and the Vice Chair of the Foundation Board from among their own voting members, provided, that the two positions will alternate between voting groups described in Article 15. The Chair and the Vice Chair will each be elected for a period of two years. </p> <p>The Board also:</p> <p>Confirmed that the terms of office of the incumbent Chair and Vice Chair, at the date of entry into force of these amended bylaws, shall have commenced on the date of their respective election. This decision of the Board is subject to approval of the Bylaws by the Swiss Supervisory Authority.</p> <p>The Board decided to defer the approval of 20.3 Election Procedure of the Board Operating Procedures until the next Board meeting.</p>
2003-06-06 B05 GF/B05/DP02 Appointment of Rapporteur Appointment of Rapporteur
The appointment of Rapporteur for the Fifth Board meeting, was designated to the West and Central Africa Board member, Professor Adetokunbo (ADE) Lucas.
2003-06-06 B05 GF/B05/DP08 Monitoring and Evaluation Strategy Monitoring and Evaluation Strategy
<p>1. Asks the Secretariat with MEFA to revise the current M&amp;E Strategy document and report to the October Board meeting. </p>
2003-06-06 B05 GF/B05/DP07 Fiduciary Arrangements Fiduciary Arrangements
<p>1. The Board endorsed the policies on Fiduciary Arrangements for Grant Recipients as described in the document GF/B5/13 with the following amendments:</p> <p>a. Page 5, paragraph 12: Local Fund Agents must not vs. should not be involved in the design and implementation of the funded programs.</p>
2008-11-08 B18 GF/B18/DP15 Relationship between the Global Fund and the United Nations (UN) Relationship between the Global Fund and the United Nations (UN)
<p>The Board takes note of the approach presented in the Draft Outline for a Policy Statement on the Relationship between the Global Fund and the UN System, to be further developed by the Working Group and the Secretariat as a basis for an agreement on a new strategic partnership between the Global Fund and the UN system, to be presented at the Nineteenth Board Meeting.</p><p>The Board endorses the initiative that the Global Fund, through its Executive Director, take steps to pursue a decision by the 63<sup>rd</sup> UN General Assembly to grant Observer Status to the Global Fund. </p>
2008-11-08 B18 GF/B18/DP16 Memorandum of Understanding with the Islamic Development Bank Memorandum of Understanding with the Islamic Development Bank
The Board notes the Secretariat's continued focus on strengthening the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the memorandum of understanding with the Islamic Development Bank (the "IsDB MoU"), and requests the Executive Director to finalize and sign the IsDB MoU.
2008-11-08 B18 GF/B18/DP03 Approval of Report of the Seventeenth Board Meeting Approval of Report of the Seventeenth Board Meeting
The report of the Seventeenth Board Meeting (GF/B18/2) is approved, as amended at the Eighteenth Board Meeting.
2008-11-08 B18 GF/B18/DP10 Amendments to the Policy on Ethics and Conflicts of Interest for Global Fund Institutions Amendments to the Policy on Ethics and Conflicts of Interest for Global Fund Institutions
The Board approves the amendments to the Policy on Ethics and Conflicts of Interest for Global Fund Institutions as set out in Annex 1 (Revision 1) to the Report of the Ethics Committee (GF/B18/8).
2008-11-08 B18 GF/B18/DP08 Implementation of Recommendations From Board Retreat Implementation of Recommendations From Board Retreat
The Board takes note of the Report of the Board Retreat (GF/B18/15) and requests the Chair and the Vice-Chair of each of the Policy and Strategy Committee and Portfolio Committee to consider the recommendations in developing their work-plans. The Secretariat is requested to take action on recommendations where possible.
2009-03-12 B18 GF/B18/EDP07 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A</p><ol><li>Albania, HIV – Round 5 <br/>Grant Number(s) ALB-506-G01-H <br/> CCM Requested Amount (Total Phase 2 in US$ or Euro) $2,487,787<br/>Approved Funding Amount (Incremental in US$) $2,487,787<br/>Recommendation Category Go<br/><br/></li><li>Albania, TB – Round 5 <br/>Grant Number(s) ALB-506-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$ or Euro) $487,192 <br/> Approved Funding Amount (Incremental in US$) $487,192<br/>Recommendation Category Go<br/><br/></li><li>India, TB – Round 6 <br/>Grant Number(s) IDA-607-G09-T <br/>CCM Requested Amount (Total Phase 2 in US$ or Euro) $13,224,690 <br/>Approved Funding Amount (Incremental in US$) $12,236,167<br/>Recommendation Category Go<br/><br/></li><li>Guinea, TB – Round 5 <br/>Grant Number(s) GIN-506-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$ or Euro) Euro 2,348,655(2) <br/>Approved Funding Amount (Incremental in US$) Euro 413,717= $527,903(2) <br/>Recommendation Category Go<br/><br/></li><li>Sudan North, HIV – Round 5 <br/>Grant Number(s) SUD-506-G08-H <br/>CCM Requested Amount (Total Phase 2 in US$ or Euro) $83,128,940 <br/>Approved Funding Amount (Incremental in US$) $55,554,890<br/>Recommendation Category Go</li></ol>
2008-11-08 B18 GF/B18/DP13 Round 8 Funding Decisions (Phase 1, Phase 2, New Rolling Continuation Mechanism (RCC), Timing) Round 8 Funding Decisions (Phase 1, Phase 2, New Rolling Continuation Mechanism (RCC), Timing)
<p>The Board recognizes that Round 8 represents the highest amount of TRP-recommended proposals in the history of the Global Fund. The Board congratulates its implementing partners for demonstrating increased high quality demand to meet the needs of the people in implementing countries to fight HIV, tuberculosis and malaria. The Board acknowledges that this exceptional expression of increased demand requires a resource mobilization effort by the Board and the Secretariat. </p> <p>The measures outlined below are intended to ensure that the Global Fund can fund all recommended Round 8 proposals and make provision for future funding (including new rounds) while staying within the limits of available resources.</p> <p>The Board requests the Resource Mobilization Task Team, convened by the Chair of the Board, to provide concrete recommendations to the Board, its individual members and the Secretariat that enable urgent actions for increased Resource Mobilization efforts to address the funding needs for 2009 and 2010.</p> <p>The Board notes that the scale of resources required calls for strong support from the highest level of decision-makers at national and international level, including statements of commitment at the UN General Assembly, the UNAIDS PCB and the World Health Assembly. The Board will, where possible, endeavor to promote such high level calls for support through their respective delegations.</p> <p>The Board decides as follows:</p> <ol> <li>Round 8 Phase 1:  The Round 8 proposals to be approved for funding by the Board shall collectively be subject to a 10% adjustment for efficiency, resulting in a maximum limit of US$2.753 billion for Phase 1. The Board requests the Secretariat to report back at each Board meeting on its progress in working with Country Coordinating Mechanisms and Principal Recipients to achieve this overall 10% efficiency gain.</li> <li>Round 8 Phase 2:  The Phase 2 amount of approved Round 8 proposals shall collectively be subject to a maximum limit of US$3.087 billion (being 75% of the Phase 2 amounts in the Round 8 recommended proposals). If new resources become available, this limit may be partially or fully relaxed.</li> <li>New Rolling Continuation Channel (RCC):  The first phase of RCC proposals (RCC 1) approved by the Board in response to RCC invitations sent after the date of this decision shall each be subject to a limit of 140% of the amount of the incremental funding approved for the Phase 2 period of the relevant expiring grant. If new resources become available, this limit may be reviewed and revised or removed.</li> <li>Phase 2 and RCC:  The Board requests that, until 31 December 2010, the Secretariat work with CCMs and Principal Recipients to find efficiency savings of 10% (US$0.5 billion) in Phase 2 renewals of existing grants and upcoming RCC renewals. These savings shall be applied to financial needs in 2011.</li> <li>Timing of Rounds:  Recalling its decisions to announce an extra Call for Proposals for funding in 2008 ("Round 9"), the Board decides to extend the deadline for submission of proposals for Round 9 to 1 June 2009. The Board will consider and decide on the TRP's recommendations for funding of Round 9 proposals at its Twentieth Board Meeting in November 2009. The Board will also discuss the timing of future rounds at the Twentieth Board Meeting.</li> </ol> <p>The resourcing implications of this decision are set out in the table annexed to this decision.</p>
2008-11-08 B18 GF/B18/DP17 Memorandum of Understanding with the Stop TB Partnership Memorandum of Understanding with the Stop TB Partnership
The Board notes the Secretariat's continued focus on strengthening the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the revised memorandum of understanding with the Stop TB Partnership (the "Stop TB MoU"), and requests the Executive Director to finalize and sign the Stop TB MoU.
2008-11-08 B18 GF/B18/DP18 Gender Equality Strategy Gender Equality Strategy
The Board approves "The Global Fund's Strategy for Ensuring Gender Equality in the Response to HIV/AIDS, Tuberculosis and Malaria ("The Gender Equality Strategy")" as set out in the Addendum to the Report of the Policy and Strategy Committee (GF/B18/4, Addendum).
2008-11-08 B18 GF/B18/DP21 Follow-up of the Five-Year Evaluation Study Areas 2 and 3 Follow-up of the Five-Year Evaluation Study Areas 2 and 3
<p>The Board welcomes the recommendations of Study Area (SA) 2 of the Five-Year Evaluation, as summarized in the Report of the Technical Evaluation Reference Group (TERG) (GF/B18/11). It requests the Secretariat to report to the Policy and Strategy Committee (PSC) on the Secretariat's progress to date on responding to SA2 recommendations. The Board also requests the Secretariat to articulate a process and timeline for responding to and implementing SA 3 recommendations.</p> <p>The Board endorses the TERG's call for action for the Global Fund to work with partners to strengthen country monitoring and evaluation systems for performance and impact, to build analytical capacity in countries and to support development of country-owned impact evaluation platforms. </p> <p>The Board requests the PSC Chair, in consultation with the Chairs of the Portfolio Committee (PC) and the Finance and Audit Committee (FAC), to set up a small ad-hoc committee with the specific task of assisting the PSC to follow-up on, and respond to the 5-Year Evaluation process.</p>
2009-02-20 B18 GF/B18/EDP05 Appointment of the Chair of the Finance and Audit Committee (FAC) Appointment of the Chair of the Finance and Audit Committee (FAC)
The Board approves the appointment of Ambassador Louis Charles Viossat of the France and Spain constituency as Chair of the Finance and Audit Committee to serve for the unexpired term of Ambassador Mark Dybul.
2008-12-15 B18 GF/B18/EDP03 Approval of Funding Recommendations (Phase 2) Approval of Funding Recommendations (Phase 2)
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A</p><ol><li>Armenia, TB – Round 5<br/>Grant Number: ARM-506-G02-T<br/>CCM Requested Amount (Total Phase 2 in US$): 3,455,229 (2)<br/>Approved Funding Amount (Incremental in US$): US$3,455,229 = Euro2,740,505<br/>Recommendation Category: Conditional Go<br/><br/></li><li>Eritrea, HIV – Round 5<br/>Grant Number: ERT-506-G03-H<br/>CCM Requested Amount (Total Phase 2 in US$): 28,091,155 (1)<br/>Approved Funding Amount (Incremental in US$): 16,000,000<br/>Recommendation Category: Conditional Go<br/><br/></li><li>Indonesia, TB – Round 5<br/>Grant Number: IND-506-G05-T<br/>CCM Requested Amount (Total Phase 2 in US$): 62,310,771 (1)<br/>Approved Funding Amount (Incremental in US$): 31,663,748<br/>Recommendation Category: Conditional Go<br/><br/></li><li>Philippines, TB – Round 5<br/>Grant Number: PHL-506-G06-T<br/>CCM Requested Amount (Total Phase 2 in US$): Euro 29,682,536 (1) (2) <br/>Approved Funding Amount (Incremental in US$): Euro24,820,971 = US$31,294,280<br/>Recommendation Category: Go<br/><br/></li><li>Sudan, TB – Round 5<br/>Grant Number:SUD-506-G06-TCCM Requested Amount (Total Phase 2 in US$):16,996,951<br/>Approved Funding Amount (Incremental in US$):13,041,297<br/>Recommendation Category: Conditional Go<br/><br/></li><li>Sudan, TB – Round 5<br/>Grant Number:SUD-506-G07-T<br/>CCM Requested Amount (Total Phase 2 in US$):8,744,330 (1)<br/>Approved Funding Amount (Incremental in US$): 8,580,453<br/>Recommendation Category: Go</li></ol>
2008-11-08 B18 GF/B18/DP05 Product and Service Donations through the Global Fund Product and Service Donations through the Global Fund
<p>The Board takes note of the recommendations of the Technical Working Group, as endorsed by the majority of the Joint Steering Group. It is important to note that these recommendations do not imply a priori characterization of donation programs as positive or negative but rather make a pragmatic judgment on the current viability of the Global Fund as an implementing vehicle for product and service donations. The Board agrees the following: </p><p>(a) The Board recognizes the added value of service donations to the Secretariat and the potential added value of Global Fund grant recipients receiving service donations. </p><p>(b) The Board therefore requests the Secretariat, under the oversight of the Finance and Audit Committee and with input from the Ethics Committee, to develop guidelines for the acceptance of service donations by the secretariat and for the facilitation by the secretariat of service donations to Global Fund grant recipients. The Board requests the Secretariat to report on the development of such guidelines at the Nineteenth Board Meeting, and to report annually thereafter an itemized list of such donations received by the Secretariat.</p><p>(c) The Global Fund should not, under current conditions, accept in-kind donations of health products. The Board may re-consider this position after the Voluntary Pooled Procurement Mechanism (VPP) has operated for at least two years and sufficient evidence is available to evaluate whether the addition of a donation component to the VPP is practical, feasible and appropriate. </p><p>(d) Key considerations in undertaking any review regarding donations of health products would include: Global Fund recipients' views regarding such donations; changes in market conditions in key relevant health product categories; and consequent potential market impact of such donations.</p><p>(e) The Global Fund should not accept in-kind donations of non-health products until adequate information is available to assess the implications of doing so. The Board asks the Secretariat to gather such information and to report on progress made at the Nineteenth Board Meeting.</p>
2008-11-08 B18 GF/B18/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
Dr. William Steiger from the United States constituency is designated as Rapporteur for the Eighteenth Board Meeting.
2008-11-08 B18 GF/B18/DP06 Budget 2009 Budget 2009
<p>The Board: </p><p>1. requests the Secretariat to revise the proposed 2009 Operating Expenses Budget in light of the grant approval decisions taken at the Eighteenth Board Meeting; and</p><p>2. requests the Finance and Audit Committee (FAC) as soon as possible following the Eighteenth Board Meeting and by no later than 15 December 2008, to review the revised budget proposal and present to the Board for electronic approval, on a no objection basis, the budget in an amount not exceeding US $240.2 million in accordance with the Budget Framework, taking into account the current resource constrained environment with a view to a budget reduction.</p>
2008-11-08 B18 GF/B18/DP07 Affordable Medicines Facility - malaria Affordable Medicines Facility - malaria
<p>The Board refers to its earlier decisions regarding the Affordable Medicine Facility - malaria ("AMFM") (GF/B16/DP14 and GF/B17/DP16).</p> <p>The Board approves the Policy Framework and Implementation Plan set out in the AMFm Ad Hoc Committee Report to the Board (GF/B18/7 - the "AMFm Report") and reaffirms its decision to host and manage the AMFm for an initial phase ("Phase 1") in a limited number of countries. The Board requests the Secretariat to begin operation of Phase 1 of the AMFm.</p> <p>The Board requests the AMFm Ad Hoc Committee to continue to oversee the pre-launch preparations</p> <p>of AMFm Phase 1 in keeping with its current committee mandate up to the 19th Board meeting (and authorizes it to make minor modifications to the Policy Framework and Implementation Plan). At the 19th Board meeting, the Board will decide on the governance structure for the oversight and performance monitoring of the implementation of Phase 1.</p> <p>The Board requests the Secretariat to commission an independent technical evaluation of the roll-out of the AMFm in the AMFm Phase 1 countries. The Board requests the committee with oversight of AMFm Phase 1 to review the findings of such evaluation and to make a recommendation to the Board on its completion (estimated for the second half of 2010), at which time the Board will determine whether to expand, accelerate, terminate or suspend the AMFm business line.</p> <p>The Board acknowledges the work and support of the RBM Task Force, UNITAID and other partners and requests its partners to continue to support the development and implementation of the AMFm.</p>
2008-11-08 B18 GF/B18/DP11 Quality Assurance Policy for Pharmaceutical Products Quality Assurance Policy for Pharmaceutical Products
<p>The Board approves the Quality Assurance Policy for Pharmaceutical Products ("QA Policy") as set out in Annex 1 to the Report of the Portfolio Committee (GF/B18/5). The QA Policy shall come into effect on 1 July 2009 and shall replace the Global Fund's previous policy for the quality assurance of pharmaceutical products (as approved at the Third Board meeting and amended at subsequent Board meetings). </p><p>The Board authorizes the Secretariat to request the World Health Organization (WHO) to host the Expert Review Panel described in the QA Policy, and to conclude the necessary arrangements with the WHO.</p><p>The Board delegates to the Portfolio Committee the responsibility for overseeing the implementation of the QA Policy, including the establishment of the Expert Review Panel. The Board requests the Secretariat to provide the Portfolio Committee with an update to review the implementation of the QA Policy at the Portfolio Committee's final meeting in 2009, and thereafter, as requested by the Portfolio Committee. </p><p>The Board also requests the Secretariat, under the oversight of the Portfolio Committee, to review the current status of quality assurance for diagnostic products and make recommendations. The Board requests the Portfolio Committee to report the findings of this review at the Board's final meeting in 2009. </p>
2008-11-08 B18 GF/B18/DP22 International Task Team on HIV-related Travel Restrictions International Task Team on HIV-related Travel Restrictions
<p>The Board expresses its appreciation to UNAIDS and the International Task Team on HIV-related</p><p>Travel Restrictions for their work and its strong support for the overarching goal of the Task Team, to eliminate HIV specific restrictions related to entry stay and residence based on HIV status.</p><p>The Board takes note of the recommendations contained in GF-B18-12 Annex 1 and decides:</p><p>1. That no Board, Committee meeting, or Partnership Forum will be held in a country with an HIV-specific restriction related to entry, stay or residence based on HIV status; and</p><p>2. To support country-led efforts to review and eliminate laws, policies and practices related to HIV-specific restrictions on entry, stay and residence, through leadership, advocacy and appropriate partnerships at international, regional and national levels.</p><p>3. To work with partners to ensure countries have access to the latest guidance and information from normative agencies on this issue of HIV specific restrictions on entry, stay and residence.</p><p>The Board requests the relevant committees, based on the Task Team Report to provide recommended actions to the Board at its Nineteenth Meeting, in particular on how the Global Fund, through its policies and procedures, can finance country interventions that support the elimination of HIV-related restrictions.</p>
2009-03-27 B18 GF/B18/EDP08 Approval of Round 8 Funding Recommendations Approval of Round 8 Funding Recommendations
<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2’ proposals with composite index 3 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14:</p> <ul> <li>Brazil (Malaria) -- Euro 20,659,117;</li> <li>Colombia (Malaria) -- Euro 16,997,092;</li> <li>Serbia (HIV) -- Euro 3,766,988;</li> <li>Cape Verde (HIV) -- USD 5,321,184;</li> <li>Dominican Republic (Malaria) -- USD 4,492,517;</li> <li>Ecuador (Malaria) -- USD 8,374,965;g) Indonesia (Malaria) -- USD 73,453,889; and</li> <li>Nicaragua (HIV) -- USD 31,385,337.</li> </ul> <p>Phase 1 Upper Ceiling amounts: Prior to any reduction arising from the adjustment for efficiency applicable to Phase 1 of Round 8 in accordance with Decision Point GF/B18/DP13.The USD equivalent of proposal amounts requested in Euro is based on the UN official exchange rate effective at 1 March 2009 of USD 1= Euro 0.782.</p>
2008-11-08 B18 GF/B18/DP09 Approval of New Member for the Technical Evaluation Reference Group Approval of New Member for the Technical Evaluation Reference Group
The Board requests the Executive Director to invite Dr Lixia Wang to become a member of the Technical Evaluation Reference Group. 
2008-11-08 B18 GF/B18/DP20 Phased Roll-out of National Strategy Applications, with First Learning Wave Phased Roll-out of National Strategy Applications, with First Learning Wave
<p>The Board refers to its decision (GF/B15/DP17) on National Strategy Applications ("NSAs"), requesting that the Policy and Strategy Committee (PSC) recommend to the Board a plan and policies for bringing into operation a National-Strategy Applications procedure, based on the principles set forth in that decision. The Board reiterates its commitment to the development of a credible, shared validation approach for national strategies, which will form the basis of the NSA procedure once it becomes available.</p> <p>To learn lessons with regard to other aspects of the NSA procedure, the Board authorizes the Secretariat to bring it into operation through a phased roll-out, which shall begin with a first wave of NSAs ("the First Learning Wave") in a limited number of countries. The First Learning Wave shall be aimed at drawing policy and operational lessons to inform a broader roll-out of the NSA procedure.</p> <p>The principles underlying the Board's decisions on:</p> <ul> <li>"dual-track financing" (as described in GF/B15/DP14);</li> <li>the strategic approach to health systems strengthening (as described in GF/B15/DP6); and</li> <li>the Comprehensive Funding Policy (GF/B15/DP27)</li> </ul> <p>shall be applied to the First Learning Wave.</p> <p>The initial funding of grants in the First Learning Wave shall be approved by the Board for a period that shall not exceed two years.</p> <p>The Board authorizes the Secretariat to make exceptions to existing policies and procedures to the extent necessary to implement the First Learning Wave. Such exceptions may relate, but are not limited, to the following:</p> <ol type="a"> <li>The type and format of information to demonstrate eligibility of the NSAs;</li> <li>The submission and review procedures and policies for applications for Global Fund financing (including the timing of submission and the format of applications);</li> <li>The Technical Review Panel (TRP) terms of reference, including TRP procedures, compensation arrangements for TRP members, criteria for review of NSAs (including the national strategy itself) and interaction with CCM members and other relevant stakeholders during review; and</li> <li>The Phase 2 review (including the timing of the Phase 2 review and renewal decision).</li> </ol> <p>Any exceptions to existing policies and procedures made in connection with the First Learning Wave shall be consistent with the Framework Document of the Global Fund.</p> <p>In implementing the First Learning Wave, the Secretariat shall take into account the outcome of the deliberations of the UNAIDS Programme Coordinating Board at its meeting in December 2008, the IHP+ consultations on the validation process and other relevant stakeholder consultations.</p> <p>The Secretariat shall report to the PSC at its first meeting in 2009 on progress of implementation of the First Learning Wave. The TRP-recommended applications emanating from the First Learning Wave shall receive the same funding priority as proposals submitted under the Rounds-Based Channel (provided that, in a resource-constrained environment, precedence is given to previously approved but unfunded rounds-based proposals).</p> <p>The Secretariat will also propose to the PSC, once they have been identified, modifications to existing Global Fund policies that would be necessary to launch a broader roll-out of the NSA procedure.</p> <p>The authority granted to the Secretariat under this decision point will continue for the duration of the grants approved within the First Learning Wave.</p>
2008-11-08 B18 GF/B18/DP19 Global Fund Architecture Global Fund Architecture
<p>The Board acknowledges the work of the Policy and Strategy Committee and Secretariat in reviewing the architecture issues related to the current financing model of the Global Fund.</p> <p>The Board recognizes that certain key improvements may be implemented immediately, while other potential improvements require further consideration and development.</p> <p>A. Endorsement of a "single stream of funding per Principal Recipient per disease" model:</p> <p>The Board endorses, in principle, the recommendation that future architectural changes shall be based on a "single stream of funding per Principal Recipient per disease" model, recognizing that:</p> <ol> <li>The Secretariat will present to the Policy and Strategy Committee, at its first meeting in 2009, a detailed design for implementation of this model, including an analysis of all necessary changes to Global Fund policy required to implement this model; and</li> <li>The Policy and Strategy Committee will present the model for Board approval at the Nineteenth Board Meeting.</li> </ol> <p>B. Changes to be implemented beginning in Round 10:</p> <p>Recognizing that the Board has made the following previous decisions in order to progress towards greater alignment of Global Fund processes with country cycles:</p> <ul> <li>To announce, with significant advance notice, a fixed set of dates for future rounds of funding (GF/B14/DP12) and to call for two rounds of funding in 2008 (GF/B17/DP23);</li> <li>The opportunity for applicants to re-submit a revised version of the same proposal that was recommended by the TRP as a 'Category 3' proposal (GF/B17/DP23); and</li> <li>The opportunity for the TRP to recommend RCC proposals for funding conditional upon the removal of a limited set of specific elements from the disease proposal (GF/B14/DP9).</li> </ul> <p>The Board now decides to reflect the above decisions in future rounds, commencing with Round 10, as follows:</p> <ol> <li>The Secretariat shall issue a minimum of two Calls for Proposals in each calendar year, which shall be issued at dates that fall 6 months after each other, and on as close to the same dates each year as is practicable;</li> <li>Applicants whose proposals are recommended as 'Category 3' proposals by the TRP, shall be entitled to re-submit, in the next round, a revised version of the same proposal that was recommended by the TRP as a 'Category 3' proposal;</li> <li>The TRP may, when recommending proposals as 'Category 1' or 'Category 2' (including 'Category 2B' proposals), recommend relevant proposals for funding conditional upon the removal of a limited set of specific elements from the disease proposal (which removal is not subject to a right of appeal); and</li> <li>The Board requests the Secretariat to prepare amendments to the TRP Terms of Reference as necessary to implement the decisions described above.</li> </ol>
2008-11-08 B18 GF/B18/DP14 Approval of Round 8 Approval of Round 8
<ol> <li>The Board approves, in principle, all the Round 8 proposals that were recommended for funding by the Technical Review Panel (TRP).</li> <li>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) as 'Category 1' and 'Category 2' with composite indices 8, 6, and 5, as listed in Annex 2 (Revision 2) to the Report of the Technical Review Panel and Secretariat on Round 8 Proposals (GF/B18/10), subject to Decision Point GF/B18/13 and paragraphs 4 to 5 below.</li> <li>The remaining Round 8 proposals recommended for funding by the TRP and identified as 'Category 2' proposals with composite index 3 and 'Category 2B' will be approved for funding for an initial two years (subject to Decision Point GF/B18/13 and paragraph 5 below): <ol type="i"> <li>through Board confirmation by email (or, if appropriate, at the Nineteenth Board Meeting), as funds become available under the terms of the Comprehensive Funding Policy; and</li> <li>based on the composite ranking of such proposals in compliance with Board's decision entitled 'Prioritization in Resource Constrained Environments' (GF/B8/2, p. 13).</li> </ol> <br />In the interim, the Board requests the Secretariat to proceed with the TRP clarifications and the LFA assessments with respect to those proposals.</li> <li>The applicants whose proposals are recommended for funding as 'Category 1' shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than eight weeks after the applicant's receipt of notification in writing from the Secretariat of the Board's decision.</li> <li>The applicants whose proposals are recommended for funding as 'Category 2' (including the subset of proposals identified as 'Category 2B') shall: <ol type="i"> <li>provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after receipt of notification in writing by the Secretariat to the applicant of this Board decision; and</li> <li>conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</li> </ol> </li> <li>The Board declines to approve for funding those proposals recommended by the TRP as 'Category 3' proposals as indicated in Annex 2 in GF/B18/10. Such applicants may resubmit a revised version of the same proposal in Round 9.</li> <li>The Board declines to approve for funding those proposals recommended by the TRP as 'Category 4' as indicated in Annex 2 to GF/B18/10.</li> </ol>
2003-06-06 B05 GF/B05/DP18 Committee Report: GPC Committee Report: GPC
<p>The Board recognised and thanked Mr Claudio Spinedi for the very valuable contribution he has made to the establishment of the Global Fund and wished him well in his new responsibilities.</p>
2007-04-27 B15 GF/B15/DP10 Confidentiality of Recordings of Executive Sessions Confidentiality of Recordings of Executive Sessions
The Board approves the amendments to the Global Fund Documents Policy, as presented in the Report of the Policy and Strategy Committee (GF/B15/6), Annex 4.
2003-06-06 B05 GF/B05/DP16 Committee Report: MEFA Committee Report: MEFA
<p>The Board adopts the Procurement Policy for the Secretariat as presented.</p> <p>The Board appoints Ernst &amp; Young, Ltd. as external auditor of the Global Fund</p>
2003-06-06 B05 GF/B05/DP12 Partnership Forum Partnership Forum
<p>The Board took the following decisions:</p> <p>1. Decide on a location for the Forum</p> <p>The location for the Partnership Forum will be ______________ [and the indicative number of participants therefore ____________.]</p> <p>2. Mandate the Chair of the Board to establish a Steering Committee for the Forum.</p> <p>The Chair is mandated to form a Steering Committee.</p> <p>3. Mandate the Secretariat to proceed with a process for contracting a conference organiser for the Forum.</p> <p>The Secretariat is mandated to proceed with the contracting of a conference organiser firm.</p>
2010-04-30 B21 GF/B21/DP14 Membership of the Ethics Committee and Amendments to the Ethics Committee’s Terms of Reference Membership of the Ethics Committee and Amendments to the Ethics Committee’s Terms of Reference
<p>The Board approves the appointment of the Dr Aishath Shiham from the South East Asia Constituency as a member of the Ethics Committee until the adjournment of the first Board meeting of 2011.</p><p>The Board also approves the amendments to the Ethics Committee's Terms of Reference as follows:</p><p><b>AMENDED TERMS OF REFERENCE OF THE ETHICS COMMITTEE</b> </p><p><b>Ethics Committee (EC)</b> </p><ul type="disc"><li>Develop and promote on an ongoing basis a values and integrity framework, and provide guidance and information on the related policies including the Policy on Ethics and Conflict of Interest for Global Fund Institutions (CoI Policy), and all codes of conduct;</li></ul><ul type="disc"><li>Provide oversight for ethical and related reputational risks;</li></ul><ul type="disc"><li>Oversee the CoI Policy and its implementation, and advise the bodies and staff of the Global Fund on conflict of interest and ethics issues;</li></ul><ul type="disc"><li>Resolve differences in the interpretation of conflict of interest;</li></ul><ul type="disc"><li>At its discretion, bring any conflict issue it may consider necessary to the Board for discussion and determination;</li></ul><ul type="disc"><li>Take such other actions as are consistent with the Global Fund Bylaws, Board Operating Procedures, COI Policy and a values and integrity framework, as are necessary and appropriate for achieving the objectives of the Committee;</li></ul><ul type="disc"><li>Review the Secretariat's bi-annual report of secondment staff appointments;</li></ul><ul type="disc"><li>Keep appropriate written records of its activities; and</li></ul><ul type="disc"><li>Report annually to the Foundation Board.</li></ul>
2010-08-15 B21 GF/B21/EDP17 Extension of time to fulfil a ‘Condition’ – Multi-Country Africa (MAW-607-G01-H) Extension of time to fulfil a ‘Condition’ – Multi-Country Africa (MAW-607-G01-H)
<p>The Board refers to condition number 2 in its decision approving as a "Conditional Go" the Phase 2 of the Round 6 HIV grant of Multi-Country Africa (MAW-607-G01-H) ("Condition 2") which states that:</p><p><i>"Not later than 31 August 2010 and based on programmatic and financial data from 30 months of implementation (ie 28 Feb 2010) an independent evaluation of the program should be conducted to assess: a) the effectiveness and efficiency of the program activities, including M&amp;E activities - compared with having the same activities funded under the national programs; b) the regional coordinating mechanism that has been put in place to allow patients to be transferred to different sites to access treatment in a coordinated way across the 5 countries; and, c) whether the grant activities and budget overlap with, duplicate, or are complementary to activities and funding covered by national programs. Funding for Years 4 and 5 of the program shall be subject to the Global Fund‘s satisfactory review of the results of the evaluation."</i></p><p>The Board decides to extend the deadline in Condition 2 from 31 August 2010 to 17 October 2010 to allow the Secretariat adequate time to review the independent evaluation report.</p>
2010-04-30 B21 GF/B21/DP11 Approval of 2009 Financial Statements Approval of 2009 Financial Statements
The Board approves the 2009 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young.
2010-04-30 B21 GF/B21/DP08 Exception to the Terms of Reference of the Technical Review Panel for Round 10 Exception to the Terms of Reference of the Technical Review Panel for Round 10
The Board decides to make an exception to Article 17 of the Terms of Reference of the Technical Review Panel (Annex 1 of GF/B21/5, Revision 1) only for Round 10 to permit existing Permanent TRP Members to serve more than four Rounds to ensure that a sufficient pool of experienced TRP Members are available on which to draw on for Round 10. 
2010-07-15 B21 GF/B21/EDP08 Waiver of a ‘Condition’ – Niger (NGR-506-G04-M and MGR-506-G05-T) Waiver of a ‘Condition’ – Niger (NGR-506-G04-M and MGR-506-G05-T)
The Board acknowledges that, due to serious governance issues at the Ministry of Public Health, frequent changes of the Minister and a volatile political situation in Niger the condition upon which the Board approved the Round 5 malaria and tuberculosis grants to the United Nations Development Program (NGR-506-G04-M and NGR-506-G05-T) has not been fulfilled. However, the Board decides to waive this condition in light of the context in Niger.
2010-11-19 B21 GF/B21/EDP27 November Phase 2 decision to commit additional funding for the proposals listed in Schedule A November Phase 2 decision to commit additional funding for the proposals listed in Schedule A
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>7</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached table detailing total recommended funding amount of US$ 102,377,215 for the following grants: NEP-708-G06-M ; IRN-708-G02-M ; IRN-708-G03-T ; SLE-708-G03-T ; SUD-708-G09-M ; MDG-708-G09-M ; AFG-708-G04-H ; AFG-708-G05-H ; ZAM-708-G16-T ; ZAM-708-G18-T ; ZAM-708-G17-M ; ZAM-708-G19-M ; GIN-607-G05-M</p>
2010-12-10 B21 GF/B21/EDP32 The Secretariat’s recommendation to replace the funding ceilings for the November Phase 2 decisions for Zambia (GF/B21/EDP27) with corrected funding ceilings The Secretariat’s recommendation to replace the funding ceilings for the November Phase 2 decisions for Zambia (GF/B21/EDP27) with corrected funding ceilings
<p>Referring to its earlier decision on 23 November 2010 (GF/B21/EDP27), the Board:</p> <ol> <li>Notes a transcription error was made in the reporting of the amounts requested and the Secretariat‘s recommendation for incremental funding for the Phase 2 period for the Zambia grants numbered ZAM-708-G18-T and ZAM-708-G17-M listed in Schedule A of that earlier decision point.</li> <li>Decides to amend its funding decision for the two Zambia grants numbered ZAM-708-G18-T and ZAM-708-G17-M, by replacing the earlier approved amounts with the corrected funding amounts as set out in Schedule A to this decision point, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>1</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each of affected proposals shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 102,377,215 for the following grants: NEP-708-G06-M ; IRN-708-G02-M ; IRN-708-G03-T ; SLE-708-G03-T ; SUD-708-G09-M ; MDG-708-G09-M ; AFG-708-G04-H ; AFG-708-G05-H ; ZAM-708-G16-T ; ZAM-708-G18-T ; ZAM-708-G17-M ; ZAM-708-G19-M ; GIN-607-G05-M</p>
2010-10-24 B21 GF/B21/EDP24 Additional funding for Nigeria (NGA S10-G17-H) Additional funding for Nigeria (NGA S10-G17-H)
The Board approves additional funding for the Phase 1 period of the Round 9 Nigeria HIV/AIDS proposal to accelerate the scale-up of prevention of mother-to-child transmission interventions in the amount of up to US$ 29,325,424 subject to TRP clarifications and conditions within a limited timeframe. Approval is given for this amount on the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and is based on the understanding that the overall life-time budget for the proposal of US$ 341,019,908 does not change by this Decision.
2010-04-30 B21 GF/B21/DP07 Revisions to the Terms of Reference of the Technical Review Panel Revisions to the Terms of Reference of the Technical Review Panel
<p>The Board decides to amend the Terms of Reference of the Technical Review Panel, as set forth in Annex 1 of the Report of the Portfolio Implementation Committee (GF/B21/5, Revision 2).</p> <p>The Board decides that for the final re-submission wave of the Rolling Continuation Channel (RCC), the Terms of Reference as amended at the Nineteenth Board Meeting (GF/B19/DP16), will be applicable.</p>
2010-04-30 B21 GF/B21/DP20 Exploring Options for Optimizing Synergies with Maternal and Child Health Exploring Options for Optimizing Synergies with Maternal and Child Health
<p>The Global Fund Board recognizes that the health-related Millennium Development Goals are interlinked. Achieving MDG 6 (combating HIV, malaria and TB and other diseases), MDG 4 (reducing child mortality) and MDG 5 (improving maternal health) can only be approached in an integrated manner and the success of one MDG depends on progress on all others.</p> <p>The Board acknowledges that HIV, tuberculosis and malaria place a heavy burden on the health of women and children. In sub-Saharan Africa, HIV is responsible for 46 per cent of all deaths among women of reproductive age. HIV, TB and malaria are among the most common indirect causes of maternal deaths. All three diseases heavily impact on the health of children: Children account for more than 80 per cent of malaria, and over 2 million children are living with HIV, 90 per cent of them living in sub-Saharan Africa. </p> <p>The Board notes the efforts of a broad range of partners who are working to accelerate action and to scale up integrated services, and especially applauds the efforts of MCH advocates, who have been tireless in their efforts to improve the health and save the lives of women and children.</p> <p>The Board is encouraged by the contributions of the Global Fund in financing country-led programs that improve maternal and child health, including scaling up PMTCT services, malaria prevention and treatment, anti-retroviral therapy, integration of sexual and reproductive health services with HIV/AIDS programmes and support for children orphaned by HIV/AIDS. The Global Fund investments are also strengthening health and community systems, and supporting a range of interventions to promote gender equality and equity, as articulated in the Gender Equality Strategy (Decision Point GF/B18/DP18).</p> <p>The Board supports the efforts of countries to integrate MCH within their HIV/AIDS, TB and malaria programmes, and strongly encourages CCMs to look at opportunities to scale up an integrated health response that includes MCH in their applications for HIV/AIDS, TB, malaria and HSS. </p> <p>However, the Board notes that despite support for integrated MCH services through the current Global Fund portfolio, some areas along the continuum of care in maternal and child health will not be addressed by 2015. These areas, as outlined in the Consensus for Maternal, Newborn and Child Health, include comprehensive family planning, skilled care for women and newborns during and after pregnancy and childbirth. </p> <p>The Board encourages countries and partners, as a matter of urgency, to work together in the context of opportunities presented through grant reprogramming, Round 10, and changes to the Global Fund grant architecture to urgently scale up investments in MCH in the context of the Global Fund's core mandate. </p> <p>The Board strongly encourages CCMs to identify opportunities to scale up an integrated health response that includes MCH in their applications for HIV/AIDS, tuberculosis, malaria and HSS.</p> <p>The Board agrees to work with partners in exploring ways to further enhance and integrate the Global Fund's contributions in this area within the context of national strategies and integrated approaches.</p> <p>The Board requests the Secretariat to review and elaborate the potential options and their implications for enhancing the contributions of the Global Fund to MCH, recognizing the urgent need for additional and sufficient financing for MCH as well as for AIDS, tuberculosis and malaria, and exploring how this will impact on existing Global Fund policies, partnerships, resource mobilization, procedures, and operations, including CCMs, TRP and staffing at the Secretariat. The Board further requests the Secretariat to report on this matter at the 14th Policy and Strategy Committee meeting for its recommendation to the Twenty-Second Board Meeting.</p>
2010-06-14 B21 GF/B21/EDP04 June 2010 Phase 2 Funding Decision June 2010 Phase 2 Funding Decision
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>2</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 81,600,858<span> for the following grants: </span>BEN-708-G07-M ; BTN-708-G05-M ; CIV-607-G06-M ; LSO-708-G05-H ; NEP-708-G08-T ; NGR-708-G07-M ; MAL-607-G04-M ; MON-708-G05-H ; MWP-708-G07-T ; PRY-708—G03-T ; SNG-708-G07-M ; THA-708-G09-M</p>
2010-08-04 B21 GF/B21/EDP10 Approval of the Final Resubmission Wave of RCC Proposals Approval of the Final Resubmission Wave of RCC Proposals
<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposal recommended for funding by the Technical Review Panel (TRP) as "Category 2" which is listed in Annex 1 to the Report of the TRP and the Secretariat on Funding Recommendation for the Final Resubmission Wave of Rolling Continuation Channel Proposals (the "Final Resubmission Wave RCC Report"). The Board approves funding for up to three years for the proposal (indicated as "Total 3 Years" in Annex 1 to the Final Resubmission Wave RCC Report). The Board‘s approval is made with the clear understanding that the grant amount requested is an upper ceiling subject to TRP clarifications and grant negotiations rather than a final approved grant amount. For further clarity, this decision is subject to the revised Comprehensive Funding Policy approved at the Twentieth Board meeting.</li><li>The applicant whose proposal is recommended for funding as "Category 2" shall: <ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board‘s decision; and</li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat‘s receipt of the applicant‘s initial detailed response to the issues raised for clarification and/or adjustment.</li></ol></li><li>The Board declines to approve for funding proposals categorized by the TRP as "Category 3B" as indicated in Annex 1 to the Final Resubmission Wave RCC Report. Such applicants are encouraged to submit a revised proposal through the Rounds-Based Channel, taking into account the TRP‘s recommendations. The Board approves, on an exceptional basis, a two week extension of the Round 10 submission deadline (i.e. to 3 September 2010) for such applicants.</li></ol>
2010-08-10 B21 GF/B21/EDP12 Extension of Grant Signing Deadline for Haiti Round 8 Malaria Proposal Extension of Grant Signing Deadline for Haiti Round 8 Malaria Proposal
The Board extends the deadline for the signing of the Round 8 Haiti Malaria Proposal to 11 February 2011.
2010-04-30 B21 GF/B21/DP19 Launch of Round 10 Launch of Round 10
<p>1. Recognizing the continued need for countries to maintain and scale up their national programs to fight HIV/AIDS, tuberculosis and malaria and reaffirming the Board's commitment for the new architecture for grant funding, the Board urges donors to make firm pledges at the Replenishment Meeting in October 2010 to meet the expected demand and to allow the scaling up of life saving treatment.</p> <p>2. With reference to its decision regarding the launch of the next Round of proposals (GF/B20/DP30), the Board requests the Secretariat to issue a Call for Proposals for Round 10, on or about 20 May 2010 with a submission date on or about 20 August 2010, and to provide for review of those proposals in time for approval at the Twenty-Second Board Meeting in December 2010.</p> <p>3. The Call for Proposals for Round 10 shall include a provision for a dedicated funding stream for proposals which focus only on Most at Risk Populations (GF/B21/DP18).</p> <p>4. In determining the amount of assets available to be committed for Round 10 at the time of approval of the proposals, only pledges to be received within (and for use within) the period up to and including 31 December 2011 shall be considered. Notwithstanding Article 3d of the Comprehensive Funding Policy, the determination of available assets as at 31 December 2011 will be updated at the end of the first quarter of 2011 in relation to new pledges. </p> <p>5. In the event that insufficient resources are available to approve all TRP recommended proposals, the provisions of Decision Point GF/B21/DP17 will apply.</p>
2010-04-30 B21 GF/B21/DP06 Incremental Funding and Related Commitment for 2011 Incremental Funding and Related Commitment for 2011
<p>The Board refers to its decision made at the Twentieth Board Meeting on the Global Fund Architecture Review (GF/B20/DP31) and takes note of document GF/PSC13/04 regarding the mechanism under which additional funding to accelerate strongly performing programs can be made available at the time of grant renewal.</p> <p>Therefore, the Board decides as follows:</p> <ul> <li>Approves the establishment of a dedicated funding envelope to allow for additional funds to be committed to programs on the basis of demonstrated strong performance and impact at the time of the requests for and approval of additional commitments under the Periodic Reviews and Commitments Policy (the "Incremental Funding at grant renewal").</li> <li>Allocates for this purpose an amount of 30 million US$ as a funding reserve for 2011, and will consider establishing a funding reserve for 2012 at its meeting in November 2011.</li> <li>Requests the Secretariat to implement this mechanism and manage this funding reserve in line with the procedure defined in Annex 2 of the PSC Report to the Board (GF/B21/4).</li> <li>Replaces references to "Scale-up Funds" in the Comprehensive Funding Policy of the Global Fund (Annex 5 Version 2 of GF/B20/12) with "Incremental Funding at grant renewal".</li> </ul>
2010-07-15 B21 GF/B21/EDP09 Extension of the Rolling Continuation Channel (RCC) Phase 1 Term for the Rwanda Round 3 (RWN-304-G03-M) Extension of the Rolling Continuation Channel (RCC) Phase 1 Term for the Rwanda Round 3 (RWN-304-G03-M)
The Board acknowledges that the Secretariat intends to use the new Grant Score Card which is being developed for the Periodic Review under the New Architecture for future RCC Mid-term Performance Reviews. In order to allow sufficient time for the Rwanda Round 3 RCC Malaria grant (RWN-304-G03-M) to be reviewed under the new Grant Score Card and, if approved for further funding by the Board, to allow sufficient time for the grant to be negotiated and signed, the Board approves a six month no cost extension to the RCC Phase 1 term of the grant so that the term shall now expire on 1 April 2011.
2010-04-30 B21 GF/B21/DP02 Approval of Agenda Approval of Agenda
The agenda for the Twenty-First Board Meeting (GF/B21/1, Revision 1), as amended, is approved.
2010-06-14 B21 GF/B21/EDP05 Additional funding for Continuity of Services for Papua New Guinea (PNG-405-G02-H) Additional funding for Continuity of Services for Papua New Guinea (PNG-405-G02-H)
<p>The Board approves additional funding for up to two years for the Continuity of Services for the proposal listed in Schedule B, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p><p>See attached tabledetailing total recommended funding amount of US$ 1,856,418 for the following grant: PNG-405-G02-H</p>
2010-12-10 B21 GF/B21/EDP30 Additional funding for Round 7 Lesotho HIV grant (LSO-708-G05-H) Additional funding for Round 7 Lesotho HIV grant (LSO-708-G05-H)
The Board approves additional funding up to US$ 4,998,103 for the Phase 2 period of the Round 7 Lesotho HIV grant (LSO-708-G05-H) to improve the quality and scale of PMTCT activities, subject to TRP clarifications and conditions within a limited timeframe. The Board approves the revised Phase 2 incremental amount up to US$ 20,247,629 which includes an additional sum of US$ 4,998,103 allocated for PMTCT activities. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its risk management function.
2010-08-15 B21 GF/B21/EDP13 August 2010 Phase 2 Funding Decision August 2010 Phase 2 Funding Decision
<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).<sup>4</sup></p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 84,840,661 <span>for the following grants: </span>PKS-708-G08-M ; MWP-708-G06-H ; JAM-708-G02-H ; NGR-708-G08-H ; LBR-708-G05-M</p>
2010-04-30 B21 GF/B21/DP09 FAC Reattribution of 2009 Budget (AMFm) FAC Reattribution of 2009 Budget (AMFm)
In light of the considerations set out in the Finance and Audit Committee's Report to the Board (GF/B21/6), the Board approves the reattribution of US$ 2.85 million of the Affordable Medicines Facility - malaria (AMFm) professional fees budget from 2009 to 2010.
2010-04-30 B21 GF/B21/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Karlo Boras from the Developing NGOs constituency is designated as Rapporteur for the Twenty-First Board Meeting.</p>
2003-06-06 B05 GF/B05/DP17 Committee Report: PMPC Committee Report: PMPC
<p>The Board:</p> <p>(a) Approved the Eligibility criteria for the fourth and subsequent rounds of applications to the Global Fund as presented in Part 3 of the PMPC report.</p> <p>(b) Endorsed recommendations related to procurement of Diagnostics and other non-Pharmaceutical products and the quality and monitoring processes. The Board also acknowledged the different operational issues surrounding in-kind donations.</p> <p>(c) Took note of the work and discussions on principles of additionality as well as assistance needed to ensure that Neediest and Poorest countries receive funding from the Global Fund.</p> <p>I think we have consensus on this issue. It is decided as presented. </p> <p>The recommendations were approved as presented.</p>
2003-06-06 B05 GF/B05/DP15 Legal Status Update Legal Status Update
<p>The Board:</p> <p>1. Requests the Swiss authorities to examine, with the Federal Council, the possibility of granting privileges and immunities to the Global Fund and its different bodies in Switzerland, equivalent to those granted an international organization, through the conclusion of a headquarters agreement signed with Switzerland.</p> <p>2. Asks the Secretariat to work closely with WHO to record key areas of concern and identify mutually agreed and tangible solutions to improve the functioning of the Administrative Services Agreement to ensure greater administrative efficiencies and independent authority for decisions and actions for the Global Fund.</p> <p>3. Asks the Secretariat to continue to clarify the implications of moving to the status of an Intergovernmental Organization, including how to ensure a strong governance role for the private sector, NGOs and civil society that meets the Global Fund's commitment to the public-private partnership.</p>
2003-06-06 B05 GF/B05/DP14 Annual Report Annual Report
<p>The Board approved the first draft of the 2002 - 2003 Global Fund Annual Report.</p>
2003-06-06 B05 GF/B05/DP01 Welcome to New Members Welcome to New Members
<p>A new member of the Board was welcomed; Mr Shigeki Sumi, Deputy Director General of the Department of Multinational Cooperation in the Ministry of Foreign Affairs from Japan. </p><p> Also welcomed was recently designated alternate for the West and Central Africa constituency, Dr Urbain [Olanguena] Awono (OWOENO), Minister of Public Health of Cameroon.</p>
2003-06-06 B05 GF/B05/DP05 Policy on funding of proposals Policy on funding of proposals
<p>1. The Board endorses these principles for funding Round Three grant obligations:</p> <p>a. The Board may approve proposals and commit funds for two years up to the cumulative amount pledged until and including the current year.</p> <p>b. A sufficient amount of cash and/or liquid assets to meet the full cost of two years of implementation of approved grants must be deposited with the Trustee or readily available on demand prior to the Secretariat signing a grant agreement. </p> <p>2. The Board: </p> <p>a. Asks the TRP to refine the recommendations in category 2 in a way that will facilitate the Board's prioritization of proposals for approval and requests the Secretariat, in consultation with the PMPC, to propose criteria* to be agreed by the Board for prioritizing TRP-recommended proposals, if sufficient funds are not available to immediately approve all TRP-recommended proposals.</p> <p>*Based on the Framework Document and the Guidelines for Proposals for the Third Round</p> <p>b. Asks the Secretariat, in consultation with the PMPC, to develop options for prioritizing TRP-recommended Round 3 proposals by the end of July, with information provided to the Board by mid-August, and bring these to the Board for approval at the October Board meeting.</p> <p>3. The Board asked the Secretariat in consultation with the World Bank, other partners, PMPC and MEFA to develop a comprehensive policy on funding of grant obligations, for approval at the October 2003 Board meeting.</p> <p>4. The Board asked the Secretariat in consultation with MEFA to define reserve levels as a contingency to fund successful appeals to be presented to the Board for approval at the October 2003 Board meeting.</p>
2003-08-20 B05 GF/B05/EDP01 Approval of Appeal of the Colombia HIV/AIDS Component Approval of Appeal of the Colombia HIV/AIDS Component
<p>At the Fourth Board Meeting, the Global Fund Board approved an Appeal Mechanism for countries whose proposals had been rejected twice and who where placed in Category 3.</p><p>The Board reviewed these recommendations and endorsed the recommendation for approval of the Colombia HIV/AIDS Component.</p><p>The Colombia proposal is reclassified under Category 2.</p>
2003-06-06 B05 GF/B05/DP04 Approval of Report of Fourth Board Meeting Approval of Report of Fourth Board Meeting
<p>The Report of the Fourth Board Meeting was adopted with the following amendments: remove 4E on page 20; correct that the Minister of Rwanda was present not the current listed ministers of Africa; page 34, paragraph 6: delete the last sentence of paragraph 6.</p> <p>It was requested the reports be shorter, with focus on actions and decisions.</p>
2003-09-03 B05 GF/B05/EDP02 Audited Financial Statements 2002 Audited Financial Statements 2002
<p>The Board:</p><ol><li>Notes<span> that </span><span>the Chair andVice Chair of the Board and the Chair of the MEFA Committee have all agreed torequest Board approval of this decision via email;<br/><br/></span></li><li>Having reviewed the external audit and report of the Global Fund’s 2002 Financial Statements, commissioned by the Board at its June Meeting, and since completed by the external auditors, Ernst and Young;<br/><br/></li><li>Having noted the unqualified opinion reached by the auditors;<br/><br/></li><li>Approves the Auditor’s Report andAudited Financial Statements for 2002, prepared by Ernst and Young;<br/><br/></li><li>Approves the 2002 Annual Report for issuance on 22 September 2002 at the United Nations General Assembly.</li></ol>
2010-09-01 B21 GF/B21/EDP19 Approval of Russian Federation Continuity of Services (RUS-405-G03-H) Approval of Russian Federation Continuity of Services (RUS-405-G03-H)
<ol><li>The Board acknowledges that while the Russian Federation does not meet all the eligibility criteria for Global Fund support for upper middle income countries: <ol><li type="a">there is a need for continuing ARV treatment for 12,258 patients currently on treatment for the three month period (September – November 2010) who are being transitioned into the National Program; and</li><li type="a">the Russian Federation also requires additional time to finalize the transition of ARV treatment of 4669 migrants and prisoners into the National Treatment Program.</li></ol></li><li>The Board therefore approves an incremental amount of US$ 16,623,895 with the understanding that by not later than 31 March 2011, the CCM will submit to the Global Fund a transition plan for migrants and prisoners describing how the patients on treatment will be funded from Government and other sources after the end of one year period approved for Continuity of Services (1 September 2010 to 31 August 2011).</li></ol>
2010-04-30 B21 GF/B21/DP16 Interim Exception to the Global Fund’s Quality Assurance Policy for Pharmaceutical Products Interim Exception to the Global Fund’s Quality Assurance Policy for Pharmaceutical Products
<p>1. The Board approves a restatement of the Interim Exception to the Global Fund's Quality Assurance Policy for Pharmaceutical Products as set out in Annex 4 to the MDC Report to the Board (GF/B21/8 Revision 1, Annex 4). This interim exception expires on 31 December 2010.</p><p>2. The Board requests the Secretariat to work on an urgent basis with WHO to establish a process for the Expert Review Panel (ERP) to specifically consider and assist to deal with exceptional cases in the future. Such exceptional cases would be limited to situations in which financing provided by the Global Fund would be used to procure a Finished Pharmaceutical Product (FPP) of a formulation for which:</p><p>(i) no available<a id="OLE_LINK2" name="OLE_LINK2">*</a> FPP complies with the quality standards of the Global Fund's Quality Assurance Policy; and</p><p>(ii) WHO has made a determination, based on the available information, that no therapeutic alternatives exist that would be adequate for the specific country or region of intended use. </p><p>In such exceptional cases, ERP review should include an assessment of the clinical risk of providing ineffective or no treatment, in addition to a quality risk analysis. If necessary, the Terms of Reference of the ERP shall be revised accordingly. </p><p>* 'Available' means that the manufacturer can supply the requested quantity of the FPP within not less than 90 days of the requested delivery date.</p>
2010-04-30 B21 GF/B21/DP10 Exceptions to the Salary Threshold Exceptions to the Salary Threshold
<p>The Board delegates its authority to the Chair and Vice Chair of the Finance and Audit Committee ("FAC") together with one constituency member from the Dono<a id="OLE_LINK1" name="OLE_LINK1"></a>rs block and one constituency member from the Implementers block invited by the Chair of the FAC (the "Remuneration Group") to approve new staff salaries that exceed the threshold of CHF 245,000 set in the Global Fund Human Resources Policy Framework. The approval of salaries will be based on criteria proposed by the FAC and approved by the Board. The Remuneration Group will inform the Board of its decisions when the Board meets in Executive Session. Decisions on the salary of the Executive Director remain with the Board.</p> <p>The Board requests the Executive Director to present to the Remuneration Group:</p> <p>i) The existing exceptions to the threshold; and</p> <p>ii) On an on-going basis, the salaries that exceed the threshold as a result of increases given to staff based on satisfactory justifications.</p> <p>The threshold may be adjusted by the Remuneration Group, when needed, taking into account the process set out in the Global Fund Human Resources Policy Framework (GF/EDP/08/16 - Annex 1, Section 2.3).</p>
2010-08-15 B21 GF/B21/EDP14 The Technical Review Panel (TRP) recommendation to commit additional funding for Lao PDR (LAO-708-G09-M) The Technical Review Panel (TRP) recommendation to commit additional funding for Lao PDR (LAO-708-G09-M)
<p>The Board approves additional funding for the Phase 2 period of the Round 7 Lao PDR Malaria grant (LAO-708-G09-M) as a ‗Conditional Go‘ in the amount of up to US$ 15,390,435, subject to TRP clarifications and conditions within a limited timeframe. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its regular performance-based evaluation criteria.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p>
2010-05-14 B21 GF/B21/EDP03 Secretariat’s request to the Board with respect to an extension of time to fulfill a ‘Condition’ - Gabon Secretariat’s request to the Board with respect to an extension of time to fulfill a ‘Condition’ - Gabon
<p>The Board acknowledges that, due to unforeseen delays in program implementation as well as political disturbances in Gabon, the condition 1b. upon which the Board approved the Round 5 malaria grant to the Government of Gabon (GAB-509-G04-M) will not be fulfilled by its current deadline of 19 May 2010. The Board decides to revise this condition 1b to read:</p><p><i>"Within 16 months of signing the Phase 2 extension, a Global Fund internal performance review shall be carried out to assess programmatic and management (including financial) performance of the grant. If the results of this review are not satisfactory to the Global Fund, the grant shall be terminated."</i></p>
2010-11-10 B21 GF/B21/EDP26 Extension of Grant Signing Deadlines: Round 9 and AMFm Proposals Extension of Grant Signing Deadlines: Round 9 and AMFm Proposals
<p>The Board extends the deadline for the signing of grant documentation for the proposals listed in Annex A for three months to 10 February 2011.</p><p>The Board also extends the Phase 2 Period of the AMFm host grant in Uganda (UGD-405-G5-M) until 10 February 2011 and authorizes the host grant activities specified for that grant in Annex A to be implemented.</p>
2010-08-15 B21 GF/B21/EDP15 Declination to approve additional funding for Sri Lanka (SRL-607-G08-T) Declination to approve additional funding for Sri Lanka (SRL-607-G08-T)
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 6 Sri Lanka TB grant (SRL-607-G08-T).</p><p>See attached table.</p>
2010-12-10 B21 GF/B21/EDP31 Discontinuation of funding for the Gabon Round 5 Malaria grant (GAB-509-G04-M) Discontinuation of funding for the Gabon Round 5 Malaria grant (GAB-509-G04-M)
The Board acknowledges that the condition upon which the Board approved continued funding to Gabon Round 5 Malaria grant (GAB-509-G04-M) to the Ministry of Health and Public Hygiene of Gabon required the Principal Recipient to achieve a satisfactory level of performance within sixteen months of signature of the Phase 2 Grant Agreement. Recognizing that the condition has not been fulfilled, the Board decides to discontinue funding for the remaining period of the grant and requests the Secretariat to close out the grant in accordance with its delegated authority for Grant Closure Activities (GF/B17/DP6).
2010-08-20 B21 GF/B21/EDP18 Technical Review Panel Recruitment 2010-2012 Technical Review Panel Recruitment 2010-2012
<p>The Board approves the appointment of the following:</p><ol><li>Anupong Chitwarakorn (HIV/AIDS), Stephen Mills (HIV/AIDS), Anthony David Harries (Tuberculosis), Frank Adae Bonsu (Tuberculosis), Daniel Tarantola (Cross-cutting), Mari Nagai (Cross-cutting), Lev Khodakevich (Cross-cutting), Claudia Surjadjaja (Cross-cutting) and Lucie Blok (Cross-cutting) as Permanent Technical Review Panel (TRP) Members to serve for up to four Rounds commencing from Round 10;</li><li>In respect of Round 10, the twenty (20) persons identified as Alternate Members as presented in Annex 1 of this Report (B21/EDP/18); and</li><li>The membership of the Technical Review Panel Support Group (as presented in Annex 1 of this Report (B21/EDP/18)), comprising the pool of experts from which TRP membership will be replenished in the event of TRP vacancies as they may arise.</li></ol><p>Each Permanent TRP, Alternate and Support Group Member has been recommended by the Portfolio and Implementation Committee and the Executive Director of the Global Fund Secretariat.</p>
2010-04-30 B21 GF/B21/DP12 Secretariat Office Space Secretariat Office Space
<p>The Board refers to its decision made at the Twentieth Board Meeting on Secretariat Office Space (GF/B20/DP19). Having reviewed the draft development contract (GF/B21/6 - Annex 4) pertaining to the development of a building in which the Secretariat would lease office space, the Board requests the Finance and Audit Committee to approve the development contract for signature by the Secretariat once it is finalized and report on this issue to the Board at the Twenty-Second Board Meeting. </p>
2010-04-30 B21 GF/B21/DP13 Review of the Comprehensive Funding Policy Review of the Comprehensive Funding Policy
<p>The Board refers to the Chair's Summary of the Third Global Fund Voluntary Replenishment (2011-2013) Preparatory Meeting (the "Preparatory Meeting") noting that participants at the meeting "without at this stage taking any collective positions on the substance of the issue - encouraged the Board to review the comprehensive funding policy." The Board also refers to the briefing note entitled "Use of Promissory Notes and Similar Obligations as a Means of Contributing to the Global Fund," prepared by the Secretariat at the request of participants of the Preparatory Meeting.</p><p>The Board requests the Finance and Audit Committee to conduct a review of the Global Fund Comprehensive Funding Policy, with the support of the Secretariat and through a balanced and inclusive process. Considering the relevance of this review for the Third Voluntary Replenishment, the Board requests the FAC to provide to the Board its analysis and recommendations on the use of promissory notes and similar obligations and its impact on the Comprehensive Funding Policy prior to 30 June 2010. Any proposed changes to the Comprehensive Funding Policy would be considered by the FAC after 30 June 2010 and recommendations would be provided by the FAC to the Board before the Twenty-Second Board Meeting. </p>
2003-06-06 B05 GF/B05/DP06 TRP Renewal TRP Renewal
<p>The Board approves the following proposal:</p> <ol> <li>The list of persons selected for the TRP by the PMPC and the Executive Director (as in Annex 2).</li> <li>The launch of the TRP renewal process for 2004, on the basis of the recommendations and lessons learned contained in the PMPC report (GF/B5/9).</li> <li>Add a TB specialist to the TRP.</li> </ol>
2023-12-01 B50 GF/B50/EDP02 Additional Funding from the COVID-19 Response Mechanism Additional Funding from the COVID-19 Response Mechanism
<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards and implemented through 31 December 2025;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B50/ER02 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants, in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>